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of our work and stemming from serendipitous observations, we also developed an 
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of the products obtained was further illustrated by their expeditious conversion to highly 
enantioenriched acyclic as well as cyclic aldol products, the latter hitherto inaccessible by 
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peroxid, ein preiswertes und umweltfreundliches Oxidationsmittel. Des Weiteren wurde resul-
tierend aus unerwarteten Beobachtungen im Verlauf der Arbeit eine bis zu diesem Zeitpunkt 
beispiellose, effektive Methode zur asymmetrischen Hydroperoxidierung von α,β-Enonen 
entwickelt, welche in einem Schritt fünfgliedrige cyclische, und auch bicyclische Peroxy-
hemiketale in optisch aktiver Form liefert. Den synthetische Nutzen und die Vielseitigkeit der 
erhaltenen Verbindungen belegt deren direkte Umsetzung zu hoch enantiomerenange-
reicherten acyclischen als auch cyclischen Aldolprodukten, wovon letztere bisher nicht 
andersweitig synthetisch zugänglich waren. Darüber hinaus dienen die Peroxyhemiketale als 
Ausgangssubstanz für die Synthese von optisch aktiven, potentiell biologisch relevanten 1,2-
Dioxolanen. Unsere Epoxidierung beinhaltet eine konzeptuell interessante Verknüpfung von 
etablierten organokatalytischen Aktivierungsmodi, bekannt als Iminium-Ionen und Enamin-
Katalyse, und die zugrunde liegenden mechanistischen Aspekte werden vorgestellt und 
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1 Introduction 
Although the origin of chirality is still obscure,[1] it is the source of diverse phenomena at the 
macro- and microscopic level, governing our environment and the existence of living 
organisms. The principles of molecular chirality were established over a century ago by van’t 
Hoff and LeBel, but awareness of how they affect the biological activity of molecules is much 
more recent.[2] 
The biological machinery made up from the basic building blocks of life - chiral amino acids, 
sugars, and lipids - is susceptible to enantioselective interactions. Biological systems are thus 
commonly capable of differentiating between enantiomeric forms of chiral molecules, 
including odorants, pheromones, agrochemicals, environmental pollutants and, most 
importantly, drug compounds. The two different enantiomers of a compound may have 
distinctly different effects on a given biological system. For instance, naturally occurring α-
ionone of violets exhibits (R)-configuration and, differs significantly from the (S)-enantiomer 
in its olfactory properties (Figure 1.1).[3] 
 
O O
(S)-α-ionone
woody, cedar-like
threshold: 20-40 μg kg-1
(R)-α-ionone
bloomy, violet-like
threshold: 0.5-5 μg kg-1  
Figure 1.1 Enantiomers of α-ionone. 
 
Due to increased interest in the consequences of chirality on physical, biological and 
pharmacological properties of molecules,[4] the preparation of pure stereoisomers has become 
a topic of great importance, and methods of supplying optically pure materials are being 
intensively pursued. Nature has provided a variety of enantiomerically pure compounds 
referred to as the chiral pool, which can be subjected to further transformations. Besides this 
there are two general methods for obtaining enantiopure compounds: resolution of racemic 
mixtures and asymmetric synthesis. Among the stereoselective synthetic methodologies, 
catalytic processes hold a prominent place. In 1996, Nicolaou and Sorensen stated that “in a 
catalytic asymmetric reaction, a small amount of an enantiomerically pure catalyst, either an 
enzyme or a synthetic, soluble transition metal complex, is used to produce large quantities of 
an optically active compound from a precursor that may be chiral or achiral.”[5] However, 
during the last decade, organocatalysis, catalysis by low-molecular weight organic 
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molecules,a has garnered increased importance within the realm of asymmetric catalysis by 
allowing a broad and diverse array of equally efficient and selective transformations, thereby 
complementing metal and biocatalysis.[6] 
Organocatalysis can even offer certain advantages over metal-catalyzed and biocatalytic 
methods: in particular, its operational simplicity and practicability represent major benefits. 
Most organocatalysts are readily available from inexpensive starting materials and are 
typically bench-stable and robust (inert towards moisture and oxygen). Thus, organocatalytic 
reactions generally do not require inert reaction conditions. They can regularly be conducted 
in wet solvents under an aerobic atmosphere. Indeed, the presence of water is often beneficial 
to the reaction rate and selectivity. In addition, organocatalytic - and thus commonly metal-
free - methods are especially attractive in food and drug related contexts for the preparation of 
pharmaceutical products and agrochemicals that do not tolerate residual heavy metal 
impurities, not even in trace amounts. 
 
This thesis deals with the utilization of organocatalysis for the synthesis of chiral, enantiopure 
epoxides. The importance of epoxides in organic synthesis arises partly from the occurrence 
of the strained three-membered ring unit in a number of interesting natural products, but more 
so because the stereospecific ring opening of epoxides allows straightforward elaboration to 
useful new functionality.[7] Nature’s chiral pool has not proven to be a useful direct source of 
optically active epoxides for synthetic applications. Instead, enantioenriched epoxides have 
been accessed in indirect fashion via multistep procedures. These, however, tend to be 
inherently inefficient, and the range of epoxides available by this approach is also quite 
limited. As a consequence, the preparation of enantioenriched epoxides has long stood as a 
particularly significant endeavor in asymmetric synthesis. In particular, the identification of 
catalytic asymmetric olefin epoxidation methods has been an area of active research for 
several decades.[8] 
 
In the following chapters, both the history of organocatalysis and catalytic asymmetric 
epoxidation will be briefly outlined. This serves as a prelude for our own journey through the 
development of new organocatalytic asymmetric epoxidations and hydroperoxidations of α,β-
unsaturated ketones - with its fair share of reaction design, rational analysis, and serendipitous 
discovery. 
 
                                                 
a Organocatalysts may contain metals if these play exclusively a structure-defining role and are not involved in 
the working principle. 
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2.1 Asymmetric Organocatalysis 
For a long time, the realm of asymmetric catalysis was dominated by metal and biocatalysis. 
Yet, at the beginning of this century, List’s discovery of the (S)-proline-catalyzed direct 
asymmetric intermolecular aldol reaction[9] together with the development of an asymmetric 
Diels-Alder reaction catalyzed by a chiral imidazolidinone salt by MacMillan et al.[10] have 
raised awareness of the potential of purely organic molecules as efficient catalysts for a 
variety of asymmetric transformations and brought to life the term “organocatalysis” to 
address this research field (Scheme 2.1). 
 
 
Scheme 2.1 (a) (S)-proline (1)-catalyzed direct asymmetric intermolecular aldol reaction; (b) Imidazolidinone 
(2) salt-catalyzed enantioselective Diels-Alder reaction. 
 
2.1.1 Historical Development 
Organocatalysis has a rich background as it is suggested that extraterrestrial, enantiomerically 
enriched amino acids such as (S)-alanine and (S)-isovaline played a decisive role in the 
prebiotic formation of key building blocks such as sugars by promoting the self-aldol reaction 
of glycolaldehydes in water.[11] In this way, the reactions might have led to the introduction 
and widespread of homochirality in the living world. The historic roots of organocatalysis 
date back to the mid of the 19th century with von Liebig’s accidentally discovery of what is 
today considered the first organocatalytic reaction, the transformation of dicyan into oxamide 
in the presence of an aqueous solution of acetaldehyde.[12] In the early 1900s, Bredig’s 
pioneering studies on the use of natural Cinchona alkaloids as enantioselective catalysts were 
motivated by searching the chemical origin of enzyme activity observed in living 
organisms.[13] In this context, he developed the first asymmetric organocatalytic reaction by 
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adding hydrogen cyanide to benzaldehyde in the presence of catalytic amounts of either 
quinine (3) or quinidine (4) (Scheme 2.2). These studies were conceptually groundbreaking, 
although the enantiomeric ratio remained rather low (~ 55:45 er), and initiated a line of 
research which had been continued by Pracejus[14] (~ 60:40 er) and others. 
 
Scheme 2.2 First enantioselective organocatalytic reaction: asymmetric hydrocyanation of benzaldehyde by 
Bredig. 
 
Another key event in the history of organocatalysis was the use of (S)-proline as an 
aldolization catalyst by Hajos and Parrish at Hoffmann-La Roche[15] and Eder, Sauer, and 
Wiechert at Schering[16] in the early 1970s (Scheme 2.3). Their parallel studies were 
decisively inspired by the seminal work of Knoevenagel in the late 19th century.[17] 
 
 
Scheme 2.3 Hajos-Parrish-Eder-Sauer-Wiechert reaction catalyzed by (S)-proline (1). 
 
Nonetheless, the real potential of this chemistry was only revealed three decades later by the 
groups of List and MacMillan who have demonstrated that aminocatalysis, the activation of 
carbonyl groups via enamine and iminium ion intermediates, is indeed a general concept for 
(asymmetric) catalysis (cf. Scheme 2.1). Evolving from a small collection of chemically 
unique and unusual, mechanistically poorly understood reactions, organocatalysis has 
advanced at a truly breathtaking pace since its birth in 2000 and has during the last ten years 
grown into a thriving area of research, which today represents the third pillar of asymmetric 
catalysis besides metal and biocatalysis.[6] 
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2.1.2 Classification 
Organocatalysis can be divided into four areas: Lewis base, Lewis acid, Brønsted base and 
Brønsted acid catalysis.[18] The corresponding (simplified) catalytic cycles are depicted in 
Scheme 2.4. Accordingly, Lewis base catalysts (B:) initiate the catalytic cycle via 
nucleophilic addition to the substrate (S). The resulting complex undergoes a reaction and 
then releases the product (P) and the catalyst for further turnover. Lewis acid catalysts (A) 
activate nucleophilic substrates (S:) in a similar manner. Brønsted base and acid catalytic 
cycles are initiated via a (partial) deprotonation or protonation, respectively. 
 
 
Scheme 2.4 (Simplified) catalytic cycles of Lewis base, Lewis acid, Brønsted base, and Brønsted acid catalysis. 
 
The majority of organocatalysts are N-, C-, O-, P-, and S-based Lewis bases such as amines, 
carbenes, formamides, phosphanes, phosphoramides, and sulfides. Of those, nitrogen-based 
systems account for the largest share, partly due to their abundance in the chiral pool. Lewis 
base organocatalysts operate through diverse mechanisms and convert the substrates into 
either activated nucleophiles or electrophiles. Typical reactive intermediates are iminium ions, 
enamines, acyl ammonium ions,[19] 1-, 2-, or 3-ammonium enolates,[20] among others. The 
underlying principle of the work discussed within this thesis is the activation of carbonyl 
compounds as enamine or iminium ion, which represents the basis of what is often called 
aminocatalysis. 
 
2.1.3 Aminocatalysis 
The roots of modern aminocatalysis trace back to the pioneering work of Knoevenagel who, 
at the turn of the 19th century, found that primary and secondary amines, as well as their salts, 
catalyze the aldol condensation of β-ketoesters or malonates with aldehydes or ketones.[21] 
Remarkably, Knoevenagel himself suggested a possible role of imine formation with the 
amine catalyst in the course of the reaction.[21b] In the first half of the 19th century, Kuhn and 
Fischer and Marschall discovered that amines and amine salts also catalyze aldol addition 
and condensation reactions.[22] The first iminium-catalyzed conjugate addition reaction to α,β-
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unsaturated carbonyl compounds was reported in 1937 by Langenbeck using piperidinium 
acetate as catalyst for the hydration of crotonaldehyde.[23] In the history of iminium catalysis, 
further important landmarks are: (a) the discovery of iminium-catalyzed transimination by 
Cordes and Jencks,[24] (b) the reports of Baum and Viehe, and more recently Jung et al., on 
the acceleration of Diels-Alder reactions provided by α,β-unsaturated iminium ions,[25] (c) the 
proline-catalyzed deracemization of a thianone intermediate in the synthesis of erythromycin 
by Woodward and co-workers,[26] and most importantly (d) the use of alkali metal and 
ammonium proline salts in the conjugate addition of malonates to α,β-unsaturated aldehydes 
and ketones in the pioneering work of Yamaguchi and Taguchi between 1991 and 1996.[27] 
 
Today’s aminocatalytic transformations of carbonyl compounds via iminium ion and enamine 
intermediates using chiral primary and secondary amines (as well as their salts) as 
organocatalysts, hinges upon four distinct activation modes and is categorized accordingly in: 
(a) enamine, (b) iminium ion, (c) dienamine, and (d) SOMO catalysis, which involves the 
formation of enamine radical cations.[28] 
All distinct activation modes have in common that the initial step constitutes the reversible 
formation of an iminium ion by condensation of the amine (salt) catalyst (A) with the 
carbonyl compound (Scheme 2.5). The formation of iminium ion B effectively lowers the 
LUMO energy of the system (a) - as does the coordination of a Lewis acid (b). As a result, 
both nucleophilic additions and α-deprotonation become more facile. α-Deprotonation leads 
to the generation of enamine C, which is more nucleophilic than the enol form of the parent 
carbonyl compound. The formation of the enamine corresponds to a raise in the HOMO 
energy of the system and allows for subsequent reaction with a range of electrophiles to 
obtain α-functionalized carbonyl compounds. For conjugated π-systems, the electronic 
redistribution induced by the formation of iminium ion D facilitates nucleophilic additions (c), 
including conjugate additions as well as pericyclic reactions. γ-Deprotonation, finally, 
generates dienamine intermediates (vide infra). 
In all aspects, the principle of aminocatalytic activation emulates the mechanism of the 
activation of carbonyl compounds by Lewis acids. In reactions of α,β-unsaturated ketones the 
steric and electronic similarity of the two carbonyl substituents does not generally permit high 
levels of discrimination between the free electron lone pairs in the metal-association step, 
which is essential for attaining high stereocontrol in the following transformation. In 
aminocatalysis by contrast, iminium ion formation overcomes the necessity of discriminating 
between the free electron lone pairs. 
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Scheme 2.5 Activation of carbonyl compounds by aminocatalysis (a, c) vs. Lewis acid catalysis (b, d). (LA: 
Lewis acid; E: electrophile; Nu: nucleophile) 
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An overview of the divergent reaction pathways and functionalizations amenable to (a) 
aldehydes and ketones or (b) enals and enones, respectively, by means of aminocatalysis is 
provided in Scheme 2.6. 
 
Scheme 2.6 (a) Aminocatalytic activation modes and divergent reaction pathways with aldehydes and 
ketones. 
 
 
Scheme 2.6 (b) Aminocatalytic activation modes and divergent reaction pathways with enals and enones. 
 
More recently, the formation of dienamines F from α,β-unsaturated iminium ions by γ-depro-
tonation has been synthetically exploited to give rise to γ-functionalized enals upon reaction 
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with electrophiles (Scheme 2.6).[29] Their use as electron rich dienes in Diels-Alder reaction 
has also been reported.[30] A fourth synthetic tool constitutes the SOMO activation of carbonyl 
compounds. Oxidation of the initially formed enamine C affords a radical cation E which 
allows the use of a group of reagents that has previously not been applicable to aminocatalysis 
such radicals (e.g. TEMPO), π-nucleophiles (e.g. allylsilanes, styrenes), or halides (e.g. 
LiCl).[31] 
Enamine and iminium ion catalysis are two divergent reaction modes in organocatalysis, 
though sharing a common origin. Enamine catalysis proceeds via iminium ion formation and 
almost always results in iminium ion formation (cf. Scheme 2.6). In a complementary fashion, 
conjugate addition of a nucleophile to an iminium ion generates an enamine intermediate G 
which can in turn react with another electrophile.[32] The interdependency of those two 
catalytic intermediates (cf. Scheme 2.7, (a)) combined with the ability of most amine catalysts 
to promote several types of transformations based on different activation modes side by side 
makes aminocatalysis the perfect platform for domino and tandem or cascade reactions and a 
powerful tool in the construction of complex molecular skeletons in a highly stereocontrolled 
manner as illustrated with numerous elegant examples in the recent literature.[33] 
One example which presumably operates through the same mechanistic rationale, is the 
amine-catalyzed asymmetric epoxidation of α,β-unsaturated carbonyl compounds with alkyl 
hydroperoxides or hydrogen peroxide as studied within this thesis. In the course of this 
reaction, the hydroperoxide serves as both the nucleophile and the electrophile (Scheme 
2.7, (b)). 
 
 
 
Scheme 2.7 (a) General picture of the iminium ion-enamine interdependency; (b) iminium ion-enamine 
interplay in the nucleophilic epoxidation reaction. (Nu-H: nucleophile; E: electrophile; R = H, Alk) 
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hydroperoxides or hydrogen peroxide as studied within this thesis. In the course of this 
reaction, the hydroperoxide serves as both the nucleophile and the electrophile (Scheme 
2.7, (b)). 
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2.1.3.1 Asymmetric Counteranion-Directed Catalysis (ACDC) 
Most chemical reactions proceed via charged intermediates or transition states. Such “polar 
reactions” can be influenced by the counterion, especially if conducted in organic solvents, 
where ion pairs are ineffectively separated by the solvent. Although efficient asymmetric 
catalytic transformations involving anionic intermediates with chiral, cationic catalysts have 
been realized in the context of phase-transfer catalysis,[34] analogous versions of inverted 
polarity attaining reasonable enantioselectivity have been elusive until recently. Attempts 
toward this end have been undertaken by Arndtsen and Nelson and co-workers (Scheme 2.8, 
eq. (a) and (b)).[35] Both groups applied chiral borate anions such as BINOL-derived borate 5 
to several catalytic transformations including copper-catalyzed aziridination and 
cyclopropanation of olefins and ring opening reactions of meso-aziridinium ions, albeit with 
only moderate success. The highest enantioselectivity observed in all those reactions was 
67:33 er along with a yield of 3% of the desired product by using a chiral tartrate-derived 
borate anion.[35a] Lacour et al. studied the influence of chiral TRISPHAT anions on 
enantioselective olefin epoxidation reactions catalyzed by iminium ion 6. However, only 
racemic product was obtained (eq. (c)).[36] 
 
 
 
Scheme 2.8 Preliminary attempts toward the use of chiral counteranions in asymmetric catalysis. 
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It was not until recently that the use of chiral counteranions in asymmetric catalysis was 
brought to a useful level of enantioselectivity. 
In recent years, chiral BINOL phosphates of the general structure 7 (Scheme 2.9, (a)) have 
emerged as powerful Brønsted acid catalysts triggered by the seminal works of Akiyama and 
Terada in 2004 on their use in asymmetric Mannich-type reactions.[37] Chiral BINOL-derived 
phosphoric acids are believed to function as specific Brønsted acid catalysts.a The substrate 
(S) is protonated by the catalyst HX* generating a chiral ion pair [(S−H)+ X*−], in which the 
asymmetry is communicated by the chiral counteranion X*− (Scheme 2.9 ((b); with Cat = H). 
 
 
Scheme 2.9 (a) Chiral BINOL-derived phosphoric acids (e.g. TRIP (7a)); (b) general concept of asymmetric 
counteranion-directed catalysis (ACDC) (with Cat = H: special case of Brønsted acid catalysis). (S: substrate; P: 
product; CatX: catalyst; X*−: chiral anion) 
 
Studies undertaken in our laboratory pushed forward the generalization and conceptualization 
of this approach, namely asymmetric counteranion-directed catalysis (ACDC), by expanding 
it to catalyst systems with Cat ≠ H (Scheme 2.9, (b)). The efficiency of this concept was 
initially illustrated with various highly enantioselective catalytic transformations based on 
iminium ion catalysis (Scheme 2.10).[38] Remarkably, the highest enantioselectivities were 
consistently observed when using the chiral BINOL-based phosphoric acid TRIP (7a), 
bearing sterically demanding 2,4,6-triisopropylphenyl substituents at the 3,3'-positions of the 
binaphthyl scaffold, as chirality inducing counteranion (Scheme 2.9, (a)).[39] Later, the ACDC 
concept was further expanded to Lewis acid and transition-metal catalysis, by our[40] and other 
research groups.[41] The asymmetry transfer from the chiral counteranion X*− to the activated 
substrate (Cat−S)+ within a tight ion pair [(Cat−S)+ X*−] (Scheme 2.9, (b); Cat ≠ H) is most 
likely the result of a cooperative effect of electrostatic and coordinative interactions 
conceivably assisted by hydrogen bonding. 
 
                                                 
a Specific Brønsted acid catalysis relies on the use of strong Brønsted acids as catalysts. 
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Scheme 2.10 The ACDC concept in iminium ion catalysis: application to the transfer hydrogenation of (a) enals 
and (b) enones as well as (c) the epoxidation of enals. 
 
The ACDC approach to asymmetric catalysis offers a manifest advantage compared with 
traditional strategies for catalyst design and optimization. Combinatorial libraries of ACDC 
catalysts are readily accessible by interchanging the two catalyst components separately. In 
addition, when using two chiral components matched combinations commonly allows further 
improvement of the asymmetric induction as has been demonstrated in the asymmetric 
transfer hydrogenation of ketones catalyzed by the (S)-valin-tert-butyl ester (9) (R)-TRIP salt 
[(S)-9 • (R)-TRIP] (Scheme 2.10, (b)). This strategy will also find application in the work 
described within this thesis. 
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2.1.3.2 Primary Amine Salt Catalysts 
At the outset, the focus of modern aminocatalysis was on the use of chiral secondary amine 
catalysts, especially substituted pyrrolidines, proline, or imidazolidinone derivatives, for the 
activation and functionalization of carbonyl compounds. In contrast, chiral primary amine 
catalysts have been largely neglected, possibly due to unfavorable imine-enamine 
equilibria.[42] This is surprising in view of the fact that early studies on aminocatalysis have 
already included the use of primary amino acids, amines and amine salts as catalysts,[22b, 43] 
and even more so since primary amine catalysis is effectively exploited by natural enzymes 
such as type I aldolases and decarboxylases, both containing catalytically active lysine 
residues (Figure 2.1).[44] 
 
 
Figure 2.1 Active site of type I rabbit muscle FDP (fructose-1,6-diphosphate) aldolase.[44] 
 
Only recently has primary amine catalysis emerged as a powerful tool for the iminium ion 
activation of challenging classes of unsaturated carbonyl compounds such as sterically 
demanding α,β-unsaturated ketones and α-branched enals which are difficult to activate with 
conventional secondary amine catalysts.[45] Owing to reduced steric requirements, the use of 
primary amines overcomes the inherent difficulties of secondary amine catalysts in generating 
congested covalent iminium ion intermediates, and thus enables transformations of sterically 
demanding carbonyl compounds which have previously not been realized through secondary 
amine catalysis (D1 and D3, Scheme 2.11). Primary amine catalysts may provide higher 
equilibrium concentrations of the requisite iminium ion (D2 and D4), and thus account for 
increased reaction rates. 
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Scheme 2.11 Iminium ion activation of (a) α,β-unsaturated ketones and (b) α-branched α,β-enals: secondary vs. 
primary amine catalysts. 
 
The past years since 2005 have witnessed the rapid development of catalytic asymmetric 
transformations employing chiral primary amine catalysts.[45] Selected examples are depicted 
in Scheme 2.12. 
Ishihara et al. succeeded in activating α-substituted acroleins, in particular α-(acyloxy)acro-
leins, for Diels-Alder and [2+2] cycloaddition reactions by using novel primary amine 11 
together with an acid co-catalyst.[46] First evidence of the potential of primary amines as 
iminium ion activators of α,β-unsaturated ketones was provided by Chin and co-workers in 
2006. Their synthesis of warfarin, a widely prescribed anticoagulant, via conjugate addition of 
4-hydroxycoumarin to benzylideneacetone was catalyzed by (S,S)-DPEN (1,2-
diphenylethylenediamine; 12) in the presence of acetic acid (eq. (b)).[35] In the same year, List 
and Martin disclosed the use of (S)-valin-tert-butyl ester (9) (R)-TRIP salt [(S)-9 • (R)-TRIP] 
as highly efficient catalyst in the asymmetric transferhydrogenation of cyclic and acyclic α,β-
enones (cf. Scheme 2.10, (b)).[38c] Moreover, primary amines derived from naturally abundant 
Cinchona alkaloids were shown to provide an effective and general catalyst platform for 
asymmetric transformations of α,β-unsaturated ketones, including conjugate additions and 
pericyclic reactions.[47] The seminal report on their use as iminium ion activator of α,β-
unsaturated ketones was disclosed by Chen and Deng et al. in 2007.[48] Amino(9-deoxy)epi-
quinine (13) as its TFA salt efficiently mediated the enantioselective vinylogous conjugate 
addition of α,α-dicyanoalkenes to benzylideneacetone and derivatives (Scheme 2.12, (c)). 9-
Amino(9-deoxy)epiquinine (13) and analogues, whose chemistry has been pioneered by 
Brunner and co-workers,[49] have rapidly gained immense popularity and have found 
widespread application in primary amine catalysis. This is testified by not less than 50 
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unsaturated ketones was disclosed by Chen and Deng et al. in 2007.[48] Amino(9-deoxy)epi-
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publications since 2007 on their use as chiral organocatalysts from various research groups all 
around the world including the groups of Melchiorre, Connon, Deng and our group among 
others.[45, 50] 
 
 
 
Scheme 2.12 Iminium ion catalysis with primary amine salt catalysts: seminal reports. 
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2.2 Catalytic Asymmetric Epoxidation of Electron-Deficient Olefins 
 
2.2.1 Milestones in Catalytic Asymmetric Olefin Epoxidations 
Olefin epoxidation holds a venerable place in the history of catalytic asymmetric synthesis. 
The pioneering work by Sharpless in the early 1980s on the titanium-tartrate-catalyzed 
asymmetric epoxidation of allylic alcohols (Scheme 2.13), paved the way for much of today’s 
catalytic asymmetric synthesis.[51] 
 
 
Scheme 2.13 Sharpless’ catalytic asymmetric epoxidation of allylic alcohols. 
 
Following this discovery, much progress has been made towards the asymmetric epoxidation 
of other classes of olefins. Jacobsen and Katsuki introduced manganese-salen complexes as 
valuable catalysts for the catalytic asymmetric epoxidation of unfunctionalized, and 
particularly (Z)-disubstituted olefins (Scheme 2.14).[52] 
 
 
Scheme 2.14 Jacobsen-Katsuki epoxidation. 
 
More recently, the work of several groups, in particular Shi and co-workers, established 
dioxiranes, generated in situ from chiral ketones and Oxone, as asymmetric epoxidation 
reagents for a range of alkenes, especially (E)-disubstituted olefins (Scheme 2.15).[53] 
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Scheme 2.15 Asymmetric epoxidation catalyzed by chiral ketones. 
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The advances made in this field have increased greatly the number of enantiomerically 
enriched epoxides available for use in organic synthesis. Although a few different methods 
exist for the asymmetric epoxidation of electron-deficient olefins (vide infra), no system has 
gained widespread popularity amongst synthetic organic chemists.[54] However, due to the 
value of the corresponding optically active epoxides as versatile synthetic intermediates, 
much effort is devoted to the development of a general, highly enantioselective method 
applicable to a wide range of electron-deficient olefins. 
 
2.2.2 Weitz-Scheffer Epoxidation 
The general approach for the epoxidation of electron-deficient olefins is their treatment with 
alkaline hydroperoxides, well-known as the Weitz-Scheffer epoxidation.[55] It is well-
established that epoxide formation occurs via a two-step mechanism (Scheme 2.16), which 
was first proposed by Bunton and Minkoff.[56] Conjugate addition of a peroxyanion generated 
from hydrogen peroxide or alkyl hydroperoxides under basic conditions at the β-position of 
an α,β-unsaturated ketone 16 affords β-peroxyenolate 17. Subsequent intramolecular 
nucleophilic displacement at the proximal oxygen atom breaks the weak O-O single bond 
with concomitant ejection of a leaving group - hydroxide or alkoxide - to furnish epoxide 18. 
 
 
 
Scheme 2.16 (a) Two-step mechanism of the Weitz-Scheffer epoxidation: conjugate addition of a hydro- or alkyl 
peroxide followed by epoxide ring closure; (b) putative transition state for epoxide ring closure. 
 
The non-stereospecificity of these reactions is a strong indication for the formation of an 
intermediate 17 in the course of the reaction. Unlike for epoxidations with peracids, the 
alkene geometry is not necessarily retained in the epoxide. For example, the epoxidation of 
both trans- and cis-configured α,β-unsaturated ketones with alkaline hydrogen peroxide in 
methanol furnishes predominantly the corresponding trans-epoxide. The non-stereospecificity 
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further implies that hydroperoxide addition is fast, reversible, and causes isomerisation by 
rotation about the vinylic bond in the peroxyenolate 17.[57] 
Electron-deficient olefins exhibit low reactivity toward common electrophilic oxidants such 
as meta-chloroperbenzoic acid (MCPBA). However, under Weitz-Scheffer conditions they are 
selectively epoxidized in the presence of electron-rich olefins. 
Extensive research has been devoted to the development of asymmetric versions of the Weitz-
Scheffer epoxidation owing to the synthetic importance of enantiomerically enriched α,β-
epoxyketones as chiral building blocks and products of pharmaceutical and biological interest 
(cf. Figure 2.2, vide infra). 
In the mid-1970s, Wynberg et al. disclosed the first asymmetric Weitz-Scheffer epoxidation of 
trans-chalcone and derivatives attaining enantioselectivities of up to 77:23 er (Scheme 
2.17).[58] Cinchona alkaloid-derived quaternary ammonium salts were applied as chiral phase-
transfer catalysts with either hydrogen peroxide, tert-butyl hydroperoxide, or sodium hypo-
chlorite as the oxidant under biphasic reaction conditions. Pseudoenantiomeric[59]a catalysts 
19 and 20 derived from quinine and quinidine, respectively, produced opposite epoxide 
enantiomers. 
 
 
 
Scheme 2.17 First asymmetric Weitz-Scheffer epoxidation by Wynberg using N-benzylquininium or –quinidini-
um chloride 19 or 20 as chiral phase-transfer catalyst. 
 
The phase-transfer catalyzed nucleophilic asymmetric epoxidation for the first time provided 
access to enantiomerically enriched chalcone- and naphthoquinone-derived epoxides, and 
moreover, this approach represents one of the first methods in general for the synthesis of 
optically active epoxides. 
                                                 
a  Pseudoenantiomeric catalysts are diastereomers that afford antipodal products in catalytic asymmetric 
transformations. The configuration of catalysts 19 and 20 is inverted at C-8 and C-9 whereas it is identical at N-1, 
C-4, and C-5. Likewise, the starting materials, the naturally abundant cinchona alkaloids quinine and quinidine, 
are pseudoenantiomers themselves. 
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2.2.3 Synthetic Versatility of α,β-Epoxy Ketones 
Enantiomerically enriched α,β-epoxy ketones are of particular value due to their dense 
functionalization.[60] Such optically active epoxides may be transformed into numerous 
products (i. a. pharmaceuticals, agricultural chemicals, and fragrances), where it is distinctly 
advantageous to use chiral starting materials of high optical purity. Both the epoxide and the 
adjacent ketone group constitute the starting point for manifold transformations as depicted in 
Figure 2.2.[7, 60-61] Since epoxide opening almost invariably occurs with inversion of configu-
ration, the stereochemistry of the product can be reliably predicted. 
 
 
 
Figure 2.2 Selected one-step transformations of α,β-epoxy ketones. (Nu = nucleophile; E = electrophile) 
 
2.2.4 State of the Art: Catalytic Asymmetric Epoxidation of α,β-Unsaturated Ketones 
Since the pioneering report of Wynberg in 1976, the catalytic asymmetric epoxidation of α,β-
unsaturated ketones has been the subject of numerous investigations, and a number of useful 
methodologies have been developed.[8, 54] Moreover, the scope of asymmetric Weitz-Scheffer-
type epoxidations was extended to various electron-deficient olefins including nitro olefins[62] 
and α,β-unsaturated sulfones.[63] In the following section, the state of the art in catalytic 
asymmetric epoxidation of α,β-unsaturated ketones will be outlined. 
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2.2.3 Synthetic Versatility of α,β-Epoxy Ketones 
Enantiomerically enriched α,β-epoxy ketones are of particular value due to their dense 
functionalization.[60] Such optically active epoxides may be transformed into numerous 
products (i. a. pharmaceuticals, agricultural chemicals, and fragrances), where it is distinctly 
advantageous to use chiral starting materials of high optical purity. Both the epoxide and the 
adjacent ketone group constitute the starting point for manifold transformations as depicted in 
Figure 2.2.[7, 60-61] Since epoxide opening almost invariably occurs with inversion of configu-
ration, the stereochemistry of the product can be reliably predicted. 
 
 
 
Figure 2.2 Selected one-step transformations of α,β-epoxy ketones. (Nu = nucleophile; E = electrophile) 
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2.2.4.1 Asymmetric Phase-Transfer Catalysis 
Asymmetric phase-transfer catalysis (PTC) is a powerful strategy applicable to a wide range 
of transformations that proceed through anionic intermediates. 
The most commonly used phase-transfer catalysts for the catalytic asymmetric epoxidation of 
α,β-unsaturated ketones are alkylated Cinchona alkaloids. Based on the seminal studies of 
Wynberg et al. (cf. Chapter 2.2.2), contributions from several research groups during the late 
1990s led to dramatic improvements in terms of scope and level of enantioselection of the 
enone epoxidation. The groups of Lygo[64] and Corey[65] achieved significant improvements 
by structural modification of the original Wynberg-type phase-transfer catalysts 19 and 20 
(Scheme 2.17).[64-66] In particular, the introduction of a large 9-anthracenylmethyl group in 
place of the benzyl group at the quinuclidine nitrogen and a benzyl group on the secondary 
alcohol at C-9 in phase-transfer catalyst 21 was found to have a profound effect on the 
enantioselectivity of the epoxidation reaction (up to 99:1 er) (Scheme 2.18).[64a] Aqueous 
solutions of hypochlorites emerged as the oxidizing agents of choice giving superior results 
when compared to hydrogen peroxide, whenever O-alkylated Cinchona alkaloid-derived 
phase-transfer catalysts such as 21 were employed. Corey found that the use of freshly 
prepared 65% potassium hypochlorite at lower temperature instead of sodium hypochlorite 
led to further improvement in enantioselectivities.[65] 
 
 
Scheme 2.18 Asymmetric PTC: enone epoxidation according to Lygo and Corey with N-9-anthracenylmethyl-
O-benzyl-modified dihydroquinine-derived phase-transfer catalysts 21. 
 
Whereas the epoxidation reaction turned out to be general for a broad range of trans-chalcone 
derivatives, α,β-enones bearing alkyl substituents at the β-position furnished epoxides with 
reduced enantioselectivity. Moreover, substrates with enolizable alkyl groups adjacent to the 
ketone (substituent R2) gave only low conversions under the standard reaction conditions 
(<10%), and the starting material was recovered in high yield. Competing enolization is the 
most likely explanation for this observation.[67] 
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Recently, C2-symmetric axially chiral quaternary N-spiroammonium salts such as catalysts 
22a or 22b were introduced by the Maruoka group as powerful chiral phase-transfer 
catalysts.[68] By means of these catalysts, the high enantioselectivities achieved for chalcone-
type substrates were also retained for α,β-enones bearing alkyl substituents at the β-position, 
and moreover, for β-benzylidene-α-indanone and its tetralone analogue (Scheme 2.19). 
 
 
Scheme 2.19 Catalytic asymmetric epoxidation of α,β-unsaturated ketones (including β-benzylidene-α-
indanone) with PTCs 22a or 22b by Maruoka et al. 
 
2.2.4.2 Polyamino Acid-Mediated Epoxidation (Juliá-Colonna Epoxidation) 
The polyamino acid-catalyzed asymmetric epoxidation of α,β-unsaturated ketones was first 
reported by Juliá and Colonna and co-workers in the early 1980s.[69] The original reaction 
conditions were triphasic, consisting of the insoluble polyamino acid catalyst (poly-L-alanine 
(PLA) or poly-L-leucine (PLL)), an aqueous solution of sodium hydroxide, aqueous hydrogen 
peroxide as the oxidant, and a solution of chalcone in an organic solvent (Scheme 2.20). A 
range of α,β-enones, in particular chalcone and simple analogues, were epoxidized with high 
enantioselectivities (generally ≥ 95:5 er). It was found that the level of enantiocontrol of the 
epoxidation was dependent on the chain length of the polyamino acid and increased as the 
average chain length increased from 10 to 30 residues. Somewhat surprisingly, poly-L-valine 
emerged to be completely ineffective as epoxidation catalyst.[70] 
 
 
 
Scheme 2.20 Scope of the Juliá-Colonna epoxidation under triphasic reaction conditions. 
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Despite the excellent enantioselectivity, a number of problems limited the applicability of this 
methodology, namely the long reaction times even for relatively reactive substrates such as 
chalcone and the narrow substrate scope. In particular, enolizable substrates such as 
benzylidene acetone are found to be epoxidized very slowly or not at all. 
Extensive studies by Roberts and co-workers resulted in significant improvements to 
overcome these limitations. The modified reaction conditions comprised the use of a non-
aqueous solvent, an organic base (e. g. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)), water-
free oxidants such as urea-hydrogen peroxide (UHP) or percarbonate, along with 
immobilized poly-L-leucine as catalyst.[71] These non-aqueous, biphasic reaction conditions 
allowed for greatly enhanced reaction rates (from ca. 24 h to 30 min in the case of chalcone) 
and lower catalyst loadings (5 instead of 20 mol%). Moreover, substantial expansion of the 
range of α,β-enones was achieved and previously unreactive enolizable substrates such as 
benzylidene acetone as well as those bearing alkyl groups at the β-position readily underwent 
the epoxidation reaction (Scheme 2.21).[71c] 
 
 
Scheme 2.21 Expanded substrate scope under Robert’s biphasic reaction conditions.[71c] 
 
The mechanism of the polyleucine-catalyzed epoxidation is still under investigation.[57, 72] 
Kinetic studies indicate that the reaction proceeds via the reversible addition of polyleucine-
bound hydroperoxide to the enone.[73] 
 
2.2.4.3 Metal Peroxides in Combination with Chiral Ligands 
Several methods for the catalytic asymmetric epoxidation of α,β-unsaturated ketones rely on 
the use of a chiral ligand coordinated to the metal atom of a metal peroxide, which then 
effects a Weitz-Scheffer epoxidation. A number of metals and chiral ligands have been used 
for this purpose and the most successful approaches are discussed below. 
Jackson et al. had previously established the use of lithium tert-butylperoxide generated 
in situ from n-butyl lithium and tert-butyl hydroperoxide (TBHP) together with stoichiometric 
amounts of diethyl tartrate (DET) for the epoxidation of trans-chalcone resulting in moderate 
yield and enantioselectivity (81:19 er) of the chalcone epoxide (Scheme 2.22, (a)). However, 
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upon replacement of n-butyllithium by dibutylmagnesium, catalytic amounts of the chiral 
ligand DET and the base were sufficient to provide high levels of asymmetric induction on a 
range of chalcone-type substrates (Scheme 2.22, (b)).[74] 
 
 
 
Scheme 2.22 Jackson’s asymmetric chalcone epoxidation using either the (a) stoichiometric lithium tert-butyl 
peroxide−(+)-DET or the (b) catalytic magnesium tert-butyl peroxide−(+)-DET system. 
 
Intriguingly, the catalytic magnesium system provided epoxides antipodal to those obtained 
using stoichiometric lithium peroxides, despite employing the identical enantiomer of the 
chiral ligand (+)-DET. The Jackson group further optimized the magnesium-based catalyst 
system and identified conditions which not only tolerated chalcone-type substrates but were 
applicable to a variety of enolizable aliphatic enones without loss of catalyst efficiency 
(Scheme 2.23).[75] 
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hydroperoxide in combination with 4 Å molecular sieves at lower catalyst loadings of both 
dibutylmagnesium and diisopropyl tartrate further enhanced the operational simplicity and 
practicability of the process which was illustrated by a large scale synthesis of 4,5-epoxy-3-
hexanone in good yields along with improved enantioselectivity of 96.5:3.5 er (Scheme 2.23, 
(b)) compared to 85.5:14.5 er previously attained (Scheme 2.23, (a)).[75b] Jackson’s catalytic 
asymmetric epoxidation of aliphatic α,β-enones proceeds with the highest enantioselectivities 
obtained prior to this work for this substrate class. 
 
Probably the most general method for the catalytic asymmetric epoxidation of α,β-
unsaturated carbonyl compounds was developed by Shibasaki and co-workers and uses a 
combination of lanthanoid alkoxides and BINOL or its derivatives with alkyl hydroperoxides 
as the oxygen source.[76] Two types of catalyst systems exist: (a) one of them is represented 
by the general structure LnM3[(R)-BINOL] (Ln=lanthanoid, M=alkali metal) and comprises 
alkali metals whereas (b) the other one is alkali metal-free. In both cases oligomeric 
complexes between the lanthanoid metal and BINOL are formed. 
Alkali metal-free catalyst systems gave superior results in the catalytic asymmetric 
epoxidation of α,β-unsaturated ketones. The choice of the optimal lanthanoid metal depended 
on the nature of the enone substrate. The lanthanum-(R)-3-hydroxymethyl-BINOL complex 
(La-(R)-23a) in combination with cumyl hydroperoxide (CHP) was the ideal choice for the 
epoxidation of aromatic chalcone-type substrates (Scheme 2.24, (a)), whereas the catalytic 
activity for aliphatic α,β-unsaturated ketones could be improved by the use of ytterbium 
complexes along with TBHP as the oxidant (Scheme 2.24, (b)).[77] 
 
 
Scheme 2.24 Catalytic asymmetric epoxidation of α,β-unsaturated ketones with lanthanoid-BINOL complexes 
according to Shibasaki et al.[77a] 
 
Remarkably, the alkali metal-free complex ytterbium-(R)-3-hydroxymethyl-BINOL (Yb-(R)-
23a) converted cis-enones to the corresponding cis-epoxides in good yields and with high 
levels of asymmetric induction when using TBHP as the oxygen source (Scheme 2.25).[78] 
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Only for aromatic cis-enones (R2 = Ar) minor amounts (up to 32%) of the corresponding 
trans-epoxy ketones were formed at the same time. This report is remarkable since it 
constitutes one of the rare examples of the selective formation of cis-epoxides through 
nucleophilic epoxidation of cis-olefins.[67] 
 
 
Scheme 2.25 Catalytic asymmetric formation of cis-epoxides from cis-enones by Shibasaki et al.[78] 
 
Later on, Inanaga et al. found that the use of additives such as triphenylphosphine oxide or 
tris(4-flourophenyl)phosphine oxide led to enhanced reaction rates which allowed for 
significantly shortened reaction times (Scheme 2.26).[77c, 79] The optimized conditions applied 
best to chalcone-type substrates (up to >99.5:0.5 er) whereas simple aliphatic enones lagged 
behind in terms of the level of enantiocontrol (93.5:6.5 er with R1=PhCH2CH2, R2=Me). 
 
 
Scheme 2.26 Catalytic asymmetric epoxidation of α,β-unsaturated ketones with a lanthanum-BINOL complex 
and triarylphosphine oxide as additive according to Inanaga et al.[79b] 
 
According to the authors, the increased catalyst activity resulted from the deoligomerization 
of the lanthanoid-BINOL complexes through coordinative saturation of the lanthanoid metal 
with additional ligands.[79c] 
Shibasaki’s lanthanoid-BINOL and related catalyst systems proved to be very general,[76a] and 
found widespread application in the catalytic asymmetric epoxidation of α,β-unsaturated 
esters,[80] amides,[81] and several ester surrogates such as N-acylpyrroles[82] or imidazoles.[83] 
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2.2.5 Recent Advances: The Organocatalytic Approach 
This chapter focuses on catalytic asymmetric epoxidations of α,β-unsaturated carbonyl 
compounds mediated by small molecule organocatalysts such as (S)-proline and its 
derivatives. Recent advances within the realm of phase-transfer catalysis, the Julia-Colonna, 
and the Shi epoxidation, which can be considered borderline organocatalytic, were covered in 
the previous chapter (Chapter 2.2.4). 
 
2.2.5.1 Organocatalytic Asymmetric Epoxidation of α,β-Unsaturated Aldehydes 
The development of new organocatalytic methods − in particular of those based on iminium 
ion catalysis − for the asymmetric epoxidation of α,β-unsaturated carbonyl compounds has 
advanced this research field decisively by extending the substrate scope beyond ester, amide, 
and chalcone derivatives. 
In 2005, Jørgensen and co-workers presented the first direct catalytic asymmetric epoxidation 
of α,β-unsaturated aldehydes, a reaction that had remained a challenge to chemists.[84] Indeed 
direct approaches to enantiomerically enriched α,β-epoxy aldehydes were hitherto not 
available. In the presence of catalytic amounts of the chiral secondary amine α,α-[3,5-
bis(trifluoromethyl)phenyl]prolinol trimethylsilyl ether (24) and with aqueous hydrogen 
peroxide as the oxidant, a range of α,β-epoxy aldehydes could be obtained in high yields 
along with high enantioselectivities from both aromatic and aliphatic enals in a single step 
(Scheme 2.27). 
 
 
Scheme 2.27 First catalytic asymmetric epoxidation of α,β-unsaturated aldehydes by Jørgensen et al.[84] 
 
This seminal work also revealed the compatibility of amine catalysts with various oxidants 
and dispelled scepticism, which predicted severe difficulties from catalyst degradation via 
competing catalyst N-oxidation. 
Alternative protocols for the catalytic asymmetric epoxidation of α,β-unsaturated aldehydes 
based on iminium ion activation were developed by the MacMillan and List groups. 
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MacMillan and co-workers identified chiral imidazolidinone 25 as its perchlorate salt to 
effectively mediate the epoxidation reaction with hypervalent iodine reagents as oxidants 
(which are rarely used in nucleophilic epoxidation reactions) (Scheme 2.28).[85] A mechanistic 
study with 15N labelled imidazolidinone catalyst 25 revealed that iodosobenzene indeed 
brought about slow catalyst degradation by oxidation. Thus, key to achieving high levels of 
both reaction efficiency and enantioselectivity was the use of [(N-Nosylimino)iodo]benzene 
(PhI=NNs) as an iodosobenzene surrogate which, in the presence of acetic acid, provided a 
slow release of iodosobenzene over time (‘internal syringe pump’). 
 
 
Scheme 2.28 Catalytic asymmetric epoxidation of α,β-unsaturated aldehydes by MacMillan et al. 
 
List and Wang successfully applied the ACDC concept to the catalytic asymmetric 
epoxidation of α,β-unsaturated aldehydes.[38a] Among all combinations tested, catalyst salt 
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MacMillan and co-workers identified chiral imidazolidinone 25 as its perchlorate salt to 
effectively mediate the epoxidation reaction with hypervalent iodine reagents as oxidants 
(which are rarely used in nucleophilic epoxidation reactions) (Scheme 2.28).[85] A mechanistic 
study with 15N labelled imidazolidinone catalyst 25 revealed that iodosobenzene indeed 
brought about slow catalyst degradation by oxidation. Thus, key to achieving high levels of 
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2  Background 
28 
Remarkably, symmetrically β,β-disubstituted enals such as senecialdehyde (3-methylbutenal) 
gave the desired epoxides with excellent enantioselectivities up to 97:3 er in the presence of 
the ACDC catalyst [10 • (R)-TRIP] (Scheme 2.30, (a)). This represents a great advancement 
compared to the results obtained with the catalyst system described by Jørgensen and co-
workers, where this substrate class was converted into the corresponding epoxides with 
significantly lower enantioselectivities (87.5:12.5 er; cf. Scheme 2.30, (a)). Moreover, this 
observation raises interesting mechanistic questions. Since the initial conjugate addition 
product is achiral, the stereogenic center is created during the epoxide ring closure. 
Consequently, the chiral BINOL phosphate (R)-TRIP (7a) must be involved in this C−O 
bond-forming event and presumably assists the enantioselective cyclization of the achiral 
peroxyenamine intermediate (Scheme 2.30, (b)). 
 
 
Scheme 2.30 (a) Catalytic asymmetric epoxidation of senecialdehyde according to List and Wang; (b) Proposed 
reaction pathway. 
 
2.2.5.2 Organocatalytic Asymmetric Epoxidation of α,β-Unsaturated Ketones 
Unfortunately, secondary amine catalysts such as trimethylsilyl diarylprolinol ether 24 and 
related compounds which efficiently mediated the catalytic asymmetric epoxidation of α,β-
unsaturated aldehydes turned out to be less active to completely inactive for the epoxidation 
of α,β-unsaturated ketones. 
Lattanzi and later Zhao and co-workers identified unprotected α,α-diarylprolinol derivatives 
such as 26a or 26b and other structurally diverse β-amino alcohols to provide an effective 
platform for the epoxidation of an array of electron deficient olefins including α,β-
unsaturated ketones with tert-butylhydroperoxide as the oxidant (Scheme 2.31, (a) and (b)).[86] 
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Scheme 2.31 Catalytic asymmetric epoxidation of electron deficient olefins including α,β-unsaturated ketones 
by (a) Lattanzi[86c] and (b) Zhao et al.[86j] 
 
Within these reports it was proposed by the authors that α,α-diarylprolinol catalysts may be 
operating through hydrogen bonding interactions. TBHP may be activated via general base 
catalysis by the prolinol derivative (Figure 2.3). 
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Figure 2.3 Proposed mode of activation of electron deficient olefins by diarylprolinol derivatives via 
hydrogen bonding interaction. (R1 = Ar, Alk; R2 = Ar, Alk, CO2R, CCl3, CF3) 
 
The formation of iminium ions between α,β-unsaturated ketones and catalysts 26a-b as an 
alternative activation pathway was ruled out by the authors given the known unreactive nature 
of enone carbonyls and the detrimental effect of an acid co-catalyst on the outcome of those 
reactions. a  Moreover, a strong solvent effect could be detected further supporting the 
involvement of non-covalent hydrogen bonding interactions. However, whereas this method 
is well developed for chalcone and derivatives, it was scarcely applied to simple aliphatic 
enones, and when so, giving inferior results and enantioselectivities of 87.5:12.5 er at the 
most. In addition, the present epoxidation protocol requires the use of TBHP as the oxidant. 
Aqueous hydrogen peroxide which is an inexpensive and environmentally benign alternative 
cannot be employed.[86f] 
                                                 
a Although smaller in number, reports exist which denote the activation of enone systems as iminium ion in the 
presence of secondary amine (salt) catalysts. 
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Furthermore, chiral guanidines have been explored as base catalysts in the nucleophilic 
epoxidation of different types of α,β-enones. Promising, but not yet fully satisfactory levels of 
stereocontrol have been achieved to date by means of this approach.[87] In contrast, chiral 
guanidinium salts as well as bifunctional guanidinium-urea and guanidinium-hydroxyl 
organocatalysts delivered α,β-epoxy ketones mostly derived from chalcone-type substrates in 
high yields and with good to high enantioselectivities with either hydrogen peroxide or TBHP 
as the oxidant.[88] 
A catalytic asymmetric epoxidation of α,β-unsaturated ketones truly relying on iminium ion 
activation of the enone carbonyls and a method giving highly enantioenriched α,β-epoxy 
ketones from simple aliphatic enones had not been put into practice prior to this work. 
 
2.2.6 Asymmetric Epoxidation of Cyclic α,β-Unsaturated Ketones 
Cyclic enones constitute a special class of α,β-unsaturated ketones. Up to a ring size with 
n ≤ 4, they feature a (Z)-configured double bond as well as a rigid s-trans conformation of the 
enone moiety in their thermodynamically stable form (Scheme 2.32). 
 
Scheme 2.32 Asymmetric epoxidation of simple cyclic enones. 
 
Strained (E)-2-cycloheptenone (n = 2), -octenone (n = 3), and –nonenone (n = 4) can only be 
generated via photoisomerization.[89] As the ring size increases, the amount of strain decreases 
and (E)-configured cycloalkenones (n ≥ 5) are the stable isomers. 
Cyclic systems (n ≤ 4) are restricted to the s-trans conformation, which avoids problems 
arising from s-cis/s-trans interconversion. By contrast, in open-chain systems the equilibrium 
between the s-cis and s-trans conformer has to be taken into account. Based on this, one 
might suspect that the minimal conformational flexibility inherent in cyclic enones would 
facilitate their asymmetric epoxidation. Yet, the asymmetric epoxidation of s-trans-fixed 
cyclic enones under Weitz-Scheffer conditions has been little studied to date. Indeed, some 
asymmetric Weitz-Scheffer-epoxidations rigorously require s-cis conformation of acceptors, 
and are thus not applicable to cyclic enones.[90] Successful implementations of cyclic enones 
in asymmetric nucleophilic epoxidations had been limited to particular substrate classes such 
as benzoquinone,[91] naphthoquinones,[92] the respective monoketals,[93] isoflavones,[94] and 
perinaphthenone prior to this work.[67] 
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Until 2008, to the best of our knowledge, there was not a single general method available 
which would allow for the highly enantioselective (catalytic) epoxidation of simple cyclic 
enones.[95] The literature precedence for the (catalytic) asymmetric epoxidation of 2-
cyclohexenone is compiled in Table 2.1. 
 
Table 2.1 Comprehensive data for the (catalytic) asymmetric epoxidation of 2-cyclohexenone. 
 
 
 
 
 
The highest enantioselectivity of 81.5:18.5 er was attained by Baba and co-workers in 1986 
by using a quinine-derived bis(phase-transfer catalyst) 27 together with 9-methylflourenyl 
hydroperoxide (28) as the oxidant (Table 2.1).[95-96] All other attempts gave inferior results.[69a, 
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cyclohexenone, but not so for 3-methyl-2-cyclohexenone since this olefin may be too 
sterically crowded to be epoxidized with tert-butylhydroperoxide.[97a] 
The development of a highly enantioselective and general catalytic epoxidation of cyclic 
enones was desirable in light of the synthetic value of enantiomerically pure cyclic α,β-epoxy 
ketones,[98] and even more so due to the absence of such a method prior to this work.a 
 
2.3 Synthesis and Relevance of 3-Hydroxy-1,2-dioxolanes and 1,2-Dioxolanes 
3-Hydroxy-1,2-dioxolanes (Scheme 2.33) and 1,2-dioxolanes are organic peroxides. Both 
contain an O-O bond embedded in a five-membered ring. 3-Hydroxy-1,2-dioxolanes are 
cyclic peroxyhemiketals of β-hydroperoxy carbonyl compounds with the equilibrium 
distribution being dependent on the precise structure and substitution pattern of those 
compounds. However, monocyclic peroxyhemiketals are of remarkable stability and the 
content of the ring-opened form in the equilibrium mixture is low as detected by 13C NMR 
(no carbonyl resonances) (vide infra). 
 
 
Scheme 2.33 Equilibrium between cyclic peroxyhemiketals and β-hydroperoxy carbonyl compounds. 
 
Peroxide-containing natural products, including several examples of 3-hydroxy-1,2-
dioxolanes and related ring systems, occur widely in nature and often possess desirable 
pharmacological properties as pointed out in the following section.[99] 
 
2.3.1 Peroxidic Natural Products 
The most prominent example among all peroxide natural products is the active antimalarial 
agent sesquiterpene 1,2,4-trioxane artemisinin (qinghaosu, 30) isolated from the common 
shrub Artemisia annua (sweet wormwood) (Figure 2.4).[100] Similar antimalarial activities 
were found for the naturally occurring peroxides yingzhaosu A (31) and yingzhaosu C (32) 
containing a 1,2-dioxane core structure.[101] 
 
                                                 
a The asymmetric epoxidation of higher homologues has indeed not been studied at all and for the asymmetric 
epoxidation of cyclopentenone only one literature report is known to date.[96d] 
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Figure 2.4 Peroxidic natural products with antimalarial activity. 
 
However, the most aggressive parasite, Plasmodium falciparum, is showing first resistance 
effects to artemisinin and its semisynthetic derivatives.[102] Consequently, there is an urgent 
need for the development of new effective antimalarial remedies. Synthetic cyclic peroxides 
command increasing attention. They offer a structurally simpler, synthetically readily 
accessible alternative to artemisinin (30) and its analogues. Therefore, much effort is devoted 
to the development of new strategies for the synthesis of novel cyclic peroxidic compounds of 
diverse structures to identify a promising new lead in search of efficient antimalarials.[103] 
Strikingly, tetroxane 33, trioxane 34, or trioxolane 35 show artemisinin-like antimalarial 
activity although their carbocyclic skeletons bear no resemblance to that of artemisinin 
(Figure 2.5).[103-104] 
 
 
 
Figure 2.5 Potent antimalarial drug candidates: tetroxane 33, trioxane 34, and trioxolane 35. 
 
Accordingly, it is not necessary to simulate the artemisinin framework to secure superior 
antimalarial potency. The indispensable feature for antimalarial efficacy appears to be the 
peroxide unit.[105] 
Naturally occurring five-membered cyclic peroxides containing a 1,2-dioxolane unit such as 
plakinic acid A 36a (a member of the plakinic acid natural products family characterized by a 
common 1,2-dioxolane-3-acetic acid “head” and different aliphatic “tails”),[106] or mycan-
gimycin 37, but also synthetic 1,2-dioxolane-based analogues display anticancer, antifungal, 
and antiplasmodial activity (Figure 2.6).[107] 
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Figure 2.6 Naturally occurring plakinic acid A (36a) and mycangimycin (37). 
 
2.3.2 General Methods for the Synthesis of 3-Hydroxy-1,2-dioxolanes 
The methods to introduce a peroxide functionality into organic compounds are limited. In the 
synthesis of most peroxides, irrespective of their structural complexity, the peroxide moiety is 
pre-formed and introduced as either a) molecular oxygen (through a reaction with singlet 
oxygen or radical trapping with triplet oxygen), b) by nucleophilic addition of hydrogen or 
alkyl peroxides, or c) by reaction with ozone.[108] 
Syntheses of 3-hydroxy-1,2-dioxolanes (cf. Scheme 2.33) have been achieved by various 
methods.[109] Currently available methodologies mainly rely on the reaction of hydrogen 
peroxide or singlet oxygen with α,β-unsaturated carbonyl compounds or exploit the aerobic 
oxidation of cyclopropanols. These methods will be briefly introduced in the following 
sections. A direct enantioselective approach to 3-hydroxy-1,2-dioxolanes from simple, readily 
available starting materials had not been described prior to this work. 
 
2.3.2.1 Aerobic Oxidation of Cyclopropanol Derivatives 
Cyclopropanols undergo ring-opening under metal-catalyzed aerobic oxidation; when 
subjected to single-electron oxidants Fe(acac)3, Cu(acac)2, VO(acac)2, or Mn(II) abietate 
under an atmosphere of oxygen, they are converted to β-hydroperoxo ketones which exist in 
equilibrium predominantly as the cyclic peroxyhemiketals (vide infra, Scheme 2.34).[110] 
Among the metal salts listed above, Mn(II) abietate and Mn(II) acetylacetonate did not only 
mediate the aerobic oxidation of bicyclic cyclopropanols but also of simple, readily available 
cyclopropanols of the general structure 38.[110d] The reaction proceeds via the successive 
formation of an alkoxy radical 39 and a β-carbonyl radical 40. The oxidation of cyclopropanol 
derivatives provides expedient access to cyclic peroxyhemiketals 41a; yet, this transformation 
holds little promise for the development of an asymmetric version since it proceeds through a 
radical pathway involving the ablation of preexisting stereocenters. 
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Scheme 2.34 Aerobic oxidation of cyclopropanols 38 to cyclic peroxyhemiketals 41a.[110d] 
 
2.3.2.2 Nucleophilic Addition of Peroxides to α,β-Unsaturated Ketones 
Nucleophilic conjugate addition of alkaline hydrogen peroxide to α,β-unsaturated ketones 16 
generates β-peroxyenolate intermediates 17 which undergo ring closure to form α,β-
epoxyketones 18 (cf. Scheme 2.16). Alternatively, intermediates 17 can be intercepted by 
protonation to afford cyclic peroxyhemiketals 41a (Scheme 2.35). 
 
 
Scheme 2.35 Competing reaction pathways under Weitz-Scheffer reaction conditions: epoxide formation vs. 
protonation of β-peroxyenolate intermediate 17. (Base = i.a. NaOH, LiOH, t-BuNH2) 
 
Although β-peroxyenolates 17 show an overwhelming preference for epoxide formation, 
cyclic peroxyhemiketals of type 41a have occasionally been observed as by-products of 
Weitz-Scheffer-type epoxidations of α,β-unsaturated ketones 16. Their formation was first 
noticed in 1950 by Nazarov and Akhrem who studied the epoxidation of mesityl oxide.[111] 
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Although this method provides in most cases low yields (< 20%) of 3-hydroxy-l,2-dioxolanes, 
it is highly valuable and still used on a preparative scale due to the limited number of 
operationally simple alternative approaches to this substrate class.[114] Extension of this 
approach to an asymmetric route to 3-hydroxy-l,2-dioxolanes seems feasible since it has 
previously been demonstrated in the context of asymmetric Weitz-Scheffer-type epoxidations, 
that it is possible to render the conjugate addition of hydrogen peroxide to α,β-unsaturated 
carbonyl compounds enantioselective in the presence of a chiral catalyst. 
 
2.3.2.3 Singlet Photooxygenation 
Akin to the reaction with alkaline hydrogen peroxide (vide supra), photooxygenation with 
singlet oxygen (1O2) provides direct access to 3-hydroxy-1,2-dioxolanes from α,β-unsaturated 
carbonyl compounds in a single step. As shown in Scheme 2.36, (a), pulegone (42) readily 
reacts with singlet oxygen to give ene adduct 43b, which spontaneously cyclizes to the 
corresponding peroxyhemiketal 43a.[115] Analogous results were obtained with α,β-
unsaturated aldehydes: tiglic aldehyde (44) gave peroxyhemiacetal 45 in 96% yield (Scheme 
2.36, (b)).[116] α,β-Unsaturated carbonyl compounds with fixed s-cis conformation are more 
rapidly oxidized by singlet oxygen than conformationally flexible substrates whereas those 
substrates which are constrained to the s-trans conformation did not participate at all in the 
reaction. 
 
 
Scheme 2.36 Photooxygenation of α,β-unsaturated carbonyl compounds with singlet oxygen.[115-116] 
 
The oxidative thermolysis of cyclic α-azo hydroperoxides developed by Baumstark et al. 
demonstrates an alternative method for the direct synthesis of 3-hydroxy-1,2-dioxolanes.[117] 
Dussault and co-workers have disclosed stereoselective routes to 3-alkoxy-substituted-1,2-
dioxolanes. Methoxymethyl (MOM)-protected 3-hydroxy-1,2-dioxolanes were obtained via 
regio- and diastereoselective photooxygenations of chiral, racemic (Z)-allylstannanes by 
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singlet oxygen.[118] Stereospecific cyclization of hydroperoxy acetals onto chiral, 
enantiomerically enriched oxetanes furnished optically active 3-methoxy-1,2-dioxolanes,[119] 
a strategy which was later exploited in the context of the synthesis of plakinic acid A 
(36a).[106] 
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3 Objectives of this Ph.D. Work 
 
The vast majority of organic compounds contain oxygenated functionalities. One of the main 
pathways for the introduction of oxygen into organic molecules is via the epoxidation of carbon-
carbon double bonds. Thus, olefin epoxidation constitutes a central transformation in organic 
chemistry and one of the main routes to access epoxides on both a laboratory and an industrial scale. 
Asymmetric olefin epoxidation, in particular catalytic asymmetric olefin epoxidation, has gained 
increasing importance since optically active epoxides are valuable chiral building blocks and versatile 
synthetic intermediates.[8] Their enantioselective production is a subject of considerable interest for 
academia as well as for industry. In view of the industrial applicability, catalytic asymmetric 
epoxidation methods should employ considerably safe oxidants and produce little waste. Hydrogen 
peroxide meets these criteria. It is low in cost, safe to handle, readily available, and generates water as 
the only by-product. Hence, it is probably the best oxidant with respect to environmental and 
economic considerations.a, [120] 
 
Despite the wealth of catalytic asymmetric epoxidations of α,β-unsaturated ketones, particular 
substrate classes still pose a challenge to synthetic chemists. Indeed, most methods described 
to date are tailored to chalcone-type substrates but give inferior results with other enone 
classes. For instance, a highly enantioselective epoxidation of simple cyclic enones (such as 
cyclohexenone) has not been reported thus far (cf. Chapter 2.2.6). Similarly, there is no 
general method for the epoxidation of enolizable aliphatic acyclic enones, let alone using 
hydrogen peroxide as the oxidant (cf. Chapter 2.2.4). The related peroxidation of ketones, 
which generates the synthetically and medicinally relevant 1,2-dioxolane unit, is equally 
orphaned of any catalytic asymmetric method that proceeds with high enantioselectivity. 
 
The goal of this Ph.D. work was to develop an efficient and general method for the catalytic 
asymmetric epoxidation of cyclic as well as acyclic α,β−unsaturated ketones with hydrogen 
peroxide as environmentally benign and atom-economic oxidant. In the event, our work also 
allowed the serendipitous discovery of a highly enantioselective catalytic hydroperoxidation 
of enones which directly delivers the valuable 3-hydroxy-1,2-dioxolane-moiety. 
 
Recently, iminium ion catalysis was successfully applied to the enantioselective epoxidation 
of α,β-unsaturated aldehydes by the groups of Jørgensen, MacMillan, and our group using 
                                                 
a Indeed, in certain circumstances, hydrogen peroxide is even better than oxygen insofar as oxygen-organic 
mixtures are prone to spontaneous ignition. 
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catalytic amounts of chiral secondary amines or amine salts (cf. Section 2.2.5.1).[84-85, 121] 
Inspired by these findings, we reasoned that it should be possible to develop a conceptually 
similar asymmetric Weitz-Scheffer-type epoxidation of α,β-unsaturated ketones with 
hydroperoxides as potential oxidants (Scheme 3.1).[55a] 
 
 
Scheme 3.1 Intended organocatalytic asymmetric epoxidation of (cyclic and acyclic) α,β-unsaturated ketones. 
 
However, for the activation of α,β-unsaturated ketones as iminium ion, primary amine salts 
have emerged as superior catalysts in many cases due to steric constraints.[45b] In particular, 
the successful application of chiral primary amine salt [(S)-9 • (R)-TRIP] in the catalytic 
asymmetric transfer hydrogenation of cyclic as well as acyclic enones established in our 
group (Scheme 3.2),[38c] encouraged us to accept the challenge of developing a catalytic 
asymmetric epoxidation process of such substrates based on the same concept. 
 
 
Scheme 3.2 Catalytic asymmetric transfer hydrogenation of α,β-unsaturated ketones catalyzed by chiral 
primary amine salt [(S)-9 • (R)-TRIP (7a)]. 
 
The common feature of catalysts [10 • (R)-TRIP]a (cf. Scheme 2.29) and [(S)-9 • (R)-TRIP] 
developed in our group for the enantioselective epoxidation of α,β-unsaturated aldehydes and 
transfer hydrogenation of enones, respectively, is the chiral counteranion TRIP. In the enal 
epoxidation, TRIP is the single source of chiral information in the system, whereas in the 
enone reduction the matched combination of (R)-TRIP with (S)-valin-tert-butyl ester (9) 
                                                 
a [bis(3,5-bis(trifluoromethyl)benzyl)amine (10) • (R)-TRIP (7a)]. 
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accounts for excellent enantioselectivities. Thus, both methods illustrate successful 
implementations of the ACDC-concept in asymmetric catalysis (see Section 2.1.3.1). 
Our strategy for the catalytic asymmetric epoxidation is outlined in the following section. 
Mechanistically, the reaction was envisaged to proceed via asymmetric iminium ion catalysis 
by means of a chiral primary amine salt [R-NH2 • HX]* (Figure 3.1). Initial reversible 
formation of iminium ion A may effectively lower the LUMO energy of the substrate and 
thus activate the enone (e.g. 2-cyclohexenone (46a)) for the enantioselective conjugate 
addition of hydroperoxide ROOH (R = H, Alk). Subsequent intramolecular nucleophilic 
substitution at the proximal oxygen atom may break the weak peroxide bond of β-peroxy 
enamine intermediate B and close the epoxide ring. Finally, hydrolysis of α,β-epoxy iminium 
ion C releases the product (e.g. 2,3-epoxycyclohexanone (48a)) and regenerates the catalyst. 
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Figure 3.1 Proposed catalytic cycle for the asymmetric epoxidation of α,β-unsaturated ketones, as 
exemplified by the reaction of 2-cyclohexenone (46a), catalyzed by a chiral primary amine salt [R-NH2 • HX]*. 
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4 Results and Discussion 
Simple cyclic enones have generally been omitted within the vast majority of studies on the 
asymmetric epoxidation of α,β-unsaturated ketones. Thus, we decided to focus on these 
challenging cyclic substrates as a departure point before extending the methodology to 
different types of α,β-unsaturated ketones. 
 
4.1 Catalytic Asymmetric Epoxidation of Cyclic Enones 
4.1.1 Screening Studies 
The screening studies were carried out in a collaborative effort with X. Wang. 
4.1.1.1 Development and Optimization of the Catalytic System 
Initial experiments were devoted to identifying an effective system for the catalytic 
asymmetric epoxidation of cyclic enones employing 2-cyclohexenone (46a) as the model 
substrate. The results of our comprehensive screening studies are summarized in Table 4.1. At 
the outset, we tested dibenzylamine together with (S)-TRIP [50 • (S)-TRIP], a combination, 
which had previously emerged as an efficient catalyst system for the asymmetric epoxidation 
of α,β-unsaturated aldehydes developed by X. Wang in our group (cf. Scheme 2.29).[38a] 
Aqueous hydrogen peroxide was chosen as the oxidant and reactions were conducted in 
dioxane (0.25 M) at 50 °C. Yet, the activity of [50 • (S)-TRIP] in the asymmetric epoxidation 
of 2-cyclohexenone (46a) was rather low and moreover, 2,3-epoxycyclohexanone (48a) was 
generated with only low enantioselectivity (entry 1). Chiral primary amine salt [(S)-9 • (R)-
TRIP] had proven to be a powerful catalyst for the asymmetric transfer hydrogenation of 
cyclic and acyclic ketones (cf. Scheme 3.2).[38c] However, [(S)-9 • (R)-TRIP] as well as its 
diastereomeric salt [(S)-9 • (S)-TRIP] performed worse in the asymmetric epoxidation of 2-
cyclohexenone (46a) and afforded epoxide 48a with low enantiomeric excess albeit in good 
yields (entries 2-3). In the presence of the amino acid (S)-tert-leucine (51), the desired product 
was formed with moderate enantioselectivity of 73.5:26.5 er, yet again at very low rates 
(entry 4). Its tert-butyl ester 52, however, did not mediate the epoxidation reaction (entry 5). 
In contrast, the combination with (R)-TRIP gave epoxide 48a in high yield and slightly higher 
optical purity than that attained with the corresponding salt [(S)-9 • (R)-TRIP] derived from 
(S)-valine (entry 6 vs. entry 3). This result nicely illustrates the crucial effect of an acid co-
catalyst (or acidic functionality embedded in the catalyst motif) in the present transformation. 
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Notably, (S)-proline (1) displayed high catalytic activity but generated epoxide 48a with low 
enantioselectivity (entry 7).[27a-c, 122] 
 
Table 4.1 Evaluation of various catalyst systems for the catalytic asymmetric epoxidation of 2-
cyclohexenone (46a). 
 
Entry               Amine Acid co-catalyst [mol%] t [h] Yield [%]a erb 
1  50 (S)-TRIP 10 72 22 58:42 
2 
 
(S)-9 
(S)-TRIP 10 24 92 56:44 
3 (R)-TRIP 10 24 73 62:38 
4 
 
(S)-51 - - 72 30 73.5:26.5 
5 
 
(S)-52 
- - 72 - - 
6 (R)-TRIP 10 72 95 67.5:32.5 
7 (S)-proline 1 - - 72 90 58.5:41.5 
8 
 
53 (R)-TRIP 10 48 85 66:34 
9 
 
54 (R)-TRIP 10 48 >99 73.5:26.5 
10 NH2
 
55 (R)-TRIP 10 24 95 59:41 
11 
 
56 (R)-TRIP 10 24 99 59.5:40.5 
12 
 
(S)-57 
(S)-TRIP 10 24 >99 55.5:44.5 
13 (R)-TRIP 10 24 >99 56:44 
14 
 
(S)-58 
(S)-TRIP 10 24 >99 75:25 
15 (R)-TRIP 10 24 >99 80:20 
aDetermined by GC. bDetermined by chiral GC. 
 
Next, we turned our attention to salts of primary aromatic amines. A broad variety of aniline 
derivatives were evaluated with p-methoxyphenyl amine (53) and 2-amino fluorene (54) in 
combination with TRIP giving the best results with good yields and enantiomeric ratios of up 
to 73.5:26.5 er (entries 8-9).[123] In contrast, benzyl amines 55 and 56 showed superior 
catalytic activity, yet induced lower levels of enantioselectivity (entries 10-11). 
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At this point, we speculated that the use of a bifunctional amine catalyst might benefit the 
catalyst efficiency. A directing group in close proximity to the primary amine functionality 
could direct the attack of the hydroperoxide nucleophile as suggested in Figure 4.1. 
 
 
Figure 4.1 Pre-transition state assembly invoking a directing effect of a bifunctional amine catalyst. (FG = i. a. 
OH, NH2) 
 
Based on this hypothesis, we tested various chiral amino alcohols such as (S)-2-amino-2-
phenylethanol (57) and (S)-2-amino-1,1,2-triphenylethanol (58) with the latter being sterically 
encumbered and conformationally rigidified due to the geminal diphenyl substitution (entries 
12-15). Indeed, amino alcohol (S)-58 in combination (R)-TRIP gave full conversion after 24 
hours along with an increased enantiomeric ratio of 80:20 which was the highest observed at 
this point of the screening experiments (entry 15). 
 
Encouraged by this result, we went on to study different types of bifunctional primary amines 
among them (S)-BINAM (2,2'-diamino-1,1'-binaphthalene; 59), (R,R)-DACH (1,2-
diaminocyclohexane; 60), (R,R)-DPEN (1,2-diphenylethylenediamine; 12), (R,R)-DPEN 
derivative 61, (S)-2-aminomethylpyrrolidine (62), as well as primary amines derived from 
naturally occurring Cinchona alkaloids (Table 4.2). In particular, the TFA salts of (R,R)-
DPEN 12 and 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) emerged as powerful catalysts 
giving the desired epoxide 48a with high yield and enantiomeric ratios of 95:5 and 96:4 er, 
respectively (entries 3 and 5). Notably, truncated forms of 13, the 2-aminomethyl quinuc-
lidines 63 and 64, proved to be highly active, yet less enantioselective (entries 7-12). 
4 Results and Discussion 
 43
At this point, we speculated that the use of a bifunctional amine catalyst might benefit the 
catalyst efficiency. A directing group in close proximity to the primary amine functionality 
could direct the attack of the hydroperoxide nucleophile as suggested in Figure 4.1. 
 
 
Figure 4.1 Pre-transition state assembly invoking a directing effect of a bifunctional amine catalyst. (FG = i. a. 
OH, NH2) 
 
Based on this hypothesis, we tested various chiral amino alcohols such as (S)-2-amino-2-
phenylethanol (57) and (S)-2-amino-1,1,2-triphenylethanol (58) with the latter being sterically 
encumbered and conformationally rigidified due to the geminal diphenyl substitution (entries 
12-15). Indeed, amino alcohol (S)-58 in combination (R)-TRIP gave full conversion after 24 
hours along with an increased enantiomeric ratio of 80:20 which was the highest observed at 
this point of the screening experiments (entry 15). 
 
Encouraged by this result, we went on to study different types of bifunctional primary amines 
among them (S)-BINAM (2,2'-diamino-1,1'-binaphthalene; 59), (R,R)-DACH (1,2-
diaminocyclohexane; 60), (R,R)-DPEN (1,2-diphenylethylenediamine; 12), (R,R)-DPEN 
derivative 61, (S)-2-aminomethylpyrrolidine (62), as well as primary amines derived from 
naturally occurring Cinchona alkaloids (Table 4.2). In particular, the TFA salts of (R,R)-
DPEN 12 and 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) emerged as powerful catalysts 
giving the desired epoxide 48a with high yield and enantiomeric ratios of 95:5 and 96:4 er, 
respectively (entries 3 and 5). Notably, truncated forms of 13, the 2-aminomethyl quinuc-
lidines 63 and 64, proved to be highly active, yet less enantioselective (entries 7-12). 
4 Results and Discussion 
 43
At this point, we speculated that the use of a bifunctional amine catalyst might benefit the 
catalyst efficiency. A directing group in close proximity to the primary amine functionality 
could direct the attack of the hydroperoxide nucleophile as suggested in Figure 4.1. 
 
 
Figure 4.1 Pre-transition state assembly invoking a directing effect of a bifunctional amine catalyst. (FG = i. a. 
OH, NH2) 
 
Based on this hypothesis, we tested various chiral amino alcohols such as (S)-2-amino-2-
phenylethanol (57) and (S)-2-amino-1,1,2-triphenylethanol (58) with the latter being sterically 
encumbered and conformationally rigidified due to the geminal diphenyl substitution (entries 
12-15). Indeed, amino alcohol (S)-58 in combination (R)-TRIP gave full conversion after 24 
hours along with an increased enantiomeric ratio of 80:20 which was the highest observed at 
this point of the screening experiments (entry 15). 
 
Encouraged by this result, we went on to study different types of bifunctional primary amines 
among them (S)-BINAM (2,2'-diamino-1,1'-binaphthalene; 59), (R,R)-DACH (1,2-
diaminocyclohexane; 60), (R,R)-DPEN (1,2-diphenylethylenediamine; 12), (R,R)-DPEN 
derivative 61, (S)-2-aminomethylpyrrolidine (62), as well as primary amines derived from 
naturally occurring Cinchona alkaloids (Table 4.2). In particular, the TFA salts of (R,R)-
DPEN 12 and 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) emerged as powerful catalysts 
giving the desired epoxide 48a with high yield and enantiomeric ratios of 95:5 and 96:4 er, 
respectively (entries 3 and 5). Notably, truncated forms of 13, the 2-aminomethyl quinuc-
lidines 63 and 64, proved to be highly active, yet less enantioselective (entries 7-12). 
4 Results and Discussion 
 43
At this point, we speculated that the use of a bifunctional amine catalyst might benefit the 
catalyst efficiency. A directing group in close proximity to the primary amine functionality 
could direct the attack of the hydroperoxide nucleophile as suggested in Figure 4.1. 
 
 
Figure 4.1 Pre-transition state assembly invoking a directing effect of a bifunctional amine catalyst. (FG = i. a. 
OH, NH2) 
 
Based on this hypothesis, we tested various chiral amino alcohols such as (S)-2-amino-2-
phenylethanol (57) and (S)-2-amino-1,1,2-triphenylethanol (58) with the latter being sterically 
encumbered and conformationally rigidified due to the geminal diphenyl substitution (entries 
12-15). Indeed, amino alcohol (S)-58 in combination (R)-TRIP gave full conversion after 24 
hours along with an increased enantiomeric ratio of 80:20 which was the highest observed at 
this point of the screening experiments (entry 15). 
 
Encouraged by this result, we went on to study different types of bifunctional primary amines 
among them (S)-BINAM (2,2'-diamino-1,1'-binaphthalene; 59), (R,R)-DACH (1,2-
diaminocyclohexane; 60), (R,R)-DPEN (1,2-diphenylethylenediamine; 12), (R,R)-DPEN 
derivative 61, (S)-2-aminomethylpyrrolidine (62), as well as primary amines derived from 
naturally occurring Cinchona alkaloids (Table 4.2). In particular, the TFA salts of (R,R)-
DPEN 12 and 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) emerged as powerful catalysts 
giving the desired epoxide 48a with high yield and enantiomeric ratios of 95:5 and 96:4 er, 
respectively (entries 3 and 5). Notably, truncated forms of 13, the 2-aminomethyl quinuc-
lidines 63 and 64, proved to be highly active, yet less enantioselective (entries 7-12). 
4  Results and Discussion 
44 
Table 4.2 Evaluation of various bifunctional amine salts for the catalytic asymmetric epoxidation of 2-
cyclohexenone (46a). 
 
Entry Amine Acid co-catalyst [mol%] Yield [%]a erb 
1 
 
(S)-59 TFA 10 71 38:62 
2 
 
(R,R)-60 TFA 10 98 82:18 
3  
(R,R)-DPEN 
(R,R)-12 TFA 10 95 95:5 
4 
 
(R,R)-61 TFA 10 77 93:7 
5 
 
9-NH2-epiQ 
13 TFA 20 76 4:96 
6 
 
(S)-62 (S)-TRIP 10 84 94:6 
7c 
 
(8S)-63 TFA 10 >99 56:44 
8c (8S)-63 TFA 20 >99 58:42 
9c (8S)-63 (S)-TRIP 10 >99 63:37 
10c 
 
(8R)-64 TFA 10 96 38:62 
11c (8R)-64 TFA 20 >99 31.5:68.5 
12c (8R)-64 (S)-TRIP 10 >99 18:82 
aDetermined by GC. bDetermined by chiral GC. c12 h. 
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The most promising catalyst candidates (R,R)-DPEN 12 and 9-amino(9-deoxy)epiquinine (9-
NH2-epiQ; 13) were subjected to further screening experiments to refine the catalyst 
composition with respect to the nature of the acid co-catalyst. In doing so, we took into 
account the decisive effect of chiral counteranions in catalytic asymmetric transformations as 
recently revealed in our laboratories.[38b] A range of variously 3,3'-disubstituted chiral 
BINOL-derived phosphoric acids were tested in combination with (R,R)-DPEN. The first 
attempts were performed with chiral BINOL phosphate TRIP (7a) bearing sterically 
demanding 2,4,6-triisopropylphenyl substituents at the 3,3'-positions (Table 4.3). TRIP had 
already surfaced as the chiral counteranion of choice in several catalytic asymmetric 
transformations developed in our group. Indeed, also in the epoxidation of 2-cyclohexenone 
(46a), none of the chiral BINOL phosphates tested could compete with TRIP in terms of both 
activity and enantioselectivity. Pairing of (R,R)-DPEN 12 with (S)-TRIP in a 1:1 ratio 
improved both the yield and the enantioselectivity compared to the reaction catalyzed by 
[(R,R)-DPEN • TFA] (entry 3). In contrast, the results obtained with [(R,R)-DPEN • (R)-
TRIP] were inferior and denoted a significant matched/mismatched scenario (entry 5). 
Moreover, we evaluated other chiral acid motifs. In the presence of chiral BINOL-derived N-
triflyl phosphoramide 65, (R,R)-2,3-epoxycyclohexanone (48a) was formed in only moderate 
yield and reduced enantioselectivity (86:14 er) (entry 6). 
Notably, the use of achiral diphenyl phosphate salt [(R,R)-DPEN • 66] resulted in excellent 
enantioselectivity of 96:4 er; nevertheless increased by-product formation was observed 
(entry 7). When TRIP was used in combination with meso-DPEN (meso-12), and thus was the 
only source of chirality in the system, the enantioselectivity remained low (entry 11). 
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Table 4.3 Evaluation of different acid co-catalysts in combination with (R,R)-DPEN ((R,R)-12). 
 
 
 
Entry Acid co-catalyst [mol%] Yield [%]a erb 
1 TFA 10 95 95:5 
2 TFA 20 88c 94:6 
3 (S)-TRIP 10 99 96:4 
4 (S)-TRIP 20 91 92:8 
5 (R)-TRIP 10 49 90:10 
6 (S)-65 10 38 86:14 
7 (PhO)2PO(OH) (66) 10 77c 96:4 
8 HCl 10 60 90.5:9.5 
9 p-TsOH • H2O 10 92 89.5:10.5 
10 TfOH 10 30 73:27 
11d (R)-TRIP 10 95 42:58 
aDetermined by GC. bDetermined by chiral GC. cBy-product formation was observed. dmeso-DPEN (meso-12) 
was used. 
 
In addition, we evaluated a variety of DPEN derivatives bearing either electron-donating or 
electron-withdrawing substituents at the phenyl rings in combination with TRIP. Yet, none of 
the derivatives studied was able to enhance the stereocontrol obtained with unsubstituted 
(R,R)-DPEN ((R,R)-12). 
In parallel, we investigated the use of Cinchona alkaloid-derived primary amines in the 
epoxidation of 2-cyclohexenone (46a) (Table 4.4). In particular, 9-amino(9-deoxy)epiquinine 
(13) generated epoxide 48a in high yield along with an excellent enantioselectivity of 96:4 er 
(entry 1). The results obtained with analogous primary amines 67-70 derived from quinidine, 
cupreidine, cinchonidine, or cinchonine, respectively, were slightly inferior (entries 4-7). In 
contrast, amine 71 derived from 6'-isopropoxycinchonidine and 9-amino(9-deoxy)epidihydro-
quinine (72) both furnished epoxide 48a with comparable efficiencies (entries 8-9); the 
former one even afforded a slightly higher yield and enantioselectivity of 96.5:3.5 er than 9-
amino(9-deoxy)epiquinine (13) under otherwise identical conditions. However, we have 
selected amine 13 for further investigations since it is readily accessible from quinine via a 
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two step-one pot sequence whereas the synthesis of the 6'-isopropoxy derivative 71 requires a 
lengthy five-step procedure (cf. Chapter 4.7.1). Intriguingly, 9-amino(9-deoxy)quinine (9-
NH2-Q; 73) featuring the natural configuration of quinine at C-9 was less active and 
significantly less enantioselective compared to amine 13. Indeed, the opposite enantiomer 
(R,R)-48a was generated with only 79:21 er (entry 10). In general, pseudoenantiomeric amine 
catalysts such as quinine-derived 13 and quinidine-derived 67 provide antipodal 2,3-
epoxycyclohexanone (48a) with similar levels of enantiocontrol (entries 1 and 4). 
 
Table 4.4 Screening of various Cinchona alkaloid-derived primary amines. 
 
 
Entry 9-NH2 Cinchona alkaloid derivative Conv. [%]a Yield [%]a erb
1 13 (9-NH2-epiQ) 97 76 96:4 
2c 13 (9-NH2-epiQ) 95 82 96:4 
3d 13 (9-NH2-epiQ) 97 93 97:3 
4 67 (9-NH2-epiQD) 94 87 6:94 
5d 68 98 89 91:9 
6 69 full 77 94.5:5.5 
7 70 full 78 7:93 
8 71 96 83 96.5:3.5 
9 72 96 75 95.5:4.5 
10e 73 (9-NH2-Q) 82 80 21:79 
aDetermined by GC. bDetermined by chiral GC. c24 h. dAt 30 °C. e72 h. 
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In the course of our screening studies, we noted that prolonged reaction times had a 
detrimental effect on the yield. Whereas a yield of 82%a of epoxide 48a was detected after 
24 h (entry 2), only 76%a were present in the reaction mixture after continued heating for 48 h 
(entry 1). In addition, increased side product formation presumably resulting from product 
decomposition was noticable under these conditions. Similarly, decreasing the temperature 
from 50 °C to 30 °C proved beneficial to the reaction (entry 3). Taking these observations into 
account, (S,S)-2,3-epoxycyclohexanone (48a) was obtained in 93% yielda and with excellent 
enantioselectivity of 97:3 er in the presence of 10 mol% of [13 • 2 TFA]. 
Attempts to refine the catalyst composition with regard to the acid co-catalyst (Table 4.5), 
confirmed [13 • 2 TFA] as the optimum choice. A ratio of 1:1 amine 13/TFA resulted in 
somewhat lower catalytic activity (entry 2). However, both increasing and decreasing the 
loading of TFA only marginally influenced the reaction outcome in terms of yields and 
enantioselectivities (entries 2-3). With diphenyl phosphoric acid (66) as co-catalyst, 2,3-
epoxycyclohexanone was obtained in 94% yield and 96:4 er (entry 13). This value could be 
further enhanced to 97:3 er by pairing 9-amino(9-deoxy)epiquinine (13) with (R)-TRIP (entry 
14). However, [13 • (R)-TRIP] exhibited significantly decreased catalytic activity. Notably, 
combining (S)-TRIP with 9-amino(9-deoxy)epiquinidine (67) furnished the (R,R)-isomer of 
48a with 96:4 er (entry 17) whereas catalyst [67 • 2 TFA] generated epoxide (R,R)-48a with a 
reduced 94:6 er (cf. Table 4.4, entry 5). Subsequent optimization experiments were carried 
out with [13 • 2 TFA]. 
 
                                                 
a Yield determined by GC with an internal standard method. 
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Table 4.5 Screening of acid co-catalysts for the epoxidation of 2-cyclohexenone (46a) with 9-amino(9-
deoxy)epiquinine (13). 
 
Entry        Acid co-catalyst Acid conc. [mol%] Conv. [%]a Yield [%]a erb
1c TFA  20 97 93 97:3 
2c   10 90 89 96.5:3.5 
3c   30 97 90 96.5:3.5 
4 HCl  10 79 70 87:13 
5   20 85 69 92:8 
6 DNBA  10 92 92 93:7 
7 
 
74 10 85 85 93.5:6.5 
8  20 88 88 93.5:6.5 
9 
 
(S)-75 
10 88 88 93.5:6.5 
10 20 91 91 94:6 
11 
 
(R)-75 
10 89 89 94.5:5.5 
12 20 93 89 95:5 
13 (PhO)2PO(OH) 66 10 94 94 96:4 
14 (R)-TRIP 7a 10 56 50 97:3 
15 (S)-TRIP 7a 10 56 50 87:13 
16d (R)-TRIP 7a 10 71 69 15:85 
17d (S)-TRIP 7a 10 65 65 4:96 
aDetermined by GC. bDetermined by chiral GC. cAt 30 °C for 20 h. d9-Amino(9-deoxy)epiquinidine (67; 10 mol%) 
was used. 
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4.1.1.2 Optimization of the Reaction Conditions 
After having identified two efficient catalytic systems - [9-NH2-epiQ (13) • 2 TFA] and 
[(R,R)-DPEN • (S)-TRIP] (Table 4.6), our objective was to further optimize the reaction 
conditions prior to investigating the scope of the asymmetric epoxidation reaction. 
 
Table 4.6 Catalytic asymmetric epoxidation of 2-cyclohexenone (46a). 
 
 
Entry Catalyst Product Temp. [°C] Conv. [%]a Yield [%]b erc
1 
 
[9-NH2-epiQ (13) • 2 TFA] 
(S,S)-48a 30 97 58 (93) 97:3
2 
Ph
H3N NH2
Ph
O
P
O O
O-
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr
i-Pr +
 
[(R,R)-DPEN • (S)-TRIP] 
(R,R)-48a 50 full 68 (99) 96:4
aDetermined by GC. bYields of pure, isolated products. Values in parenthesis correspond to yields determined by 
GC with an internal standard method. cDetermined by chiral GC. 
 
With both catalyst systems, the crude reaction mixtures were extremely clean as determined 
by GC and 1H NMR and cyclohexenone epoxide 48a was the only product detected; only its 
pronounced volatility precluded the obtention of high isolated yields (Table 4.6). The absolute 
configuration of 2,3-epoxycyclohexanone (48a) was established by comparing the optical 
rotation with literature values.[97a] 
In the context of the reaction optimization, we also wanted to evaluate the applicability of 
different oxygen sources. Not only is aqueous hydrogen peroxide unquestionably the most 
favourable oxidant besides molecular oxygen, but it also proved superior to all the other 
oxygen sources tested (Table 4.7). In particular, 50 wt% aqueous hydrogen peroxide afforded 
cyclohexenone epoxide 48a with slightly higher enantioselectivity and higher yield than the 
less concentrated reagent (entries 1-2). The use of anhydrous H2O2 sources (urea-hydrogen 
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peroxide (UHP) or sodium percarbonate) gave inferior results in terms of both reactivity and 
selectivity (entries 3-4). Alkylhydroperoxides were also tested (entries 5-6). Among them, 
tert-butylhydroperoxide furnished the desired product in good yield but with moderate optical 
purity. As expected, electrophilic oxidants were generally less effective in epoxidizing the 
electron-deficient double bond of 2-cyclohexenone (46a) (entries 7-10). 
 
Table 4.7 Evaluation of different oxidants for the epoxidation of 2-cyclohexenone (46a) catalyzed by [(R,R)-
DPEN • (S)-TRIP]. 
 
Entry Oxidant Yield [%]a erb 
1 H2O2 (50 wt%) 99 96:4 
2 H2O2 (30 wt%) 96 95:5 
3 UHP 69 87:13 
4 (H2O2)3(Na2CO3)2 10 52.5:47.5 
5c TBHP (5.5 M in decane) 71 74:26 
6c CMHP (~80% in cumene) 10 71:29 
7c PhI=O <5 n.d. 
8c KHSO5 20 79.5:20.5 
9c m-CBPA 18 n.d. 
10c NaBO3 • H2O 12 67.5:32.5 
aDetermined by GC. bDetermined by chiral GC. c72 h. 
 
Both catalyst components of [(R,R)-DPEN • (S)-TRIP] are commercially available. Yet, due 
to the high molecular weight of the BINOL-derived phosphoric acid (S)-TRIP, a reduction in 
catalyst loading seemed desirable. However, this led to a drop in activity while the 
enantioselectivity remained essentially unaffected (Table 4.8, entries 2-4). We hypothesized 
that it might be possible to counter the loss of acitivity by keeping the concentration of the 
amine component (R,R)-DPEN constant while lowering the loading of (S)-TRIP. Previously, 
this strategy had proven successful in the catalytic asymmetric transfer hydrogenation of α,β-
unsaturated ketones.[124] However, the results depicted in Table 4.8 indicate that a 1:1 (R,R)-
DPEN/(S)-TRIP ratio is crucial to obtain high enantioselectivity. Lowering the loading of (S)-
TRIP while keeping the concentration of (R,R)-DPEN constant had a detrimental effect on 
both the activity and selectivity of the catalyst system (entries 5-8). 
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catalyst loading seemed desirable. However, this led to a drop in activity while the 
enantioselectivity remained essentially unaffected (Table 4.8, entries 2-4). We hypothesized 
that it might be possible to counter the loss of acitivity by keeping the concentration of the 
amine component (R,R)-DPEN constant while lowering the loading of (S)-TRIP. Previously, 
this strategy had proven successful in the catalytic asymmetric transfer hydrogenation of α,β-
unsaturated ketones.[124] However, the results depicted in Table 4.8 indicate that a 1:1 (R,R)-
DPEN/(S)-TRIP ratio is crucial to obtain high enantioselectivity. Lowering the loading of (S)-
TRIP while keeping the concentration of (R,R)-DPEN constant had a detrimental effect on 
both the activity and selectivity of the catalyst system (entries 5-8). 
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Table 4.8 Optimization of the loading of the (R,R)-DPEN/(S)-TRIP catalyst system. 
 
 
Entry (S)-TRIP [mol%] (R,R)-DPEN [mol%] Yield [%]a erb
1 20 20 91 96:4 
2 10 10 99 96:4 
3 5 5 78 95:5 
4c 1 1 38 97:3 
5 5 10 80 95:5 
6 3 10 65 93.5:6.5 
7 2 10 49 90.5:9.5 
8 1 10 30 85:15 
aDetermined by GC. bDetermined by chiral GC. c72 h. 
 
Screening of different solvents revealed that ethereal solvents are vital for high catalytic 
activity (Table 4.9). Among all ethereal solvents tested, 1,4-dioxane afforded the best results 
(entries 1 and 10). With catalyst [(R,R)-DPEN • (S)-TRIP], excellent results were also 
obtained in dimethoxyethane (DME) (entry 13). In chlorinated solvents and non-polar 
solvents such as hexane and toluene the catalytic efficiency was greatly reduced (entries 7-
9, 17). Polar solvents including methanol, ethanol, DMSO, and DMF had been tested 
previously under slightly modified conditions, and overall gave inferior results than all the 
ethereal solvents. 
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Table 4.9 Solvent screening. 
 
 
Catalyst [13 • 2 TFA] [(R,R)-DPEN • (S)-TRIP] 
Solvent Entry Yield [%]a er (S,S)b Entry Yield [%]a er (R,R)b
1,4-dioxane 1 93 96.5:3.5 10 99 96:4 
MTBE 2 89 84:16 12 99 95:5 
DME 3 90 91:9 13 96 96:4 
Et2O 4 86 73.5:26.5 14 97 94.5:5.5 
n-Bu2O 5 69 57:43 15 88 90.5:9.5 
THF 6 n.d. n.d. 16 99 94:6 
hexane 7 69 59.5:40.5 17 83 84:16 
toluene 8 50 58.5:41.5 18 n.d. n.d. 
CH2Cl2 9 41 74:26 19 n.d. n.d. 
aDetermined by GC. bDetermined by chiral GC. 
 
Before investigating the scope of the reaction, we sought the possibility of increasing the 
substrate concentration (thus minimizing the amount of solvent required). However, a 
substrate concentration of 0.5 M brought about reduced enantioselectivity and increased the 
formation of by-products in the epoxidation of 2-cyclohexenone (46a). We were similarly 
interested in decreasing the loading of hydrogen peroxide. However, a slight reduction to 1.25 
equivalents of hydrogen peroxide resulted in a pronounced drop in the reaction rate as such 
that the reaction did not reach full conversion within 48 hours of reaction time. 
 
4.1.2 Reaction Scope and Discussion 
After having established optimal conditions for the highly enantioselective epoxidation of 2-
cyclohexenone (46a), we became interested in exploring the scope of this new catalytic 
asymmetric transformation to cyclic α,β-unsaturated ketones of different ring sizes and with 
different substitution patterns. The following protocol was applied: catalyst salts [(R,R)-
DPEN • (S)-TRIP] or [9-NH2-epiQ (13)• 2 TFA] were prepared in situ by mixing chiral 
primary amines ((R,R)-DPEN or 9-NH2-epiQ (13); 10 mol%) with the respective acids ((S)-
TRIP: 10 mol%; TFA: 20 mol%) in dioxane for 10 min at room temperature. Then, cyclic 
enone 46 (0.25 M) was added followed by the addition of aqueous hydrogen peroxide (50 
wt%; 1.5 equiv) and the reaction mixture was stirred at 30-50 °C for 24-48 hours. 
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4.1.2.1 Scope of Substituted Cyclohexenones 
At the outset, we focused on 2-cyclohexenones bearing substituents at the 4-, 5-, and 6-
positions (Table 4.10). Both catalyst systems [(R,R)-DPEN • (S)-TRIP] and [13 • 2 TFA] 
efficiently mediated the epoxidation of 4,4-dimethyl-2-cyclohexenone (46b) to afford the 
corresponding epoxides (R,R)- and (S,S)-48b, respectively, in high yields along with high 
enantiomeric ratio of 97:3 in both cases (entries 3-4). Substitution at the 5-position was well 
tolerated by the catalyst system [(R,R)-DPEN • (S)-TRIP], whereas [13 • 2 TFA] provided 
5,5-dimethyl-substituted 2,3-epoxycyclohexanones 48c and 48d with slightly lower enantio-
selectivity, albeit in a comparable yield (entries 5-8). 
 
Table 4.10 Substrate scope I: 4-, 5-, and 6-substituted 2-cyclohexenones.a 
 
 
Entry Catalyst Enone Product  Yield [%]a erb 
1 
2 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP]  
46a 
 
48a 
(S,S)-48a 
(R,R)-48a 
58 (93) 
68 (99) 
97:3 
96:4 
3 
4 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP] 
 
46b 
 
48b 
(S,S)-48b 
(R,R)-48b 
84 
80 
97:3 
97:3 
5 
6 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP]  
46c 
 
48c 
(S,S)-48c 
(R,R)-48c 
72 
76 
96:4 
98:2 
7 
8 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP]  
46d 
 
48d 
(S,S)-48d 
(R,R)-48d 
52 
63 
95.5:4.5 
96.5:3.5 
9c 
10c 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP]  
rac-46e 
 
48e 
(2S,3S)-48e
(2R,3R)-48e
47 
34 
n.d. 
n.d. 
aYields of pure, isolated products. Values in parenthesis correspond to yields determined by GC. bDetermined by 
chiral GC. cAt 50 °C. 
                                                 
a Results obtained in collaboration with X. Wang. 
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68 (99) 
97:3 
96:4 
3 
4 
[13 • 2 TFA] 
[(R,R)-12 • (S)-TRIP] 
 
46b 
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80 
97:3 
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47 
34 
n.d. 
n.d. 
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chiral GC. cAt 50 °C. 
                                                 
a Results obtained in collaboration with X. Wang. 
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To evaluate the effect of substituents at the 6-position, we studied the epoxidation of racemic 
6-methyl-2-cyclohexenone (rac-46e). This substrate exhibited with both catalyst systems a 
significantly reduced reactivity compared to 4- and 5-substituted cyclohexenone: With 
[13 • 2 TFA] (10 mol%) after 48 h at 50 °C, a mixture of cis- and trans-epoxides 48e were 
formed in 47% yield; and in even lower yield of 34% in the presence of the catalyst [(R,R)-
DPEN • (S)-TRIP] (10 mol%) under otherwise identical conditions (entries 9-10). Presumably, 
steric constraints may hinder iminum ion formation and may account for the low reactivity of 
6-methyl-2-cyclohexenone (46e). 
 
Next, we investigated the epoxidation of 3-methyl-2-cyclohexenone (46f). Both catalyst 
systems were tested and to our delight, [13 • 2 TFA] gave the desired epoxide 48f as the (S,S)-
isomer in good yield along with high enantioselectivity (70%, 98:2 er) (Table 4.11, entry 1), 
while [(R,R)-DPEN • (S)-TRIP] was both considerably less active and less enantioselective 
providing (R,R)-48f in only 90.5:9.5 er (entry 3). In combination with TFA as acid co-catalyst, 
(R,R)-DPEN displayed slightly higher catalytic efficiency (entries 4-5). By using catalytic 
amounts of [(R,R)-DPEN • TFA], (R,R)-3-methyl-2,3-epoxycyclohexanone (48f) was formed 
in 71% yield along with 92.5:7.5 er (entry 4). 
 
Table 4.11 Catalytic asymmetric epoxidation of 3-methyl-2-cyclohexenone (46f). 
 
 
Entry Catalyst Product Conv. [%]a Yield [%]b erc 
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3 [(R,R)-12 • (S)-TRIP] (R,R)-48f 66 (47) 90.5:9.5 
4 [(R,R)-12 • TFA] (R,R)-48f 81 (71) 92.5:7.5 
5 [(R,R)-12 • 2 TFA] (R,R)-48f 90 (58) 90:10 
aDetermined by GC. bYields of pure, isolated products. Values in parenthesis correspond to yields determined by 
GC. cDetermined by chiral GC. dAt 30 °C for 24 h. 
 
While studying the scope of 3-substituted cyclohexenones, [9-NH2-epiQ (13) • 2 TFA] 
emerged as highly efficient and general catalyst giving a broad range of 3-substituted 2,3-
epoxycyclohexanones 48f-48m in good to high yields and with excellent enantiomeric ratios 
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of up to 99.5:0.5 (Table 4.12, entries 1-9).a A wide variety of linear and branched alkyl 
substituents including ethyl, isopropyl, isobutyl, benzyl, and phenethyl groups were well 
tolerated and the corresponding epoxides 48 were obtained with consistently high 
enantioselectivity. Even cyclohexenone 46j bearing a sterically demanding tert-butyl group at 
the 3-position was readily converted into the corresponding epoxide 48j with essentially 
perfect stereocontrol (99.5:0.5 er) (entry 5). Pleasingly, for 3-substituted cyclohexenones, the 
pseudoenantiomeric catalyst [67 • 2 TFA] (with amine 67 derived from quinidine, cf. Table 
4.4) provided access to antipodal epoxides with equally high enantioselectivities as 
demonstrated for 3-benzyl-2-cyclohexenone (46m) (entry 9). 
 
Table 4.12 Substrate scope II: 3-substituted 2-cyclohexenones. 
 
dioxane (0.25 M), 50 °C, 48 h
[13 2 TFA] (10 mol%)
H2O2 (50 wt%; 1.5 equiv)
O O
R
O
R46 48
N
N
MeO
NH2
H
13  
Entry R Enone Product Yield [%]a erb 
1c Me 46f (2S,3S)-48f 70 98:2 
2d Et 46g (2S,3S)-48g 73 98.5:1.5 
3 i-Bu 46h (2S,3R)-48h 73 98:2 
4 i-Pr 46i (2S,3R)-48i 79 99:1 
5 t-Bu 46j (2S,3R)-48j 68 99.5:0.5 
6 allyl 46k (2S,3R)-48k 23 97.5:2.5 
7 CH2CH2Ph 46l (2S,3R)-48l 84 98.5:1.5 
8 CH2Ph 46m (2S,3R)-48m 78 99:1 
9e CH2Ph 46m (2R,3S)-48m 77 1.5:98.5 
10 Ph 46n (2S,3R)-48n 0 - 
11 vinyl 46o (2S,3R)-48o 0 - 
12 ethinyl 46p (2S,3R)-48p 0 - 
aYields of pure, isolated products. bDetermined by chiral GC. cAt 30 °C for 24 h. d30 h. e[67 • 2 TFA] (10 mol%) 
was used as the catalyst. 
 
In the case of 3-allyl-2-cyclohexenone (46k), partial isomerization of the terminal double 
bond into conjugation with the α,β-enone moiety accounts for the low yield of 23% of 3-allyl-
2,3-epoxycyclohexanone (48k) (entry 6). This facile isomerization is probably enhanced upon 
                                                 
a Catalyst system [(R,R)-DPEN • (S)-TRIP] exhibited low catalytic efficiency also with other 3-substituted 2-
cyclohexenones; i.a. (2R,3S)-3-benzyl-2,3-epoxycyclohexanone (48m) was obtained in 35% yield and 86:14 er 
and (2R,3S)-3-isopropyl-2,3-epoxycyclohexanone (48i) in 36% yield and 89.5:10.5 er, respectively. 
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formation of the iminium ion A, which should lead to increased acidity in the γ'-position 
(Scheme 4.1). 
 
 
Scheme 4.1 Catalytic asymmetric epoxidation of 3-allyl-2-cyclohexenone (46k). (aDetermined by GC.) 
 
3-(Prop-1-en-1-yl)-2-cyclohexenone (76) is not susceptible to epoxidation under our reaction 
conditions neither at the endocyclic double bond (1,4-addition of hydrogen peroxide) nor at 
the acyclic double bond (1,6-addition). Accordingly, both 3-vinyl- and 3-ethinyl-2-
cyclohexenones 46o and 46p as further examples of α,β-γ,δ-unsaturated cyclic ketones could 
not be converted into the desired epoxides (Table 4.12, entries 11 and 12). The related 3-
phenyl-2-cyclohexenone 46n, as a representative of 3-aryl substituted cyclohexenones, did 
not productively engage in the reaction either (entry 10). Extended conjugation either through 
an aromatic or olefinic substituent at the 3-position seems to affect the electronic properties of 
the system to the point that conjugate addition of hydrogen peroxide does not proceed. 
Ketoisophorone (46q) gave the corresponding epoxide 48q in a reasonable yield along with 
high enantioselectivity of 96:4 er (Scheme 4.2). However, this enedione substrate turned out 
to be less reactive, and therefore 20 mol% [13 • 2 TFA] were employed in the reaction.a 
 
 
Scheme 4.2 Catalytic asymmetric epoxidation of ketoisophorone (46q). (aDetermined by GC.) 
 
                                                 
a [(R,R)-DPEN • TFA] and [(R,R)-DPEN • (S)-TRIP] were tested, but gave inferior results (~40% conversion, 
80:20 and 93:7 er, respectively). 
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phenyl-2-cyclohexenone 46n, as a representative of 3-aryl substituted cyclohexenones, did 
not productively engage in the reaction either (entry 10). Extended conjugation either through 
an aromatic or olefinic substituent at the 3-position seems to affect the electronic properties of 
the system to the point that conjugate addition of hydrogen peroxide does not proceed. 
Ketoisophorone (46q) gave the corresponding epoxide 48q in a reasonable yield along with 
high enantioselectivity of 96:4 er (Scheme 4.2). However, this enedione substrate turned out 
to be less reactive, and therefore 20 mol% [13 • 2 TFA] were employed in the reaction.a 
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Unfortunately, physiologically relevant vitamin K3 (menadion, 77) did not participate in the 
epoxidation reaction under the present reaction conditions, neither did benzoquinone 
dimethylmonoacetal (78) (Figure 4.2). 
 
 
Figure 4.2 Current limitations of the catalytic asymmetric enone epoxidation. 
 
In addition, α-substituted cyclic enones did not respond productively to iminium ion catalysis 
as exemplified by the attempted epoxidation of 2-methyl-2-cyclohexenone (79). Even after 
prolonged reaction times up to five days at 50 °C in the presence of either catalyst [9-NH2-
epiQ (13) • 2 TFA] or [(R,R)-DPEN • (S)-TRIP], only a trace amount of product could be 
detected by GC-MS. 
The inherent difficulties in generating congested iminium ion intermediates from ketone 
substrates have been partly overcome with the rising use of primary amine catalysts. Owing to 
reduced steric constraints, primary amines are (in contrast to most secondary amines) able to 
activate sterically demanding ketone substrates. Nevertheless, the activation of α-substituted 
α,β-unsaturated ketones remains challenging in this context and has, to the best of our 
knowledge, not been implemented to date (cf. Scheme 2.11). 
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4.1.2.2 Scope of Cyclic Enones of Different Ring Sizes 
Cyclic α,β-unsaturated ketones of different ring sizes were subjected to our catalytic 
asymmetric epoxidation protocol in the presence of catalytic amounts of [9-NH2-epiQ 
(13) • 2 TFA] or [(R,R)-DPEN • (S)-TRIP]. Except for 2-cyclopentenone (46r), the 
corresponding epoxides 48a, 48s-48x were generated in high yields and with high optical 
purity by using either of the two catalyst systems (Table 4.13). 
Cycloheptenone oxide 48s was provided by both catalyst systems with excellent enantiomeric 
ratios of 99:1 with [(R,R)-DPEN • (S)-TRIP] and >99.5:0.5 with [13 • 2 TFA] (entries 5-6). 
Moreover, catalyst [13 • 2 TFA] afforded 3-substituted cycloheptenone oxides 48t-u in high 
yields along with outstanding enantioselectivities (entries 7-8). The corresponding eight-
membered ring epoxide 48v was obtained from 2-cyclooctenone (46v) in good yield and high 
enantioselectivity (55%, 98:2 er) (entry 9). In addition, we studied macrocyclic enones in the 
epoxidation reaction. These proved to be somewhat more reactive than the seven- and eight-
membered ring analogues, just as cyclohexenone and its derivatives. As the ring size 
increased, the 9-amino(9-deoxy)epiquinine TFA salt [13 • 2 TFA] gave superior results 
compared to the catalyst system [(R,R)-DPEN • (S)-TRIP]. The two examples of macrocyclic 
enones nicely illustrate this trend: whereas epoxycyclododecanone 48w was still obtained in 
an enantiomeric ratio of 97:3 er with [(R,R)-DPEN • (S)-TRIP] (entry 11), epoxycyclopenta-
decanone 48x was formed in a slightly reduced 95.5:4.5 er (entry 14). Since both rings are 
large enough to allow s-cis and s-trans conformational interconversion, they resemble acyclic 
enones in their conformational flexibility. Indeed, we had found, during our studies with 
acyclic enones as substrates, that catalyst [(R,R)-DPEN • (S)-TRIP] gave inferior results 
compared to [13 • 2 TFA] with this substrate class (cf. Table 4.21). 
Yet, the quinine-derived catalyst system [13 • 2 TFA] proved highly efficient and gave 
macrocyclic epoxides 48w-x in high yields along with outstanding enantioselectivities of 
99.5:0.5 er in both cases (entries 10 and 12). Pleasingly, the pseudoenantiomeric catalyst salt 
[67 • 2 TFA] derived from quinidine gave epoxide 48x with the opposite sense and identical 
magnitude of stereoinduction (0.5:99.5 er) (entry 13). 
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Table 4.13 Substrate scope III: cyclic enones of different ring sizes. 
 
 
Entry Catalyst Enone Product  Yield [%]a erb 
1c 
2c 
[13 • 2 TFA] 
[(R,R)-DPEN • (S)-TRIP]  
46r 
 
48r 
(S,S)-48r 
(R,R)-48r 
(33) 
(33) 
87:13 
90:10 
3d 
4d 
[13 • 2 TFA] 
[(R,R)-DPEN • (S)-TRIP]  
46a 
 
48a 
(S,S)-48a 
(R,R)-48a 
58 (93) 
68 (>99) 
97:3 
96:4 
5 
6 
[13 • 2 TFA] 
[(R,R)-DPEN • (S)-TRIP]  
46s 
 
48s 
(S,S)-48s 
(R,R)-48s 
62 
65e 
>99.5:0.5
99:1 
  
  
   
7 
8 
[13 • 2 TFA] 
[13 • 2 TFA] 
R = Et: 46t 
R = CH2Ph: 46u
R = Et: 48t 
R = CH2Ph: 48u
(S,S)-48t 
(S,R)-48u 
82 
85 
>99.5:0.5
>99.5:0.5
9f [13 • 2 TFA] 
 
46v 
 
48v 
(S,S)-48v 55 98:2 
10 
11g 
[13 • 2 TFA] 
[(R,R)-DPEN • (S)-TRIP] 
O
 
46w 
 
48w 
(2S,3R)-48w 
(2R,3S)-48w 
92 
92 
99.5:0.5
97:3 
12 
13 
14g 
[13 • 2 TFA] 
[67 • 2 TFA] 
[(R,R)-DPEN • (S)-TRIP]  
46x 
O
O
 
48x 
(2S,3R)-48x 
(2R,3S)-48x 
(2R,3S)-48x 
87 
86 
52 
99.5:0.5
99.5:0.5
95.5:4.5
aYields of pure, isolated products. Values in parenthesis correspond to yields determined by GC. bDetermined by 
chiral GC. c48 h. dAt 30/35 °C. eDetermined by 1H NMR analysis of the crude mixture. fCrude product was treated 
with 1N NaOH (1 equiv) in THF. gAt 35 °C for 48 h. 
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Cyclopentenone epoxide 48r was obtained in moderate yield along with a good 
enantioselectivity of 90:10 er with catalyst [(R,R)-DPEN • (S)-TRIP] and still with 87:13 er in 
the presence of [9-NH2-epiQ (13) • 2 TFA] (entries 1-2), which are the highest enantioselec-
tivities reported to date for the catalytic asymmetric epoxidation of 2-cyclopentenone 
(46r).[97d] Nevertheless, the results obtained with 2-cyclopentenone are only moderate if 
compared with those for cyclohexenone and higher homologues, which is a general 
phenomenon observed in catalytic asymmetric conjugate additions to cyclic enones.[125] 
Likewise, cyclopentenone is a special case in our epoxidation reaction and requires an 
individual treatment. Thus, a separate catalyst screening was conducted dedicated to the 
epoxidation of 2-cyclopentenone (46r) and the results are summarized and discussed in 
Chapter 4.1.2.5. 
Whereas the epoxides were essentially the only products observed in the reaction of 2-
cyclopentenone, 2-cyclohexenone, as well as the macrocyclic enones, 2-cycloheptenone (46s) 
and 2-cyclooctenone (46v) afforded a second product along with the expected epoxide. This 
product was identified as the conjugate addition product of hydrogen peroxide. Such β-hydro-
peroxycycloalkanones exist in equilibrium with the bicyclic peroxyhemiketals as depicted in 
Scheme 4.3. 
 
 
Scheme 4.3 Primary amine salt-catalyzed reaction of seven- and eight-membered cyclic enones 46s and 46v 
with hydrogen peroxide. 
 
A detailed analysis of this observation, as well as a study of the influence of different 
catalysts and reaction conditions on the product distribution, will be presented in Chapter 
4.2.2.6. 
 
4.1.2.3 Toward (Dynamic) Kinetic Resolutions of 4-Substituted Cyclohexenones 
At this juncture, we were intrigued by the asymmetric epoxidation of racemic 4-substituted 
cyclohexenones of the general structure rac-80. We envisaged that one enantiomer of the 
starting material rac-80 might react preferentially in the sense of a kinetic resolution (KR) of 
cyclohexenones via asymmetric epoxidation as depicted in Scheme 4.4, (a). Thus, 
synthetically valuable enantioenriched 4-substituted cyclohexenones 80 and enantioenriched 
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epoxy cyclohexanones 81 would be concomitantly obtained. We might even encounter a case 
of dynamic kinetic resolution (DKR) if interconversion of iminium ions A and C via a 
dienamine intermediate B would proceed at rates greater than those of the epoxidation 
pathways (krac»k>kent; Scheme 4.4, (b)). An analogous scenario may be anticipated for the 
chiral amine salt-catalyzed asymmetric epoxidation of 6-substituted cyclohexenones rac-46e 
(Scheme 4.4). Racemization of the corresponding 6-substituted α,β-unsaturated iminium ions 
(equivalent to the iminium ions A) via a cross-conjugated dienamine intermediate may occur 
more readily due to the increased acidity of the α'-position of cyclohexenone compared to the 
vinylogous γ-position.[126] However, since the iminium ion formation with substrate rac-46e 
seems to be hindered by steric constraints caused by the substituent at the 6-position (Table 
4.10, entries 9-10), we decided to start our investigations with 4-substituted racemic 
substrates rac-80. 
 
Scheme 4.4 General scheme for the (a) kinetic resolution (KR) or (b) dynamic kinetic resolution (DKR) of 4- 
(or 6-) substituted cyclohexenones via asymmetric epoxidation. 
 
To test our hypothesis, 4-methyl-2-cyclohexenone (rac-80a) was subjected to the standard 
reaction conditions and samples were taken at different time intervals (Table 4.14). GC 
analysis of the samples revealed that both diastereomeric epoxides cis- and trans-81a were 
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formed with high enantioselectivities at similar rates (54:46 dr(trans/cis)). In stark contrast, 
the racemic synthesis with alkaline hydrogen peroxide in methanol proceeded with a 
diastereoselectivity of 74:26 dr in favour of the trans-epoxide 81a.[127] 
This result represents a manifest case of strong catalyst control. The configuration of the 
substrate appears to play only a minor role and, therefore, (dynamic) kinetic resolution did not 
take place - at least not to a synthetically useful extent. At 55% conversion the starting 
material exhibited an enantiomeric ratio of only 56:44. 
 
Table 4.14 Asymmetric epoxidation of racemic 4-methyl-2-cyclohexenone (rac-80a). 
 
 
Entry t [h] conv. [%]a dr (trans/cis)a er (trans-81a)b er (cis-81a)b er (80a)b
1 4 55 54:46 n.d. n.d n.d 
2 26 94 54:46 93.5:6.5 99:1 56:44 
aDetermined by GC. bDetermined by chiral GC. 
 
Interestingly, the cis- and trans-epoxides 81a were obtained with in both cases high, yet 
noticeably different levels of enantiocontrol. Whereas cis-81a was formed in an excellent 
enantiomeric ratio of 99:1 er, corresponding trans-81a exhibited a considerably lower optical 
purity (93.5:6.5 er). This can be rationalized through analysis of the putative pre-transition 
state assemblies depicted in Scheme 4.5. 
Singleton and co-workers have found that the lowest-energy transition state structure for the 
conjugate addition of tert-butyl hydroperoxide to 4-methyl-2-cyclohexenone is the one which 
combines the prerequisite axial attack of the nucleophile with the methyl group adopting a 
pseudo-axial rather than a pseudo-equatorial orientation.[128] Despite the concomitant strain 
caused by the latter orientation, this transition state structure is favored since an equatorial 
substituent at C-4 would suffer from unfavorable interactions with the incoming tert-butyl 
peroxy anion. 
Accordingly, Scheme 4.5 shows the possible pre-transition state assemblies A-D for the 
conjugate addition of hydrogen peroxide to the α,β-unsaturated iminium ions generated from 
(S)- and (R)-4-methyl-2-cyclohexenone (A/B and C/D, respectively) and 9-amino(9-
deoxy)epiquinine (13) (simplified as R-NH2). Trans-epoxide trans-81a arises from a reaction 
proceeding through half-chair C. Both catalyst and substrate direct the hydrogen peroxide 
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attack to the si-face of the double bond. The addition of hydrogen peroxide through half-chair 
A to generate cis-epoxide cis-81a occurs as well in accordance with catalyst control on the si-
face of the molecule. However, in this setting, the pseudo-equatorial methyl group at C-4 
experiences steric interactions with the incoming nucleophile. Thus, half-chair A may have an 
inherent tendency to undergo ring inversion and place the methyl group in pseudo-axial 
orientation (cf. half-chair B). Subsequent axial attack of hydrogen peroxide to half-chair B 
would afford the opposite enantiomer of trans-81a accounting for its lower experimentally 
obtained enantioselectivity compared to the corresponding cis-81a. 
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Scheme 4.5 Pre-transition state assemblies A-D for the conjugate addition of hydrogen peroxide to 4-methyl-2-
cyclohexenone-derived iminium ions. 
 
We tried to improve the efficiency of the envisaged kinetic resolution by increasing the size 
of the substituent R in rac-80. 
4-tert-Butyl-2-cyclohexenone 80b gave trans-epoxide 81ba in 48% yield, after 4 d at 50 °C in 
the presence of catalyst salt [13 • 2 TFA], with a diastereomeric ratio of 92:8 (trans/cis).b 
Although the remaining starting material (44%) was significantly enantioenriched with 86:14 
er, the enantiomeric ratio of trans-epoxide 81b remained relatively low (79.5:20.5 er) 
(Scheme 4.6). 
                                                 
a The relative configuration was assigned by NOE analysis. 
b Racemate was obtained with alkaline hydrogen peroxide in methanol with 98:2 dr. 
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inherent tendency to undergo ring inversion and place the methyl group in pseudo-axial 
orientation (cf. half-chair B). Subsequent axial attack of hydrogen peroxide to half-chair B 
would afford the opposite enantiomer of trans-81a accounting for its lower experimentally 
obtained enantioselectivity compared to the corresponding cis-81a. 
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Scheme 4.5 Pre-transition state assemblies A-D for the conjugate addition of hydrogen peroxide to 4-methyl-2-
cyclohexenone-derived iminium ions. 
 
We tried to improve the efficiency of the envisaged kinetic resolution by increasing the size 
of the substituent R in rac-80. 
4-tert-Butyl-2-cyclohexenone 80b gave trans-epoxide 81ba in 48% yield, after 4 d at 50 °C in 
the presence of catalyst salt [13 • 2 TFA], with a diastereomeric ratio of 92:8 (trans/cis).b 
Although the remaining starting material (44%) was significantly enantioenriched with 86:14 
er, the enantiomeric ratio of trans-epoxide 81b remained relatively low (79.5:20.5 er) 
(Scheme 4.6). 
                                                 
a The relative configuration was assigned by NOE analysis. 
b Racemate was obtained with alkaline hydrogen peroxide in methanol with 98:2 dr. 
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Scheme 4.6 Asymmetric epoxidation of racemic 4-tert-butyl-2-cyclohexenone (rac-80b). (aDetermined by GC; 
bDetermined by chiral GC.) 
 
We rationalized this observation in an analogous manner to the reaction with 4-methyl-2-
cyclohexenone (80a), by analyzing the corresponding plausible pre-transition state assemblies 
(cf. Scheme 4.5). In addition, we take into account the increased bulkiness of the tert-butyl 
group at C-4 and its resultant reluctance towards adopting a pseudo-axial orientation. The 
large size of this substituent may further multiply steric interactions arising from cis-selective 
axial attack of hydrogen peroxide. Thus, we invoke pre-transition state assemblies A'and D', 
with the tert-butyl group in pseudo-equatorial orientation, and assume an equatorial attack of 
hydrogen peroxide, which is in line with trans-epoxide 81b being formed as essentially a 
single diastereomer (Scheme 4.7). The observed enantioselectivity, however, remains only 
moderate (79.5:20.5 er) as a consequence of this. 
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butyl-2-cyclohexenone-derived iminium ions. 
 
Further attempts to achieve higher efficiency in the kinetic resolution of racemic 4-substituted 
cyclohexenones rac-80 via asymmetric epoxidation should strive to assist the interconversion 
of the enantiomers of the starting material. For instance, if Hagemann’s ester (Figure 4.3) is 
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employed, the expected increased acidity at the γ-position may render dynamic kinetic 
resolutions via dienamine formation more feasible (cf. Scheme 4.4).[129] 
 
 
Figure 4.3 Hagemann’s ester. 
 
4.1.2.4 Epoxidation of Enantioenriched 5-Substituted Cyclohexenones 
We were further interested how our catalyst system would deal with pre-existing stereocenters 
embedded in the ring scaffold which cannot be equilibrated in the course of the reaction. To 
this end, we prepared chiral enantioenriched 5-phenyl-3-methyl-2-cyclohexenone ((S)-83) 
according to a method previously developed in our group (Scheme 4.8).[123] The aldol 
cyclodehydration of 4-substituted 2,6-heptandiones such as 82 in presence of the chiral 
catalyst [13 • 3 HOAc] afforded 5-substituted-3-methyl-2-cyclohexenones in high yields and 
with enantioselectivities greater than 95:5 er. 
 
 
Scheme 4.8 Synthesis of (S)-5-phenyl-3-methyl-2-cyclohexenone ((S)-83).[123] 
 
We then subjected enantiomerically enriched (S)-83 to our epoxidation reaction. The results 
are depicted in Table 4.15.a 
 
                                                 
a One-pot syntheses of epoxide 84 starting from diketone 82 are possible in the presence of catalyst [67 • 2 TCA] 
but have not been optimized. 
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Table 4.15 Catalytic asymmetric epoxidation of (S)-83 with pseudoenantiomeric catalysts [9-NH2-
epiQ (13) • 2 TFA] and [9-NH2-epiQD (67) • 2 TFA]. 
 
 
Entry Catalyst Conv. [%]a Yield [%]a dr (trans/cis)a er (trans-84)b
1 [13 • 2 TFA] 83 75 97:3 98.5:1.5 
2 [67 • 2 TFA] 79 74 63:37 92.5:7.5 
aDetermined by GC. bDetermined by chiral GC. 
 
Both catalysts tested − [13 • 2 TFA] and its pseudoenantiomeric form [67 • 2 TFA] − 
mediated the epoxidation of cyclohexenone (S)-83 with similar rates. However, whereas 
[13 • 2 TFA] gave epoxide 84 with a diastereomeric ratio of 97:3 (trans/cis) and an enantio-
meric ratio of 98.5:1.5 (trans), the latter gave epoxide 84 as a 63:37 (trans/cis) mixture of 
diastereomers along with inferior enantioselectivity of 92.5:7.5 er (major).a 
In the presence of catalyst [13• 2 TFA], the epoxidation of the major enantiomer (S)-83 is 
directed by both the catalyst and the substrate to the si-face of the enone (Scheme 4.9, A). On 
the contrary, the reaction of the minor enantiomer (R)-83 (via B) is kinetically disfavoured 
and thus, we observed an enantiomeric enrichment in trans-epoxide 84. 
In general, pseudoenantiomeric catalyst [67 • 2 TFA] derived from quinidine preferentially 
delivers hydrogen peroxide from the re-face. However, the asymmetric epoxidation of 
cyclohexenone (S)-83 in the presence of [67 • 2 TFA] furnished a mixture of diastereomers 
(63:37 dr) in favour of the trans-epoxide 84 which was obtained in reduced optical purity of 
only 92.5:7.5 er. Putative pre-transition state assemblies C-E imply that the reaction of the 
minor enantiomer (R)-83 is kinetically favoured in the presence of catalyst [67 • 2 TFA]. 
Moreover, trans-epoxide 84 is obtained as the major product; this presumably arises since 
pre-transition state assembly C, which may account for the formation of cis-epoxide 84, 
suffers from disadvantageous steric interactions with the phenyl substituent. Therefore, 
inverted half-chair D with the phenyl group in pseudo-equatorial orientation may as well 
come into consideration, which would explain the formation of significant quantities of the 
trans-epoxide 84 via the preferred axial attack (from the si-face of the molecule regardless of 
the catalyst’s bias). 
                                                 
a Racemate was obtained with alkaline hydrogen peroxide in methanol with 94:6 dr from racemic enone 83. 
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The racemate synthesis with alkaline hydrogen peroxide in methanol proceeded with a 
diastereoselectivity of 94:6 (trans/cis), which could be either enhanced to 97:3 with catalyst 
[13 • 2 TFA] (matched case) or reduced to 63:37 with catalyst [67 • 2 TFA] (mismatched 
case). However, it was not possible to invert the diastereoselectivity within the bias of the 
cyclic system. In addition, this experiment lends further experimental support to the 
assignment of the absolute stereochemistry of 3-substituted-2,3-epoxycyclohexanones 
generated with quinine-derived catalyst [13 • 2 TFA] as (S,S) (as we have also deduced by 
analogy to 2,3-epoxycyclohexanone). 
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The racemate synthesis with alkaline hydrogen peroxide in methanol proceeded with a 
diastereoselectivity of 94:6 (trans/cis), which could be either enhanced to 97:3 with catalyst 
[13 • 2 TFA] (matched case) or reduced to 63:37 with catalyst [67 • 2 TFA] (mismatched 
case). However, it was not possible to invert the diastereoselectivity within the bias of the 
cyclic system. In addition, this experiment lends further experimental support to the 
assignment of the absolute stereochemistry of 3-substituted-2,3-epoxycyclohexanones 
generated with quinine-derived catalyst [13 • 2 TFA] as (S,S) (as we have also deduced by 
analogy to 2,3-epoxycyclohexanone). 
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4.1.2.5 Cyclopentenone: A Special Case 
A problem connected to cyclopentenone substrates is a considerable “flatness” of the 
molecules, rendering them less sensitive to the steric requirements of the chiral catalyst. As a 
result, lower enantioselectivities are obtained than with cyclohexenone or higher 
homologues.[125a] Another common issue associated with the use of cyclopentenone as 
substrate pertains to its high reactivity. The enolate generated after conjugate addition is 
reactive enough to undergo conjugate addition to unreacted cyclopentenone.a, [130] 
In the catalytic epoxidation reaction, 2-cyclopentenone (46r) gave inferior results in terms of 
both yield and enantioselectivity compared with other cyclic enone substrates. Nevertheless, 
an enantiomeric ratio of 90:10 still represents the highest level of asymmetric induction 
attained to date for the epoxidation of this particular substrate (Table 4.16, cf. Table 4.13). 
 
Table 4.16 Catalytic asymmetric epoxidation of 2-cyclopentenone (46r). 
 
 
Entry Catalyst Product Yield [%]a erb 
1 [9-NH2-epiQ (13) • 2 TFA] (S,S)-48r 33 87:13 
2 [(R,R)-DPEN • (S)-TRIP] (R,R)-48r 33 90:10 
aDetermined by GC. bDetermined by chiral GC. 
 
Indeed, only one report is known in the current literature which addresses the epoxidation of 
cyclopentenone.[97d] By using chiral diketopiperazine-derived hydroperoxide 85 as 
stoichiometric oxidant, 2,3-epoxycyclopentanone (48r) was generated in 31% yield and 56:44 
er (Figure 4.4). 
 
Figure 4.4 Diketopiperazine-derived hydroperoxide 85 by Laschat et al. 
 
Eager to address the challenge that cyclopentenones pose to asymmetric catalysis, we re-
evaluated the catalytic potential of a variety of chiral primary amine salts for the epoxidation 
of cyclopentenone (Table 4.17). (R,R)-DPEN (12) as its TFA salt showed to be slightly less 
                                                 
a This is in accordance with our observation that 2-cyclopentenone (46r) dimerizes in the presence of the 
catalytic salt [13 • 2 TFA] as detected by GC-MS and ESI-MS. 
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active and at the same time considerably less enantioselective than when employed in 
combination with (S)-TRIP (entries 1-2). Enantioselectivities attained with 9-amino(9-
deoxy)epicinchona alkaloid derivatives 13, 67-72 (as their diTFA salts) (cf. Table 4.4) all 
ranged between 84:16 and 86.5:13.5 er with cyclopentenone epoxide 48r being generated in 
27-45% yield. Re-screening different solvents for the cyclopentenone epoxidation confirmed 
dioxane as the solvent of choice. The use of mono TFA salt [13 • TFA] increased the catalytic 
activity slightly and afforded the desired product in 44% yield with essentially equal optical 
purity (87:13 er) (entry 3), whereas a 1:3 amine/TFA ratio resulted in a drop of 
enantioselectivity to 79.5:20.5 er (entry 6). As for 2-cyclohexenone, the epoxidation 
proceeded with low enantioselectivity in the presence of amine 73 (9-NH2-Q; cf. Table 4.4) 
featuring the natural (R)-configuration of quinine at C-9 (entry 7). We then had a look at 
different acid co-catalysts. Pleasingly, the use of diphenyl phosphoric acid (66) instead of 
TFA enhanced the catalytic activity, and moreover had a positive impact on the 
enantioselectivity. In the presence of [13 • DPPOH], 2,3-epoxycyclopentanone was furnished 
in 52% yield with an enantiomeric ratio of 88.5:11.5 (entry 8). Unfortunately, replacing 
achiral diphenyl phosphate by chiral phosphate counteranions, e.g. TRIP (7a), could not 
improve the result (entries 10-13). 
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Table 4.17 Evaluation of various primary amine salts for the catalytic asymmetric epoxidation of 2-
cyclopentenone (46r). 
 
Entry Amine Acid co-catalyst [mol%] Yield [%]a erb 
1 (R,R)-DPEN TFA 10 19 17.5:82.5 
2 (R,R)-DPEN TFA 20 28 29:71 
3 
13 
TFA 10 44 87:13 
4 TFA 20 33 87:13 
5c TFA 20 45 87:13 
6 TFA 30 34 79.5:20.5 
7 73 TFA 20 42d 65:35 
8 13 (PhO)2PO(OH) (66) 10 52 88.5:11.5 
9 13 (PhO)2PO(OH) (66) 20 50e 72.5:27.5 
10 13 (S)-TRIP 10 23 77:23 
11 13 (S)-TRIP 20 22 56:44 
12 13 (R)-TRIP 10 21 88:12 
13 13 (R)-TRIP 20 29 69:31 
14c,f 13 TFA 20 26 88:12 
aDetermined by GC. bDetermined by chiral GC. c[13 • 2 TFA] (20 mol%), 48 h. d72 h. eIncreased side product 
formation observed. fWith 3-methyl-2-cyclopentenone as substrate. 
 
Beside improving the enantioselectivity of the process, we also strove to identify an 
exceedingly active primary amine salt catalyst with regard to the use of 3-substituted cyclo-
pentenone derivatives (e.g. 3-methyl-2-cyclopentenone) which exhibit reduced reactivity 
compared to the parent compound (entry 14).a 
With this aim, we re-evaluated truncated Cinchona alkaloid derivatives α-(aminomethyl)-
quinuclidines 63 and 64 (Table 4.18). In particular, 64 effectively mediated the epoxidation 
reaction. In combination with (S)-TRIP in a 1:1 ratio, epoxide 48r was formed in 91% yield 
after 24 h and with a promising enantioselectivity of 76.5:23.5 er (entry 11). However, 
screening of a wide range of chiral BINOL-derived phosphoric acids bearing different 
substituents at the 3,3'-positions could not improve the result. 
 
                                                 
a This trend had previously been observed with the six-membered ring analogues. 
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a This trend had previously been observed with the six-membered ring analogues. 
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Table 4.18 Evaluation of truncated Cinchona alkaloid catalysts 63 and 64 in the catalytic asymmetric 
epoxidation of 2-cyclopentenone (46r). 
 
dioxane (0.25 M), 50 °C, 24 h
63 or 64 (10 mol%)
acid co-catalyst
H2O2 (50 wt%; 1.5 equiv)
O O
O
46r (R,R)-48r  
Entry Diamine Acid co-catalyst [mol%] Yield [%]a erb 
1 
 
- - 21c rac 
2 TFA 10 69 55:45 
3 TFA 20 67 54.5:45.5 
4 DPPOH (66) 10 57 rac 
5 DPPOH (66) 20 31 rac 
6 (S)-TRIP 10 59 63:37 
7 (R)-TRIP 10 62 48:52 
8 
 
- - 28c 46.5:53.5 
9 TFA 10 80 44:56 
10 TFA 20 82d 34.5:65.5 
11 (S)-TRIP 10 91 23.5:76.5 
12 (R)-TRIP 10 49 43:57 
13 (S)-TRIP 20 91 29:71 
aDetermined by GC. bDetermined by chiral GC. c48 h. d18 h. 
 
Encouraged by the results obtained with α-(aminomethyl)quinuclidine (64), we sought a way 
to modify the catalyst structure to enhance its stereoselectivity while at the same time 
retaining the high catalytic activity. We envisaged that α-(aminobenzyl)quinuclidine (86a), 
bearing an additional phenyl group at C-9 could meet these criteria (Figure 4.5, (a)). We 
speculated that such a de-novo designed catalyst motif would ideally merge the high 
enantioselectivity of Cinchona alkaloid-derived catalysts such as 9-amino(9-deoxy)epiquinine 
(13) with the significantly more active truncated representative 64, presumably due to reduced 
steric congestion surrounding the primary amine function. 
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Figure 4.5 (a) Design of α-(aminobenzyl)quinuclidine (86a) as new catalyst target structure; and (b) retro-
synthetic analysis of 86a. 
 
α-(Aminobenzyl)quinuclidine (86a) was obtained in two steps from quinuclidine according to 
the retrosynthetic strategy presented in Figure 4.5 (b). α-Lithiation of quinuclidine and 
subsequent reaction of the lithiated species with benzaldehyde gave α-(hydroxylbenzyl)qui-
nuclidine. The aminoalcohol was further converted into α-(aminobenzyl)quinuclidine (86a) 
via a Mitsunobu reaction with azide followed by a Staudinger reduction to afford the desired 
amine. A detailed presentation and discussion of this synthetic approach is provided in 
Chapter 4.7.1.2. 
Separation of the enantiomers of racemic 86a was attempted by chiral HPLC. Unfortunately, 
only the erythro- but not the threo-isomer of 86a could be readily separated and tested as 
chiral catalyst in combination with different acid co-catalysts in the asymmetric epoxidation 
of 2-cyclopentenone (46r) (Table 4.19; entries 3-8). The best result was obtained by using 
erythro-86a as its di TFA salt (entry 4). Under these conditions, epoxycyclopentanone 48r 
was generated in a maximum yield of 54% along with moderate enantioselectivity of 74:26 er. 
threo-86a was tested in racemic form to at least estimate its catalytic potential in the 
attempted asymmetric transformation (entries 1-2). Indeed, the threo-isomer turned out to be 
slightly more active than the erythro-form and afforded cyclopentenone epoxide 48r in 65% 
yield at best (entry 1). This is not surprising since the threo-isomer resembles the powerful 
epicinchona alkaloid derivatives such as 9-NH2-epiQ (13) with regard to the relative 
configuration at the carbon atoms C-8 and C-9. On the opposite, the erythro-diastereomer of 
86a just like 9-amino(9-deoxy)quinine (73) resembles natural Cinchona alkaloids, which in 
general display inferior catalytic potential compared with the epicinchona alkaloid analogues 
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as has already been demonstrated in many cases including our epoxidation reaction of cyclic 
enones (cf. Table 4.4). Thus, future efforts in this area are aimed at providing the threo-86a in 
enantiomerically pure form to finally evaluate its catalytic activity and selectivity in the 
asymmetric epoxidation of 2-cyclopentenone (46r) among other asymmetric transformations. 
 
Table 4.19 Catalytic asymmetric epoxidation of 2-cyclopentenone (46r) in the presence of α-(amino-
benzyl)quinuclidine (86a) as catalyst. 
 
 
 
Entry Amine Acid co-catalyst [mol%] Yield [%]a erb 
1 rac-threo-86a TFA 10 65 - 
2 rac-threo-86a TFA 20 37 - 
3c (-)-erythro-86a TFA 10 5 74:26 
4c (-)-erythro-86a TFA 20 54 74:26 
5c (-)-erythro-86a (S)-TRIP 10 9 64:36 
6c (-)-erythro-86a (S)-TRIP 20 29 65:35 
7c (+)-erythro-86a (S)-TRIP 10 5 32.5:67.5 
8c (+)-erythro-86a (S)-TRIP 20 32 32:68 
aDetermined by GC. bDetermined by chiral GC. c30 h. 
 
 
 
During our screening studies, amino acid ester salts had turned out as highly active albeit 
poorly enantioselective catalysts. However, the encouraging results obtained with the DPEN-
based catalyst [(R,R)-DPEN • (S)-TRIP] and the recent reports in the literature on the 
successful implementation of various chiral diamine catalysts, especially those bearing a 
primary amine moiety (some of which are readily availabe from naturally abundant amino 
acids), prompted us to further investigate on this.[131] For this purpose, diamines exhibiting 
primary, secondary, and tertiary amine functionalities were quickly assembled through 
conventional synthetic methods (cf. Chapter 4.7.2) and tested in the epoxidation reaction 
(Table 4.20). Unfortunately, the original result obtained with [(R,R)-DPEN • (S)-TRIP] as 
catalyst could not be further improved. 
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Table 4.20 Screening of diamines 87-89 for the catalytic asymmetric epoxidation of 2-cyclopentenone (46r). 
 
 
              diamine 
        acid 
 
87 
 
88 
 
89a 
 yield [%]a er b yield [%]a er b yield [%]a er b 
TFA (10 mol%) 27 74:26 36 60.5:39.5 82 71:29 
TFA (20 mol%) 28 69.5:30.5 51 59.5:40.5 60 73.5:26.5 
(S)-TRIP (10 mol%) 28 82.5:17.5 36 62.5:37.5 47 66.5:33.5 
(R)-TRIP (10 mol%) 31 85:15 38 41.5:58.5 48 74.5:25.5 
- 6 69.5:30.5 10 58.5:41.5 35 62.5:37.5 
aDetermined by GC. bDetermined by chiral GC. 
 
In conclusion, during our screening studies for the catalytic asymmetric epoxidation of 2-
cyclopentenone (46r), we have identified an alternative, highly active, yet moderately 
enantioselective catalyst system for the enantioselective epoxidation of five-membered cyclic 
enones: [64• (S)-TRIP] (cf. Table 4.18). Due to the increased catalytic activity of [64• (S)-
TRIP] compared to the previously employed catalysts [9-NH2-epiQ (13)• 2 TFA] and [(R,R)-
DPEN • (S)-TRIP], the less reactive 3-substituted cyclopentenone derivative 90 could be 
converted to the corresponding epoxide 2,3-epoxy-3-phenethyl-cyclopentanone (91) in 
reasonable yield of 65% with an enantiomeric ratio of 85.5:14.5 er. As a comparison, after 48 
h, the reaction catalyzed by [13 • 2 TFA] had reached only 32% conversion as determined by 
GC. However, under those conditions the product was formed with superior enantioselectivity 
of 91:9 er. 
 
 
 
Scheme 4.10 Asymmetric epoxidation of 3-substituted cyclopentenone 90 catalyzed by [64 • (S)-TRIP]. 
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enones: [64• (S)-TRIP] (cf. Table 4.18). Due to the increased catalytic activity of [64• (S)-
TRIP] compared to the previously employed catalysts [9-NH2-epiQ (13)• 2 TFA] and [(R,R)-
DPEN • (S)-TRIP], the less reactive 3-substituted cyclopentenone derivative 90 could be 
converted to the corresponding epoxide 2,3-epoxy-3-phenethyl-cyclopentanone (91) in 
reasonable yield of 65% with an enantiomeric ratio of 85.5:14.5 er. As a comparison, after 48 
h, the reaction catalyzed by [13 • 2 TFA] had reached only 32% conversion as determined by 
GC. However, under those conditions the product was formed with superior enantioselectivity 
of 91:9 er. 
 
 
 
Scheme 4.10 Asymmetric epoxidation of 3-substituted cyclopentenone 90 catalyzed by [64 • (S)-TRIP]. 
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4.1.3 Summary and Conclusions 
 
In summary, we have successfully developed a method for the highly enantioselective 
epoxidation of simple cyclic enones catalyzed by chiral primary amine salts and employing 
aqueous hydrogen peroxide as a cheap and environmentally benign oxidant. 
Prior to this work, and in spite of the wealth of enantioselective enone epoxidation methods 
known to date, cyclic α,β-epoxy ketones such as 48 have been difficult to access in optically 
active form. Indeed, there was no single asymmetric epoxidation method available which was 
applicable to a broad range of simple cyclic enones of the general structure 46 to furnish the 
corresponding epoxides with satisfying yields and enantioselectivities (cf. Chapter 2.2.6). 
In the course of our screening studies we have identified two powerful and complementary 
chiral primary amine salt catalysts which efficiently mediated the desired transformation: the 
[(R,R)-DPEN (12) • (S)-TRIP (7a)] salt and 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) as 
its trifluoroacetic acid salt [9-NH2-epiQ (13) • 2 TFA]. Both catalyst salts have in common the 
bifunctional nature of the amine component. Whereas the primary amine group was found to 
be crucial for catalytic activity, the second basic site seems to direct the attack of the 
hydrogen peroxide as depicted in Figure 4.1, thus presumably accounting for the improved 
selectivities typically attained in reactions with diamine catalyst salts (cf. Table 4.2). 
Using either catalyst [(R,R)-DPEN • (S)-TRIP] or [9-NH2-epiQ • 2 TFA] at 10 mol% loadings, 
we achieved the highly enantioselective epoxidation of variously substituted cyclohexenone 
derivatives 46. The (R,R)-DPEN-based catalyst system turned out to be particularly suitable 
for cyclohexenone derivatives 46 equipped with substituents at the 4- and 5-positions (Table 
4.10). The 9-amino(9-deoxy)epiquinine salt [9-NH2-epiQ • 2 TFA] provided in addition an 
array of 3-substituted 2,3-epoxycyclohexanones 48 with high yields along with excellent 
enantioselectivities of up to 99.5:0.5 er - including inter alia epoxides 48i-j bearing sterically 
demanding isopropyl and even tert-butyl substituents at the 3-position (Table 4.12). 
Moreover, both catalyst systems were applicable to cyclic enones of different ring sizes 
(Table 4.13). Macrocyclic enones such as 2-cyclododecenone (46v) and 2-
cyclopentadecenone (46x) could be converted into the corresponding epoxides in high yields 
and outstanding enantioselectivity of 99.5:0.5 er in the presence of Cinchona alkaloid-derived 
catalyst [9-NH2-epiQ (13) • 2 TFA]. Interestingly, seven and eight-membered cyclic enones 
46s and 46v, respectively, provided mixtures of the corresponding α,β-epoxyketones along 
with the unanticipated bicyclic peroxyhemiketals 116 and 117 (Scheme 4.3), which will be 
the subject of further investigations described within this thesis (cf. Chapter 4.2.2.6). 
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Among the cyclic enone series, cyclopentenones proved to be particularly challenging 
substrates (cf. Chapter 4.1.2.5). In the reaction of 2-cyclopentenone (46r), both of our 
catalytic systems showed significantly reduced activity and selectivity compared with the 
reactions of the higher homologues. Therefore, we initiated a separate screening to identify a 
chiral primary amine salt with superior catalytic efficiency for the epoxidation of 
cyclopentenone and derivatives. Truncated Cinchona alkaloid 64 (cf. Table 4.18) equipped 
with a less sterically hindered primary amine group than the parent 9-amino(9-
deoxy)epiquinine (13) displayed promising catalytic activity. Gratifyingly, the 
enantioselectivity of 65.5:34.5 er obtained with [64• 2 TFA] could be increased to 76.5:23.5 
er by pairing amine 64 with the chiral BINOL phosphate TRIP (7a). At the same time, the 
high catalytic activity is retained, which also renders catalyst system [64• (S)-TRIP] suitable 
for the epoxidation of less reactive 3-substituted cyclopentenone derivatives such as 3-
phenethyl-2-cyclopentenone (Scheme 4.10). Although not yet optimal, we anticipate that 
these encouraging results may constitute a valid starting point for further developments, 
inspiring future research in this area. 
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4.2 Catalytic Asymmetric Epoxidation and Hydroperoxidation of Acyclic Enones 
After having established a highly efficient and general method for the asymmetric epoxidation 
of cyclic enones catalyzed by chiral primary amine salts, we became interested in expanding 
the scope to acyclic substrates with a focus on aliphatic enolizable enones which still 
constitute challenging substrates for the currently available epoxidation methods. 
4.2.1 Screening Studies 
4.2.1.1 Initial Results 
In a first attempt, we applied the optimized reaction conditions for the epoxidation of cyclic 
enones with 9-amino(9-deoxy)epiquinine (9-NH2-epiQ, 13) TFA salt as the catalyst system to 
the epoxidation of 3-decen-2-one (92a) as an example of a simple aliphatic acyclic enolizable 
enone. After 20 h, we obtained a product mixture consisting of the desired trans-epoxide 93a 
in excellent enantioselectivity of >99.5:0.5 er along with the cyclic peroxyhemiketal (PHK) 
94a in a ratio of 43 to 57 as determined by 1H NMR of the crude mixture (Scheme 4.11). 
 
 
 
Scheme 4.11 Catalytic asymmetric epoxidation of 3-decen-2-one (92a): initial attempt. (aDetermined by 
1H NMR.) 
 
This result was surprising in view of the fact that peroxyhemiketals are typically only isolated 
in minor amounts (as by-products) in Weitz-Scheffer reactions, due to the overwhelming 
preference for epoxide formation under those conditions (cf. Chapter 2.3.2).[111-113] Thus, we 
were highly intrigued by our observation of a peroxyhemiketal-selective “epoxidation” 
reaction, even more so since a catalytic asymmetric hydroperoxidation of α,β-unsaturated 
ketones to obtain optically active peroxides such as 94a was unprecedented in the literature. 
At this stage, we speculated that the chiral amine salt catalyst, e.g. [13 • 2 TFA], might not 
only render enantioselective the conjugate addition of hydrogen peroxide but also affect the 
product distribution between epoxide and peroxyhemiketal. Thus, we decided to optimize the 
catalyst system and reaction conditions towards increased peroxyhemiketal formation. 
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In this context, we tested alternative catalyst systems in the hydroperoxidation-epoxidation 
reaction of 6-phenyl-3-hexen-2-one (92b). (R,R)-DPEN salts such as [(R,R)-DPEN • TFA], 
[(R,R)-DPEN • 2TFA], [(R,R)-DPEN • (S)-TRIP], and [(R,R)-DPEN • (R)-TRIP] displayed 
moderate to high catalytic activity, yet gave inferior results in terms of enantioselectivity with 
acyclic compared to the previously studied cyclic substrates (Table 4.21, entries 3-6). Among 
all catalysts tested, 9-amino(9-deoxy)epiquinine (9-NH2-epiQ, 13) coped best with the main 
challenge arising from the transition from cyclic to acyclic enones, which presumably is the 
control of the s-cis and s-trans geometry, and afforded excellent enantioselectivity also for 
acyclic substrates when employed together with an acid co-catalyst (TFA) in a ratio of 1:2 
(entry 2). A 1:1 amine/TFA ratio led to only slightly lower enantioselectivity, but 
significantly reduced catalyst activity (entry 1). 
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α,β-epoxy iminium ion D (step (d)). However, the epoxidation pathway may be converted 
into a hydroperoxidation pathway if β-peroxyenamine B may be trapped by protonation (step 
(e)). β-Hydroperoxy iminium ion C may release a β-peroxyketone upon hydrolysis (step (f)), 
which in the case of acyclic enones such 3-decen-2-one (92a) exists in equilibrium 
exclusively as the cyclic peroxyhemiketal 94. 
Indeed, there are only isolated cases evident in the literature where the β-hydroperoxide  
generated by conjugate addition of hydrogen peroxide to α,β-unsaturated carbonyl 
compounds could be isolated.[111-113, 132] Yet, none of them allows access to β-hydroperoxides 
in optically active form. 
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Scheme 4.12 Hypothetical catalytic cycle: hydroperoxidation vs. epoxidation pathway in the reaction of acyclic 
enones (92). 
 
As for the epoxidation of cyclic enones, we reckoned that while the primary amine function of 
9-amino(9-deoxy)epiquinine (13) activates the enone as iminium ion in cooperation with the 
acid co-catalyst, the quinuclidine moiety either as the free base (Figure 4.6, E), or in 
protonated form (F) may bind the hydrogen peroxide via hydrogen bonding interactions,[48a] 
thereby bringing it into close proximity to the reactive center and directing its attack to one 
face of the double bond. 
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Figure 4.6 Putative pre-transition state assemblies E and F for the conjugate addition of hydrogen peroxide to 
iminium ion A. 
 
When the epoxide is formed the O–O bond must be anti-periplanar to the enamine π-system 
to enable overlap with the O–O anti-bonding orbital. Taking this into account, we rationalized 
the preference for the hydroperoxidation pathway under our reaction conditions as an 
apparent failure of peroxyenamine intermediate B to adopt the requisite O–O bond orientation 
by which the enamine is optimally aligned for epoxide formation to take place such as in B' 
(Scheme 4.12). Presumably, secondary catalyst-substrate interactions via hydrogen bonding 
between the peroxyenamine moiety and the covalently linked Cinchona alkaloid scaffold 
might rigidify β-peroxyenamine intermediate B. This might impede its bond-rotational 
freedom (cf. equilibrium between B and B'). As a result, the peroxyenamine intermediate B 
may be stabilized and the barrier associated with epoxide formation may have become so high 
that peroxyenamine B is relegated to protonation and the reaction terminated at the 
hydroperoxidation stage. 
On the basis of our mechanistic hypothesis, we reckoned that we could possibly further 
influence the peroxy hemiketal to epoxide ratio by the choice of the acid co-catalyst and by 
further fine-tuning of the reaction conditions. In this, we considered that an increased water 
content in the system might benefit the protonation and subsequent hydrolysis of β-
peroxyenamine intermediate B prior to the irreversible epoxide ring closure. The acidity of 
the acid co-catalyst might influence the partitioning of the peroxyenamine intermediate B 
between the hydroperoxidation and epoxidation pathways insofar that a relatively strong acid 
co-catalyst might interfere with the multipoint binding interactions to the covalently linked 
quinine scaffold, with the result that the conformational rigidity might be reduced. Moreover, 
a strong acid co-catalyst should be able to bring forward epoxide formation by enhancement 
of the nucleofugacity of the hydroxyl moiety by protonation of the distal oxygen atom of the 
peroxy moiety in intermediate B. On the contrary, the use of a weaker acid might promote the 
hydroperoxidation pathway. 
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4.2.1.2 Optimization of the Catalytic System 
Indeed, when we studied the influence of different acid co-catalysts on the reaction of enone 
substrate 92a with hydrogen peroxide in the presence of 9-amino(9-deoxy)epiquinine (9-NH2-
epiQ; 13) as its TFA salt [13 • 2 TFA], we found a correlation between the pKa value of the 
acid and the peroxyhemiketal to epoxide ratio (Table 4.22).[133] Whereas a relatively strong 
acid such as para-toluene sulfonic acid gave predominately the epoxide (entries 1-3), the 
peroxyhemiketal was obtained as major product in presence of weaker acids (entries 4-29). 
Moreover, a decrease in temperature favoured PHK formation. Whereas the PHK-epoxide 
ratio was 57:43 at 50 °C, (entry 4) it could be increased to 73:27 by lowering the temperature 
to 10 °C albeit at the expense of reactivity (entry 8); 32 °C appeared to be optimal with regard 
to both selectivity and reactivitiy (entry 5). An increase in the amount of acid co-catalyst 
slightly enhanced the catalyst activity; however, the increased activity came along with 
reduced PHK selectivity (entries 7-8). The use of acids with a pKa greater than 2 benefits the 
peroxyhemiketal-epoxide ratio but entails diminished catalyst efficiency. 2,4-Dinitrobenzoic 
acid (pKa ~2.17) does promote the reaction giving a PHK-epoxide ratio of 75:25 - albeit at a 
lower rate (entry 24). The same holds true for 3,3,3-trifluoropropanoic acid (pKa 3.07) (entry 
10). However, acetic acid (pKa 4.76) as well as benzoic acid (pKa 4.20) were both ineffective 
(entries 19-20, 23). The best compromise between selectivity and reactivity was exhibited by 
trichloroacetic acid (pKa 0.65) with a PHK-epoxide ratio of 72:28 and virtually full 
conversion after 24 h at 28 °C (entry 15). Thus the 9-amino(9-deoxy)epiquinine (13) TCA salt 
[13 • 2 TCA] was used in further optimization experiments. 
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acid and the peroxyhemiketal to epoxide ratio (Table 4.22).[133] Whereas a relatively strong 
acid such as para-toluene sulfonic acid gave predominately the epoxide (entries 1-3), the 
peroxyhemiketal was obtained as major product in presence of weaker acids (entries 4-29). 
Moreover, a decrease in temperature favoured PHK formation. Whereas the PHK-epoxide 
ratio was 57:43 at 50 °C, (entry 4) it could be increased to 73:27 by lowering the temperature 
to 10 °C albeit at the expense of reactivity (entry 8); 32 °C appeared to be optimal with regard 
to both selectivity and reactivitiy (entry 5). An increase in the amount of acid co-catalyst 
slightly enhanced the catalyst activity; however, the increased activity came along with 
reduced PHK selectivity (entries 7-8). The use of acids with a pKa greater than 2 benefits the 
peroxyhemiketal-epoxide ratio but entails diminished catalyst efficiency. 2,4-Dinitrobenzoic 
acid (pKa ~2.17) does promote the reaction giving a PHK-epoxide ratio of 75:25 - albeit at a 
lower rate (entry 24). The same holds true for 3,3,3-trifluoropropanoic acid (pKa 3.07) (entry 
10). However, acetic acid (pKa 4.76) as well as benzoic acid (pKa 4.20) were both ineffective 
(entries 19-20, 23). The best compromise between selectivity and reactivity was exhibited by 
trichloroacetic acid (pKa 0.65) with a PHK-epoxide ratio of 72:28 and virtually full 
conversion after 24 h at 28 °C (entry 15). Thus the 9-amino(9-deoxy)epiquinine (13) TCA salt 
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Table 4.22 Evaluation of the influence of acid co-catalysts (HX) on the PHK 94a to epoxide 93a ratio in the 
[13 • HX]-catalyzed reaction of 3-decen-2-one (92a) with aqueous hydrogen peroxide. 
 
 
 
Entry Acid co-catalyst (HX) pKa (H2O)a [mol%] T [° C] Conv. [%]b 94a:93ac er(93a)d 
1 
pTsOH • H2O -2.80 
20 28 82 (48 h) 35:65 98:2 
2 30 28 98 (48 h)e 31:69 92:8 
3 30 10 65 (48 h) 35:65 94.5:5.5 
4 
 
(TFA) 
0.52 
20 50 full (20 h) 57:43 >99.5:0.5 
5 20 32 full (24 h) 68:32 >99.5:0.5 
6 20 28 95 (24 h) 70:30 >99.5:0.5 
7 30 28 97 (48 h) 72:28 >99.5:0.5 
8 30 10 76 (48 h) 73:27 >99.5:0.5 
9 
 
n.a. 20 32 97 (24 h) 69:31 >99.5:0.5 
10 
 
3.07 20 32 44 (28 h) n.d. 99.5:0.5 
11 
 
n.a. 20 32 full (24 h) 68:32 >99.5:0.5
12 OH
O
F
F  
1.24 20 32 88 (48 h) 78:22 >99.5:0.5 
13 
 
(TCA) 
0.65 
20 50 full (20 h) 60:40 >99.5:0.5 
14 20 32 full (24 h) 70:30 >99.5:0.5 
15 20 28 97 (24 h) 72:28 >99.5:0.5 
16 20 20 90 (48 h) 75:25 >99.5:0.5 
17 20 10 79 (48 h) 75:25 >99.5:0.5 
18 
 
1.35 20 32 84 (48 h) 77:23 >99.5:0.5 
19 
HOAc 4.76 
20 28 <10 n.d. n.d.
20 30 28 <10 n.d. n.d.
21 EtCO2H 4.87 20 28 <10 n.d. n.d.
22 i-PrCO2H n.a. 20 28 <10 n.d. n.d.
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Entry Acid pKa (H2O)a [mol%] T [° C] Conv. [%]b 94a:93ac er(93a)d 
23 PhCO2H 4.20 20 28 15 n.d. 95.5:4.5 
24 2,4-(NO2)2-C6H4CO2H 2.17f 20 32 98% (48 h) 75:25 99.5:0.5 
25 4-NO2-C6H4CO2H 3.44 20 32 45 (28 h) n.d. n.d.
26 2,6-F2-C6H3CO2H n.a. 20 32 52 (28 h) n.d. n.d.
27 3,5-(CF3)2-C6H3CO2H n.a. 20 32 43 (28 h) n.d. n.d.
28 4-Cl-C6H4CO2H 3.99 20 32 23 (28 h) n.d. n.d.
29 (PhO)2PO(OH) 1.29g 20 32 96 (24 h) 64:36 99.5:0.5 
aThe pKa values are adopted from the pKa compilations of Williams and Bordwell.[133] bDetermined by GC. 
cDetermined by 1H NMR of the crude mixture. dDetermined by chiral GC. eExtensive side product formation 
observed.[134] fpKa of 2-NO2-C6H4CO2H gpKa of (MeO)2PO(OH). 
 
4.2.1.3 Optimization of the Reaction Conditions 
Further experiments were aimed at evaluating the dependency of the product distribution on 
the reaction time. To this end, samples were taken from an exemplary reaction at different 
time intervals (Table 4.23). The PHK-epoxide ratio remained unchanged between 4.5 and 28 
hours of reaction time (entries 1-3). Only upon extended stirring of the reaction for 10 days, 
did the peroxide to epoxide ratio drop from 72:28 to 66:34 (entry 4). Although this is only a 
slight decrease in peroxide, it is crucial to stop the hydroperoxidation reactions without delay 
once the starting material is consumed to ensure maximum yields of the PHK products. 
 
Table 4.23 Tracing the peroxyhemiketal to epoxide ratio over time. 
 
 
Entry t [h] Conv. [%]a 94a:93a ratioa 
1 4.5 42 71:29 
2 24 97 72:28 
3 28 full 72:28 
4 10 d full 66:34 
aDetermined by 1H NMR of the crude mixture. 
 
Next, we were interested in reducing the catalyst loading as much as possible without 
affecting its efficiency (Scheme 4.13). However, with only 5 mol% [13 • 3 TCA] the reaction 
rate dropped significantly and the reaction was complete only after 48 h.a Based on this result, 
10 mol% of catalyst were used in further experiments. 
                                                 
a [13 • 3 TCA] was chosen instead of  [13 • 2 TCA] since a 3:1 acid/9-amino(9-deoxy)epiquinine ratio seemed to 
have a beneficial effect on the catalyst activity (Table 4.22, entry 6 vs. 7). 
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Scheme 4.13 Effect of the catalyst loading on the reaction efficiency. (aDetermined by 1H NMR of the crude 
mixture; bDetermined by chiral GC.) 
 
A screening of different ethereal solvents validated 1,4-dioxane as the solvent of choice, as 
previously observed in the catalytic asymmetric epoxidation of cyclic enones (Table 4.24, 
entry 5; cf. Table 4.9). In Et2O and MTBE the catalyst system [13 • 2 TCA] showed 
comparable activity; yet the PHK to epoxide ratio was unfavourably affected (entries 2 and 4). 
Nonetheless, both may be alternative solvents for applications which directly target epoxide 
synthesis rather than formation of peroxyhemiketals (cf. Chapter 4.2.2.2). Moreover, MTBE 
might also be a suitable substitute for 1,4-dioxane in large-scale applications (with the 
advantage of MTBE being for instance its lower hazardous potential). 
Increasing the substrate concentration from 0.25 M to 0.5 M had a positive effect on the PHK-
epoxide ratio but was accompanied by increasing formation of unidentified side products 
(entry 6). As the concentration was lowered (0.125 M), proportionally more epoxide was 
obtained (entry 7). On the basis of these results, the screening studies were continued in 
dioxane at a substrate concentration of 0.25 M (entry 5). 
 
Table 4.24 Screening of various ethereal solvents at different concentrations. 
 
solvent, 32 °C, 24 h
[13 2 TCA] (10 mol%)
H2O2 (50 wt%; 1.5 equiv)
n-C6H13 Me
O
n-C6H13
O O
Me
OH
94a (~1:1 dr)92a
n-C6H13 Me
O
O
93a  
Entry Solvent Conc. [M] Conv. [%]a 94a:93a ratiob er(93a)c 
1 THF 0.25 43 n.d. n.d. 
2 Et2O 0.25 99 65:35 99:1 
3 DME 0.25 38 n.d. n.d. 
4 MTBE 0.25 full 68:32 99.5:0.5 
5 dioxane 0.25 full 70:30 >99.5:0.5 
6 dioxane 0.5 fulld 71:29 >99.5:0.5 
7 dioxane 0.125 89 67:33 >99.5:0.5 
aDetermined by GC. bDetermined by 1H NMR of the crude mixture. cDetermined by chiral GC. dIncreasing side 
product formation observed. 
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Next, we focused on the effect of the concentration of hydrogen peroxide (Table 4.25). Two 
trends emerged: The peroxyhemiketal to epoxide ratio increased as the amount of hydrogen 
peroxide increased (entries 1-4). Moreover, the use of less concentrated solutions of hydrogen 
peroxide (30 wt% instead of 50 wt%-solutions) had a beneficial effect (entry 2 vs. 5). A PHK-
epoxide ratio of 80:20 was obtained by using 3 equivalents of a 30 wt% aqueous hydrogen 
peroxide solution (entry 7). Indeed, higher dilution (25 wt% aqueous hydrogen peroxide) 
further increased this value albeit at the expense of catalyst efficiency with regard to both 
activity and selectivity (entries 8-11). 
 
Table 4.25 Optimization of the hydrogen peroxide concentration. 
 
n-C6H13 Me
O
n-C6H13
O O
Me
OH
94a (~1:1 dr)
dioxane (0.25 M), 32 °C
[13 2 TCA] (10 mol%)
aqueous H2O2
92a
n-C6H13 Me
O
O
93a  
Entry H2O2 equiv. H2O2 conc. [wt%] Conv. [%]a 94a:93a ratiob er(93a)c 
1 1.2 50 full (24 h) 65:35 >99.5:0.5 
2 1.5 50 full (24 h) 70:30 >99.5:0.5 
3 2 50 full (24 h) 71:29 >99.5:0.5 
4 5 50 full (24 h) 76:24 99.5:0.5 
5 1.5 30 full (24 h) 76:24 >99.5:0.5 
6d 1.5 30 full (36 h) 77:23 >99.5:0.5 
7 3 30 full (24 h) 80:20 >99.5:0.5 
8 1.5 25 full (30 h) 78:22 >99.5:0.5 
9 3 25 full (30 h) 81:19 99.5:0.5 
10 1.5 10 79 (6 d) 78:22 99:1 
11 1.5 5 57 (6 d) n.d. 98:2 
aDetermined by GC. bDetermined by 1H NMR of the crude mixture. cDetermined by chiral GC. dAt 28 °C. 
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4.2.1.4 Tert-butylhydroperoxide as the Oxidant 
Although hydrogen peroxide is arguably the most attractive oxidant with respect to environ-
mental and economic considerations it was interesting to find out how our system would 
respond to other oxidants. Initial experiments with aqueous tert-butylhydroperoxide (70 wt%) 
gave also promising, yet inferior results compared to the catalytic reaction with aqueous 
hydrogen peroxide as oxidant under otherwise identical conditions (Table 4.26). 
 
Table 4.26 Screening of alternative oxidants: tert-butylhydroperoxide. 
 
 
Entry R1 R2 Enone Peroxide Epoxide Yield (95:93 ratio) [%]a er(93)b 
1 Me Et 92c (5S)-95c (4R,5S)-93c 88 (82:6) 14.5:85.5 
2 n-C6H13 Me 92a (4R)-95a (3S,4R)-93a 91 (55)c (70:21) 99:1 
aDetermined by GC. bDetermined by chiral GC. cIsolated yield of pure 95a in parentheses. 
 
Very much like in the catalytic reaction with hydrogen peroxide, α,β-epoxy ketone 93 was 
only formed in minor amounts. In contrast, the product of the conjugate addition of tert-
butylhydroperoxide (TBHP) – tert-butylperoxide 95 was obtained as the major product with 
high selectivities. An intriguing feature was the inverted enantiofacial selectivity observed in 
the reaction of 4-hexen-3-one (92c) compared to the corresponding hydrogen peroxide 
reaction (entry 1, cf. Table 4.30, entry 18). 
In general, we assume that acyclic α,β-unsaturated ketones 92 or the corresponding 
unsaturated iminium ions generated in the presence of catalyst [13 • 2 TXA] (with X = Cl, F), 
respectively, react preferentially in the s-trans conformation which is in agreement with the 
observed absolute stereochemistry of both cyclic and acyclic enones (cf. Chapter 4.5.4). We 
speculate that the formation of the opposite epoxide enantiomer might indicate participation 
of the s-cis conformation. Moreover, epoxide 93c was formed with relatively low enantio-
selectivity of 85.5:14.5 er which may support a competition of s-cis and s-trans reactive 
conformations. 
The equilibrium distribution of s-trans and s-cis conformations of α,β-unsaturated ketones 
depends on the extent of van der Waals interaction between substituents (Table 4.27).[135] In 
3-penten-2-one (R1=R2=Me) the mole fraction of the s-cis conformer in equilibrium amounts 
to 30% (entry 2). Yet, this value progressively increases as the size of the alkyl group R2 
4 Results and Discussion 
 87
4.2.1.4 Tert-butylhydroperoxide as the Oxidant 
Although hydrogen peroxide is arguably the most attractive oxidant with respect to environ-
mental and economic considerations it was interesting to find out how our system would 
respond to other oxidants. Initial experiments with aqueous tert-butylhydroperoxide (70 wt%) 
gave also promising, yet inferior results compared to the catalytic reaction with aqueous 
hydrogen peroxide as oxidant under otherwise identical conditions (Table 4.26). 
 
Table 4.26 Screening of alternative oxidants: tert-butylhydroperoxide. 
 
 
Entry R1 R2 Enone Peroxide Epoxide Yield (95:93 ratio) [%]a er(93)b 
1 Me Et 92c (5S)-95c (4R,5S)-93c 88 (82:6) 14.5:85.5 
2 n-C6H13 Me 92a (4R)-95a (3S,4R)-93a 91 (55)c (70:21) 99:1 
aDetermined by GC. bDetermined by chiral GC. cIsolated yield of pure 95a in parentheses. 
 
Very much like in the catalytic reaction with hydrogen peroxide, α,β-epoxy ketone 93 was 
only formed in minor amounts. In contrast, the product of the conjugate addition of tert-
butylhydroperoxide (TBHP) – tert-butylperoxide 95 was obtained as the major product with 
high selectivities. An intriguing feature was the inverted enantiofacial selectivity observed in 
the reaction of 4-hexen-3-one (92c) compared to the corresponding hydrogen peroxide 
reaction (entry 1, cf. Table 4.30, entry 18). 
In general, we assume that acyclic α,β-unsaturated ketones 92 or the corresponding 
unsaturated iminium ions generated in the presence of catalyst [13 • 2 TXA] (with X = Cl, F), 
respectively, react preferentially in the s-trans conformation which is in agreement with the 
observed absolute stereochemistry of both cyclic and acyclic enones (cf. Chapter 4.5.4). We 
speculate that the formation of the opposite epoxide enantiomer might indicate participation 
of the s-cis conformation. Moreover, epoxide 93c was formed with relatively low enantio-
selectivity of 85.5:14.5 er which may support a competition of s-cis and s-trans reactive 
conformations. 
The equilibrium distribution of s-trans and s-cis conformations of α,β-unsaturated ketones 
depends on the extent of van der Waals interaction between substituents (Table 4.27).[135] In 
3-penten-2-one (R1=R2=Me) the mole fraction of the s-cis conformer in equilibrium amounts 
to 30% (entry 2). Yet, this value progressively increases as the size of the alkyl group R2 
4 Results and Discussion 
 87
4.2.1.4 Tert-butylhydroperoxide as the Oxidant 
Although hydrogen peroxide is arguably the most attractive oxidant with respect to environ-
mental and economic considerations it was interesting to find out how our system would 
respond to other oxidants. Initial experiments with aqueous tert-butylhydroperoxide (70 wt%) 
gave also promising, yet inferior results compared to the catalytic reaction with aqueous 
hydrogen peroxide as oxidant under otherwise identical conditions (Table 4.26). 
 
Table 4.26 Screening of alternative oxidants: tert-butylhydroperoxide. 
 
 
Entry R1 R2 Enone Peroxide Epoxide Yield (95:93 ratio) [%]a er(93)b 
1 Me Et 92c (5S)-95c (4R,5S)-93c 88 (82:6) 14.5:85.5 
2 n-C6H13 Me 92a (4R)-95a (3S,4R)-93a 91 (55)c (70:21) 99:1 
aDetermined by GC. bDetermined by chiral GC. cIsolated yield of pure 95a in parentheses. 
 
Very much like in the catalytic reaction with hydrogen peroxide, α,β-epoxy ketone 93 was 
only formed in minor amounts. In contrast, the product of the conjugate addition of tert-
butylhydroperoxide (TBHP) – tert-butylperoxide 95 was obtained as the major product with 
high selectivities. An intriguing feature was the inverted enantiofacial selectivity observed in 
the reaction of 4-hexen-3-one (92c) compared to the corresponding hydrogen peroxide 
reaction (entry 1, cf. Table 4.30, entry 18). 
In general, we assume that acyclic α,β-unsaturated ketones 92 or the corresponding 
unsaturated iminium ions generated in the presence of catalyst [13 • 2 TXA] (with X = Cl, F), 
respectively, react preferentially in the s-trans conformation which is in agreement with the 
observed absolute stereochemistry of both cyclic and acyclic enones (cf. Chapter 4.5.4). We 
speculate that the formation of the opposite epoxide enantiomer might indicate participation 
of the s-cis conformation. Moreover, epoxide 93c was formed with relatively low enantio-
selectivity of 85.5:14.5 er which may support a competition of s-cis and s-trans reactive 
conformations. 
The equilibrium distribution of s-trans and s-cis conformations of α,β-unsaturated ketones 
depends on the extent of van der Waals interaction between substituents (Table 4.27).[135] In 
3-penten-2-one (R1=R2=Me) the mole fraction of the s-cis conformer in equilibrium amounts 
to 30% (entry 2). Yet, this value progressively increases as the size of the alkyl group R2 
4 Results and Discussion 
 87
4.2.1.4 Tert-butylhydroperoxide as the Oxidant 
Although hydrogen peroxide is arguably the most attractive oxidant with respect to environ-
mental and economic considerations it was interesting to find out how our system would 
respond to other oxidants. Initial experiments with aqueous tert-butylhydroperoxide (70 wt%) 
gave also promising, yet inferior results compared to the catalytic reaction with aqueous 
hydrogen peroxide as oxidant under otherwise identical conditions (Table 4.26). 
 
Table 4.26 Screening of alternative oxidants: tert-butylhydroperoxide. 
 
 
Entry R1 R2 Enone Peroxide Epoxide Yield (95:93 ratio) [%]a er(93)b 
1 Me Et 92c (5S)-95c (4R,5S)-93c 88 (82:6) 14.5:85.5 
2 n-C6H13 Me 92a (4R)-95a (3S,4R)-93a 91 (55)c (70:21) 99:1 
aDetermined by GC. bDetermined by chiral GC. cIsolated yield of pure 95a in parentheses. 
 
Very much like in the catalytic reaction with hydrogen peroxide, α,β-epoxy ketone 93 was 
only formed in minor amounts. In contrast, the product of the conjugate addition of tert-
butylhydroperoxide (TBHP) – tert-butylperoxide 95 was obtained as the major product with 
high selectivities. An intriguing feature was the inverted enantiofacial selectivity observed in 
the reaction of 4-hexen-3-one (92c) compared to the corresponding hydrogen peroxide 
reaction (entry 1, cf. Table 4.30, entry 18). 
In general, we assume that acyclic α,β-unsaturated ketones 92 or the corresponding 
unsaturated iminium ions generated in the presence of catalyst [13 • 2 TXA] (with X = Cl, F), 
respectively, react preferentially in the s-trans conformation which is in agreement with the 
observed absolute stereochemistry of both cyclic and acyclic enones (cf. Chapter 4.5.4). We 
speculate that the formation of the opposite epoxide enantiomer might indicate participation 
of the s-cis conformation. Moreover, epoxide 93c was formed with relatively low enantio-
selectivity of 85.5:14.5 er which may support a competition of s-cis and s-trans reactive 
conformations. 
The equilibrium distribution of s-trans and s-cis conformations of α,β-unsaturated ketones 
depends on the extent of van der Waals interaction between substituents (Table 4.27).[135] In 
3-penten-2-one (R1=R2=Me) the mole fraction of the s-cis conformer in equilibrium amounts 
to 30% (entry 2). Yet, this value progressively increases as the size of the alkyl group R2 
4  Results and Discussion 
88 
increases beyond methyl. Although the situation in the corresponding iminium ions might 
differ significantly, the s-cis/s-trans equilibrium should always be considered while analyzing 
the results obtained with acyclic enone substrates. 
 
Table 4.27 Equilibrium distribution of s-trans and s-cis conformations of α,β-unsaturated ketones.[135] 
 
 
Entry R1 R2 s-trans [%] s-cis [%] 
1 H Me 73 27 
2 Me Me 70 30 
3 Me Et 55 45 
4 Me i-Pr 30 70 
5 Me t-Bu 0 100 
 
Nevertheless, it can not be ruled out that the reaction of 4-hexen-3-one (92c) proceeds through 
a distinct, competing mechanism which accounts for the inverted enantiofacial selectivity, 
potentially involving activation by hydrogen bonding interactions. 
In fact, subsequent experiments validated the assumption of a substrate-specific effect in that 
our standard substrate 3-decen-2-one (92a) showed the same facial selectivity as previously 
observed in the reaction with hydrogen peroxide as terminal oxidant (Table 4.26, entry 2). 
With TBHP as oxidant under otherwise identical reaction conditions, tert-butylperoxide 95a 
was obtained in good yield along with high enantioselectivity of 99:1 er. 
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Thus, tert-butyl hydroperoxide not only constitutes an alternative oxidant for the synthesis of 
epoxides but also provides concise access to interesting optically active β-alkylperoxy ketones 
95 via conjugate addition. Yet, hydrogen peroxide meets all criteria for future applications 
potentially also on an industrial scale: it is inexpensive, readily available, and gives water as 
the only by-product. Thus, we continued our research with hydrogen peroxide as the oxidant 
of choice. 
In 2008, after our group has introduced 9-amino(9-deoxy)epiquinine (13) (as its TFA salt) as 
powerful catalyst for the epoxidation of cyclic enones, the Deng group reported a catalytic 
asymmetric alkylperoxidation of α,β-unsaturated ketones using the same catalyst system [9-
NH2-epiQ (13) • 2-3 TFA] (Scheme 4.14).[121, 136] 
 
 
 
Scheme 4.14 Catalytic asymmetric alkylperoxidation of α,β-unsaturated ketones according to Deng et al.[136] 
 
Further oxidants were not tested since a broad screening of potential oxidizing reagents had 
already been carried out in the context of the asymmetric epoxidation of 2-cyclohexenone (cf. 
Table 4.7). 
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4.2.2 Reaction Scope and Discussion 
Once we had identified the optimal catalyst system and established the optimal reaction 
conditions, we proceeded to investigate the scope of this novel asymmetric transformation. 
The following protocol was applied: the catalytic asymmetric hydroperoxidation of α,β-
unsaturated ketones 92 was conducted in dioxane (0.25 M) at 32 °C in the presence of 9-
amino(9-deoxy)epiquinine TCA salt [13 • 2 TCA] (10 mol%) and with 30 wt% aqueous 
hydrogen peroxide (3 equiv) as oxidant to afford optically active peroxyhemiketal 
diastereomers 94 virtually as a 1:1 mixture of C-1 hemiketal epimers in good yields along 
with high enantioselectivities. Details of the scope of the catalytic asymmetric hydroperoxi-
dation are outlined in the following Section 4.2.2.1. 
 
4.2.2.1 Hydroperoxidation of α,β-Unsaturated Ketones 
The catalytic asymmetric hydroperoxidation of α,β-unsaturated ketones 92 proved to have a 
broad substrate scope. Various α,β-enones 92 were converted to the optically active peroxy-
hemiketals 94 in reasonable to good yields (30-72%) along with high enantioselectivities 
(96:4 to 98.5:1.5 er). In general, the only detected by-products were the corresponding 
epoxides 93, which are easily separated from peroxides 94. The absolute configuration of 
products 94 and 93 was established by reducing peroxide 94b to the corresponding aldol-type 
product 4-hydroxy-6-phenyl-2-hexanone (96b) (see Chapter 4.3.2) and comparing its optical 
rotation with literature data.[137] 4-Hydroxy-6-phenyl-2-hexanone (96b) was obtained as the 
(R)-isomer; absolute configurations of other products 94 and 93 were assigned by analogy. 
α,β-Unsaturated methyl ketones 92 (R2=Me) with linear as well as α'- and β'-branched alkyl 
residues R1 at the β-position were suitable substrates (Table 4.28, entries 1-4). Compared with 
92a-b, and d, 4-cyclohexyl-3-buten-2-one (92e) proved to be slightly less reactive. Moreover, 
the percentage of peroxyhemiketal decreased as the degree of branching in the substituent R1 
increased. With 3-decen-2-one (R1=n-C6H13) it accounted for 80% of the PHK-epoxide 
product mixture, whereas a cyclohexyl substituent such as in enone 92e reduced it to 68%. 
Moreover, our hydroperoxidation reaction features high functional group compatibility 
(entries 5-10). Enones equipped with an ester, keto, or protected hydroxyl group, a halide, or 
an olefin were well tolerated. Notably, the survival of acid labile acetal and silyl ether functio-
nalities testifies the mildness of the adopted reaction conditions (Table 2, entries 7-8). The 
hydroperoxidation reactions were generally conducted on a 0.5 or 1 mmol scale; yet a 3 mmol 
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(~500 mg) scale affected neither the isolated yield nor the observed enantioselectivity 
(entry 1). 
 
Table 4.28 Scope of the hydroperoxidation of α,β-unsaturated methyl ketones 92. 
 
 
Entry R1 Enone Product 94:93 ratioa Yield [%]b er(94)c 
1d n-C6H13 92a 94a 80:20 65 98.5:1.5 
2 PhCH2CH2 92b 94b 78:22 68 97:3 
3 i-Bu 92d 94d 71:29 61 97.5:2.5 
4 Cy 92e 94e 68:32 54 98:2 
5  92f 94f 80:20 69 97.5:2.5 
6  92g 94g 79:21 72 97:3 
7  92h 94h 76:24 64 96.5:3.5 
8 
 
92i 94i 80:20 68 98:2 
9 
 
92j 94j 85:15 70 96.5:3.5 
10e 
 
92k 94k 63:37 30 96:4 
11e  92l 94l - 25
f (98:2)g 
aDetermined by 1H NMR of the crude mixture. bYields of pure, isolated products. cDetermined by chiral GC after 
conversion to the corresponding epoxide with 1N NaOH (1 equiv) in THF. dReaction conducted on a 3 mmol scale. 
eWith [13 • 2 TFA] (10 mol%), H2O2 (50 wt%; 1.5 equiv). f69% conv. determined by 1H NMR. ger of the initially 
formed epoxide 93l. 
 
The hydroperoxidation product derived from keto-enone 92k was isolated in 30% yield. 
1H NMR analysis of the purified peroxidic product 94k revealed a mixture of three isomeric 
peroxyhemiketals consisting of the two 3-hydroxy-1,2-dioxolane diastereomers 94k' and 3-
hydroxy-1,2-dioxane 94k'' which was formed via hemiketalization of the remote keto group 
and obtained as a single diastereomer. The relative configuration of compound 94k'' depicted 
in Scheme 4.15 was tentatively assigned on the basis of anomeric stabilization. 
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Scheme 4.15 Hydroperoxidation of keto-enone 92k: formation of regioisomeric peroxyhemiketals 94k' and 
94k''. (aDetermined by 1H NMR.) 
 
Table 4.29 displays the results obtained with α,β-unsaturated ketones 92 bearing substituents 
R2 other than methyl (R2 ≠ Me). All enones 92c, m-o smoothly participated in the reaction 
and alterations of the steric properties of the aliphatic ketone substituent did not impact 
negatively on the enantioselectivity. However, the desired peroxide was obtained in varying 
yields depending on the steric bias of the substrate (entries 2-6). Increasing the steric demand 
of residue R2 impeded the formation of peroxyhemiketals in favour of the corresponding 
epoxides. For instance, replacing the methyl group in enone 92a (R2 = Me) by an n-pentyl 
group decreased the peroxide to epoxide ratio from 80:20 to 45:55 (entry 1 vs. 2). Somewhat 
surprisingly, with a β'-branched isobutyl group as ketone substituent R2, essentially only the 
epoxide was isolated (entry 3). On the contrary, sterically crowded isopropyl ketone 92o 
exhibited greatly reduced reactivity but still allowed for a reasonable yield of 39% of peroxide 
94o in slightly lower enantioselectivity of 96:4 er (entry 4). Increasing the steric demand of 
substituent R1 also affected the reaction, yet to a minor extent: Whereas 3-hexen-4-one (92c) 
gave 74% of peroxyhemiketal in the crude product mixture, this value was reduced to 63% in 
3-tetradecen-4-one (92p) (entry 5 vs. 6). 
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Table 4.29 Influence of the substituent R2 on the peroxide to epoxide ratio. 
 
 
Entry R1 R2 Enone Product 94:93 ratioa Yield [%]b er(94)c 
1d n-C6H13 Me 92a 94a 80:20 (57:43) 65 98.5:1.5 
2 n-C5H11 n-C5H11 92m 94m 45:55 (25:75) 40 97:3 
3 n-C5H11 i-Bu 92n 94n 5:95 (<1:>99) -e - 
4f Me i-Pr 92o 94o 50:50 39g 96:4 
5 Me Et 92c 94c 74:26 (67:33) 56 97:3 
6 n-C9H19 Et 92p 94p 63:37 (47:53) 48 98:2 
aDetermined by 1H NMR of the crude mixture. Values in parentheses correspond to the reaction with [13 • 2 TFA] 
(10 mol%), H2O2 (50 wt%; 1.5 equiv) at 50 °C. bYields of pure, isolated products. cDetermined by chiral GC after 
conversion to the corresponding epoxide with 1N NaOH (1 equiv) in THF. dConducted on a 3 mmol scale. e90% 
conv. determined by 1H NMR. fWith [13 • 2 TFA] (20 mol%), H2O2 (50 wt%; 1.5 equiv) at 50 °C. g96% conv. 
determined by 1H NMR. 
 
The influence of the reaction conditions on the product distribution between PHK and 
epoxide is dependent on the nature of the substrate as highlighted by the 94:93 values given in 
parentheses for the reaction catalyzed by [13 • 2 TFA] at 50 °C with 50 wt% hydrogen 
peroxide (1.5 equiv). With 7-tridecen-6-one (92m) an increase from 25:75 to 45:55 could be 
achieved by optimizing the reaction conditions (cf. Chapter 4.2.1) which then allows for 
synthetically useful yields of peroxyhemiketal 94m (entry 2). 
 
4.2.2.2 Epoxidation of Acyclic α,β-Unsaturated Ketones 
The reaction of acyclic α,β-unsaturated ketones 92 with hydrogen peroxide in the presence of 
a 9-amino(9-deoxy)epiquinine (13) salt can further serve as entry to optically active α,β-
epoxy ketones 93. 
To this end, [13 • 2 TFA] (10 mol%) was used as catalyst system at 50 °C in dioxane 
(0.25 M) together with 50 wt% hydrogen peroxide (1.5 equiv) as oxidant. These conditions 
bring forward epoxide formation with the result that the epoxide content of the crude product 
mixture is proportionally higher than under the conditions previously established for the 
hydroperoxidation reaction (cf.Chapter 4.2.1.3). 
Yet under the “epoxidation conditions”, substantial amounts of peroxides 94 are still detected 
as by-products in the crude product mixture. Neither prolonged reaction times nor elevated 
temperatures were sufficient to significantly increase the epoxide yield (Table 4.30, entry 2). 
Cyclic peroxyhemiketals of the general type 94 are known to be transformed to the 
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corresponding epoxides under basic conditions (Scheme 4.16, (a)).[110b, 110d] Thus, basic work-
up of the crude product mixture will always enable quantitative epoxide formation 
independent of the initial product distribution between peroxyhemiketal 94 and epoxide 93 
(Scheme 4.16, (b)). 
 
 
Scheme 4.16 (a) Mechanism of the peroxyhemiketal-epoxide rearrangement; (b) General strategy for the 
epoxidation of α,β-unsaturated ketones 92. 
 
Peroxide 94c was cleanly converted to α,β-epoxy ketone 93c in the presence of catalytic 
amounts of aqueous NaOH (Scheme 4.17). However, the reaction was greatly accelerated 
without affecting the optical purity of the product when stoichiometric amounts of base were 
used. 
 
 
Scheme 4.17 Peroxyhemiketal-to-epoxide rearrangement mediated by aqueous NaOH. 
 
Initial attempts to conduct the basic rearrangement following the catalytic reaction in the 
sense of a sequential one-pot process gave good to high yields of pure, isolated α,β-epoxy 
ketones 93 albeit with slightly reduced enantioselectivities. Thus, we decided to carry out an 
aqueous work-up once the hydroperoxidation-epoxidation reaction was complete, and then 
treat the crude product containing peroxide 94 and epoxide 93 with 1N aqueous NaOH (1 
equiv) in THF or diethyl ether at room temperature until TLC analysis indicated full 
conversion to the epoxide (generally within less than 20 min). According to this protocol, a 
wide range of α,β-epoxy ketones 93 were obtained in good to high yields (50-90%) as a 
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single diastereomer along with excellent enantioselectivities (96.5:3.5 to 99.5:0.5 er) (Table 
4.30). 
 
Table 4.30 Substrate scope of the catalytic asymmetric epoxidation of α,β-unsaturated ketones 92. 
 
 
 
Entry R1 R2 Enone Product 94:93 ratioa Yield [%]b erc 
1 n-C6H13 Me 92a 93a 57:43 75 98.5:1.5 
2d n-C6H13 Me 92a 93a 51:49 n.d. n.d. 
3e n-C6H13 Me 92a ent-93a 70:30 81 96:4 
4 PhCH2CH2 Me 92b 93b 56:44 85 98.5:1.5 
5e PhCH2CH2 Me 92b ent-93b 72:28 90 95:5 
6i PhCH2 Me 92q 93q 47:53 70a,f 99:1 
7 i-Bu Me 92d 93d 71:29 77 98.5:1.5 
8 
 
Me 92r 93r 45:55 81 >99.5:0.5
9 i-Pr Me 92s 93s 52:48 50g 98:2 
10 Cy Me 92e 93e 42:58 84 98.5:1.5 
11  Me 92f 93f 63:37 76 98.5:1.5 
12  Me 92g 93g 67:33 75 98.5:1.5 
13  Me 92h 93h 58:42 88 98:2 
14 
 
Me 92i 93i 66:34 72 98.5:1.5 
15h 
 
Me 92j 93j 68:32 81 98:2 
16i 
 
Me 92k 93k 58:42 40 98.5:1.5 
17i  Me 92l 93l 50:50 51
j 98:2 
18 Me Et 92c 93c 67:33 55g 98.5:1.5 
19 n-C9H19 Et 92p 93p 47:53 82 99:1 
20k n-C5H11 n-C5H11 92m 93m 25:75 76 99:1 
21k,i n-C5H11 i-Bu 92n 93n <1:>99 81 >99.5:0.5
22k Me i-Pr 92o 93o 50:50 60g 96.5:3.5 
aDetermined by 1H NMR of the crude mixture.bYields of pure, isolated products. cDetermined by chiral GC. d7 d. 
eWith [67 • 2 TFA] (10 mol%). fSum of 93q and the corresponding PHK 94q (at 94% conv. determined by 
1H NMR). gReduced yield due to the high volatility of the product. hNaOEt (1 equiv) was used instead of NaOH. 
iSecond step was omitted. jSum of 93l and the corresponding PHK 94q (at 69% conv. determined by 1H NMR). 
kWith [13 • 2 TFA] (20 mol%). 
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Various α,β-enones 92 bearing linear and branched alkyl groups both at the β-position and 
adjacent to the carbonyl were suitable substrates giving optically active epoxides 93 regard-
less of the steric congestion in >98.5:1.5 er in most of the cases. Substrates which stood out 
were 6,6-dimethyl-3-hepten-2-one (92r) and 2-methyl-5-undecen-4-one (92n) (entries 8 and 
21). Both furnished the corresponding epoxides 93r and 93n, respectively, with an 
exceptional enantiomeric ratio of >99.5:0.5 and in high yields. Moreover, with enone 92n the 
epoxide was the only product detected whereas formation of the corresponding 
peroxyhemiketal was not observed. 
Gratifyingly, pseudoenantiomeric 9-amino(9-deoxy)epiquinidine (9-NH2-epiQD; 67) as its 
TFA salt afforded opposite enantiomeric epoxides with only slightly lower enantioselectivity, 
as exemplified by the epoxidation of enones 92a-b in presence of [67 • 2 TFA] (entries 3 and 
5). Pseudoenantiomeric catalyst [67 • 2 TFA] emerged as slightly more active than its 
quinine-derived analogue [13 • 2 TFA] and the corresponding epoxides 93a-b were obtained 
in high yields along with 96:4 er and 95:5 er, respectively. 
In contrast to the hydroperoxidation, the procedure for the epoxidation requires basic 
conditions for the peroxide-epoxide rearrangement which creates an additional challenge in 
terms of functional group compatibility (entries 11-17). Enones 92f-i corresponded well to the 
two-step protocol and gave the desired functionalized α,β-epoxy ketones 93f-i in good yields 
and high enantioselectivities. Clean conversion of dienone 92f to α,β-epoxy ketone 93f 
illustrated the selectivity for electron-deficient olefins. Despite the short exposure time, the 
ethyl ester group of enone 92j was partly saponified in the presence of 1N NaOH (1 equiv) 
resulting in only a moderate 47% yield of epoxide 93j, yet in high enantioselectivity of 98:2 
er. The use of NaOEt (1 equiv) as base in ethanol cleared that issue and α,β-epoxy ketone 93j 
was isolated in 81% yield and identical optical purity (entry 15). In case of substrate 92k, the 
second step was omitted since the base treatment did not improve the yield of epoxide 93k 
(26%, 96:4 er). Product loss might arise from competing base-catalyzed aldol reaction. Thus, 
epoxide 93k was isolated from the peroxide-epoxide product mixture in 40% yield along with 
98.5:1.5 er (entry 16). 
The reaction of 9-hydroxy-3-nonen-2-one (92l) equipped with an unprotected hydroxyl group 
stopped at 69% conversion as determined by 1H NMR of the crude product and did not 
progress even upon extended runtime (entry 17). Epoxide 93l could not be easily separated by 
column chromatography from the remaining starting material and was obtained in a moderate 
yield of 20% along with the corresponding peroxyhemiketal 94l (25%), albeit with high 
enantioselectivity (98:2 er). 
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Unprotected hydroxyl enones 92t-u were less suitable substrates for our catalytic reaction 
(Scheme 4.18). The nature of the competing pathway was dependent on the chain length 
between the hydroxyl group and the enone moiety. Whereas 7-hydroxy-3-hepten-2-one (92t) 
furnished exclusively racemic substituted tetrahydrofuran 97 via intramolecular conjugate 
addition of the pendant hydroxyl group (Scheme 4.18, (a)), 6-hydroxy-3-hexen-2-one (92u) 
suffered from elimination as major side reaction which generated hexa-3,5-dien-2-one (98) a 
as side product (Scheme 4.18, (b)). 
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Scheme 4.18 Specific side reaction patterns with substrates 92t and 92u. (aDetermined by 1H NMR; bDetermined by 
GC.) 
 
Enones equipped with free hydroxyl groups constitute problematic substrates giving either 
low conversion or diverse side reactions. However, CAN-catalyzed deprotection of the THP 
ether functionality in epoxide 93h cleanly provided 3,4-epoxy-9-hydroxy-2-nonanone (93l) in 
88% yield (Scheme 4.19).[138] Deprotection of the THP ether under standard conditions using 
catalytic para-toluenesulfonic acid in methanol was impeded by competing epoxide ring 
opening entailing a moderate yield of product 93l. 
 
 
 
Scheme 4.19 CAN-catalyzed THP ether deprotection of epoxide 93h. 
 
                                                 
a Determined by GC-MS. 
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4  Results and Discussion 
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4.2.2.3 Effect of the Enone Geometry 
We also investigated the influence of the olefin geometry on the [13 • 2 TFA]-catalyzed 
epoxidation reaction. Remarkably, enones (E)-92b and (Z)-92b furnished the same 
enantiomer of trans-epoxide 93b in very high enantioselectivity evidencing its complete 
stereoconvergency (Scheme 4.20). Thus, this transformation does not require the use of pure 
enone isomers 92; E/Z-mixtures can also be employed (if necessary) without any problems. 
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Scheme 4.20 Effect of the enone geometry on the catalytic asymmetric epoxidation reaction: illustration of the 
stereoconvergency. 
 
GC-MS analysis of samples taken from the epoxidation of pure (Z)-enone 92b revealed the 
formation of the (E)-enone 92b indicating a rapid isomerisation of the (Z)-enone to the 
corresponding (E)-isomer under reaction conditions prior to enantioselective epoxidation. (Z)-
enone 92b also isomerizes in the presence of only catalytic amounts of the primary amine salt 
[13 • 2 TFA] - and without assistance of hydrogen peroxide. This suggests that isomerization 
takes place via a dienamine intermediate which allows free rotation about the carbon-carbon 
single bound as illustrated in Scheme 4.21. 
The observation that trans-epoxide 92b was formed from (Z)-enone 92b with slightly lower 
optical purity than in the reaction of the corresponding (E)-enone may be rationalized by a 
minor contribution of conjugate addition of hydrogen peroxide prior to isomerization to the 
iminium ion A with (Z)-configuration which should deliver the opposite enantiomeric product 
(cf. Figure 4.16 vide infra). 
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Scheme 4.21 Isomerization of (Z)-enone (Z)-92b in the presence of [13 • 2 TFA] via dienamine intermediates B 
and C. 
 
The progress of the isomerization was monitored by GC-MS. Samples were taken from the 
reaction mixture at different time intervals and GC-MS analysis revealed that the starting (Z)-
enone 92b was isomerized after 20, 40, and 120 min to 35, 50 and 75%, respectively. After 15 
h, the (E)-isomer accounted for 99% of enone 92b. Only trace amounts of (Z)-enone 92b were 
present in the reaction mixture at this stage. Moreover in absence of hydrogen peroxide, 
regioisomeric enone iso-92 was detected by GC-MS after extended reaction times. Whereas γ-
protonation of dienamine C gives rise to the formation of (E)-92b (via iminium ion D), 
regioisomeric enone iso-92 presumably is generated via competing α-protonation.a, [139] An 
alternative mechanism for the double bond isomerisation may be taken into considerations 
which is the reversible conjugate addition of the amine base 9-amino(9-deoxy)epiquinine 
(13).[140] 
However, the observation of deconjugated starting material iso-92 in the reaction mixture 
supports the involvement of dienamine intermediates in the isomerisation process. Dienamine 
intermediates may according to the present mechanistic rationale explain best the observation 
of a typically thermodynamically unfavourable isomerization of an conjugated double bond 
out of conjugation (cf. Scheme 4.21). 
Undesired deconjugation was also observed in the epoxidation of 4-benzyl-3-buten-2-one 
(92q) (Scheme 4.22). With enone 92q, “deconjugation” becomes a favourable pathway since 
                                                 
a The sterically demanding 9-amino(9-deoxy)epiquinine (13) catalyst may somewhat shield the α-position and 
thus hinder α-protonation in favour of competing γ-protonation. 
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100 
in contrast to other acyclic substrates 92 the double bond in the isomerized product iso-92q 
benefits from conjugation with the phenyl ring. The isomerisation hampered the isolation of 
epoxide 93q since it could not be readily separated by column chromatography from the 
isomerized starting material iso-92q. 
 
 
Scheme 4.22 Catalytic asymmetric epoxidation of 4-benzyl-3-buten-2-one (92q): double bond isomerization as 
side reaction. (aDetermined by 1H NMR of the crude mixture; bDetermined by chiral GC.) 
 
4.2.2.4 Current Limitations 
Currently, the catalytic asymmetric epoxidation is limited to aliphatic enones (Table 4.31). 
Among those, β-monosubstituted enones are more reactive than β,β-disubstituted analogues 
(entry 1; cf. Chapter 4.2.2.5). 4-Oxoenoates did not undergo our epoxidation reaction 
although their use in related transformations via asymmetric iminium ion catalysis is well-
precedented in the literature (entries 2-3). To date, neither substitution at the α-position, nor 
extended conjugation of the double bond is tolerated, as illustrated by the reaction of 1-
acetylcyclohexene (103) (entry 4) and β-ionone (104) (entry 5), respectively. Moreover, a 
benzyloxy group at the γ-position impeded the reaction (entry 6), whereas enones with remote 
protected hydroxyl functionalities readily reacted with hydrogen peroxide (vide supra). 
Benzylideneacetone (106a) gave the corresponding epoxide in less than 10% yield as detected 
by GC-MS albeit with high enantioselectivity of 98.5:1.5 er (entry 7). Even catalyst [64 • (S)-
TRIP] (cf. Table 4.2), which exhibited superior catalytic activity compared with [13 • 2 TFA] 
in the asymmetric epoxidation of 2-cyclopentenone (46r), was unable to efficiently mediate 
the reaction (entry 8). In both cases, considerable amounts of the starting material 106a 
decomposed to phenylacetaldehydea (up to 12%) presumably via a Dakin pathway. The use of 
a benzylideneacetone derivative bearing electron withdrawing substituents at the phenyl ring 
(4'-nitrophenyl-3-buten-2-one, 106b), and thus constituting a more potent acceptor substrate, 
suppressed this side reaction, but overall did not improve the results (entry 9). Other aromatic 
enones such as furfurylidenacetone (107), 1-phenyl-2-buten-1-one (108), or chalcone (109) 
proved to be unreactive under the present reaction conditions (entries 10-12). Thus, both 
                                                 
a Determined by GC-MS. 
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substituents R1 and R2 are limited to alkyl groups.[136], a Indeed, the same substrate scope 
limitation has previously been detected in several iminium-catalytic transformations of α,β-
unsaturated ketones employing 9-amino(9-deoxy)epicinchona alkaloid catalysts. Indeed, the 
substituent R2 adjacent to the ketone only very rarely tolerates aromatic rings.[141] In this, our 
catalytic epoxidation of α,β-unsaturated ketones very much complements conventional 
methods such as metal-catalyzed or Juliá-Colonna epoxidations. 
Somewhat surprisingly, terminal enones were unsuitable substrates (entry 13), in the presence 
of catalyst [13 • 2 TFA] as well as [64 • (S)-TRIP]. We speculate that in the case of more 
active Michael acceptors, conjugate addition of 9-amino(9-deoxy)epiquinine (13) to form β-
amino ketones is favoured over the 1,2-addition to the ketone carbonyl group, even more so 
since hydrogen peroxide is not a particular strong nucleophile to compete with (Scheme 4.23). 
 
 
Scheme 4.23 Reversible acid-catalyzed conjugate addition of 9-amino(9-deoxy)epiquinine (13) to 3-octenone 
(110a). 
 
To support our hypothesis, we conducted the epoxidation of 3-decen-2-one (92a) in the 
presence of the terminal enone 7-octen-6-one (110a). Epoxide 93a derived from 3-decen-2-
one (92a) was still generated, yet at lower rates. This is consistent with the assumption of the 
catalyst being captured as β-amino ketone and only partly released from this “catalyst resting 
state” keeping its absolute concentration low.[142] 
 
                                                 
a Deng and co-workers reported identical substrate scope limitations in their [13 • 3 TFA]-catalyzed asymmetric 
alkylperoxidation of α,β-unsaturated ketones with TBHP and related oxidants. 
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Table 4.31 Limitations of the catalytic asymmetric epoxidation-hydroperoxidation of α,β-unsaturated ketones. 
 
R1 R2
O
dioxane (0.25 M), 50-70 °C, 48 h
[13 2 TFA] (10 mol%)
H2O2 (50 wt%; 1.5-3 equiv)
R1 R2
O
O
R4 R4
R3 R3 O O
R2
R3
R1
OH
R4  
 
Entry R1 R4 R3 R2 Enone Conv. [%]a erb 
1 
 
H Me Me 100 43 (23) - 
2 CO2Et H H Me 101 - - 
3 CO2Et H Me Me 102 - - 
4 
                     
H Me 103 - - 
5 
 
H H Me 104 <10 n.d. 
6 BnOCH2 H H Me 105 28 (20) n.d. 
7 Ph H H Me 106a 15 (5) 98.5:1.5 
8d Ph H H Me 106a <10 (3) 99.5:0.5 
9 4-NO2-C6H4 H H Me 106b - - 
10 
 
H H Me 107 <5 n.d. 
11 Me H H Ph 108 - - 
12 Ph H H Ph 109 - - 
13 H H H n-C5H11 110a - - 
aDetermined by GC. Values in parentheses correspond to the total yield of PHK and epoxide determined by GC. 
bDetermined by chiral GC. d[64 • (S)-TRIP] (10 mol%) was used. 
 
4.2.2.5 Application to β,β-Disubstituted α,β-Unsaturated Ketones 
The scope of the catalytic asymmetric hydroperoxidation-epoxidation reaction was further 
explored by using β,β-disubstituted α,β-unsaturated ketones as potential substrates. 
This substrate class had turned out to be considerably less reactive than β-monosubstituted 
analogues and only moderate conversions of up to 43% were achieved with citral-derived 
enone 100 (Table 4.32). Under the reaction conditions, E/Z-isomerization of the starting 
material 100 took place - presumably via a dienamine intermediate (cf. Scheme 4.21), and 
from both the E-and Z-isomer of citral-derived enone 100, the trans-isomer of epoxide 111 
was generated predominantly. In the case of β,β-disubstituted enones, the E/Z-interconversion 
of enone 100 also seems to proceed at higher rates than the conjugate addition of hydrogen 
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4 
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13 H H H n-C5H11 110a - - 
aDetermined by GC. Values in parentheses correspond to the total yield of PHK and epoxide determined by GC. 
bDetermined by chiral GC. d[64 • (S)-TRIP] (10 mol%) was used. 
 
4.2.2.5 Application to β,β-Disubstituted α,β-Unsaturated Ketones 
The scope of the catalytic asymmetric hydroperoxidation-epoxidation reaction was further 
explored by using β,β-disubstituted α,β-unsaturated ketones as potential substrates. 
This substrate class had turned out to be considerably less reactive than β-monosubstituted 
analogues and only moderate conversions of up to 43% were achieved with citral-derived 
enone 100 (Table 4.32). Under the reaction conditions, E/Z-isomerization of the starting 
material 100 took place - presumably via a dienamine intermediate (cf. Scheme 4.21), and 
from both the E-and Z-isomer of citral-derived enone 100, the trans-isomer of epoxide 111 
was generated predominantly. In the case of β,β-disubstituted enones, the E/Z-interconversion 
of enone 100 also seems to proceed at higher rates than the conjugate addition of hydrogen 
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peroxide which allowed us to employ a 73:27 mixture of E and Z isomers of 100 without 
noticeably affecting the reaction outcome. Detection of dienone iso-100 by 1H NMR and GC 
analysis of the crude product mixture denoted the isomerisation of α,β-enone 100 to the β,γ-
unsaturated derivative as competing side reaction. This behaviour has been observed earlier 
with 4-benzyl-3-buten-2-one (92q) (cf. Scheme 4.20). 
 
Table 4.32 Screening studies: hydroperoxidation-epoxidation of 4,8-dimethyl-3,7-nonadien-2-one (100). 
 
 
Entry E/Z(100)a TXA 
H2O2 
[equiv] 
T 
[° C] 
conv.
[%]a
E/Z(100')a
Yield (trans/cis) 
111 [%]a 
er(111)c 
Yield 
112 [%]a
1 4:96 TCA 3 32 14 17:83 4 n.d. 5 
2 4:96 TFA 3 50 30 26:74 7 (77:23) n.d. 14 
3 95:5 TCA 3 32 29 83:17 5 n.d. 8 
4 95:5 TFA 3 50 42 76:24 5 (85:15) n.d. 17 
5 95:5 TFA 1.5d 50 43 74:26 3 n.d. 20 
6 95:5 TFA 1.5d 70 65b 64:36 12b (81:19) 
90.5:9.5 er(trans) 
57:43 er(cis) 
40b 
7e 73:27 TFA 3d 70 85b 66:34 10b (88:12) 
95.5:4.5 er(trans) 
59.5:40.5 er(cis) 
69b 
aDetermined by GC. bDetermined by 1H NMR of the crude mixture. cDetermined by chiral GC. d50 wt% aqueous 
H2O2 was used. e[13 • 2 TFA] (20 mol%) was used. 
 
Forcing reaction conditions comprising increased catalyst and hydrogen peroxide loadings at 
elevated temperature proved essential to achieve reasonable conversions (entries 6-7). Under 
not yet fully optimized reaction conditions, peroxyhemiketal 112 was obtained in 56% yield 
with an enantiomeric ratio of 78:22 er. Epoxide 111 was formed concomitantly in 10% yield 
and 88:12 dr(trans/cis) with 95.5:4.5 er for the trans- and 59.5:40.5 er for the cis-isomer, 
respectively (Scheme 4.24). 
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Scheme 4.24 Catalytic asymmetric hydroperoxidation of 4,8-dimethyl-3,7-nonadien-2-one (100) (73:27 E/Z). 
(aDetermined by 1H NMR.) 
 
As illustrated by the group of Dussault, 3-hydroxy-1,2-dioxolanes such as 112 may function 
as key intermediates in the synthesis of plakinic acid natural products (cf. Figure 2.6) which 
display promising antitumor and antifungal activity.[114] 
 
Another β,β-disubstituted α,β-unsaturated ketone which was examined in the catalytic 
asymmetric epoxidation reaction was mesityloxide. Mesityloxide (113) is in contrast to citral-
derived enone 100, symmetrically substituted at the β-position. The enantiodetermining step 
is not the conjugate addition but the epoxide ring closure (like in the case of terminal enones) 
(Scheme 4.25). Thus, the intended transformation may proceed via iminium ion activation but 
is probably classified correctly as (intramolecular) asymmetric enamine catalysis rather than 
asymmetric iminium ion catalysis.[38a] 
 
 
Scheme 4.25 Catalytic asymmetric Weitz-Scheffer epoxidation of mesityloxide (113). 
 
Table 4.33 summarizes the attempts toward a catalytic asymmetric epoxidation of 
mesityloxide (113). In the presence of catalyst [13 • 2 TFA] at 50 °C, epoxide 114 was 
obtained in only moderate yield and enantioselectivity (28%, 81:19 er) (entry 1). The greater 
part (38%) of the product of the conjugate addition of H2O2 remained as peroxyhemiketal 115 
in which the β-position does not constitute a stereogenic center. In order to carry a higher 
amount of peroxide forward to the epoxide stage we repeated the experiment at elevated 
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temperature. At 70 °C, α,β-epoxy ketone 114 was obtained in slightly higher yield of 32%, 
albeit in lower optical purity (57:43 er). 
 
Table 4.33 Screening studies: epoxidation of mesityloxide (113). 
 
 
Entry Catalyst Conv. [%]a Yield (114)a Yield (115)a er (114)b 
1 [13 • 2 TFA] 66 28 38 19:81 
2 [(R,R)-DPEN • TFA] 10 7 3 74.5:25.5 
3 [(R,R)-DPEN • (S)-TRIP] 66 34 32 93.5:6.5 
aDetermined by 1H NMR of the crude mixture. bDetermined by (chiral) GC. c70 °C. 
 
Recently our group solved the problem of highly enantioselective epoxidation of 
symmetrically β,β-disubstituted α,β-unsaturated aldehydes, e.g. 3-methyl-2-butenal, by using 
a chiral catalyst [10 • (S)-TRIP] featuring TRIP as chiral counteranion (cf. Scheme 2.30). 
Inspired by this work, we tested catalyst [(R,R)-DPEN • (S)-TRIP] which had proven to 
efficiently mediate the asymmetric epoxidation of cyclic enones in the epoxidation of 
mesityloxide (113) envisaging high asymmetric induction from a TRIP-assisted cyclization of 
the β-peroxyenamine intermediate A (cf. Scheme 4.25). Indeed, epoxide 114 was obtained 
with increased enantioselectivity of 93.5:6.5 er in moderate yield of 32% (entry 3). To 
quantify the impact of the chiral counteranion TRIP on the enantioselectivity of the reaction, 
we conducted the epoxidation with catalytic amounts of [(R,R)-DPEN • TFA]. Yet, this 
catalyst furnished epoxide 114 with significantly reduced optical purity, and moreover, 
exhibited dramatically lower catalytic activity (entry 2). 
 
4.2.2.6 Medium and Large Ring Enones Revisited 
Whereas epoxides were the only products observed in the primary amine salt-catalyzed 
reaction of hydrogen peroxide with five- and six-membered as well as large ring enones (cf. 
Chapter 4.1.2.2), 2-cycloheptenone (46s) and 2-cyclooctenone (46v) provided under identical 
reaction conditions a product mixture consisting of the expected epoxides 48s and 48v along 
with peroxidic by-products 116 and 117 - both in optically active form - as previously 
described for acyclic enones (Scheme 4.26). Yet, in contrast to monocyclic peroxyhemiketals 
94 derived from acyclic enones, varying amounts of cyclic β-hydroperoxyketones 116b and 
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94 derived from acyclic enones, varying amounts of cyclic β-hydroperoxyketones 116b and 
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117b, which in solution exist in equilibrium with the corresponding bicyclic peroxyhemi-
ketals (116a and 117a), could be detected by NMR. 
Scheme 4.26 displays the results obtained for the reaction of 2-cycloheptenone (46s) and 2-
cyclooctenone (46v) with the 9-amino(9-deoxy)epiquinine salt [13 • 2 TFA] as catalyst (cf. 
Table 4.10). 2-Cycloheptenone (46s) afforded predominantly the expected α,β-epoxy ketone 
48s, which was isolated in 65% yield with excellent enantioselectivity of >99.5:0.5 er 
(Scheme 4.26, (a)). In contrast, β-hydroperoxycyclooctanone 117b was obtained as the major 
product (30:70 48v/117) in the reaction of eight-membered ring enone 46v. Moreover, 
significant amounts of deconjugated 3-cyclooctenone iso-46v could be detected by GC and 1H 
NMR of the crude product mixture.a  Yet, as previously seen for acyclic enones 92 (cf. 
Scheme 4.16, (a)), peroxide 117 can be transformed to the corresponding epoxide under basic 
conditions and thus, 2,3-epoxycyclooctanone (48v) was finally obtained in 55% yield with 
98:2 er over two steps (Scheme 4.26, (b)).b 
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Scheme 4.26 Catalytic reaction of 2-cycloheptenone (46s) and -octenone (46v): formation of peroxidic by-
products. (aDetermined by 1H NMR of the crude mixture; bYields of pure, isolated products; cDetermined by 
chiral GC.) 
 
The peroxidic compounds 116 and 117 piqued our interest since both substances had not been 
previously described in the literature. Notably, the bicyclic peroxidic structure (of 116b and 
117b) resembles potent antimalarial agents. With the goal of optimizing the yield of the 
                                                 
a Iso-46v was detected in the crude product mixture prior to treatment with base. Deconjugation was also noticed 
in the reaction of 2-cycloheptenone (46s), yet only to a negligible extent (~1%). 
b  The same two-step protocol was applied to 2-cycloheptenone (46s). Yet, the yield was not significantly 
improved to compensate for the loss of enantioselectivity (96.5:3.5 er). 
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peroxidic products at the expense of the corresponding epoxides, we evaluated various 
catalyst systems in the reaction of 2-cycloheptenone (46s) and 2-cyclooctenone (46v). 
Since the peroxidic compound 116 was only isolated in 29% yield under the original reaction 
conditions (cf. Scheme 4.26, (a)), we were pleased to see that the previously observed product 
distribution was inverted by conducting the reaction with [13 • 2 TCA] as catalyst and 30 wt% 
hydrogen peroxide (3 equiv) at 32 °C (Table 4.34, entries 1-2), as previously optimized for 
the hydroperoxidation of acyclic enones. Under those conditions, peroxyhemiketal 116 
accounted for 77% of the product mixture as detected by 1H NMR and was generated with 
only a slight loss of enantioselectivity (99:1 er). Catalyst [(R,R)-DPEN• (S)-TRIP] displayed 
the same selectivity as [13 • 2 TFA] and provided antipodal epoxide (2R,3R)-48s as the major 
product with high enantioselectivity (99:1 er) (entry 3, cf. Table 4.13, entry 6). DPEN-based 
catalyst systems lacking the chiral counteranion TRIP gave inferior results with regard to both 
yields and enantioselectivities (entries 4-5). 
 
Table 4.34 Evaluation of different catalyst systems for the reaction of 2-cycloheptenone (46s). 
 
 
Entry Catalyst Conv. [%]a  48s:116a er(48s)b 
1 [13 • 2 TFA] 97 (2S,3S)-48s 68:32 >99.5:0.5 
2c [13 • 2 TCA] 89 (2S,3S)-48s 23:77 99:1 
3 [(R,R)-DPEN • (S)-TRIP] 98 (2R,3R)-48s 70:30 1:99 
4 [(R,R)-DPEN • TFA] 66 (2R,3R)-48s 41:59 4:96 
5 [(R,R)-DPEN • 2 TFA] 87 (2R,3R)-48s 55:45 2:98 
aDetermined by 1H NMR of the crude product. bDetermined by chiral GC. cAt 32 °C with H2O2 (30 wt%; 3 equiv). 
 
Similar trends were observed with 2-cyclooctenone (Table 4.35). The amount of peroxidic 
product 117 could be further increased by applying the optimized hydroperoxidation 
conditions (entries 1-2). Catalyst [(R,R)-DPEN• (S)-TRIP] gave comparable results, yet at 
slightly reduced catalyst activity (entry 3). Moreover, simple TFA salts [(R,R)-DPEN• 1-2 
TFA] exhibited lower catalytic activity, and again their use brought about an erosion of 
enantioselectivity (entries 4-5). Interestingly, in contrast to five- and six-membered cyclic 
enones for which DPEN-mono-TFA salt afforded superior results than DPEN-di-TFA salt, 
their catalytic efficiency is inverted with cycloheptenone and cyclooctenone. 
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Table 4.35 Evaluation of different catalyst systems for the reaction of 2-cyclooctenone (46v). 
 
 
entry catalyst conv. [%]a product 48v:117a er(48v)b 
1 [13 • 2 TFA] 99 (2S,3S)-48v 30:70 >99.5:0.5 
2c [13 • 2 TCA] 91 (2S,3S)-48v 12:88 >99.5:0.5 
3 [(R,R)-DPEN • (S)-TRIP] 80 (2R,3R)-48v 37:63 1:99 
4 [(R,R)-DPEN • TFA] 52 (2R,3R)-48v 26:74 10.5:89.5 
5 [(R,R)-DPEN • 2 TFA] 71 (2R,3R)-48v 19:81 9:91 
aDetermined by 1H NMR of the crude product. bDetermined by chiral GC. cAt 32 °C with H2O2 (30 wt%; 3 equiv). 
 
Under the optimum conditions, peroxidic compounds 116 and 117 were isolated in 
synthetically useful yields of 55 and 59%, respectively (Scheme 4.27). 
 
 
 
Scheme 4.27 Catalytic asymmetric hydroperoxidation of (a) 2-cycloheptenone (46s) and (b) 2-cyclooctenone 
(48v). (aYields of pure, isolated products; bDetermined by chiral GC; cDetermined by 1H NMR of the crude 
product.) 
 
Interestingly, hydroperoxidation product 116 exists in equilibrium preferentially as bicyclic 
peroxyhemiketal 116a rather than as hydroperoxyketone 116b (Scheme 4.28). The precise 
ratio is depending on the solvent with the concentration of peroxyhemiketal being slightly 
increased in non-coordinating solvents such as CHCl3. In contrast, peroxidic product 117 
derived from 2-cyclooctenone (46v) exists predominantly as hydroperoxyketone 117b. DFT 
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calculationsa revealed the existence of an internal hydrogen bond which may account for the 
stabilization of hydroperoxyketones 116b and 117b as illustrated in Scheme 4.28; though, due 
to geometric considerations less so in the case of the seven-membered ring. 
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Scheme 4.28 Mole fractions of bicyclic peroxyhemiketals and β-hydroperoxyketones in different solvents at 
ambient temperature. 
 
Alike in the case of acyclic enones, the use of tert-butyl hydroperoxide as oxidant instead of 
hydrogen peroxide generated predominantly the conjugate addition product in the reaction 
catalyzed by [13 • 2 TFA], thereby offering an alternative entry to peroxidic compounds 
related to 116 and 117 (cf. Chapter 4.2.1.4). 
In contrast to 2-cycloheptenone (46s) and 2-cyclooctenone (46v), 3-substituted cyclo-
heptenone derivatives afforded exclusively the corresponding epoxide. Thus, our approach to 
such bicyclic peroxyhemiketals is complementary to that of Blanco et al. - the oxidation of 
bicyclic cyclopropanols - which is only feasible for the synthesis of 3-substituted bicyclic 
peroxides.[110a, 110b] 
While studying the epoxidation of cyclic enones of different ring sizes, macrocyclic enones 
attracted our attention and we came across very intriguing observations: in contrast to both 
acyclic enones and medium ring enones, macrocyclic enones give almost exclusively 
epoxides in the reaction with hydrogen peroxide and [13• 2 TFA] (or [(R,R)-DPEN • (S)-
TRIP]) as catalyst (Table 4.36, entries 1 and 3; cf. Chapter 4.1.2.2). Moreover, these epoxides 
are formed with an outstanding optical purity of 99.5:0.5 er. Even under reaction conditions 
which usually promote the hydroperoxidation pathway (conditions B), the maximum yield of 
bicyclic peroxyhemiketal remained below 10% (entries 2 and 4). 
 
                                                 
a Density functional theory (DFT) computation at the B3LYP/6-31G* level of theory (Vacuum) was performed 
using Spartan ’08 Windows from Wavefunction, Inc. 
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Table 4.36 Catalytic asymmetric epoxidation of macrocyclic enones: cyclododecenone (46w) (n = 3) and 
cyclopentadecenone (46x) (n = 6). 
 
 
 
Entry (E)-enone (E)-epoxide PHK Conditionsa Epoxide:PHKb Yield (epoxide) [%] er(epoxide)c
1 46w 48w 118 A 100:0 92 99.5:0.5 
2 46w 48w 118 B 97:3 n.d. 99.5:0.5 
3 46x 48x 119 A 96:4 87 99.5:0.5 
4 46x 48x 119 B 91:9 n.d. 99.5:0.5 
aConditions A: [13 • 2 TFA] (10 mol%), H2O2 (50 wt%; 1.5 equiv), dioxane (0.25 M), 50 °C, 20 h; Conditions B: 
[13• 2 TCA] (10 mol%), H2O2 (30 wt%; 3 equiv), dioxane (0.25 M), 32 °C, 20 h. bDetermined by 1H NMR of the 
crude mixture. cDetermined by chiral GC. 
 
We presume that conformational constraints in the seven- and eight-membered ring systems, 
in contrast to 2-cyclohexenone, may hamper the peroxyenamine intermediate in adopting the 
proper conformation for epoxide ring closure which requires the antiperiplanar alignment of 
the π-system of the enamine with the O-O single bond. Those difficulties might be reflected 
in the accumulation of hydroperoxidation product in the course of the reaction. Large rings 
are very flexible, and show complex conformational behaviour. Presumably, as a result, 
cyclododecenone and cyclopentadecenone alike cyclohexenone provide almost exclusively 
the corresponding α,β-epoxyketones both under epoxidation (A) and hydroperoxidation (B) 
conditions. 
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It might be interesting to study the cyclic enone series continuously to identify a cross-over 
point from which on the amount of peroxyhemiketal would start decreasing whereas the 
epoxide formation begins rising again (Figure 4.7). A correlation with the inherent ring strain 
seems likely. 
 
 
 
Figure 4.7 Cyclic enone series: concentration of hydroperoxide and epoxide against ring size. (blue: epoxide; 
red: peroxide; green: ring strain/CH2 of the corresponding cycloalkanes).[135] 
 
In contrast, acyclic enones possess enhanced conformational freedom. Yet, at the transition to 
acylic enones, other conformational considerations as for instance the allylic strain might 
become decisive. 
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4.2.3 Summary and Conclusions 
 
After having developed a method for the asymmetric epoxidation of cyclic α,β-unsaturated 
ketones (cf. Chapter 4.1), we became further interested in expanding the scope of this 
powerful transformation. We therefore turned our attention toward acyclic substrates. In 
particular, salts of the readily available quinine-derived primary amine 9-amino(9-
deoxy)epiquinine (9-NH2-epiQ; 13) retained their high catalytic activity and selectivity for the 
reaction with hydrogen peroxide when facing acyclic rather than cyclic substrates (Table 
4.21). 
Our work with acyclic enones is marked by two major achievements, namely: the 
development of a catalytic asymmetric hydroperoxidation to furnish optically active 3-
hydroxy-1,2-dioxolanes; and the implementation of a highly enantioselective epoxidation 
protocol applicable to a broad array of acyclic aliphatic, enolizable enones, a substrate class 
which has long eluded existing catalytic systems. 
Interestingly, both transformations share a common origin. Initial experiments with acyclic 
enones 92 had revealed that those substrates (in contrast to cyclic enones) furnish product 
mixtures comprising the expected α,β-epoxyketones 93 along with unanticipated five-
membered cyclic peroxyhemiketals 94 upon exposure to aqueous hydrogen peroxide in the 
presence of a primary amine catalyst (Scheme 4.11). Notably, such an asymmetric 
hydroperoxidation reaction has not previously been reported in the literature. Optimization 
studies revealed factors affecting the product distribution between peroxyhemiketals and the 
corresponding epoxides. By adjusting the amount and concentration of the hydrogen peroxide 
used (30 wt%; 3 equiv; Table 4.25) and the choice of the acid co-catalyst (TCA instead of 
TFA; Table 4.22), we were able to identify reaction conditions which allowed the obtention of 
good isolated yields (up to 72%) of highly enantiomerically enriched 3-hydroxy-1,2-
dioxolanes (up to 98.5:1.5 er). The asymmetric hydroperoxidation is applicable to a range of 
enones 92 and high enantiomeric ratios are obtained irrespective of the substitution pattern as 
far as β-substituted enones are concerned (Table 4.28). The yields vary only slightly, and 
typically decrease to some extent as the steric demand of the enone substituents increases 
(Table 4.29). The mild reaction conditions are testified by the high functional group 
compatibility. Enone substrates 92h and 92i equipped with acid labile functional groups are 
well tolerated and cleavage of the TBS or THP ethers was not observed. 3-Hydroxy-1,2-
dioxolanes 94 can furthermore serve as valuable precursors to optically active aldol products 
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typically decrease to some extent as the steric demand of the enone substituents increases 
(Table 4.29). The mild reaction conditions are testified by the high functional group 
compatibility. Enone substrates 92h and 92i equipped with acid labile functional groups are 
well tolerated and cleavage of the TBS or THP ethers was not observed. 3-Hydroxy-1,2-
dioxolanes 94 can furthermore serve as valuable precursors to optically active aldol products 
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96 and 1,2-dioxolanes such as 127 as will be illustrated within the next Chapter (cf.Chapter 
4.3). 
Importantly, they can be cleanly converted to the corresponding epoxides 93 under basic 
conditions. Based on this, we have converged initially obtained product mixtures (of 
peroxides and epoxides) selectively to the epoxide by treatment with 1N NaOH once the 
starting material was consumed. According to this protocol, we prepared a broad range of 
trans-epoxides 93 in good to high yields (up to 90%) and excellent enantioselecivities of up to 
>99.5:0.5 as demonstrated with substrates 92n and 92r (Table 4.30). Once again functional 
groups are well-tolerated, and notably, the process proceeds with full stereoconvergency 
which allows the use of E/Z isomeric enone mixtures as starting materials without affecting 
the reaction outcome (Scheme 4.20). 
Encouraging results have also been obtained with β,β-disubstituted enones which are 
generally less reactive than their β-monosubstituted counterparts when using primary amine 
salt catalysts such as [9-NH2-epiQ (13)• 2 TFA] (cf. Chapter 4.2.2.5). Remarkably, citral-
derived enone 100 provided the corresponding peroxyhemiketal 112 in good yield and 
encouraging enantioselectivity of 78:22 er when reacted with aqueous hydrogen peroxide in 
the presence of [13• 2 TFA] (Scheme 4.24). Peroxyhemiketals similar to compound 112 
might play a pivotal role toward the enantioselective synthesis of members of the plakinic 
acid natural product family (cf. Figure 2.6). Moreover, structurally interesting optically active 
bicyclic peroxidic compounds of potentially biological importance were obtained in the 
reaction of seven- and eight-memberd cyclic enones as substrates (cf. Chapter 4.2.2.6). 
Gratifyingly, the use of the pseudoenantiomeric catalyst as [9-NH2-epiQD (67)• 2 TFA] 
derived from naturally abundant quinidine (instead of quinine), provides an entry to the 
antipodal product series with only slightly reduced enantioselectivity as has been highlighted 
with the syntheses of α,β-epoxyketones ent-93a and ent-93b (Table 4.30). 
Overall, our asymmetric epoxidation process significantly advances the area of chemical 
space formed by highly enantioenriched α,β-epoxyketones. Indeed, and thanks to the 
groundbreaking advances in olefin cross-metathesis, such compounds can now be fashioned 
in only two steps (Scheme 4.29). 
 
4 Results and Discussion 
 113
96 and 1,2-dioxolanes such as 127 as will be illustrated within the next Chapter (cf.Chapter 
4.3). 
Importantly, they can be cleanly converted to the corresponding epoxides 93 under basic 
conditions. Based on this, we have converged initially obtained product mixtures (of 
peroxides and epoxides) selectively to the epoxide by treatment with 1N NaOH once the 
starting material was consumed. According to this protocol, we prepared a broad range of 
trans-epoxides 93 in good to high yields (up to 90%) and excellent enantioselecivities of up to 
>99.5:0.5 as demonstrated with substrates 92n and 92r (Table 4.30). Once again functional 
groups are well-tolerated, and notably, the process proceeds with full stereoconvergency 
which allows the use of E/Z isomeric enone mixtures as starting materials without affecting 
the reaction outcome (Scheme 4.20). 
Encouraging results have also been obtained with β,β-disubstituted enones which are 
generally less reactive than their β-monosubstituted counterparts when using primary amine 
salt catalysts such as [9-NH2-epiQ (13)• 2 TFA] (cf. Chapter 4.2.2.5). Remarkably, citral-
derived enone 100 provided the corresponding peroxyhemiketal 112 in good yield and 
encouraging enantioselectivity of 78:22 er when reacted with aqueous hydrogen peroxide in 
the presence of [13• 2 TFA] (Scheme 4.24). Peroxyhemiketals similar to compound 112 
might play a pivotal role toward the enantioselective synthesis of members of the plakinic 
acid natural product family (cf. Figure 2.6). Moreover, structurally interesting optically active 
bicyclic peroxidic compounds of potentially biological importance were obtained in the 
reaction of seven- and eight-memberd cyclic enones as substrates (cf. Chapter 4.2.2.6). 
Gratifyingly, the use of the pseudoenantiomeric catalyst as [9-NH2-epiQD (67)• 2 TFA] 
derived from naturally abundant quinidine (instead of quinine), provides an entry to the 
antipodal product series with only slightly reduced enantioselectivity as has been highlighted 
with the syntheses of α,β-epoxyketones ent-93a and ent-93b (Table 4.30). 
Overall, our asymmetric epoxidation process significantly advances the area of chemical 
space formed by highly enantioenriched α,β-epoxyketones. Indeed, and thanks to the 
groundbreaking advances in olefin cross-metathesis, such compounds can now be fashioned 
in only two steps (Scheme 4.29). 
 
4 Results and Discussion 
 113
96 and 1,2-dioxolanes such as 127 as will be illustrated within the next Chapter (cf.Chapter 
4.3). 
Importantly, they can be cleanly converted to the corresponding epoxides 93 under basic 
conditions. Based on this, we have converged initially obtained product mixtures (of 
peroxides and epoxides) selectively to the epoxide by treatment with 1N NaOH once the 
starting material was consumed. According to this protocol, we prepared a broad range of 
trans-epoxides 93 in good to high yields (up to 90%) and excellent enantioselecivities of up to 
>99.5:0.5 as demonstrated with substrates 92n and 92r (Table 4.30). Once again functional 
groups are well-tolerated, and notably, the process proceeds with full stereoconvergency 
which allows the use of E/Z isomeric enone mixtures as starting materials without affecting 
the reaction outcome (Scheme 4.20). 
Encouraging results have also been obtained with β,β-disubstituted enones which are 
generally less reactive than their β-monosubstituted counterparts when using primary amine 
salt catalysts such as [9-NH2-epiQ (13)• 2 TFA] (cf. Chapter 4.2.2.5). Remarkably, citral-
derived enone 100 provided the corresponding peroxyhemiketal 112 in good yield and 
encouraging enantioselectivity of 78:22 er when reacted with aqueous hydrogen peroxide in 
the presence of [13• 2 TFA] (Scheme 4.24). Peroxyhemiketals similar to compound 112 
might play a pivotal role toward the enantioselective synthesis of members of the plakinic 
acid natural product family (cf. Figure 2.6). Moreover, structurally interesting optically active 
bicyclic peroxidic compounds of potentially biological importance were obtained in the 
reaction of seven- and eight-memberd cyclic enones as substrates (cf. Chapter 4.2.2.6). 
Gratifyingly, the use of the pseudoenantiomeric catalyst as [9-NH2-epiQD (67)• 2 TFA] 
derived from naturally abundant quinidine (instead of quinine), provides an entry to the 
antipodal product series with only slightly reduced enantioselectivity as has been highlighted 
with the syntheses of α,β-epoxyketones ent-93a and ent-93b (Table 4.30). 
Overall, our asymmetric epoxidation process significantly advances the area of chemical 
space formed by highly enantioenriched α,β-epoxyketones. Indeed, and thanks to the 
groundbreaking advances in olefin cross-metathesis, such compounds can now be fashioned 
in only two steps (Scheme 4.29). 
 
4 Results and Discussion 
 113
96 and 1,2-dioxolanes such as 127 as will be illustrated within the next Chapter (cf.Chapter 
4.3). 
Importantly, they can be cleanly converted to the corresponding epoxides 93 under basic 
conditions. Based on this, we have converged initially obtained product mixtures (of 
peroxides and epoxides) selectively to the epoxide by treatment with 1N NaOH once the 
starting material was consumed. According to this protocol, we prepared a broad range of 
trans-epoxides 93 in good to high yields (up to 90%) and excellent enantioselecivities of up to 
>99.5:0.5 as demonstrated with substrates 92n and 92r (Table 4.30). Once again functional 
groups are well-tolerated, and notably, the process proceeds with full stereoconvergency 
which allows the use of E/Z isomeric enone mixtures as starting materials without affecting 
the reaction outcome (Scheme 4.20). 
Encouraging results have also been obtained with β,β-disubstituted enones which are 
generally less reactive than their β-monosubstituted counterparts when using primary amine 
salt catalysts such as [9-NH2-epiQ (13)• 2 TFA] (cf. Chapter 4.2.2.5). Remarkably, citral-
derived enone 100 provided the corresponding peroxyhemiketal 112 in good yield and 
encouraging enantioselectivity of 78:22 er when reacted with aqueous hydrogen peroxide in 
the presence of [13• 2 TFA] (Scheme 4.24). Peroxyhemiketals similar to compound 112 
might play a pivotal role toward the enantioselective synthesis of members of the plakinic 
acid natural product family (cf. Figure 2.6). Moreover, structurally interesting optically active 
bicyclic peroxidic compounds of potentially biological importance were obtained in the 
reaction of seven- and eight-memberd cyclic enones as substrates (cf. Chapter 4.2.2.6). 
Gratifyingly, the use of the pseudoenantiomeric catalyst as [9-NH2-epiQD (67)• 2 TFA] 
derived from naturally abundant quinidine (instead of quinine), provides an entry to the 
antipodal product series with only slightly reduced enantioselectivity as has been highlighted 
with the syntheses of α,β-epoxyketones ent-93a and ent-93b (Table 4.30). 
Overall, our asymmetric epoxidation process significantly advances the area of chemical 
space formed by highly enantioenriched α,β-epoxyketones. Indeed, and thanks to the 
groundbreaking advances in olefin cross-metathesis, such compounds can now be fashioned 
in only two steps (Scheme 4.29). 
 
4  Results and Discussion 
114 
R1 R2
O
R1
O
R2
Ru
PCy3
Cl
Cl
NN MesMes
Ph
92
138 (cat.)
C2H4
N
N
MeO
NH2
H
[13 2 TFA] (cat.)
R1
O
R2
93
Oaqueous H2O2
H2O
 
 
Scheme 4.29 Concise access to optically active α,β-epoxyketones via a CM-epoxidation sequence. 
 
Cross metathesis of any functionalized terminal olefin with the appropriate vinyl ketone (cf. 
Table 4.41, vide infra), followed by organocatalytic epoxidation delivers the highly valuable 
epoxyketone building blocks. This synthetic manifold can be contrasted with the more 
“classical” approach to those compounds, relying on preparation of a suitable allylic alcohol 
(typically employing Wittig and related olefinations), followed by Sharpless epoxidation and 
finally adjustment of the oxidation state.[143] It is evident that both the low atom and redox 
economy of this “classical” blueprint render it fairly unattractive from the standpoint of 
synthetic efficiency. Conversely, the merits of the approach described in Scheme 4.29 to these 
valuable intermediates rest precisely on both its high atom economy and the conceptual and 
practical advantages of employing two catalytic transformations to rapidly increase molecular 
complexity. 
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4.3 Synthetic Transformations of Optically Active α,β-Epoxy Ketones and 3-
Hydroxy-1,2-dioxolanes 
 
4.3.1 One-Pot Synthesis of Aldol Products from α,β-Unsaturated Ketones 
The aldol reaction is arguably one of the most important methods for the formation of 
carbon–carbon bonds. It creates β-hydroxy carbonyl compounds of high interest as key 
intermediates in construction of a variety of important natural products and drugs. Extensive 
research is therefore devoted toward the development of highly efficient direct catalytic 
enantioselective aldol reactions employing either synthetic metal complexes, enzymes, or 
purely organic molecules as chiral catalysts.[28a, 44, 144] 
Despite the progress made in recent years mainly within the realm of organocatalysis, the use 
of α-unsubstituted, and thus readily enolizable aldehydes 120 is generally problematic. That is 
the case also in aldol reactions catalyzed by proline or proline derivatives with this substrate 
class affording inferior enantioselectivities compared to aromatic aldehydes and low yields 
due to competing self-aldolization and the formation of condensation products (Scheme 
4.30).[145] 
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Scheme 4.30 Aldol addition of acetone to α-unbranched aliphatic aldehydes 120 catalyzed by (S)-proline 
(1)[145d] and proline derivatives (122-123).[145a-c] 
 
4 Results and Discussion 
 115
4.3 Synthetic Transformations of Optically Active α,β-Epoxy Ketones and 3-
Hydroxy-1,2-dioxolanes 
 
4.3.1 One-Pot Synthesis of Aldol Products from α,β-Unsaturated Ketones 
The aldol reaction is arguably one of the most important methods for the formation of 
carbon–carbon bonds. It creates β-hydroxy carbonyl compounds of high interest as key 
intermediates in construction of a variety of important natural products and drugs. Extensive 
research is therefore devoted toward the development of highly efficient direct catalytic 
enantioselective aldol reactions employing either synthetic metal complexes, enzymes, or 
purely organic molecules as chiral catalysts.[28a, 44, 144] 
Despite the progress made in recent years mainly within the realm of organocatalysis, the use 
of α-unsubstituted, and thus readily enolizable aldehydes 120 is generally problematic. That is 
the case also in aldol reactions catalyzed by proline or proline derivatives with this substrate 
class affording inferior enantioselectivities compared to aromatic aldehydes and low yields 
due to competing self-aldolization and the formation of condensation products (Scheme 
4.30).[145] 
 
OOH
35%, 86.5:13.5 er 34%, 86.5:13.5 er
organocatalyst OOHO
H
O
*conditions
N
H
CO2H
acetone or
acetone (20 vol%)/CHCl3
r.t., 3-7 d
N
H
O
N HN
O
O
NH2
CO2H122 (1 mol%)
n-C5H11
OOH
28%, 86.5:13.5 er
N
H
HN
O
PH
PH
HO
123 (20 mol%)
n-C5H11
OOH
n-C4H9
OOH
12%, 93:7 er
OOH
47%, 93.5:6.3 er
R
120 121
R
(a)
(b)
(c)
1 (10-20 mol%)
acetone
r.t., 4-72 h
acetone (0.5 M)
25 °C, 24-48 h
 
Scheme 4.30 Aldol addition of acetone to α-unbranched aliphatic aldehydes 120 catalyzed by (S)-proline 
(1)[145d] and proline derivatives (122-123).[145a-c] 
 
4 Results and Discussion 
 115
4.3 Synthetic Transformations of Optically Active α,β-Epoxy Ketones and 3-
Hydroxy-1,2-dioxolanes 
 
4.3.1 One-Pot Synthesis of Aldol Products from α,β-Unsaturated Ketones 
The aldol reaction is arguably one of the most important methods for the formation of 
carbon–carbon bonds. It creates β-hydroxy carbonyl compounds of high interest as key 
intermediates in construction of a variety of important natural products and drugs. Extensive 
research is therefore devoted toward the development of highly efficient direct catalytic 
enantioselective aldol reactions employing either synthetic metal complexes, enzymes, or 
purely organic molecules as chiral catalysts.[28a, 44, 144] 
Despite the progress made in recent years mainly within the realm of organocatalysis, the use 
of α-unsubstituted, and thus readily enolizable aldehydes 120 is generally problematic. That is 
the case also in aldol reactions catalyzed by proline or proline derivatives with this substrate 
class affording inferior enantioselectivities compared to aromatic aldehydes and low yields 
due to competing self-aldolization and the formation of condensation products (Scheme 
4.30).[145] 
 
OOH
35%, 86.5:13.5 er 34%, 86.5:13.5 er
organocatalyst OOHO
H
O
*conditions
N
H
CO2H
acetone or
acetone (20 vol%)/CHCl3
r.t., 3-7 d
N
H
O
N HN
O
O
NH2
CO2H122 (1 mol%)
n-C5H11
OOH
28%, 86.5:13.5 er
N
H
HN
O
PH
PH
HO
123 (20 mol%)
n-C5H11
OOH
n-C4H9
OOH
12%, 93:7 er
OOH
47%, 93.5:6.3 er
R
120 121
R
(a)
(b)
(c)
1 (10-20 mol%)
acetone
r.t., 4-72 h
acetone (0.5 M)
25 °C, 24-48 h
 
Scheme 4.30 Aldol addition of acetone to α-unbranched aliphatic aldehydes 120 catalyzed by (S)-proline 
(1)[145d] and proline derivatives (122-123).[145a-c] 
 
4 Results and Discussion 
 115
4.3 Synthetic Transformations of Optically Active α,β-Epoxy Ketones and 3-
Hydroxy-1,2-dioxolanes 
 
4.3.1 One-Pot Synthesis of Aldol Products from α,β-Unsaturated Ketones 
The aldol reaction is arguably one of the most important methods for the formation of 
carbon–carbon bonds. It creates β-hydroxy carbonyl compounds of high interest as key 
intermediates in construction of a variety of important natural products and drugs. Extensive 
research is therefore devoted toward the development of highly efficient direct catalytic 
enantioselective aldol reactions employing either synthetic metal complexes, enzymes, or 
purely organic molecules as chiral catalysts.[28a, 44, 144] 
Despite the progress made in recent years mainly within the realm of organocatalysis, the use 
of α-unsubstituted, and thus readily enolizable aldehydes 120 is generally problematic. That is 
the case also in aldol reactions catalyzed by proline or proline derivatives with this substrate 
class affording inferior enantioselectivities compared to aromatic aldehydes and low yields 
due to competing self-aldolization and the formation of condensation products (Scheme 
4.30).[145] 
 
OOH
35%, 86.5:13.5 er 34%, 86.5:13.5 er
organocatalyst OOHO
H
O
*conditions
N
H
CO2H
acetone or
acetone (20 vol%)/CHCl3
r.t., 3-7 d
N
H
O
N HN
O
O
NH2
CO2H122 (1 mol%)
n-C5H11
OOH
28%, 86.5:13.5 er
N
H
HN
O
PH
PH
HO
123 (20 mol%)
n-C5H11
OOH
n-C4H9
OOH
12%, 93:7 er
OOH
47%, 93.5:6.3 er
R
120 121
R
(a)
(b)
(c)
1 (10-20 mol%)
acetone
r.t., 4-72 h
acetone (0.5 M)
25 °C, 24-48 h
 
Scheme 4.30 Aldol addition of acetone to α-unbranched aliphatic aldehydes 120 catalyzed by (S)-proline 
(1)[145d] and proline derivatives (122-123).[145a-c] 
 
4  Results and Discussion 
116 
With the catalytic asymmetric hydroperoxidation/epoxidation of α,β-unsaturated ketones 92, 
we hold a powerful reaction that affords peroxides and epoxides with excellent 
enantioselectivities of up to >99.5:0.5 er for a range of enones bearing aliphatic enolizable 
substituents at the β-position and adjacent to the ketone group (cf. Chapter 4.2.2). 
We became intrigued by the idea of developing a one-pot synthesis of optically active aldol-
type products 96 from α,β-unsaturated ketones 92 which capitalizes on this highly enantio-
selective transformation. Notably, such a process would overall represent a formal olefin 
hydration. 
 
 
Scheme 4.31 Asymmetric, one-pot synthesis of aldol products from α,β-enones. 
 
3-Hydroxy-1,2-dioxolanes 94 are readily converted to the corresponding β-hydroxy ketones 
by a variety of reducing agents such as trivalent phosphorus compounds,[110c, 146] sulfur-based 
reducing agents,[147] or by catalytic hydrogenation (Scheme 4.32).[112] 
 
 
Scheme 4.32 Reduction of peroxyhemiketals 94 to aldol-type products 96 by (a) P(OEt)3 and (b) NaHSO3. 
 
For the one-pot synthesis of β-hydroxy ketones 96, triethyl phosphite was added directly to 
the reaction mixture once the hydroperoxidation of α,β-unsaturated ketones 92 was complete 
as indicated by TLC analysis. The best results were obtained via the portionwise addition of 5 
equivalents of P(OEt)3. According to this protocol, aldol-type products 96 were isolated in 
good yields along with high enantioselectivities of up to 97:3 er (Table 4.37). 
The reduction of 3-hydroxy-1,2-dioxolanes 94 with trivalent phosphorus reagents PX3 is 
considered to proceed via a sequence involving biphilic insertion of PX3 into the O-O bond 
followed by scission of the phosphorane intermediate A and elimination of X3P=O to yield 
directly β-hydroxy ketones 96 (Scheme 4.33).[146] 
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the reaction mixture once the hydroperoxidation of α,β-unsaturated ketones 92 was complete 
as indicated by TLC analysis. The best results were obtained via the portionwise addition of 5 
equivalents of P(OEt)3. According to this protocol, aldol-type products 96 were isolated in 
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The reduction of 3-hydroxy-1,2-dioxolanes 94 with trivalent phosphorus reagents PX3 is 
considered to proceed via a sequence involving biphilic insertion of PX3 into the O-O bond 
followed by scission of the phosphorane intermediate A and elimination of X3P=O to yield 
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Scheme 4.33 Mechanism of the reduction of 3-hydroxy-1,2-dioxolanes 94 by trivalent phosphorus reagents PX3. 
 
Table 4.37 Scope of the one-pot synthesis of aldol-type products 96 from α,β-enones 92. 
 
R1 R2
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dioxane (0.25 M), 32 °C, 12-48 h
then P(OEt)3 (5 equiv)
0°C to 32°C, 10 h
[13 2 TCA] (10 mol%)
H2O2 (30 wt%; 3 equiv)
92
R1 R2
O
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Entry R Enone Product Yield [%]b erc 
1 n-C6H13 92a 96a 59 97:3 
2 PhCH2CH2 92b 96b 53 96.5:3.5 
3 i-Bu 92d 96d 56 96.5:3.5 
4 Cy 92e 96e 46 96:4 
5  92f 96f 55 96:4 
aDetermined by 1H NMR of the crude product. bYields of pure, isolated products. cDetermined by chiral HPLC/GC. 
 
Alternatively, catalytic hydrogenation effected the desired transformation to give aldol 
products 96 with the same level of enantioselectivity as illustrated with the reaction of 3-
decen-2-one (92a).a 
 
dioxane (0.25 M), 32 °C, 24 h
2. H2 (1 atm), Pd/C (15% wt)
MeOH
1. [13 2 TCA] (10 mol%)
H2O2 (30 wt%; 3 equiv)
n-C6H13 Me
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61% yield, 97:3 er
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Scheme 4.34 Alternative protcol: aldol synthesis from α,β-enones through a hydroperoxidation-hydrogenation 
sequence.b 
 
Employing comparatively simple starting materials - α,β-unsaturated ketones 92 and 
hydrogen peroxide, this approach nicely complements aldol reactions catalyzed by proline 
and its derivatives since it affords high enantioselectivities also for β-hydroxy ketones 96 
                                                 
a Due to the incompatibility of the reaction conditions of the hydroperoxidation and the hydrogenation, this 
transformation was carried out in a stepwise fashion simply interrupted by an aqueous work-up alike in the 
epoxidation protocol. 
b This reaction was carried out by O. Lifchits. 
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formally derived from α-unbranched aldehydes 120 (cf. Scheme 4.30). This asymmetric 
hydroperoxidation-reduction sequence also represents an attractive and simple solution to the 
long-standing challenge of enantioselectively adding water to α,β-unsaturated ketones.[137, 148] 
 
4.3.2 Synthesis of Aldol Products by Reductive Cleavage of α,β-Epoxy Ketones 
Regioselective α-reduction of α,β-epoxyketones is a synthetically useful transformation 
providing an alternative to the aldol addition for the formation of β-hydroxy ketones (Scheme 
4.35). 
 
Scheme 4.35 β-Hydroxy ketones (a) via aldol addition or (b) through reductive epoxide cleavage. 
 
Nevertheless, this transformation is far from trivial due the presence of a reducible ketone 
functional group combined with the intrinsic instability of β-hydroxy ketone systems (which 
tend to give rise to the formation of enones and other by-products). Several reducing agents 
have been investigated for this particular process with the most prominent being single 
electron-transfer reagents such as aluminium amalgam[149] and samarium diiodide,[150] or 
organoselenium reagents.[151] 
 
Catalytic asymmetric epoxidation of cyclic enones 46 with hydrogen peroxide in the presence 
of 9-amino(9-deoxy)epiquinine salt [13 • 2 TFA] provides concise access to highly enantioen-
riched cyclic α,β-epoxyketones 48 as outlined in Chapter 4.1.2. These cyclic α,β-
epoxyketones 48 may function as precursors to optically active cyclic aldol products 124 
which are difficult to access by any other means.[152] In addition, the reductive cleavage of the 
epoxide ring of acyclic α,β-epoxyketones 93 complements the hydroperoxidation-reduction 
sequence (see Chapter 4.3.1) for those acyclic enone substrates 92 which give only minor 
amounts of peroxyhemiketal (or none at all) (cf. Table 4.29). 
Reductive epoxide cleavage of α,β-epoxycyclohexanone (48a) with samarium diiodide 
afforded 3-hydroxycyclohexanone (124a) in 52% yield. In the event, the formation of several 
by-products was concomitantly observed. In contrast, treatment of 48a with phenyl selenide 
anion (generated from diphenyl diselenide by reduction with sodium borohydride) was more 
effective and furnished cyclic aldol product 124a in excellent yield of 94% within a very short 
reaction time (<5 min) (Scheme 4.36).[151a] Most importantly, the optical purity of the starting 
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material (96.5:3.5 er) was retained under the reaction conditions and 3-hydroxycyclo-
hexanone (124a) was isolated for the first time in enantiomerically enriched form with 96:4 er. 
 
 
 
Scheme 4.36 Reductive cleavage of optically active cyclic α,β-epoxyketones. 
 
Remarkably, tertiary cyclic aldol product 124b was obtained from 2,3-epoxy-3-
methylcyclohexanone (48f) (98:2 er) in 87% yield with only a slight loss of enantiopurity 
(95.5:4.5 er). Whereas seven-membered ring epoxide 48s (n = 2, R = H) afforded 3-
hydroxycycloheptanone (124c) in analogous fashion with a high yield and excellent 
enantioselectivity (84%, 99:1 er), the reaction of 2,3-epoxycyclooctanone (48v) proceeded 
rather sluggishly, and after 60 h, GC-MS analysis indicated a conversion of 95%.a At this 
stage, 3-hydroxycyclooctanone (124d) was isolated in a yield of 53%. Moreover, 3-hydroxy-
2-(phenylselanyl)cyclooctanone, an intermediate which is formed upon epoxide opening by 
phenyl selenide anion via SN2-substitution at the α-carbon atom (cf. intermediate A, Scheme 
4.37),[153] was recovered from the reaction mixture in 15% yield. Somewhat surprisingly, an 
erosion of optical purity took place in the course of the reaction: whereas the starting material 
48v exhibited an optical purity of 97:3 er, eight-membered cyclic aldol 124d was obtained 
with only 86:14 er. 
 
                                                 
a We discovered a catalytic effect of the eight-membered ring peroxide 117 on the reductive cleavage of 2,3-
epoxycyclooctanone 48v which is to date unknown in nature. Full conversion to 3-hydroxycyclooctanone 124d 
was achieved within 10 min at ambient temperature albeit once again with erosion of optical purity. 
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Scheme 4.37 (a) Generation of sodium phenylseleno(triethyl)borate complex Na[PhSeB(OEt)3]; (b) Mechanism 
of the reductive cleavage of α,β-epoxyketones by benzeneselenolate. 
 
Notably, cyclic aldol products 124a-d have not, to the best of our knowledge, been reported in 
the literature in optically active form to this date. The synthesis of seven- and eight-membered 
cyclic aldol products 124c and 124d is of particular value in light of the fact that they can not 
(easily) be accessed via aldol disconnection. Intramolecular aldol reactions of keto-aldehydes 
of the general type 125 give rise to six-membered cyclic aldol products 126 through enolexo-
aldolizations rather than to 3-hydroxycycloheptanone (124c) or −octanone (124d) through 
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Scheme 4.39 Enolexo-aldolizations of keto-aldehydes of the general type 125 according to (a) List et al.[154] and 
(b) Baati et al.[155] 
 
We speculate that the reactivity differences between six- and eight-membered α,β-
epoxyketones 48a and 48v arise from their different conformations. Minimized energy 
structures and LUMO orbitals of α,β-epoxyketones ent-48a and ent-48v are depicted in 
Scheme 4.40.a Whereas the α-position of α,β-epoxycyclohexanone (48a) appears accessible 
and the LUMO orbital at the carbonyl group ideally aligned for stabilizing interactions with 
the benzeneselenolate nucleophile (anticipating an SN2-displacement of the Cα-O bond), the 
α-position in the corresponding eight-membered ring epoxyketone 48v seems to be sterically 
encumbered. Moreover, according to the model the trajectory of the incoming nucleophile lies 
in the node plane of the LUMO orbital. This should minimize the possibility for stabilizing 
orbital interactions during the SN2 displacement and hamper the reductive cleavage. 
                                                 
a Density functional theory (DFT) computation at the B3LYP/6-31G* level (Vacuum) was performed using 
Spartan ’08 Windows from Wavefunction, Inc. 
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Scheme 4.40 Minimized energy structures and LUMO orbitals of (a) α,β-epoxycyclohexanone 48a and (b) α,β-
epoxycyclooctanone 48v (grey: C, red: O, white: H; O-Cα-C=O: 48a: -111.02°, 48v: -34.15°; Cβ-Cα-C=O: 48a: -
177.04°, 48v: 116.95°). 
 
The reaction of hydrogen peroxide and acyclic enone 92n equipped with an iso-butyl group as 
ketone substituent afforded in the presence of 9-amino(9-deoxy)epiquinine salt [13 • 2 TCA] 
essentially exclusively α,β-epoxyketone 93n and only traces of the desired peroxyhemiketal 
94n (93n:94n = 95:5; cf. Table 4.29, entry 3). Thus, the asymmetric hydroperoxidation-
reduction sequence (see Chapter 4.3.1) is not feasible to access the aldol product in this 
particular case. However, 6-hydroxy-2-methyl-4-undecanone (96n) was readily obtained in 
excellent yield and enantioselectivity (99:1 er) via reductive cleavage of the corresponding 
epoxyketone 93n (Scheme 4.41). 
 
 
Scheme 4.41 Synthesis of aldol product 96n by reductive cleavage of α,β-epoxyketone 93n.a 
 
4.3.3 Synthesis of 1,2-Dioxolanes from Peroxyhemiketals 
The noticeable lack of asymmetric syntheses of 1,2-dioxolanes in the chemical literature 
stimulated us to seek for approaches to this substrate class based on our methodology.[109a] We 
envisaged optically active 3-hydroxy-1,2-dioxolanes 94 as potential precursors which may be 
converted into the corresponding 1,2-dioxolanes 127 upon reduction (Scheme 4.42 (a)), a 
                                                 
a This experiment was carried out by O. Lifchits. 
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transformation which has not been described to date. Whereas reduction to aldol products 96 
proceeds with cleavage of the O-O single bond (cf. Chapter 4.3.1, Scheme 4.42 (b)), the 
synthesis of 1,2-dioxolane 127 requires a chemoselective reduction which does not affect the 
O-O linkage. 
 
 
Scheme 4.42 Complementary reduction pathways of 3-hydroxy-1,2-dioxolanes 94: (a) via O-O bond cleavage to 
give aldol products 96 and (b) via C-O bond cleavage to afford 1,2-dioxolanes 127. 
 
Several Lewis acids are known to mediate the ionization of peroxyacetals and hemiacetals to 
provide peroxocarbenium ions which can be trapped by various nucleophiles.[114, 156] 
Applying this strategy, Dussault et al. accomplished the synthesis of 1,2-dioxolanes (in 
racemic form) from 3-alkoxy-1,2-dioxolanes and allylsilanes, silyl enol ethers, and silyl 
ketene acetals as nucleophiles.[114] 
Guided by this precedent, we carried out the reduction of 3-alkoxy-1,2-dioxolane 128 in the 
presence of titanium tetrachloride as Lewis acid and triethylsilane as reducing agent to obtain 
1,2-dioxolane 127 in 80% yield and a 75:25 diastereomeric ratio in favor of the cis-isomer 
(Scheme 4.43, (a)).[157] Changing to n-tributylsilane under otherwise identical conditions 
slightly improved the diastereomeric ratio to 82:18. 
 
 
 
Scheme 4.43 Silane reduction of (a) 3-alkoxy-1,2-dioxolane 128 mediated by TiCl4 and (b) 3-hydroxy-1,2-
dioxolane 94a mediated by TfOH. (aDetermined by 1H NMR of the crude product.) 
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Moreover, 1,2-dioxolane 127 could be directly obtained in good yield and only slightly lower 
diastereoselectivity (67:23 dr) via reduction of 3-hydroxy-1,2-dioxolane 94a with triethyl-
silane in the presence of stoichiometric amounts of triflic acid (Scheme 4.43, (b)), which 
presumably generates triethylsilyl triflate as catalytically active species under the reaction 
conditions. Whereas related Brønsted acid-mediated reductions of hemiacetals are well-
precedented, a corresponding transformation with peroxyhemiketals has not been described to 
date. Notably, this is also the first report on the direct conversion of peroxyhemiketals into the 
corresponding dioxolanes, obviating the need for prior formation of a peroxyketal. 
 
4.4 Summary and Conclusions 
 
In summary, the synthetic usefulness of the peroxyhemiketal and epoxide products obtained 
could be demonstrated. In retrospect, the former intermediates allowed the greatest versatility 
due to the combination of their high-energy O-O bond and the hemiketal linkage. Not only 
could they lead to their epoxide counterparts (cf. Chapter 4.2.2.2), but also to aldol products 
96 (Chapter 4.3.1) and 1,2-dioxolanes such as 127 (Chapter 4.3.3) simply through appropriate 
choice of reaction conditions. While the thus obtained aldols are actually generated with 
higher enantioselectivities than those currently afforded by state-of-the-art aldol technology 
(e.g. proline-catalyzed aldol reaction), the enantioenriched 1,2-dioxolanes represent intriguing 
and biologically relevant substructures in their own right. 
In addition, the epoxides 48 derived from cyclic enones afforded, through reductive epoxide 
cleavage, a new class of chiral enantioenriched cyclic aldols 124 which (to the best of our 
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4.5 Mechanistic Considerations 
4.5.1 Evaluation of Modified Catalysts: Structure-Activity Relationships 
Mechanistically, we propose the epoxidation/hydroperoxidation reaction to proceed via 
activation of α,β-unsaturated ketones 46 and 92 as iminium ions in the presence of chiral 
amine salt catalysts [9-NH2-epiQ • 2 TXA] (X = F, Cl) or [(R,R)-DPEN • (S)-TRIP]. The 
amine catalysts which proved optimal in terms of both activity and selectivity, 9-amino(9-
deoxy)epiquinine (13) and (R,R)-diphenylethylenediamine (12), both possess, in addition to a 
primary amine functionality, (at least) one additional basic site being either another primary 
or a tertiary amine moiety. Thus, we suggest that the second basic amine site may bring in 
hydrogen peroxide via hydrogen bonding interactions, pre-organize the transition state, and 
direct its attack toward one enantiotopic face of the double bond of cyclic enones 46 or 
acyclic enones 92. 
 
Figure 4.8 Hypothetical pre-transition state assembly for the catalytic epoxidation/hydroperoxidation of α,β-
unsaturated ketones 46 or 92. 
 
To provide experimental support for our proposed mechanism based on iminium ion catalysis 
we performed the epoxidation reaction of 2-cyclohexenone 46a in the presence of various 
modified catalyst systems (Table 4.38). These experiments revealed that both primary amine 
functionality and acid co-catalyst are crucial for high catalyst efficiency. 
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Table 4.38 Evaluation of modified catalyst systems for the catalytic asymmetric epoxidation of 2-
cyclohexenone (46a). 
 
 
Entry Catalyst Yield [%]a erb 
1 [13 • 2 TFA] 82 96:4 
2 13 45 92:8 
3 [129 • 2 TFA] 13 67:33 
4 quinine (130) 0 - 
5c quinine (130) 0 - 
6 [130 • TFA] 0 - 
7 131 12 rac. 
8 [131 • 2 TFA] 18 76.5:23.5 
9 132 <5 rac. 
10 [132 • 2 TFA] <5 77:23 
11 [(R,R)-DPEN • (S)-TRIP] 92 4:96 
12d [(R,R)-DPEN • (S)-TRIP] 10 5:95 
13 (R,R)-DPEN 43 48:52 
14 [133 • TFA] 92 17:83 
15 134 0 - 
16 [134 • TFA] 0 - 
17 [134 • (S)-TRIP] 0 - 
aDetermined by GC. bDetermined by chiral GC. c20 mol% quinine was used. dWith 4Å MS. 
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Whereas [13 • 2 TFA] efficiently promotes the reaction giving epoxycyclohexanone 48a in 
high yield and excellent enantiomeric ratio (82%, 96:4 er; entry 1), the use of 9-amino(9-
deoxy)epiquinine (13) in absence of TFA entailed somewhat lower enantioselectivity and a 
significantly reduced reaction rate (45%, 92:8 er; entry 2). Moreover, derivatives of 9-
amino(9-deoxy)epiquinine which lack the primary amine group such as monomethylated 129, 
thiourea- and sulfonamide-functionalized 131 and 132, and quinine (130) itself showed very 
low catalytic activity (with or without acid co-catalyst) or were not catalytically active at all 
(entries 3-10). Similar trends were detected upon modifying the catalyst system [(R,R)-
DPEN • (S)-TRIP] (entry 11). When only (R,R)-DPEN was present in the reaction mixture, 
epoxide 48a was generated in modest yield and essentially without stereocontrol 
(43%, 48:52 er; entry 13). Blocking one of the primary amine groups by tosylation, which 
concomitantly decreases its basicity, preserved the catalytic activity but led to inferior 
enantiocontrol (92%, 17:83 er; entry 14). This may suggest that amine 133 - due to the 
absence of the second, presumably directing basic site - does not achieve the same high 
degree of transition state organization, which then translates to a lower enantioselectivity of 
product 48a. Tetramethylated DPEN derivative 134 did not promote the reaction, which 
nicely demonstrates once more that the primary amine group is a vital prerequisite for catalyst 
activity (entries 15-17). Similar structure selectivity relationships were also identified for 
other catalyst motifs such as 1,2-diaminocyclohexane (DACH; 60) (cf. Chapter 4.1.1.1). 
In the presence of molecular sieves, catalyst turnover was inhibited and 2,3-
epoxycyclohexanone (48a) was generated in only 10% yield, albeit with essentially equally 
high enantioselectivity of 95:5 er. 
Overall, these experiments provide strong support for the catalytic asymmetric epoxidation of 
2-cyclohexenone (46a) (as a representative of other α,β-unsaturated ketones) proceeding via 
iminium ion catalysis, and not via general base catalysis or phase-transfer catalysis. In 
addition, the substrate scope commonly observed in phase transfer catalysis complements the 
one of our reaction. Whereas PTC consistently affords higher yields of the desired epoxide 
with 5-and 6-substituted cyclohexenones compared to 4-mono- or disubstituted derivatives, 
the trend in our reaction is vice versa. This indicates that steric hindrance in proximity to the 
carbonyl group has a detrimental effect on our reaction, which supposedly proceeds via 
iminiun ion catalysis, but not so in phase-transfer catalysis.[96] 
The interruption of catalyst turnover in the presence of molecular sieves neatly testifies to the 
crucial role of water in the reaction (entry 12). This observation is consistent with the 
assumption of a catalytic cycle based on iminium ion activation of α,β-unsaturated ketones, 
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insofar as water is essential for catalyst turnover since the catalyst is regenerated by 
hydrolysis of intermediate iminium ions. 
 
4.5.2 ESI-MS Studies 
To gain further insight into the reaction mechanism of the epoxidation-hydroperoxidation 
process we monitored the progress of the reaction by using Electrospray-Ionization Mass 
Spectroscopy (ESI-MS). For this purpose we carried out the reaction of 3-decen-2-one (92a) 
with hydrogen peroxide in the presence of catalytic amounts of the 9-amino(9-
deoxy)epiquinine catalyst salt [9-NH2-epiQ (13) • 2 TXA] (X = F, Cl): once under the 
standard conditions of the epoxidation reaction (Scheme 4.44, (a)), and the other time 
according to the optimized hydroperoxidation protocol (Scheme 4.44, (b)). 
 
 
 
Scheme 4.44 Test reactions for ESI-MS analysis: reaction of 3-decen-2-one (92a) with hydrogen peroxide under 
(a) epoxidation and (b) hydroperoxidation conditions. 
 
Samples were taken from the reaction mixtures at different time intervals over 24 hours and 
submitted to ESI-MS analysis. Spectra recorded prior to hydrogen peroxide addition and after 
1 and 12 hours of reaction time, respectively, are depicted in the following figures (Figure 4.9, 
4.12 and 4.15). 
It should be noted that 3-decen-2-one (92a), its corresponding epoxide 93a and peroxide 94a 
could not be detected by ESI-MS, as the spectrometer utilized could only detect molecules 
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Figure 4.9 ESI-MS spectrum of reaction (a) recorded prior to H2O2-addition. (MW: molecular weight; EM: 
exact mass) 
 
The fact that the signal at m/z 460 could not be detected any longer after addition of hydrogen 
peroxide (Figure 4.10), indicates that iminium ion A is consumed by hydrogen peroxide, and 
thus validates our assumption that iminium ions such as A are indeed intermediates in our 
epoxidation/hydroperoxidation reaction. The signal corresponding to 9-amino(9-deoxy)epi-
quinine at m/z 324 [(13+H)+] is still present. Yet, after 1 h of reaction time, two new signals 
have appeared at m/z 476 and 494, which match the masses of the iminium ion B derived 
from 2,3-epoxy-2-decanone (93a) and iminium ion C derived from the corresponding β-
hydroperoxyketone which upon hydrolysis affords peroxyhemiketal 94a. The fact that the 
signal of the unsaturated iminium ion A at m/z 460 cannot be detected in the presence of 
hydrogen peroxide suggests that its concentration remains low under reaction conditions. 
Thus, based on these results, we may propose that neither the conjugate H2O2-addition nor the 
intramolecular epoxide closure, but indeed the formation of the iminium ion intermediate A 
represents the rate-limiting step of these transformations. 
In particular in reaction (a) run at 50 °C, additional signals at m/z 340, 492, and 510 can be 
detected which presumably arise from the oxidation of the catalyst under reaction conditions 
(Figure 4.10, (a)). Since an excess of oxidant was used and the amine was employed in 
catalytic amount, it is reasonable to expect oxidation of the amine to occur. The signal at 
m/z 340 may correspond to monooxygenated 9-amino(9-deoxy)epiquinine 13+O. Moreover, 
signals at m/z 492 and 510 were assigned to iminium ions B+O and C+O, analogous to B and C, 
yet incorporating oxygenated 9-amino(9-deoxy)epiquinine 13+O instead of 13. On the contrary, 
in reaction (b) run at 32 °C only one signal of low intensitiy at m/z 510 was detected to 
witness beginning catalyst oxidation (Figure 4.10, (b)). 
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Figure 4.10 ESI-MS spectra after 1 hour from the reaction (a) with [13 • 2 TFA] at 50 °C and (b) [13 • 2 TCA] 
at 32 °C. 
 
After 12 hours at 50 °C, the ESI-MS spectrum of the sample from reaction (a) indicates 
extensive catalyst oxidation (Figure 4.13, (a)). Strong signals at m/z 340 and 492 match (as 
mentioned above) monooxygenated 9-amino(9-deoxy)epiquinine 13+O and its corresponding 
iminium ion formed with α,β-epoxy decanone B+O, respectively. On the contrary, signals at 
m/z 324, 476, and 494 have suffered a considerable loss of intensity. The epoxidation of 
decenone at 50 °C with [13 • 2 TFA] (10 mol%) generally requires 10 hours to go to 
completion. Partially oxidized amine 13+O could already be detected after 1 h of reaction time 
(at ~20% conversion). Intriguingly, the oxidation of 9-amino(9-deoxy)epiquinine 13 to 13+O 
seems to not shut down the catalytic cycle. The fact that we can detect signals at m/z  492 and 
510, which presumably correspond to α,β-epoxy and β-peroxy iminium ions B+O and C+O, 
respectively, allows us to conclude that the primary amine functionality of the catalyst may 
remain intact and able to effect iminium ion activation of α,β-unsaturated ketones. We 
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assume that amine 13 gets oxidized to the N-oxide at either the tertiary quinuclidine or 
chinoline nitrogen and suggest the structures depicted in Figure 4.11 for compound 13+O. Due 
to its higher basicity and nucleophilicity, the quinuclidine nitrogen atom should get oxidized 
preferentially to form the N-oxide 13+O,1.[158] However, in addition, the molecular confor-
mation of amine 13 and the precise reaction conditions may play a critical role.[159] In the 
presence of two equivalents of the acid co-catalysts (TFA or TCA), the quinuclidine nitrogen 
may mostly exist in protonated form what should impede its oxidation. Double oxidation of 
amine 13, in other words a signal at m/z 356, could not be perceived throughout the ESI-MS 
experiments. 
 
Figure 4.11 Proposed structures of regioisomeric 9-amino(9-deoxy)epiquinine N-oxides 13+O,1 and 13+O,2. 
 
What is intriguing about these results is, that the epoxide 93a continues to be formed in 
outstanding enantioselectivities in the presence of 13+O as competing catalytic species. Thus, 
we suspect that 13+O likewise mediates the epoxidation reaction via a highly organized 
transition state despite. In the α,β-unsaturated iminium ion derived from N-oxide 13+O,1, 
which lacks the quinuclidine nitrogen as directing element, the N-oxide itself may bring in 
hydrogen peroxide for the conjugate addition (Figure 4.12). 
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Figure 4.12 N-oxide as directing element. 
 
Signals attributed to catalyst oxidation were also perceived with increasing intensity in the 
reaction with [13 • 2 TFA] at 32 °C (Figure 4.13, (b)). Yet in this case, the signals at m/z 324, 
476 and 494 still dominate the picture which reveals the higher reaction temperature of 50 °C 
compared to 32 °C as a major cause of catalyst oxygenation.[160] 
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assume that amine 13 gets oxidized to the N-oxide at either the tertiary quinuclidine or 
chinoline nitrogen and suggest the structures depicted in Figure 4.11 for compound 13+O. Due 
to its higher basicity and nucleophilicity, the quinuclidine nitrogen atom should get oxidized 
preferentially to form the N-oxide 13+O,1.[158] However, in addition, the molecular confor-
mation of amine 13 and the precise reaction conditions may play a critical role.[159] In the 
presence of two equivalents of the acid co-catalysts (TFA or TCA), the quinuclidine nitrogen 
may mostly exist in protonated form what should impede its oxidation. Double oxidation of 
amine 13, in other words a signal at m/z 356, could not be perceived throughout the ESI-MS 
experiments. 
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Figure 4.13 ESI-MS spectra after 12 hours from the reaction (a) with [13 • 2 TFA] at 50 °C and (b) 
[13 • 2 TCA] at 32 °C. 
 
The complete data of the putative intermediates of the hydroperoxidation-epoxidation process 
found during the ESI-MS investigation is summarized in Table 4.39. 
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Table 4.39 Potential intermediates found during ESI-MS studies. 
 
species 
 
    
 13+H A B C B+O 
HRMS      
formula C20H26N3O C30H42N3O C30H42N3O2 C30H44N3O3 C30H44N3O3 
found 324.207039 460.332803 476.327879 494.338147 492.322675 
calcd 324.206741 460.332238 476.327154 494.337720 494.322065 
error[ppm] 0.92 1.23 1.52 0.86 1.24 
 
4.5.3 Further Mechanistic Investigations 
In particular, one intriguing feature of our hydroperoxidation-epoxidation reaction piqued our 
interest: namely, the truly outstanding enantioselectivity of >99.5:0.5 er (in most of the cases) 
observed for the initially formeda epoxides 93 in the reaction of acyclic α,β-enones 92 in the 
presence of catalytic amounts of [9-NH2-epiQ (13) • 2 TXA] (X = F, Cl). However, the 
peroxyhemiketals 94 which were obtained concomitantly with the epoxides generally 
exhibited a slightly lower optical purity (cf. Scheme 4.45). 
 
 
Scheme 4.45 Catalytic asymmetric hydroperoxidation-epoxidation of 3-decen-2-one (92a): discrepancy in 
optical purity between epoxide 93a and peroxide 94a. (aDetermined by 1H NMR of the crude mixture.) 
 
This observation suggests that a kinetic resolution is associated with the epoxide ring closure 
step, as verified through a control experiment. In the event, cyclization of racemic 
peroxyhemiketal rac-94a took place upon treatment with catalyst salt [13 • 2 TFA] in dioxane 
at 50 °C, giving scalemic epoxide (3S,4R)-93a and PHK (5S)-94a at 44% conversion (Scheme 
4.46).[38a, 161] 
                                                 
a Initially formed refers to the epoxide fraction which is formed directly under the reaction conditions, and not 
through conversion of the corresponding peroxyhemiketal to the epoxide while treating the crude mixture with 
base (NaOH). 
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Scheme 4.46 Kinetic resolution I: racemic peroxyhemiketal in the presence of catalyst [13 • 2 TFA]. 
(aDetermined by 1H NMR.) 
 
Moreover, optically active peroxyhemiketal (R)-94a with an enantiomeric ratio of 98.5:1.5 er 
was resolved by converting it into the epoxide in the presence of catalyst [13 • 2 TCA] 
(Scheme 4.47). 
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n-C6H13
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Scheme 4.47 Kinetic resolution II: Optically active peroxyhemiketal in the presence of catalyst [13 • 2 TFA]. 
(aDetermined by GC/MS.) 
 
Both experiments clearly demonstrate that chiral catalyst [13 • 2 TXA] (X = F, Cl) is indeed 
involved in the conversion of peroxyhemiketals 94 to epoxides 93 under our reaction 
conditions with the effect of a moderately efficient kinetic resolution accompanying this 
reaction step. This kinetic resolution may well contribute to the truly outstanding 
enantioselectivities observed for epoxides 93 generated under reaction conditions. Yet, for the 
same reason, peroxides 94 are obtained with slightly lower enantiomeric ratios. The “true” 
enantioselectivity of the conjugate addition of hydrogen peroxide for the reaction depicted in 
Scheme 4.45 may thus lie at about 99:1 er. 
Another explanation could be put forward to account for the observation of slightly lower 
enantioselectivity values for peroxyhemiketals: under the basic conditions of the 
peroxyhemiketal-epoxide rearrangement (carried out prior to er-determination)a the conjugate 
addition of hydrogen peroxide could exhibit (to some extent) reversibility since those 
conditions resemble classic Weitz-Scheffer reaction conditions. Nevertheless, since enone 
formation was not perceived under those conditions while rearranging purified PHKs, we 
believe that the slightly reduced optical purity is indeed a result of the resolution of PHKs by 
epoxide formation. 
 
                                                 
a Enantiomeric ratios were determined after converting the peroxyhemiketals to the corresponding epoxides. 
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4.5.4 Summary and Conclusions 
 
4.5.4.1 Proposed Catalytic Cycle 
Based on experimental evidence and the information gained from the ESI-MS studies, we 
propose the catalytic cycle, which is depicted for clarity again in Figure 4.14, for the catalytic 
asymmetric hydroperoxidation and epoxidation of α,β-unsaturated ketones 92 in the presence 
of catalytic amounts of [13 • 2 TXA] (X = F, Cl).a In the case of cyclic enones 46 (except for 
2-cycloheptenone 46s and -octenone 46v), only the epoxidation pathway is relevant. 
The catalytic cycle is initiated by the reversible formation of α,β-unsaturated iminium ion A 
from the enone and the catalyst (step (a)) to activate the substrate, by lowering its LUMO 
energy. Conjugate nucleophilic addition of hydrogen peroxide then takes place in the 
following step (step (b)). 
In Weitz-Scheffer epoxidations under basic conditions, hydroperoxide anion is the active 
nucleophile and the addition step is considered to be fast and reversible as confirmed by 
kinetic data.[57, 162] Under our reaction conditions in the presence of catalyst salts [13 • 2 TXA] 
(X = F, Cl) including two equivalents of either TFA or TCA, neutral hydrogen peroxide rather 
than the hydroperoxide anion may be the active nucleophile,b and the conjugate addition is 
most likely irreversible and constitutes the enantiodetermining step of the catalytic cycle. The 
same holds true for the epoxidation in the presence of catalyst system [(R,R)-DPEN • (S)-
TRIP].c An alternative scenario would be a reversible addition of hydrogen peroxide followed 
by an enantioselective irreversible epoxide ring closure. However, this possibility could be 
excluded by the experiment presented in Scheme 4.46. That is to say, the epoxide should have 
been furnished with the same enantioselectivity as under reaction conditions if the latter 
assumption was valid.d Besides, β-peroxycyclooctanone (117) was isolated in 97:3 er (cf. 
Scheme 4.27). If the addition step was reversible and not irreversible and under kinetic 
control, this β-peroxy compound would have been inevitably obtained in racemic form. 
                                                 
a The reaction catalyzed by [(R,R)-DPEN • (S)-TRIP] supposedly proceeds in an analogous fashion. 
b pKa(H2O2) 11.8, for comparison: pKa(quinuclidine) 11.1, pKa(i-PrNH2) 10.7, pKa(benzyl amine) 9.34, 
pKa(quinoline) 4.85 
c pKa(2,3-diaminobutane, rac.) 10.00, 6.91. 
d Alternatively, a cross-over experiment could have been carried out by mixing a peroxyhemiketal with a 
different enone substrate under reaction condition in the absence of H2O2. 
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most likely irreversible and constitutes the enantiodetermining step of the catalytic cycle. The 
same holds true for the epoxidation in the presence of catalyst system [(R,R)-DPEN • (S)-
TRIP].c An alternative scenario would be a reversible addition of hydrogen peroxide followed 
by an enantioselective irreversible epoxide ring closure. However, this possibility could be 
excluded by the experiment presented in Scheme 4.46. That is to say, the epoxide should have 
been furnished with the same enantioselectivity as under reaction conditions if the latter 
assumption was valid.d Besides, β-peroxycyclooctanone (117) was isolated in 97:3 er (cf. 
Scheme 4.27). If the addition step was reversible and not irreversible and under kinetic 
control, this β-peroxy compound would have been inevitably obtained in racemic form. 
                                                 
a The reaction catalyzed by [(R,R)-DPEN • (S)-TRIP] supposedly proceeds in an analogous fashion. 
b pKa(H2O2) 11.8, for comparison: pKa(quinuclidine) 11.1, pKa(i-PrNH2) 10.7, pKa(benzyl amine) 9.34, 
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c pKa(2,3-diaminobutane, rac.) 10.00, 6.91. 
d Alternatively, a cross-over experiment could have been carried out by mixing a peroxyhemiketal with a 
different enone substrate under reaction condition in the absence of H2O2. 
4 Results and Discussion 
 135
4.5.4 Summary and Conclusions 
 
4.5.4.1 Proposed Catalytic Cycle 
Based on experimental evidence and the information gained from the ESI-MS studies, we 
propose the catalytic cycle, which is depicted for clarity again in Figure 4.14, for the catalytic 
asymmetric hydroperoxidation and epoxidation of α,β-unsaturated ketones 92 in the presence 
of catalytic amounts of [13 • 2 TXA] (X = F, Cl).a In the case of cyclic enones 46 (except for 
2-cycloheptenone 46s and -octenone 46v), only the epoxidation pathway is relevant. 
The catalytic cycle is initiated by the reversible formation of α,β-unsaturated iminium ion A 
from the enone and the catalyst (step (a)) to activate the substrate, by lowering its LUMO 
energy. Conjugate nucleophilic addition of hydrogen peroxide then takes place in the 
following step (step (b)). 
In Weitz-Scheffer epoxidations under basic conditions, hydroperoxide anion is the active 
nucleophile and the addition step is considered to be fast and reversible as confirmed by 
kinetic data.[57, 162] Under our reaction conditions in the presence of catalyst salts [13 • 2 TXA] 
(X = F, Cl) including two equivalents of either TFA or TCA, neutral hydrogen peroxide rather 
than the hydroperoxide anion may be the active nucleophile,b and the conjugate addition is 
most likely irreversible and constitutes the enantiodetermining step of the catalytic cycle. The 
same holds true for the epoxidation in the presence of catalyst system [(R,R)-DPEN • (S)-
TRIP].c An alternative scenario would be a reversible addition of hydrogen peroxide followed 
by an enantioselective irreversible epoxide ring closure. However, this possibility could be 
excluded by the experiment presented in Scheme 4.46. That is to say, the epoxide should have 
been furnished with the same enantioselectivity as under reaction conditions if the latter 
assumption was valid.d Besides, β-peroxycyclooctanone (117) was isolated in 97:3 er (cf. 
Scheme 4.27). If the addition step was reversible and not irreversible and under kinetic 
control, this β-peroxy compound would have been inevitably obtained in racemic form. 
                                                 
a The reaction catalyzed by [(R,R)-DPEN • (S)-TRIP] supposedly proceeds in an analogous fashion. 
b pKa(H2O2) 11.8, for comparison: pKa(quinuclidine) 11.1, pKa(i-PrNH2) 10.7, pKa(benzyl amine) 9.34, 
pKa(quinoline) 4.85 
c pKa(2,3-diaminobutane, rac.) 10.00, 6.91. 
d Alternatively, a cross-over experiment could have been carried out by mixing a peroxyhemiketal with a 
different enone substrate under reaction condition in the absence of H2O2. 
4 Results and Discussion 
 135
4.5.4 Summary and Conclusions 
 
4.5.4.1 Proposed Catalytic Cycle 
Based on experimental evidence and the information gained from the ESI-MS studies, we 
propose the catalytic cycle, which is depicted for clarity again in Figure 4.14, for the catalytic 
asymmetric hydroperoxidation and epoxidation of α,β-unsaturated ketones 92 in the presence 
of catalytic amounts of [13 • 2 TXA] (X = F, Cl).a In the case of cyclic enones 46 (except for 
2-cycloheptenone 46s and -octenone 46v), only the epoxidation pathway is relevant. 
The catalytic cycle is initiated by the reversible formation of α,β-unsaturated iminium ion A 
from the enone and the catalyst (step (a)) to activate the substrate, by lowering its LUMO 
energy. Conjugate nucleophilic addition of hydrogen peroxide then takes place in the 
following step (step (b)). 
In Weitz-Scheffer epoxidations under basic conditions, hydroperoxide anion is the active 
nucleophile and the addition step is considered to be fast and reversible as confirmed by 
kinetic data.[57, 162] Under our reaction conditions in the presence of catalyst salts [13 • 2 TXA] 
(X = F, Cl) including two equivalents of either TFA or TCA, neutral hydrogen peroxide rather 
than the hydroperoxide anion may be the active nucleophile,b and the conjugate addition is 
most likely irreversible and constitutes the enantiodetermining step of the catalytic cycle. The 
same holds true for the epoxidation in the presence of catalyst system [(R,R)-DPEN • (S)-
TRIP].c An alternative scenario would be a reversible addition of hydrogen peroxide followed 
by an enantioselective irreversible epoxide ring closure. However, this possibility could be 
excluded by the experiment presented in Scheme 4.46. That is to say, the epoxide should have 
been furnished with the same enantioselectivity as under reaction conditions if the latter 
assumption was valid.d Besides, β-peroxycyclooctanone (117) was isolated in 97:3 er (cf. 
Scheme 4.27). If the addition step was reversible and not irreversible and under kinetic 
control, this β-peroxy compound would have been inevitably obtained in racemic form. 
                                                 
a The reaction catalyzed by [(R,R)-DPEN • (S)-TRIP] supposedly proceeds in an analogous fashion. 
b pKa(H2O2) 11.8, for comparison: pKa(quinuclidine) 11.1, pKa(i-PrNH2) 10.7, pKa(benzyl amine) 9.34, 
pKa(quinoline) 4.85 
c pKa(2,3-diaminobutane, rac.) 10.00, 6.91. 
d Alternatively, a cross-over experiment could have been carried out by mixing a peroxyhemiketal with a 
different enone substrate under reaction condition in the absence of H2O2. 
4  Results and Discussion 
136 
via
HN
+
-
R2
X
R1
N
O
OH
H
HX
NH
R2R1
O
R1 R2
O
H2O
O
R2R1
O
H2O
H2O2
NH2
N
*
X-
N *
+
93
92
NH
R2R1
O
O
N
X-*
+
R2
OO OH
R1
94
hydroperoxidation
pathway
N
N
MeO
NH2
H
[13 2 TXA]
(a) (b)
(f)
(c)
(d)
H
*
HN
+
R2
X-
R1
N
*
HN
R2
X-
N
O
OH
H
+
B'
HN
R2
O
OHR1
N
*
HX
R1
epoxidation
pathway
H2O
(e)
(~H+)
2 TXA
A
B
D
C
 
 
Figure 4.14 Proposed catalytic cycle for the epoxidation and hydroperoxidation in the reaction of α,β-
unsaturated ketones 92 and cyclic enones 46s and 46v. (TXA with X = F, Cl) 
 
The conjugate addition of hydrogen peroxide generates β-peroxyenamine intermediate B (step 
(b)). This intermediate can either pursue the epoxidation pathway and afford epoxide 93 via 
intramolecular nucleophilic substitution at the proximal oxygen atom (step (c)) followed by 
hydrolysis (step (d)) or remain at the hydroperoxidation stage to deliver 3-hydroxy-1,2-
dioxolane 94 after protonation (step (e)) and hydrolysis (step (f)). It is the β-peroxyenamine 
intermediate B which cyclizes to provide epoxide 93 and not the corresponding enol form. 
Beside the enamine being more nucleophilic, cyclization of the corresponding β-peroxyenol 
would not result in an enhancement of the enantioselectivity as revealed in independent 
experiments (cf. Scheme 4.47). Cyclic peroxyhemiketals 94 derived from acyclic α,β-
unsaturated ketones 92 exist in equilibrium with the acylic form. However, the equilibrium 
distribution favours the peroxyhemiketal whereas the acyclic form cannot be perceived by 
NMR. On the contrary, with seven- and eight membered cyclic enones 46s and 46v, the β-
peroxyketone form significantly contributes to the equilibrium mixture of hydroperoxidation 
products 116 and 117 as detected by NMR. Both the epoxidation and the hydroperoxidation 
pathway are terminated by hydrolysis of an iminium ion D or C to release the product and 
regenerate the catalyst (step (d) and (f), respectively). 
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The epoxidation of cyclic enones in the presence of catalytic amounts of either [13 • 2 TFA] 
or [(R,R)-DPEN • (S)-TRIP] are assumed to proceed accordingly. Presumably, due to 
conformational constraints, in five- and six-membered as well as in macrocyclic enones, only 
epoxide formation is observed. Thus, the hydroperoxidation manifold is not operative in those 
cases (cf. Figure 3.1). 
Based on the ESI-MS investigations, we may take into account an alternative, simultaneously 
operating catalytic cycle with N-oxide 13+O (as its TFA salt) as the catalytically active 
species.a 
 
4.5.4.2 Rationalizing the Absolute Stereochemistry 
Of major interest is the identification of a plausible model for the transition state of the H2O2-
conjugate addition to the α,β-enone, which constitutes the enantiodetermining step of the 
hydroperoxidation-epoxidation process. Such an endeavour may allow us to rationalize the 
observed absolute stereochemistry with both primary amine salt catalyst systems [9-NH2-
epiQ (13) • 2 TFA] and [(R,R)-DPEN • (S)-TRIP]. 
DFT calculationsb at the B3LYP/6-31G* level of theory (Vacuum) on the structure of the 
relevant α,β-unsaturated iminium ions Z-A and E-A (cf. Figure 4.15; with 2-cyclohexenone 
(46a) as the substrate) revealed a steric shielding of the re-face by the quinoline moiety of 9-
amino(9-deoxy)epiquinine (13) in the Z-configured iminium ion Z-A (Figure 4.15, (a)). A 
preferred attack at the si-face of the cyclohexenone is in accordance with the absolute 
stereochemistry observed with 9-amino(9-deoxy)epiquinine-based catalyst systems (cf. Table 
4.5). On the contrary, the E-configured iminium ion, which is higher in energy, would suggest 
a re-face attack of hydrogen peroxide in contradiction with the experimental observations 
(Figure 4.15, (b)). Thus, Z-configured iminium ion Z-A might be invoked as a working model 
for the transition state structure. 
 
                                                 
a In particular for reactions conducted at elevated temperatures of 50 °C or higher. 
b DFT calculations were performed using Spartan ’08 Windows from Wavefunction, Inc. 
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Figure 4.15 Calculated structures of (a) Z-configured α,β-unsaturated iminium ions Z-A and (b) E-configured 
α,β-unsaturated iminium ions E-A. 
 
At this stage, a directing effect of the second basic amine site of catalyst 9-NH2-epiQ (13) 
could not be testified by calculations. DFT Calculations conducted on structures of the 
corresponding iminium ions Z-A and E-A generated from (R,R)-DPEN (12) with 2-
cyclohexenone gave similar results. However, it might be desirable to calculate structures of 
the pivotal α,β-unsaturated iminium ions A in solution and at a higher level of theory. 
Furthermore, it might be critical to take the influence of the counteranion into account. 
DFT calculations need not, however, be the single tool used in order to gain access to 
structural data of those intermediates. For instance, it would be particularly interesting to 
synthesize imines resulting from the condensation of an array of enone substrates and the 
primary amines 9-NH2-epiQ (13) or (R,R)-DPEN (12). These imines should, at the outset, be 
carefully analyzed for their structural features. Addition of equimolar amounts of (S)-TRIP or 
TFA would then generate iminium salts A. At this stage, single-crystal X-ray diffraction 
studies could prove extremely useful to shed further light into the geometric and structural 
intricacies of these iminium ions in the solid state. Relating these structures to the in situ 
formed analogues in solution might finally allow us to gaze at “snapshots” of our transition 
state structures. Other acids (beside TFA and (S)-TRIP) might be tested - both to eventually 
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facilitate crystallization of iminium ion A and for assessment of its counterion’s influence on 
structure. 
 
 
 
Scheme 4.48 Proposed preparation of α,β-unsaturated iminium ions A for X-ray structure analysis. 
 
The observed absolute configuration of 2,3-epoxycyclohexanone (48a) and 4-hydroxy-6-
phenyl-2-hexanone (96b) (derived from the corresponding peroxyhemiketal 94b through 
P(OEt)3-reduction) was established by comparison of their optical rotation with literature 
values;[97a, 137] absolute configurations of cyclic as well as acyclic epoxides 48 and 93, and 
peroxyhemiketals 94 were assigned by analogy considering an uniform mechanistic path. 
The absolute stereochemistry observed is the result of a si(β)-attacka in the [13 • 2 TFA]-
catalyzed epoxidation of cyclic enones 46 (n = 0-3) (re(β)-attack with catalyst [(R,R)-
DPEN • (S)-TRIP]), and of a re(β)-attack in the corresponding reaction of acyclic enones 92 
(Figure 4.16, (a) and (b)). Based on the assumption that the bias of the catalyst system is 
identical for both cyclic and acyclic substrates, the absolute stereochemistry observed for 
acyclic enones would be consistent with those substrates (or more precisely the corresponding 
α,β-unsaturated iminium ions generated with the amine salt catalyst) reacting preferentially in 
s-trans conformation. 
 
 
Figure 4.16 (a) si(β)-Attack in the [13 • 2 TFA]-catalyzed epoxidation of cyclic enones (n = 0-3), and re(β)-
attack in the [13 • 2 TXA]-catalyzed hydroperoxidation/epoxidation of (b) acyclic enones and (c) macrocyclic 
enones (n = 7-10). (X = F, Cl) 
 
                                                 
a Due to a change in priority of the substituent attached to the β-carbon, compounds 46h-m formally undergo 
attack from the re(β)-face in the presence of catalyst [13 • 2 TFA], although in practice there is no change in 
facial selectivity. 
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Macrocyclic enones 46w-x gave exclusively trans-configured epoxides when exposed to 
hydrogen peroxide in the presence of catalytic amounts of [13 • 2 TXA]. These enone rings 
are large enough to allow s-cis and s-trans conformational interconversion and due to their 
conformationally flexibility, we assume them to behave similarly to the acyclic substrates – 
implying a re(β)-attack (Figure 4.16, (c)). 
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4.6 Preparation of Starting Materials 
4.6.1 Preparation of Cyclic α,β-Unsaturated Ketones 
The synthesis of six- to fifteen-membered cyclic α,β-unsaturated ketones was carried out 
following two general strategies: firstly, through the addition of Grignard reagents to 3-
ethoxy-2-cyclohexenone (135) and 3-ethoxy-2-cycloheptenone (136) according to the method 
of Woods and co-workers (Table 4.40),[163] a  and secondly, via Saegusa oxidation of the 
corresponding saturated cyclic ketones in case of six-, and eight- to fifteen-membered ring 
cyclic enones 80 and 46v-x (Scheme 4.50).[164] 
 
Table 4.40 Synthesis of 3-substituted 2-cyclohexenones and 2-cycloheptenones 46 according to the method of 
Woods et al.[163] 
 
Entry R n Product Yield [%]b 
1 i-Pr 1 46i 71 
2 allyl 1 46k 47 
3 PhCH2 1 46m 76 
4 Ph 1 46n 98 
5 vinyl 1 46o 75 
6 ethinyl 1 46p 77 
7 Et 2 46t 45a 
8 PhCH2 2 46u 61a 
aOverall yield from 1,3-cycloheptadione. 
 
Whereas 3-ethoxy-2-cyclohex-2-enone (135) is commercially available, 3-ethoxy-2-
cycloheptenone (136) was obtained from 1,3-cycloheptanedione and ethanol in the presence 
of a catalytic amount of p-toluenesulfonic acid at a Dean-Stark trap in 90% yield.[165] 
For the synthesis of 3-tert-butyl-2-cyclohexenone (46j) the addition of tert-butyl magnesium 
chloride to the vinylogous ester 135 proved to be less practical. The desired product was 
obtained in a non satisfying yield of <15% due to increased formation of by-products caused 
by using the sterically hindered Grignard reagent. However, tert-butyl-substituted enone 46j 
                                                 
a Cyclic enones 46g, h and l were prepared by N. J. A. Martin through the same route. 
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could be readily accessed in 58% yield by a palladium-catalyzed allylic oxidation of 1-tert-
butylcyclohexene developed by Corey and Yu (Scheme 4.49).[166] 
 
 
Scheme 4.49 Synthesis of 3-tert-butyl-2-cyclohexenone (46j) through palladium-catalyzed allylic oxidation. 
 
Cyclic enones 80 and 46v-x were prepared via Saegusa oxidation from the corresponding 
saturated cyclic ketones.a First, the cyclic ketones were converted to the trimethylsilyl enol 
ethers, which were then dissolved in dimethylsulfoxide and subjected to catalytic amounts of 
palladium acetate under an atmosphere of oxygen as stoichiometric oxidant (Scheme 4.50). 
Under those conditions (Larock modification) the use of catalytic palladium acetate is 
sufficient, whereas the original Saegusa oxidation requires stoichiometric palladium acetate 
and employs acetonitrile as the solvent.[167] 
 
 
Scheme 4.50 Synthesis of cyclic enones 80 and 46v-x through a Saegusa oxidation (Larock modification).[167] 
 
To further explore the substrate scope, we studied the asymmetric epoxidation of 2-methyl-2-
cyclohexenone (79) as an example for an α-substituted cyclic α,β-unsaturated ketone. To this 
end, 2-methyl-2-cyclohexenone (79) was prepared in two steps from 2-cyclohexenone (46a) 
according to the reaction sequence depicted in Scheme 4.51 comprising the α-iodination of 2-
cyclohexenone and subsequent iron-catalyzed cross coupling of 2-iodo-2-cyclohexenone 
(137) with methyl magnesium bromide.[168] 
                                                 
a Cyclic enones 46v-x were prepared in collaboration with X. Wang. 
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Scheme 4.51 Synthesis of 2-methyl-2-cyclohexenone (79) via α-iodination and iron-catalyzed cross coupling. 
(aReduced yield of 79 due to its high volatility.) 
 
4.6.2 Preparation of Acyclic α,β-Unsaturated Ketones 
Acyclic α,β-unsaturated methylketones were prepared either by cross metathesis of a terminal 
olefin with methyl vinyl ketone in the presence of Grubbs second generation catalyst 138 
(Table 4.41),[169] or through a Wittig reaction of various aldehydes with 1-(triphenylphosphor-
anylidene)-2-propanone (Table 4.42). 
 
Table 4.41 Synthesis of acyclic α,β-unsaturated ketones 92 by cross metathesis. 
 
Entry R1 Enone Yield [%]a 
1  92g 78 
2  92j 80 
3 
 
92k 99 
4  92l 94 
5  92t 99 
6  92u 64 
aYields of pure, isolated products. 
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Table 4.42 Synthesis of various acyclic α,β-unsaturated ketones 92, 101 and 105 through a Wittig reaction. 
 
 
Entry R1 Enone Yield [%]a 
1 PhCH2CH2 92b 75 
2 PhCH2 92q 26 
3 i-Bu 92d 60 
4  92r 56 
5 Cy 92e 92 
6  92f 88 
7  92h 85 
8  92i 72 
9 CO2Et 101 50 
10 BnOCH2 105 88 
aYields of pure, isolated products. 
 
Most of the aldehydes were commercially available except for aldehydes 139h and 139i, 
which were prepared from the corresponding diols in two steps via monoprotection with 
either tert-butyl-dimethylsilyl chloride or dihydropyrane (DHP), followed by oxidation of the 
monoprotected diols 140 to the corresponding aldehydes 139h-i (Scheme 4.52). 
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Scheme 4.52 Synthesis of aldehydes 139h-i. 
 
Comparing the results of the epoxidation and hydroperoxidation reactions conducted with 
enones 92 (R2 ≠ Me) with those obtained in the reactions of methyl ketones 92 (R2 = Me) may 
allow us to evaluate the influence of the substituent R2 on the reaction outcome. 
α,β-Unsaturated ketones of the general structure 92 with R2 ≠ Me were prepared in two steps 
from α,β-unsaturated aldehydes through Grignard addition followed by Swern oxidation or 
oxidation with MnO2 of the resultant allylic alcohol (Scheme 4.53).[170] 
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Scheme 4.53 Grignard addition-oxidation sequence: synthesis of enones 92m-n, p.a 
 
Alternatively, an aldol-dehydration sequence provided concise access to such enones 92 
(R2 ≠ Me).[171] This strategy was used for the synthesis of 2-methyl-4-hexen-3-one (92o) 
(Scheme 4.54). 
O O OMs
O OHO LDA (1.05 equiv)
THF, 78 °C, 30 min
then acetaldehyde
(2.5 equiv)
78 °C, 1 h
MsCl (1.18 equiv)
pyridine, 0 °C, 16 h
141
95%
142
63%
92o
62%
Et2O, r.t.
Et3N (1.5 equiv)
 
Scheme 4.54 Aldol-dehydration sequence: synthesis of 2-methyl-4-hexen-3-one (92o). 
 
To investigate the effect of the enone geometry on the asymmetric epoxidation reaction 
catalyzed by 9-amino(9-deoxy)epiquinine (13) TFA salt (cf. Scheme 4.20), we prepared (Z)-
6-phenyl-3-hexen-2-one (Z)-92b in three steps from commercially available 4-phenyl-1-
butyne according to a reaction sequence described by Heathcock et al. (Scheme 4.55).[171] 
Reaction of the lithiated alkyne with acetaldehyde gave propargylic alcohol 143, which was 
oxidized with PCC to the corresponding ketone 144. Finally, Lindlar reduction of the alkyne 
gave the desired (Z)-enone in an overall yield of 55%. 
 
                                                 
a Enones 92m-n, p were prepared by X. Wang. 
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Scheme 4.55 Synthesis of (Z)-6-phenyl-3-hexen-2-one ((Z)-92b). 
 
Trisubstituted α,β-unsaturated methyl ketone 100 - both the (E)- and (Z)-isomer - were 
prepared from citral to study the effect of an additional substituent attached to the β-position 
and to see if those enones are suitable substrates in the asymmetric epoxidation/hydro-
peroxidation reaction (see Chapter 4.2.2.5). Citral, which constitutes a mixture of geranial and 
neral in a 64:36 ratio, was converted to secondary alcohols 145 by the addition of methyl 
lithium. Subsequent Ley oxidation gave methyl ketones 100 as a mixture of (E)- and (Z)-
isomers. Pure fractions of each isomer were readily obtained by column chromatography 
(Scheme 4.56).[172] 
 
 
Scheme 4.56 Synthesis of 4,8-dimethylnona-3,7-dien-2-one (100). 
 
4.7 Catalyst Synthesis 
4.7.1 Synthesis of Chiral Primary Amines based on the Quinuclidine Scaffold 
 
4.7.1.1 Synthesis of 9-Amino(9-deoxy) Cinchona Alkaloid Derivatives 
9-Amino(9-deoxy)epiquinine (13) was first prepared by Brunner et al. in 1995 from naturally 
abundant quinine via a Mitsunobu reaction with hydrazoic acid followed by an in situ 
Staudinger reduction of the azide intermediate.[49a] Whereas Brunner et al. mostly explored 
the catalytic potential of amides derived from 9-amino(9-deoxy)cinchona alkaloids in 
asymmetric transformations,[49b, 173] 9-amino(9-deoxy)cinchona alkaloids themselves have 
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only recently drawn considerable attention as primary amine catalysts in organocatalysis, both 
enamine and iminium ion catalysis (cf. Chapter 2.1.3.2).[50c, 174] 
In 2005, Sóos et al. reported a modified synthesis of 9-amino(9-deoxy)cinchona alkaloids, in 
which hydrazoic acid was replaced by a less hazardous azide source – diphenylphosphoryl 
azide (DPPA).[175] Starting from quinine (Q), 9-amino(9-deoxy)epiquinine (13) was obtained 
in 76% yield, and moreover, a range of 9-amino(9-deoxy)epicinchona alkaloid derivatives 
were prepared from the parent 9-hydroxy-substituted compounds in good yields (42-77%) 
according to this operationally simple one pot-two step reaction sequence (Scheme 4.57). 
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then H2O, r.t., overnight
76%
quinine (Q) 13
 
Scheme 4.57 Synthesis of 9-amino(9-deoxy)cinchona alkaloids and derivatives through a Mitsunobu 
reaction/Staudinger reduction sequence. 
 
In the case of 9-amino(9-deoxy)cinchona alkaloid derivatives 71 and 73, the corresponding 9-
hydroxy-substituted precursors, 6'-isopropoxycinchonidine (146) and epiquinine (147), 
respectively, were not commercially available. However, both compounds could be readily 
accessed from quinine in only two steps according to literature procedures (Scheme 4.58).[92d, 
176] 
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9-Amino(9-deoxy)epicupreidine (68) bearing a free hydroxy group as potential hydrogen 
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4.7.1.2 De-Novo Design and Synthesis of α-(Aminobenzyl)quinuclidine 
α-(Aminobenzyl)quinuclidine (86a) can be regarded as truncated 9-amino(9-deoxy)cinchona 
alkaloids featuring a less hindered primary amine group due to the replacement of the 
quinoline moiety by a smaller phenyl group. Thus, we anticipated α-(aminobenzyl)quinuc-
lidine (86a) in combination with a suitable acid co-catalyst to be considerably more effective 
in activating sterically demanding and less reactive enone substrates such as 2-
cyclopentenone (46r) as iminium ions compared to, for instance, sterically congested 9-
amino(9-deoxy)epiquinine (13) (cf. Chapter 4.1.2.5). We based our hypothesis on the 
observed high catalytic activity of salts of α-(aminomethyl)quinuclidine derivatives 63 and 64 
featuring a primary amine function located at a primary carbon atom in the epoxidation of 
various cyclic enones including 2-cyclopentenone (46r) (cf. Table 4.18). 
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We planned to access compound 86 in two steps from quinuclidine. First, quinuclidine is 
lithiated at the α-position and then reacted with benzaldehyde to give α-(hydroxyl-
benzyl)quinuclidine (150), which is in the second step converted into α-(amino-
benzyl)quinuclidine (86a) by the reaction sequence described above (cf. Scheme 4.56) 
consisting of a Mitsunobu reaction to stereoselectively introduce the azide and subsequent 
Staudinger reduction to afford the corresponding amine. Finally, classical resolution 
techniques or separation by chiral preparative HPLC would allow access to the pure 
enantiomers of the target compound 86a. 
The group of Kessar has demonstrated that α-deprotonation of quinuclidine with Schlosser-
Lochmann base is possible upon activation of the quinuclidine nitrogen either as the N-oxide 
or by complexation with borontrifluoride.[177] They also sought to develop this chemistry into 
an enantioselective process by performing the α-lithiation in the presence of (-)-sparteine, 
however attaining only moderate enantioselectivities (up to 70:30 er).[178] 
Following their procedure, α-lithiation of the quinuclidine borontrifluoride complex and 
quenching of the α-lithiated species with benzaldehyde afforded α-(hydroxylbenzyl)quinuc-
lidine (150) as an approximately 1:1 mixture of diastereomers, a  which could be readily 
separated during the work-up procedure, and further purified by column chromatography. 
Recrystallization afforded both the threo- and the erythro-isomer of 150 in a yield of 26% and 
31%, respectively (Scheme 4.60). Subsequently, both isomers were stereoselectively 
converted into amines 86a, and the enantiomers of erythro-86a were separated by chiral 
HPLC. Despite numerous attempts, no separation was achieved until now in case of threo-86a, 
as it was the case at the alcohol stage (erythro-150 and threo-150).[175] 
                                                 
a Despite several reruns, we were not able to reproduce the diastereoselectivity of >12:1 (threo/erythro) reported 
by the Kessar group. 
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Scheme 4.60 Synthesis of racemic α-(aminobenzyl)quinuclidine (threo- and erythro-86a). 
 
4.7.2 Synthesis of Amino Acid-derived Diamines 
Recently, optically active diamines which are readily accessible from commercially available 
and naturally abundant amino acids in only a few steps, have emerged as highly efficient 
catalysts for a wide range of transformations proceeding via enamine or iminium ion 
catalysis.[179] Thus, we became interested to evaluate their catalytic potential in our 
epoxidation reaction, in particular in the asymmetric epoxidation of 2-cyclopentenone (46r) 
which had emerged as especially challenging substrate among the cyclic enone series. For this 
purpose, we prepared different diamines bearing (at least) one primary amine functionality 
through conventional synthetic routes, including peptide coupling chemistry. First, the amide 
bond is formed, which then gets reduced in the next step to obtain the desired diamines 
(Figure 4.17). 
 
 
Figure 4.17 General strategy for the synthesis of optically active diamines from the corresponding amino acids. 
 
For the synthesis of primary−primary amine 87 and primary−secondary amine 88, the amide 
bond was formed by simple aminolysis of the respective amino acid ester, followed by 
reduction with lithium aluminium hydride. 
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Scheme 4.61 (a) Synthesis of primary−primary diamine 87; (b) synthesis of primary−secondary diamine 88. 
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yields. 
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All diamines 87-89 were tested as catalysts in the asymmetric epoxidation of 2-
cyclopentenone, albeit with only moderate success (cf. Table 4.20). 
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4.7.3 Synthesis of BINOL-derived Phosphoric Acids 
At the outset of our studies, only chiral phosphoric acids derived from unsubstituted (S)- or 
(R)-BINOL were commercially available. All other chiral BINOL-derived phosphoric acids 7 
were obtained via phosphorylation of appropriately 3,3'-disubstituted BINOL derivatives 156, 
which could be readily accessed from commercially available enantiomerically pure (S)- or 
(R)-BINOL in four steps involving cross coupling methods (Scheme 4.63). 
 
 
Scheme 4.63 Retrosynthetic approach to the preparation of 3,3'-disubstituted BINOL-derived phosphates 7. 
(R = Ar; X = B(OH)2, Br) 
 
Depending on the nature of the substituents R at the 3,3'-positions, two different cross-
coupling strategies were applied: Most aromatic residues were successfully introduced via 
palladium-catalyzed Suzuki-Miyaura coupling of boronic diacid 157 and the respective 
aromatic halide according to the procedures of Jørgensen et al. and Wipf et al. (Scheme 
4.64).[180] 
 
 
Scheme 4.64 General procedure for the synthesis of BINOL phosphates 7 via Suzuki-Miyaura cross-coupling. 
 
The introduction of sterically hindered substituents such as the 2,4,6-triisopropylphenyl group 
of the chiral phosphoric acid TRIP (7a) was accomplished via a nickel-catalyzed Kumada 
cross coupling of dibromide 158a and the respective aryl magnesium bromide.a The pre-
paration of the chiral phosphoric acid TRIP was developed and optimized by A. M. Seayad 
according to the procedures of Schrock et al. and Akiyama et al. (Scheme 4.65).[181] 
 
                                                 
aSuzuki-Miyaura reaction of boronic diacid 157 with 2,4,6-triisopropylphenyl bromide afforded poor yields of 
the dicoupling product. 
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Scheme 4.65 Synthesis of TRIP (7a) via Kumada cross-coupling. 
 
The synthesis of sterically hindered 3,3'-bis(triphenylsilyl)-1,1'-bi-2-naphthol hydrogen 
phosphate (7b)[182] relied on the remarkably facile 1,3-rearrangement of O-silylated dibromide 
158c to 3,3'-disilylated BINOL derivative 159 as the key step.[183] 
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Scheme 4.66 Synthesis of bis(triphenylsilyl)-substituted phosphoric acid (S)-7b via -Osilyl to -Csilyl 
rearrangement. 
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5 Summary 
Our laboratory has a long-term interest in the development of organocatalytic asymmetric 
epoxydation methods, since optically active epoxides are valuable chiral building blocks and 
versatile synthetic intermediates. 
This Ph.D. thesis describes the successful development of organocatalytic asymmetric 
epoxidation and hydroperoxidation reactions of α,β-unsaturated ketones with aqueous 
hydrogen peroxide as the oxidant in the presence of catalytic amounts of a chiral primary 
amine salt. The focus was placed on challenging substrate classes such as simple cyclic 
enones and enolizable aliphatic acyclic enones. Indeed, and despite the wealth of 
enantioselective enone epoxidation methods known, these substrates have been systematically 
omitted and their enantioselective epoxidation is a challenge thus far unmet by the synthetic 
community. 
 
At the outset, we concentrated our work on the asymmetric epoxidation of cyclic α,β-
unsaturated ketones. In the course of our studies, we identified two powerful and 
complementary catalytic systems based on chiral primary amines for the desired 
transformation: the [(R,R)-DPEN • (S)-TRIP] salt and 9-amino(9-deoxy)epiquinine (9-NH2-
epiQ; 13) as its trifluoroacetic acid salt [9-NH2-epiQ • 2 TFA] (Figure 5.1). 
 
 
Figure 5.1 Catalyst systems developed for the asymmetric epoxidation of cyclic α,β-enones. 
 
Using these chiral primary amine salts as catalysts at 10 mol% loadings, we achieved an 
efficient asymmetric epoxidation of variously substituted cyclic enones of different ring sizes, 
in good to high yields along with excellent enantioselectivities of up to > 99.5:0.5 er in many 
cases (Scheme 5.1). 
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Scheme 5.1 Catalytic asymmetric epoxidation of cyclic α,β-unsaturated ketones. (aYields of pure, isolated 
products; bDetermined by GC with an internal standard method.) 
 
Mechanistically, we propose the reaction to proceed via activation of the α,β-unsaturated 
ketones as iminium ions (cf. Figure 3.1). This assumption was supported by structure-activity 
relationships uncovered during our evaluation of modified catalyst candidates (cf. Chapter 
4.5.1). Since primary amine catalysts equipped with a second basic amine functionality gave 
superior results in terms of enantioselectivity, we hypothesized that this additional binding 
site might bring the hydrogen peroxide into close proximity to the reactive center (via 
hydrogen bonding interactions) and direct its attack to one of the enantiotopic faces of the 
double bond (Figure 5.2). 
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Figure 5.2 Pre-transition state assembly invoking a directing effect of the bifunctional amine catalyst’s 
second amino group. 
 
In addition, our efforts were aimed at evaluating the synthetic potential of optically active 
cyclic α,β-epoxyketones 48. We envisaged them to function as precursors to enantiomerically 
enriched cyclic aldol products through reductive epoxide opening. After screening different 
reduction methods, we identified conditions which provided cyclic aldol products 124 of 
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different ring sizes in excellent yields. It should be noted that these aldols, which were 
obtained essentially without loss of optical purity, would be particularly difficult to access by 
any other synthetic means (Scheme 5.2). 
 
 
Scheme 5.2 Cyclic aldols through reductive epoxide cleavage. 
 
We then became interested in expanding the scope of our catalytic asymmetric epoxidation 
reaction. Thus, the second part of this thesis concerned the work with acyclic α,β-unsaturated 
ketones. It could quickly be established that the 9-amino(9-deoxy)epiquinine (9-NH2-epiQ; 13) 
TFA salt was furthermore a viable catalytic system for the reaction of acyclic enones with 
aqueous hydrogen peroxide. In contrast to the reaction of cyclic substrates under identical 
reaction conditions, we found that acyclic enones 92 provide mixtures of trans-epoxides 93 
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Scheme 5.4 Catalytic asymmetric hydroperoxidation of α,β-unsaturated ketones 92. 
 
An exception among the cyclic enones constituted 2-cycloheptenone (46s) and the 
corresponding eight-membered ring enone (46v), which in analogous fashion to the acyclic 
substrates afforded bicyclic peroxyhemiketals along with the expected epoxides (Scheme 5.5). 
Those bicyclic peroxyhemiketals, which have not been described previously, piqued our 
interest since their bicyclic peroxidic scaffold resembles potent antimalarial agents. After 
optimization, both compounds 116 and 117 were obtained in good yields and with high 
optical purity. 
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Scheme 5.5 Catalytic asymmetric hydroperoxidation of 2-cycloheptenone (46s) and 2-cyclooctenone (48v). 
 
The versatility of cyclic peroxyhemiketals 94 (cf. Scheme 5.4) was illustrated by converting 
them into epoxides 93, aldol products 96, and 1,2-dioxolane 127 (Scheme 5.6). 
Epoxides 93 were obtained via base-mediated rearrangement of crude hydroperoxidation 
products (cf. Chapter 4.2.2.2), whereas silane reduction of peroxyhemiketals 94 in the 
presence of a Brønsted acid afforded 1,2-dioxolane 127 (cf. Chapter 4.3.3). The reduction to 
aldol products 96 could be accomplished in situ by the addition of P(OEt)3 directly to the 
reaction mixture once the hydroperoxidation of α,β-unsaturated ketones 92 was complete (cf. 
Chapter 4.3.1). Alternatively, the crude hydroperoxidation product could be subjected to 
catalytic hydrogenation. The hydroperoxidation-reduction sequence furnished aldol products 
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which are formally derived from linear α-unbranched aldehydes with high enantioselectivities. 
This is particularly interesting in view of the fact that α-unbranched aldehydes still represent 
challenging substrates in proline-catalyzed aldol reactions. 
Remarkably, aldols 96, epoxides 93 and 1,2-dioxolane 127 could all be readily accessed in 
nearly enantiopure fashion, at will from a common peroxyhemiketal precursor. 
 
 
 
Scheme 5.6 Versatility of cyclic peroxyhemiketals 94: syntheses of epoxides 93, aldol products 96, and 1,2-
dioxolane 127. 
 
Our postulated mechanism invokes the formation of a peroxyenamine intermediate B 
resulting from the conjugate addition of hydrogen peroxide to the activated enone A (cf. 
Figure 5.2). This intermediate can either undergo ring closure providing epoxides 93 or 
furnish peroxyhemiketals 94 upon hydrolysis (Scheme 5.7). Experimental support of this 
hypothesis was inter alia provided by monitoring the reaction by ESI-MS (cf. Chapter 
1284.5.2). 
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Scheme 5.7 Competing reaction pathways accounting for both the formation of peroxyhemiketals 94 and 
epoxides 93. 
 
An intriguing feature of our asymmetric hydroperoxidation-epoxidation reaction of α,β-
unsaturated ketones is the complete stereoconvergency. We have demonstrated that both E- 
and Z-isomers of a respective enone furnish the same enantiomer of the corresponding trans-
epoxide in equally high enantioselectivity, with the isomerization most likely taking place via 
a dienamine intermediate (cf. Chapter 4.2.2.3). 
 
Interestingly, the use of pseudoenantiomeric 9-amino(9-deoxy)epiquinidine (9-NH2-epiQD; 
67) instead of 9-NH2-epiQ (13) as the primary amine component provided antipodal products 
with equally high enantioselectivity as has been demonstrated for cyclic as well as acyclic 
substrates. We thus hold an efficient synthetic entry to either enantiomeric series of the 
compounds described throughout this dissertation. 
Finally, it should be pointed out that a significant and general strength of the 
hydroperoxidation and epoxidation methods presented in this thesis lies in the use of aqueous 
hydrogen peroxide as the oxidant. Hydrogen peroxide meets all criteria for future applications 
potentially also on an industrial scale. It is an environmentally benign and economic oxidant: 
cheap, readily available, and gives water as the only by-product. 
 
 
Part of this work has been published in scientific journals: 
 
“Catalytic Asymmetric Hydroperoxidation of α,β-Unsaturated Ketones”: An Approach to 
Enantiopure Peroxyhemiketals, Epoxides, and Aldols”: C. M. Reisinger, X. Wang, B. List, 
Angew. Chem., Int. Ed. 2008, 47, 8112-8115; Angew. Chem., 2008, 120, 8232-8235. 
 
“Catalytic Asymmetric Epoxidation of Cyclic Enones”: X. Wang, C. M. Reisinger, B. List,  
J. Am. Chem. Soc. 2008, 130, 6070-6071. 
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6 Outlook 
As can be inferred from the chemistry described in the previous chapters, there are exciting 
perspectives ahead for further development of our catalytic asymmetric epoxidation and 
hydroperoxidation reactions. 
9-Amino(9-deoxy)epiquinine as its TFA salt ([9-NH2-epiQ • 2 TFA]) proved to be a highly 
efficient and general iminium ion activator of cyclic as well as acyclic α,β-unsaturated ketone 
substrates, allowing the highly enantioselective conjugate addition of hydrogen peroxide. It 
might be desirable to explore the catalytic potential of such chiral primary amine salts in 
enantioselective epoxidation and hydroperoxidation reactions of other, sterically demanding 
α,β-unsaturated carbonyl compounds. In this context, future efforts might address the 
catalytic enantioselective epoxidation of α-substituted-α,β-unsaturated aldehydes in the 
presence of chiral primary amine salts such as [9-NH2-epiQ • 2 TFA] and others.[46c, 50b] To 
date, there is no general and efficient method available for the direct epoxidation of this class 
of so-called α-branched-α,β-unsaturated aldehydes.[184] Noteworthy, the corresponding 
optically active epoxyaldehydes constitute attractive chiral building blocks and pivotal 
intermediates in many natural product syntheses. Strikingly, current synthetic strategies 
typically rely on reaction sequences involving Sharpless asymmetric epoxidation of allylic 
alcohols followed by oxidation of the intermediate epoxyalcohols. A direct epoxidation of α-
branched-α,β-unsaturated aldehydes would thus pave the way for the synthesis of such 
epoxyaldehydes with significantly improved redox economy.[185] 
Initial attempts toward the direct asymmetric epoxidation of α-substituted-α,β-enals afforded 
very promising results, and clearly warrant further optimization efforts. For instance, 
epoxyaldehyde 159 was formed in 37% yield along with good enantioselectivity of 93:7 er 
from 2-methyl-2-pentenal (158) in the presence of catalytic amounts of [9-NH2-epiQ • 2 TFA] 
and hydrogen peroxide as the oxidant (Scheme 6.1). 
 
 
Scheme 6.1 Initial attempt toward the direct asymmetric epoxidation of α-substituted-α,β-unsaturated 
aldehydes. 
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Most of the work in this thesis focused on asymmetric epoxidations and hydroperoxidations 
of α,β-unsaturated ketones. Whereas aliphatic enones gave the corresponding α,β-
epoxyketones with good yields and excellent enantioselectivities, aromatic enones were not 
tolerated. In addition, vinyl ketones 110 constituted the second major limitation regarding the 
scope of α,β-unsaturated ketones. These substrates proved to be essentially unreactive under 
the conditions of the catalytic reaction, an observation which was attributed to catalyst 
inhibition (cf. Section 4.2.2.4). Despite the synthetic importance of optically active terminal 
epoxides, to date no general and highly enantioselective method has been identified for their 
direct preparation; more so when terminal α,β-epoxyketones 160 are considered.[186] Guided 
by this challenge, we envisage that the use of preformed achiral β-hydroperoxy ketones-cyclic 
peroxyhemiketals 161 might prove beneficial,[113a, 113b] since they could allow us to 
circumvent difficulties associated with the conjugate addition of hydrogen peroxide in the 
presence of the primary amine catalyst (Scheme 6.2, step (a)). Subsequent chiral primary 
amine or chiral primary amine salt-catalyzed transformation of such achiral β-hydroperoxy 
ketones via asymmetric enamine catalysis would give rise to the formation of the desired 
enantiomerically enriched epoxides (step (b)). 
 
 
Scheme 6.2 Proposed two step approach to terminal α,β-epoxy ketones 160 starting from vinyl ketones 110. 
 
Preliminary experiments have demonstrated the viability of this approach. In the presence of 
[(R,R)-DPEN • (S)-TRIP] at a loading of 10 mol%, α,β-epoxyketone 160a was formed in 
50% yield and with encouraging enantioselectivity of 58.5:41.5 er from cyclic 
peroxyhemiketal 161a (Scheme 6.3). Future work might be directed toward evaluating 
different catalyst motifs and optimizing the reaction conditions. In addition, the successful 
implementation of asymmetric enamine catalysis has earlier been illustrated by our group in 
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the context of asymmetric epoxidations of both symmetrically β,β-disubstituted enals[38a] and 
enones (cf. Section 4.2.2.5). 
 
 
Scheme 6.3 [(R,R)-DPEN • (S)-TRIP]-catalyzed transformation of cyclic peroxyhemiketal 161a into scalemic 
epoxyketone 160a. 
 
Another interesting expansion of these methodologies would be the coupling of our 
asymmetric epoxidation and hydroperoxidation of α,β-unsaturated ketones with an efficient 
kinetic or dynamic kinetic resolution process. Based on our previous experiments toward 
(dynamic) kinetic resolutions via asymmetric epoxidation within the bias of a cyclic system, 
future attempts might preferentially focus on acyclic racemic enone substrates according to 
the general strategy depicted in Scheme 6.4. 
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Scheme 6.4 Proposed (dynamic) kinetic resolution of α,β-unsaturated ketones via asymmetric epoxidation. 
 
Progress has also been made toward the de-novo design of chiral primary amine catalysts of 
the general structure 86 based on the quinuclidine scaffold. Racemic synthesis of 86 
according to the strategy introduced in Chapter 4.7.1.2, followed by the separation of the 
diastereomers and subsequent resolution would afford single enantiomers of both threo- and 
erythro-derivatives (Scheme 6.5). This promising direction of research might lead to the 
identification of new, potent primary amine catalysts with superior catalytic activity compared 
with parent Cinchona alkaloid-derived catalyst motifs. In particular, the de-novo approach 
may significantly facilitate catalyst optimization since one is not restricted to naturally 
abundant Cinchona alkaloids as starting materials. This further renders such compounds the 
ideal platform to conduct systematic structure-selectivity studies.[187] Moreover, it nicely 
circumvents one of the most stringent, inherent limitations of the of Cinchona alkaloids in 
asymmetric catalysis: the inaccessibility of a truly enantiomeric form of these compounds. 
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Scheme 6.5 Rapid library generation of de-novo designed chiral aminoquinuclidine derivatives. 
 
Given the impressive results obtained with our epoxidation and hydroperoxidation processes, 
we believe that the methods described herein might be mature enough to be tested in the 
context of natural product synthesis. In particular, the optically active 3-hydroxy-1,2-
dioxolanes made available in one step from α,β-unsaturated ketones through asymmetric 
hydroperoxidation could allow the development of a concise route to various members of the 
plakinic acid natural product family. These naturally ocurring peroxidic compounds display 
promising antitumor and antifungal activity.[114] Only one asymmetric synthesis of plakinic 
acid A (36a; cf. Figure 2.6) has been reported to date. It is striking to note that this synthesis 
comprises 23 steps in a linear sequence with an overall yield of 5.7%, while requiring the use 
of ethereal hydrogen peroxide and semipreparative HPLC separation techniques.[106] 
Providing access to peroxyketals of the general type 162 in optically active form as described 
in Chapter 4.2.2.5 may pave the way to concise asymmetric syntheses of a broad range of 1,2-
dioxolane acetic acid derivatives 36. These should include naturally occurring representatives 
as well as synthetic analogues which might exhibit improved pharmacological activities, all 
prepared according to the unified retrosynthetic strategy depicted in Figure 6.1.[114] 
 
 
 
Figure 6.1 Proposed retrosynthesis of 1,2-dioxolane-3-acetic acids from α,β-unsaturated ketones. 
 
In recent years, macrocyclic natural products have gained increasing attention. They often 
display remarkable biological activities, and many of these compounds (or their derivatives) 
are used as drugs.[188] Our intriguing discovery of an asymmetric epoxidation of macrocyclic 
enones proceeding under mild reaction conditions with extremely high stereocontrol might 
provide intriguing synthetic versatility. In particular, we find the possibility of effecting 
stereoselective, catalyst-controlled late-stage introduction of epoxide functionality onto a 
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macrocyclic core very enticing. Such a possibility would clearly expand the toolbox of 
existing strategies toward the synthesis of macrocyclic natural products and their derivatives. 
One strength of our method is its stereoconvergency. Regardless of the geometry of a 
macrocyclic enone precursor (available inter alia through ring-closing metathesis or through 
Wittig and related olefination reactions), the (E)-configured macrocyclic epoxide would be 
generated exclusively. Moreover, pseudoenantiomeric amine catalysts (derived from quinine 
and quinidine) would allow concise access to diastereomeric products suitable for SAR 
studies with equally high enantioselectivity. Possible target molecules to illustrate the 
feasibility of a late-stage introduction of an epoxide moiety via chiral primary amine-
catalyzed asymmetric epoxidation of enones might be among others Novaxenicin B[189] or 
Cespihypotin C (Figure 6.2).[190] 
 
 
Figure 6.2 Natural products Novaxenicin B and Cespihypotin C. 
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7.1 General Experimental Conditions 
 
Solvents and reagents 
All solvents were purified by distillation before use following standard procedures. Absolute 
solvents were obtained by distillation over appropriate drying agent (vide infra) and then kept 
under an atmosphere of argon: diethyl ether, tetrahydrofuran, toluene, and n-hexane (sodium, 
benzophenone as indicator), chloroform, dichloromethane, triethylamine (calcium hydride), 
ethanol (magnesium). Absolute 1,4-dioxane, TBME, di(n-butyl)ether, DME, NMP, 
acetonitrile, and DMSO were purchased from Sigma-Aldrich and used as received. Other 
commercial reagents were obtained from various sources and used without further 
purification. 
 
Inert gas atmosphere 
Air and moisture-sensitive reactions were conducted under an argon atmosphere. Argon was 
obtained from Air Liquide with higher than 99.5% purity. All organocatalytic reactions within 
this thesis were carried out without exclusion of air and moisture. 
 
Chromatographic methods 
Reactions were mostly monitored by thin layer chromatography (TLC) using silica gel 
precoated glass plates (E. Merck, 0.25 mm thickness, silica gel 60F-254) or silica gel 
precoated aluminium foil plates (Macherey-Nagel MN, 0.20 mm thickness, Polygram SIL 
G/UV254). The spots were visualized with UV-light (λ = 254 nm) and/or by staining with 
anisaldehyde, phosphomolybdic acid, ninhydrin, dinitrophenylhydrazine, or potassium 
permanganate stains. Preparative scale TLC was conducted on Macherey-Nagel glass plates 
with a thickness of 0.25, 1, or 2 mm silica gel, respectively. 
Flash column chromatography was performed using silica gel 60 (Merck, 60 Å, 230-400 
mesh 0.040-0.063 mm) and separations were either conducted at slightly elevated pressure in 
a glass column or using the automated Sepacore Flash system from Büchi, consisting of 
fraction collector C-660, UV-photometer C-635, and pump module C-605. 
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Nuclear magnetic resonance spectroscopy (NMR) 
Spectra were recorded on Bruker DPX 300 (1H: 300 MHz, 13C: 75 MHz), Bruker AV 400 
(1H: 400 MHz, 13C: 100 MHz), and Bruker AV 500 (1H: 500 MHz, 13C: 125 MHz) spectro-
meters at room temperature (298 K). Chemical shifts for protons and carbons are reported in 
parts per million (ppm) relative to tetramethylsilane as internal standard or to the residual 
signal of the NMR solvents (e.g. CD2Cl2: δ H 5.32, δ C 53.8, CDCl3: δ H 7.26, δ C 77.0, 
THF-d8: δ H 3.58, δ C 67.6). Chemical shifts for phosphorus are reported relative to H3PO4 as 
external standard. The 1H NMR multiplicities are assigned as follows: singlet (s), doublet (d), 
triplet (t), q (quartet), quin (quintet), sext (sextet), sept (septet), m (multiplet), broad (br). The 
coupling constants (J) are reported in Hertz (Hz). The signals have been assigned using 1D 
and 2D experiments. 
 
Gas chromatography (GC) 
Gas chromatography (GC) was performed on HP 6890 and 5890 Series instruments (carrier 
gas: hydrogen) equipped with a split-mode capillary injection system and a flame ionization 
detector (FID). 
The enantiomeric ratios of chiral molecules were determined using chiral columns containing 
the following chiral stationary phases: 
BGB 176: 2,3-dimethyl-6-tert-butyldimethylsilyl-β-cyclodextrin 
(achiral component: SE-52 or BGB-15); 30 m × 0.25 mm × 0.25 mm. 
BGB 178: 2,3-diethyl-6-tert-butyldimethylsilyl-β-cyclodextrin 
(achiral component: OV-1701); 30 m × 0.25 mm × 0.25 mm. 
G-TA: trifluoroacetyl-γ-cyclodextrin; 30 m × 0.25 mm × 0.25 mm. 
Ivadex 1: dimethylpentyl-β-cyclodextrin (achiral component: PS086); 25 m × 0.25 mm × 
0.25 mm. 
Ivadex 7: diethyl-tert-butyl-dimethyl-β-cyclodextrin; 25 m × 0.25 mm × 0.25 mm. 
Lipodex A: hexakis(2,3,6-tri-O-pentyl)-α-cyclodextrin; 25 m × 0.25 mm × 0.25 mm. 
Lipodex E: octakis(2,6-O-dipentyl-3-O-butyryl)-γ-cyclodextrin; 25 m × 0.25 mm × 0.25 
mm. 
Lipodex G: octakis(2,3-O-dipentyl-6-O-methyl-γ-cyclodextrin; 25 m × 0.25 mm × 0.25 
mm. 
Hydrodex-β-TBDAC: 
heptakis(2,3-O-diacetyl-6-O-tert-butyldimethyl-silyl)-β-cyclodextrin; 
25 m × 0.25 mm × 0.25 mm. 
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GC-MS couplings were performed on an Agilent Technology GC 6890 Series and MSD 5973 
(carrier gas: helium) with HP6890 Series Injector, employing an MN Optima®5 column 
(30 m × 0.25 mm × 0.25 mm). The mass spectra were recorded with an Agilent Technology 
5973 Network MSD. 
 
Mass spectrometry (MS) 
Mass spectra were measured on a Finnigan MAT 8200 (70 eV) or MAT 8400 (70 eV) by 
electron ionization, chemical ionization, of fast atom/ion bombardment techniques. High 
resolution masses were determined on a Bruker APEX III FT-MS (7 T magnet). All masses 
are given in atomic units/elementary charge (m/z) and reported in percentage relative to the 
basic peak. The mechanistic studies (cf. Chapter 4.5.2) were performed by ESI-MS with a 
Finnigan Ultra Mass TSQ 7000. 
 
Specific rotation ([α]) 
Optical rotations were measured on a Perkin Elmer 343 or Rudolph Analytical Autopol IV 
polarimeter using a 1 mL cell with a path length of 1 dm at the temperature and wavelength 
indicated, with “D” referring to the sodium D-line wavelength (589 nm). Concentrations are 
given in g/100 mL. 
 
Determination of the optical purity 
Enantiomeric ratios (er) were determined either by chiral GC or chiral HPLC analysis (as 
specified in the individual experiments) by comparing the samples with the appropriate 
racemic mixtures. The optical purity of peroxyhemiketals 94 was determined after converting 
it to the corresponding epoxide (with 1N NaOH (1 equiv) in Et2O) or to the corresponding 
aldol-type product (with triethylphosphite (2 equiv) in Et2O). Racemic samples of epoxides 
were obtained by reaction of the enone with alkaline, aqueous hydrogen peroxide. These 
reactions were conducted in methanol in the presence of either tert-butylamine or NaOH as 
the catalytic base.[191] Racemic samples of aldol products were obtained through aldol 
reaction of the respective aldehyde with acetone catalyzed by either KOH or rac-proline. 
Racemic cyclic aldol products were obtained by reductive cleavage of the epoxide of racemic 
α,β-epoxyketones. The absolute configuration of 2,3-epoxycyclohexanone (48a) and 4-
hydroxy-6-phenyl-2-hexanone (96b) (derived from the corresponding peroxyhemiketal 94b 
through P(OEt)3-reduction) was established by comparison of their optical rotation with 
literature values.[97a, 137] All other absolute configurations were assigned by analogy. 
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7.2 Catalytic Asymmetric Epoxidation of Cyclic Enones 
7.2.1 General Procedure[121] 
 
 
 
Conditions A: Catalyst salt [(R,R)-DPEN • (S)-TRIP] was prepared in situ by stirring (R,R)-
DPEN ((R,R)-12; 10.6 mg, 0.05 mmol, 10 mol%) and (S)-TRIP ((S)-7a; 37.6 mg, 0.05 mmol, 
10 mol%) in dioxane (2 mL) for 20 minutes at room temperature. Then, cyclic enone 46 (0.5 
mmol, 1.0 equiv) was added, and 20 minutes later, aqueous hydrogen peroxide (50 wt%; 46 
μL, 0.75 mmol, 1.5 equiv). After 12-72 h of stirring at 30-50 °C, the reaction mixture was 
extracted with Et2O (3×10 mL). The combined organic phases were washed with brine, dried 
(Na2SO4), and filtered. For the highly volatile products 48a and 48r, the resulting solution 
was analyzed by GC for yield and er determination. Removal of the volatiles furnished the 
crude product, which was purified by flash column chromatography (silica gel, eluent: Et2O-
pentane) to afford pure cyclic α,β-epoxy ketone 48. 
 
Conditions B: Catalyst salt [13 • 2 TFA] was prepared in situ by the addition of 9-amino(9-
deoxy)epiquinine (13; 32.3 mg, 0.1 mmol, 10 mol%) to a solution of trifluoroacetic acid 
(TFA; 15.3 μL, 0.2 mmol, 20 mol%) in dioxane (4 mL). Then, cyclic enone 46 (1.0 mmol, 1.0 
equiv) was added, and 20 minutes later, aqueous hydrogen peroxide (50 wt%; 92 μL, 1.5 
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with Et2O (3×25 mL). The combined organic phases were washed with brine, dried (Na2SO4), 
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7.2.2 Scope of Optically Active Cyclic α,β-Epoxyketones 
2,3-Epoxycyclohexanone (48a) 
Conditions A: After 48 h at 35 °C, the conversion was determined to be 99% 
by GC using an Optima-5-Accent column (5 min at 40°C, 5.0 °C/min until 
100 °C, 25 °C/min until 250 °C, 1.0 min at 250°C, 0.35 bar He; starting 
material: τR = 12.35 min, product: τR = 15.66 min). After purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) (2R,3R)-48a was obtained as a clear 
liquid (76 mg, 678 µmol, 68% (reduced yield due to the high volatility of 48a); 96:4 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 105 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 16.62 min, minor enantiomer: τR = 16.23 min. 
Optical rotation [α]23D = +101.2 (c = 1.0, CH2Cl2, 96:4 er (2R,3R)), [Lit.:[97a] (2S,3S)-48a, 
[α]rtD = −38.0 (c = 0.82, CH2Cl2, 60:40 er)] 
Conditions B: After 24 h at 30 °C, the conversion was determined to be 91% 
by GC using an Optima-5-Accent column (5 min at 40°C, 5.0 °C/min until 
100 °C, 25 °C/min until 250 °C, 1.0 min at 250°C, 0.35 bar He; starting 
material: τR = 12.34 min, product: τR = 15.65 min). After purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) (2S,3S)-48a was obtained as a clear 
liquid (65 mg, 580 µmol, 58% (reduced yield due to the high volatility of 48a); 97:3 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 105 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 16.22 min, minor enantiomer: τR = 17.08 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.57-3.55 (m, 1H, CH2CepoH), 3.15 (d, J = 4.2 Hz, 1H, 
CepoHC(=O)), 2.47 (dt, J = 17.5, 4.6 Hz, 1H, CHHC(=O)), 2.26-2.19 (m, 1H, CHHCepoH), 
2.07-2.00 (m, 1H, CHHC(=O)), 1.94-1.84 (m, 2H, CHHCepoH and CH2CHHCH2), 1.69-1.60 
(m, 1H, CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.0 (C=O), 56.2 (CH2CHepo), 55.4 (CHepoC(=O)), 36.7 
(CH2C(=O)), 23.2 (CH2CHepo), 17.3 (CH2CH2CH2). 
The analytical data were identical in all respects to those of the commercially available 2,3-
epoxycyclohexanone (48a; Sigma-Aldrich). 
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(2R,3R)-4,4-Dimethyl-2,3-epoxycyclohexanone ((2R,3R)-48b) 
Conditions A: The title compound was isolated after 48 h at 35 °C and 
purification by flash column chromatography (silica gel, 2% Et2O in pentane) 
as a clear liquid (56 mg, 400 µmol, 80%; 97:3 er). The enantiomeric ratio 
was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 
°C, 1.5 °C/min until 170 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 25.75 min, minor enantiomer: τR = 21.91 min. 
1H NMR (500 MHz, CDCl3) δ 3.20 (d, J = 3.9 Hz, 1H, CepoHC(=O)), 3.15 (dd, J = 4.0, 1.3 
Hz, 1H, CMe2CepoH), 2.37 (ddd, J = 18.9, 6.3, 3.1 Hz, 1H, CHHC(=O)), 2.20-2.13 (m, 1H, 
CHHC(=O)), 1.88 (ddd, J = 13.6, 11.8, 6.4 Hz, 1H, CHHCqMe2), 1.31 (dddd, J = 13.6, 7.1, 
3.0, 1.2 Hz, 1H, CHHCqMe2), 1.19 (s, 3H, CH3), 1.04 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 205.9 (C=O), 64.1 (CMe2CHepo), 55.9 (CHepoC(=O)), 33.1 
(CH2C(=O)), 30.7 (CqMe2), 29.7 (CH2CqMe2), 27.4 (CH3), 22.8 (CH3). 
MS (EI) m/z (%) 140 [M+] (14), 124 (2), 111 (20), 97 (27), 85 (58), 69 (100), 55 (73), 43 (29), 
41 (95), 39 (32), 29 (31). 
HRMS calcd for C8H12O2 [M+] 140.0839, found 140.0837. 
 
(2R,3R)-5,5-Dimethyl-2,3-epoxycyclohexanone ((2R,3R)-48c) 
Conditions A: The title compound was isolated after 48 h at 35 °C and 
purification by flash column chromatography (silica gel, 3% Et2O in 
pentane) as a clear liquid (53 mg, 757 µmol, 76%; 98:2 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 29.57 min, minor enantiomer: τR = 27.55 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.48 (t, J = 4.1 Hz, 1H, CH2CepoH), 3.14 (d, J = 3.8 Hz, 1H, 
CepoHC(=O)), 2.61 (d, J = 13.2 Hz, 1H, CHHC(=O)), 2.00 (d, J = 15.4 Hz, 1H, CHHCHepo), 
1.86-1.74 (m, 2H, CHHC(=O) and CHHCHepo), 1.00 (s, 3H, CH3), 0.90 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 207.5 (C=O), 57.4 (CHepoC(=O)), 55.0 (CH2CHepo), 49.0 
(CH2C(=O)), 37.5 (CH2CHepo), 37.4 (CqMe2), 31.0 (CH3), 28.1 (CH3). 
GC-MS (EI-DE) m/z (%) 140 [M+] (20), 125 (1), 112 (4), 97 (20), 83 (100), 79 (8), 69 (28), 
55 (90), 53 (13), 43 (19), 41 (73), 39 (34), 27 (20). 
HRMS calcd for C8H12O2 [M+] 140.0839, found 140.0837. 
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Conditions A: The title compound was isolated after 48 h at 35 °C and 
purification by flash column chromatography (silica gel, 2% Et2O in pentane) 
as a clear liquid (56 mg, 400 µmol, 80%; 97:3 er). The enantiomeric ratio 
was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 
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41 (95), 39 (32), 29 (31). 
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Conditions A: The title compound was isolated after 48 h at 35 °C and 
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(CH2C(=O)), 30.7 (CqMe2), 29.7 (CH2CqMe2), 27.4 (CH3), 22.8 (CH3). 
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41 (95), 39 (32), 29 (31). 
HRMS calcd for C8H12O2 [M+] 140.0839, found 140.0837. 
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(2R,3R)-4,4-Dimethyl-2,3-epoxycyclohexanone ((2R,3R)-48b) 
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as a clear liquid (56 mg, 400 µmol, 80%; 97:3 er). The enantiomeric ratio 
was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 
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3.0, 1.2 Hz, 1H, CHHCqMe2), 1.19 (s, 3H, CH3), 1.04 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 205.9 (C=O), 64.1 (CMe2CHepo), 55.9 (CHepoC(=O)), 33.1 
(CH2C(=O)), 30.7 (CqMe2), 29.7 (CH2CqMe2), 27.4 (CH3), 22.8 (CH3). 
MS (EI) m/z (%) 140 [M+] (14), 124 (2), 111 (20), 97 (27), 85 (58), 69 (100), 55 (73), 43 (29), 
41 (95), 39 (32), 29 (31). 
HRMS calcd for C8H12O2 [M+] 140.0839, found 140.0837. 
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1H NMR (300 MHz, CD2Cl2) δ 3.48 (t, J = 4.1 Hz, 1H, CH2CepoH), 3.14 (d, J = 3.8 Hz, 1H, 
CepoHC(=O)), 2.61 (d, J = 13.2 Hz, 1H, CHHC(=O)), 2.00 (d, J = 15.4 Hz, 1H, CHHCHepo), 
1.86-1.74 (m, 2H, CHHC(=O) and CHHCHepo), 1.00 (s, 3H, CH3), 0.90 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 207.5 (C=O), 57.4 (CHepoC(=O)), 55.0 (CH2CHepo), 49.0 
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GC-MS (EI-DE) m/z (%) 140 [M+] (20), 125 (1), 112 (4), 97 (20), 83 (100), 79 (8), 69 (28), 
55 (90), 53 (13), 43 (19), 41 (73), 39 (34), 27 (20). 
HRMS calcd for C8H12O2 [M+] 140.0839, found 140.0837. 
 
O
O
C8H12O2
140,18
O
O
C8H12O2
140,18
7 Experimental Part 
 171
(2R,3R)-3,5,5-Trimethyl-2,3-epoxycyclohexanone ((2R,3R)-48d) 
Conditions A: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1.5% Et2O in 
pentane) as a clear liquid (48 mg, 623 µmol, 62%; 96:4 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(60 °C, 1.0 °C/min until 90 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 27.80 min, minor enantiomer: τR = 27.24 min. 
1H NMR (500 MHz, CDCl3) δ 3.01 (s, 1H, CepoH), 2.58 (d, J = 13.5 Hz, 1H, CHHC(=O)), 
2.04 (d, J = 14.7 Hz, 1H, CqepoCHH), 1.77 (ddd, J = 13.4, 2.0, 1.0 Hz, 1H, CHHC(=O)), 1.70 
(dd, J = 14.8, 2.2 Hz, 1H, CqepoCHH), 1.38 (s, 3H, CqepoCH3), 0.98 (s, 3H, CH3), 0.87 (s, 3H, 
CH3). 
13C NMR (75 MHz, CDCl3) δ 207.8 (C=O), 64.2 (Cqepo), 61.4 (CHepo), 48.0 (CH2C(=O)), 
42.7 (CH2Cqepo), 36.1 (CqMe2), 30.8 (Cq(CH3)2), 27.8 (Cq(CH3)2), 24.0 (CqepoCH3). 
MS (EI-DE) m/z (%) 154 [M+] (30), 139 (33), 126 (17), 111 (12), 97 (25), 83 (100), 69 (50), 
55 (39), 53 (9), 43 (40), 41 (65), 29 (23). 
HRMS calcd for C9H14O2 [M+] 154.0992, found 154.0994. 
 
(2S,3S)-2,3-Epoxy-3-methylcyclohexanone ((2S,3S)-48f) 
Conditions B: The title compound was isolated after 24 h at 30 °C and 
purification by flash column chromatography (silica gel, 2-10% Et2O in 
pentane) as a clear oil (88 mg, 698 µmol, 70% (reduced yield due to the high 
volatility of 48f); 98:2 er). The enantiomeric ratio was determined by GC using a chiral BGB-
178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 105 °C, 20 °C/min until 220 °C, 10 min 
at 220 °C, 0.5 bar H2); major enantiomer: τR = 16.79 min, minor enantiomer: τR = 19.18 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.01 (s, 1H, CepoH), 2.42 (dt, J = 17.6, 4.1 Hz, 1H, 
CHHC(=O)), 2.13-1.84 (m, 4H, CHHC(=O), CH2Cqepo, and CH2CHHCH2), 1.66-1.58 (m, 1H, 
CH2CHHCH2), 1.42 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 206.7 (C=O), 62.6 (Cqepo), 62.3 (CHepo), 36.1 (CH2C(=O)), 
28.7 (CH2Cqepo), 22.3 (CH3), 17.5 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 126 [M+] (78), 111 (8), 97 (46), 83 (35), 81 (21), 79 (5), 71 (79), 69 (26), 
67 (8), 58 (3), 55 (61), 53 (12), 43 (89), 41 (100), 39 (49), 31 (2), 27 (36). 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0680, found 126.0681. 
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(2R,3R)-3,5,5-Trimethyl-2,3-epoxycyclohexanone ((2R,3R)-48d) 
Conditions A: The title compound was isolated after 48 h at 50 °C and 
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(2R,3R)-3,5,5-Trimethyl-2,3-epoxycyclohexanone ((2R,3R)-48d) 
Conditions A: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1.5% Et2O in 
pentane) as a clear liquid (48 mg, 623 µmol, 62%; 96:4 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(60 °C, 1.0 °C/min until 90 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 27.80 min, minor enantiomer: τR = 27.24 min. 
1H NMR (500 MHz, CDCl3) δ 3.01 (s, 1H, CepoH), 2.58 (d, J = 13.5 Hz, 1H, CHHC(=O)), 
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42.7 (CH2Cqepo), 36.1 (CqMe2), 30.8 (Cq(CH3)2), 27.8 (Cq(CH3)2), 24.0 (CqepoCH3). 
MS (EI-DE) m/z (%) 154 [M+] (30), 139 (33), 126 (17), 111 (12), 97 (25), 83 (100), 69 (50), 
55 (39), 53 (9), 43 (40), 41 (65), 29 (23). 
HRMS calcd for C9H14O2 [M+] 154.0992, found 154.0994. 
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(2R,3R)-3,5,5-Trimethyl-2,3-epoxycyclohexanone ((2R,3R)-48d) 
Conditions A: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1.5% Et2O in 
pentane) as a clear liquid (48 mg, 623 µmol, 62%; 96:4 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(60 °C, 1.0 °C/min until 90 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 27.80 min, minor enantiomer: τR = 27.24 min. 
1H NMR (500 MHz, CDCl3) δ 3.01 (s, 1H, CepoH), 2.58 (d, J = 13.5 Hz, 1H, CHHC(=O)), 
2.04 (d, J = 14.7 Hz, 1H, CqepoCHH), 1.77 (ddd, J = 13.4, 2.0, 1.0 Hz, 1H, CHHC(=O)), 1.70 
(dd, J = 14.8, 2.2 Hz, 1H, CqepoCHH), 1.38 (s, 3H, CqepoCH3), 0.98 (s, 3H, CH3), 0.87 (s, 3H, 
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42.7 (CH2Cqepo), 36.1 (CqMe2), 30.8 (Cq(CH3)2), 27.8 (Cq(CH3)2), 24.0 (CqepoCH3). 
MS (EI-DE) m/z (%) 154 [M+] (30), 139 (33), 126 (17), 111 (12), 97 (25), 83 (100), 69 (50), 
55 (39), 53 (9), 43 (40), 41 (65), 29 (23). 
HRMS calcd for C9H14O2 [M+] 154.0992, found 154.0994. 
 
(2S,3S)-2,3-Epoxy-3-methylcyclohexanone ((2S,3S)-48f) 
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1H NMR (400 MHz, CD2Cl2) δ 3.01 (s, 1H, CepoH), 2.42 (dt, J = 17.6, 4.1 Hz, 1H, 
CHHC(=O)), 2.13-1.84 (m, 4H, CHHC(=O), CH2Cqepo, and CH2CHHCH2), 1.66-1.58 (m, 1H, 
CH2CHHCH2), 1.42 (s, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 206.7 (C=O), 62.6 (Cqepo), 62.3 (CHepo), 36.1 (CH2C(=O)), 
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(2S,3S)-3-Ethyl-2,3-epoxycyclohexanone ((2S,3S)-48g) 
Conditions B: The title compound was isolated after 30 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 5-10% Et2O in pentane) as 
a clear oil (102 mg, 728 µmol, 73% ; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 
115 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 23.73 
min, minor enantiomer: τR = 25.43 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.03 (s, 1H, CepoH), 2.45 (dt, J = 17.4, 4.3 Hz, 1H, 
CHHC(=O)), 2.12-1.95 (m, 2H, CHHC(=O) and CHHCqepo), 1.94-1.83 (m, 2H, CHHCqepo 
and CH2CHHCH2), 1.78-1.61 (m, 3H, CH2CH3 and CH2CHHCH2), 0.96 (t, J = 7.5 Hz, 3H, 
CH3). 
13C NMR (100 MHz, CD2Cl2) δ 206.9 (C=O), 66.3 (Cqepo), 61.1 (CHepo), 36.4 (CH2C(=O)), 
29.2 (CH2CH3), 26.5 (CH2Cqepo), 17.8 (CH2CH2CH2), 8.8 (CH3). 
MS (EI-DE) m/z (%) 140 [M+] (90), 125 (5), 111 (49), 107 (1), 97 (55), 95 (24), 85 (79), 79 
(12), 67 (24), 57 (30), 55 (84), 43 (38), 41 (100), 39 (58), 29 (92), 27 (77). 
HRMS (EI-FE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
 
(2S,3R)-2,3-Epoxy-3-isobutylcyclohexanone ((2S,3R)-48h) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (123 mg, 731 µmol, 73%; 98:2 er). The enantio-
meric ratio was determined by GC using a chiral BGB-178/OV-1701 
column 30 m (80 °C, 0.8 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 
bar H2); major enantiomer: τR = 43.77 min, minor enantiomer: τR = 45.20 min. 
1H NMR (400 MHz, CD2Cl2) δ 2.98 (s, 1H, CepoH), 2.45 (dt, J = 17.4, 4.3 Hz, 1H, 
C(=O)CHH), 2.11-1.81 (m, 5H, C(=O)CHH, CH2Cqepo, CHMe2, and CH2CHHCH2), 1.67-
1.60 (m, 2H, CH2CHHCH2 and CHHi-Pr), 1.40 (dd, J = 13.8, 8.1 Hz, 1H, CHHi-Pr), 0.96 (d, 
J = 6.6 Hz, 3H, CH(CH3)2), 0.91 (d, J = 6.6 Hz, 3H, CH(CH3)2). 
13C NMR (75 MHz, CD2Cl2) δ 206.9 (C=O), 64.8 (Cqepo), 61.8 (CHepo), 45.4 (CH2i-Pr), 36.4 
(C(=O)CH2), 26.5 (CH2Cqepo), 25.4 (CHMe2), 23.2 (CH(CH3)2), 22.7 (CH(CH3)2), 17.7 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 168 [M+] (45), 153 (7), 139 (7), 126 (36), 112 (31), 79 (32), 67 (43), 55 
(56), 41 (100), 39 (43), 27 (54). 
HRMS (EI-FE) calcd for C10H16O2 [M+] 168.1149, found 168.1150. 
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(2S,3R)-2,3-Epoxy-3-isopropylcyclohexanone ((2S,3R)-48i) 
Conditions B: The title compound was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 5-10% Et2O in pentane) as 
a clear oil (121 mg, 785 µmol, 79%; 99:1 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 
120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 27.79 
min, minor enantiomer: τR = 29.24 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.03 (s, 1H, CepoH), 2.46 (dt, J = 17.3, 4.7 Hz, 1H, 
CHHC(=O)), 2.11-1.99 (m, 2H, CHHC(=O) and CHHCqepo), 1.95-1.83 (m, 2H, CHHCqepo 
and CH2CHHCH2), 1.70-1.60 (m, 2H, CH2CHHCH2 and CHMe2), 1.03 (d, J = 6.8 Hz, 3H, 
CH(CH3)2), 0.97 (d, J = 7.0 Hz, 3H, CH(CH3)2). 
13C NMR (100 MHz, CD2Cl2) δ 207.0 (C=O), 69.3 (Cqepo), 61.1 (CHepo), 36.6 (CH2C(=O)), 
34.5 (CHMe2), 23.3 (CH2Cqepo), 18.1 (CH2CH2CH2), 18.0 (CH(CH3)2), 17.9 (CH(CH3)2). 
MS (EI-DE) m/z (%) 154 [M+] (61), 139 (4), 125 (24), 111 (78), 99 (34), 81 (41), 71 (6), 69 
(30), 55 (93), 53 (18), 43 (84), 41 (100), 29 (32), 27 (56) 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0993, found 154.0994. 
 
(2S,3R)-3-tert-Butyl-2,3-epoxycyclohexanone ((2S,3R)-48j) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (57 mg, 339 µmol, 68%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 125 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 13.22 min, minor enantiomer: tR = 14.25 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (s, 1H, CepoH), 2.46 (dt, J = 17.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.19-2.13 (m, 1H, CH2), 2.07-1.99 (m, 1H, CH2), 1.95-1.86 (m, 2H, CH2), 1.67-
1.60 (m, 1H, CH2), 0.97 (s, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 70.5 (Cqepo), 59.2 (CepoH), 36.1 (CH2C(=O)), 
34.0 (CqMe3), 25.4 (3C, CH3), 23.2 (CqepoCH2), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 168 [M+] (22), 153 (5), 139 (14), 125 (39), 113 (15), 96 (87), 83 (24), 69 
(61), 55 (100), 41 (57), 29 (26). 
HRMS (EI-FE) calcd for C10H16O2 [M+] 168.1150, found 168.1150. 
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MS (EI-DE) m/z (%) 154 [M+] (61), 139 (4), 125 (24), 111 (78), 99 (34), 81 (41), 71 (6), 69 
(30), 55 (93), 53 (18), 43 (84), 41 (100), 29 (32), 27 (56) 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0993, found 154.0994. 
 
(2S,3R)-3-tert-Butyl-2,3-epoxycyclohexanone ((2S,3R)-48j) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (57 mg, 339 µmol, 68%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 125 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 13.22 min, minor enantiomer: tR = 14.25 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (s, 1H, CepoH), 2.46 (dt, J = 17.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.19-2.13 (m, 1H, CH2), 2.07-1.99 (m, 1H, CH2), 1.95-1.86 (m, 2H, CH2), 1.67-
1.60 (m, 1H, CH2), 0.97 (s, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 70.5 (Cqepo), 59.2 (CepoH), 36.1 (CH2C(=O)), 
34.0 (CqMe3), 25.4 (3C, CH3), 23.2 (CqepoCH2), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 168 [M+] (22), 153 (5), 139 (14), 125 (39), 113 (15), 96 (87), 83 (24), 69 
(61), 55 (100), 41 (57), 29 (26). 
HRMS (EI-FE) calcd for C10H16O2 [M+] 168.1150, found 168.1150. 
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(2S,3R)-2,3-Epoxy-3-isopropylcyclohexanone ((2S,3R)-48i) 
Conditions B: The title compound was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 5-10% Et2O in pentane) as 
a clear oil (121 mg, 785 µmol, 79%; 99:1 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 
120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 27.79 
min, minor enantiomer: τR = 29.24 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.03 (s, 1H, CepoH), 2.46 (dt, J = 17.3, 4.7 Hz, 1H, 
CHHC(=O)), 2.11-1.99 (m, 2H, CHHC(=O) and CHHCqepo), 1.95-1.83 (m, 2H, CHHCqepo 
and CH2CHHCH2), 1.70-1.60 (m, 2H, CH2CHHCH2 and CHMe2), 1.03 (d, J = 6.8 Hz, 3H, 
CH(CH3)2), 0.97 (d, J = 7.0 Hz, 3H, CH(CH3)2). 
13C NMR (100 MHz, CD2Cl2) δ 207.0 (C=O), 69.3 (Cqepo), 61.1 (CHepo), 36.6 (CH2C(=O)), 
34.5 (CHMe2), 23.3 (CH2Cqepo), 18.1 (CH2CH2CH2), 18.0 (CH(CH3)2), 17.9 (CH(CH3)2). 
MS (EI-DE) m/z (%) 154 [M+] (61), 139 (4), 125 (24), 111 (78), 99 (34), 81 (41), 71 (6), 69 
(30), 55 (93), 53 (18), 43 (84), 41 (100), 29 (32), 27 (56) 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0993, found 154.0994. 
 
(2S,3R)-3-tert-Butyl-2,3-epoxycyclohexanone ((2S,3R)-48j) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (57 mg, 339 µmol, 68%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 125 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 13.22 min, minor enantiomer: tR = 14.25 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (s, 1H, CepoH), 2.46 (dt, J = 17.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.19-2.13 (m, 1H, CH2), 2.07-1.99 (m, 1H, CH2), 1.95-1.86 (m, 2H, CH2), 1.67-
1.60 (m, 1H, CH2), 0.97 (s, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 70.5 (Cqepo), 59.2 (CepoH), 36.1 (CH2C(=O)), 
34.0 (CqMe3), 25.4 (3C, CH3), 23.2 (CqepoCH2), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 168 [M+] (22), 153 (5), 139 (14), 125 (39), 113 (15), 96 (87), 83 (24), 69 
(61), 55 (100), 41 (57), 29 (26). 
HRMS (EI-FE) calcd for C10H16O2 [M+] 168.1150, found 168.1150. 
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(2S,3R)-2,3-Epoxy-3-allylcyclohexanone ((2S,3R)-48k) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 2-15% Et2O in 
pentane) as a clear oil (34.8 mg, 229 μmol, 23%; 97.5:2.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (21 min at 125 °C, 14 °C/min until 230 °C, 10 min at 230°C, 0.6 bar 
H2); major enantiomer: τR = 24.39 min, minor enantiomer: τR = 25.96 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.77 (ddt, J = 17.0, 10.1, 7.1 Hz, 1H, CH=CH2), 5.17-5.13 (m, 
2H, CH=CH2), 3.06 (s, 1H, CepoH), 2.48-2.38 (m, 3H, CH2CH=CH2 and CHHC(=O)), 2.13-
2.09 (m, 1H, CH2, cycl.), 2.05-1.98 (m, 1H, CH2, cycl.), 1.93-1.85 (m, 2H, CH2, cycl.), 1.67-1.61 
(m, 1H, CH2, cycl.). 
13C NMR (125 MHz, CD2Cl2) δ 206.5 (C=O), 132.3 (CH=CH2), 119.1 (CH=CH2), 64.7 
(Cqepo), 60.6 (CHepo), 40.6 (CH2CH=CH2), 36.3 (CH2C(=O)), 26.7 (CH2Cqepo), 17.7 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 152 [M+] (8), 137 (4), 123 (60), 109 (13), 97 (41), 91 (11), 79 (53), 69 
(29), 67 (61), 55 (85), 53 (23), 41 (100), 39 (55), 29 (18), 27 (31). 
HRMS (EI-FE) calcd for C9H12O2 [M+] 152.0836, found 152.0837. 
 
(E)-3-(1-propenyl)cyclohex-2-enone (76) 
The title compound (70.2 mg, 516 μmol, 52%) was obtained as a side product 
in the epoxidation reaction of 3-allylcyclohex-2-enone (46k) under the 
conditions B. 
1H NMR (500 MHz, CD2Cl2) δ 6.30-6.22 (m, 2H, Cq=CH and CH=CHCH3), 5.81-5.80 (m, 
1H, CH=CHCH3), 2.45 (t, J = 5.9 Hz, CH2C(=O)), 2.34 (t, J = 6.6 Hz, CH2Cq=CH), 2.00 
(quint, J = 6.4 Hz, CH2CH2CH2), 1.87 (d, J = 5.6 Hz, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 202.2 (C=O), 157.9 (Cq=CH), 134.2 (CH=CH), 133.0 
(CH=CH), 126.4 (Cq=CH), 38.2 (CH2C(=O)), 25.4 (CH2Cq=CH), 23.0 (CH2CH2CH2), 19.2 
(CH3). 
 
(2S,3R)-2,3-Epoxy-3-phenethylcyclohexanone ((2S,3R)-48l) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1-10% Et2O in 
pentane) as a clear oil (182 mg, 843 µmol, 84%; 98.5:1.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 
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(2S,3R)-2,3-Epoxy-3-allylcyclohexanone ((2S,3R)-48k) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 2-15% Et2O in 
pentane) as a clear oil (34.8 mg, 229 μmol, 23%; 97.5:2.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (21 min at 125 °C, 14 °C/min until 230 °C, 10 min at 230°C, 0.6 bar 
H2); major enantiomer: τR = 24.39 min, minor enantiomer: τR = 25.96 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.77 (ddt, J = 17.0, 10.1, 7.1 Hz, 1H, CH=CH2), 5.17-5.13 (m, 
2H, CH=CH2), 3.06 (s, 1H, CepoH), 2.48-2.38 (m, 3H, CH2CH=CH2 and CHHC(=O)), 2.13-
2.09 (m, 1H, CH2, cycl.), 2.05-1.98 (m, 1H, CH2, cycl.), 1.93-1.85 (m, 2H, CH2, cycl.), 1.67-1.61 
(m, 1H, CH2, cycl.). 
13C NMR (125 MHz, CD2Cl2) δ 206.5 (C=O), 132.3 (CH=CH2), 119.1 (CH=CH2), 64.7 
(Cqepo), 60.6 (CHepo), 40.6 (CH2CH=CH2), 36.3 (CH2C(=O)), 26.7 (CH2Cqepo), 17.7 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 152 [M+] (8), 137 (4), 123 (60), 109 (13), 97 (41), 91 (11), 79 (53), 69 
(29), 67 (61), 55 (85), 53 (23), 41 (100), 39 (55), 29 (18), 27 (31). 
HRMS (EI-FE) calcd for C9H12O2 [M+] 152.0836, found 152.0837. 
 
(E)-3-(1-propenyl)cyclohex-2-enone (76) 
The title compound (70.2 mg, 516 μmol, 52%) was obtained as a side product 
in the epoxidation reaction of 3-allylcyclohex-2-enone (46k) under the 
conditions B. 
1H NMR (500 MHz, CD2Cl2) δ 6.30-6.22 (m, 2H, Cq=CH and CH=CHCH3), 5.81-5.80 (m, 
1H, CH=CHCH3), 2.45 (t, J = 5.9 Hz, CH2C(=O)), 2.34 (t, J = 6.6 Hz, CH2Cq=CH), 2.00 
(quint, J = 6.4 Hz, CH2CH2CH2), 1.87 (d, J = 5.6 Hz, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 202.2 (C=O), 157.9 (Cq=CH), 134.2 (CH=CH), 133.0 
(CH=CH), 126.4 (Cq=CH), 38.2 (CH2C(=O)), 25.4 (CH2Cq=CH), 23.0 (CH2CH2CH2), 19.2 
(CH3). 
 
(2S,3R)-2,3-Epoxy-3-phenethylcyclohexanone ((2S,3R)-48l) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1-10% Et2O in 
pentane) as a clear oil (182 mg, 843 µmol, 84%; 98.5:1.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 
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(2S,3R)-2,3-Epoxy-3-allylcyclohexanone ((2S,3R)-48k) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 2-15% Et2O in 
pentane) as a clear oil (34.8 mg, 229 μmol, 23%; 97.5:2.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (21 min at 125 °C, 14 °C/min until 230 °C, 10 min at 230°C, 0.6 bar 
H2); major enantiomer: τR = 24.39 min, minor enantiomer: τR = 25.96 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.77 (ddt, J = 17.0, 10.1, 7.1 Hz, 1H, CH=CH2), 5.17-5.13 (m, 
2H, CH=CH2), 3.06 (s, 1H, CepoH), 2.48-2.38 (m, 3H, CH2CH=CH2 and CHHC(=O)), 2.13-
2.09 (m, 1H, CH2, cycl.), 2.05-1.98 (m, 1H, CH2, cycl.), 1.93-1.85 (m, 2H, CH2, cycl.), 1.67-1.61 
(m, 1H, CH2, cycl.). 
13C NMR (125 MHz, CD2Cl2) δ 206.5 (C=O), 132.3 (CH=CH2), 119.1 (CH=CH2), 64.7 
(Cqepo), 60.6 (CHepo), 40.6 (CH2CH=CH2), 36.3 (CH2C(=O)), 26.7 (CH2Cqepo), 17.7 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 152 [M+] (8), 137 (4), 123 (60), 109 (13), 97 (41), 91 (11), 79 (53), 69 
(29), 67 (61), 55 (85), 53 (23), 41 (100), 39 (55), 29 (18), 27 (31). 
HRMS (EI-FE) calcd for C9H12O2 [M+] 152.0836, found 152.0837. 
 
(E)-3-(1-propenyl)cyclohex-2-enone (76) 
The title compound (70.2 mg, 516 μmol, 52%) was obtained as a side product 
in the epoxidation reaction of 3-allylcyclohex-2-enone (46k) under the 
conditions B. 
1H NMR (500 MHz, CD2Cl2) δ 6.30-6.22 (m, 2H, Cq=CH and CH=CHCH3), 5.81-5.80 (m, 
1H, CH=CHCH3), 2.45 (t, J = 5.9 Hz, CH2C(=O)), 2.34 (t, J = 6.6 Hz, CH2Cq=CH), 2.00 
(quint, J = 6.4 Hz, CH2CH2CH2), 1.87 (d, J = 5.6 Hz, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 202.2 (C=O), 157.9 (Cq=CH), 134.2 (CH=CH), 133.0 
(CH=CH), 126.4 (Cq=CH), 38.2 (CH2C(=O)), 25.4 (CH2Cq=CH), 23.0 (CH2CH2CH2), 19.2 
(CH3). 
 
(2S,3R)-2,3-Epoxy-3-phenethylcyclohexanone ((2S,3R)-48l) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1-10% Et2O in 
pentane) as a clear oil (182 mg, 843 µmol, 84%; 98.5:1.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 
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(2S,3R)-2,3-Epoxy-3-allylcyclohexanone ((2S,3R)-48k) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 2-15% Et2O in 
pentane) as a clear oil (34.8 mg, 229 μmol, 23%; 97.5:2.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (21 min at 125 °C, 14 °C/min until 230 °C, 10 min at 230°C, 0.6 bar 
H2); major enantiomer: τR = 24.39 min, minor enantiomer: τR = 25.96 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.77 (ddt, J = 17.0, 10.1, 7.1 Hz, 1H, CH=CH2), 5.17-5.13 (m, 
2H, CH=CH2), 3.06 (s, 1H, CepoH), 2.48-2.38 (m, 3H, CH2CH=CH2 and CHHC(=O)), 2.13-
2.09 (m, 1H, CH2, cycl.), 2.05-1.98 (m, 1H, CH2, cycl.), 1.93-1.85 (m, 2H, CH2, cycl.), 1.67-1.61 
(m, 1H, CH2, cycl.). 
13C NMR (125 MHz, CD2Cl2) δ 206.5 (C=O), 132.3 (CH=CH2), 119.1 (CH=CH2), 64.7 
(Cqepo), 60.6 (CHepo), 40.6 (CH2CH=CH2), 36.3 (CH2C(=O)), 26.7 (CH2Cqepo), 17.7 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 152 [M+] (8), 137 (4), 123 (60), 109 (13), 97 (41), 91 (11), 79 (53), 69 
(29), 67 (61), 55 (85), 53 (23), 41 (100), 39 (55), 29 (18), 27 (31). 
HRMS (EI-FE) calcd for C9H12O2 [M+] 152.0836, found 152.0837. 
 
(E)-3-(1-propenyl)cyclohex-2-enone (76) 
The title compound (70.2 mg, 516 μmol, 52%) was obtained as a side product 
in the epoxidation reaction of 3-allylcyclohex-2-enone (46k) under the 
conditions B. 
1H NMR (500 MHz, CD2Cl2) δ 6.30-6.22 (m, 2H, Cq=CH and CH=CHCH3), 5.81-5.80 (m, 
1H, CH=CHCH3), 2.45 (t, J = 5.9 Hz, CH2C(=O)), 2.34 (t, J = 6.6 Hz, CH2Cq=CH), 2.00 
(quint, J = 6.4 Hz, CH2CH2CH2), 1.87 (d, J = 5.6 Hz, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 202.2 (C=O), 157.9 (Cq=CH), 134.2 (CH=CH), 133.0 
(CH=CH), 126.4 (Cq=CH), 38.2 (CH2C(=O)), 25.4 (CH2Cq=CH), 23.0 (CH2CH2CH2), 19.2 
(CH3). 
 
(2S,3R)-2,3-Epoxy-3-phenethylcyclohexanone ((2S,3R)-48l) 
Conditions B: The title compound was isolated after 48 h at 50 °C and 
purification by flash column chromatography (silica gel, 1-10% Et2O in 
pentane) as a clear oil (182 mg, 843 µmol, 84%; 98.5:1.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 
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column 30 m (100 °C, 1.2 °C/min until 180 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 
bar H2); major enantiomer: τR = 56.99 min, minor enantiomer: τR = 58.46 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.31-7.27 (m, 2H, CHar), 7.23-7.18 (m, 3H, CHar), 3.01 (s, 
1H, CepoH), 2.74 (t, J = 8.3 Hz, 2H, CH2Ph), 2.46 (dt, J = 17.0, 4.7 Hz, 1H, C(=O)CHH), 
2.20-2.12 (m, 1H, CHHCqepo), 2.08-1.87 (m, 5H, C(=O)CHH, CHHCqepo, CH2CHHCH2, and 
CH2CH2Ph), 1.71-1.62 (m, 1H, CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.5 (C=O), 141.5 (Cqar), 128.8 (2C, CHar), 128.6 (2C, 
CHar), 126.5 (CHar, p), 65.1 (Cqepo), 61.4 (CHepo), 38.2 (CH2CH2Ph), 36.3 (C(=O)CH2), 31.2 
(CH2Ph), 26.9 (CH2Cqepo), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 216 [M+] (2), 198 (2), 187 (1), 169 (3), 154 (1), 143 (11), 128 (4), 104 
(100), 97 (13), 91 (69), 79 (13), 69 (5), 65 (17), 55 (12), 41 (31). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1149, found 216.1150. 
 
3-Benzyl-2,3-epoxycyclohexanone (48m) 
Conditions B: The title compound (2S,3R)-48m was isolated after 48 h at 
50 °C and purification by flash column chromatography (silica gel, 2-10% 
Et2O in pentane) as a clear oil (158 mg, 781 µmol, 78%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 175 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); 
major enantiomer: τR = 45.74 min, minor enantiomer: τR = 46.65 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48a was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 2-10% Et2O in pentane) 
as a clear oil (156 mg, 771 µmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral Hydrodex-β-TBDAc column 25 m (100 °C, 1.2 °C/min until 175 °C, 
20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: τR = 46.37 min, 
minor enantiomer: τR = 45.88 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.34-7.21 (m, 5H, C6H5), 3.04 (s, 1H, CepoH), 2.98 (s, 2H, 
CH2Ph), 2.44 (dt, J = 17.7, 4.4 Hz, 1H, C(=O)CHH), 2.10-1.95 (m, 2H, C(=O)CHH and 
CHHCqepo), 1.89-1.80 (m, 2H, CHHCqepo and CH2CHHCH), 1.65-1.56 (m, 1H, 
CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.4 (C=O), 136.2 (Cqar), 130.0 (2C, CHar), 128.8 (2C, 
CHar), 127.3 (CHar, p), 65.4 (Cqepo), 60.8 (CHepo), 42.4 (CH2Ph), 36.4 (C(=O)CH2), 26.7 
(CH2Cqepo), 17.6 (CH2CH2CH2). 
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column 30 m (100 °C, 1.2 °C/min until 180 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 
bar H2); major enantiomer: τR = 56.99 min, minor enantiomer: τR = 58.46 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.31-7.27 (m, 2H, CHar), 7.23-7.18 (m, 3H, CHar), 3.01 (s, 
1H, CepoH), 2.74 (t, J = 8.3 Hz, 2H, CH2Ph), 2.46 (dt, J = 17.0, 4.7 Hz, 1H, C(=O)CHH), 
2.20-2.12 (m, 1H, CHHCqepo), 2.08-1.87 (m, 5H, C(=O)CHH, CHHCqepo, CH2CHHCH2, and 
CH2CH2Ph), 1.71-1.62 (m, 1H, CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.5 (C=O), 141.5 (Cqar), 128.8 (2C, CHar), 128.6 (2C, 
CHar), 126.5 (CHar, p), 65.1 (Cqepo), 61.4 (CHepo), 38.2 (CH2CH2Ph), 36.3 (C(=O)CH2), 31.2 
(CH2Ph), 26.9 (CH2Cqepo), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 216 [M+] (2), 198 (2), 187 (1), 169 (3), 154 (1), 143 (11), 128 (4), 104 
(100), 97 (13), 91 (69), 79 (13), 69 (5), 65 (17), 55 (12), 41 (31). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1149, found 216.1150. 
 
3-Benzyl-2,3-epoxycyclohexanone (48m) 
Conditions B: The title compound (2S,3R)-48m was isolated after 48 h at 
50 °C and purification by flash column chromatography (silica gel, 2-10% 
Et2O in pentane) as a clear oil (158 mg, 781 µmol, 78%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 175 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); 
major enantiomer: τR = 45.74 min, minor enantiomer: τR = 46.65 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48a was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 2-10% Et2O in pentane) 
as a clear oil (156 mg, 771 µmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral Hydrodex-β-TBDAc column 25 m (100 °C, 1.2 °C/min until 175 °C, 
20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: τR = 46.37 min, 
minor enantiomer: τR = 45.88 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.34-7.21 (m, 5H, C6H5), 3.04 (s, 1H, CepoH), 2.98 (s, 2H, 
CH2Ph), 2.44 (dt, J = 17.7, 4.4 Hz, 1H, C(=O)CHH), 2.10-1.95 (m, 2H, C(=O)CHH and 
CHHCqepo), 1.89-1.80 (m, 2H, CHHCqepo and CH2CHHCH), 1.65-1.56 (m, 1H, 
CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.4 (C=O), 136.2 (Cqar), 130.0 (2C, CHar), 128.8 (2C, 
CHar), 127.3 (CHar, p), 65.4 (Cqepo), 60.8 (CHepo), 42.4 (CH2Ph), 36.4 (C(=O)CH2), 26.7 
(CH2Cqepo), 17.6 (CH2CH2CH2). 
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column 30 m (100 °C, 1.2 °C/min until 180 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 
bar H2); major enantiomer: τR = 56.99 min, minor enantiomer: τR = 58.46 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.31-7.27 (m, 2H, CHar), 7.23-7.18 (m, 3H, CHar), 3.01 (s, 
1H, CepoH), 2.74 (t, J = 8.3 Hz, 2H, CH2Ph), 2.46 (dt, J = 17.0, 4.7 Hz, 1H, C(=O)CHH), 
2.20-2.12 (m, 1H, CHHCqepo), 2.08-1.87 (m, 5H, C(=O)CHH, CHHCqepo, CH2CHHCH2, and 
CH2CH2Ph), 1.71-1.62 (m, 1H, CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.5 (C=O), 141.5 (Cqar), 128.8 (2C, CHar), 128.6 (2C, 
CHar), 126.5 (CHar, p), 65.1 (Cqepo), 61.4 (CHepo), 38.2 (CH2CH2Ph), 36.3 (C(=O)CH2), 31.2 
(CH2Ph), 26.9 (CH2Cqepo), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 216 [M+] (2), 198 (2), 187 (1), 169 (3), 154 (1), 143 (11), 128 (4), 104 
(100), 97 (13), 91 (69), 79 (13), 69 (5), 65 (17), 55 (12), 41 (31). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1149, found 216.1150. 
 
3-Benzyl-2,3-epoxycyclohexanone (48m) 
Conditions B: The title compound (2S,3R)-48m was isolated after 48 h at 
50 °C and purification by flash column chromatography (silica gel, 2-10% 
Et2O in pentane) as a clear oil (158 mg, 781 µmol, 78%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 175 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); 
major enantiomer: τR = 45.74 min, minor enantiomer: τR = 46.65 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48a was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 2-10% Et2O in pentane) 
as a clear oil (156 mg, 771 µmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral Hydrodex-β-TBDAc column 25 m (100 °C, 1.2 °C/min until 175 °C, 
20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: τR = 46.37 min, 
minor enantiomer: τR = 45.88 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.34-7.21 (m, 5H, C6H5), 3.04 (s, 1H, CepoH), 2.98 (s, 2H, 
CH2Ph), 2.44 (dt, J = 17.7, 4.4 Hz, 1H, C(=O)CHH), 2.10-1.95 (m, 2H, C(=O)CHH and 
CHHCqepo), 1.89-1.80 (m, 2H, CHHCqepo and CH2CHHCH), 1.65-1.56 (m, 1H, 
CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.4 (C=O), 136.2 (Cqar), 130.0 (2C, CHar), 128.8 (2C, 
CHar), 127.3 (CHar, p), 65.4 (Cqepo), 60.8 (CHepo), 42.4 (CH2Ph), 36.4 (C(=O)CH2), 26.7 
(CH2Cqepo), 17.6 (CH2CH2CH2). 
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column 30 m (100 °C, 1.2 °C/min until 180 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 
bar H2); major enantiomer: τR = 56.99 min, minor enantiomer: τR = 58.46 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.31-7.27 (m, 2H, CHar), 7.23-7.18 (m, 3H, CHar), 3.01 (s, 
1H, CepoH), 2.74 (t, J = 8.3 Hz, 2H, CH2Ph), 2.46 (dt, J = 17.0, 4.7 Hz, 1H, C(=O)CHH), 
2.20-2.12 (m, 1H, CHHCqepo), 2.08-1.87 (m, 5H, C(=O)CHH, CHHCqepo, CH2CHHCH2, and 
CH2CH2Ph), 1.71-1.62 (m, 1H, CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.5 (C=O), 141.5 (Cqar), 128.8 (2C, CHar), 128.6 (2C, 
CHar), 126.5 (CHar, p), 65.1 (Cqepo), 61.4 (CHepo), 38.2 (CH2CH2Ph), 36.3 (C(=O)CH2), 31.2 
(CH2Ph), 26.9 (CH2Cqepo), 17.8 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 216 [M+] (2), 198 (2), 187 (1), 169 (3), 154 (1), 143 (11), 128 (4), 104 
(100), 97 (13), 91 (69), 79 (13), 69 (5), 65 (17), 55 (12), 41 (31). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1149, found 216.1150. 
 
3-Benzyl-2,3-epoxycyclohexanone (48m) 
Conditions B: The title compound (2S,3R)-48m was isolated after 48 h at 
50 °C and purification by flash column chromatography (silica gel, 2-10% 
Et2O in pentane) as a clear oil (158 mg, 781 µmol, 78%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 175 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); 
major enantiomer: τR = 45.74 min, minor enantiomer: τR = 46.65 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48a was isolated after 48 h at 50 °C and purifi-
cation by flash column chromatography (silica gel, 2-10% Et2O in pentane) 
as a clear oil (156 mg, 771 µmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral Hydrodex-β-TBDAc column 25 m (100 °C, 1.2 °C/min until 175 °C, 
20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: τR = 46.37 min, 
minor enantiomer: τR = 45.88 min. 
1H NMR (400 MHz, CD2Cl2) δ 7.34-7.21 (m, 5H, C6H5), 3.04 (s, 1H, CepoH), 2.98 (s, 2H, 
CH2Ph), 2.44 (dt, J = 17.7, 4.4 Hz, 1H, C(=O)CHH), 2.10-1.95 (m, 2H, C(=O)CHH and 
CHHCqepo), 1.89-1.80 (m, 2H, CHHCqepo and CH2CHHCH), 1.65-1.56 (m, 1H, 
CH2CHHCH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.4 (C=O), 136.2 (Cqar), 130.0 (2C, CHar), 128.8 (2C, 
CHar), 127.3 (CHar, p), 65.4 (Cqepo), 60.8 (CHepo), 42.4 (CH2Ph), 36.4 (C(=O)CH2), 26.7 
(CH2Cqepo), 17.6 (CH2CH2CH2). 
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MS (EI-DE) m/z (%) 202 [M+] (60), 184 (5), 173 (53), 156 (4), 145 (12), 129 (46), 117 (21), 
91 (100), 78 (11), 65 (28), 55 (28), 51 (15), 39 (36). 
HRMS (EI-DE) calcd for C13H14O2 [M+] 202.0991, found 202.0994. 
 
(2R,3S)-2,6,6-Trimethyl-2,3-epoxy-1,4-cyclohexanedione ((2R,3S)-48q) 
Conditions B: 20 mol% catalytic salt [13 • 2 TFA] was used. The title 
compound was isolated after 48 h at 50 °C and purification by flash 
column chromatography (silica gel, 2.5% Et2O in pentane) as a clear oil 
(82 mg, 488 μmol, 49%; 96:4 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 130°C, 20 
°C/min until 220°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.27 min, minor 
enantiomer: τR = 22.67 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.49 (d, J = 1.1 Hz, 1H, CepoH), 3.15 (d, J = 13.6 Hz, 1H, 
CHH), 2.15 (dd, J = 13.5, 1.2 Hz, 1H, CHH), 1.55 (s, 3H, CH3), 1.28 (s, 3H, CH3), 1.08 (s, 
3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 205.6 (C=O), 204.1 (C=O), 64.8 (Cqepo), 62.8 (CHepo), 47.0 
(CH2), 45.5 (CqMe2), 26.9 (CH3), 26.1 (CH3), 15.9 (CqepoCH3). 
MS (EI) m/z (%) 168 [M+] (59), 153 (27), 125 (65), 85 (77), 83 (21), 69 (34), 56 (100), 43 
(91), 41 (95), 39 (41), 27 (34). 
HRMS calcd for C9H12O3 [M+] 168.0785, found 168.0786. 
 
(2R,3R)-2,3-Epoxycyclopentanone ((2R,3R)-48r) 
Conditions A: After 48 h at 50 °C, the conversion was determined to be 33% 
by GC and the enantiomeric ratio was determined to be 90:10 er by chiral GC 
using a Lipodex E column 25 m (60 °C, 1.2 °C/min until 90 °C, 18 °C/min 
until 220 °C, 10 min at 220°C, 0.5 bar H2); major enantiomer: τR = 14.49 min, minor 
enantiomer: τR = 13.33 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.89-3.88 (m, 1H, CH2CHepo), 3.26 (d, J = 2.6 Hz, 1H, 
CHepoC(=O)), 2.37-2.17 (m, 2H, CHH), 2.09-1.97 (m, 2H, CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 58.3 (CHepoC(=O)), 55.2 (CH2CHepo), 30.9 
(CH2C(=O)), 23.5 (CH2CHepo). 
GC-MS (GC-EI) m/z (%) 98 [M+] (41), 82 (13), 69 (25), 55 (22), 53 (6), 42 (100), 39 (37), 31 
(1), 27 (18). 
HRMS (EI-FE) calcd for C5H6O2 [M+] 98.0367, found 98.0368. 
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MS (EI-DE) m/z (%) 202 [M+] (60), 184 (5), 173 (53), 156 (4), 145 (12), 129 (46), 117 (21), 
91 (100), 78 (11), 65 (28), 55 (28), 51 (15), 39 (36). 
HRMS (EI-DE) calcd for C13H14O2 [M+] 202.0991, found 202.0994. 
 
(2R,3S)-2,6,6-Trimethyl-2,3-epoxy-1,4-cyclohexanedione ((2R,3S)-48q) 
Conditions B: 20 mol% catalytic salt [13 • 2 TFA] was used. The title 
compound was isolated after 48 h at 50 °C and purification by flash 
column chromatography (silica gel, 2.5% Et2O in pentane) as a clear oil 
(82 mg, 488 μmol, 49%; 96:4 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 130°C, 20 
°C/min until 220°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.27 min, minor 
enantiomer: τR = 22.67 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.49 (d, J = 1.1 Hz, 1H, CepoH), 3.15 (d, J = 13.6 Hz, 1H, 
CHH), 2.15 (dd, J = 13.5, 1.2 Hz, 1H, CHH), 1.55 (s, 3H, CH3), 1.28 (s, 3H, CH3), 1.08 (s, 
3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 205.6 (C=O), 204.1 (C=O), 64.8 (Cqepo), 62.8 (CHepo), 47.0 
(CH2), 45.5 (CqMe2), 26.9 (CH3), 26.1 (CH3), 15.9 (CqepoCH3). 
MS (EI) m/z (%) 168 [M+] (59), 153 (27), 125 (65), 85 (77), 83 (21), 69 (34), 56 (100), 43 
(91), 41 (95), 39 (41), 27 (34). 
HRMS calcd for C9H12O3 [M+] 168.0785, found 168.0786. 
 
(2R,3R)-2,3-Epoxycyclopentanone ((2R,3R)-48r) 
Conditions A: After 48 h at 50 °C, the conversion was determined to be 33% 
by GC and the enantiomeric ratio was determined to be 90:10 er by chiral GC 
using a Lipodex E column 25 m (60 °C, 1.2 °C/min until 90 °C, 18 °C/min 
until 220 °C, 10 min at 220°C, 0.5 bar H2); major enantiomer: τR = 14.49 min, minor 
enantiomer: τR = 13.33 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.89-3.88 (m, 1H, CH2CHepo), 3.26 (d, J = 2.6 Hz, 1H, 
CHepoC(=O)), 2.37-2.17 (m, 2H, CHH), 2.09-1.97 (m, 2H, CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 58.3 (CHepoC(=O)), 55.2 (CH2CHepo), 30.9 
(CH2C(=O)), 23.5 (CH2CHepo). 
GC-MS (GC-EI) m/z (%) 98 [M+] (41), 82 (13), 69 (25), 55 (22), 53 (6), 42 (100), 39 (37), 31 
(1), 27 (18). 
HRMS (EI-FE) calcd for C5H6O2 [M+] 98.0367, found 98.0368. 
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MS (EI-DE) m/z (%) 202 [M+] (60), 184 (5), 173 (53), 156 (4), 145 (12), 129 (46), 117 (21), 
91 (100), 78 (11), 65 (28), 55 (28), 51 (15), 39 (36). 
HRMS (EI-DE) calcd for C13H14O2 [M+] 202.0991, found 202.0994. 
 
(2R,3S)-2,6,6-Trimethyl-2,3-epoxy-1,4-cyclohexanedione ((2R,3S)-48q) 
Conditions B: 20 mol% catalytic salt [13 • 2 TFA] was used. The title 
compound was isolated after 48 h at 50 °C and purification by flash 
column chromatography (silica gel, 2.5% Et2O in pentane) as a clear oil 
(82 mg, 488 μmol, 49%; 96:4 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 130°C, 20 
°C/min until 220°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.27 min, minor 
enantiomer: τR = 22.67 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.49 (d, J = 1.1 Hz, 1H, CepoH), 3.15 (d, J = 13.6 Hz, 1H, 
CHH), 2.15 (dd, J = 13.5, 1.2 Hz, 1H, CHH), 1.55 (s, 3H, CH3), 1.28 (s, 3H, CH3), 1.08 (s, 
3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 205.6 (C=O), 204.1 (C=O), 64.8 (Cqepo), 62.8 (CHepo), 47.0 
(CH2), 45.5 (CqMe2), 26.9 (CH3), 26.1 (CH3), 15.9 (CqepoCH3). 
MS (EI) m/z (%) 168 [M+] (59), 153 (27), 125 (65), 85 (77), 83 (21), 69 (34), 56 (100), 43 
(91), 41 (95), 39 (41), 27 (34). 
HRMS calcd for C9H12O3 [M+] 168.0785, found 168.0786. 
 
(2R,3R)-2,3-Epoxycyclopentanone ((2R,3R)-48r) 
Conditions A: After 48 h at 50 °C, the conversion was determined to be 33% 
by GC and the enantiomeric ratio was determined to be 90:10 er by chiral GC 
using a Lipodex E column 25 m (60 °C, 1.2 °C/min until 90 °C, 18 °C/min 
until 220 °C, 10 min at 220°C, 0.5 bar H2); major enantiomer: τR = 14.49 min, minor 
enantiomer: τR = 13.33 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.89-3.88 (m, 1H, CH2CHepo), 3.26 (d, J = 2.6 Hz, 1H, 
CHepoC(=O)), 2.37-2.17 (m, 2H, CHH), 2.09-1.97 (m, 2H, CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 58.3 (CHepoC(=O)), 55.2 (CH2CHepo), 30.9 
(CH2C(=O)), 23.5 (CH2CHepo). 
GC-MS (GC-EI) m/z (%) 98 [M+] (41), 82 (13), 69 (25), 55 (22), 53 (6), 42 (100), 39 (37), 31 
(1), 27 (18). 
HRMS (EI-FE) calcd for C5H6O2 [M+] 98.0367, found 98.0368. 
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MS (EI-DE) m/z (%) 202 [M+] (60), 184 (5), 173 (53), 156 (4), 145 (12), 129 (46), 117 (21), 
91 (100), 78 (11), 65 (28), 55 (28), 51 (15), 39 (36). 
HRMS (EI-DE) calcd for C13H14O2 [M+] 202.0991, found 202.0994. 
 
(2R,3S)-2,6,6-Trimethyl-2,3-epoxy-1,4-cyclohexanedione ((2R,3S)-48q) 
Conditions B: 20 mol% catalytic salt [13 • 2 TFA] was used. The title 
compound was isolated after 48 h at 50 °C and purification by flash 
column chromatography (silica gel, 2.5% Et2O in pentane) as a clear oil 
(82 mg, 488 μmol, 49%; 96:4 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 1.2 °C/min until 130°C, 20 
°C/min until 220°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.27 min, minor 
enantiomer: τR = 22.67 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.49 (d, J = 1.1 Hz, 1H, CepoH), 3.15 (d, J = 13.6 Hz, 1H, 
CHH), 2.15 (dd, J = 13.5, 1.2 Hz, 1H, CHH), 1.55 (s, 3H, CH3), 1.28 (s, 3H, CH3), 1.08 (s, 
3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 205.6 (C=O), 204.1 (C=O), 64.8 (Cqepo), 62.8 (CHepo), 47.0 
(CH2), 45.5 (CqMe2), 26.9 (CH3), 26.1 (CH3), 15.9 (CqepoCH3). 
MS (EI) m/z (%) 168 [M+] (59), 153 (27), 125 (65), 85 (77), 83 (21), 69 (34), 56 (100), 43 
(91), 41 (95), 39 (41), 27 (34). 
HRMS calcd for C9H12O3 [M+] 168.0785, found 168.0786. 
 
(2R,3R)-2,3-Epoxycyclopentanone ((2R,3R)-48r) 
Conditions A: After 48 h at 50 °C, the conversion was determined to be 33% 
by GC and the enantiomeric ratio was determined to be 90:10 er by chiral GC 
using a Lipodex E column 25 m (60 °C, 1.2 °C/min until 90 °C, 18 °C/min 
until 220 °C, 10 min at 220°C, 0.5 bar H2); major enantiomer: τR = 14.49 min, minor 
enantiomer: τR = 13.33 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.89-3.88 (m, 1H, CH2CHepo), 3.26 (d, J = 2.6 Hz, 1H, 
CHepoC(=O)), 2.37-2.17 (m, 2H, CHH), 2.09-1.97 (m, 2H, CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 58.3 (CHepoC(=O)), 55.2 (CH2CHepo), 30.9 
(CH2C(=O)), 23.5 (CH2CHepo). 
GC-MS (GC-EI) m/z (%) 98 [M+] (41), 82 (13), 69 (25), 55 (22), 53 (6), 42 (100), 39 (37), 31 
(1), 27 (18). 
HRMS (EI-FE) calcd for C5H6O2 [M+] 98.0367, found 98.0368. 
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2,3-Epoxycycloheptanone (48s) 
Conditions A: The title compound (2R,3R)-48s was isolated after 20 h at 
30 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (41 mg, 325 µmol, 65%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 23.46 min, minor enantiomer: τR = 20.62 min. 
Conditions B: The title compound (2S,3S)-48s was isolated after 24 h at 
50 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (78 mg, 621 µmol, 62%; >99.5:0.5 er). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 
m (80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); 
major enantiomer: τR = 20.66 min, minor enantiomer: τR = 24.29 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.37-3.35 (m, 2H, CHepo), 2.62 (ddd, J = 13.6, 11.3, 3.8 Hz, 
1H, C(=O)CHH), 2.48-2.40 (m, 1H, CHHCHepo), 2.30-2.23 (m, 1H, C(=O)CHH), 1.87-1.63 
(m, 4H, C(=O)CH2CHH, CHHCHepo, and CH2CH2CHepo), 1.06-0.91 (m, 1H, 
C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.1 (C=O), 59.5 (C(=O)CHepo), 55.1 (CH2CHepo), 40.6 
(C(=O)CH2), 27.5 (CH2CHepo), 23.6 (C(=O)CH2CH2), 23.1 (CH2CH2CHepo). 
GC-MS (GC-EI) m/z (%) 126 [M+] (16), 110 (12), 97 (33), 83 (24), 81 (35), 79 (14), 70 (58), 
68 (32), 55 (79), 41 (100), 39 (52), 27 (37). 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0679, found 126.0681. 
 
(2S,3S)-2,3-Epoxy-3-ethylcycloheptanone ((2S,3S)-48t) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5% Et2O in 
pentane) as a clear oil (127 mg, 824 µmol, 82%; >99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 18.25 
min, minor enantiomer: τR = 19.50 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.20 (d, J = 1.3 Hz, 1H, CepoH), 2.67 (ddd, J = 13.5, 11.0, 4.1 
Hz, 1H, C(=O)CHH), 2.24-2.18 (m, 1H, C(=O)CHH), 2.18-2.12 (m, 1H, CHHCqepo), 1.87-
O
O
Et
C9H14O2
154,21
O
O
C7H10O2
126,15
O
O
C7H10O2
126,15
7 Experimental Part 
 177
 
2,3-Epoxycycloheptanone (48s) 
Conditions A: The title compound (2R,3R)-48s was isolated after 20 h at 
30 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (41 mg, 325 µmol, 65%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 23.46 min, minor enantiomer: τR = 20.62 min. 
Conditions B: The title compound (2S,3S)-48s was isolated after 24 h at 
50 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (78 mg, 621 µmol, 62%; >99.5:0.5 er). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 
m (80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); 
major enantiomer: τR = 20.66 min, minor enantiomer: τR = 24.29 min. 
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(C(=O)CH2), 27.5 (CH2CHepo), 23.6 (C(=O)CH2CH2), 23.1 (CH2CH2CHepo). 
GC-MS (GC-EI) m/z (%) 126 [M+] (16), 110 (12), 97 (33), 83 (24), 81 (35), 79 (14), 70 (58), 
68 (32), 55 (79), 41 (100), 39 (52), 27 (37). 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0679, found 126.0681. 
 
(2S,3S)-2,3-Epoxy-3-ethylcycloheptanone ((2S,3S)-48t) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5% Et2O in 
pentane) as a clear oil (127 mg, 824 µmol, 82%; >99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 18.25 
min, minor enantiomer: τR = 19.50 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.20 (d, J = 1.3 Hz, 1H, CepoH), 2.67 (ddd, J = 13.5, 11.0, 4.1 
Hz, 1H, C(=O)CHH), 2.24-2.18 (m, 1H, C(=O)CHH), 2.18-2.12 (m, 1H, CHHCqepo), 1.87-
O
O
Et
C9H14O2
154,21
O
O
C7H10O2
126,15
O
O
C7H10O2
126,15
7 Experimental Part 
 177
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Conditions A: The title compound (2R,3R)-48s was isolated after 20 h at 
30 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (41 mg, 325 µmol, 65%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 23.46 min, minor enantiomer: τR = 20.62 min. 
Conditions B: The title compound (2S,3S)-48s was isolated after 24 h at 
50 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (78 mg, 621 µmol, 62%; >99.5:0.5 er). 
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1H NMR (300 MHz, CD2Cl2) δ 3.37-3.35 (m, 2H, CHepo), 2.62 (ddd, J = 13.6, 11.3, 3.8 Hz, 
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(C(=O)CH2), 27.5 (CH2CHepo), 23.6 (C(=O)CH2CH2), 23.1 (CH2CH2CHepo). 
GC-MS (GC-EI) m/z (%) 126 [M+] (16), 110 (12), 97 (33), 83 (24), 81 (35), 79 (14), 70 (58), 
68 (32), 55 (79), 41 (100), 39 (52), 27 (37). 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0679, found 126.0681. 
 
(2S,3S)-2,3-Epoxy-3-ethylcycloheptanone ((2S,3S)-48t) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5% Et2O in 
pentane) as a clear oil (127 mg, 824 µmol, 82%; >99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 18.25 
min, minor enantiomer: τR = 19.50 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.20 (d, J = 1.3 Hz, 1H, CepoH), 2.67 (ddd, J = 13.5, 11.0, 4.1 
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2,3-Epoxycycloheptanone (48s) 
Conditions A: The title compound (2R,3R)-48s was isolated after 20 h at 
30 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (41 mg, 325 µmol, 65%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 23.46 min, minor enantiomer: τR = 20.62 min. 
Conditions B: The title compound (2S,3S)-48s was isolated after 24 h at 
50 °C and purification by flash column chromatography (silica gel, 3-15% 
Et2O in pentane) as a clear liquid (78 mg, 621 µmol, 62%; >99.5:0.5 er). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 
m (80 °C, 1.5 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); 
major enantiomer: τR = 20.66 min, minor enantiomer: τR = 24.29 min. 
1H NMR (300 MHz, CD2Cl2) δ 3.37-3.35 (m, 2H, CHepo), 2.62 (ddd, J = 13.6, 11.3, 3.8 Hz, 
1H, C(=O)CHH), 2.48-2.40 (m, 1H, CHHCHepo), 2.30-2.23 (m, 1H, C(=O)CHH), 1.87-1.63 
(m, 4H, C(=O)CH2CHH, CHHCHepo, and CH2CH2CHepo), 1.06-0.91 (m, 1H, 
C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.1 (C=O), 59.5 (C(=O)CHepo), 55.1 (CH2CHepo), 40.6 
(C(=O)CH2), 27.5 (CH2CHepo), 23.6 (C(=O)CH2CH2), 23.1 (CH2CH2CHepo). 
GC-MS (GC-EI) m/z (%) 126 [M+] (16), 110 (12), 97 (33), 83 (24), 81 (35), 79 (14), 70 (58), 
68 (32), 55 (79), 41 (100), 39 (52), 27 (37). 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0679, found 126.0681. 
 
(2S,3S)-2,3-Epoxy-3-ethylcycloheptanone ((2S,3S)-48t) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5% Et2O in 
pentane) as a clear oil (127 mg, 824 µmol, 82%; >99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 18.25 
min, minor enantiomer: τR = 19.50 min. 
1H NMR (400 MHz, CD2Cl2) δ 3.20 (d, J = 1.3 Hz, 1H, CepoH), 2.67 (ddd, J = 13.5, 11.0, 4.1 
Hz, 1H, C(=O)CHH), 2.24-2.18 (m, 1H, C(=O)CHH), 2.18-2.12 (m, 1H, CHHCqepo), 1.87-
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1.66 (m, 5H, CHHCqepo, C(=O)CH2CHH, CH2CH2Cqepo, and CHHCH3), 1.59-1.49 (m, 1H, 
CHHCH3), 1.13-1.02 (m, 1H, C(=O)CH2CHH), 0.93 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 210.7 (C=O), 65.0 (CHepo), 64.9 (Cqepo), 41.1 (C(=O)CH2), 
31.9 (CH2CH3), 31.4 (CH2Cqepo), 25.3 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo), 9.1 (CH3). 
GC-MS (GC-EI) m/z (%) 154 [M+] (1), 138 (1), 125 (11), 109 (12), 98 (68), 93 (8), 83 (29), 
67 (35), 55 (100), 53 (16), 41 (65), 29 (57), 27 (23). 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0995, found 154.0994. 
 
(2S,3R)-3-Benzyl-2,3-epoxycycloheptanone ((2S,3R)-48u) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (184 mg, 851 µmol, 85%; >99.5:0.5 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (2% i-PrOH 
in heptane, 0.5 mL/min); major enantiomer: τR = 13.74 min, minor enantiomer: τR = 14.83 
min. 
1H NMR (400 MHz, CD2Cl2) δ 7.33-7.22 (m, 5H, C6H5), 3.20 (d, J = 1.2 Hz, 1H, CepoH), 
2.94 (dd, J = 18.8, 14.3 Hz, 2H, CH2Ph), 2.67 (ddd, J = 13.4, 11.0, 4.0 Hz, 1H, C(=O)CHH), 
2.25-2.16 (m, 2H, C(=O)CHH and CHHCqepo), 1.86-1.63 (m, 4H, CHHCqepo, CH2CH2Cqepo, 
and C(=O)CH2CHH), 1.11-1.00 (m, 1H, C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 136.5 (Cqar), 130.1 (2C, CHar), 128.8 (2C, CHar), 
127.2 (CHar, p), 64.6 (CHepo), 64.1 (Cqepo), 44.6 (CH2Ph), 41.1 (C(=O)CH2), 31.7 (CH2Cqepo), 
25.2 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo). 
MS (EI-DE) m/z (%) 216 [M+] (22), 198 (3), 187 (19), 169 (6), 159 (3), 143 (7), 129 (12), 118 
(30), 104 (4), 97 (20), 91 (100), 78 (8), 65 (18), 55 (11), 41 (23). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1152, found 216.1150. 
 
(2S,3S)-2,3-Epoxycyclooctanone ((2S,3S)-48v) 
Conditions B: After 24 h at 50 °C and base treatment of the crude product 
in THF, purification by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless solid (77 mg, 
550 µmol, 55%; 98:2 er). The enantiomeric ratio was determined by GC using a chiral BGB-
176/SE-52 30 m (80 °C, 2 °C/min until 135 °C, 18 °C/min until 220 °C, 10 min at 220°C, 0.6 
bar H2); major enantiomer: τR = 23.43 min, minor enantiomer: τR = 21.95 min. 
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1.66 (m, 5H, CHHCqepo, C(=O)CH2CHH, CH2CH2Cqepo, and CHHCH3), 1.59-1.49 (m, 1H, 
CHHCH3), 1.13-1.02 (m, 1H, C(=O)CH2CHH), 0.93 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 210.7 (C=O), 65.0 (CHepo), 64.9 (Cqepo), 41.1 (C(=O)CH2), 
31.9 (CH2CH3), 31.4 (CH2Cqepo), 25.3 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo), 9.1 (CH3). 
GC-MS (GC-EI) m/z (%) 154 [M+] (1), 138 (1), 125 (11), 109 (12), 98 (68), 93 (8), 83 (29), 
67 (35), 55 (100), 53 (16), 41 (65), 29 (57), 27 (23). 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0995, found 154.0994. 
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enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (2% i-PrOH 
in heptane, 0.5 mL/min); major enantiomer: τR = 13.74 min, minor enantiomer: τR = 14.83 
min. 
1H NMR (400 MHz, CD2Cl2) δ 7.33-7.22 (m, 5H, C6H5), 3.20 (d, J = 1.2 Hz, 1H, CepoH), 
2.94 (dd, J = 18.8, 14.3 Hz, 2H, CH2Ph), 2.67 (ddd, J = 13.4, 11.0, 4.0 Hz, 1H, C(=O)CHH), 
2.25-2.16 (m, 2H, C(=O)CHH and CHHCqepo), 1.86-1.63 (m, 4H, CHHCqepo, CH2CH2Cqepo, 
and C(=O)CH2CHH), 1.11-1.00 (m, 1H, C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 136.5 (Cqar), 130.1 (2C, CHar), 128.8 (2C, CHar), 
127.2 (CHar, p), 64.6 (CHepo), 64.1 (Cqepo), 44.6 (CH2Ph), 41.1 (C(=O)CH2), 31.7 (CH2Cqepo), 
25.2 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo). 
MS (EI-DE) m/z (%) 216 [M+] (22), 198 (3), 187 (19), 169 (6), 159 (3), 143 (7), 129 (12), 118 
(30), 104 (4), 97 (20), 91 (100), 78 (8), 65 (18), 55 (11), 41 (23). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1152, found 216.1150. 
 
(2S,3S)-2,3-Epoxycyclooctanone ((2S,3S)-48v) 
Conditions B: After 24 h at 50 °C and base treatment of the crude product 
in THF, purification by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless solid (77 mg, 
550 µmol, 55%; 98:2 er). The enantiomeric ratio was determined by GC using a chiral BGB-
176/SE-52 30 m (80 °C, 2 °C/min until 135 °C, 18 °C/min until 220 °C, 10 min at 220°C, 0.6 
bar H2); major enantiomer: τR = 23.43 min, minor enantiomer: τR = 21.95 min. 
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1.66 (m, 5H, CHHCqepo, C(=O)CH2CHH, CH2CH2Cqepo, and CHHCH3), 1.59-1.49 (m, 1H, 
CHHCH3), 1.13-1.02 (m, 1H, C(=O)CH2CHH), 0.93 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 210.7 (C=O), 65.0 (CHepo), 64.9 (Cqepo), 41.1 (C(=O)CH2), 
31.9 (CH2CH3), 31.4 (CH2Cqepo), 25.3 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo), 9.1 (CH3). 
GC-MS (GC-EI) m/z (%) 154 [M+] (1), 138 (1), 125 (11), 109 (12), 98 (68), 93 (8), 83 (29), 
67 (35), 55 (100), 53 (16), 41 (65), 29 (57), 27 (23). 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0995, found 154.0994. 
 
(2S,3R)-3-Benzyl-2,3-epoxycycloheptanone ((2S,3R)-48u) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (184 mg, 851 µmol, 85%; >99.5:0.5 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (2% i-PrOH 
in heptane, 0.5 mL/min); major enantiomer: τR = 13.74 min, minor enantiomer: τR = 14.83 
min. 
1H NMR (400 MHz, CD2Cl2) δ 7.33-7.22 (m, 5H, C6H5), 3.20 (d, J = 1.2 Hz, 1H, CepoH), 
2.94 (dd, J = 18.8, 14.3 Hz, 2H, CH2Ph), 2.67 (ddd, J = 13.4, 11.0, 4.0 Hz, 1H, C(=O)CHH), 
2.25-2.16 (m, 2H, C(=O)CHH and CHHCqepo), 1.86-1.63 (m, 4H, CHHCqepo, CH2CH2Cqepo, 
and C(=O)CH2CHH), 1.11-1.00 (m, 1H, C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 136.5 (Cqar), 130.1 (2C, CHar), 128.8 (2C, CHar), 
127.2 (CHar, p), 64.6 (CHepo), 64.1 (Cqepo), 44.6 (CH2Ph), 41.1 (C(=O)CH2), 31.7 (CH2Cqepo), 
25.2 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo). 
MS (EI-DE) m/z (%) 216 [M+] (22), 198 (3), 187 (19), 169 (6), 159 (3), 143 (7), 129 (12), 118 
(30), 104 (4), 97 (20), 91 (100), 78 (8), 65 (18), 55 (11), 41 (23). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1152, found 216.1150. 
 
(2S,3S)-2,3-Epoxycyclooctanone ((2S,3S)-48v) 
Conditions B: After 24 h at 50 °C and base treatment of the crude product 
in THF, purification by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless solid (77 mg, 
550 µmol, 55%; 98:2 er). The enantiomeric ratio was determined by GC using a chiral BGB-
176/SE-52 30 m (80 °C, 2 °C/min until 135 °C, 18 °C/min until 220 °C, 10 min at 220°C, 0.6 
bar H2); major enantiomer: τR = 23.43 min, minor enantiomer: τR = 21.95 min. 
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1.66 (m, 5H, CHHCqepo, C(=O)CH2CHH, CH2CH2Cqepo, and CHHCH3), 1.59-1.49 (m, 1H, 
CHHCH3), 1.13-1.02 (m, 1H, C(=O)CH2CHH), 0.93 (t, J = 7.5 Hz, 3H, CH3). 
13C NMR (75 MHz, CD2Cl2) δ 210.7 (C=O), 65.0 (CHepo), 64.9 (Cqepo), 41.1 (C(=O)CH2), 
31.9 (CH2CH3), 31.4 (CH2Cqepo), 25.3 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo), 9.1 (CH3). 
GC-MS (GC-EI) m/z (%) 154 [M+] (1), 138 (1), 125 (11), 109 (12), 98 (68), 93 (8), 83 (29), 
67 (35), 55 (100), 53 (16), 41 (65), 29 (57), 27 (23). 
HRMS (EI-FE) calcd for C9H14O2 [M+] 154.0995, found 154.0994. 
 
(2S,3R)-3-Benzyl-2,3-epoxycycloheptanone ((2S,3R)-48u) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-10% Et2O in 
pentane) as a clear oil (184 mg, 851 µmol, 85%; >99.5:0.5 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (2% i-PrOH 
in heptane, 0.5 mL/min); major enantiomer: τR = 13.74 min, minor enantiomer: τR = 14.83 
min. 
1H NMR (400 MHz, CD2Cl2) δ 7.33-7.22 (m, 5H, C6H5), 3.20 (d, J = 1.2 Hz, 1H, CepoH), 
2.94 (dd, J = 18.8, 14.3 Hz, 2H, CH2Ph), 2.67 (ddd, J = 13.4, 11.0, 4.0 Hz, 1H, C(=O)CHH), 
2.25-2.16 (m, 2H, C(=O)CHH and CHHCqepo), 1.86-1.63 (m, 4H, CHHCqepo, CH2CH2Cqepo, 
and C(=O)CH2CHH), 1.11-1.00 (m, 1H, C(=O)CH2CHH). 
13C NMR (75 MHz, CD2Cl2) δ 210.3 (C=O), 136.5 (Cqar), 130.1 (2C, CHar), 128.8 (2C, CHar), 
127.2 (CHar, p), 64.6 (CHepo), 64.1 (Cqepo), 44.6 (CH2Ph), 41.1 (C(=O)CH2), 31.7 (CH2Cqepo), 
25.2 (C(=O)CH2CH2), 23.9 (CH2CH2Cqepo). 
MS (EI-DE) m/z (%) 216 [M+] (22), 198 (3), 187 (19), 169 (6), 159 (3), 143 (7), 129 (12), 118 
(30), 104 (4), 97 (20), 91 (100), 78 (8), 65 (18), 55 (11), 41 (23). 
HRMS (EI-DE) calcd for C14H16O2 [M+] 216.1152, found 216.1150. 
 
(2S,3S)-2,3-Epoxycyclooctanone ((2S,3S)-48v) 
Conditions B: After 24 h at 50 °C and base treatment of the crude product 
in THF, purification by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless solid (77 mg, 
550 µmol, 55%; 98:2 er). The enantiomeric ratio was determined by GC using a chiral BGB-
176/SE-52 30 m (80 °C, 2 °C/min until 135 °C, 18 °C/min until 220 °C, 10 min at 220°C, 0.6 
bar H2); major enantiomer: τR = 23.43 min, minor enantiomer: τR = 21.95 min. 
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1H NMR (500 MHz, CD2Cl2) δ 3.70 (d, J = 5.4 Hz, 1H, CHepoC(=O)), 3.22 (ddd, J = 9.8, 5.3, 
3.7 Hz, 1H, CH2CHepo), 2.66 (ddd, J = 13.2, 7.7, 4.2 Hz, 1H, CHHC(=O)), 2.30 (ddd, J = 13.6, 
10.1, 3.6 Hz, 1H, CHHC(=O)), 2.19-2.14 (m, 1H, CHHCHepo), 1.94-1.87 (m, 1H, 
CHHCH2C(=O)), 1.77-1.70 (m, 1H, CHH(CH2)2CHepo), 1.69-1.62 (m, 1H, CHHCH2C(=O)), 
1.60-1.51 (m, 2H, CH2CH2CHepo), 1.49-1.40 (m, 1H, CHH(CH2)2CHepo), 0.99-0.91 (m, 1H, 
CHHCHepo). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 58.8 (CHepoC(=O)), 55.7 (CH2CHepo), 43.0 
(CH2C(=O)), 27.2 (2C, CH2CHepo and CH2(CH2)2CHepo), 24.7 (CH2CH2C(=O)), 24.6 
(CH2CH2CHepo). 
MS (EI-DE) m/z (%) 140 [M+] (18), 111 (5), 97 (16), 83 (37), 79 (17), 70 (30), 57 (27), 55 
(100), 53 (11), 41 (84), 39 (43), 27 (45). 
HRMS (EI-DE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
 
(E)-(2S,3R)-2,3-Epoxycyclododecanone ((2S,3R)-48w) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) as a white solid (45 mg, 229 μmol, 92%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25 m (100 °C, 1.2 °C/min until 170 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 54.36 min, minor enantiomer: τR = 53.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.51 (d, J = 1.6 Hz, 1H, CepoHC(=O)), 2.93 (td, J = 9.5, 2.2 
Hz, 1H, CH2CepoH), 2.91-2.87 (m, 1H, CHHC(=O)), 2.32-2.67 (m, 1H, CHHC(=O)), 2.23-
2.17 (m, 1H, CHHCepoH), 1.84-1.69 (m, 3H, -(CH2)n-), 1.54-1.35 (m, 9H, -(CH2)n-), 1.29-
1.24 (m, 1H, -(CH2)n-), 1.20-1.12 (m, 2H, -(CH2)n- and CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 206.9 (C=O), 61.2 (CH2CepoH), 59.2 (CepoHC(=O)), 41.4 
(CH2C(=O)), 32.2 (CH2CepoH), 26.9 (CH2), 26.5 (CH2), 25.7 (CH2), 25.5 (CH2), 24.4 (CH2), 
24.0 (CH2), 23.2 (CH2). 
MS (EI) m/z (%) 196 [M+] (8), 178 (1), 168 (1), 149 (2), 139 (4), 135 (6), 121 (14), 111 (29), 
107 (8), 98 (54), 84 (31), 67 (36), 55 (100), 41 (92), 29 (39). 
HRMS (EI-DE) calcd for C12H20O2 [M+] 196.1465, found 196.1463. 
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1H NMR (500 MHz, CD2Cl2) δ 3.70 (d, J = 5.4 Hz, 1H, CHepoC(=O)), 3.22 (ddd, J = 9.8, 5.3, 
3.7 Hz, 1H, CH2CHepo), 2.66 (ddd, J = 13.2, 7.7, 4.2 Hz, 1H, CHHC(=O)), 2.30 (ddd, J = 13.6, 
10.1, 3.6 Hz, 1H, CHHC(=O)), 2.19-2.14 (m, 1H, CHHCHepo), 1.94-1.87 (m, 1H, 
CHHCH2C(=O)), 1.77-1.70 (m, 1H, CHH(CH2)2CHepo), 1.69-1.62 (m, 1H, CHHCH2C(=O)), 
1.60-1.51 (m, 2H, CH2CH2CHepo), 1.49-1.40 (m, 1H, CHH(CH2)2CHepo), 0.99-0.91 (m, 1H, 
CHHCHepo). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 58.8 (CHepoC(=O)), 55.7 (CH2CHepo), 43.0 
(CH2C(=O)), 27.2 (2C, CH2CHepo and CH2(CH2)2CHepo), 24.7 (CH2CH2C(=O)), 24.6 
(CH2CH2CHepo). 
MS (EI-DE) m/z (%) 140 [M+] (18), 111 (5), 97 (16), 83 (37), 79 (17), 70 (30), 57 (27), 55 
(100), 53 (11), 41 (84), 39 (43), 27 (45). 
HRMS (EI-DE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
 
(E)-(2S,3R)-2,3-Epoxycyclododecanone ((2S,3R)-48w) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) as a white solid (45 mg, 229 μmol, 92%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25 m (100 °C, 1.2 °C/min until 170 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 54.36 min, minor enantiomer: τR = 53.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.51 (d, J = 1.6 Hz, 1H, CepoHC(=O)), 2.93 (td, J = 9.5, 2.2 
Hz, 1H, CH2CepoH), 2.91-2.87 (m, 1H, CHHC(=O)), 2.32-2.67 (m, 1H, CHHC(=O)), 2.23-
2.17 (m, 1H, CHHCepoH), 1.84-1.69 (m, 3H, -(CH2)n-), 1.54-1.35 (m, 9H, -(CH2)n-), 1.29-
1.24 (m, 1H, -(CH2)n-), 1.20-1.12 (m, 2H, -(CH2)n- and CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 206.9 (C=O), 61.2 (CH2CepoH), 59.2 (CepoHC(=O)), 41.4 
(CH2C(=O)), 32.2 (CH2CepoH), 26.9 (CH2), 26.5 (CH2), 25.7 (CH2), 25.5 (CH2), 24.4 (CH2), 
24.0 (CH2), 23.2 (CH2). 
MS (EI) m/z (%) 196 [M+] (8), 178 (1), 168 (1), 149 (2), 139 (4), 135 (6), 121 (14), 111 (29), 
107 (8), 98 (54), 84 (31), 67 (36), 55 (100), 41 (92), 29 (39). 
HRMS (EI-DE) calcd for C12H20O2 [M+] 196.1465, found 196.1463. 
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1H NMR (500 MHz, CD2Cl2) δ 3.70 (d, J = 5.4 Hz, 1H, CHepoC(=O)), 3.22 (ddd, J = 9.8, 5.3, 
3.7 Hz, 1H, CH2CHepo), 2.66 (ddd, J = 13.2, 7.7, 4.2 Hz, 1H, CHHC(=O)), 2.30 (ddd, J = 13.6, 
10.1, 3.6 Hz, 1H, CHHC(=O)), 2.19-2.14 (m, 1H, CHHCHepo), 1.94-1.87 (m, 1H, 
CHHCH2C(=O)), 1.77-1.70 (m, 1H, CHH(CH2)2CHepo), 1.69-1.62 (m, 1H, CHHCH2C(=O)), 
1.60-1.51 (m, 2H, CH2CH2CHepo), 1.49-1.40 (m, 1H, CHH(CH2)2CHepo), 0.99-0.91 (m, 1H, 
CHHCHepo). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 58.8 (CHepoC(=O)), 55.7 (CH2CHepo), 43.0 
(CH2C(=O)), 27.2 (2C, CH2CHepo and CH2(CH2)2CHepo), 24.7 (CH2CH2C(=O)), 24.6 
(CH2CH2CHepo). 
MS (EI-DE) m/z (%) 140 [M+] (18), 111 (5), 97 (16), 83 (37), 79 (17), 70 (30), 57 (27), 55 
(100), 53 (11), 41 (84), 39 (43), 27 (45). 
HRMS (EI-DE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
 
(E)-(2S,3R)-2,3-Epoxycyclododecanone ((2S,3R)-48w) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) as a white solid (45 mg, 229 μmol, 92%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25 m (100 °C, 1.2 °C/min until 170 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 54.36 min, minor enantiomer: τR = 53.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.51 (d, J = 1.6 Hz, 1H, CepoHC(=O)), 2.93 (td, J = 9.5, 2.2 
Hz, 1H, CH2CepoH), 2.91-2.87 (m, 1H, CHHC(=O)), 2.32-2.67 (m, 1H, CHHC(=O)), 2.23-
2.17 (m, 1H, CHHCepoH), 1.84-1.69 (m, 3H, -(CH2)n-), 1.54-1.35 (m, 9H, -(CH2)n-), 1.29-
1.24 (m, 1H, -(CH2)n-), 1.20-1.12 (m, 2H, -(CH2)n- and CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 206.9 (C=O), 61.2 (CH2CepoH), 59.2 (CepoHC(=O)), 41.4 
(CH2C(=O)), 32.2 (CH2CepoH), 26.9 (CH2), 26.5 (CH2), 25.7 (CH2), 25.5 (CH2), 24.4 (CH2), 
24.0 (CH2), 23.2 (CH2). 
MS (EI) m/z (%) 196 [M+] (8), 178 (1), 168 (1), 149 (2), 139 (4), 135 (6), 121 (14), 111 (29), 
107 (8), 98 (54), 84 (31), 67 (36), 55 (100), 41 (92), 29 (39). 
HRMS (EI-DE) calcd for C12H20O2 [M+] 196.1465, found 196.1463. 
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1H NMR (500 MHz, CD2Cl2) δ 3.70 (d, J = 5.4 Hz, 1H, CHepoC(=O)), 3.22 (ddd, J = 9.8, 5.3, 
3.7 Hz, 1H, CH2CHepo), 2.66 (ddd, J = 13.2, 7.7, 4.2 Hz, 1H, CHHC(=O)), 2.30 (ddd, J = 13.6, 
10.1, 3.6 Hz, 1H, CHHC(=O)), 2.19-2.14 (m, 1H, CHHCHepo), 1.94-1.87 (m, 1H, 
CHHCH2C(=O)), 1.77-1.70 (m, 1H, CHH(CH2)2CHepo), 1.69-1.62 (m, 1H, CHHCH2C(=O)), 
1.60-1.51 (m, 2H, CH2CH2CHepo), 1.49-1.40 (m, 1H, CHH(CH2)2CHepo), 0.99-0.91 (m, 1H, 
CHHCHepo). 
13C NMR (125 MHz, CD2Cl2) δ 207.3 (C=O), 58.8 (CHepoC(=O)), 55.7 (CH2CHepo), 43.0 
(CH2C(=O)), 27.2 (2C, CH2CHepo and CH2(CH2)2CHepo), 24.7 (CH2CH2C(=O)), 24.6 
(CH2CH2CHepo). 
MS (EI-DE) m/z (%) 140 [M+] (18), 111 (5), 97 (16), 83 (37), 79 (17), 70 (30), 57 (27), 55 
(100), 53 (11), 41 (84), 39 (43), 27 (45). 
HRMS (EI-DE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
 
(E)-(2S,3R)-2,3-Epoxycyclododecanone ((2S,3R)-48w) 
Conditions B: The title compound was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) as a white solid (45 mg, 229 μmol, 92%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25 m (100 °C, 1.2 °C/min until 170 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 54.36 min, minor enantiomer: τR = 53.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.51 (d, J = 1.6 Hz, 1H, CepoHC(=O)), 2.93 (td, J = 9.5, 2.2 
Hz, 1H, CH2CepoH), 2.91-2.87 (m, 1H, CHHC(=O)), 2.32-2.67 (m, 1H, CHHC(=O)), 2.23-
2.17 (m, 1H, CHHCepoH), 1.84-1.69 (m, 3H, -(CH2)n-), 1.54-1.35 (m, 9H, -(CH2)n-), 1.29-
1.24 (m, 1H, -(CH2)n-), 1.20-1.12 (m, 2H, -(CH2)n- and CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 206.9 (C=O), 61.2 (CH2CepoH), 59.2 (CepoHC(=O)), 41.4 
(CH2C(=O)), 32.2 (CH2CepoH), 26.9 (CH2), 26.5 (CH2), 25.7 (CH2), 25.5 (CH2), 24.4 (CH2), 
24.0 (CH2), 23.2 (CH2). 
MS (EI) m/z (%) 196 [M+] (8), 178 (1), 168 (1), 149 (2), 139 (4), 135 (6), 121 (14), 111 (29), 
107 (8), 98 (54), 84 (31), 67 (36), 55 (100), 41 (92), 29 (39). 
HRMS (EI-DE) calcd for C12H20O2 [M+] 196.1465, found 196.1463. 
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(E)-2,3-Epoxycyclopentadecanone (48x) 
Conditions B: The title compound (2S,3R)-48x was isolated after 20 h at 
50 °C and purification by flash column chromatography (silica gel, 5-15% 
Et2O in pentane) as a white solid (52 mg, 218 µmol, 87%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25m (100 °C, 1.2 °C/min until 185 °C, 18 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 65.00 min, minor enantiomer: τR = 63.68 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48x was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-15% Et2O in 
pentane) as a white solid (51 mg, 215 µmol, 86%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 190 °C, 18 °C/min until 230 °C, 5 min at 320 °C, 0.6 bar H2); major 
enantiomer: τR = 64.72 min, minor enantiomer: τR = 65.60 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.27 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.01 (td, J = 8.6, 2.7 
Hz, 1H, CH2CepoH), 2.47-2.39 (m, 2H, CH2C(=O)), 2.06-2.00 (m, 1H, CHHCepoH), 1.73-1.63 
(m, 2H, -(CH2)n-), 1.53-1.50 (m, 2H, -(CH2)n-), 1.39-1.21 (m, 17H, -(CH2)n- and CepoHCHH). 
13C NMR (125 MHz, CD2Cl2) δ 207.0 (C=O), 60.2 (CepoHC(=O)), 59.2 (CH2CepoH), 37.6 
(CH2C(=O)), 31.0 (CH2CepoH), 27.5 (CH2), 27.1 (CH2), 26.9 (CH2), 26.6 (CH2), 26.4 (CH2), 
26.4 (CH2), 26.2 (CH2), 25.7 (CH2), 24.9 (CH2), 22.6 (CH2). 
MS (EI) m/z (%) 238 [M+] (19), 220 (1), 209 (1), 195 (3), 177 (3), 163 (3), 149 (3), 121 (12), 
111 (29), 98 (48), 81 (38), 67 (39), 55 (100), 41 (86), 29 (34). 
HRMS (EI-DE) calcd for C15H26O2 [M+] 238.1931, found 238.1933. 
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(E)-2,3-Epoxycyclopentadecanone (48x) 
Conditions B: The title compound (2S,3R)-48x was isolated after 20 h at 
50 °C and purification by flash column chromatography (silica gel, 5-15% 
Et2O in pentane) as a white solid (52 mg, 218 µmol, 87%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25m (100 °C, 1.2 °C/min until 185 °C, 18 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 65.00 min, minor enantiomer: τR = 63.68 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48x was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-15% Et2O in 
pentane) as a white solid (51 mg, 215 µmol, 86%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 190 °C, 18 °C/min until 230 °C, 5 min at 320 °C, 0.6 bar H2); major 
enantiomer: τR = 64.72 min, minor enantiomer: τR = 65.60 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.27 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.01 (td, J = 8.6, 2.7 
Hz, 1H, CH2CepoH), 2.47-2.39 (m, 2H, CH2C(=O)), 2.06-2.00 (m, 1H, CHHCepoH), 1.73-1.63 
(m, 2H, -(CH2)n-), 1.53-1.50 (m, 2H, -(CH2)n-), 1.39-1.21 (m, 17H, -(CH2)n- and CepoHCHH). 
13C NMR (125 MHz, CD2Cl2) δ 207.0 (C=O), 60.2 (CepoHC(=O)), 59.2 (CH2CepoH), 37.6 
(CH2C(=O)), 31.0 (CH2CepoH), 27.5 (CH2), 27.1 (CH2), 26.9 (CH2), 26.6 (CH2), 26.4 (CH2), 
26.4 (CH2), 26.2 (CH2), 25.7 (CH2), 24.9 (CH2), 22.6 (CH2). 
MS (EI) m/z (%) 238 [M+] (19), 220 (1), 209 (1), 195 (3), 177 (3), 163 (3), 149 (3), 121 (12), 
111 (29), 98 (48), 81 (38), 67 (39), 55 (100), 41 (86), 29 (34). 
HRMS (EI-DE) calcd for C15H26O2 [M+] 238.1931, found 238.1933. 
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(E)-2,3-Epoxycyclopentadecanone (48x) 
Conditions B: The title compound (2S,3R)-48x was isolated after 20 h at 
50 °C and purification by flash column chromatography (silica gel, 5-15% 
Et2O in pentane) as a white solid (52 mg, 218 µmol, 87%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc 
column 25m (100 °C, 1.2 °C/min until 185 °C, 18 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 65.00 min, minor enantiomer: τR = 63.68 min. 
Conditions B: 9-amino(9-deoxy)epiquinidine (67) was used (instead of 13). 
The title compound (2R,3S)-48x was isolated after 20 h at 50 °C and 
purification by flash column chromatography (silica gel, 5-15% Et2O in 
pentane) as a white solid (51 mg, 215 µmol, 86%; 99.5:0.5 er). The 
enantiomeric ratio was determined by GC using a chiral Hydrodex-β-TBDAc column 25 m 
(100 °C, 1.2 °C/min until 190 °C, 18 °C/min until 230 °C, 5 min at 320 °C, 0.6 bar H2); major 
enantiomer: τR = 64.72 min, minor enantiomer: τR = 65.60 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.27 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.01 (td, J = 8.6, 2.7 
Hz, 1H, CH2CepoH), 2.47-2.39 (m, 2H, CH2C(=O)), 2.06-2.00 (m, 1H, CHHCepoH), 1.73-1.63 
(m, 2H, -(CH2)n-), 1.53-1.50 (m, 2H, -(CH2)n-), 1.39-1.21 (m, 17H, -(CH2)n- and CepoHCHH). 
13C NMR (125 MHz, CD2Cl2) δ 207.0 (C=O), 60.2 (CepoHC(=O)), 59.2 (CH2CepoH), 37.6 
(CH2C(=O)), 31.0 (CH2CepoH), 27.5 (CH2), 27.1 (CH2), 26.9 (CH2), 26.6 (CH2), 26.4 (CH2), 
26.4 (CH2), 26.2 (CH2), 25.7 (CH2), 24.9 (CH2), 22.6 (CH2). 
MS (EI) m/z (%) 238 [M+] (19), 220 (1), 209 (1), 195 (3), 177 (3), 163 (3), 149 (3), 121 (12), 
111 (29), 98 (48), 81 (38), 67 (39), 55 (100), 41 (86), 29 (34). 
HRMS (EI-DE) calcd for C15H26O2 [M+] 238.1931, found 238.1933. 
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(E)-2,3-Epoxycyclopentadecanone (48x) 
Conditions B: The title compound (2S,3R)-48x was isolated after 20 h at 
50 °C and purification by flash column chromatography (silica gel, 5-15% 
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(m, 2H, -(CH2)n-), 1.53-1.50 (m, 2H, -(CH2)n-), 1.39-1.21 (m, 17H, -(CH2)n- and CepoHCHH). 
13C NMR (125 MHz, CD2Cl2) δ 207.0 (C=O), 60.2 (CepoHC(=O)), 59.2 (CH2CepoH), 37.6 
(CH2C(=O)), 31.0 (CH2CepoH), 27.5 (CH2), 27.1 (CH2), 26.9 (CH2), 26.6 (CH2), 26.4 (CH2), 
26.4 (CH2), 26.2 (CH2), 25.7 (CH2), 24.9 (CH2), 22.6 (CH2). 
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(2S,3S)-2,3-Epoxy-4-methylcyclohexanone ((2S,3S)-81a) 
Conditions B: After 24 h at 30 °C, the conversion was determined to be 94% 
(54:46 dr (trans/cis)) by GC/MS. The enantiomeric ratio was determined by 
GC using a chiral BGB-178/OV-1701 column 30 m (80 °C, 0.8 °C/min until 
105 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2). trans-81a: 
93.5:6.5 er (major enantiomer: τR = 27.25 min, minor enantiomer: τR = 29.13 min); cis-81a: 
99:1 er (minor enantiomer: τR = 28.64 min, minor enantiomer: τR = 29.65 min). 
trans-81a: 1H NMR (500 MHz, CD2Cl2) δ 3.37 (dd, J = 3.7, 2.2 Hz, 1H, CHCHepo), 3.15 (d, J 
= 4.0 Hz, 1H, CHepoC(=O)), 2.46-2.40 (m, 2H, CHMe and CHHC(=O)), 2.18-2.04 (m, 2H, 
CHHC(=O) and CHHCH), 1.48-1.41 (m, 1H, CHHCH), 1.08 (d, J = 7.2 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 206.5 (C=O), 66.0 (CHCHepo), 61.7 (CHepoC(=O)), 33.3 
(CH2C(=O)), 27.9 (CHMe), 25.6 (CH2CH), 15.9 (CH3). 
GC-MS (GC-EI) m/z (%) 126 [M+]. 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0680, found 126.0681. 
cis-81a: 1H NMR (500 MHz, CD2Cl2) δ 3.38 (d, J = 3.9 Hz, 1H, CHCHepo), 3.16 (d, J = 3.8 
Hz, 1H, CHepoC(=O)), 2.42 (ddd, J = 18.6, 5.0, 3.5 Hz, 1H, CHHC(=O)), 2.19-2.12 (m, 1H, 
CHMe), 2.07 (ddd, J = 18.6, 11.8, 6.9 Hz, 1H, CHHC(=O)), 1.67-1.57 (m, 2H, CH2CH), 1.22 
(d, J = 6.9 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 205.6 (C=O), 60.1 (CHCHepo), 55.9 (CHepoC(=O)), 36.5 
(CH2C(=O)), 29.3 (CHMe), 24.1 (CH2CH), 18.8 (CH3). 
GC-MS (GC-EI) m/z (%) 126 [M+]. 
HRMS (EI-FE) calcd for C7H10O2 [M+] 126.0680, found 126.0681. 
 
(2S,3S)-2,3-Epoxy-4-tert-butylcyclohexanone ((2S,3S)-81b) 
Conditions B: After 96 h at 50 °C, the conversion was determined to be 
56% by GC/MS with a yield of epoxide 81b of 48% (92:8 dr (trans/cis)). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (100 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 
0.5 bar H2). trans-81b:a 79.5:20.5 er (major enantiomer: τR = 26.00 min, minor enantiomer: τR 
= 29.01 min).[192] 
                                                 
a  Relative configuration was assigned on the basis of NOE correlations in collaboration with the NMR 
department of the Max-Planck-Institut für Kohlenforschung. 
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56% by GC/MS with a yield of epoxide 81b of 48% (92:8 dr (trans/cis)). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (100 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 
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Conditions B: After 96 h at 50 °C, the conversion was determined to be 
56% by GC/MS with a yield of epoxide 81b of 48% (92:8 dr (trans/cis)). 
The enantiomeric ratio was determined by GC using a chiral Hydrodex-β-
TBDAc column 25 m (100 °C, 1.2 °C/min until 220 °C, 10 min at 220 °C, 
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56% by GC/MS with a yield of epoxide 81b of 48% (92:8 dr (trans/cis)). 
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trans-81b: 1H NMR (400 MHz, CDCl3) δ 3.49-3.47 (m, 1H, CHCHepo), 3.15 (d, J = 3.8 Hz, 
1H, CHepoC(=O)), 2.70-2.62 (m, 1H, CHHC(=O)) 2.15-2.09 (m, 1H,CHHC(=O)), 2.02-1.94 
(m, 2H, CHt-Bu and CHHCH), 1.74-1.64 (m, 1H, CHHCH), 0.99 (s, 9H, CH3). 
13C NMR (100 MHz, CDCl3) δ 208.3 (C=O), 61.5 (CHCHepo), 55.2 (CHepoC(=O)), 43.5 
(CHt-Bu), 34.7 (CH2C(=O)), 32.6 (CqMe3), 27.6 (3C, CH3), 26.1 (CH2CH). 
MS (EI-DE) m/z (%) 168 [M+] (8), 153 (1), 139 (4), 125 (2), 112 (21), 107 (4), 97 (8), 83 (24), 
70 (32), 67 (11), 57 (100), 41 (43), 39 (16), 29 (19). 
HRMS (EI-FE) calcd for C10H16O2 [M+] 168.1152, found 168.1150. 
 
trans-(2S,3S,5S)-2,3-Epoxy-3-methyl-5-phenylcyclohexanone (trans-(2S,3S,5S)-84) 
Conditions B: After 48 h at 50 °C, the conversion was determined to be 83% 
by GC/MS with a yield of epoxide 84 of 75% (97:3 dr (trans/cis)). The 
enantiomeric ratio was determined to be 98.5:1.5 by chiral GC using a 
Hydrodex-β-TBDAc column 25 m (80 °C, 1.2 °C/min until 180 °C, 20 °C/min 
until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 67.61 min, minor 
enantiomer: τR = 69.91 min). 
1H NMR (500 MHz, CD2Cl2) δ 7.33 (t, J = 7.7 Hz, 2H, CHPh, m), 7.24-7.20 (m, 3H, CHPh, o, p), 
3.34 (tt, J = 12.3, 4.5 Hz, 1H, CHPh), 3.14 (s, 1H, CHepo), 2.63 (dd, J = 18.7, 4.9 Hz, 1H, 
CHHC(=O)), 2.34 (dd, J = 14.3, 3.9 Hz, 1H, CHHCqMe), 2.23 (dd, J = 18.6, 12.7 Hz, 1H, 
CHHC(=O)), 2.11 (dd, J = 15.0, 12.4 Hz, 1H, CHHCqMe), 1.49 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 205.3 (C=O), 143.8 (CqPh), 129.0 (2C, CHPh, m), 127.3 (2C, 
CHPh, o), 127.1 (CHPh, p), 61.5 (CHepo), 61.4 (Cqepo), 44.0 (CH2C(=O)), 36.8 (CH2Cqepo), 34.3 
(CHPh), 21.9 (CH3). 
MS (EI-DE) m/z (%) 202 [M+] (23), 184 (17), 174 (68), 159 (84), 145 (47), 131 (100), 115 
(49), 103 (84), 91 (74), 85 (33), 77 (62), 69 (50), 65 (22), 51 (31), 43 (54), 27 (16). 
HRMS (EI-FE) calcd for C13H14O2 [M+] 202.0993, found 202.0994. 
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trans-81b: 1H NMR (400 MHz, CDCl3) δ 3.49-3.47 (m, 1H, CHCHepo), 3.15 (d, J = 3.8 Hz, 
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13C NMR (100 MHz, CDCl3) δ 208.3 (C=O), 61.5 (CHCHepo), 55.2 (CHepoC(=O)), 43.5 
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trans-81b: 1H NMR (400 MHz, CDCl3) δ 3.49-3.47 (m, 1H, CHCHepo), 3.15 (d, J = 3.8 Hz, 
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(2S,3S)-2,3-Epoxy-3-phenethyl-cyclopentanone ((2S,3S)-91) 
Conditions A: Amine 64 was used (instead of (R,R)-DPEN (12)). The title 
compound was isolated after 48 h at 50 °C and purification by flash column 
chromatography (silica gel, 15-20% Et2O in pentane) as a clear oil (66 mg, 
326 μmol, 65%; 85.5:14.5 er). The enantiomeric ratio was determined by GC 
using a chiral Lipodex E column 25 m (80 °C, 1.2 °C/min until 180 °C, 18 
°C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); major enantiomer: τR = 68.62 min, minor 
enantiomer: τR = 67.99 min. 
1H NMR (500 MHz, CD2Cl2) δ 7.31-7.27 (m, 2H, CHPh, m), 7.21-7.19 (m, 3H, CHPh, o, p), 3.10 
(s, 1H, CepoH), 2.81-2.71 (m, 2H, PhCH2CH2), 2.37-2.27 (m, 2H, CH2CHHC(=O) and 
CHHCH2C(=O)), 2.23-2.12 (m, 2H, PhCH2CH2), 2.10-2.03 (m, 1H, CH2CHHC(=O)), 2.02-
1.97 (m, 1H, CHHCH2C(=O)). 
13C NMR (125 MHz, CD2Cl2) δ 210.5 (C=O), 141.1 (CqPh), 128.5 (2C, CHPh, m), 128.3 (2C, 
CHPh, o), 126.2 (CHar, p), 68.5 (Cqepo), 60.4 (CepoH), 33.6 (PhCH2CH2), 32.5 (CH2C(=O)), 31.1 
(PhCH2), 26.0 (CH2CH2C(=O)). 
MS (EI-DE) m/z (%) 202 [M+] (7), 173 (1), 155 (1), 142 (2), 130 (28), 104 (11), 91 (100), 83 
(19), 77 (6), 65 (12), 55 (11), 39 (7), 29 (5). 
HRMS (EI-FE) calcd for C13H14O2 [M+] 202.0992, found 202.0994. 
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7.3 Catalytic Asymmetric Hydroperoxidation and Epoxidation of Acyclic Enones 
7.3.1 Catalytic Asymmetric Hydroperoxidation of Acyclic Enones 
7.3.1.1 General Procedure[193] 
 
 
 
Catalyst salt [13 • 2 TCA] was prepared in situ by the addition of 9-amino(9-deoxy)epiquinine 
(13; 32.3 mg, 0.1 mmol, 10 mol%) to a solution of trichloroacetic acid (32.6 mg, 0.2 mmol, 
20 mol%) in dioxane (4 mL). Then, enone 92 (1.0 mmol, 1.0 equiv) was added, and 20 
minutes later, aqueous hydrogen peroxide (30 wt%, 304 μL, 3.0 mmol, 3 equiv). After 20-48 
h of stirring at 32°C, the reaction mixture was extracted with Et2O (3×25 mL) and the 
combined organic phases were washed with brine, dried (Na2SO4), filtered, and concentrated 
in vacuo. The crude product was subjected to flash column chromatography (silica gel, eluent: 
Et2O-pentane) to afford the corresponding pure peroxyhemiketal 94. The optical purity was 
determined after converting the peroxyhemiketal to the corresponding epoxide (with 1N 
NaOH (1 equiv) in Et2O) or to the corresponding aldol-type product (with triethylphosphite (2 
equiv) in Et2O). 
 
7.3.1.2 Scope of Optically Active 3-Hydroxy-1,2-dioxolanes 
 
(5R)-5-Hexyl-3-methyl-1,2-dioxolan-3-ol ((5R)-94a): Peroxyhemiketal 94a was prepared 
according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-10% Et2O in pentane) 
provided the title compound 94a as a colorless oil (123 mg, 653 μmol, 65%; 98.5:1.5 er). The 
enantiomeric ratio was determined after converting peroxyhemiketal 94a into the 
corresponding epoxide 93a. The enantiomers were analyzed by GC using a chiral BGB-
176/SE-52 column 29.5 m (80 °C, 1.2 °C/min until 115 °C, 18 °C/min until 220 °C, 10 min at 
220 °C, 0.6 bar H2); major enantiomer: τR = 24.41 min, minor enantiomer: τR = 26.10 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
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1H NMR (500 MHz, CD2Cl2) δ 4.41-4.36 (m, 1H), 4.31-4.26 (m, 1H), 2.96 (br s, 2H), 2.77-
2.72 (m, 1H), 2.69-2.65 (m, 1H), 2.26-2.18 (m, 2H), 1.72-1.55 (m, 4H), 1.52 (s, 3H), 1.51 (s, 
3H), 1.47-1.35 (m, 2H), 1.34-1.24 (m, 14H), 0.89-0.87 (m, 6H). 
13C NMR (125 MHz, CD2Cl2) δ 105.9, 105.0, 82.7, 81.3, 53.1, 52.8, 35.2, 32.6, 32.3, 32.2, 
29.8, 29.7, 26.7, 26.5, 23.4, 23.1, 23.1, 22.9, 14.4, 14.4. 
MS (EI-DE) m/z (%) 188 [M+] (1), 155 (56), 137 (3), 113 (8), 95 (7), 81 (5), 71 (63), 55 (14), 
43 (100), 29 (12). 
HRMS (EI-FE) calcd for C10H20O3 [M+] 188.1413, found 188.1412. 
 
(5R)-3-Methyl-5-phenethyl-1,2-dioxolan-3-ol ((5R)-94b): Peroxyhemiketal 94a was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-40% Et2O in pentane) provided 
the title compound 94a as a colorless oil (141 mg, 677 μmol, 68%; 97:3 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94b into the corresponding epoxide 
93b. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 30 m 
(80 °C, 1.2 °C/min until 145 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 46.17 min, minor enantiomer: τR = 47.42 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 7.30-7.27 (m, 4H), 7.21-7.18 (m, 6H), 4.43-4.37 (m, 1H), 
4.34-4.28 (m, 1H), 2.94-2.93 (m, 2H), 2.80-2.61 (m, 6H), 2.30-2.22 (m, 2H), 2.06-1.97 (m, 
2H), 1.95-1.88 (m, 1H), 1.77-1.70 (m, 1H), 1.54 (s, 3H), 1.51 (s, 3H). 
13C NMR (125 MHz, CD2Cl2) δ 142.0, 141.8, 129.0, 129.0, 128.9, 128.9, 126.6, 126.5, 106.0, 
105.0, 81.8, 80.5, 52.9, 52.8, 37.0, 34.5, 32.9, 32.7, 23.4, 22.8. 
MS (EI-DE) m/z (%) 208 [M+] (trace), 190 (3), 174 (10), 159 (2), 148 (2), 131 (15), 117 (21), 
104 (93), 91 (100), 87 (7), 77 (15), 65 (14), 58 (4), 51 (9), 43 (77), 39 (6). 
HRMS (CI-FE, i-butane) calcd for C12H17O3 [M+H]+ 209.1175, found 209.1178. 
 
(5R)-3-Ethyl-5-methyl-1,2-dioxolan-3-ol ((5R)-94c): The title compound was isolated after 
24 h at 32 °C and purification by flash column chromatography (silica gel, 
10-30% Et2O in pentane) as a colorless oil (74 mg, 560 μmol, 56%; 97:3 er). 
The enantiomeric ratio was determined after converting dioxolane 94c to the 
corresponding epoxide 93c. The enantiomers were analyzed by GC using a chiral BGB-
178/BGB-15 column 30 m (60 °C, 1.0 °C/min until 80 °C, 18 °C/min until 220 °C, 10 min at 
Ph
O O
OH
C12H16O3
208,25
C6H12O3
132,16
Me
O O
Et
OH
7 Experimental Part 
 185
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MS (EI-DE) m/z (%) 188 [M+] (1), 155 (56), 137 (3), 113 (8), 95 (7), 81 (5), 71 (63), 55 (14), 
43 (100), 29 (12). 
HRMS (EI-FE) calcd for C10H20O3 [M+] 188.1413, found 188.1412. 
 
(5R)-3-Methyl-5-phenethyl-1,2-dioxolan-3-ol ((5R)-94b): Peroxyhemiketal 94a was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-40% Et2O in pentane) provided 
the title compound 94a as a colorless oil (141 mg, 677 μmol, 68%; 97:3 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94b into the corresponding epoxide 
93b. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 30 m 
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220 °C, 0.4 bar H2); major enantiomer: τR = 14.73 min, minor enantiomer: τR = 15.98 min. 
Characterized as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, CD2Cl2) δ 4.60 (app. sext, J = 6.2 Hz, 1H, CH), 4.40-4.32 (m, 1H, CH), 
3.12 (br s, 2H, OH), 2.71 (dd overlapped, J = 12.8, 7.5 Hz, 1H, CHHcycl.), 2.69 (dd 
overlapped, J = 12.6, 7.1 Hz, 1H, CHHcycl.), 2.17 (dd overlapped, J = 12.6, 5.8 Hz, 1H, 
CHHcycl.), 2.13 (dd overlapped, J = 12.8, 8.5 Hz, 1H, CHHcycl.), 1.84-1.71 (m, 4H, CH2CH3), 
1.30 (d, J = 6.3 Hz, 3H, CH3CH), 1.26 (d, J = 6.1 Hz, 3H, CH3CH), 1.02 (t overlapped, J = 
7.5 Hz, 3H, CH2CH3), 1.00 (t overlapped, J = 7.6 Hz, 3H, CH2CH3). 
13C NMR (100 MHz, CD2Cl2) 108.5 (CqOH), 107.3 (CqOH), 78.4 (CH), 76.9 (CH), 52.3 
(CH2, cycl.), 52.0 (CH2, cycl.), 29.9 (CH2CH3), 29.7 (CH2CH3), 20.3 (CH3CH), 17.0 (CH3CH), 
9.2 (CH2CH3), 8.9 (CH2CH3). 
MS (EI-DE) m/z (%) 132 [M+] (3), 115 (1), 99 (100), 91 (1), 87 (3), 85 (27), 81 (4), 75 (3), 71 
(24), 69 (3), 61 (25), 57 (59), 43 (60), 31 (9), 29 (40), 27 (14). 
HRMS (EI-FE) calcd for C6H12O3 [M+] 132.0785, found 132.0786. 
 
(5R)-5-Isobutyl-3-methyl-1,2-dioxolan-3-ol ((5R)-94d): Peroxyhemiketal 94a was prepared 
according to the general procedure. The reaction mixture was stirred for 
36 h at 32 °C. Purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in pentane) provided the title 
compound 94a as a colorless oil (98 mg, 612 μmol, 61%; 97.5:2.5 er). The enantiomeric ratio 
was determined after converting peroxyhemiketal 94d into the corresponding epoxide 93d. 
The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 30 m (60 °C, 
0.8 °C/min until 80 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 15.10 min, minor enantiomer: τR = 17.20 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.53-4.47 (m, 1H), 4.39-4.33 (m, 1H), 3.03-2.98 (m, 2H), 
2.79-2.75 (m, 1H), 2.71-2.67 (m, 1H), 2.25-2.21 (m, 1H), 2.20-2.17 (m, 1H), 1.73-1.56 (m, 
4H), 1.53 (s, 3H), 1.51 (s, 3H), 1.50-1.44 (m, 1H), 1.30-1.25 (m, 1H), 0.93-0.90 (m, 12H). 
13C NMR (125 MHz, CD2Cl2) δ 105.9, 104.9, 81.3, 79.7, 53.7, 53.2, 44.1, 41.7, 26.6, 26.1, 
23.5, 23.3, 23.2, 22.9, 22.8, 22.5. 
MS (EI-DE) m/z (%) 160 [M+] (2), 135 (0.09), 127 (39), 109 (10), 95 (3), 85 (12), 77 (1), 71 
(96), 69 (14), 57 (23), 43 (100), 41 (25), 29 (18). 
HRMS (EI-FE) calcd for C8H16O3 [M]+ 160.1098, found 160.1099. 
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(5R)-5-Isobutyl-3-methyl-1,2-dioxolan-3-ol ((5R)-94d): Peroxyhemiketal 94a was prepared 
according to the general procedure. The reaction mixture was stirred for 
36 h at 32 °C. Purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in pentane) provided the title 
compound 94a as a colorless oil (98 mg, 612 μmol, 61%; 97.5:2.5 er). The enantiomeric ratio 
was determined after converting peroxyhemiketal 94d into the corresponding epoxide 93d. 
The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 30 m (60 °C, 
0.8 °C/min until 80 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 15.10 min, minor enantiomer: τR = 17.20 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.53-4.47 (m, 1H), 4.39-4.33 (m, 1H), 3.03-2.98 (m, 2H), 
2.79-2.75 (m, 1H), 2.71-2.67 (m, 1H), 2.25-2.21 (m, 1H), 2.20-2.17 (m, 1H), 1.73-1.56 (m, 
4H), 1.53 (s, 3H), 1.51 (s, 3H), 1.50-1.44 (m, 1H), 1.30-1.25 (m, 1H), 0.93-0.90 (m, 12H). 
13C NMR (125 MHz, CD2Cl2) δ 105.9, 104.9, 81.3, 79.7, 53.7, 53.2, 44.1, 41.7, 26.6, 26.1, 
23.5, 23.3, 23.2, 22.9, 22.8, 22.5. 
MS (EI-DE) m/z (%) 160 [M+] (2), 135 (0.09), 127 (39), 109 (10), 95 (3), 85 (12), 77 (1), 71 
(96), 69 (14), 57 (23), 43 (100), 41 (25), 29 (18). 
HRMS (EI-FE) calcd for C8H16O3 [M]+ 160.1098, found 160.1099. 
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(5S)-5-Cyclohexyl-3-methyl-1,2-dioxolan-3-ol ((5S)-94e): Peroxyhemiketal 94e was 
prepared according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided the 
title compound 94e as a colorless oil (101 mg, 542 μmol, 54%; 98:2 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94e into the corresponding epoxide 
93e. The enantiomers were analyzed by GC using a chiral BGB-176/SE-52 column 29.5 m 
(80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 32.73 min, minor enantiomer: τR = 33.99 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.11-4.06 (m, 1H), 4.05-4.00 (m, 1H), 3.00 (br s, 2H), 2.68-
2.64 (m, 1H), 2.60-2.56 (m, 1H), 2.34-2.28 (m, 2H), 1.91-1.86 (m, 1H), 1.83-1.79 (m, 1H), 
1.75-1.53 (m, 10H), 1.52 (s, 3H), 1.50 (s, 3H), 1.31-1.12 (m, 6H), 1.08-0.90 (m, 4H). 
13C NMR (125 MHz, CD2Cl2) δ 105.8, 105.0, 86.7, 85.2, 51.1, 50.3, 42.6, 41.2, 30.3, 29.9, 
29.7, 29.3, 26.8, 26.7, 26.4, 26.3, 26.1, 26.0, 23.4, 22.6. 
MS (EI-DE) m/z (%) 186 [M+] (2), 153 (50), 135 (14), 125 (1), 111 (8), 95 (16), 83 (71), 71 
(60), 67 (20), 55 (100), 43 (95), 29 (21). 
HRMS (CI-FE, NH3) calcd for C10H22NO3 [M+NH4]+ 204.1598, found 204.1600. 
 
(5R)-5-(3-Butenyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94f): Peroxyhemiketal 94f was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided 
the title compound 94f as a colorless oil (109 mg, 689 μmol, 69%; 97.5:2.5 er). The 
enantiomeric ratio was determined after converting peroxyhemiketal 94f into the 
corresponding aldol-type product 96f. The enantiomers were analyzed by HPLC using a 
chiral Chiralpak IA column (10% iPrOH/heptane, 0.5 mL/min); major enantiomer: τR = 13.19 
min, minor enantiomer: τR = 12.41 min. Characterized as mixture of hemiketal epimers (1:1 
dr). 
1H NMR (500 MHz, CD2Cl2) δ 5.86-5.77 (m, 2H), 5.07-5.02 (m, 2H), 5.00-4.96 (m, 2H), 
4.44-4.39 (m, 1H), 4.34-4.28 (m, 1H), 3.10 (br s, 2H), 2.80-2.76 (m, 1H), 2.69-2.65 (m, 1H), 
2.29-2.25 (m, 1H), 2.24-2.21 (m, 1H), 2.19-2.05 (m, 4H), 1.83-1.75 (m, 2H), 1.73-1.54 (m, 
2H), 1.53 (s, 3H), 1.51 (s, 3H). 
O O
OH
C10H18O3
186,25
O O
OH
C8H14O3
158,19
7 Experimental Part 
 187
(5S)-5-Cyclohexyl-3-methyl-1,2-dioxolan-3-ol ((5S)-94e): Peroxyhemiketal 94e was 
prepared according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided the 
title compound 94e as a colorless oil (101 mg, 542 μmol, 54%; 98:2 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94e into the corresponding epoxide 
93e. The enantiomers were analyzed by GC using a chiral BGB-176/SE-52 column 29.5 m 
(80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 32.73 min, minor enantiomer: τR = 33.99 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.11-4.06 (m, 1H), 4.05-4.00 (m, 1H), 3.00 (br s, 2H), 2.68-
2.64 (m, 1H), 2.60-2.56 (m, 1H), 2.34-2.28 (m, 2H), 1.91-1.86 (m, 1H), 1.83-1.79 (m, 1H), 
1.75-1.53 (m, 10H), 1.52 (s, 3H), 1.50 (s, 3H), 1.31-1.12 (m, 6H), 1.08-0.90 (m, 4H). 
13C NMR (125 MHz, CD2Cl2) δ 105.8, 105.0, 86.7, 85.2, 51.1, 50.3, 42.6, 41.2, 30.3, 29.9, 
29.7, 29.3, 26.8, 26.7, 26.4, 26.3, 26.1, 26.0, 23.4, 22.6. 
MS (EI-DE) m/z (%) 186 [M+] (2), 153 (50), 135 (14), 125 (1), 111 (8), 95 (16), 83 (71), 71 
(60), 67 (20), 55 (100), 43 (95), 29 (21). 
HRMS (CI-FE, NH3) calcd for C10H22NO3 [M+NH4]+ 204.1598, found 204.1600. 
 
(5R)-5-(3-Butenyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94f): Peroxyhemiketal 94f was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided 
the title compound 94f as a colorless oil (109 mg, 689 μmol, 69%; 97.5:2.5 er). The 
enantiomeric ratio was determined after converting peroxyhemiketal 94f into the 
corresponding aldol-type product 96f. The enantiomers were analyzed by HPLC using a 
chiral Chiralpak IA column (10% iPrOH/heptane, 0.5 mL/min); major enantiomer: τR = 13.19 
min, minor enantiomer: τR = 12.41 min. Characterized as mixture of hemiketal epimers (1:1 
dr). 
1H NMR (500 MHz, CD2Cl2) δ 5.86-5.77 (m, 2H), 5.07-5.02 (m, 2H), 5.00-4.96 (m, 2H), 
4.44-4.39 (m, 1H), 4.34-4.28 (m, 1H), 3.10 (br s, 2H), 2.80-2.76 (m, 1H), 2.69-2.65 (m, 1H), 
2.29-2.25 (m, 1H), 2.24-2.21 (m, 1H), 2.19-2.05 (m, 4H), 1.83-1.75 (m, 2H), 1.73-1.54 (m, 
2H), 1.53 (s, 3H), 1.51 (s, 3H). 
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(5S)-5-Cyclohexyl-3-methyl-1,2-dioxolan-3-ol ((5S)-94e): Peroxyhemiketal 94e was 
prepared according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided the 
title compound 94e as a colorless oil (101 mg, 542 μmol, 54%; 98:2 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94e into the corresponding epoxide 
93e. The enantiomers were analyzed by GC using a chiral BGB-176/SE-52 column 29.5 m 
(80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 32.73 min, minor enantiomer: τR = 33.99 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.11-4.06 (m, 1H), 4.05-4.00 (m, 1H), 3.00 (br s, 2H), 2.68-
2.64 (m, 1H), 2.60-2.56 (m, 1H), 2.34-2.28 (m, 2H), 1.91-1.86 (m, 1H), 1.83-1.79 (m, 1H), 
1.75-1.53 (m, 10H), 1.52 (s, 3H), 1.50 (s, 3H), 1.31-1.12 (m, 6H), 1.08-0.90 (m, 4H). 
13C NMR (125 MHz, CD2Cl2) δ 105.8, 105.0, 86.7, 85.2, 51.1, 50.3, 42.6, 41.2, 30.3, 29.9, 
29.7, 29.3, 26.8, 26.7, 26.4, 26.3, 26.1, 26.0, 23.4, 22.6. 
MS (EI-DE) m/z (%) 186 [M+] (2), 153 (50), 135 (14), 125 (1), 111 (8), 95 (16), 83 (71), 71 
(60), 67 (20), 55 (100), 43 (95), 29 (21). 
HRMS (CI-FE, NH3) calcd for C10H22NO3 [M+NH4]+ 204.1598, found 204.1600. 
 
(5R)-5-(3-Butenyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94f): Peroxyhemiketal 94f was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided 
the title compound 94f as a colorless oil (109 mg, 689 μmol, 69%; 97.5:2.5 er). The 
enantiomeric ratio was determined after converting peroxyhemiketal 94f into the 
corresponding aldol-type product 96f. The enantiomers were analyzed by HPLC using a 
chiral Chiralpak IA column (10% iPrOH/heptane, 0.5 mL/min); major enantiomer: τR = 13.19 
min, minor enantiomer: τR = 12.41 min. Characterized as mixture of hemiketal epimers (1:1 
dr). 
1H NMR (500 MHz, CD2Cl2) δ 5.86-5.77 (m, 2H), 5.07-5.02 (m, 2H), 5.00-4.96 (m, 2H), 
4.44-4.39 (m, 1H), 4.34-4.28 (m, 1H), 3.10 (br s, 2H), 2.80-2.76 (m, 1H), 2.69-2.65 (m, 1H), 
2.29-2.25 (m, 1H), 2.24-2.21 (m, 1H), 2.19-2.05 (m, 4H), 1.83-1.75 (m, 2H), 1.73-1.54 (m, 
2H), 1.53 (s, 3H), 1.51 (s, 3H). 
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(5S)-5-Cyclohexyl-3-methyl-1,2-dioxolan-3-ol ((5S)-94e): Peroxyhemiketal 94e was 
prepared according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided the 
title compound 94e as a colorless oil (101 mg, 542 μmol, 54%; 98:2 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 94e into the corresponding epoxide 
93e. The enantiomers were analyzed by GC using a chiral BGB-176/SE-52 column 29.5 m 
(80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 32.73 min, minor enantiomer: τR = 33.99 min. Characterized as mixture of 
hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, CD2Cl2) δ 4.11-4.06 (m, 1H), 4.05-4.00 (m, 1H), 3.00 (br s, 2H), 2.68-
2.64 (m, 1H), 2.60-2.56 (m, 1H), 2.34-2.28 (m, 2H), 1.91-1.86 (m, 1H), 1.83-1.79 (m, 1H), 
1.75-1.53 (m, 10H), 1.52 (s, 3H), 1.50 (s, 3H), 1.31-1.12 (m, 6H), 1.08-0.90 (m, 4H). 
13C NMR (125 MHz, CD2Cl2) δ 105.8, 105.0, 86.7, 85.2, 51.1, 50.3, 42.6, 41.2, 30.3, 29.9, 
29.7, 29.3, 26.8, 26.7, 26.4, 26.3, 26.1, 26.0, 23.4, 22.6. 
MS (EI-DE) m/z (%) 186 [M+] (2), 153 (50), 135 (14), 125 (1), 111 (8), 95 (16), 83 (71), 71 
(60), 67 (20), 55 (100), 43 (95), 29 (21). 
HRMS (CI-FE, NH3) calcd for C10H22NO3 [M+NH4]+ 204.1598, found 204.1600. 
 
(5R)-5-(3-Butenyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94f): Peroxyhemiketal 94f was 
prepared according to the general procedure. The reaction mixture was 
stirred for 36 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 5-30% Et2O in pentane) provided 
the title compound 94f as a colorless oil (109 mg, 689 μmol, 69%; 97.5:2.5 er). The 
enantiomeric ratio was determined after converting peroxyhemiketal 94f into the 
corresponding aldol-type product 96f. The enantiomers were analyzed by HPLC using a 
chiral Chiralpak IA column (10% iPrOH/heptane, 0.5 mL/min); major enantiomer: τR = 13.19 
min, minor enantiomer: τR = 12.41 min. Characterized as mixture of hemiketal epimers (1:1 
dr). 
1H NMR (500 MHz, CD2Cl2) δ 5.86-5.77 (m, 2H), 5.07-5.02 (m, 2H), 5.00-4.96 (m, 2H), 
4.44-4.39 (m, 1H), 4.34-4.28 (m, 1H), 3.10 (br s, 2H), 2.80-2.76 (m, 1H), 2.69-2.65 (m, 1H), 
2.29-2.25 (m, 1H), 2.24-2.21 (m, 1H), 2.19-2.05 (m, 4H), 1.83-1.75 (m, 2H), 1.73-1.54 (m, 
2H), 1.53 (s, 3H), 1.51 (s, 3H). 
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13C NMR (125 MHz, CD2Cl2) δ 138.3, 138.1, 115.5, 115.4, 105.9, 105.0, 81.9, 80.6, 52.8, 
52.7, 34.4, 31.9, 30.9, 30.7, 23.4, 22.8. 
MS (EI-DE) m/z (%) 140 (trace), 125 (10), 107 (2), 97 (2), 83 (10), 71 (18), 55 (28), 43 (100), 
41 (13), 29 (14). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [M+H]+ 159.1020, found 159.1021. 
 
(5R)-5-(3-Bromopropyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94g): Peroxyhemiketal 94g was 
prepared according to the general procedure. The reaction mixture 
was stirred for 24 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 25-40% Et2O in pentane) 
provided the title compound 94g as a colorless oil (81 mg, 360 μmol, 72%; 97:3 er). The 
enantiomeric ratio was determined after converting dioxolane 94g into the corresponding 
epoxide 93g. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 
30 m (100 °C, 1.2 °C/min until 135 °C, 18 °C/min until 220 °C, 5 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 19.07 min, minor enantiomer: τR = 20.64 min. Contains traces of (E)-
7-chloro-3,4-epoxyheptan-2-one. Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.36 (s, 1H, OH), 5.33 (s, 1H, OH), 4.38-4.32 (m, 1H, CH), 
4.25-4.18 (m, 1H, CH), 3.51-3.40 (m, 4H, CH2Br), 2.68-2.64 (m, 1H, CH2COH), 2.61-2.55 
(m, 1H, CH2COH), 2.22-2.17 (m, 1H, CH2COH), 2.16-2.10 (m, 1H, CH2COH), 2.00-1.80 (m, 
4H, CH2), 1.79-1.68 (m, 3H, CH2), 1.63-1.54 (m, 1H, CH2), 1.41 (s, 3H, CH3), 1.39 (s, 3H, 
CH3). 
13C NMR (100 MHz, THF-d8): δ 105.9 (Cq), 104.9 (Cq), 81.9 (CH), 80.7 (CH), 53.6 
(COCH2CO), 53.5 (COCH2CO), 34.4 (CH2), 34.4 (CH2, 2C), 31.9 (CH2), 31.0 (CH2), 30.9 
(CH2), 24.6 (CH3), 23.6 (CH3). 
 
(5R)-3-Methyl-5-(5-(tetrahydro-2H-pyran-2-yloxy)pentyl)-1,2-dioxolan-3-ol ((5R)-94h): 
Peroxyhemiketal 94h was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C. 
Purification of the crude product by flash column chromate-
graphy (silica gel, 30-40% Et2O in pentane) provided the title compound 94h (87 mg, 318 
μmol, 64%; 96.5:3.5 er) as a colorless oil. The enantiomeric ratio was determined after 
converting peroxyhemiketal 94h into the corresponding THP-deprotected epoxide 99. The 
enantiomers were analyzed by GC using a chiral Ivadex 1 column 25m (80 °C, 1.0 °C/min 
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13C NMR (125 MHz, CD2Cl2) δ 138.3, 138.1, 115.5, 115.4, 105.9, 105.0, 81.9, 80.6, 52.8, 
52.7, 34.4, 31.9, 30.9, 30.7, 23.4, 22.8. 
MS (EI-DE) m/z (%) 140 (trace), 125 (10), 107 (2), 97 (2), 83 (10), 71 (18), 55 (28), 43 (100), 
41 (13), 29 (14). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [M+H]+ 159.1020, found 159.1021. 
 
(5R)-5-(3-Bromopropyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94g): Peroxyhemiketal 94g was 
prepared according to the general procedure. The reaction mixture 
was stirred for 24 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 25-40% Et2O in pentane) 
provided the title compound 94g as a colorless oil (81 mg, 360 μmol, 72%; 97:3 er). The 
enantiomeric ratio was determined after converting dioxolane 94g into the corresponding 
epoxide 93g. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 
30 m (100 °C, 1.2 °C/min until 135 °C, 18 °C/min until 220 °C, 5 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 19.07 min, minor enantiomer: τR = 20.64 min. Contains traces of (E)-
7-chloro-3,4-epoxyheptan-2-one. Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.36 (s, 1H, OH), 5.33 (s, 1H, OH), 4.38-4.32 (m, 1H, CH), 
4.25-4.18 (m, 1H, CH), 3.51-3.40 (m, 4H, CH2Br), 2.68-2.64 (m, 1H, CH2COH), 2.61-2.55 
(m, 1H, CH2COH), 2.22-2.17 (m, 1H, CH2COH), 2.16-2.10 (m, 1H, CH2COH), 2.00-1.80 (m, 
4H, CH2), 1.79-1.68 (m, 3H, CH2), 1.63-1.54 (m, 1H, CH2), 1.41 (s, 3H, CH3), 1.39 (s, 3H, 
CH3). 
13C NMR (100 MHz, THF-d8): δ 105.9 (Cq), 104.9 (Cq), 81.9 (CH), 80.7 (CH), 53.6 
(COCH2CO), 53.5 (COCH2CO), 34.4 (CH2), 34.4 (CH2, 2C), 31.9 (CH2), 31.0 (CH2), 30.9 
(CH2), 24.6 (CH3), 23.6 (CH3). 
 
(5R)-3-Methyl-5-(5-(tetrahydro-2H-pyran-2-yloxy)pentyl)-1,2-dioxolan-3-ol ((5R)-94h): 
Peroxyhemiketal 94h was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C. 
Purification of the crude product by flash column chromate-
graphy (silica gel, 30-40% Et2O in pentane) provided the title compound 94h (87 mg, 318 
μmol, 64%; 96.5:3.5 er) as a colorless oil. The enantiomeric ratio was determined after 
converting peroxyhemiketal 94h into the corresponding THP-deprotected epoxide 99. The 
enantiomers were analyzed by GC using a chiral Ivadex 1 column 25m (80 °C, 1.0 °C/min 
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13C NMR (125 MHz, CD2Cl2) δ 138.3, 138.1, 115.5, 115.4, 105.9, 105.0, 81.9, 80.6, 52.8, 
52.7, 34.4, 31.9, 30.9, 30.7, 23.4, 22.8. 
MS (EI-DE) m/z (%) 140 (trace), 125 (10), 107 (2), 97 (2), 83 (10), 71 (18), 55 (28), 43 (100), 
41 (13), 29 (14). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [M+H]+ 159.1020, found 159.1021. 
 
(5R)-5-(3-Bromopropyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94g): Peroxyhemiketal 94g was 
prepared according to the general procedure. The reaction mixture 
was stirred for 24 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 25-40% Et2O in pentane) 
provided the title compound 94g as a colorless oil (81 mg, 360 μmol, 72%; 97:3 er). The 
enantiomeric ratio was determined after converting dioxolane 94g into the corresponding 
epoxide 93g. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 
30 m (100 °C, 1.2 °C/min until 135 °C, 18 °C/min until 220 °C, 5 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 19.07 min, minor enantiomer: τR = 20.64 min. Contains traces of (E)-
7-chloro-3,4-epoxyheptan-2-one. Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.36 (s, 1H, OH), 5.33 (s, 1H, OH), 4.38-4.32 (m, 1H, CH), 
4.25-4.18 (m, 1H, CH), 3.51-3.40 (m, 4H, CH2Br), 2.68-2.64 (m, 1H, CH2COH), 2.61-2.55 
(m, 1H, CH2COH), 2.22-2.17 (m, 1H, CH2COH), 2.16-2.10 (m, 1H, CH2COH), 2.00-1.80 (m, 
4H, CH2), 1.79-1.68 (m, 3H, CH2), 1.63-1.54 (m, 1H, CH2), 1.41 (s, 3H, CH3), 1.39 (s, 3H, 
CH3). 
13C NMR (100 MHz, THF-d8): δ 105.9 (Cq), 104.9 (Cq), 81.9 (CH), 80.7 (CH), 53.6 
(COCH2CO), 53.5 (COCH2CO), 34.4 (CH2), 34.4 (CH2, 2C), 31.9 (CH2), 31.0 (CH2), 30.9 
(CH2), 24.6 (CH3), 23.6 (CH3). 
 
(5R)-3-Methyl-5-(5-(tetrahydro-2H-pyran-2-yloxy)pentyl)-1,2-dioxolan-3-ol ((5R)-94h): 
Peroxyhemiketal 94h was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C. 
Purification of the crude product by flash column chromate-
graphy (silica gel, 30-40% Et2O in pentane) provided the title compound 94h (87 mg, 318 
μmol, 64%; 96.5:3.5 er) as a colorless oil. The enantiomeric ratio was determined after 
converting peroxyhemiketal 94h into the corresponding THP-deprotected epoxide 99. The 
enantiomers were analyzed by GC using a chiral Ivadex 1 column 25m (80 °C, 1.0 °C/min 
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13C NMR (125 MHz, CD2Cl2) δ 138.3, 138.1, 115.5, 115.4, 105.9, 105.0, 81.9, 80.6, 52.8, 
52.7, 34.4, 31.9, 30.9, 30.7, 23.4, 22.8. 
MS (EI-DE) m/z (%) 140 (trace), 125 (10), 107 (2), 97 (2), 83 (10), 71 (18), 55 (28), 43 (100), 
41 (13), 29 (14). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [M+H]+ 159.1020, found 159.1021. 
 
(5R)-5-(3-Bromopropyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94g): Peroxyhemiketal 94g was 
prepared according to the general procedure. The reaction mixture 
was stirred for 24 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 25-40% Et2O in pentane) 
provided the title compound 94g as a colorless oil (81 mg, 360 μmol, 72%; 97:3 er). The 
enantiomeric ratio was determined after converting dioxolane 94g into the corresponding 
epoxide 93g. The enantiomers were analyzed by GC using a chiral BGB-176/BGB-15 column 
30 m (100 °C, 1.2 °C/min until 135 °C, 18 °C/min until 220 °C, 5 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 19.07 min, minor enantiomer: τR = 20.64 min. Contains traces of (E)-
7-chloro-3,4-epoxyheptan-2-one. Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.36 (s, 1H, OH), 5.33 (s, 1H, OH), 4.38-4.32 (m, 1H, CH), 
4.25-4.18 (m, 1H, CH), 3.51-3.40 (m, 4H, CH2Br), 2.68-2.64 (m, 1H, CH2COH), 2.61-2.55 
(m, 1H, CH2COH), 2.22-2.17 (m, 1H, CH2COH), 2.16-2.10 (m, 1H, CH2COH), 2.00-1.80 (m, 
4H, CH2), 1.79-1.68 (m, 3H, CH2), 1.63-1.54 (m, 1H, CH2), 1.41 (s, 3H, CH3), 1.39 (s, 3H, 
CH3). 
13C NMR (100 MHz, THF-d8): δ 105.9 (Cq), 104.9 (Cq), 81.9 (CH), 80.7 (CH), 53.6 
(COCH2CO), 53.5 (COCH2CO), 34.4 (CH2), 34.4 (CH2, 2C), 31.9 (CH2), 31.0 (CH2), 30.9 
(CH2), 24.6 (CH3), 23.6 (CH3). 
 
(5R)-3-Methyl-5-(5-(tetrahydro-2H-pyran-2-yloxy)pentyl)-1,2-dioxolan-3-ol ((5R)-94h): 
Peroxyhemiketal 94h was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C. 
Purification of the crude product by flash column chromate-
graphy (silica gel, 30-40% Et2O in pentane) provided the title compound 94h (87 mg, 318 
μmol, 64%; 96.5:3.5 er) as a colorless oil. The enantiomeric ratio was determined after 
converting peroxyhemiketal 94h into the corresponding THP-deprotected epoxide 99. The 
enantiomers were analyzed by GC using a chiral Ivadex 1 column 25m (80 °C, 1.0 °C/min 
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until 155 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.6 bar H2); major enantiomer: τR = 
60.79 min, minor enantiomer: τR = 61.52 min. Characterized as mixture of diastereomers. 
1H NMR (400 MHz, THF-d8) δ 5.30 (s, 2H, OH), 5.26 (s, 2H, OH), 4.53 (t, J = 3.2 Hz, 4H, 
CHTHP), 4.34-4.28 (m, 2H, CH), 4.21-4.14 (m, 2H, CH), 3.80-3.74 (m, 4H, OCHHTHP), 3.67 
(dt, J = 9.5, 6.6 Hz, 4H, THPOCHH), 3.44-3.38 (m, 4H, OCHHTHP), 3.30 (dt, J = 9.5, 6.4 Hz, 
4H, THPOCHH), 2.65-2.53 (m, 4H, CH2CqOH), 2.18-2.07 (m, 4H, CH2CqOH), 1.84-1.76 (m, 
4H, CH2), 1.65-1.42 (m, 40H, CH2), 1.40 (s, 12H, CH3), 1.38 (s, 12H, CH3). 
13C NMR (100 MHz, THF-d8) δ 105.8 (2C, CqOH), 104.9 (2C, CqOH), 99.3 (4C, OCHO), 82.7 
(2C, CH2CHCH2), 81.3 (2C, CH2CHCH2), 68.0 (4C, THPOCH2), 62.3 (4C, OCH2, THP), 54.0 
(2C, CH2CqOH), 53.6 (2C, CH2CqOH), 35.8 (2C, CH2), 33.3 (2C, CH2), 31.9 (4C, CH2), 31.0 
(2C, CH2), 30.9 (2C, CH2), 27.6 (2C, CH2), 27.5 (2C, CH2), 27.5 (2C, CH2), 27.3 (2C, CH2), 
26.9 (4C, CH2), 24.4 (2C, CH3), 23.8 (2C, CH3), 20.5 (4C, CH2). 
MS (EI-DE) m/z (%) 274 [M+] (trace), 185 (2), 173 (1), 155 (1), 139 (1), 115 (1), 99 (6), 85 
(100), 81 (9), 69 (9), 55 (13), 43 (38). 
HRMS (ESI+) calcd for C14H26O5Na [(M+Na)+] 297.1670, found 297.1672. 
 
(5R)-5-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94i): Per-
oxyhemiketal 94i was prepared according to the general procedure. 
The reaction mixture was stirred for 36 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 15-20% 
Et2O in pentane) provided the title compound as a colorless oil (89 mg, 340 μmol, 68%; 98:2 
er). The enantiomeric ratio was determined after converting peroxyhemiketal 94i into the 
corresponding epoxide 93i. The enantiomers were analyzed by GC using a chiral BGB-
176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 150 °C, 18 °C/min until 220 °C, 5 min at 
320 °C, 0.5 bar H2); major enantiomer: τR = 34.84 min, minor enantiomer: τR = 35.96 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.34 (s, 1H, OH), 5.28 (s, 1H, OH), 4.52-4.46 (m, 1H, CH), 
4.35-4.28 (m, 1H, CH), 3.85-3.64 (m, 4H, TBSOCH2), 2.69-2.55 (m, 2H, CH2CqOH), 2.25-
2.15 (m, 2H, CH2CqOH), 1.92-1.75 (m, 3H, TBSOCH2CH2), 1.64-1.55 (m, 1H, 
TBSOCH2CH2), 1.41 (s, 3H, CqOHCH3), 1.39 (s, 3H, CqOHCH3), 0.90 (s, 18H, Cq(CH3)3), 
0.04 (s, 12H, Si(CH3)2). 
13C NMR (100 MHz, THF-d8) δ 105.8 (CqOH), 104.9 (CqOH), 79.9 (CH), 78.3 (CH), 61.3 
(TBSOCH2), 61.0 (TBSOCH2), 53.8 (CH2CqOH), 53.6 (CH2CqOH), 38.9 (TBSOCH2CH2), 
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until 155 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.6 bar H2); major enantiomer: τR = 
60.79 min, minor enantiomer: τR = 61.52 min. Characterized as mixture of diastereomers. 
1H NMR (400 MHz, THF-d8) δ 5.30 (s, 2H, OH), 5.26 (s, 2H, OH), 4.53 (t, J = 3.2 Hz, 4H, 
CHTHP), 4.34-4.28 (m, 2H, CH), 4.21-4.14 (m, 2H, CH), 3.80-3.74 (m, 4H, OCHHTHP), 3.67 
(dt, J = 9.5, 6.6 Hz, 4H, THPOCHH), 3.44-3.38 (m, 4H, OCHHTHP), 3.30 (dt, J = 9.5, 6.4 Hz, 
4H, THPOCHH), 2.65-2.53 (m, 4H, CH2CqOH), 2.18-2.07 (m, 4H, CH2CqOH), 1.84-1.76 (m, 
4H, CH2), 1.65-1.42 (m, 40H, CH2), 1.40 (s, 12H, CH3), 1.38 (s, 12H, CH3). 
13C NMR (100 MHz, THF-d8) δ 105.8 (2C, CqOH), 104.9 (2C, CqOH), 99.3 (4C, OCHO), 82.7 
(2C, CH2CHCH2), 81.3 (2C, CH2CHCH2), 68.0 (4C, THPOCH2), 62.3 (4C, OCH2, THP), 54.0 
(2C, CH2CqOH), 53.6 (2C, CH2CqOH), 35.8 (2C, CH2), 33.3 (2C, CH2), 31.9 (4C, CH2), 31.0 
(2C, CH2), 30.9 (2C, CH2), 27.6 (2C, CH2), 27.5 (2C, CH2), 27.5 (2C, CH2), 27.3 (2C, CH2), 
26.9 (4C, CH2), 24.4 (2C, CH3), 23.8 (2C, CH3), 20.5 (4C, CH2). 
MS (EI-DE) m/z (%) 274 [M+] (trace), 185 (2), 173 (1), 155 (1), 139 (1), 115 (1), 99 (6), 85 
(100), 81 (9), 69 (9), 55 (13), 43 (38). 
HRMS (ESI+) calcd for C14H26O5Na [(M+Na)+] 297.1670, found 297.1672. 
 
(5R)-5-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94i): Per-
oxyhemiketal 94i was prepared according to the general procedure. 
The reaction mixture was stirred for 36 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 15-20% 
Et2O in pentane) provided the title compound as a colorless oil (89 mg, 340 μmol, 68%; 98:2 
er). The enantiomeric ratio was determined after converting peroxyhemiketal 94i into the 
corresponding epoxide 93i. The enantiomers were analyzed by GC using a chiral BGB-
176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 150 °C, 18 °C/min until 220 °C, 5 min at 
320 °C, 0.5 bar H2); major enantiomer: τR = 34.84 min, minor enantiomer: τR = 35.96 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.34 (s, 1H, OH), 5.28 (s, 1H, OH), 4.52-4.46 (m, 1H, CH), 
4.35-4.28 (m, 1H, CH), 3.85-3.64 (m, 4H, TBSOCH2), 2.69-2.55 (m, 2H, CH2CqOH), 2.25-
2.15 (m, 2H, CH2CqOH), 1.92-1.75 (m, 3H, TBSOCH2CH2), 1.64-1.55 (m, 1H, 
TBSOCH2CH2), 1.41 (s, 3H, CqOHCH3), 1.39 (s, 3H, CqOHCH3), 0.90 (s, 18H, Cq(CH3)3), 
0.04 (s, 12H, Si(CH3)2). 
13C NMR (100 MHz, THF-d8) δ 105.8 (CqOH), 104.9 (CqOH), 79.9 (CH), 78.3 (CH), 61.3 
(TBSOCH2), 61.0 (TBSOCH2), 53.8 (CH2CqOH), 53.6 (CH2CqOH), 38.9 (TBSOCH2CH2), 
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until 155 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.6 bar H2); major enantiomer: τR = 
60.79 min, minor enantiomer: τR = 61.52 min. Characterized as mixture of diastereomers. 
1H NMR (400 MHz, THF-d8) δ 5.30 (s, 2H, OH), 5.26 (s, 2H, OH), 4.53 (t, J = 3.2 Hz, 4H, 
CHTHP), 4.34-4.28 (m, 2H, CH), 4.21-4.14 (m, 2H, CH), 3.80-3.74 (m, 4H, OCHHTHP), 3.67 
(dt, J = 9.5, 6.6 Hz, 4H, THPOCHH), 3.44-3.38 (m, 4H, OCHHTHP), 3.30 (dt, J = 9.5, 6.4 Hz, 
4H, THPOCHH), 2.65-2.53 (m, 4H, CH2CqOH), 2.18-2.07 (m, 4H, CH2CqOH), 1.84-1.76 (m, 
4H, CH2), 1.65-1.42 (m, 40H, CH2), 1.40 (s, 12H, CH3), 1.38 (s, 12H, CH3). 
13C NMR (100 MHz, THF-d8) δ 105.8 (2C, CqOH), 104.9 (2C, CqOH), 99.3 (4C, OCHO), 82.7 
(2C, CH2CHCH2), 81.3 (2C, CH2CHCH2), 68.0 (4C, THPOCH2), 62.3 (4C, OCH2, THP), 54.0 
(2C, CH2CqOH), 53.6 (2C, CH2CqOH), 35.8 (2C, CH2), 33.3 (2C, CH2), 31.9 (4C, CH2), 31.0 
(2C, CH2), 30.9 (2C, CH2), 27.6 (2C, CH2), 27.5 (2C, CH2), 27.5 (2C, CH2), 27.3 (2C, CH2), 
26.9 (4C, CH2), 24.4 (2C, CH3), 23.8 (2C, CH3), 20.5 (4C, CH2). 
MS (EI-DE) m/z (%) 274 [M+] (trace), 185 (2), 173 (1), 155 (1), 139 (1), 115 (1), 99 (6), 85 
(100), 81 (9), 69 (9), 55 (13), 43 (38). 
HRMS (ESI+) calcd for C14H26O5Na [(M+Na)+] 297.1670, found 297.1672. 
 
(5R)-5-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94i): Per-
oxyhemiketal 94i was prepared according to the general procedure. 
The reaction mixture was stirred for 36 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 15-20% 
Et2O in pentane) provided the title compound as a colorless oil (89 mg, 340 μmol, 68%; 98:2 
er). The enantiomeric ratio was determined after converting peroxyhemiketal 94i into the 
corresponding epoxide 93i. The enantiomers were analyzed by GC using a chiral BGB-
176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 150 °C, 18 °C/min until 220 °C, 5 min at 
320 °C, 0.5 bar H2); major enantiomer: τR = 34.84 min, minor enantiomer: τR = 35.96 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.34 (s, 1H, OH), 5.28 (s, 1H, OH), 4.52-4.46 (m, 1H, CH), 
4.35-4.28 (m, 1H, CH), 3.85-3.64 (m, 4H, TBSOCH2), 2.69-2.55 (m, 2H, CH2CqOH), 2.25-
2.15 (m, 2H, CH2CqOH), 1.92-1.75 (m, 3H, TBSOCH2CH2), 1.64-1.55 (m, 1H, 
TBSOCH2CH2), 1.41 (s, 3H, CqOHCH3), 1.39 (s, 3H, CqOHCH3), 0.90 (s, 18H, Cq(CH3)3), 
0.04 (s, 12H, Si(CH3)2). 
13C NMR (100 MHz, THF-d8) δ 105.8 (CqOH), 104.9 (CqOH), 79.9 (CH), 78.3 (CH), 61.3 
(TBSOCH2), 61.0 (TBSOCH2), 53.8 (CH2CqOH), 53.6 (CH2CqOH), 38.9 (TBSOCH2CH2), 
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until 155 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.6 bar H2); major enantiomer: τR = 
60.79 min, minor enantiomer: τR = 61.52 min. Characterized as mixture of diastereomers. 
1H NMR (400 MHz, THF-d8) δ 5.30 (s, 2H, OH), 5.26 (s, 2H, OH), 4.53 (t, J = 3.2 Hz, 4H, 
CHTHP), 4.34-4.28 (m, 2H, CH), 4.21-4.14 (m, 2H, CH), 3.80-3.74 (m, 4H, OCHHTHP), 3.67 
(dt, J = 9.5, 6.6 Hz, 4H, THPOCHH), 3.44-3.38 (m, 4H, OCHHTHP), 3.30 (dt, J = 9.5, 6.4 Hz, 
4H, THPOCHH), 2.65-2.53 (m, 4H, CH2CqOH), 2.18-2.07 (m, 4H, CH2CqOH), 1.84-1.76 (m, 
4H, CH2), 1.65-1.42 (m, 40H, CH2), 1.40 (s, 12H, CH3), 1.38 (s, 12H, CH3). 
13C NMR (100 MHz, THF-d8) δ 105.8 (2C, CqOH), 104.9 (2C, CqOH), 99.3 (4C, OCHO), 82.7 
(2C, CH2CHCH2), 81.3 (2C, CH2CHCH2), 68.0 (4C, THPOCH2), 62.3 (4C, OCH2, THP), 54.0 
(2C, CH2CqOH), 53.6 (2C, CH2CqOH), 35.8 (2C, CH2), 33.3 (2C, CH2), 31.9 (4C, CH2), 31.0 
(2C, CH2), 30.9 (2C, CH2), 27.6 (2C, CH2), 27.5 (2C, CH2), 27.5 (2C, CH2), 27.3 (2C, CH2), 
26.9 (4C, CH2), 24.4 (2C, CH3), 23.8 (2C, CH3), 20.5 (4C, CH2). 
MS (EI-DE) m/z (%) 274 [M+] (trace), 185 (2), 173 (1), 155 (1), 139 (1), 115 (1), 99 (6), 85 
(100), 81 (9), 69 (9), 55 (13), 43 (38). 
HRMS (ESI+) calcd for C14H26O5Na [(M+Na)+] 297.1670, found 297.1672. 
 
(5R)-5-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94i): Per-
oxyhemiketal 94i was prepared according to the general procedure. 
The reaction mixture was stirred for 36 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 15-20% 
Et2O in pentane) provided the title compound as a colorless oil (89 mg, 340 μmol, 68%; 98:2 
er). The enantiomeric ratio was determined after converting peroxyhemiketal 94i into the 
corresponding epoxide 93i. The enantiomers were analyzed by GC using a chiral BGB-
176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 150 °C, 18 °C/min until 220 °C, 5 min at 
320 °C, 0.5 bar H2); major enantiomer: τR = 34.84 min, minor enantiomer: τR = 35.96 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.34 (s, 1H, OH), 5.28 (s, 1H, OH), 4.52-4.46 (m, 1H, CH), 
4.35-4.28 (m, 1H, CH), 3.85-3.64 (m, 4H, TBSOCH2), 2.69-2.55 (m, 2H, CH2CqOH), 2.25-
2.15 (m, 2H, CH2CqOH), 1.92-1.75 (m, 3H, TBSOCH2CH2), 1.64-1.55 (m, 1H, 
TBSOCH2CH2), 1.41 (s, 3H, CqOHCH3), 1.39 (s, 3H, CqOHCH3), 0.90 (s, 18H, Cq(CH3)3), 
0.04 (s, 12H, Si(CH3)2). 
13C NMR (100 MHz, THF-d8) δ 105.8 (CqOH), 104.9 (CqOH), 79.9 (CH), 78.3 (CH), 61.3 
(TBSOCH2), 61.0 (TBSOCH2), 53.8 (CH2CqOH), 53.6 (CH2CqOH), 38.9 (TBSOCH2CH2), 
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36.7 (TBSOCH2CH2), 26.6 (6C, Cq(CH3)3), 24.3 (CqOHCH3), 23.7 (CqOHCH3), 19.2 (2C, 
CqMe3), 5.02 (2C, Si(CH3)2), 5.05 (2C, Si(CH3)2). 
MS (EI-DE) m/z (%) 205 (1), 187 (1), 173 (1), 157 (2), 145 (8), 131 (32), 115 (22), 101 (26), 
89 (9), 75 (100), 59 (12), 43 (24), 29 (4). 
HRMS (ESI+) calcd for C12H26O4SiNa [(M+Na)+] 285.1491, found 285.1493. 
 
(5R)-5-(3-Ethoxy-3-oxopropyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94j): Peroxyhemiketal 
94j was prepared according to the general procedure. The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the crude 
product by flash column chromatography (silica gel, 25-50% Et2O in 
pentane) provided the title compound 94j (71 mg, 348 μmol, 70%; 96.5:3.5 er) as a colorless 
oil. The enantiomeric ratio was determined after converting peroxyhemiketal 94j into the 
corresponding epoxide 93j. The enantiomers were analyzed by GC using a chiral BGB-
176/SE-52 column 30 m (80 °C, 1.2 °C/min until 130 °C, 18 °C/min until 220 °C, 5 min at 
320 °C, 0.5 bar H2); major enantiomer: τR = 36.32 min, minor enantiomer: τR = 37.59 min. 
Characterized as mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, CD2Cl2) δ 4.47-4.41 (m, 1H, CH), 4.38-4.31 (m, 1H, CH), 4.11 (q 
overlapped, J = 7.2 Hz, 2H, CH2CH3), 4.10 (q overlapped, J = 7.1 Hz, 2H, CH2CH3), 2.83-
2.78 (m, 1H, CH2CqOH), 2.71-2.51 (m, 3H, CH2COH and OH), 2.45-2.22 (m, 6H, CH2), 2.05-
1.90 (m, 3H, CH2), 1.81-1.73 (m, 1H, CH2), 1.53 (s, 3H, CH3), 1.51 (s, 3H, CH3), 1.24 (t 
overlapped, J = 7.2 Hz, 3H, CH2CH3), 1.23 (t overlapped, J = 7.3 Hz, 3H, CH2CH3). 
13C NMR (100 MHz, CD2Cl2) δ 172.9 (C=O), 172.8 (C=O), 105.5 (CqOH), 104.5 (CqOH), 
80.8 (CH), 79.8 (CH), 60.7 (CH2CH3), 60.5 (CH2CH3), 52.3 (CH2, cycl.), 51.9 (CH2, cycl.), 30.7 
(CH2), 30.6 (CH2), 29.9 (CH2), 27.2 (CH2), 22.9 (CH3), 22.3 (CH3), 14.1 (CH2CH3), 14.0 
(CH2CH3). 
MS (EI) m/z (%) 172 (3), 141 (2), 126 (11), 115 (5), 98 (28), 85 (13), 73 (12), 55 (13), 43 
(100), 29 (37). 
HRMS (ESI+) calcd for C9H16O5Na [(M+Na)+] 227.0890, found 227.0890. 
 
(5R)-5-(3-Oxobutyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94k): Peroxyhemiketal 94k was 
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36.7 (TBSOCH2CH2), 26.6 (6C, Cq(CH3)3), 24.3 (CqOHCH3), 23.7 (CqOHCH3), 19.2 (2C, 
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Characterized as mixture of hemiketal epimers (1:1 dr). 
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pentane) provided the title compound 94k (26 mg, 151 μmol, 30%; 96:4 er) as a colorless oil. 
The enantiomeric ratio was determined after converting peroxyhemiketal 94k into the 
corresponding epoxide 93k The enantiomers were analyzed by GC using a chiral BGB-
176/SE-52 column 30 m (80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 
220 °C, 0.5 bar H2); major enantiomer: τR = 28.87 min, minor enantiomer: τR = 30.28 min. 
Characterized as a mixture of three hemiketal isomers (~1:1:0.8). 
1H NMR (500 MHz, THF-d8) 3-hydroxy-1,2-dioxolane (mixture of 
hemiketal epimers (dr~1:1)): δ 5.33 (br s, 1H, OH), 5.30 (br s, 1H, 
OH), 4.37-4.28 (m, 1H, CH), 4.21-1.25 (m, 1H, CH), 2.64 (dd, J = 
12.0, 7.0 Hz, 1H, CH2, cycl.), 2.58-2.46 (m, 3H, CH2, cycl.), 2.20-2.05 (m, 
10H, CH3C(=O) and CH2(C=O)), 1.88-1.62 (m, 4H, CH2CH2CH), 1.40 
(s, 3H, CH3CqOH), 1.38 (s, 3H, CH3CqOH); 3-hydroxy-1,2-dioxane: 
5.34 (br s, 1H, OH), 4.37-4.28 (m, 1H, CH), 2.58-2.46 (m, 4H, CH2CqOH and CH2C(=O)), 
2.20-2.05 (m, 3H, CH3C(=O)), 1.88-1.62 (m, 2H, CHCH2, cycl.), 1.39 (s, 3H, CH3CqOH). 
13C NMR (125 MHz, THF-d8) 3-hydroxy-1,2-dioxolane (mixture of hemiketal epimers 
(dr~1:1)): δ 206.8 (C=O), 206.5 (C=O), 105.9 (CqOH), 105.0 (CqOH), 81.8 (CH), 80.6 (CH), 
53.5 (CH2, cycl.), 53.4 (CH2, cycl.), 40.3 (CH2C(=O)), 40.2 (CH2C(=O)), 29.8 (CH3C(=O)), 29.8 
(CH3C(=O)), 29.7 (CH2CH), 27.1 (CH2CH), 24.3 (CH3CqOH), 23.6 (CH3CqOH); 3-hydroxy-
1,2-dioxane: δ 204.4 (C=O), 99.2 (CqOH), 77.5 (CH), 47.6 (CH2C(=O)), 34.2 (CH2CqOH), 31.0 
(CH3C(=O)), 26.9 (CHCH2, cycl.), 26.7 (CH3CqOH). 
 
(5R)-5-(5-Hydroxypentyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94l): Peroxyhemiketal 94l was 
prepared according to the general procedure. Catalyst 
[13 • 2 TFA] (10 mol%) was used together with 50 wt% aqueous 
hydrogen peroxide (1.5 equiv) as oxidant. The reaction mixture 
was stirred for 36 h at 50 °C. Purification of the crude reaction mixture by flash column 
chromatography (silica gel, 10-40% Et2O in CH2Cl2) provided the title compound 94l (12 mg, 
63.1 μmol, 25%) as a colorless oil along with a mixture of the corresponding epoxide 93l (11 
mg, 64.0 μmol, 26%; 98:2 er) and unreacted starting material 92l (10 mg, 65.0 μmol, 
26%). Characterized as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.31 (s, 1H, CqOH), 5.27 (s, 1H, CqOH), 4.34-4.28 (m, 1H, 
CH), 4.17 (quint, J = 7.3 Hz, 1H, CH), 3.46 (t, J = 5.5 Hz, 4H, CH2OH), 3.35 (br s, 2H, 
CH2OH), 2.64-2.55 (m, 2H, CH2, cycl.), 2.20-2.07 (m, 2H, CH2, cycl.), 1.67-1.31 (m, 16H, -
(CH2)4-), 1.40 (s overlapped, 3H, CH3), 1.38 (s overlapped, 3H, CH3). 
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pentane) provided the title compound 94k (26 mg, 151 μmol, 30%; 96:4 er) as a colorless oil. 
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2.20-2.05 (m, 3H, CH3C(=O)), 1.88-1.62 (m, 2H, CHCH2, cycl.), 1.39 (s, 3H, CH3CqOH). 
13C NMR (125 MHz, THF-d8) 3-hydroxy-1,2-dioxolane (mixture of hemiketal epimers 
(dr~1:1)): δ 206.8 (C=O), 206.5 (C=O), 105.9 (CqOH), 105.0 (CqOH), 81.8 (CH), 80.6 (CH), 
53.5 (CH2, cycl.), 53.4 (CH2, cycl.), 40.3 (CH2C(=O)), 40.2 (CH2C(=O)), 29.8 (CH3C(=O)), 29.8 
(CH3C(=O)), 29.7 (CH2CH), 27.1 (CH2CH), 24.3 (CH3CqOH), 23.6 (CH3CqOH); 3-hydroxy-
1,2-dioxane: δ 204.4 (C=O), 99.2 (CqOH), 77.5 (CH), 47.6 (CH2C(=O)), 34.2 (CH2CqOH), 31.0 
(CH3C(=O)), 26.9 (CHCH2, cycl.), 26.7 (CH3CqOH). 
 
(5R)-5-(5-Hydroxypentyl)-3-methyl-1,2-dioxolan-3-ol ((5R)-94l): Peroxyhemiketal 94l was 
prepared according to the general procedure. Catalyst 
[13 • 2 TFA] (10 mol%) was used together with 50 wt% aqueous 
hydrogen peroxide (1.5 equiv) as oxidant. The reaction mixture 
was stirred for 36 h at 50 °C. Purification of the crude reaction mixture by flash column 
chromatography (silica gel, 10-40% Et2O in CH2Cl2) provided the title compound 94l (12 mg, 
63.1 μmol, 25%) as a colorless oil along with a mixture of the corresponding epoxide 93l (11 
mg, 64.0 μmol, 26%; 98:2 er) and unreacted starting material 92l (10 mg, 65.0 μmol, 
26%). Characterized as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 5.31 (s, 1H, CqOH), 5.27 (s, 1H, CqOH), 4.34-4.28 (m, 1H, 
CH), 4.17 (quint, J = 7.3 Hz, 1H, CH), 3.46 (t, J = 5.5 Hz, 4H, CH2OH), 3.35 (br s, 2H, 
CH2OH), 2.64-2.55 (m, 2H, CH2, cycl.), 2.20-2.07 (m, 2H, CH2, cycl.), 1.67-1.31 (m, 16H, -
(CH2)4-), 1.40 (s overlapped, 3H, CH3), 1.38 (s overlapped, 3H, CH3). 
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13C NMR (100 MHz, THF-d8) 105.8 (CqOH), 104.9 (CqOH), 82.7 (CH), 81.4 (CH), 62.7 
(CH2OH), 62.7 (CH2OH), 54.0 (CH2, cycl.), 53.6 (CH2, cycl.), 35.9 (CH2), 34.3 (CH2), 34.2 
(CH2), 33.4 (CH2), 27.6 (CH2), 27.3 (CH2), 27.3 (CH2), 27.1 (CH2), 24.4 (CH3), 23.8 (CH3). 
MS (EI-DE) m/z (%) 157 (5), 139 (5), 125 (1), 121 (3), 111 (2), 103 (1), 97 (13), 81 (15), 79 
(4), 71 (21), 55 (18), 43 (100), 41 (26), 31 (13). 
HRMS (ESI+) calcd for C9H18AgO4 [(M+Ag)+] 297.0249, found 297.0249. 
 
(5R)-3,5-Dipentyl-1,2-dioxolan-3-ol ((5R)-94m): Peroxyhemiketal 94m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94m as a colorless oil (46 mg, 201 μmol, 40%; 97:3 er). 
The enantiomeric ratio was determined after converting dioxolane 94m into the 
corresponding epoxide 93m. The enantiomers were analyzed by GC using a chiral G-TA 
column 30 m (80 °C, 1 °C/min until 130 °C, 18 °C/min until 180 °C, 10 min at 320 °C, 0.9 
bar H2); major enantiomer: τR = 43.80 min, minor enantiomer: τR = 43.02 min. Characterized 
as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.20 (s, 1H, OH), 5.16 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.15-4.09 (m, 1H, CH), 2.61-2.52 (m, 2H, CH2CqOH), 2.10-2.04 (m, 2H, CH2CqOH), 1.68-
1.26 (m, 32H, CH2), 0.92-0.88 (m, 12H, CH3). 
13C NMR (125 MHz, THF-d8) δ 107.7 (CqOH), 106.9 (CqOH), 82.6 (CH), 81.0 (CH), 52.4 
(CH2, cycl.), 52.1 (CH2, cycl.), 38.3 (CH2), 37.9 (CH2), 35.8 (CH2), 33.4 (CH2), 33.4 (CH2), 33.3 
(CH2), 33.1 (CH2), 33.0 (CH2), 27.4 (CH2), 27.2 (CH2), 25.9 (CH2), 25.7 (CH2), 23.8 (3C, 
CH2), 23.7 (CH2), 14.7 (2C, CH3), 14.7 (CH3), 14.6 (CH3). 
MS (EI) m/z (%) 230 [M+] (1), 197 (100), 159 (1), 141 (3), 127 (30), 117 (5), 99 (50), 81 (6), 
71 (30), 55 (30), 43 (90), 29 (24). 
HRMS (EI-DE) calcd for C13H26O3 [M+] 230.1880, found 230.1882. 
 
(5R)-3-Isopropyl-5-methyl-1,2-dioxolan-3-ol ((5R)-94o): Peroxyhemiketal 94o was 
obtained by the general procedure. Catalyst salt [13 • 2 TCA] (20 mol%) 
were used and the reaction mixture was stirred for 48 h at 32 °C. 
Purification of the crude product by flash column chromatography (silica gel, 
30-40% Et2O in pentane) provided the title compound 94o (57 mg, 391 μmol, 39%; 96:4 er) 
as a colorless oil. The enantiomeric ratio was determined after converting peroxyhemiketal 
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13C NMR (100 MHz, THF-d8) 105.8 (CqOH), 104.9 (CqOH), 82.7 (CH), 81.4 (CH), 62.7 
(CH2OH), 62.7 (CH2OH), 54.0 (CH2, cycl.), 53.6 (CH2, cycl.), 35.9 (CH2), 34.3 (CH2), 34.2 
(CH2), 33.4 (CH2), 27.6 (CH2), 27.3 (CH2), 27.3 (CH2), 27.1 (CH2), 24.4 (CH3), 23.8 (CH3). 
MS (EI-DE) m/z (%) 157 (5), 139 (5), 125 (1), 121 (3), 111 (2), 103 (1), 97 (13), 81 (15), 79 
(4), 71 (21), 55 (18), 43 (100), 41 (26), 31 (13). 
HRMS (ESI+) calcd for C9H18AgO4 [(M+Ag)+] 297.0249, found 297.0249. 
 
(5R)-3,5-Dipentyl-1,2-dioxolan-3-ol ((5R)-94m): Peroxyhemiketal 94m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94m as a colorless oil (46 mg, 201 μmol, 40%; 97:3 er). 
The enantiomeric ratio was determined after converting dioxolane 94m into the 
corresponding epoxide 93m. The enantiomers were analyzed by GC using a chiral G-TA 
column 30 m (80 °C, 1 °C/min until 130 °C, 18 °C/min until 180 °C, 10 min at 320 °C, 0.9 
bar H2); major enantiomer: τR = 43.80 min, minor enantiomer: τR = 43.02 min. Characterized 
as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.20 (s, 1H, OH), 5.16 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.15-4.09 (m, 1H, CH), 2.61-2.52 (m, 2H, CH2CqOH), 2.10-2.04 (m, 2H, CH2CqOH), 1.68-
1.26 (m, 32H, CH2), 0.92-0.88 (m, 12H, CH3). 
13C NMR (125 MHz, THF-d8) δ 107.7 (CqOH), 106.9 (CqOH), 82.6 (CH), 81.0 (CH), 52.4 
(CH2, cycl.), 52.1 (CH2, cycl.), 38.3 (CH2), 37.9 (CH2), 35.8 (CH2), 33.4 (CH2), 33.4 (CH2), 33.3 
(CH2), 33.1 (CH2), 33.0 (CH2), 27.4 (CH2), 27.2 (CH2), 25.9 (CH2), 25.7 (CH2), 23.8 (3C, 
CH2), 23.7 (CH2), 14.7 (2C, CH3), 14.7 (CH3), 14.6 (CH3). 
MS (EI) m/z (%) 230 [M+] (1), 197 (100), 159 (1), 141 (3), 127 (30), 117 (5), 99 (50), 81 (6), 
71 (30), 55 (30), 43 (90), 29 (24). 
HRMS (EI-DE) calcd for C13H26O3 [M+] 230.1880, found 230.1882. 
 
(5R)-3-Isopropyl-5-methyl-1,2-dioxolan-3-ol ((5R)-94o): Peroxyhemiketal 94o was 
obtained by the general procedure. Catalyst salt [13 • 2 TCA] (20 mol%) 
were used and the reaction mixture was stirred for 48 h at 32 °C. 
Purification of the crude product by flash column chromatography (silica gel, 
30-40% Et2O in pentane) provided the title compound 94o (57 mg, 391 μmol, 39%; 96:4 er) 
as a colorless oil. The enantiomeric ratio was determined after converting peroxyhemiketal 
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13C NMR (100 MHz, THF-d8) 105.8 (CqOH), 104.9 (CqOH), 82.7 (CH), 81.4 (CH), 62.7 
(CH2OH), 62.7 (CH2OH), 54.0 (CH2, cycl.), 53.6 (CH2, cycl.), 35.9 (CH2), 34.3 (CH2), 34.2 
(CH2), 33.4 (CH2), 27.6 (CH2), 27.3 (CH2), 27.3 (CH2), 27.1 (CH2), 24.4 (CH3), 23.8 (CH3). 
MS (EI-DE) m/z (%) 157 (5), 139 (5), 125 (1), 121 (3), 111 (2), 103 (1), 97 (13), 81 (15), 79 
(4), 71 (21), 55 (18), 43 (100), 41 (26), 31 (13). 
HRMS (ESI+) calcd for C9H18AgO4 [(M+Ag)+] 297.0249, found 297.0249. 
 
(5R)-3,5-Dipentyl-1,2-dioxolan-3-ol ((5R)-94m): Peroxyhemiketal 94m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94m as a colorless oil (46 mg, 201 μmol, 40%; 97:3 er). 
The enantiomeric ratio was determined after converting dioxolane 94m into the 
corresponding epoxide 93m. The enantiomers were analyzed by GC using a chiral G-TA 
column 30 m (80 °C, 1 °C/min until 130 °C, 18 °C/min until 180 °C, 10 min at 320 °C, 0.9 
bar H2); major enantiomer: τR = 43.80 min, minor enantiomer: τR = 43.02 min. Characterized 
as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.20 (s, 1H, OH), 5.16 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.15-4.09 (m, 1H, CH), 2.61-2.52 (m, 2H, CH2CqOH), 2.10-2.04 (m, 2H, CH2CqOH), 1.68-
1.26 (m, 32H, CH2), 0.92-0.88 (m, 12H, CH3). 
13C NMR (125 MHz, THF-d8) δ 107.7 (CqOH), 106.9 (CqOH), 82.6 (CH), 81.0 (CH), 52.4 
(CH2, cycl.), 52.1 (CH2, cycl.), 38.3 (CH2), 37.9 (CH2), 35.8 (CH2), 33.4 (CH2), 33.4 (CH2), 33.3 
(CH2), 33.1 (CH2), 33.0 (CH2), 27.4 (CH2), 27.2 (CH2), 25.9 (CH2), 25.7 (CH2), 23.8 (3C, 
CH2), 23.7 (CH2), 14.7 (2C, CH3), 14.7 (CH3), 14.6 (CH3). 
MS (EI) m/z (%) 230 [M+] (1), 197 (100), 159 (1), 141 (3), 127 (30), 117 (5), 99 (50), 81 (6), 
71 (30), 55 (30), 43 (90), 29 (24). 
HRMS (EI-DE) calcd for C13H26O3 [M+] 230.1880, found 230.1882. 
 
(5R)-3-Isopropyl-5-methyl-1,2-dioxolan-3-ol ((5R)-94o): Peroxyhemiketal 94o was 
obtained by the general procedure. Catalyst salt [13 • 2 TCA] (20 mol%) 
were used and the reaction mixture was stirred for 48 h at 32 °C. 
Purification of the crude product by flash column chromatography (silica gel, 
30-40% Et2O in pentane) provided the title compound 94o (57 mg, 391 μmol, 39%; 96:4 er) 
as a colorless oil. The enantiomeric ratio was determined after converting peroxyhemiketal 
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13C NMR (100 MHz, THF-d8) 105.8 (CqOH), 104.9 (CqOH), 82.7 (CH), 81.4 (CH), 62.7 
(CH2OH), 62.7 (CH2OH), 54.0 (CH2, cycl.), 53.6 (CH2, cycl.), 35.9 (CH2), 34.3 (CH2), 34.2 
(CH2), 33.4 (CH2), 27.6 (CH2), 27.3 (CH2), 27.3 (CH2), 27.1 (CH2), 24.4 (CH3), 23.8 (CH3). 
MS (EI-DE) m/z (%) 157 (5), 139 (5), 125 (1), 121 (3), 111 (2), 103 (1), 97 (13), 81 (15), 79 
(4), 71 (21), 55 (18), 43 (100), 41 (26), 31 (13). 
HRMS (ESI+) calcd for C9H18AgO4 [(M+Ag)+] 297.0249, found 297.0249. 
 
(5R)-3,5-Dipentyl-1,2-dioxolan-3-ol ((5R)-94m): Peroxyhemiketal 94m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 48 h at 32 °C. Purification of the crude product by 
flash column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94m as a colorless oil (46 mg, 201 μmol, 40%; 97:3 er). 
The enantiomeric ratio was determined after converting dioxolane 94m into the 
corresponding epoxide 93m. The enantiomers were analyzed by GC using a chiral G-TA 
column 30 m (80 °C, 1 °C/min until 130 °C, 18 °C/min until 180 °C, 10 min at 320 °C, 0.9 
bar H2); major enantiomer: τR = 43.80 min, minor enantiomer: τR = 43.02 min. Characterized 
as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.20 (s, 1H, OH), 5.16 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.15-4.09 (m, 1H, CH), 2.61-2.52 (m, 2H, CH2CqOH), 2.10-2.04 (m, 2H, CH2CqOH), 1.68-
1.26 (m, 32H, CH2), 0.92-0.88 (m, 12H, CH3). 
13C NMR (125 MHz, THF-d8) δ 107.7 (CqOH), 106.9 (CqOH), 82.6 (CH), 81.0 (CH), 52.4 
(CH2, cycl.), 52.1 (CH2, cycl.), 38.3 (CH2), 37.9 (CH2), 35.8 (CH2), 33.4 (CH2), 33.4 (CH2), 33.3 
(CH2), 33.1 (CH2), 33.0 (CH2), 27.4 (CH2), 27.2 (CH2), 25.9 (CH2), 25.7 (CH2), 23.8 (3C, 
CH2), 23.7 (CH2), 14.7 (2C, CH3), 14.7 (CH3), 14.6 (CH3). 
MS (EI) m/z (%) 230 [M+] (1), 197 (100), 159 (1), 141 (3), 127 (30), 117 (5), 99 (50), 81 (6), 
71 (30), 55 (30), 43 (90), 29 (24). 
HRMS (EI-DE) calcd for C13H26O3 [M+] 230.1880, found 230.1882. 
 
(5R)-3-Isopropyl-5-methyl-1,2-dioxolan-3-ol ((5R)-94o): Peroxyhemiketal 94o was 
obtained by the general procedure. Catalyst salt [13 • 2 TCA] (20 mol%) 
were used and the reaction mixture was stirred for 48 h at 32 °C. 
Purification of the crude product by flash column chromatography (silica gel, 
30-40% Et2O in pentane) provided the title compound 94o (57 mg, 391 μmol, 39%; 96:4 er) 
as a colorless oil. The enantiomeric ratio was determined after converting peroxyhemiketal 
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94o into the corresponding epoxide 94o. The enantiomers were analyzed by GC using a chiral 
Lipodex G column 25 m (50 °C, 1.2 °C/min until 80 °C, 18 °C/min until 220 °C, 10 min at 
230 °C, 0.5 bar H2); major enantiomer: τR = 8.36 min, minor enantiomer: τR = 8.80 min. 
Characterized as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 6.98 (s, 1H, OH), 6.97 (s, 1H, OH), 6.34 (app. sext, J = 6.3 
Hz, 1H, CHCH2), 6.10-6.03 (m, 1H, CHCH2), 4.51 (dd, J = 12.6, 7.3 Hz, 1H, CHH), 4.33 
(dd, J = 12.1, 6.8 Hz, 1H, CHH), 3.93 (dd, J = 12.0, 6.3 Hz, 1H, CHH), 3.81 (dd, J = 12.6, 
8.5 Hz, 1H, CHH), 3.72 (hept, J = 7.0 Hz, 2H, CHMe2), 3.09 (d, J = 6.0 Hz, 3H, CH3CH), 
3.04 (d, J = 6.3 Hz, 3H, CH3CH), 2.81 (t, J = 6.8 Hz, 12H, CH(CH3)2). 
13C NMR (125 MHz, THF-d8) δ 110.2 (CqOH), 109.2 (CqOH), 78.6 (CHCH2), 76.9 (CHCH2), 
52.0 (CH2), 51.8 (CH2), 36.1 (CHMe2), 35.9 (CHMe2), 20.3 (CH3), 19.1 (CH3), 18.8 (CH3), 
18.3 (CH3), 18.1 (CH3), 17.4 (CH3). 
GC-MS (GC-EI) m/z (%) 146 [M+] (trace), 128 (1), 113 (12), 103 (6), 85 (4), 71 (22), 61 (17), 
43 (100), 27 (8). 
HRMS (EI-FE) calcd for C7H14O3 [M+] 146.0941, found 146.0943. 
 
3-Ethyl-5-nonyl-1,2-dioxolan-3-ol (94p): Peroxyhemiketal 94p was prepared according to 
the general procedure. The reaction mixture was stirred for 
48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94p as a colorless oil (59 mg, 240 μmol, 48%; 98:2 er). 
The enantiomeric ratio was determined after converting dioxolane 94p into the corresponding 
epoxide 93p. The enantiomers were analyzed by GC using a chiral Lipodex E column 25 m 
(100 °C, 1.2 °C/min until 180 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 37.10 min, minor enantiomer: τR = 35.28 min. Characterized as a 
mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.18 (s, 1H, OH), 5.15 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.12 (quint, J = 7.1 Hz, 1H, CH), 2.61-2.50 (m, 2H, CH2CqOH), 2.10-2.02 (m, 2H, CH2CqOH), 
1.71-1.52 (m, 7H, CH2), 1.42-1.36 (m, 3H, CH2), 1.35-1.26 (m, 26H, CH2), 0.97 (t, J = 7.6 
Hz, 3H, CqOHCH2CH3), 0.96 (t, J = 7.6 Hz, 3H, CqOHCH2CH3), 0.89 (t, J = 6.8 Hz, 6H, CH3). 
13C NMR (125 MHz, THF-d8) 108.1 (CqOH), 107.2 (CqOH), 82.7 (CH), 81.1 (CH), 51.9 
(CH2, cycl.), 51.5 (CH2, cycl.), 35.7 (CH2), 33.3 (CH2), 33.2 (2C, CH2), 31.2 (CH2), 30.9 (CH2), 
30.9 (CH2), 30.9 (CH2), 30.8 (CH2), 30.8 (CH2), 30.8 (CH2), 30.8 (CH2), 30.6 (2C, CH2), 27.7 
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94o into the corresponding epoxide 94o. The enantiomers were analyzed by GC using a chiral 
Lipodex G column 25 m (50 °C, 1.2 °C/min until 80 °C, 18 °C/min until 220 °C, 10 min at 
230 °C, 0.5 bar H2); major enantiomer: τR = 8.36 min, minor enantiomer: τR = 8.80 min. 
Characterized as a mixture of hemiketal epimers (1:1 dr). 
1H NMR (400 MHz, THF-d8) δ 6.98 (s, 1H, OH), 6.97 (s, 1H, OH), 6.34 (app. sext, J = 6.3 
Hz, 1H, CHCH2), 6.10-6.03 (m, 1H, CHCH2), 4.51 (dd, J = 12.6, 7.3 Hz, 1H, CHH), 4.33 
(dd, J = 12.1, 6.8 Hz, 1H, CHH), 3.93 (dd, J = 12.0, 6.3 Hz, 1H, CHH), 3.81 (dd, J = 12.6, 
8.5 Hz, 1H, CHH), 3.72 (hept, J = 7.0 Hz, 2H, CHMe2), 3.09 (d, J = 6.0 Hz, 3H, CH3CH), 
3.04 (d, J = 6.3 Hz, 3H, CH3CH), 2.81 (t, J = 6.8 Hz, 12H, CH(CH3)2). 
13C NMR (125 MHz, THF-d8) δ 110.2 (CqOH), 109.2 (CqOH), 78.6 (CHCH2), 76.9 (CHCH2), 
52.0 (CH2), 51.8 (CH2), 36.1 (CHMe2), 35.9 (CHMe2), 20.3 (CH3), 19.1 (CH3), 18.8 (CH3), 
18.3 (CH3), 18.1 (CH3), 17.4 (CH3). 
GC-MS (GC-EI) m/z (%) 146 [M+] (trace), 128 (1), 113 (12), 103 (6), 85 (4), 71 (22), 61 (17), 
43 (100), 27 (8). 
HRMS (EI-FE) calcd for C7H14O3 [M+] 146.0941, found 146.0943. 
 
3-Ethyl-5-nonyl-1,2-dioxolan-3-ol (94p): Peroxyhemiketal 94p was prepared according to 
the general procedure. The reaction mixture was stirred for 
48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94p as a colorless oil (59 mg, 240 μmol, 48%; 98:2 er). 
The enantiomeric ratio was determined after converting dioxolane 94p into the corresponding 
epoxide 93p. The enantiomers were analyzed by GC using a chiral Lipodex E column 25 m 
(100 °C, 1.2 °C/min until 180 °C, 18 °C/min until 220 °C, 10 min at 320 °C, 0.5 bar H2); 
major enantiomer: τR = 37.10 min, minor enantiomer: τR = 35.28 min. Characterized as a 
mixture of hemiketal epimers (1:1 dr). 
1H NMR (500 MHz, THF-d8) δ 5.18 (s, 1H, OH), 5.15 (s, 1H, OH), 4.33-4.28 (m, 1H, CH), 
4.12 (quint, J = 7.1 Hz, 1H, CH), 2.61-2.50 (m, 2H, CH2CqOH), 2.10-2.02 (m, 2H, CH2CqOH), 
1.71-1.52 (m, 7H, CH2), 1.42-1.36 (m, 3H, CH2), 1.35-1.26 (m, 26H, CH2), 0.97 (t, J = 7.6 
Hz, 3H, CqOHCH2CH3), 0.96 (t, J = 7.6 Hz, 3H, CqOHCH2CH3), 0.89 (t, J = 6.8 Hz, 6H, CH3). 
13C NMR (125 MHz, THF-d8) 108.1 (CqOH), 107.2 (CqOH), 82.7 (CH), 81.1 (CH), 51.9 
(CH2, cycl.), 51.5 (CH2, cycl.), 35.7 (CH2), 33.3 (CH2), 33.2 (2C, CH2), 31.2 (CH2), 30.9 (CH2), 
30.9 (CH2), 30.9 (CH2), 30.8 (CH2), 30.8 (CH2), 30.8 (CH2), 30.8 (CH2), 30.6 (2C, CH2), 27.7 
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94o into the corresponding epoxide 94o. The enantiomers were analyzed by GC using a chiral 
Lipodex G column 25 m (50 °C, 1.2 °C/min until 80 °C, 18 °C/min until 220 °C, 10 min at 
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Characterized as a mixture of hemiketal epimers (1:1 dr). 
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GC-MS (GC-EI) m/z (%) 146 [M+] (trace), 128 (1), 113 (12), 103 (6), 85 (4), 71 (22), 61 (17), 
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HRMS (EI-FE) calcd for C7H14O3 [M+] 146.0941, found 146.0943. 
 
3-Ethyl-5-nonyl-1,2-dioxolan-3-ol (94p): Peroxyhemiketal 94p was prepared according to 
the general procedure. The reaction mixture was stirred for 
48 h at 32 °C. Purification of the crude product by flash 
column chromatography (silica gel, 10-20% Et2O in 
pentane) provided the title compound 94p as a colorless oil (59 mg, 240 μmol, 48%; 98:2 er). 
The enantiomeric ratio was determined after converting dioxolane 94p into the corresponding 
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(CH2), 27.5 (CH2), 23.9 (2C, CH2), 14.7 (2C, (CH2)8CH3), 9.9 (CqOHCH2CH3), 9.7 
(CqOHCH2CH3). 
MS (EI) m/z (%) 244 [M+] (1), 211 (77), 197 (1), 181 (1), 155 (9), 137 (2), 95 (8), 85 (50), 71 
(17), 57 (100), 43 (46), 29 (34). 
HRMS (EI-DE) calcd for C14H28O3 [M+] 244.2038, found 244.2038. 
 
7.3.2 Synthesis of (R)-4-(Tert-butylperoxy)decan-2-one ((R)-95a) 
The general procedure[193] described in Section 7.3.1.1 for the catalytic asymmetric hydro-
peroxidation of α,β-unsaturated ketones 92 was followed. tert-Butylhydroperoxide (70 wt%; 
103 μL, 0.75 mmol, 1.5 equiv) was used under otherwise identical reaction conditions. 
 
 
 
Purification by flash column chromatography (silica gel, 1-20% Et2O in pentane) gave 
peroxide 95a (67 mg, 274 μmol, 55%) along with the corresponding epoxide 93a (~17 mg, 
100 μmol, 20%; 99:1 er) (vide infra), both as colorless oils. 
1H NMR (500 MHz, CD2Cl2) δ 4.37-4.32 (m, 1H, CH), 2.79 (dd, J = 15.2, 6.6 Hz, 1H, 
CHHC(=O)), 2.43 (dd, J = 15.7, 5.2 Hz, 1H, CHHC(=O)), 2.15 (s, 3H, C(=O)CH3), 1.56-1.25 
(m, 10H, (CH2)5), 1.19 (s, 9H, Cq(CH3)3), 0.88 (t, J = 6.9 Hz, 3H, (CH2)5CH3), 
13C NMR (125 MHz, CD2Cl2) δ 207.5 (C=O), 80.5 (Cq) 80.4 (CH), 48.0 (CH2C(=O)), 33.4 
(CH2), 31.2 (CH2), 30.9 (CH3C(=O)), 29.7 (CH2), 26.5 (3C, Cq(CH3)3), 25.9 (CH2), 23.0 
(CH2), 14.2 ((CH2)5CH3). 
MS (EI-DE) m/z (%) 244 [M+] (trace), 188 (4), 171 (5), 155 (80), 137 (4), 127 (1), 113 (23), 
95 (5), 85 (7), 71 (15), 57 (100), 43 (70), 29 (10). 
HRMS (ESI+) calcd for C14H28O3Na1 [(M+Na)+] 267.1928, found 267.1931. 
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7.3.3 Catalytic Asymmetric Epoxidation of Acyclic Enones 
7.3.3.1 General Procedure[193] 
 
R1 R2
O
92
R1, R2 = Alk
dioxane (0.25 M), 50 °C, 12-48 h
2. 1N NaOH (1 equiv)
THF/Et2O, r.t., 10 min-1 h
1. [13 2 TFA] (10 mol%)
H2O2 (50 wt%; 1.5 equiv)
R1 R2
O
O
93
 
 
Catalyst salt [13 • 2 TFA] was prepared in situ by the addition of amine 13 (32.3 mg, 0.1 
mmol, 10 mol%) to a solution of trifluoroacetic acid (15.3 μL, 0.2 mmol, 20 mol%) in 
dioxane (4 mL). Then enone 92 (1.0 mmol, 1.0 equiv) was added, and 20 minutes later, 
aqueous hydrogen peroxide (50 wt%, 92 μL, 1.5 mmol, 1.5 equiv). After 12-48 h at 50°C, the 
reaction mixture was extracted with Et2O (3×25 mL). The combined organic phases were 
washed with brine and concentrated under reduced pressure to a volume of 5 mL. Aqueous 
1N NaOH solution (1.0 mL, 1.0 mmol, 1.0 equiv) was added and the reaction mixture stirred 
until TLC analysis indicated complete conversion to the epoxide (10 min to 1 h). The reaction 
mixture was extracted with Et2O (3×25 mL), and the combined organic phases were washed 
with brine, dried (Na2SO4), and filtered. Evaporation of the solvent furnished the crude 
product, which was purified by flash column chromatography (silica gel, eluent: Et2O-
pentane) to afford pure α,β-epoxy ketones 93. 
7.3.3.2 Scope of Optically Active α,β-Epoxyketones 
(E)-(3S,4R)-3,4-Epoxy-2-decanone (3S,4R)-93a): Epoxide (3S,4R)-93a was prepared 
according to the general procedure. The reaction mixture was stirred 
for 12 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93a 
as a colorless oil (127 mg, 747 μmol, 75%; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 
120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 19.73 
min, minor enantiomer: τR = 21.60 min. 
(E)-(3R,4S)-3,4-Epoxy-2-decanone ((3R,4S)-93a): 9-Amino(9-deoxy)epiquinidine (67) was 
used (instead of 13) under otherwise identical conditions. The 
reaction mixture was stirred for 12 h at 50 °C. Purification by flash 
column chromatography (silica gel, 1-20% Et2O in pentane) 
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7.3.3 Catalytic Asymmetric Epoxidation of Acyclic Enones 
7.3.3.1 General Procedure[193] 
 
R1 R2
O
92
R1, R2 = Alk
dioxane (0.25 M), 50 °C, 12-48 h
2. 1N NaOH (1 equiv)
THF/Et2O, r.t., 10 min-1 h
1. [13 2 TFA] (10 mol%)
H2O2 (50 wt%; 1.5 equiv)
R1 R2
O
O
93
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provided the title compound 93a as a colorless oil (137 mg, 807 μmol, 81%; 96:4 er). The 
enantiomeric ratio was determined by GC using a chiral BGB-176/SE-52 column 30 m (80 °C, 
1.2 °C/min until 115°C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 25.06 min, minor enantiomer: τR = 24.13 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.14 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.05 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.02 (s, 3H, CH3C(=O)), 1.64-1.55 (m, 2H, CH2CHepo), 1.49-1.41 (m, 
2H, CH2CH2CHepo), 1.37-1.25 (m, 6H, (CH2)3CH3), 0.89 (t, J = 7.0 Hz, 3H, (CH2)5CH3). 
13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.4 (CHepoC(=O)), 58.6 (CH2CHepo), 32.4 
(CH2CHepo), 32.2 (CH2), 29.5 (CH2), 26.3 (CH2CH2CHepo), 24.8 (CH3C(=O)), 23.1 (CH2), 
14.4 ((CH2)5CH3). 
GC-MS (GC-EI) m/z (%) 170 [M+] (trace), 139 (7), 125 (1), 109 (4), 97 (12), 85 (54), 81 (9), 
69 (21), 55 (41), 43 (100), 39 (9), 29 (17). 
HRMS (CI-FE, i-butane) calcd for C10H19O2 [(M+H)+] 171.1384, found 171.1385. 
 
(E)-(3S,4R)-3,4-Epoxy-6-phenyl-2-hexanone ((3S,4R)-93b): Epoxide (3S,4R)-93b was 
prepared according to the general procedure. The reaction mixture was 
stirred for 12 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93b as a 
colorless oil (162 mg, 854 μmol, 85%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 140 °C, 20 
°C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 45.23 min, minor 
enantiomer: τR = 46.65 min. 
(E)-(3R,4S)-3,4-Epoxy-6-phenyl-2-hexanone ((3R,4S)-93b): Epoxide (3R,4S)-93b was 
prepared according to the general procedure. 9-Amino(9-
deoxy)epiquinidine  (67) was used (instead of 13) under otherwise 
identical conditions. The reaction mixture was stirred for 12 h at 50 °C. 
Purification by flash column chromatography (silica gel, 1-20% Et2O in pentane) provided the 
title compound 93b as a colorless oil (171 mg, 901 μmol, 90%; 95:5 er). The enantiomeric 
ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 
°C/min until 160 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major 
enantiomer: τR = 47.30 min, minor enantiomer: τR = 46.86 min. 
1H NMR (500 MHz, CD2Cl2) δ 7.32-7.28 (m, 2H, CHPh), 7.23-7.20 (m, 3H, CHPh), 3.15 (d, J 
= 1.8 Hz, 1H, CHepoC(=O)), 3.09 (td, J = 5.6, 1.8 Hz, 1H, CH2CHepo), 2.85-2.72 (m, 2H, 
PhCH2), 1.99 (s, 3H, CH3), 1.96-1.91 (m, 2H, CH2CHepo). 
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13C NMR (125 MHz, CD2Cl2) δ 205.7 (C=O), 141.3 (CqPh), 129.1 (2C, CHPh), 128.9 (2C, 
CHPh), 126.7 (CHPh, p), 60.3 (CHepoC(=O)), 58.1 (CH2CHepo), 34.1 (CH2), 32.5 (CH2), 25.0 
(CH3). 
MS (EI-DE) m/z (%) 190 [M+] (4), 172 (4), 157 (2), 147 (14), 134 (5), 129 (37), 117 (38), 104 
(34), 91 (100), 85 (22), 77 (8), 65 (17), 57 (8), 51 (6), 43 (64), 27 (5). 
HRMS (EI-FE) calcd for C12H14O2 [M+] 190.0992, found 190.0994. 
 
(E)-(3S,4R)-3,4-Epoxy-5-phenyl-2-hexanone ((3S,4R)-93q): Epoxide (3S,4R)-93q was 
prepared according to the general procedure. Catalyst [13 • 3 TFA] was used 
under otherwise identical conditions. After 12 h at 50 °C, the conversion was 
determined to be 94% by 1H NMR of the crude mixture (37% epoxide 93q, 
33% 5-benzyl-3-methyl-1,2-dioxolan-3-ol (94q), 24% (E)-5-phenylpent-4-en-2-one (iso-92q, 
vide infra)). The enantiomeric ratio of epoxide 93q was determined to be 99:1 er by GC using 
a chiral Lipodex E column 25 m (80 °C, 1.2 °C/min until 145 °C, 18 °C/min until 220 °C, 10 
min at 220 °C, 0.5 bar H2); major enantiomer: τR = 42.87 min, minor enantiomer: τR = 41.72 
min. 
1H NMR (500 MHz, CDCl3) δ 7.32-7.21 (m, 5H, C6H5), 3.28 (td, J = 5.2, 1.9 Hz, 1H, 
CH2CHepo), 3.22 (d, J = 1.6 Hz 1H, CHepoC(=O)), 2.93 (app. qd, J = 14.4, 5.2 Hz, 2H, 
PhCH2), 2.02 (s, 3H, CH3). 
(E)-5-Phenylpent-4-en-2-one (iso-92q): 1H NMR (500 MHz, CDCl3) δ 7.35-7.21 (m, 5H, 
C6H5), 6.45 (d, J = 16.0 Hz, 1H, PhCH=), 6.28 (dt, J = 15.8, 7.5 Hz, 1H, 
=CHCH2), 3.31 (d, J = 7.2 Hz, 2H, =CHCH2), 2.19 (3H, CH3). 
 
(E)-(3S,4R)-3,4-Epoxy-6-methyl-2-heptanone ((3S,4R)-93d): Epoxide (3S,4R)-93d was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93d as a 
colorless oil (109 mg, 768 μmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/BGB-15 column 30 m (60 °C, 0.8 °C/min until 80 °C, 18 °C/min 
until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 15.45 min, minor 
enantiomer: τR = 17.76 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.12 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.06 (td, J = 5.8, 1.9 
Hz, 1H, CH2CHepo), 2.03 (s, 3H, CH3C(=O)), 1.83 (hept, J = 6.7 Hz, 1H, CHMe2), 1.48 (dd, J 
= 6.5 Hz, 2H, CH2), 0.98 (d, J = 4.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 4.6 Hz, 3H, CH(CH3)2). 
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Hz, 1H, CH2CHepo), 2.03 (s, 3H, CH3C(=O)), 1.83 (hept, J = 6.7 Hz, 1H, CHMe2), 1.48 (dd, J 
= 6.5 Hz, 2H, CH2), 0.98 (d, J = 4.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 4.6 Hz, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 205.7 (C=O), 141.3 (CqPh), 129.1 (2C, CHPh), 128.9 (2C, 
CHPh), 126.7 (CHPh, p), 60.3 (CHepoC(=O)), 58.1 (CH2CHepo), 34.1 (CH2), 32.5 (CH2), 25.0 
(CH3). 
MS (EI-DE) m/z (%) 190 [M+] (4), 172 (4), 157 (2), 147 (14), 134 (5), 129 (37), 117 (38), 104 
(34), 91 (100), 85 (22), 77 (8), 65 (17), 57 (8), 51 (6), 43 (64), 27 (5). 
HRMS (EI-FE) calcd for C12H14O2 [M+] 190.0992, found 190.0994. 
 
(E)-(3S,4R)-3,4-Epoxy-5-phenyl-2-hexanone ((3S,4R)-93q): Epoxide (3S,4R)-93q was 
prepared according to the general procedure. Catalyst [13 • 3 TFA] was used 
under otherwise identical conditions. After 12 h at 50 °C, the conversion was 
determined to be 94% by 1H NMR of the crude mixture (37% epoxide 93q, 
33% 5-benzyl-3-methyl-1,2-dioxolan-3-ol (94q), 24% (E)-5-phenylpent-4-en-2-one (iso-92q, 
vide infra)). The enantiomeric ratio of epoxide 93q was determined to be 99:1 er by GC using 
a chiral Lipodex E column 25 m (80 °C, 1.2 °C/min until 145 °C, 18 °C/min until 220 °C, 10 
min at 220 °C, 0.5 bar H2); major enantiomer: τR = 42.87 min, minor enantiomer: τR = 41.72 
min. 
1H NMR (500 MHz, CDCl3) δ 7.32-7.21 (m, 5H, C6H5), 3.28 (td, J = 5.2, 1.9 Hz, 1H, 
CH2CHepo), 3.22 (d, J = 1.6 Hz 1H, CHepoC(=O)), 2.93 (app. qd, J = 14.4, 5.2 Hz, 2H, 
PhCH2), 2.02 (s, 3H, CH3). 
(E)-5-Phenylpent-4-en-2-one (iso-92q): 1H NMR (500 MHz, CDCl3) δ 7.35-7.21 (m, 5H, 
C6H5), 6.45 (d, J = 16.0 Hz, 1H, PhCH=), 6.28 (dt, J = 15.8, 7.5 Hz, 1H, 
=CHCH2), 3.31 (d, J = 7.2 Hz, 2H, =CHCH2), 2.19 (3H, CH3). 
 
(E)-(3S,4R)-3,4-Epoxy-6-methyl-2-heptanone ((3S,4R)-93d): Epoxide (3S,4R)-93d was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93d as a 
colorless oil (109 mg, 768 μmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/BGB-15 column 30 m (60 °C, 0.8 °C/min until 80 °C, 18 °C/min 
until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 15.45 min, minor 
enantiomer: τR = 17.76 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.12 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.06 (td, J = 5.8, 1.9 
Hz, 1H, CH2CHepo), 2.03 (s, 3H, CH3C(=O)), 1.83 (hept, J = 6.7 Hz, 1H, CHMe2), 1.48 (dd, J 
= 6.5 Hz, 2H, CH2), 0.98 (d, J = 4.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 4.6 Hz, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 205.7 (C=O), 141.3 (CqPh), 129.1 (2C, CHPh), 128.9 (2C, 
CHPh), 126.7 (CHPh, p), 60.3 (CHepoC(=O)), 58.1 (CH2CHepo), 34.1 (CH2), 32.5 (CH2), 25.0 
(CH3). 
MS (EI-DE) m/z (%) 190 [M+] (4), 172 (4), 157 (2), 147 (14), 134 (5), 129 (37), 117 (38), 104 
(34), 91 (100), 85 (22), 77 (8), 65 (17), 57 (8), 51 (6), 43 (64), 27 (5). 
HRMS (EI-FE) calcd for C12H14O2 [M+] 190.0992, found 190.0994. 
 
(E)-(3S,4R)-3,4-Epoxy-5-phenyl-2-hexanone ((3S,4R)-93q): Epoxide (3S,4R)-93q was 
prepared according to the general procedure. Catalyst [13 • 3 TFA] was used 
under otherwise identical conditions. After 12 h at 50 °C, the conversion was 
determined to be 94% by 1H NMR of the crude mixture (37% epoxide 93q, 
33% 5-benzyl-3-methyl-1,2-dioxolan-3-ol (94q), 24% (E)-5-phenylpent-4-en-2-one (iso-92q, 
vide infra)). The enantiomeric ratio of epoxide 93q was determined to be 99:1 er by GC using 
a chiral Lipodex E column 25 m (80 °C, 1.2 °C/min until 145 °C, 18 °C/min until 220 °C, 10 
min at 220 °C, 0.5 bar H2); major enantiomer: τR = 42.87 min, minor enantiomer: τR = 41.72 
min. 
1H NMR (500 MHz, CDCl3) δ 7.32-7.21 (m, 5H, C6H5), 3.28 (td, J = 5.2, 1.9 Hz, 1H, 
CH2CHepo), 3.22 (d, J = 1.6 Hz 1H, CHepoC(=O)), 2.93 (app. qd, J = 14.4, 5.2 Hz, 2H, 
PhCH2), 2.02 (s, 3H, CH3). 
(E)-5-Phenylpent-4-en-2-one (iso-92q): 1H NMR (500 MHz, CDCl3) δ 7.35-7.21 (m, 5H, 
C6H5), 6.45 (d, J = 16.0 Hz, 1H, PhCH=), 6.28 (dt, J = 15.8, 7.5 Hz, 1H, 
=CHCH2), 3.31 (d, J = 7.2 Hz, 2H, =CHCH2), 2.19 (3H, CH3). 
 
(E)-(3S,4R)-3,4-Epoxy-6-methyl-2-heptanone ((3S,4R)-93d): Epoxide (3S,4R)-93d was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93d as a 
colorless oil (109 mg, 768 μmol, 77%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/BGB-15 column 30 m (60 °C, 0.8 °C/min until 80 °C, 18 °C/min 
until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 15.45 min, minor 
enantiomer: τR = 17.76 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.12 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.06 (td, J = 5.8, 1.9 
Hz, 1H, CH2CHepo), 2.03 (s, 3H, CH3C(=O)), 1.83 (hept, J = 6.7 Hz, 1H, CHMe2), 1.48 (dd, J 
= 6.5 Hz, 2H, CH2), 0.98 (d, J = 4.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 4.6 Hz, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.5 (CHepoC(=O)), 57.6 (CH2CHepo), 41.1 
(CH2), 27.0 (CHMe2), 24.9 (CH3C(=O)), 23.1 (CH(CH3)2), 22.6 (CH(CH3)2). 
MS (EI-DE) m/z (%) 142 [M+] (2), 127 (6), 100 (10), 85 (100), 81 (6), 74 (2), 69 (3), 57 (26), 
55 (12), 43 (79), 41 (14), 27 (11). 
HRMS (CI-FE, i-butane) calcd for C8H15O2 [(M+H)+] 143.1071, found 143.1072. 
 
(E)-(3S,4R)-3,4-Epoxy-6,6-dimethyl-2-heptanone ((3S,4R)-93r): Epoxide (3S,4R)-93r was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93r as a 
colorless oil (127 mg, 812 μmol, 81%; >99.5:0.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.0 °C/min until 100 °C, 20 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 15.39 min, minor 
enantiomer: τR = 16.03 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.10-3.07 (m, 2H, CHepo), 2.04 (s, 3H, CH3C(=O)), 1.53-1.44 
(m, 2H, CH2), 1.00 (s, 9 H, Cq(CH3)3). 
13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.2 (CHepoC(=O)), 56.2 (CH2CHepo), 46.3 
(CH2), 31.1 (CqMe3), 29.9 (3C, Cq(CH3)3), 25.0 (CH3C(=O)). 
GC-MS (GC-EI) m/z (%) 156 [M+] (trace), 141 (1), 125 (1), 107 (1), 100 (11), 95 (4), 85 
(53), 69 (16), 57 (97), 43 (100), 41 (41), 29 (24), 27 (7). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1227, found 157.1229. 
 
(E)-(3S,4R)-3,4-Epoxy-5-methyl-2-hexanone ((3S,4R)-93s): Epoxide (3S,4R)-93s was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93s as a 
colorless oil (64 mg, 497 μmol, 50% (reduced yield due to the high volatility of 93s); 98:2 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(15 min at 60 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR 
= 8.34 min, minor enantiomer: τR = 10.30 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 2.87 (dd, J = 6.6, 1.9 
Hz, 1H, CHCHepo), 2.03 (s, 3H, CH3C(=O)), 1.62 (hept, J = 6.7 Hz, 1H, CHMe2), 1.03 (d, J = 
6.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 7.0, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.5 (CHepoC(=O)), 57.6 (CH2CHepo), 41.1 
(CH2), 27.0 (CHMe2), 24.9 (CH3C(=O)), 23.1 (CH(CH3)2), 22.6 (CH(CH3)2). 
MS (EI-DE) m/z (%) 142 [M+] (2), 127 (6), 100 (10), 85 (100), 81 (6), 74 (2), 69 (3), 57 (26), 
55 (12), 43 (79), 41 (14), 27 (11). 
HRMS (CI-FE, i-butane) calcd for C8H15O2 [(M+H)+] 143.1071, found 143.1072. 
 
(E)-(3S,4R)-3,4-Epoxy-6,6-dimethyl-2-heptanone ((3S,4R)-93r): Epoxide (3S,4R)-93r was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93r as a 
colorless oil (127 mg, 812 μmol, 81%; >99.5:0.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.0 °C/min until 100 °C, 20 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 15.39 min, minor 
enantiomer: τR = 16.03 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.10-3.07 (m, 2H, CHepo), 2.04 (s, 3H, CH3C(=O)), 1.53-1.44 
(m, 2H, CH2), 1.00 (s, 9 H, Cq(CH3)3). 
13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.2 (CHepoC(=O)), 56.2 (CH2CHepo), 46.3 
(CH2), 31.1 (CqMe3), 29.9 (3C, Cq(CH3)3), 25.0 (CH3C(=O)). 
GC-MS (GC-EI) m/z (%) 156 [M+] (trace), 141 (1), 125 (1), 107 (1), 100 (11), 95 (4), 85 
(53), 69 (16), 57 (97), 43 (100), 41 (41), 29 (24), 27 (7). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1227, found 157.1229. 
 
(E)-(3S,4R)-3,4-Epoxy-5-methyl-2-hexanone ((3S,4R)-93s): Epoxide (3S,4R)-93s was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93s as a 
colorless oil (64 mg, 497 μmol, 50% (reduced yield due to the high volatility of 93s); 98:2 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(15 min at 60 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR 
= 8.34 min, minor enantiomer: τR = 10.30 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 2.87 (dd, J = 6.6, 1.9 
Hz, 1H, CHCHepo), 2.03 (s, 3H, CH3C(=O)), 1.62 (hept, J = 6.7 Hz, 1H, CHMe2), 1.03 (d, J = 
6.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 7.0, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.5 (CHepoC(=O)), 57.6 (CH2CHepo), 41.1 
(CH2), 27.0 (CHMe2), 24.9 (CH3C(=O)), 23.1 (CH(CH3)2), 22.6 (CH(CH3)2). 
MS (EI-DE) m/z (%) 142 [M+] (2), 127 (6), 100 (10), 85 (100), 81 (6), 74 (2), 69 (3), 57 (26), 
55 (12), 43 (79), 41 (14), 27 (11). 
HRMS (CI-FE, i-butane) calcd for C8H15O2 [(M+H)+] 143.1071, found 143.1072. 
 
(E)-(3S,4R)-3,4-Epoxy-6,6-dimethyl-2-heptanone ((3S,4R)-93r): Epoxide (3S,4R)-93r was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93r as a 
colorless oil (127 mg, 812 μmol, 81%; >99.5:0.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.0 °C/min until 100 °C, 20 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 15.39 min, minor 
enantiomer: τR = 16.03 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.10-3.07 (m, 2H, CHepo), 2.04 (s, 3H, CH3C(=O)), 1.53-1.44 
(m, 2H, CH2), 1.00 (s, 9 H, Cq(CH3)3). 
13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.2 (CHepoC(=O)), 56.2 (CH2CHepo), 46.3 
(CH2), 31.1 (CqMe3), 29.9 (3C, Cq(CH3)3), 25.0 (CH3C(=O)). 
GC-MS (GC-EI) m/z (%) 156 [M+] (trace), 141 (1), 125 (1), 107 (1), 100 (11), 95 (4), 85 
(53), 69 (16), 57 (97), 43 (100), 41 (41), 29 (24), 27 (7). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1227, found 157.1229. 
 
(E)-(3S,4R)-3,4-Epoxy-5-methyl-2-hexanone ((3S,4R)-93s): Epoxide (3S,4R)-93s was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93s as a 
colorless oil (64 mg, 497 μmol, 50% (reduced yield due to the high volatility of 93s); 98:2 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(15 min at 60 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR 
= 8.34 min, minor enantiomer: τR = 10.30 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 2.87 (dd, J = 6.6, 1.9 
Hz, 1H, CHCHepo), 2.03 (s, 3H, CH3C(=O)), 1.62 (hept, J = 6.7 Hz, 1H, CHMe2), 1.03 (d, J = 
6.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 7.0, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.5 (CHepoC(=O)), 57.6 (CH2CHepo), 41.1 
(CH2), 27.0 (CHMe2), 24.9 (CH3C(=O)), 23.1 (CH(CH3)2), 22.6 (CH(CH3)2). 
MS (EI-DE) m/z (%) 142 [M+] (2), 127 (6), 100 (10), 85 (100), 81 (6), 74 (2), 69 (3), 57 (26), 
55 (12), 43 (79), 41 (14), 27 (11). 
HRMS (CI-FE, i-butane) calcd for C8H15O2 [(M+H)+] 143.1071, found 143.1072. 
 
(E)-(3S,4R)-3,4-Epoxy-6,6-dimethyl-2-heptanone ((3S,4R)-93r): Epoxide (3S,4R)-93r was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 1-20% Et2O in pentane) provided the title compound 93r as a 
colorless oil (127 mg, 812 μmol, 81%; >99.5:0.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.0 °C/min until 100 °C, 20 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 15.39 min, minor 
enantiomer: τR = 16.03 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.10-3.07 (m, 2H, CHepo), 2.04 (s, 3H, CH3C(=O)), 1.53-1.44 
(m, 2H, CH2), 1.00 (s, 9 H, Cq(CH3)3). 
13C NMR (125 MHz, CD2Cl2) δ 206.2 (C=O), 60.2 (CHepoC(=O)), 56.2 (CH2CHepo), 46.3 
(CH2), 31.1 (CqMe3), 29.9 (3C, Cq(CH3)3), 25.0 (CH3C(=O)). 
GC-MS (GC-EI) m/z (%) 156 [M+] (trace), 141 (1), 125 (1), 107 (1), 100 (11), 95 (4), 85 
(53), 69 (16), 57 (97), 43 (100), 41 (41), 29 (24), 27 (7). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1227, found 157.1229. 
 
(E)-(3S,4R)-3,4-Epoxy-5-methyl-2-hexanone ((3S,4R)-93s): Epoxide (3S,4R)-93s was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93s as a 
colorless oil (64 mg, 497 μmol, 50% (reduced yield due to the high volatility of 93s); 98:2 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/BGB-15 column 30 m 
(15 min at 60 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR 
= 8.34 min, minor enantiomer: τR = 10.30 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 2.87 (dd, J = 6.6, 1.9 
Hz, 1H, CHCHepo), 2.03 (s, 3H, CH3C(=O)), 1.62 (hept, J = 6.7 Hz, 1H, CHMe2), 1.03 (d, J = 
6.6 Hz, 3H, CH(CH3)2), 0.97 (d, J = 7.0, 3H, CH(CH3)2). 
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13C NMR (125 MHz, CD2Cl2) δ 206.1 (C=O), 63.4 (CHCHepo), 59.2 (CHepoC(=O)), 30.8 
(CHMe2), 24.6 (CH3C(=O)), 18.9 (CH(CH3)2), 18.2 (CH(CH3)2). 
GC-MS (GC-EI) m/z (%) 128 [M+] (trace), 113 (14), 97 (2), 95 (13), 85 (94), 83 (1), 69 (5), 
67 (33), 65 (3), 59 (13), 55 (9), 45 (4), 43 (100), 41 (21), 39 (7), 29 (10). 
 
(E)-(3S,4R)-3,4-Epoxy-4-cyclohexyl-2-butanone ((3S,4R)-93e): Epoxide (3S,4R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93e as a 
colorless oil (140 mg, 842 μmol, 84%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/SE-52 column 29.5 m (80 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 33.22 min, minor 
enantiomer: τR = 34.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (d, J = 2.3 Hz, 1H, CHepoC(=O)), 2.86 (dd, J = 6.5, 2.3 
Hz, 1H, CHCHepo), 2.02 (s, 3H, CH3), 1.85-1.80 (m, 1H, CH2), 1.78-1.72 (m, 2H, CH2), 1.72-
1.64 (m, 2H, CH2), 1.35-1.07 (m, 6H, CHcycl. and CH2). 
13C NMR (125 MHz, CD2Cl2) δ 206.3 (C=O), 62.7 (CHCHepo), 59.3 (CHepoC(=O)), 40.4 
(CHcycl.), 30.0 (CH2), 29.3 (CH2), 26.7 (CH2), 26.1 (CH2), 26.0 (CH2), 24.8 (CH3). 
MS (EI-DE) m/z (%) 168 [M+] (2), 153 (1), 125 (1), 113 (3), 108 (7), 100 (2), 95 (11), 85 
(100), 81 (22), 70 (5), 67 (17), 55 (24), 43 (45), 29 (10). 
HRMS (ESI+) calcd for C10H16NaO2 [(M+Na)+] 191.1042, found 191.1042. 
 
(E)-(3S,4R)-3,4-Epoxy-7-octen-2-one ((3S,4R)-93f): Epoxide (3S,4R)-93f was prepared 
according to the general procedure. The reaction mixture was stirred for 
12 h at 50 °C. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93f as a colorless oil 
(107 mg, 764 μmol, 76%; 98.5:1.5 er). The enantiomeric ratio was determined by GC using a 
chiral BGB-176/BGB-15 column 30 m (80 °C, 0.8 °C/min until 100 °C, 20 °C/min until 220 
°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 11.06 min, minor enantiomer: τR = 
12.59 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H, CH=CH2), 5.07 (ddd, J 
= 17.1, 3.4, 1.7 Hz, 1H, CH=CHtransH), 5.01 (ddd, J = 10.2, 2.9, 1.3 Hz, 1H, CH=CHHcis), 
3.18 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.08 (td, J = 5.5, 1.9 Hz, 1H, CH2CHepo), 2.28-2.17 (m, 
2H, CH2=CHCH2), 2.03 (s, 3H, CH3), 1.75-1.66 (m, 2H, CH2CHepo). 
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13C NMR (125 MHz, CD2Cl2) δ 206.1 (C=O), 63.4 (CHCHepo), 59.2 (CHepoC(=O)), 30.8 
(CHMe2), 24.6 (CH3C(=O)), 18.9 (CH(CH3)2), 18.2 (CH(CH3)2). 
GC-MS (GC-EI) m/z (%) 128 [M+] (trace), 113 (14), 97 (2), 95 (13), 85 (94), 83 (1), 69 (5), 
67 (33), 65 (3), 59 (13), 55 (9), 45 (4), 43 (100), 41 (21), 39 (7), 29 (10). 
 
(E)-(3S,4R)-3,4-Epoxy-4-cyclohexyl-2-butanone ((3S,4R)-93e): Epoxide (3S,4R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93e as a 
colorless oil (140 mg, 842 μmol, 84%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/SE-52 column 29.5 m (80 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 33.22 min, minor 
enantiomer: τR = 34.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (d, J = 2.3 Hz, 1H, CHepoC(=O)), 2.86 (dd, J = 6.5, 2.3 
Hz, 1H, CHCHepo), 2.02 (s, 3H, CH3), 1.85-1.80 (m, 1H, CH2), 1.78-1.72 (m, 2H, CH2), 1.72-
1.64 (m, 2H, CH2), 1.35-1.07 (m, 6H, CHcycl. and CH2). 
13C NMR (125 MHz, CD2Cl2) δ 206.3 (C=O), 62.7 (CHCHepo), 59.3 (CHepoC(=O)), 40.4 
(CHcycl.), 30.0 (CH2), 29.3 (CH2), 26.7 (CH2), 26.1 (CH2), 26.0 (CH2), 24.8 (CH3). 
MS (EI-DE) m/z (%) 168 [M+] (2), 153 (1), 125 (1), 113 (3), 108 (7), 100 (2), 95 (11), 85 
(100), 81 (22), 70 (5), 67 (17), 55 (24), 43 (45), 29 (10). 
HRMS (ESI+) calcd for C10H16NaO2 [(M+Na)+] 191.1042, found 191.1042. 
 
(E)-(3S,4R)-3,4-Epoxy-7-octen-2-one ((3S,4R)-93f): Epoxide (3S,4R)-93f was prepared 
according to the general procedure. The reaction mixture was stirred for 
12 h at 50 °C. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93f as a colorless oil 
(107 mg, 764 μmol, 76%; 98.5:1.5 er). The enantiomeric ratio was determined by GC using a 
chiral BGB-176/BGB-15 column 30 m (80 °C, 0.8 °C/min until 100 °C, 20 °C/min until 220 
°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 11.06 min, minor enantiomer: τR = 
12.59 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H, CH=CH2), 5.07 (ddd, J 
= 17.1, 3.4, 1.7 Hz, 1H, CH=CHtransH), 5.01 (ddd, J = 10.2, 2.9, 1.3 Hz, 1H, CH=CHHcis), 
3.18 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.08 (td, J = 5.5, 1.9 Hz, 1H, CH2CHepo), 2.28-2.17 (m, 
2H, CH2=CHCH2), 2.03 (s, 3H, CH3), 1.75-1.66 (m, 2H, CH2CHepo). 
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13C NMR (125 MHz, CD2Cl2) δ 206.1 (C=O), 63.4 (CHCHepo), 59.2 (CHepoC(=O)), 30.8 
(CHMe2), 24.6 (CH3C(=O)), 18.9 (CH(CH3)2), 18.2 (CH(CH3)2). 
GC-MS (GC-EI) m/z (%) 128 [M+] (trace), 113 (14), 97 (2), 95 (13), 85 (94), 83 (1), 69 (5), 
67 (33), 65 (3), 59 (13), 55 (9), 45 (4), 43 (100), 41 (21), 39 (7), 29 (10). 
 
(E)-(3S,4R)-3,4-Epoxy-4-cyclohexyl-2-butanone ((3S,4R)-93e): Epoxide (3S,4R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93e as a 
colorless oil (140 mg, 842 μmol, 84%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/SE-52 column 29.5 m (80 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 33.22 min, minor 
enantiomer: τR = 34.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (d, J = 2.3 Hz, 1H, CHepoC(=O)), 2.86 (dd, J = 6.5, 2.3 
Hz, 1H, CHCHepo), 2.02 (s, 3H, CH3), 1.85-1.80 (m, 1H, CH2), 1.78-1.72 (m, 2H, CH2), 1.72-
1.64 (m, 2H, CH2), 1.35-1.07 (m, 6H, CHcycl. and CH2). 
13C NMR (125 MHz, CD2Cl2) δ 206.3 (C=O), 62.7 (CHCHepo), 59.3 (CHepoC(=O)), 40.4 
(CHcycl.), 30.0 (CH2), 29.3 (CH2), 26.7 (CH2), 26.1 (CH2), 26.0 (CH2), 24.8 (CH3). 
MS (EI-DE) m/z (%) 168 [M+] (2), 153 (1), 125 (1), 113 (3), 108 (7), 100 (2), 95 (11), 85 
(100), 81 (22), 70 (5), 67 (17), 55 (24), 43 (45), 29 (10). 
HRMS (ESI+) calcd for C10H16NaO2 [(M+Na)+] 191.1042, found 191.1042. 
 
(E)-(3S,4R)-3,4-Epoxy-7-octen-2-one ((3S,4R)-93f): Epoxide (3S,4R)-93f was prepared 
according to the general procedure. The reaction mixture was stirred for 
12 h at 50 °C. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93f as a colorless oil 
(107 mg, 764 μmol, 76%; 98.5:1.5 er). The enantiomeric ratio was determined by GC using a 
chiral BGB-176/BGB-15 column 30 m (80 °C, 0.8 °C/min until 100 °C, 20 °C/min until 220 
°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 11.06 min, minor enantiomer: τR = 
12.59 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H, CH=CH2), 5.07 (ddd, J 
= 17.1, 3.4, 1.7 Hz, 1H, CH=CHtransH), 5.01 (ddd, J = 10.2, 2.9, 1.3 Hz, 1H, CH=CHHcis), 
3.18 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.08 (td, J = 5.5, 1.9 Hz, 1H, CH2CHepo), 2.28-2.17 (m, 
2H, CH2=CHCH2), 2.03 (s, 3H, CH3), 1.75-1.66 (m, 2H, CH2CHepo). 
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13C NMR (125 MHz, CD2Cl2) δ 206.1 (C=O), 63.4 (CHCHepo), 59.2 (CHepoC(=O)), 30.8 
(CHMe2), 24.6 (CH3C(=O)), 18.9 (CH(CH3)2), 18.2 (CH(CH3)2). 
GC-MS (GC-EI) m/z (%) 128 [M+] (trace), 113 (14), 97 (2), 95 (13), 85 (94), 83 (1), 69 (5), 
67 (33), 65 (3), 59 (13), 55 (9), 45 (4), 43 (100), 41 (21), 39 (7), 29 (10). 
 
(E)-(3S,4R)-3,4-Epoxy-4-cyclohexyl-2-butanone ((3S,4R)-93e): Epoxide (3S,4R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided the title compound 93e as a 
colorless oil (140 mg, 842 μmol, 84%; 98.5:1.5 er). The enantiomeric ratio was determined by 
GC using a chiral BGB-176/SE-52 column 29.5 m (80 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 33.22 min, minor 
enantiomer: τR = 34.35 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.21 (d, J = 2.3 Hz, 1H, CHepoC(=O)), 2.86 (dd, J = 6.5, 2.3 
Hz, 1H, CHCHepo), 2.02 (s, 3H, CH3), 1.85-1.80 (m, 1H, CH2), 1.78-1.72 (m, 2H, CH2), 1.72-
1.64 (m, 2H, CH2), 1.35-1.07 (m, 6H, CHcycl. and CH2). 
13C NMR (125 MHz, CD2Cl2) δ 206.3 (C=O), 62.7 (CHCHepo), 59.3 (CHepoC(=O)), 40.4 
(CHcycl.), 30.0 (CH2), 29.3 (CH2), 26.7 (CH2), 26.1 (CH2), 26.0 (CH2), 24.8 (CH3). 
MS (EI-DE) m/z (%) 168 [M+] (2), 153 (1), 125 (1), 113 (3), 108 (7), 100 (2), 95 (11), 85 
(100), 81 (22), 70 (5), 67 (17), 55 (24), 43 (45), 29 (10). 
HRMS (ESI+) calcd for C10H16NaO2 [(M+Na)+] 191.1042, found 191.1042. 
 
(E)-(3S,4R)-3,4-Epoxy-7-octen-2-one ((3S,4R)-93f): Epoxide (3S,4R)-93f was prepared 
according to the general procedure. The reaction mixture was stirred for 
12 h at 50 °C. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93f as a colorless oil 
(107 mg, 764 μmol, 76%; 98.5:1.5 er). The enantiomeric ratio was determined by GC using a 
chiral BGB-176/BGB-15 column 30 m (80 °C, 0.8 °C/min until 100 °C, 20 °C/min until 220 
°C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 11.06 min, minor enantiomer: τR = 
12.59 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H, CH=CH2), 5.07 (ddd, J 
= 17.1, 3.4, 1.7 Hz, 1H, CH=CHtransH), 5.01 (ddd, J = 10.2, 2.9, 1.3 Hz, 1H, CH=CHHcis), 
3.18 (d, J = 1.9 Hz, 1H, CHepoC(=O)), 3.08 (td, J = 5.5, 1.9 Hz, 1H, CH2CHepo), 2.28-2.17 (m, 
2H, CH2=CHCH2), 2.03 (s, 3H, CH3), 1.75-1.66 (m, 2H, CH2CHepo). 
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13C NMR (125 MHz, CD2Cl2) δ 205.9 (C=O), 137.7 (CH=CH2), 115.9 (CH=CH2), 60.4 
(CHepoC(=O)), 58.1 (CH2CHepo), 31.6 (CH2), 30.5 (CH2), 25.0 (CH3). 
MS (EI-DE) m/z (%) 140 [M+] (trace), 107 (3), 97 (34), 85 (30), 79 (8), 73 (3), 67 (11), 57 
(22), 55 (11), 43 (100), 41 (34), 39 (18), 27 (13). 
HRMS (CI-FE, i-butane) calcd for C8H13O2 [(M+H)+] 141.0916, found 141.0916. 
 
(E)-(3S,4R)-7-Bromo-3,4-epoxy-2-heptanone ((3S,4R)-93g): Epoxide (3S,4R)-93g was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 10-25% Et2O in pentane) provided the title compound 93g as 
a colorless oil (77 mg, 374 μmol, 75%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (100 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.40 min, minor 
enantiomer: τR = 20.75 min. Contains 11% (determined by GC) of (E)-7-chloro-3,4-epoxy-
heptan-2-one. 
1H NMR (400 MHz, CD2Cl2) δ 3.47 (td, J = 6.6, 1.5 Hz, 2H, BrCH2), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.11-3.08 (m, 1H, CepoHCH2), 2.05-1.98 (m, 2H, BrCH2CH2), 2.03 (s, 3H, 
CH3), 1.92-1.83 (m, 1H, CHHCepoH), 1.73-1.65 (m, 1H, CHHCepoH). 
13C NMR (100 MHz, CD2Cl2): δ 205.2 (C=O), 59.5 (CepoHC(=O)), 57.1 (CepoHCH2), 33.0 
(BrCH2), 30.3 (CH2CepoH), 29.1 (BrCH2CH2), 24.4 (CH3). 
MS (EI) m/z (%) 165 (35), 163 (36), 135 (2), 121 (1), 109 (2), 95 (1), 85 (67), 69 (1), 55 (32), 
43 (100), 27 (15). 
HRMS (CI-FE) calcd for C7H12BrO2 [(M+H)+] 207.0020, found 207.0021. 
 
(E)-(3S,4R)-3,4-Epoxy-9-(tetrahydro-2H-pyran-2-yloxy)nonen-2-one ((3S,4R)-93h): 
Epoxide (3S,4R)-93h was prepared according to the general 
procedure. The reaction mixture was stirred for 18 h at 50 °C. 
Purification by flash column chromatography (silica gel, 20-
30% Et2O in pentane) provided the title compound 93h as a colorless oil (113 mg, 440 μmol, 
88%). The enantiomeric ratio was determined after deprotection of the Thp ether (cf. epoxide 
93l; vide infra). Characterized as mixture of Thp ether diastereomers. 
1H NMR (500 MHz, CD2Cl2) δ 4.53 (t, J = 3.7 Hz, 1H, O-CH-O), 3.84-3.79 (m, 1H, 
OCHHTHP), 3.69 (dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.48-3.43 (m, 1H, OCHHTHP), 3.35 
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13C NMR (125 MHz, CD2Cl2) δ 205.9 (C=O), 137.7 (CH=CH2), 115.9 (CH=CH2), 60.4 
(CHepoC(=O)), 58.1 (CH2CHepo), 31.6 (CH2), 30.5 (CH2), 25.0 (CH3). 
MS (EI-DE) m/z (%) 140 [M+] (trace), 107 (3), 97 (34), 85 (30), 79 (8), 73 (3), 67 (11), 57 
(22), 55 (11), 43 (100), 41 (34), 39 (18), 27 (13). 
HRMS (CI-FE, i-butane) calcd for C8H13O2 [(M+H)+] 141.0916, found 141.0916. 
 
(E)-(3S,4R)-7-Bromo-3,4-epoxy-2-heptanone ((3S,4R)-93g): Epoxide (3S,4R)-93g was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 10-25% Et2O in pentane) provided the title compound 93g as 
a colorless oil (77 mg, 374 μmol, 75%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (100 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.40 min, minor 
enantiomer: τR = 20.75 min. Contains 11% (determined by GC) of (E)-7-chloro-3,4-epoxy-
heptan-2-one. 
1H NMR (400 MHz, CD2Cl2) δ 3.47 (td, J = 6.6, 1.5 Hz, 2H, BrCH2), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.11-3.08 (m, 1H, CepoHCH2), 2.05-1.98 (m, 2H, BrCH2CH2), 2.03 (s, 3H, 
CH3), 1.92-1.83 (m, 1H, CHHCepoH), 1.73-1.65 (m, 1H, CHHCepoH). 
13C NMR (100 MHz, CD2Cl2): δ 205.2 (C=O), 59.5 (CepoHC(=O)), 57.1 (CepoHCH2), 33.0 
(BrCH2), 30.3 (CH2CepoH), 29.1 (BrCH2CH2), 24.4 (CH3). 
MS (EI) m/z (%) 165 (35), 163 (36), 135 (2), 121 (1), 109 (2), 95 (1), 85 (67), 69 (1), 55 (32), 
43 (100), 27 (15). 
HRMS (CI-FE) calcd for C7H12BrO2 [(M+H)+] 207.0020, found 207.0021. 
 
(E)-(3S,4R)-3,4-Epoxy-9-(tetrahydro-2H-pyran-2-yloxy)nonen-2-one ((3S,4R)-93h): 
Epoxide (3S,4R)-93h was prepared according to the general 
procedure. The reaction mixture was stirred for 18 h at 50 °C. 
Purification by flash column chromatography (silica gel, 20-
30% Et2O in pentane) provided the title compound 93h as a colorless oil (113 mg, 440 μmol, 
88%). The enantiomeric ratio was determined after deprotection of the Thp ether (cf. epoxide 
93l; vide infra). Characterized as mixture of Thp ether diastereomers. 
1H NMR (500 MHz, CD2Cl2) δ 4.53 (t, J = 3.7 Hz, 1H, O-CH-O), 3.84-3.79 (m, 1H, 
OCHHTHP), 3.69 (dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.48-3.43 (m, 1H, OCHHTHP), 3.35 
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13C NMR (125 MHz, CD2Cl2) δ 205.9 (C=O), 137.7 (CH=CH2), 115.9 (CH=CH2), 60.4 
(CHepoC(=O)), 58.1 (CH2CHepo), 31.6 (CH2), 30.5 (CH2), 25.0 (CH3). 
MS (EI-DE) m/z (%) 140 [M+] (trace), 107 (3), 97 (34), 85 (30), 79 (8), 73 (3), 67 (11), 57 
(22), 55 (11), 43 (100), 41 (34), 39 (18), 27 (13). 
HRMS (CI-FE, i-butane) calcd for C8H13O2 [(M+H)+] 141.0916, found 141.0916. 
 
(E)-(3S,4R)-7-Bromo-3,4-epoxy-2-heptanone ((3S,4R)-93g): Epoxide (3S,4R)-93g was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 10-25% Et2O in pentane) provided the title compound 93g as 
a colorless oil (77 mg, 374 μmol, 75%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (100 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.40 min, minor 
enantiomer: τR = 20.75 min. Contains 11% (determined by GC) of (E)-7-chloro-3,4-epoxy-
heptan-2-one. 
1H NMR (400 MHz, CD2Cl2) δ 3.47 (td, J = 6.6, 1.5 Hz, 2H, BrCH2), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.11-3.08 (m, 1H, CepoHCH2), 2.05-1.98 (m, 2H, BrCH2CH2), 2.03 (s, 3H, 
CH3), 1.92-1.83 (m, 1H, CHHCepoH), 1.73-1.65 (m, 1H, CHHCepoH). 
13C NMR (100 MHz, CD2Cl2): δ 205.2 (C=O), 59.5 (CepoHC(=O)), 57.1 (CepoHCH2), 33.0 
(BrCH2), 30.3 (CH2CepoH), 29.1 (BrCH2CH2), 24.4 (CH3). 
MS (EI) m/z (%) 165 (35), 163 (36), 135 (2), 121 (1), 109 (2), 95 (1), 85 (67), 69 (1), 55 (32), 
43 (100), 27 (15). 
HRMS (CI-FE) calcd for C7H12BrO2 [(M+H)+] 207.0020, found 207.0021. 
 
(E)-(3S,4R)-3,4-Epoxy-9-(tetrahydro-2H-pyran-2-yloxy)nonen-2-one ((3S,4R)-93h): 
Epoxide (3S,4R)-93h was prepared according to the general 
procedure. The reaction mixture was stirred for 18 h at 50 °C. 
Purification by flash column chromatography (silica gel, 20-
30% Et2O in pentane) provided the title compound 93h as a colorless oil (113 mg, 440 μmol, 
88%). The enantiomeric ratio was determined after deprotection of the Thp ether (cf. epoxide 
93l; vide infra). Characterized as mixture of Thp ether diastereomers. 
1H NMR (500 MHz, CD2Cl2) δ 4.53 (t, J = 3.7 Hz, 1H, O-CH-O), 3.84-3.79 (m, 1H, 
OCHHTHP), 3.69 (dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.48-3.43 (m, 1H, OCHHTHP), 3.35 
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13C NMR (125 MHz, CD2Cl2) δ 205.9 (C=O), 137.7 (CH=CH2), 115.9 (CH=CH2), 60.4 
(CHepoC(=O)), 58.1 (CH2CHepo), 31.6 (CH2), 30.5 (CH2), 25.0 (CH3). 
MS (EI-DE) m/z (%) 140 [M+] (trace), 107 (3), 97 (34), 85 (30), 79 (8), 73 (3), 67 (11), 57 
(22), 55 (11), 43 (100), 41 (34), 39 (18), 27 (13). 
HRMS (CI-FE, i-butane) calcd for C8H13O2 [(M+H)+] 141.0916, found 141.0916. 
 
(E)-(3S,4R)-7-Bromo-3,4-epoxy-2-heptanone ((3S,4R)-93g): Epoxide (3S,4R)-93g was 
prepared according to the general procedure. The reaction mixture was 
stirred for 18 h at 50 °C. Purification by flash column chromatography 
(silica gel, 10-25% Et2O in pentane) provided the title compound 93g as 
a colorless oil (77 mg, 374 μmol, 75%; 98.5:1.5 er). The enantiomeric ratio was determined 
by GC using a chiral BGB-176/BGB-15 column 30 m (100 °C, 1.2 °C/min until 135 °C, 18 
°C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 19.40 min, minor 
enantiomer: τR = 20.75 min. Contains 11% (determined by GC) of (E)-7-chloro-3,4-epoxy-
heptan-2-one. 
1H NMR (400 MHz, CD2Cl2) δ 3.47 (td, J = 6.6, 1.5 Hz, 2H, BrCH2), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.11-3.08 (m, 1H, CepoHCH2), 2.05-1.98 (m, 2H, BrCH2CH2), 2.03 (s, 3H, 
CH3), 1.92-1.83 (m, 1H, CHHCepoH), 1.73-1.65 (m, 1H, CHHCepoH). 
13C NMR (100 MHz, CD2Cl2): δ 205.2 (C=O), 59.5 (CepoHC(=O)), 57.1 (CepoHCH2), 33.0 
(BrCH2), 30.3 (CH2CepoH), 29.1 (BrCH2CH2), 24.4 (CH3). 
MS (EI) m/z (%) 165 (35), 163 (36), 135 (2), 121 (1), 109 (2), 95 (1), 85 (67), 69 (1), 55 (32), 
43 (100), 27 (15). 
HRMS (CI-FE) calcd for C7H12BrO2 [(M+H)+] 207.0020, found 207.0021. 
 
(E)-(3S,4R)-3,4-Epoxy-9-(tetrahydro-2H-pyran-2-yloxy)nonen-2-one ((3S,4R)-93h): 
Epoxide (3S,4R)-93h was prepared according to the general 
procedure. The reaction mixture was stirred for 18 h at 50 °C. 
Purification by flash column chromatography (silica gel, 20-
30% Et2O in pentane) provided the title compound 93h as a colorless oil (113 mg, 440 μmol, 
88%). The enantiomeric ratio was determined after deprotection of the Thp ether (cf. epoxide 
93l; vide infra). Characterized as mixture of Thp ether diastereomers. 
1H NMR (500 MHz, CD2Cl2) δ 4.53 (t, J = 3.7 Hz, 1H, O-CH-O), 3.84-3.79 (m, 1H, 
OCHHTHP), 3.69 (dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.48-3.43 (m, 1H, OCHHTHP), 3.35 
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(dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.15 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.06 (td, J = 5.2, 
1.9 Hz, 1H, CepoHCH2), 2.03 (s, 3H, CH3), 1.83-1.75 (m, 1H, CH2), 1.69-1.39 (m, 13H, CH2). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 98.9 (O-CH-O), 67.2 (THPOCH2), 62.2 
(OCH2, THP), 59.9 (CepoHC(=O)), 58.0 (CepoHCH2), 31.8 (CH2), 30.9 (OCHCH2), 29.7 (CH2), 
26.0 (CH2), 25.7 (CH2), 25.6 (CH2), 24.3 (CH3), 19.8 (CH2). 
MS (EI-DE) m/z (%) 256 [M+] (trace), 239 (1), 225 (2), 185 (1), 156 (11), 140 (10), 126 (6), 
111 (2), 97 (17), 85 (100), 81 (10), 67 (14), 55 (14), 43 (50), 29 (8). 
HRMS (ESI+) calcd for C14H24NaO4 [(M+Na)+] 279.1565, found 279.1567. 
 
(E)-(3S,4R)-3,4-Epoxy-9-hydroxy-2-nonanone (93l): To a vial containing Thp ether 93h 
(40.0 mg, 156 μmol) dissolved in acetonitrile (1.6 mL) and borate 
buffer (pH = 8) (1.6 mL), was added with stirring CAN (2.7 mg, 
4.68 μmol, 3 mol%). After 3 h at 60 °C, the mixture was cooled to 
room temperature, diluted with water (4 mL) and repeatedly extracted with Et2O (3×10 mL). 
The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. After purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in CH2Cl2) the alcohol 93l (24 mg, 138 μmol, 88%; 
98:2 er) was obtained as a colorless oil. The enantiomeric ratio was determined by GC using a 
chiral Ivadex 1 column 25 m (80 °C, 1.0 °C/min until 155 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 60.50 min, minor enantiomer: τR = 61.21 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.60 (t, J = 6.5 Hz, 2H, CH2OH), 3.15 (d, J = 1.6 Hz, 1H, 
CepoHC=O), 3.06 (td, J = 5.6, 1.6 Hz, 1H, CH2CepoH), 2.03 (s, 3H, CH3), 1.69-1.37 (m, 9H, 
CH2 and OH). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 62.6 (CH2OH), 59.9 (CepoHC(=O)), 58.0 
(CH2CepoH), 32.7 (CH2), 31.8 (CH2), 25.7 (CH2), 25.5 (CH2), 24.3 (CH3). 
MS (EI) m/z (%) 129 (1), 111 (2), 99 (3), 93 (4), 85 (36), 81 (13), 67 (8), 55 (31), 43 (100), 39 
(9), 31 (18). 
HRMS (CI-DE) calcd for C9H17O3 [(M+H)+] 173.1176, found 173.1178. 
 
(E)-(3S,4R)-3,4-Epoxy-6-tert-butyldimethylsilyloxyhexan-2-one ((3S,4R)-93i): Epoxide 93i 
was prepared according to the general procedure. The reaction mixture 
was stirred for 18 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 1-10% Et2O in pentane) provided the title compound 
93i as a colorless oil (88 mg, 359 μmol, 72%; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 
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(dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.15 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.06 (td, J = 5.2, 
1.9 Hz, 1H, CepoHCH2), 2.03 (s, 3H, CH3), 1.83-1.75 (m, 1H, CH2), 1.69-1.39 (m, 13H, CH2). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 98.9 (O-CH-O), 67.2 (THPOCH2), 62.2 
(OCH2, THP), 59.9 (CepoHC(=O)), 58.0 (CepoHCH2), 31.8 (CH2), 30.9 (OCHCH2), 29.7 (CH2), 
26.0 (CH2), 25.7 (CH2), 25.6 (CH2), 24.3 (CH3), 19.8 (CH2). 
MS (EI-DE) m/z (%) 256 [M+] (trace), 239 (1), 225 (2), 185 (1), 156 (11), 140 (10), 126 (6), 
111 (2), 97 (17), 85 (100), 81 (10), 67 (14), 55 (14), 43 (50), 29 (8). 
HRMS (ESI+) calcd for C14H24NaO4 [(M+Na)+] 279.1565, found 279.1567. 
 
(E)-(3S,4R)-3,4-Epoxy-9-hydroxy-2-nonanone (93l): To a vial containing Thp ether 93h 
(40.0 mg, 156 μmol) dissolved in acetonitrile (1.6 mL) and borate 
buffer (pH = 8) (1.6 mL), was added with stirring CAN (2.7 mg, 
4.68 μmol, 3 mol%). After 3 h at 60 °C, the mixture was cooled to 
room temperature, diluted with water (4 mL) and repeatedly extracted with Et2O (3×10 mL). 
The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. After purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in CH2Cl2) the alcohol 93l (24 mg, 138 μmol, 88%; 
98:2 er) was obtained as a colorless oil. The enantiomeric ratio was determined by GC using a 
chiral Ivadex 1 column 25 m (80 °C, 1.0 °C/min until 155 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 60.50 min, minor enantiomer: τR = 61.21 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.60 (t, J = 6.5 Hz, 2H, CH2OH), 3.15 (d, J = 1.6 Hz, 1H, 
CepoHC=O), 3.06 (td, J = 5.6, 1.6 Hz, 1H, CH2CepoH), 2.03 (s, 3H, CH3), 1.69-1.37 (m, 9H, 
CH2 and OH). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 62.6 (CH2OH), 59.9 (CepoHC(=O)), 58.0 
(CH2CepoH), 32.7 (CH2), 31.8 (CH2), 25.7 (CH2), 25.5 (CH2), 24.3 (CH3). 
MS (EI) m/z (%) 129 (1), 111 (2), 99 (3), 93 (4), 85 (36), 81 (13), 67 (8), 55 (31), 43 (100), 39 
(9), 31 (18). 
HRMS (CI-DE) calcd for C9H17O3 [(M+H)+] 173.1176, found 173.1178. 
 
(E)-(3S,4R)-3,4-Epoxy-6-tert-butyldimethylsilyloxyhexan-2-one ((3S,4R)-93i): Epoxide 93i 
was prepared according to the general procedure. The reaction mixture 
was stirred for 18 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 1-10% Et2O in pentane) provided the title compound 
93i as a colorless oil (88 mg, 359 μmol, 72%; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 
O
HO
O
C9H16O3
172,22
TBSO
O
O
C12H24O3Si
244,40
7 Experimental Part 
 201
(dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.15 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.06 (td, J = 5.2, 
1.9 Hz, 1H, CepoHCH2), 2.03 (s, 3H, CH3), 1.83-1.75 (m, 1H, CH2), 1.69-1.39 (m, 13H, CH2). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 98.9 (O-CH-O), 67.2 (THPOCH2), 62.2 
(OCH2, THP), 59.9 (CepoHC(=O)), 58.0 (CepoHCH2), 31.8 (CH2), 30.9 (OCHCH2), 29.7 (CH2), 
26.0 (CH2), 25.7 (CH2), 25.6 (CH2), 24.3 (CH3), 19.8 (CH2). 
MS (EI-DE) m/z (%) 256 [M+] (trace), 239 (1), 225 (2), 185 (1), 156 (11), 140 (10), 126 (6), 
111 (2), 97 (17), 85 (100), 81 (10), 67 (14), 55 (14), 43 (50), 29 (8). 
HRMS (ESI+) calcd for C14H24NaO4 [(M+Na)+] 279.1565, found 279.1567. 
 
(E)-(3S,4R)-3,4-Epoxy-9-hydroxy-2-nonanone (93l): To a vial containing Thp ether 93h 
(40.0 mg, 156 μmol) dissolved in acetonitrile (1.6 mL) and borate 
buffer (pH = 8) (1.6 mL), was added with stirring CAN (2.7 mg, 
4.68 μmol, 3 mol%). After 3 h at 60 °C, the mixture was cooled to 
room temperature, diluted with water (4 mL) and repeatedly extracted with Et2O (3×10 mL). 
The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. After purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in CH2Cl2) the alcohol 93l (24 mg, 138 μmol, 88%; 
98:2 er) was obtained as a colorless oil. The enantiomeric ratio was determined by GC using a 
chiral Ivadex 1 column 25 m (80 °C, 1.0 °C/min until 155 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 60.50 min, minor enantiomer: τR = 61.21 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.60 (t, J = 6.5 Hz, 2H, CH2OH), 3.15 (d, J = 1.6 Hz, 1H, 
CepoHC=O), 3.06 (td, J = 5.6, 1.6 Hz, 1H, CH2CepoH), 2.03 (s, 3H, CH3), 1.69-1.37 (m, 9H, 
CH2 and OH). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 62.6 (CH2OH), 59.9 (CepoHC(=O)), 58.0 
(CH2CepoH), 32.7 (CH2), 31.8 (CH2), 25.7 (CH2), 25.5 (CH2), 24.3 (CH3). 
MS (EI) m/z (%) 129 (1), 111 (2), 99 (3), 93 (4), 85 (36), 81 (13), 67 (8), 55 (31), 43 (100), 39 
(9), 31 (18). 
HRMS (CI-DE) calcd for C9H17O3 [(M+H)+] 173.1176, found 173.1178. 
 
(E)-(3S,4R)-3,4-Epoxy-6-tert-butyldimethylsilyloxyhexan-2-one ((3S,4R)-93i): Epoxide 93i 
was prepared according to the general procedure. The reaction mixture 
was stirred for 18 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 1-10% Et2O in pentane) provided the title compound 
93i as a colorless oil (88 mg, 359 μmol, 72%; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 
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(dt, J = 9.5, 6.6 Hz, 1H, THPOCHH), 3.15 (d, J = 1.9 Hz, 1H, CepoHC(=O)), 3.06 (td, J = 5.2, 
1.9 Hz, 1H, CepoHCH2), 2.03 (s, 3H, CH3), 1.83-1.75 (m, 1H, CH2), 1.69-1.39 (m, 13H, CH2). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 98.9 (O-CH-O), 67.2 (THPOCH2), 62.2 
(OCH2, THP), 59.9 (CepoHC(=O)), 58.0 (CepoHCH2), 31.8 (CH2), 30.9 (OCHCH2), 29.7 (CH2), 
26.0 (CH2), 25.7 (CH2), 25.6 (CH2), 24.3 (CH3), 19.8 (CH2). 
MS (EI-DE) m/z (%) 256 [M+] (trace), 239 (1), 225 (2), 185 (1), 156 (11), 140 (10), 126 (6), 
111 (2), 97 (17), 85 (100), 81 (10), 67 (14), 55 (14), 43 (50), 29 (8). 
HRMS (ESI+) calcd for C14H24NaO4 [(M+Na)+] 279.1565, found 279.1567. 
 
(E)-(3S,4R)-3,4-Epoxy-9-hydroxy-2-nonanone (93l): To a vial containing Thp ether 93h 
(40.0 mg, 156 μmol) dissolved in acetonitrile (1.6 mL) and borate 
buffer (pH = 8) (1.6 mL), was added with stirring CAN (2.7 mg, 
4.68 μmol, 3 mol%). After 3 h at 60 °C, the mixture was cooled to 
room temperature, diluted with water (4 mL) and repeatedly extracted with Et2O (3×10 mL). 
The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. After purification of the crude product by flash column 
chromatography (silica gel, 5-30% Et2O in CH2Cl2) the alcohol 93l (24 mg, 138 μmol, 88%; 
98:2 er) was obtained as a colorless oil. The enantiomeric ratio was determined by GC using a 
chiral Ivadex 1 column 25 m (80 °C, 1.0 °C/min until 155 °C, 20 °C/min until 220 °C, 10 min 
at 320 °C, 0.6 bar H2); major enantiomer: τR = 60.50 min, minor enantiomer: τR = 61.21 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.60 (t, J = 6.5 Hz, 2H, CH2OH), 3.15 (d, J = 1.6 Hz, 1H, 
CepoHC=O), 3.06 (td, J = 5.6, 1.6 Hz, 1H, CH2CepoH), 2.03 (s, 3H, CH3), 1.69-1.37 (m, 9H, 
CH2 and OH). 
13C NMR (125 MHz, CD2Cl2) 205.7 (C=O), 62.6 (CH2OH), 59.9 (CepoHC(=O)), 58.0 
(CH2CepoH), 32.7 (CH2), 31.8 (CH2), 25.7 (CH2), 25.5 (CH2), 24.3 (CH3). 
MS (EI) m/z (%) 129 (1), 111 (2), 99 (3), 93 (4), 85 (36), 81 (13), 67 (8), 55 (31), 43 (100), 39 
(9), 31 (18). 
HRMS (CI-DE) calcd for C9H17O3 [(M+H)+] 173.1176, found 173.1178. 
 
(E)-(3S,4R)-3,4-Epoxy-6-tert-butyldimethylsilyloxyhexan-2-one ((3S,4R)-93i): Epoxide 93i 
was prepared according to the general procedure. The reaction mixture 
was stirred for 18 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 1-10% Et2O in pentane) provided the title compound 
93i as a colorless oil (88 mg, 359 μmol, 72%; 98.5:1.5 er). The enantiomeric ratio was 
determined by GC using a chiral BGB-176/BGB-15 column 30 m (80 °C, 1.2 °C/min until 
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125 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 34.31 
min, minor enantiomer: τR = 35.48 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.76 (t, J = 6.3 Hz, 2H, TBSOCH2), 3.22-3.19 (m, 2H, 
CepoH), 2.03 (s, 3H, CH3C(=O)), 1.87-1.81 (m, 1H, CepoHCHH), 1.79-1.73 (m, 1H, 
CepoHCHH), 0.90 (s, 9H, Cq(CH3)3), 0.07 (s, 3H, Si(CH3)2), 0.06 (s, 3H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 59.9 (CepoHC(=O)), 59.6 (TBSOCH2), 55.9 
(CH2CepoH), 35.1 (CH2CepoH), 25.7 (3C, C(CH3)3), 24.3 (CqMe3), 18.2 (CH3C(=O)), −5.7 
(2C, Si(CH3)2). 
MS (EI) m/z (%) 220 (1), 205 (2), 199 (4), 187 (11), 169 (1), 157 (100), 143 (8), 131 (2), 115 
(7), 99 (4), 85 (3), 75 (16), 59 (4), 43 (9), 29 (1). 
HRMS (ESI+) calcd for C12H24O3SiNa [(M+Na)+] 267.1386, found 267.1387. 
 
(E)-(3S,4R)-Ethyl 4,5-epoxy-6-oxoheptanoate ((3S,4R)-93j): Epoxide (3S,4R)-93j was 
prepared according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Base treatment of the crude product with 
sodium ethoxide in THF followed by purification by flash column 
chromatography (silica gel, 15-30% Et2O in pentane) provided the title compound as a 
colorless oil (75 mg, 405 μmol, 81%; 98:2 er). The enantiomeric ratio was determined by GC 
using a chiral BGB-176/SE-52 column 30 m (80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 
220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 35.76 min, minor enantiomer: 
τR = 37.27 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.12 (q, J = 7.2 Hz, 2H, CH2CH3), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.16-3.14 (m, 1H, CepoHCH2), 2.45 (t, J = 7.3 Hz, 2H, CH2CO2Et), 2.03 (s, 3H, 
CH3C(=O)), 2.03-1.97 (m, 1H, CHHCepoH), 1.90-1.82 (m, 1H, CHHCepoH), 1.24 (t, J = 7.3 
Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2): δ 205.1 (C=O), 172.3 (CO2Et), 60.7 (CH2CH3), 59.8 
(CepoHC(=O)), 56.9 (CepoHCH2), 30.1 (CH2CO2Et), 27.0 (CH2CepoH), 24.5 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI) m/z (%) 186 [M+] (trace), 143 (13), 125 (1), 115 (29), 99 (15), 85 (30), 69 (7), 55 
(13), 43 (100), 29 (29). 
HRMS (CI-FE) calcd for C9H15O4 [(M+H)+] 187.0972, found 187.0970. 
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125 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 34.31 
min, minor enantiomer: τR = 35.48 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.76 (t, J = 6.3 Hz, 2H, TBSOCH2), 3.22-3.19 (m, 2H, 
CepoH), 2.03 (s, 3H, CH3C(=O)), 1.87-1.81 (m, 1H, CepoHCHH), 1.79-1.73 (m, 1H, 
CepoHCHH), 0.90 (s, 9H, Cq(CH3)3), 0.07 (s, 3H, Si(CH3)2), 0.06 (s, 3H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 59.9 (CepoHC(=O)), 59.6 (TBSOCH2), 55.9 
(CH2CepoH), 35.1 (CH2CepoH), 25.7 (3C, C(CH3)3), 24.3 (CqMe3), 18.2 (CH3C(=O)), −5.7 
(2C, Si(CH3)2). 
MS (EI) m/z (%) 220 (1), 205 (2), 199 (4), 187 (11), 169 (1), 157 (100), 143 (8), 131 (2), 115 
(7), 99 (4), 85 (3), 75 (16), 59 (4), 43 (9), 29 (1). 
HRMS (ESI+) calcd for C12H24O3SiNa [(M+Na)+] 267.1386, found 267.1387. 
 
(E)-(3S,4R)-Ethyl 4,5-epoxy-6-oxoheptanoate ((3S,4R)-93j): Epoxide (3S,4R)-93j was 
prepared according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Base treatment of the crude product with 
sodium ethoxide in THF followed by purification by flash column 
chromatography (silica gel, 15-30% Et2O in pentane) provided the title compound as a 
colorless oil (75 mg, 405 μmol, 81%; 98:2 er). The enantiomeric ratio was determined by GC 
using a chiral BGB-176/SE-52 column 30 m (80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 
220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 35.76 min, minor enantiomer: 
τR = 37.27 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.12 (q, J = 7.2 Hz, 2H, CH2CH3), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.16-3.14 (m, 1H, CepoHCH2), 2.45 (t, J = 7.3 Hz, 2H, CH2CO2Et), 2.03 (s, 3H, 
CH3C(=O)), 2.03-1.97 (m, 1H, CHHCepoH), 1.90-1.82 (m, 1H, CHHCepoH), 1.24 (t, J = 7.3 
Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2): δ 205.1 (C=O), 172.3 (CO2Et), 60.7 (CH2CH3), 59.8 
(CepoHC(=O)), 56.9 (CepoHCH2), 30.1 (CH2CO2Et), 27.0 (CH2CepoH), 24.5 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI) m/z (%) 186 [M+] (trace), 143 (13), 125 (1), 115 (29), 99 (15), 85 (30), 69 (7), 55 
(13), 43 (100), 29 (29). 
HRMS (CI-FE) calcd for C9H15O4 [(M+H)+] 187.0972, found 187.0970. 
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125 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 34.31 
min, minor enantiomer: τR = 35.48 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.76 (t, J = 6.3 Hz, 2H, TBSOCH2), 3.22-3.19 (m, 2H, 
CepoH), 2.03 (s, 3H, CH3C(=O)), 1.87-1.81 (m, 1H, CepoHCHH), 1.79-1.73 (m, 1H, 
CepoHCHH), 0.90 (s, 9H, Cq(CH3)3), 0.07 (s, 3H, Si(CH3)2), 0.06 (s, 3H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 59.9 (CepoHC(=O)), 59.6 (TBSOCH2), 55.9 
(CH2CepoH), 35.1 (CH2CepoH), 25.7 (3C, C(CH3)3), 24.3 (CqMe3), 18.2 (CH3C(=O)), −5.7 
(2C, Si(CH3)2). 
MS (EI) m/z (%) 220 (1), 205 (2), 199 (4), 187 (11), 169 (1), 157 (100), 143 (8), 131 (2), 115 
(7), 99 (4), 85 (3), 75 (16), 59 (4), 43 (9), 29 (1). 
HRMS (ESI+) calcd for C12H24O3SiNa [(M+Na)+] 267.1386, found 267.1387. 
 
(E)-(3S,4R)-Ethyl 4,5-epoxy-6-oxoheptanoate ((3S,4R)-93j): Epoxide (3S,4R)-93j was 
prepared according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Base treatment of the crude product with 
sodium ethoxide in THF followed by purification by flash column 
chromatography (silica gel, 15-30% Et2O in pentane) provided the title compound as a 
colorless oil (75 mg, 405 μmol, 81%; 98:2 er). The enantiomeric ratio was determined by GC 
using a chiral BGB-176/SE-52 column 30 m (80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 
220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 35.76 min, minor enantiomer: 
τR = 37.27 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.12 (q, J = 7.2 Hz, 2H, CH2CH3), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.16-3.14 (m, 1H, CepoHCH2), 2.45 (t, J = 7.3 Hz, 2H, CH2CO2Et), 2.03 (s, 3H, 
CH3C(=O)), 2.03-1.97 (m, 1H, CHHCepoH), 1.90-1.82 (m, 1H, CHHCepoH), 1.24 (t, J = 7.3 
Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2): δ 205.1 (C=O), 172.3 (CO2Et), 60.7 (CH2CH3), 59.8 
(CepoHC(=O)), 56.9 (CepoHCH2), 30.1 (CH2CO2Et), 27.0 (CH2CepoH), 24.5 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI) m/z (%) 186 [M+] (trace), 143 (13), 125 (1), 115 (29), 99 (15), 85 (30), 69 (7), 55 
(13), 43 (100), 29 (29). 
HRMS (CI-FE) calcd for C9H15O4 [(M+H)+] 187.0972, found 187.0970. 
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125 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 34.31 
min, minor enantiomer: τR = 35.48 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.76 (t, J = 6.3 Hz, 2H, TBSOCH2), 3.22-3.19 (m, 2H, 
CepoH), 2.03 (s, 3H, CH3C(=O)), 1.87-1.81 (m, 1H, CepoHCHH), 1.79-1.73 (m, 1H, 
CepoHCHH), 0.90 (s, 9H, Cq(CH3)3), 0.07 (s, 3H, Si(CH3)2), 0.06 (s, 3H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 59.9 (CepoHC(=O)), 59.6 (TBSOCH2), 55.9 
(CH2CepoH), 35.1 (CH2CepoH), 25.7 (3C, C(CH3)3), 24.3 (CqMe3), 18.2 (CH3C(=O)), −5.7 
(2C, Si(CH3)2). 
MS (EI) m/z (%) 220 (1), 205 (2), 199 (4), 187 (11), 169 (1), 157 (100), 143 (8), 131 (2), 115 
(7), 99 (4), 85 (3), 75 (16), 59 (4), 43 (9), 29 (1). 
HRMS (ESI+) calcd for C12H24O3SiNa [(M+Na)+] 267.1386, found 267.1387. 
 
(E)-(3S,4R)-Ethyl 4,5-epoxy-6-oxoheptanoate ((3S,4R)-93j): Epoxide (3S,4R)-93j was 
prepared according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Base treatment of the crude product with 
sodium ethoxide in THF followed by purification by flash column 
chromatography (silica gel, 15-30% Et2O in pentane) provided the title compound as a 
colorless oil (75 mg, 405 μmol, 81%; 98:2 er). The enantiomeric ratio was determined by GC 
using a chiral BGB-176/SE-52 column 30 m (80 °C, 1.2 °C/min until 130 °C, 20 °C/min until 
220 °C, 10 min at 220 °C, 0.5 bar H2); major enantiomer: τR = 35.76 min, minor enantiomer: 
τR = 37.27 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.12 (q, J = 7.2 Hz, 2H, CH2CH3), 3.20 (d, J = 2.1 Hz, 1H, 
CepoHC(=O)), 3.16-3.14 (m, 1H, CepoHCH2), 2.45 (t, J = 7.3 Hz, 2H, CH2CO2Et), 2.03 (s, 3H, 
CH3C(=O)), 2.03-1.97 (m, 1H, CHHCepoH), 1.90-1.82 (m, 1H, CHHCepoH), 1.24 (t, J = 7.3 
Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2): δ 205.1 (C=O), 172.3 (CO2Et), 60.7 (CH2CH3), 59.8 
(CepoHC(=O)), 56.9 (CepoHCH2), 30.1 (CH2CO2Et), 27.0 (CH2CepoH), 24.5 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI) m/z (%) 186 [M+] (trace), 143 (13), 125 (1), 115 (29), 99 (15), 85 (30), 69 (7), 55 
(13), 43 (100), 29 (29). 
HRMS (CI-FE) calcd for C9H15O4 [(M+H)+] 187.0972, found 187.0970. 
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(E)-(3S,4R)-7-Oxo-3,4-epoxy-2-octanone ((3S,4R)-93k): Epoxide (3S,4R)-93k was prepared 
according to the general procedure. The reaction mixture was stirred for 
24 h at 50 °C. Base treatment of the crude product was omitted. 
Purification by flash column chromatography (silica gel, 10-30% Et2O in 
pentane) provided the title compound as a colorless oil (31 mg, 202 μmol, 40%; 98.5:1.5 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/SE-52 column 30 m 
(80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 29.03 min, minor enantiomer: τR = 30.33 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.17 (d, J = 1.8 Hz, 1H, CHepoC(=O)), 3.12-3.10 (m, 1H, 
CepoHCH2), 2.56 (t, J = 7.0 Hz, 2H, CH2C(=O)), 2.13 (s, 3H, CH2C(=O)CH3), 2.01 (s, 3H, 
CHepoC(=O)CH3), 2.00-1.93 (m, 1H, CHHCepoH), 1.78-1.72 (m, 1H, CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 207.1 (CH2C=O), 205.6 (CepoHC=O), 60.2 (CepoHC(=O)), 
57.3 (CH2CepoH), 39.2 (CH2C(=O)), 30.0 (CH3C(=O)CH2), 25.9 (CH2CepoH), 24.7 
(CH3C(=O)CHepo). 
 
(E)-(4S,5R)-4,5-Epoxy-3-hexanone ((4S,5R)-93c): Epoxide (4S,5R)-93c was prepared 
according to the general procedure. The reaction mixture was stirred for 12 h 
at 50 °C. Purification by flash column chromatography (silica gel, 1-20% Et2O 
in pentane) provided the title compound 93c as a colorless oil (63 mg, 552 
μmol, 55% (reduced yield due to the high volatility of 93c); 98.5:1.5 er). The enantiomeric 
ratio was determined by GC using a chiral BGB-178/OV-1701 30 m column (60 °C, 1.0 
°C/min until 70 °C 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: 
τR = 12.45 min, minor enantiomer: τR = 12.74 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.15 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.10 (qd, J = 5.1, 2.0 
Hz, 1H, CH3CHepo), 2.44 (dq, J = 18.3, 7.4 Hz, 1H, CHH), 2.31 (dq, J = 18.5, 7.2 Hz, 1H, 
CHH), 1.37 (d, J = 5.2 Hz, 3H, CH3CHepo), 1.00 (t, J = 7.3 Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.3 (C=O), 60.9 (CHepoC(=O)), 55.0 (CH3CHepo), 31.2 
(CH2), 17.9 (CH3CHepo), 7.3 (CH2CH3). 
GC-MS (GC-EI) m/z (%) 114 [M+] (1), 99 (17), 85 (14), 83 (2), 69 (70), 57 (75), 53 (6), 43 
(14), 41 (42), 39 (18), 29 (100), 27 (26). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
 
O
O
O
C8H12O3
156,18
O
O
C6H10O2
114,14
7 Experimental Part 
 203
(E)-(3S,4R)-7-Oxo-3,4-epoxy-2-octanone ((3S,4R)-93k): Epoxide (3S,4R)-93k was prepared 
according to the general procedure. The reaction mixture was stirred for 
24 h at 50 °C. Base treatment of the crude product was omitted. 
Purification by flash column chromatography (silica gel, 10-30% Et2O in 
pentane) provided the title compound as a colorless oil (31 mg, 202 μmol, 40%; 98.5:1.5 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/SE-52 column 30 m 
(80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 29.03 min, minor enantiomer: τR = 30.33 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.17 (d, J = 1.8 Hz, 1H, CHepoC(=O)), 3.12-3.10 (m, 1H, 
CepoHCH2), 2.56 (t, J = 7.0 Hz, 2H, CH2C(=O)), 2.13 (s, 3H, CH2C(=O)CH3), 2.01 (s, 3H, 
CHepoC(=O)CH3), 2.00-1.93 (m, 1H, CHHCepoH), 1.78-1.72 (m, 1H, CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 207.1 (CH2C=O), 205.6 (CepoHC=O), 60.2 (CepoHC(=O)), 
57.3 (CH2CepoH), 39.2 (CH2C(=O)), 30.0 (CH3C(=O)CH2), 25.9 (CH2CepoH), 24.7 
(CH3C(=O)CHepo). 
 
(E)-(4S,5R)-4,5-Epoxy-3-hexanone ((4S,5R)-93c): Epoxide (4S,5R)-93c was prepared 
according to the general procedure. The reaction mixture was stirred for 12 h 
at 50 °C. Purification by flash column chromatography (silica gel, 1-20% Et2O 
in pentane) provided the title compound 93c as a colorless oil (63 mg, 552 
μmol, 55% (reduced yield due to the high volatility of 93c); 98.5:1.5 er). The enantiomeric 
ratio was determined by GC using a chiral BGB-178/OV-1701 30 m column (60 °C, 1.0 
°C/min until 70 °C 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: 
τR = 12.45 min, minor enantiomer: τR = 12.74 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.15 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.10 (qd, J = 5.1, 2.0 
Hz, 1H, CH3CHepo), 2.44 (dq, J = 18.3, 7.4 Hz, 1H, CHH), 2.31 (dq, J = 18.5, 7.2 Hz, 1H, 
CHH), 1.37 (d, J = 5.2 Hz, 3H, CH3CHepo), 1.00 (t, J = 7.3 Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.3 (C=O), 60.9 (CHepoC(=O)), 55.0 (CH3CHepo), 31.2 
(CH2), 17.9 (CH3CHepo), 7.3 (CH2CH3). 
GC-MS (GC-EI) m/z (%) 114 [M+] (1), 99 (17), 85 (14), 83 (2), 69 (70), 57 (75), 53 (6), 43 
(14), 41 (42), 39 (18), 29 (100), 27 (26). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
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(E)-(3S,4R)-7-Oxo-3,4-epoxy-2-octanone ((3S,4R)-93k): Epoxide (3S,4R)-93k was prepared 
according to the general procedure. The reaction mixture was stirred for 
24 h at 50 °C. Base treatment of the crude product was omitted. 
Purification by flash column chromatography (silica gel, 10-30% Et2O in 
pentane) provided the title compound as a colorless oil (31 mg, 202 μmol, 40%; 98.5:1.5 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/SE-52 column 30 m 
(80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 29.03 min, minor enantiomer: τR = 30.33 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.17 (d, J = 1.8 Hz, 1H, CHepoC(=O)), 3.12-3.10 (m, 1H, 
CepoHCH2), 2.56 (t, J = 7.0 Hz, 2H, CH2C(=O)), 2.13 (s, 3H, CH2C(=O)CH3), 2.01 (s, 3H, 
CHepoC(=O)CH3), 2.00-1.93 (m, 1H, CHHCepoH), 1.78-1.72 (m, 1H, CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 207.1 (CH2C=O), 205.6 (CepoHC=O), 60.2 (CepoHC(=O)), 
57.3 (CH2CepoH), 39.2 (CH2C(=O)), 30.0 (CH3C(=O)CH2), 25.9 (CH2CepoH), 24.7 
(CH3C(=O)CHepo). 
 
(E)-(4S,5R)-4,5-Epoxy-3-hexanone ((4S,5R)-93c): Epoxide (4S,5R)-93c was prepared 
according to the general procedure. The reaction mixture was stirred for 12 h 
at 50 °C. Purification by flash column chromatography (silica gel, 1-20% Et2O 
in pentane) provided the title compound 93c as a colorless oil (63 mg, 552 
μmol, 55% (reduced yield due to the high volatility of 93c); 98.5:1.5 er). The enantiomeric 
ratio was determined by GC using a chiral BGB-178/OV-1701 30 m column (60 °C, 1.0 
°C/min until 70 °C 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: 
τR = 12.45 min, minor enantiomer: τR = 12.74 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.15 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.10 (qd, J = 5.1, 2.0 
Hz, 1H, CH3CHepo), 2.44 (dq, J = 18.3, 7.4 Hz, 1H, CHH), 2.31 (dq, J = 18.5, 7.2 Hz, 1H, 
CHH), 1.37 (d, J = 5.2 Hz, 3H, CH3CHepo), 1.00 (t, J = 7.3 Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.3 (C=O), 60.9 (CHepoC(=O)), 55.0 (CH3CHepo), 31.2 
(CH2), 17.9 (CH3CHepo), 7.3 (CH2CH3). 
GC-MS (GC-EI) m/z (%) 114 [M+] (1), 99 (17), 85 (14), 83 (2), 69 (70), 57 (75), 53 (6), 43 
(14), 41 (42), 39 (18), 29 (100), 27 (26). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
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(E)-(3S,4R)-7-Oxo-3,4-epoxy-2-octanone ((3S,4R)-93k): Epoxide (3S,4R)-93k was prepared 
according to the general procedure. The reaction mixture was stirred for 
24 h at 50 °C. Base treatment of the crude product was omitted. 
Purification by flash column chromatography (silica gel, 10-30% Et2O in 
pentane) provided the title compound as a colorless oil (31 mg, 202 μmol, 40%; 98.5:1.5 er). 
The enantiomeric ratio was determined by GC using a chiral BGB-176/SE-52 column 30 m 
(80 °C, 1.2 °C/min until 120 °C, 20 °C/min until 220 °C, 10 min at 220 °C, 0.5 bar H2); major 
enantiomer: τR = 29.03 min, minor enantiomer: τR = 30.33 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.17 (d, J = 1.8 Hz, 1H, CHepoC(=O)), 3.12-3.10 (m, 1H, 
CepoHCH2), 2.56 (t, J = 7.0 Hz, 2H, CH2C(=O)), 2.13 (s, 3H, CH2C(=O)CH3), 2.01 (s, 3H, 
CHepoC(=O)CH3), 2.00-1.93 (m, 1H, CHHCepoH), 1.78-1.72 (m, 1H, CHHCepoH). 
13C NMR (125 MHz, CD2Cl2) δ 207.1 (CH2C=O), 205.6 (CepoHC=O), 60.2 (CepoHC(=O)), 
57.3 (CH2CepoH), 39.2 (CH2C(=O)), 30.0 (CH3C(=O)CH2), 25.9 (CH2CepoH), 24.7 
(CH3C(=O)CHepo). 
 
(E)-(4S,5R)-4,5-Epoxy-3-hexanone ((4S,5R)-93c): Epoxide (4S,5R)-93c was prepared 
according to the general procedure. The reaction mixture was stirred for 12 h 
at 50 °C. Purification by flash column chromatography (silica gel, 1-20% Et2O 
in pentane) provided the title compound 93c as a colorless oil (63 mg, 552 
μmol, 55% (reduced yield due to the high volatility of 93c); 98.5:1.5 er). The enantiomeric 
ratio was determined by GC using a chiral BGB-178/OV-1701 30 m column (60 °C, 1.0 
°C/min until 70 °C 20 °C/min until 220 °C, 10 min at 220 °C, 0.4 bar H2); major enantiomer: 
τR = 12.45 min, minor enantiomer: τR = 12.74 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.15 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.10 (qd, J = 5.1, 2.0 
Hz, 1H, CH3CHepo), 2.44 (dq, J = 18.3, 7.4 Hz, 1H, CHH), 2.31 (dq, J = 18.5, 7.2 Hz, 1H, 
CHH), 1.37 (d, J = 5.2 Hz, 3H, CH3CHepo), 1.00 (t, J = 7.3 Hz, 3H, CH2CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.3 (C=O), 60.9 (CHepoC(=O)), 55.0 (CH3CHepo), 31.2 
(CH2), 17.9 (CH3CHepo), 7.3 (CH2CH3). 
GC-MS (GC-EI) m/z (%) 114 [M+] (1), 99 (17), 85 (14), 83 (2), 69 (70), 57 (75), 53 (6), 43 
(14), 41 (42), 39 (18), 29 (100), 27 (26). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
 
O
O
O
C8H12O3
156,18
O
O
C6H10O2
114,14
7  Experimental Part 
204 
(E)-(4S,5R)-4,5-Epoxy-3-tetradecanone ((4S,5R)-93p): Epoxide (4S,5R)-93p was prepared 
according to the general procedure. The reaction mixture 
was stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) 
provided the title compound 93p as a colorless oil (185 mg, 817 μmol, 82%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Lipodex E column 25 m (100 °C, 1.2 
°C/min until 180 °C, 18 °C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: 
τR = 30.53 min, minor enantiomer: τR = 29.18 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.44 (dq, J = 18.3, 7.3 Hz, 1H, CHHC(=O)), 2.32 (dq, J = 18.4, 7.2 Hz, 
1H, CHHC(=O)), 1.62-1.55 (m, 2H, CH2CHepo), 1.48-1.41 (m, 2H, CH2CH2CHepo), 1.35-1.26 
(m, 12H, (CH2)6CH3), 1.01 (t, J = 7.2 Hz, 3H, C(=O)CH2CH3), 0.88 (t, J = 7.0 Hz, 3H, 
(CH2)8CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.4 (C=O), 60.0 (CHepoC(=O)), 59.0 (CH2CHepo), 32.4 
(2C, CH2), 31.2 (CH2), 30.0 (2C, CH2), 29.8 (2C, CH2), 26.3 (CH2), 23.2 (CH2), 14.4 
((CH2)8CH3), 7.4 (C(=O)CH2CH3). 
MS (EI-DE) m/z (%) 226 [M+] (2), 197 (1), 179 (1), 169 (2), 151 (3), 127 (1), 109 (4), 99 
(43), 95 (11), 81 (7), 69 (6), 57 (100), 41 (15), 29 (26). 
HRMS (ESI+) calcd for C14H26NaO2 [(M+Na)+] 249.1826, found 249.1825. 
 
(E)-(7S,8R)-7,8-Epoxy-6-tridecanone ((7S,8R)-93m): Epoxide (7S,8R)-93m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided 
the title compound 93m as a colorless oil (161 mg, 758 μmol, 76%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral G-TA column 30 m (80 °C, 1.0 
°C/min until 125 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 bar H2); major 
enantiomer: τR = 44.18 min, minor enantiomer: τR = 43.42 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.18 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 2.0 
Hz, 1H, CH2CHepo), 2.41 (ddd, J = 17.3, 8.3, 6.5 Hz, 1H, CHHC(=O)), 2.28 (ddd, J = 17.3, 
8.2, 6.8 Hz, 1H, CHHC(=O)), 1.62-1.52 (m, 4H, CH2), 1.48-1.42 (m, 2H, CH2), 1.34-1.23 (m, 
8H, CH2), 0.91-0.87 (m, 6H, CH3). 
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(E)-(4S,5R)-4,5-Epoxy-3-tetradecanone ((4S,5R)-93p): Epoxide (4S,5R)-93p was prepared 
according to the general procedure. The reaction mixture 
was stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) 
provided the title compound 93p as a colorless oil (185 mg, 817 μmol, 82%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Lipodex E column 25 m (100 °C, 1.2 
°C/min until 180 °C, 18 °C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: 
τR = 30.53 min, minor enantiomer: τR = 29.18 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.44 (dq, J = 18.3, 7.3 Hz, 1H, CHHC(=O)), 2.32 (dq, J = 18.4, 7.2 Hz, 
1H, CHHC(=O)), 1.62-1.55 (m, 2H, CH2CHepo), 1.48-1.41 (m, 2H, CH2CH2CHepo), 1.35-1.26 
(m, 12H, (CH2)6CH3), 1.01 (t, J = 7.2 Hz, 3H, C(=O)CH2CH3), 0.88 (t, J = 7.0 Hz, 3H, 
(CH2)8CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.4 (C=O), 60.0 (CHepoC(=O)), 59.0 (CH2CHepo), 32.4 
(2C, CH2), 31.2 (CH2), 30.0 (2C, CH2), 29.8 (2C, CH2), 26.3 (CH2), 23.2 (CH2), 14.4 
((CH2)8CH3), 7.4 (C(=O)CH2CH3). 
MS (EI-DE) m/z (%) 226 [M+] (2), 197 (1), 179 (1), 169 (2), 151 (3), 127 (1), 109 (4), 99 
(43), 95 (11), 81 (7), 69 (6), 57 (100), 41 (15), 29 (26). 
HRMS (ESI+) calcd for C14H26NaO2 [(M+Na)+] 249.1826, found 249.1825. 
 
(E)-(7S,8R)-7,8-Epoxy-6-tridecanone ((7S,8R)-93m): Epoxide (7S,8R)-93m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided 
the title compound 93m as a colorless oil (161 mg, 758 μmol, 76%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral G-TA column 30 m (80 °C, 1.0 
°C/min until 125 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 bar H2); major 
enantiomer: τR = 44.18 min, minor enantiomer: τR = 43.42 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.18 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 2.0 
Hz, 1H, CH2CHepo), 2.41 (ddd, J = 17.3, 8.3, 6.5 Hz, 1H, CHHC(=O)), 2.28 (ddd, J = 17.3, 
8.2, 6.8 Hz, 1H, CHHC(=O)), 1.62-1.52 (m, 4H, CH2), 1.48-1.42 (m, 2H, CH2), 1.34-1.23 (m, 
8H, CH2), 0.91-0.87 (m, 6H, CH3). 
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(E)-(4S,5R)-4,5-Epoxy-3-tetradecanone ((4S,5R)-93p): Epoxide (4S,5R)-93p was prepared 
according to the general procedure. The reaction mixture 
was stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) 
provided the title compound 93p as a colorless oil (185 mg, 817 μmol, 82%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Lipodex E column 25 m (100 °C, 1.2 
°C/min until 180 °C, 18 °C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: 
τR = 30.53 min, minor enantiomer: τR = 29.18 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.44 (dq, J = 18.3, 7.3 Hz, 1H, CHHC(=O)), 2.32 (dq, J = 18.4, 7.2 Hz, 
1H, CHHC(=O)), 1.62-1.55 (m, 2H, CH2CHepo), 1.48-1.41 (m, 2H, CH2CH2CHepo), 1.35-1.26 
(m, 12H, (CH2)6CH3), 1.01 (t, J = 7.2 Hz, 3H, C(=O)CH2CH3), 0.88 (t, J = 7.0 Hz, 3H, 
(CH2)8CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.4 (C=O), 60.0 (CHepoC(=O)), 59.0 (CH2CHepo), 32.4 
(2C, CH2), 31.2 (CH2), 30.0 (2C, CH2), 29.8 (2C, CH2), 26.3 (CH2), 23.2 (CH2), 14.4 
((CH2)8CH3), 7.4 (C(=O)CH2CH3). 
MS (EI-DE) m/z (%) 226 [M+] (2), 197 (1), 179 (1), 169 (2), 151 (3), 127 (1), 109 (4), 99 
(43), 95 (11), 81 (7), 69 (6), 57 (100), 41 (15), 29 (26). 
HRMS (ESI+) calcd for C14H26NaO2 [(M+Na)+] 249.1826, found 249.1825. 
 
(E)-(7S,8R)-7,8-Epoxy-6-tridecanone ((7S,8R)-93m): Epoxide (7S,8R)-93m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided 
the title compound 93m as a colorless oil (161 mg, 758 μmol, 76%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral G-TA column 30 m (80 °C, 1.0 
°C/min until 125 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 bar H2); major 
enantiomer: τR = 44.18 min, minor enantiomer: τR = 43.42 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.18 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 2.0 
Hz, 1H, CH2CHepo), 2.41 (ddd, J = 17.3, 8.3, 6.5 Hz, 1H, CHHC(=O)), 2.28 (ddd, J = 17.3, 
8.2, 6.8 Hz, 1H, CHHC(=O)), 1.62-1.52 (m, 4H, CH2), 1.48-1.42 (m, 2H, CH2), 1.34-1.23 (m, 
8H, CH2), 0.91-0.87 (m, 6H, CH3). 
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(E)-(4S,5R)-4,5-Epoxy-3-tetradecanone ((4S,5R)-93p): Epoxide (4S,5R)-93p was prepared 
according to the general procedure. The reaction mixture 
was stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) 
provided the title compound 93p as a colorless oil (185 mg, 817 μmol, 82%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral Lipodex E column 25 m (100 °C, 1.2 
°C/min until 180 °C, 18 °C/min until 220 °C, 5 min at 220 °C, 0.5 bar H2); major enantiomer: 
τR = 30.53 min, minor enantiomer: τR = 29.18 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.19 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.44 (dq, J = 18.3, 7.3 Hz, 1H, CHHC(=O)), 2.32 (dq, J = 18.4, 7.2 Hz, 
1H, CHHC(=O)), 1.62-1.55 (m, 2H, CH2CHepo), 1.48-1.41 (m, 2H, CH2CH2CHepo), 1.35-1.26 
(m, 12H, (CH2)6CH3), 1.01 (t, J = 7.2 Hz, 3H, C(=O)CH2CH3), 0.88 (t, J = 7.0 Hz, 3H, 
(CH2)8CH3). 
13C NMR (125 MHz, CD2Cl2) δ 208.4 (C=O), 60.0 (CHepoC(=O)), 59.0 (CH2CHepo), 32.4 
(2C, CH2), 31.2 (CH2), 30.0 (2C, CH2), 29.8 (2C, CH2), 26.3 (CH2), 23.2 (CH2), 14.4 
((CH2)8CH3), 7.4 (C(=O)CH2CH3). 
MS (EI-DE) m/z (%) 226 [M+] (2), 197 (1), 179 (1), 169 (2), 151 (3), 127 (1), 109 (4), 99 
(43), 95 (11), 81 (7), 69 (6), 57 (100), 41 (15), 29 (26). 
HRMS (ESI+) calcd for C14H26NaO2 [(M+Na)+] 249.1826, found 249.1825. 
 
(E)-(7S,8R)-7,8-Epoxy-6-tridecanone ((7S,8R)-93m): Epoxide (7S,8R)-93m was prepared 
according to the general procedure. The reaction mixture was 
stirred for 24 h at 50 °C. Purification by flash column 
chromatography (silica gel, 1-20% Et2O in pentane) provided 
the title compound 93m as a colorless oil (161 mg, 758 μmol, 76%; 99:1 er). The 
enantiomeric ratio was determined by GC using a chiral G-TA column 30 m (80 °C, 1.0 
°C/min until 125 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 bar H2); major 
enantiomer: τR = 44.18 min, minor enantiomer: τR = 43.42 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.18 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 3.01 (td, J = 5.5, 2.0 
Hz, 1H, CH2CHepo), 2.41 (ddd, J = 17.3, 8.3, 6.5 Hz, 1H, CHHC(=O)), 2.28 (ddd, J = 17.3, 
8.2, 6.8 Hz, 1H, CHHC(=O)), 1.62-1.52 (m, 4H, CH2), 1.48-1.42 (m, 2H, CH2), 1.34-1.23 (m, 
8H, CH2), 0.91-0.87 (m, 6H, CH3). 
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13C NMR (125 MHz, CD2Cl2) δ 208.1 (C=O), 60.1 (CHepoC(=O)), 58.9 (CH2CHepo), 37.8 
(CH2C(=O)), 32.4 (CH2), 32.0 (CH2), 31.9 (CH2), 26.0 (CH2), 23.4 (CH2), 23.1 (CH2), 23.0 
(CH2), 14.3 (CH3), 14.2 (CH3). 
MS (EI-DE) m/z (%) 212 [M+] (6), 169 (1), 156 (3), 141 (58), 125 (4), 112 (7), 99 (98), 95 
(12), 82 (8), 71 (76), 55 (18), 43 (100), 29 (30). 
HRMS (ESI+) calcd for C13H24NaO2 [(M+Na)+] 235.1670, found 235.1668. 
 
(E)-(5S,6R)-5,6-Epoxy-2-methyl-4-undecanone ((5S,6R)-93n): Epoxide (5S,6R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The 
reaction mixture was stirred for 48 h at 50 °C. Base treatment of 
the crude product was omitted. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93n as a colorless oil (161 mg, 812 μmol, 
81%; >99.5:0.5 er). The enantiomeric ratio was determined by GC using a chiral G-TA 
column 30 m (80 °C, 1.0 °C/min until 115 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 
bar H2); major enantiomer: τR = 30.89 min, minor enantiomer: τR = 30.09 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.16 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 2.99 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.31 (dd, J = 16.0, 6.0 Hz, 1H, CHHi-Pr), 2.15 (dd, J = 16.2, 7.1 Hz, 1H, 
CHHi-Pr), 2.11 (hept, J = 6.5 Hz, 1H, CHMe2), 1.64-1.55 (m, 2H, CH2CHepo), 1.48-1.42 (m, 
2H, CH2CH2CHepo), 1.34-1.30 (m, 4H, (CH2)2CH3), 0.92-0.88 (m, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.7 (C=O), 60.2 (CHepoC(=O)), 58.7 (CH2CHepo), 46.7 
(CH2i-Pr), 32.4 (CH2), 32.0 (CH2), 26.0 (CH2), 24.6 (CHMe2), 23.1 (CH2), 22.9 (CH(CH3)2), 
22.8 (CH(CH3)2), 14.3 ((CH2)4CH3). 
MS (EI-DE) m/z (%) 198 [M+] (1), 183 (1), 155 (1), 141 (2), 127 (33), 113 (5), 95 (6), 85 
(75), 69 (5), 57 (100), 41 (30), 29 (18). 
HRMS (ESI+) calcd for C12H22NaO2 [(M+Na)+] 221.1513, found 221.1512. 
 
(E)-(4S,5R)-4,5-Epoxy-2-Methyl-3-hexanone ((4S,5R)-93o): Epoxide (4S,5R)-93o was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 2-7% Et2O in pentane) provided the title compound as a colorless liquid 
(77 mg, 604 μmol, 60% (reduced yield due to the high volatility of 93o); 96.5:3.5 er). THF (5 
mL) was used as solvent for the base treatment with aqueous 1N NaOH. The enantiomeric 
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13C NMR (125 MHz, CD2Cl2) δ 208.1 (C=O), 60.1 (CHepoC(=O)), 58.9 (CH2CHepo), 37.8 
(CH2C(=O)), 32.4 (CH2), 32.0 (CH2), 31.9 (CH2), 26.0 (CH2), 23.4 (CH2), 23.1 (CH2), 23.0 
(CH2), 14.3 (CH3), 14.2 (CH3). 
MS (EI-DE) m/z (%) 212 [M+] (6), 169 (1), 156 (3), 141 (58), 125 (4), 112 (7), 99 (98), 95 
(12), 82 (8), 71 (76), 55 (18), 43 (100), 29 (30). 
HRMS (ESI+) calcd for C13H24NaO2 [(M+Na)+] 235.1670, found 235.1668. 
 
(E)-(5S,6R)-5,6-Epoxy-2-methyl-4-undecanone ((5S,6R)-93n): Epoxide (5S,6R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The 
reaction mixture was stirred for 48 h at 50 °C. Base treatment of 
the crude product was omitted. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93n as a colorless oil (161 mg, 812 μmol, 
81%; >99.5:0.5 er). The enantiomeric ratio was determined by GC using a chiral G-TA 
column 30 m (80 °C, 1.0 °C/min until 115 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 
bar H2); major enantiomer: τR = 30.89 min, minor enantiomer: τR = 30.09 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.16 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 2.99 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.31 (dd, J = 16.0, 6.0 Hz, 1H, CHHi-Pr), 2.15 (dd, J = 16.2, 7.1 Hz, 1H, 
CHHi-Pr), 2.11 (hept, J = 6.5 Hz, 1H, CHMe2), 1.64-1.55 (m, 2H, CH2CHepo), 1.48-1.42 (m, 
2H, CH2CH2CHepo), 1.34-1.30 (m, 4H, (CH2)2CH3), 0.92-0.88 (m, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.7 (C=O), 60.2 (CHepoC(=O)), 58.7 (CH2CHepo), 46.7 
(CH2i-Pr), 32.4 (CH2), 32.0 (CH2), 26.0 (CH2), 24.6 (CHMe2), 23.1 (CH2), 22.9 (CH(CH3)2), 
22.8 (CH(CH3)2), 14.3 ((CH2)4CH3). 
MS (EI-DE) m/z (%) 198 [M+] (1), 183 (1), 155 (1), 141 (2), 127 (33), 113 (5), 95 (6), 85 
(75), 69 (5), 57 (100), 41 (30), 29 (18). 
HRMS (ESI+) calcd for C12H22NaO2 [(M+Na)+] 221.1513, found 221.1512. 
 
(E)-(4S,5R)-4,5-Epoxy-2-Methyl-3-hexanone ((4S,5R)-93o): Epoxide (4S,5R)-93o was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 2-7% Et2O in pentane) provided the title compound as a colorless liquid 
(77 mg, 604 μmol, 60% (reduced yield due to the high volatility of 93o); 96.5:3.5 er). THF (5 
mL) was used as solvent for the base treatment with aqueous 1N NaOH. The enantiomeric 
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13C NMR (125 MHz, CD2Cl2) δ 208.1 (C=O), 60.1 (CHepoC(=O)), 58.9 (CH2CHepo), 37.8 
(CH2C(=O)), 32.4 (CH2), 32.0 (CH2), 31.9 (CH2), 26.0 (CH2), 23.4 (CH2), 23.1 (CH2), 23.0 
(CH2), 14.3 (CH3), 14.2 (CH3). 
MS (EI-DE) m/z (%) 212 [M+] (6), 169 (1), 156 (3), 141 (58), 125 (4), 112 (7), 99 (98), 95 
(12), 82 (8), 71 (76), 55 (18), 43 (100), 29 (30). 
HRMS (ESI+) calcd for C13H24NaO2 [(M+Na)+] 235.1670, found 235.1668. 
 
(E)-(5S,6R)-5,6-Epoxy-2-methyl-4-undecanone ((5S,6R)-93n): Epoxide (5S,6R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The 
reaction mixture was stirred for 48 h at 50 °C. Base treatment of 
the crude product was omitted. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93n as a colorless oil (161 mg, 812 μmol, 
81%; >99.5:0.5 er). The enantiomeric ratio was determined by GC using a chiral G-TA 
column 30 m (80 °C, 1.0 °C/min until 115 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 
bar H2); major enantiomer: τR = 30.89 min, minor enantiomer: τR = 30.09 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.16 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 2.99 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.31 (dd, J = 16.0, 6.0 Hz, 1H, CHHi-Pr), 2.15 (dd, J = 16.2, 7.1 Hz, 1H, 
CHHi-Pr), 2.11 (hept, J = 6.5 Hz, 1H, CHMe2), 1.64-1.55 (m, 2H, CH2CHepo), 1.48-1.42 (m, 
2H, CH2CH2CHepo), 1.34-1.30 (m, 4H, (CH2)2CH3), 0.92-0.88 (m, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.7 (C=O), 60.2 (CHepoC(=O)), 58.7 (CH2CHepo), 46.7 
(CH2i-Pr), 32.4 (CH2), 32.0 (CH2), 26.0 (CH2), 24.6 (CHMe2), 23.1 (CH2), 22.9 (CH(CH3)2), 
22.8 (CH(CH3)2), 14.3 ((CH2)4CH3). 
MS (EI-DE) m/z (%) 198 [M+] (1), 183 (1), 155 (1), 141 (2), 127 (33), 113 (5), 95 (6), 85 
(75), 69 (5), 57 (100), 41 (30), 29 (18). 
HRMS (ESI+) calcd for C12H22NaO2 [(M+Na)+] 221.1513, found 221.1512. 
 
(E)-(4S,5R)-4,5-Epoxy-2-Methyl-3-hexanone ((4S,5R)-93o): Epoxide (4S,5R)-93o was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 2-7% Et2O in pentane) provided the title compound as a colorless liquid 
(77 mg, 604 μmol, 60% (reduced yield due to the high volatility of 93o); 96.5:3.5 er). THF (5 
mL) was used as solvent for the base treatment with aqueous 1N NaOH. The enantiomeric 
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13C NMR (125 MHz, CD2Cl2) δ 208.1 (C=O), 60.1 (CHepoC(=O)), 58.9 (CH2CHepo), 37.8 
(CH2C(=O)), 32.4 (CH2), 32.0 (CH2), 31.9 (CH2), 26.0 (CH2), 23.4 (CH2), 23.1 (CH2), 23.0 
(CH2), 14.3 (CH3), 14.2 (CH3). 
MS (EI-DE) m/z (%) 212 [M+] (6), 169 (1), 156 (3), 141 (58), 125 (4), 112 (7), 99 (98), 95 
(12), 82 (8), 71 (76), 55 (18), 43 (100), 29 (30). 
HRMS (ESI+) calcd for C13H24NaO2 [(M+Na)+] 235.1670, found 235.1668. 
 
(E)-(5S,6R)-5,6-Epoxy-2-methyl-4-undecanone ((5S,6R)-93n): Epoxide (5S,6R)-93e was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The 
reaction mixture was stirred for 48 h at 50 °C. Base treatment of 
the crude product was omitted. Purification by flash column chromatography (silica gel, 1-
20% Et2O in pentane) provided the title compound 93n as a colorless oil (161 mg, 812 μmol, 
81%; >99.5:0.5 er). The enantiomeric ratio was determined by GC using a chiral G-TA 
column 30 m (80 °C, 1.0 °C/min until 115 °C, 20 °C/min until 180 °C, 10 min at 180 °C, 0.9 
bar H2); major enantiomer: τR = 30.89 min, minor enantiomer: τR = 30.09 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.16 (d, J = 2.0 Hz, 1H, CHepoC(=O)), 2.99 (td, J = 5.5, 1.9 
Hz, 1H, CH2CHepo), 2.31 (dd, J = 16.0, 6.0 Hz, 1H, CHHi-Pr), 2.15 (dd, J = 16.2, 7.1 Hz, 1H, 
CHHi-Pr), 2.11 (hept, J = 6.5 Hz, 1H, CHMe2), 1.64-1.55 (m, 2H, CH2CHepo), 1.48-1.42 (m, 
2H, CH2CH2CHepo), 1.34-1.30 (m, 4H, (CH2)2CH3), 0.92-0.88 (m, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 207.7 (C=O), 60.2 (CHepoC(=O)), 58.7 (CH2CHepo), 46.7 
(CH2i-Pr), 32.4 (CH2), 32.0 (CH2), 26.0 (CH2), 24.6 (CHMe2), 23.1 (CH2), 22.9 (CH(CH3)2), 
22.8 (CH(CH3)2), 14.3 ((CH2)4CH3). 
MS (EI-DE) m/z (%) 198 [M+] (1), 183 (1), 155 (1), 141 (2), 127 (33), 113 (5), 95 (6), 85 
(75), 69 (5), 57 (100), 41 (30), 29 (18). 
HRMS (ESI+) calcd for C12H22NaO2 [(M+Na)+] 221.1513, found 221.1512. 
 
(E)-(4S,5R)-4,5-Epoxy-2-Methyl-3-hexanone ((4S,5R)-93o): Epoxide (4S,5R)-93o was 
prepared according to the general procedure. 20 mol% of catalyst 
[13 • 2 TFA] was used under otherwise identical conditions. The reaction 
mixture was stirred for 48 h at 50 °C. Purification by flash column chromato-
graphy (silica gel, 2-7% Et2O in pentane) provided the title compound as a colorless liquid 
(77 mg, 604 μmol, 60% (reduced yield due to the high volatility of 93o); 96.5:3.5 er). THF (5 
mL) was used as solvent for the base treatment with aqueous 1N NaOH. The enantiomeric 
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ratio was determined by GC using a chiral Lipodex G column 25 m (50 °C, 1.2 °C/min until 
110 °C, 18 °C/min until 230 °C, 5 min at 230 °C, 0.5 bar H2); major enantiomer: τR = 8.24 
min, minor enantiomer: τR = 8.76 min. 
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HRMS (EI-FE) calcd for C7H12O2 [M+] 128.0836, found 128.0837. 
 
7.3.4 Hydroperoxidation of 4,8-Dimethylnona-3,7-dien-2-one (100) 
The general procedure[193] described in Section 7.3.1.1 for the catalytic asymmetric hydro-
peroxidation of α,β-unsaturated ketones 92 was adapted to β,β-disubstituted enone 100 by 
using 20 mol% catalyst [13 • 2 TFA] and 3 equiv. of hydrogen peroxide (50 wt%) and the 
reaction temperature was increased to 70 °C. 
 
 
 
3,5-Dimethyl-5-(4-methylpent-3-enyl)-1,2-dioxolan-3-ol (112) 
The title compound was isolated after 48 h. Purification by flash 
column chromatography (silica gel; 5-10% Et2O in pentane) as a 
colorless oil (56 mg, 280 μmol, 56%; 78:22 er). The enantiomeric 
ratio was determined after converting peroxyhemiketal 112 into the corresponding epoxide 
111 (1:1 E/Z). The enantiomers were analyzed by GC using a chiral BGB-176/SE-52 column 
30 m (60 °C, 0.5 °C/min until 105 °C, 20 °C/min until 220 °C, 10 min at 320 °C, 0.4 bar H2); 
(E)-111: major enantiomer: τR = 81.04 min, minor enantiomer: τR = 80.47 min; (Z)-111: 
major enantiomer: τR = 71.83 min, minor enantiomer: τR = 73.16 min. Characterized as a 
mixture of hemiketal epimers. 
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1H NMR (500 MHz, CDCl3) δ 5.10-5.06 (m, 2H, =CHCH2), 2.93 (br s overlapped, 1H, OH), 
2.90 (br s overlapped, 1H, OH), 2.53 (d, 1H, J = 12.8 Hz, CHHcycl.), 2.44 (s, 2H, CH2, cycl.), 
2.31 (d, 1H, J = 12.7 Hz, CHHcycl.), 2.09-1.94 (m, 4H, =CHCH2), 1.73 (ddd, 1H, J = 13.8, 
11.4, 5.3 Hz, =CHCH2CHH), 1.68-1.64 (m overlapped, 2H, =CHCH2CH2), 1.66 (s 
overlapped, 6H, CqolCH3), 1.59 (s, 6H, CqolCH3), 1.54-1.48 (m overlapped, 1H, 
=CHCH2CHH), 1.53 (s overlapped, 3H, CqOHCH3), 1.51 (s overlapped, 3H, CqOHCH3), 1.34 
(s, 3H, CqalCH3), 1.33 (s, 3H, CqalCH3). 
13C NMR (125 MHz, CDCl3) δ 132.3 (Cqol), 131.9 (Cqol), 123.8 (CHol), 123.5 (CHol), 105.9 
(CqOH), 105.7 (CqOH), 86.3 (Cqal), 85.9 (Cqal), 57.7 (CH2, cycl.), 57.1 (CH2, cycl.), 39.8 
(CHolCH2CH2), 37.9 (CHolCH2CH2), 25.7 (2C, Cqol(CH3)2), 25.2 (CH3Cqal), 23.5 (CHolCH2), 
23.2 (CH3CqOH), 23.1 (CH3CqOH), 23.0 (CHolCH2), 22.3 (CH3Cqal), 17.7 (Cqol(CH3)2), 17.6 
(Cqol(CH3)2). 
MS (EI-DE) m/z (%) 185 (1), 167 (1), 139 (1), 123 (2), 109 (5), 97 (3), 82 (16), 69 (32), 55 
(22), 43 (100), 29 (9). 
HRMS (ESI+) calcd for C11H20NaO3 [(M+Na)+] 223.1307, found 223.1305. 
 
3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (111): Epoxy ketone 111 was obtained as a colorless 
oil (9.1 mg, 50 μmol, 10% (88:12 dr(trans/cis); 95.5:4.5 er(trans), 
59.5:40.5 er(cis)). Purification by flash column chromatography (silica 
gel; 1-10% Et2O in pentane) provided pure samples of trans- and cis-
isomers of epoxy ketone 111. The enantiomeric ratio was determined by GC using a chiral 
BGB-176/SE-52 column 30 m (60 °C, 0.5 °C/min until 105 °C, 20 °C/min until 220 °C, 10 
min at 320 °C, 0.4 bar H2); (E)-111: major enantiomer: τR = 81.25 min, minor enantiomer: τR 
= 80.71 min; (Z)-111: major enantiomer: τR = 73.29 min, minor enantiomer: τR = 72.18 min. 
The analytical data were identical in all respects to those previously reported.[172, 194] 
trans-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (trans-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.12 (t, J = 7.1 Hz, 1H, =CHCH2), 
3.40 (s, 1H, CepoH), 2.17 (s, 3H, CH3C(=O)), 2.12 (app. q, 2H, 
=CHCH2), 1.77 (dd, J = 14.2, 7.1 Hz, 1H, CHHCqepo), 1.70 (s, 3H, CH3Cqol), 1.62 (s, 3H, 
CH3Cqol), 1.56-1.49 (m, 1H, CHHCqepo), 1.20 (s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.1 (C=O), 132.8 (Cqol), 123.4 (CHol), 65.2 (CepoH), 63.4 
(Cqepo), 38.5 (CHolCH2), 28.2 (CH3C(=O)), 25.8 (CH3), 24.1 (CH2Cqepo), 17.7 (CH3), 16.1 
(CH3). 
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HRMS (ESI+) calcd for C11H20NaO3 [(M+Na)+] 223.1307, found 223.1305. 
 
3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (111): Epoxy ketone 111 was obtained as a colorless 
oil (9.1 mg, 50 μmol, 10% (88:12 dr(trans/cis); 95.5:4.5 er(trans), 
59.5:40.5 er(cis)). Purification by flash column chromatography (silica 
gel; 1-10% Et2O in pentane) provided pure samples of trans- and cis-
isomers of epoxy ketone 111. The enantiomeric ratio was determined by GC using a chiral 
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=CHCH2CHH), 1.53 (s overlapped, 3H, CqOHCH3), 1.51 (s overlapped, 3H, CqOHCH3), 1.34 
(s, 3H, CqalCH3), 1.33 (s, 3H, CqalCH3). 
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BGB-176/SE-52 column 30 m (60 °C, 0.5 °C/min until 105 °C, 20 °C/min until 220 °C, 10 
min at 320 °C, 0.4 bar H2); (E)-111: major enantiomer: τR = 81.25 min, minor enantiomer: τR 
= 80.71 min; (Z)-111: major enantiomer: τR = 73.29 min, minor enantiomer: τR = 72.18 min. 
The analytical data were identical in all respects to those previously reported.[172, 194] 
trans-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (trans-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.12 (t, J = 7.1 Hz, 1H, =CHCH2), 
3.40 (s, 1H, CepoH), 2.17 (s, 3H, CH3C(=O)), 2.12 (app. q, 2H, 
=CHCH2), 1.77 (dd, J = 14.2, 7.1 Hz, 1H, CHHCqepo), 1.70 (s, 3H, CH3Cqol), 1.62 (s, 3H, 
CH3Cqol), 1.56-1.49 (m, 1H, CHHCqepo), 1.20 (s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.1 (C=O), 132.8 (Cqol), 123.4 (CHol), 65.2 (CepoH), 63.4 
(Cqepo), 38.5 (CHolCH2), 28.2 (CH3C(=O)), 25.8 (CH3), 24.1 (CH2Cqepo), 17.7 (CH3), 16.1 
(CH3). 
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MS (EI-DE) m/z (%) 182 [M+] (1), 164 (2), 149 (4), 139 (3), 121 (7), 109 (43), 99 (23), 82 
(45), 69 (56), 67 (24), 55 (18), 43 (100), 27 (10). 
HRMS (EI-FE) calcd for C11H18O2 [M+] 182.1307, found 182.1307. 
cis-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (cis-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.02 (t, J = 7.2 Hz, 1H, =CHCH2), 3.37 
(s, 1H, CepoH), 2.19 (s, 3H, CH3), 2.14-1.98 (m, 2H, =CHCH2), 1.66 (s, 
3H, CH3Cqol), 1.59 (s, 3H, CH3Cqol), 1.57-1.42 (m, 2H, CH2Cqepo), 1.40 
(s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.0 (C=O), 132.8 (Cqol), 123.3 (CHol), 66.0 (CepoH), 64.0 
(Cqepo), 32.5 (CHolCH2), 28.5 (CH3C(=O)), 25.8 (CH3), 24.4 (CH2Cqepo), 22.2 (CH3), 17.6 
(CH3). 
 
7.3.5 Hydroperoxidation of Cycloheptenone (46s) and Cyclooctenone (46v) 
The reactions of 2-cycloheptenone (46s) and 2-cyclooctenone (46v) were performed 
according to the general procedure[193] described in Section 7.3.1.1 for the catalytic 
asymmetric hydroperoxidation of acyclic α,β-unsaturated ketones 92. 
 
7,8-Dioxabicyclo[4.2.1]nonan-1-ol/ 3-hydroperoxycycloheptanone (116): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 
20-60% Et2O in pentane) provided peroxide 116 as a clear oil 
(79 mg, 551 μmol, 55%; 95:5 er). The enantiomeric ratio was 
determined after converting peroxide 116 into 2,3-epoxycycloheptanone (48s). The 
enantiomers were analyzed by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 °C, 
1.5 °C/min until 135 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 24.31 min, minor enantiomer: τR = 28.24 min. 7,8-Dioxabicyclo[4.2.1]no-
nan-1-ol (116a) exists in equilibrium with 3-hydroperoxycycloheptanone (116b): 80:20 (in 
THF). 
1H NMR (500 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 5.43 (br s, 1H, 
OH), 4.42-4.40 (m, 1H, CH), 2.61 (d, J = 12.6 Hz, 1H, CHCHHCq), 2.50 (dd, J = 12.0, 6.7 
Hz, 1H, CHCHHCq), 1.93-1.83 (m, 2H, CH2), 1.77-1.74 (m, 3H, CH2), 1.61-1.53 (m, 2H, 
CH2), 1.43-1.37 (m, 1H, CHHCH); 3-hydroperoxycycloheptanone (116b): δ 9.39 (br s, 1H, 
OOH), 4.09-4.04 (m, 1H, CH), 2.77 (dd, J = 14.7, 3.0 Hz, 1H, CHCHHC(=O)), 2.68 (dd, J = 
O
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MS (EI-DE) m/z (%) 182 [M+] (1), 164 (2), 149 (4), 139 (3), 121 (7), 109 (43), 99 (23), 82 
(45), 69 (56), 67 (24), 55 (18), 43 (100), 27 (10). 
HRMS (EI-FE) calcd for C11H18O2 [M+] 182.1307, found 182.1307. 
cis-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (cis-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.02 (t, J = 7.2 Hz, 1H, =CHCH2), 3.37 
(s, 1H, CepoH), 2.19 (s, 3H, CH3), 2.14-1.98 (m, 2H, =CHCH2), 1.66 (s, 
3H, CH3Cqol), 1.59 (s, 3H, CH3Cqol), 1.57-1.42 (m, 2H, CH2Cqepo), 1.40 
(s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.0 (C=O), 132.8 (Cqol), 123.3 (CHol), 66.0 (CepoH), 64.0 
(Cqepo), 32.5 (CHolCH2), 28.5 (CH3C(=O)), 25.8 (CH3), 24.4 (CH2Cqepo), 22.2 (CH3), 17.6 
(CH3). 
 
7.3.5 Hydroperoxidation of Cycloheptenone (46s) and Cyclooctenone (46v) 
The reactions of 2-cycloheptenone (46s) and 2-cyclooctenone (46v) were performed 
according to the general procedure[193] described in Section 7.3.1.1 for the catalytic 
asymmetric hydroperoxidation of acyclic α,β-unsaturated ketones 92. 
 
7,8-Dioxabicyclo[4.2.1]nonan-1-ol/ 3-hydroperoxycycloheptanone (116): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 
20-60% Et2O in pentane) provided peroxide 116 as a clear oil 
(79 mg, 551 μmol, 55%; 95:5 er). The enantiomeric ratio was 
determined after converting peroxide 116 into 2,3-epoxycycloheptanone (48s). The 
enantiomers were analyzed by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 °C, 
1.5 °C/min until 135 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 24.31 min, minor enantiomer: τR = 28.24 min. 7,8-Dioxabicyclo[4.2.1]no-
nan-1-ol (116a) exists in equilibrium with 3-hydroperoxycycloheptanone (116b): 80:20 (in 
THF). 
1H NMR (500 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 5.43 (br s, 1H, 
OH), 4.42-4.40 (m, 1H, CH), 2.61 (d, J = 12.6 Hz, 1H, CHCHHCq), 2.50 (dd, J = 12.0, 6.7 
Hz, 1H, CHCHHCq), 1.93-1.83 (m, 2H, CH2), 1.77-1.74 (m, 3H, CH2), 1.61-1.53 (m, 2H, 
CH2), 1.43-1.37 (m, 1H, CHHCH); 3-hydroperoxycycloheptanone (116b): δ 9.39 (br s, 1H, 
OOH), 4.09-4.04 (m, 1H, CH), 2.77 (dd, J = 14.7, 3.0 Hz, 1H, CHCHHC(=O)), 2.68 (dd, J = 
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MS (EI-DE) m/z (%) 182 [M+] (1), 164 (2), 149 (4), 139 (3), 121 (7), 109 (43), 99 (23), 82 
(45), 69 (56), 67 (24), 55 (18), 43 (100), 27 (10). 
HRMS (EI-FE) calcd for C11H18O2 [M+] 182.1307, found 182.1307. 
cis-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (cis-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.02 (t, J = 7.2 Hz, 1H, =CHCH2), 3.37 
(s, 1H, CepoH), 2.19 (s, 3H, CH3), 2.14-1.98 (m, 2H, =CHCH2), 1.66 (s, 
3H, CH3Cqol), 1.59 (s, 3H, CH3Cqol), 1.57-1.42 (m, 2H, CH2Cqepo), 1.40 
(s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.0 (C=O), 132.8 (Cqol), 123.3 (CHol), 66.0 (CepoH), 64.0 
(Cqepo), 32.5 (CHolCH2), 28.5 (CH3C(=O)), 25.8 (CH3), 24.4 (CH2Cqepo), 22.2 (CH3), 17.6 
(CH3). 
 
7.3.5 Hydroperoxidation of Cycloheptenone (46s) and Cyclooctenone (46v) 
The reactions of 2-cycloheptenone (46s) and 2-cyclooctenone (46v) were performed 
according to the general procedure[193] described in Section 7.3.1.1 for the catalytic 
asymmetric hydroperoxidation of acyclic α,β-unsaturated ketones 92. 
 
7,8-Dioxabicyclo[4.2.1]nonan-1-ol/ 3-hydroperoxycycloheptanone (116): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 
20-60% Et2O in pentane) provided peroxide 116 as a clear oil 
(79 mg, 551 μmol, 55%; 95:5 er). The enantiomeric ratio was 
determined after converting peroxide 116 into 2,3-epoxycycloheptanone (48s). The 
enantiomers were analyzed by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 °C, 
1.5 °C/min until 135 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 24.31 min, minor enantiomer: τR = 28.24 min. 7,8-Dioxabicyclo[4.2.1]no-
nan-1-ol (116a) exists in equilibrium with 3-hydroperoxycycloheptanone (116b): 80:20 (in 
THF). 
1H NMR (500 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 5.43 (br s, 1H, 
OH), 4.42-4.40 (m, 1H, CH), 2.61 (d, J = 12.6 Hz, 1H, CHCHHCq), 2.50 (dd, J = 12.0, 6.7 
Hz, 1H, CHCHHCq), 1.93-1.83 (m, 2H, CH2), 1.77-1.74 (m, 3H, CH2), 1.61-1.53 (m, 2H, 
CH2), 1.43-1.37 (m, 1H, CHHCH); 3-hydroperoxycycloheptanone (116b): δ 9.39 (br s, 1H, 
OOH), 4.09-4.04 (m, 1H, CH), 2.77 (dd, J = 14.7, 3.0 Hz, 1H, CHCHHC(=O)), 2.68 (dd, J = 
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MS (EI-DE) m/z (%) 182 [M+] (1), 164 (2), 149 (4), 139 (3), 121 (7), 109 (43), 99 (23), 82 
(45), 69 (56), 67 (24), 55 (18), 43 (100), 27 (10). 
HRMS (EI-FE) calcd for C11H18O2 [M+] 182.1307, found 182.1307. 
cis-3,4-Epoxy-4,8-dimethyl-7-nonen-2-one (cis-111) 
1H NMR (500 MHz, CD2Cl2) δ 5.02 (t, J = 7.2 Hz, 1H, =CHCH2), 3.37 
(s, 1H, CepoH), 2.19 (s, 3H, CH3), 2.14-1.98 (m, 2H, =CHCH2), 1.66 (s, 
3H, CH3Cqol), 1.59 (s, 3H, CH3Cqol), 1.57-1.42 (m, 2H, CH2Cqepo), 1.40 
(s, 3H, CH3Cqepo). 
13C NMR (125 MHz, CD2Cl2) δ 204.0 (C=O), 132.8 (Cqol), 123.3 (CHol), 66.0 (CepoH), 64.0 
(Cqepo), 32.5 (CHolCH2), 28.5 (CH3C(=O)), 25.8 (CH3), 24.4 (CH2Cqepo), 22.2 (CH3), 17.6 
(CH3). 
 
7.3.5 Hydroperoxidation of Cycloheptenone (46s) and Cyclooctenone (46v) 
The reactions of 2-cycloheptenone (46s) and 2-cyclooctenone (46v) were performed 
according to the general procedure[193] described in Section 7.3.1.1 for the catalytic 
asymmetric hydroperoxidation of acyclic α,β-unsaturated ketones 92. 
 
7,8-Dioxabicyclo[4.2.1]nonan-1-ol/ 3-hydroperoxycycloheptanone (116): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the 
crude product by flash column chromatography (silica gel, 
20-60% Et2O in pentane) provided peroxide 116 as a clear oil 
(79 mg, 551 μmol, 55%; 95:5 er). The enantiomeric ratio was 
determined after converting peroxide 116 into 2,3-epoxycycloheptanone (48s). The 
enantiomers were analyzed by GC using a chiral Hydrodex-β-TBDAc column 25 m (80 °C, 
1.5 °C/min until 135 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major 
enantiomer: τR = 24.31 min, minor enantiomer: τR = 28.24 min. 7,8-Dioxabicyclo[4.2.1]no-
nan-1-ol (116a) exists in equilibrium with 3-hydroperoxycycloheptanone (116b): 80:20 (in 
THF). 
1H NMR (500 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 5.43 (br s, 1H, 
OH), 4.42-4.40 (m, 1H, CH), 2.61 (d, J = 12.6 Hz, 1H, CHCHHCq), 2.50 (dd, J = 12.0, 6.7 
Hz, 1H, CHCHHCq), 1.93-1.83 (m, 2H, CH2), 1.77-1.74 (m, 3H, CH2), 1.61-1.53 (m, 2H, 
CH2), 1.43-1.37 (m, 1H, CHHCH); 3-hydroperoxycycloheptanone (116b): δ 9.39 (br s, 1H, 
OOH), 4.09-4.04 (m, 1H, CH), 2.77 (dd, J = 14.7, 3.0 Hz, 1H, CHCHHC(=O)), 2.68 (dd, J = 
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14.8, 8.8 Hz, 1H, CHCHHC(=O)), 2.42-2.31 (m, 2H, CH2CH2C(=O)), 1.93-1.83 (m, 2H, 
CH2), 1.77-1.74 (m, 4H, CH2). 
13C NMR (125 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 108.1 (Cq), 81.3 
(CH), 48.9 (CHCH2Cq), 37.3 (CH2), 35.9 (CH2), 24.7 (CH2), 24.3 (CH2); 3-hydroperoxy-
cycloheptanone (116b): δ 209.3 (C=O), 81.0 (CH), 48.4 (CHCH2C(=O)), 45.1 
(CH2CH2C(=O)), 35.0 (CH2), 26.2 (CH2), 25.4 (CH2). 
MS (EI-DE) m/z (%) 144 [M+] (10), 126 (1), 111 (100), 97 (16), 83 (18), 69 (12), 55 (52), 41 
(37), 39 (15), 29 (23). 
HRMS (EI-FE) calcd for C7H12O3 [M+] 144.0787, found 144.0786. 
 
3-Hydroperoxycyclooctanone/ 8,9-dioxabicyclo[5.2.1]decan-1-ol (117): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the crude 
product by flash column chromatography (silica gel, 5-35% 
Et2O in pentane) provided peroxide 117 as a clear oil (93 mg, 
571 μmol, 59%; 97:3 er). The enantiomeric ratio was 
determined after converting peroxide 117 into 2,3-epoxycyclooctanone (48v). The 
enantiomers were analyzed by GC using a chiral BGB-176/SE-52 30 m (80 °C, 2 °C/min until 
140 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major enantiomer: τR = 27.52 
min, minor enantiomer: τR = 25.41 min. 3-Hydroperoxycyclooctanone (117b) exists in 
equilibrium with 8,9-dioxabicyclo[5.2.1]decan-1-ol (117a): 70:30 (in THF). 
1H NMR (500 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 8.98 (br s, 1H, OOH), 
4.32-4.27 (m, 1H, CH), 2.91 (dd, J = 12.1, 3.6 Hz, 1H, CHCHHC(=O)), 2.87 (d, J = 11.7 Hz, 
1H, CHCHHC(=O)), 2.43-2.32 (m, 2H, CH2CH2C(=O)), 1.97-1.91 (m, 2H, CH2), 1.88-1.23 
(m, 6H, -(CH2)n-); 8,9-Dioxabicyclo[5.2.1]decan-1-ol (117a): δ 4.58-4.56 (m, 1H, CH), 3.02 
(br s, 1H, OH), 2.88-2.84 (m, 2H, CHCH2Cq), 2.19-2.13 (m, 1H, CH2), 1.98-1.28 (m, 8H, -
(CH2)n-), 0.88 (t, J = 7.6 Hz, 1H, CH2). 
13C NMR (125 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 213.9 (C=O), 82.8 
(CH), 44.0 (CHCH2C(=O)), 42.4 (CH2CH2C(=O)), 29.6 (CH2), 28.1 (CH2), 22.9 (CH2), 19.7 
(CH2); 8,9-Dioxabicyclo[5.2.1]decan-1-ol (117a): δ 105.5 (Cq), 80.1 (CH), 52.6 (CHCH2Cq), 
37.3 (CH2), 35.5 (CH2), 28.0 (CH2), 26.2 (CH2), 25.3 (CH2). 
MS (EI-DE) m/z (%) 158 [M+] (18), 141 (2), 125 (64), 107 (18), 97 (17), 83 (21), 69 (12), 55 
(100), 43 (56), 41 (44), 29 (21). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [(M+H)+] 159.1022, found 159.1021. 
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14.8, 8.8 Hz, 1H, CHCHHC(=O)), 2.42-2.31 (m, 2H, CH2CH2C(=O)), 1.93-1.83 (m, 2H, 
CH2), 1.77-1.74 (m, 4H, CH2). 
13C NMR (125 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 108.1 (Cq), 81.3 
(CH), 48.9 (CHCH2Cq), 37.3 (CH2), 35.9 (CH2), 24.7 (CH2), 24.3 (CH2); 3-hydroperoxy-
cycloheptanone (116b): δ 209.3 (C=O), 81.0 (CH), 48.4 (CHCH2C(=O)), 45.1 
(CH2CH2C(=O)), 35.0 (CH2), 26.2 (CH2), 25.4 (CH2). 
MS (EI-DE) m/z (%) 144 [M+] (10), 126 (1), 111 (100), 97 (16), 83 (18), 69 (12), 55 (52), 41 
(37), 39 (15), 29 (23). 
HRMS (EI-FE) calcd for C7H12O3 [M+] 144.0787, found 144.0786. 
 
3-Hydroperoxycyclooctanone/ 8,9-dioxabicyclo[5.2.1]decan-1-ol (117): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the crude 
product by flash column chromatography (silica gel, 5-35% 
Et2O in pentane) provided peroxide 117 as a clear oil (93 mg, 
571 μmol, 59%; 97:3 er). The enantiomeric ratio was 
determined after converting peroxide 117 into 2,3-epoxycyclooctanone (48v). The 
enantiomers were analyzed by GC using a chiral BGB-176/SE-52 30 m (80 °C, 2 °C/min until 
140 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major enantiomer: τR = 27.52 
min, minor enantiomer: τR = 25.41 min. 3-Hydroperoxycyclooctanone (117b) exists in 
equilibrium with 8,9-dioxabicyclo[5.2.1]decan-1-ol (117a): 70:30 (in THF). 
1H NMR (500 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 8.98 (br s, 1H, OOH), 
4.32-4.27 (m, 1H, CH), 2.91 (dd, J = 12.1, 3.6 Hz, 1H, CHCHHC(=O)), 2.87 (d, J = 11.7 Hz, 
1H, CHCHHC(=O)), 2.43-2.32 (m, 2H, CH2CH2C(=O)), 1.97-1.91 (m, 2H, CH2), 1.88-1.23 
(m, 6H, -(CH2)n-); 8,9-Dioxabicyclo[5.2.1]decan-1-ol (117a): δ 4.58-4.56 (m, 1H, CH), 3.02 
(br s, 1H, OH), 2.88-2.84 (m, 2H, CHCH2Cq), 2.19-2.13 (m, 1H, CH2), 1.98-1.28 (m, 8H, -
(CH2)n-), 0.88 (t, J = 7.6 Hz, 1H, CH2). 
13C NMR (125 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 213.9 (C=O), 82.8 
(CH), 44.0 (CHCH2C(=O)), 42.4 (CH2CH2C(=O)), 29.6 (CH2), 28.1 (CH2), 22.9 (CH2), 19.7 
(CH2); 8,9-Dioxabicyclo[5.2.1]decan-1-ol (117a): δ 105.5 (Cq), 80.1 (CH), 52.6 (CHCH2Cq), 
37.3 (CH2), 35.5 (CH2), 28.0 (CH2), 26.2 (CH2), 25.3 (CH2). 
MS (EI-DE) m/z (%) 158 [M+] (18), 141 (2), 125 (64), 107 (18), 97 (17), 83 (21), 69 (12), 55 
(100), 43 (56), 41 (44), 29 (21). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [(M+H)+] 159.1022, found 159.1021. 
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14.8, 8.8 Hz, 1H, CHCHHC(=O)), 2.42-2.31 (m, 2H, CH2CH2C(=O)), 1.93-1.83 (m, 2H, 
CH2), 1.77-1.74 (m, 4H, CH2). 
13C NMR (125 MHz, THF-d8) 7,8-dioxabicyclo[4.2.1]nonan-1-ol (116a): δ 108.1 (Cq), 81.3 
(CH), 48.9 (CHCH2Cq), 37.3 (CH2), 35.9 (CH2), 24.7 (CH2), 24.3 (CH2); 3-hydroperoxy-
cycloheptanone (116b): δ 209.3 (C=O), 81.0 (CH), 48.4 (CHCH2C(=O)), 45.1 
(CH2CH2C(=O)), 35.0 (CH2), 26.2 (CH2), 25.4 (CH2). 
MS (EI-DE) m/z (%) 144 [M+] (10), 126 (1), 111 (100), 97 (16), 83 (18), 69 (12), 55 (52), 41 
(37), 39 (15), 29 (23). 
HRMS (EI-FE) calcd for C7H12O3 [M+] 144.0787, found 144.0786. 
 
3-Hydroperoxycyclooctanone/ 8,9-dioxabicyclo[5.2.1]decan-1-ol (117): The reaction 
mixture was stirred for 24 h at 32 °C. Purification of the crude 
product by flash column chromatography (silica gel, 5-35% 
Et2O in pentane) provided peroxide 117 as a clear oil (93 mg, 
571 μmol, 59%; 97:3 er). The enantiomeric ratio was 
determined after converting peroxide 117 into 2,3-epoxycyclooctanone (48v). The 
enantiomers were analyzed by GC using a chiral BGB-176/SE-52 30 m (80 °C, 2 °C/min until 
140 °C, 20 °C/min until 220 °C, 10 min at 220°C, 0.6 bar H2); major enantiomer: τR = 27.52 
min, minor enantiomer: τR = 25.41 min. 3-Hydroperoxycyclooctanone (117b) exists in 
equilibrium with 8,9-dioxabicyclo[5.2.1]decan-1-ol (117a): 70:30 (in THF). 
1H NMR (500 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 8.98 (br s, 1H, OOH), 
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(br s, 1H, OH), 2.88-2.84 (m, 2H, CHCH2Cq), 2.19-2.13 (m, 1H, CH2), 1.98-1.28 (m, 8H, -
(CH2)n-), 0.88 (t, J = 7.6 Hz, 1H, CH2). 
13C NMR (125 MHz, CD2Cl2) 3-Hydroperoxycyclooctanone (117b): δ 213.9 (C=O), 82.8 
(CH), 44.0 (CHCH2C(=O)), 42.4 (CH2CH2C(=O)), 29.6 (CH2), 28.1 (CH2), 22.9 (CH2), 19.7 
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37.3 (CH2), 35.5 (CH2), 28.0 (CH2), 26.2 (CH2), 25.3 (CH2). 
MS (EI-DE) m/z (%) 158 [M+] (18), 141 (2), 125 (64), 107 (18), 97 (17), 83 (21), 69 (12), 55 
(100), 43 (56), 41 (44), 29 (21). 
HRMS (CI-FE, i-butane) calcd for C8H15O3 [(M+H)+] 159.1022, found 159.1021. 
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14.8, 8.8 Hz, 1H, CHCHHC(=O)), 2.42-2.31 (m, 2H, CH2CH2C(=O)), 1.93-1.83 (m, 2H, 
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7.4 Synthetic Transformations of Optically Active Products 
7.4.1 One-Pot Synthesis of Aldol Products 
7.4.1.1 General Procedure[193] 
 
 
 
Catalyst salt [13 • 2 TCA] was prepared in situ by the addition of 9-amino(9-deoxy)epiquinine 
(13; 32.3 mg, 0.1 mmol, 10 mol%) to a solution of trichloroacetic acid (32.6 mg, 0.2 mmol, 
20 mol%) in dioxane (4 mL). Then, enone 92 (1.0 mmol, 1.0 equiv) was added, and 20 
minutes later, aqueous hydrogen peroxide (30 wt%, 304 μL, 3.0 mmol, 3 equiv). After 36-48 
h of stirring at 32°C, triethylphosphite (519 μL, 3.0 mmol, 3 equiv) was added dropwise at 
0 °C and the reaction mixture was stirred for 10 h at room temperature. Additional 
triethylphosphite (346 μL, 2 mmol, 2 equiv) was added and the reaction was further stirred 
until TLC analysis indicated complete reduction of the peroxyhemiketals (2 h). The reaction 
mixture was repeatedly extracted with Et2O (3×25 mL) and the combined organic phases were 
washed with brine, dried (Na2SO4), and filtered. Removal of the volatiles under reduced 
pressure furnished the crude product, which was subjected to flash column chromatography 
(silica gel, eluent: Et2O-pentane) to afford the corresponding pure aldol-type product 96. 
 
7.4.1.2 Scope of Optically Active Aldol Products 
(R)-4-Hydroxy-2-decanone ((R)-96a): Aldol product (R)-96a was prepared according to the 
general procedure. The reaction mixture was stirred for 36 h at 32 °C 
followed by in situ reduction with triethylphosphite. Purification of 
the crude product by flash column chromatography (silica gel, 10-
50% Et2O in pentane) provided the title compound as a colorless oil (102 mg, 592 μmol, 59%; 
97:3 er). The enantiomeric ratio was determined by GC using a chiral G-TA column 30 m 
(80 °C, 1.0 °C/min until 115 °C, 20 °C/min, until 180 °C, 10 min at 320 °C, 0.9 bar H2); 
major enantiomer: τR = 31.94 min, minor enantiomer: τR = 31.38 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.00-3.95 (m, 1H, CH(OH)), 2.81 (br s, 1H, OH), 2.61 (dd, J 
= 17.5, 2.7 Hz, 1H, C(=O)CHH), 2.48 (dd, J = 17.5, 9.3 Hz, 1H, C(=O)CHH), 2.14 (s, 3H, 
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C(=O)CH3), 1.46-1.35 (m, 2H, CH2CH2CH(OH)), 1.34-1.26 (m, 8H, CH3(CH2)4), 0.88 (t, J = 
6.9 Hz, 3H, CH3CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 67.9 (CH(OH)), 50.3 (C(=O)CH2), 36.9 
(CH2CH2CH(OH)), 32.2 (CH2), 30.9 (C(=O)CH3), 29.6 (CH2), 25.8 (CH2), 23.0 (CH2), 14.2 
((CH2)5CH3). 
MS (EI-DE) m/z (%) 172 [M+] (trace), 154 (1), 139 (1), 125 (1), 111 (1), 96 (6), 87 (44), 84 
(2), 69 (5), 55 (17), 43 (100), 29 (11). 
HRMS (CI-FE, NH3) calcd for C10H24NO2 [(M+NH4)+] 190.1805, found 190.1807. 
 
(R)-4-Hydroxy-6-phenyl-2-hexanone ((R)-96b): Aldol product (R)-96b was prepared 
according to the general procedure. The reaction mixture was stirred for 
36 h at 32 °C followed by in situ reduction with triethylphosphite. 
Purification of the crude product by flash column chromatography 
(silica gel, 10-60% Et2O in pentane) provided the title compound as a colorless oil (102 mg, 
531 μmol, 53%; 96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral 
Chiralpak IA column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 16.75 
min, minor enantiomer: τR = 15.41 min. 
Optical rotation [α]25D = 14.8 (c = 1.1, CHCl3, 96.5:3.5 er (R)) [Lit.:[137] (R)-96b, [α]rtD = 
12.0 (c = 1.1, CHCl3, 94:6 er]. 
1H NMR (500 MHz, CD2Cl2) δ 7.29-7.26 (m, 2H, CHar, m), 7.21-7.16 (m, 3H, CHar, o, p), 4.03-
3.97 (m, 1H, CH(OH)), 2.95 (d, J = 3.5 Hz, 1H, OH), 2.81-2.75 (m, 1H, PhCHH), 2.69-2.64 
(m, 1H, PhCHH), 2.63 (dd, J = 17.7, 2.9 Hz, 1H, C(=O)CHH), 2.53 (dd, J = 17.7, 9.2 Hz, 1H, 
C(=O)CHH), 2.14 (s, 3H, CH3), 1.80-1.73 (m, 1H, PhCH2CHH), 1.70-1.64 (m, 1H, 
PhCH2CHH). 
13C NMR (125 MHz, CD2Cl2) δ 210.2 (C(=O)), 142.5 (Cqar), 128.8 (2C, CHar, o), 128.7 (2C, 
CHar, m), 126.1 (CHar, p), 67.2 (CH(OH)), 50.3 (C(=O)CH2), 38.5 (PhCH2CH2), 32.0 (PhCH2), 
30.9 (CH3). 
MS (EI-DE) m/z (%) 192 (2), 174 (34), 159 (4), 131 (29), 117 (17), 104 (17), 91 (73), 87 (9), 
77 (10), 65 (11), 58 (4), 51 (6), 43 (100), 39 (6), 27 (4). 
HRMS (CI-FE, NH3) calcd for C12H20NO2 [(M+NH4)+] 210.1493, found 210.1494. 
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HRMS (CI-FE, NH3) calcd for C12H20NO2 [(M+NH4)+] 210.1493, found 210.1494. 
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C(=O)CH3), 1.46-1.35 (m, 2H, CH2CH2CH(OH)), 1.34-1.26 (m, 8H, CH3(CH2)4), 0.88 (t, J = 
6.9 Hz, 3H, CH3CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 67.9 (CH(OH)), 50.3 (C(=O)CH2), 36.9 
(CH2CH2CH(OH)), 32.2 (CH2), 30.9 (C(=O)CH3), 29.6 (CH2), 25.8 (CH2), 23.0 (CH2), 14.2 
((CH2)5CH3). 
MS (EI-DE) m/z (%) 172 [M+] (trace), 154 (1), 139 (1), 125 (1), 111 (1), 96 (6), 87 (44), 84 
(2), 69 (5), 55 (17), 43 (100), 29 (11). 
HRMS (CI-FE, NH3) calcd for C10H24NO2 [(M+NH4)+] 190.1805, found 190.1807. 
 
(R)-4-Hydroxy-6-phenyl-2-hexanone ((R)-96b): Aldol product (R)-96b was prepared 
according to the general procedure. The reaction mixture was stirred for 
36 h at 32 °C followed by in situ reduction with triethylphosphite. 
Purification of the crude product by flash column chromatography 
(silica gel, 10-60% Et2O in pentane) provided the title compound as a colorless oil (102 mg, 
531 μmol, 53%; 96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral 
Chiralpak IA column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 16.75 
min, minor enantiomer: τR = 15.41 min. 
Optical rotation [α]25D = 14.8 (c = 1.1, CHCl3, 96.5:3.5 er (R)) [Lit.:[137] (R)-96b, [α]rtD = 
12.0 (c = 1.1, CHCl3, 94:6 er]. 
1H NMR (500 MHz, CD2Cl2) δ 7.29-7.26 (m, 2H, CHar, m), 7.21-7.16 (m, 3H, CHar, o, p), 4.03-
3.97 (m, 1H, CH(OH)), 2.95 (d, J = 3.5 Hz, 1H, OH), 2.81-2.75 (m, 1H, PhCHH), 2.69-2.64 
(m, 1H, PhCHH), 2.63 (dd, J = 17.7, 2.9 Hz, 1H, C(=O)CHH), 2.53 (dd, J = 17.7, 9.2 Hz, 1H, 
C(=O)CHH), 2.14 (s, 3H, CH3), 1.80-1.73 (m, 1H, PhCH2CHH), 1.70-1.64 (m, 1H, 
PhCH2CHH). 
13C NMR (125 MHz, CD2Cl2) δ 210.2 (C(=O)), 142.5 (Cqar), 128.8 (2C, CHar, o), 128.7 (2C, 
CHar, m), 126.1 (CHar, p), 67.2 (CH(OH)), 50.3 (C(=O)CH2), 38.5 (PhCH2CH2), 32.0 (PhCH2), 
30.9 (CH3). 
MS (EI-DE) m/z (%) 192 (2), 174 (34), 159 (4), 131 (29), 117 (17), 104 (17), 91 (73), 87 (9), 
77 (10), 65 (11), 58 (4), 51 (6), 43 (100), 39 (6), 27 (4). 
HRMS (CI-FE, NH3) calcd for C12H20NO2 [(M+NH4)+] 210.1493, found 210.1494. 
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(R)-4-Hydroxy-6-methyl-2-heptanone ((R)-96d): Aldol product (R)-96d was prepared 
according to the general procedure. The reaction mixture was stirred for 36 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (81 mg, 562 μmol, 56%; 
96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA 
column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 11.39 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.10-4.04 (m, 1H, CH(OH)), 2.84 (br s, 1H, OH), 2.58 (dd, J 
= 17.7, 2.9 Hz, 1H, CHHC(=O)), 2.47 (dd, J = 17.7, 9.2 Hz, 1H, CHHC(=O)), 2.14 (s, 3H, 
C(=O)CH3), 1.80-1.72 (m, 1H, CHMe2), 1.41 (ddd, J = 13.6, 9.1, 5.6 Hz, 1H, i-PrCHH), 1.12 
(ddd, J = 13.4, 8.6, 4.5 Hz, 1H, i-PrCHH), 0.90 (d, J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 66.0 (CH(OH)), 50.8 (C(=O)CH2), 46.0 (i-
PrCH2), 30.9 (C(=O)CH3), 24.7 (CHMe2), 23.4 (CH(CH3)2), 22.1 (CH(CH3)2). 
MS (EI-DE) m/z (%) 144 [M+] (trace), 126 (9), 111 (10), 108 (25), 93 (5), 87 (100), 83 (7), 69 
(17), 58 (20), 43 (90), 29 (5). 
HRMS (CI-FE, NH3) calcd for C8H20NO2 [(M+NH4)+] 162.1494, found 162.1494. 
 
(S)-4-Cyclohexyl-4-hydroxy-2-butanone ((S)-96e): Aldol product (S)-96e was prepared 
according to the general procedure. The reaction mixture was stirred for 48 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (78 mg, 458 μmol, 46%; 96:4 
er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column 
(10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 14.65 min, minor enantiomer: 
τR = 13.19 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.78-3.73 (m, 1H, CH(OH)), 2.77 (br s, 1H, OH), 2.61 (dd, J 
= 17.3, 2.7 Hz, 1H, CHHC(=O)), 2.49 (dd, J = 17.4, 9.9 Hz, 1H, CHHC(=O)), 2.15 (s, 3H, 
CH3), 1.84-1.79 (m, 1H, CH2), 1.77-1.71 (m, 2H, CH2), 1.68-1.61 (m, 2H, CH2), 1.35-1.27 
(m, 1H, CHcycl.), 1.26-1.10 (m, 3H, CH2), 1.07-0.94 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.6 (C(=O)), 72.0 (CH(OH)), 47.5 (C(=O)CH2), 43.4 
(CHcycl.), 30.9 (CH3), 29.2 (CH2), 28.5 (CH2), 26.9 (CH2), 26.6 (CH2), 26.5 (CH2). 
MS (EI-DE) m/z (%) 170 [M+] (trace), 152 (3), 137 (2), 112 (5), 109 (3), 95 (12), 87 (80), 83 
(6), 67 (14), 58 (9), 55 (26), 43 (100), 39 (9), 29 (10). 
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(R)-4-Hydroxy-6-methyl-2-heptanone ((R)-96d): Aldol product (R)-96d was prepared 
according to the general procedure. The reaction mixture was stirred for 36 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (81 mg, 562 μmol, 56%; 
96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA 
column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 11.39 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.10-4.04 (m, 1H, CH(OH)), 2.84 (br s, 1H, OH), 2.58 (dd, J 
= 17.7, 2.9 Hz, 1H, CHHC(=O)), 2.47 (dd, J = 17.7, 9.2 Hz, 1H, CHHC(=O)), 2.14 (s, 3H, 
C(=O)CH3), 1.80-1.72 (m, 1H, CHMe2), 1.41 (ddd, J = 13.6, 9.1, 5.6 Hz, 1H, i-PrCHH), 1.12 
(ddd, J = 13.4, 8.6, 4.5 Hz, 1H, i-PrCHH), 0.90 (d, J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 66.0 (CH(OH)), 50.8 (C(=O)CH2), 46.0 (i-
PrCH2), 30.9 (C(=O)CH3), 24.7 (CHMe2), 23.4 (CH(CH3)2), 22.1 (CH(CH3)2). 
MS (EI-DE) m/z (%) 144 [M+] (trace), 126 (9), 111 (10), 108 (25), 93 (5), 87 (100), 83 (7), 69 
(17), 58 (20), 43 (90), 29 (5). 
HRMS (CI-FE, NH3) calcd for C8H20NO2 [(M+NH4)+] 162.1494, found 162.1494. 
 
(S)-4-Cyclohexyl-4-hydroxy-2-butanone ((S)-96e): Aldol product (S)-96e was prepared 
according to the general procedure. The reaction mixture was stirred for 48 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (78 mg, 458 μmol, 46%; 96:4 
er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column 
(10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 14.65 min, minor enantiomer: 
τR = 13.19 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.78-3.73 (m, 1H, CH(OH)), 2.77 (br s, 1H, OH), 2.61 (dd, J 
= 17.3, 2.7 Hz, 1H, CHHC(=O)), 2.49 (dd, J = 17.4, 9.9 Hz, 1H, CHHC(=O)), 2.15 (s, 3H, 
CH3), 1.84-1.79 (m, 1H, CH2), 1.77-1.71 (m, 2H, CH2), 1.68-1.61 (m, 2H, CH2), 1.35-1.27 
(m, 1H, CHcycl.), 1.26-1.10 (m, 3H, CH2), 1.07-0.94 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.6 (C(=O)), 72.0 (CH(OH)), 47.5 (C(=O)CH2), 43.4 
(CHcycl.), 30.9 (CH3), 29.2 (CH2), 28.5 (CH2), 26.9 (CH2), 26.6 (CH2), 26.5 (CH2). 
MS (EI-DE) m/z (%) 170 [M+] (trace), 152 (3), 137 (2), 112 (5), 109 (3), 95 (12), 87 (80), 83 
(6), 67 (14), 58 (9), 55 (26), 43 (100), 39 (9), 29 (10). 
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(R)-4-Hydroxy-6-methyl-2-heptanone ((R)-96d): Aldol product (R)-96d was prepared 
according to the general procedure. The reaction mixture was stirred for 36 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (81 mg, 562 μmol, 56%; 
96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA 
column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 11.39 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.10-4.04 (m, 1H, CH(OH)), 2.84 (br s, 1H, OH), 2.58 (dd, J 
= 17.7, 2.9 Hz, 1H, CHHC(=O)), 2.47 (dd, J = 17.7, 9.2 Hz, 1H, CHHC(=O)), 2.14 (s, 3H, 
C(=O)CH3), 1.80-1.72 (m, 1H, CHMe2), 1.41 (ddd, J = 13.6, 9.1, 5.6 Hz, 1H, i-PrCHH), 1.12 
(ddd, J = 13.4, 8.6, 4.5 Hz, 1H, i-PrCHH), 0.90 (d, J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 66.0 (CH(OH)), 50.8 (C(=O)CH2), 46.0 (i-
PrCH2), 30.9 (C(=O)CH3), 24.7 (CHMe2), 23.4 (CH(CH3)2), 22.1 (CH(CH3)2). 
MS (EI-DE) m/z (%) 144 [M+] (trace), 126 (9), 111 (10), 108 (25), 93 (5), 87 (100), 83 (7), 69 
(17), 58 (20), 43 (90), 29 (5). 
HRMS (CI-FE, NH3) calcd for C8H20NO2 [(M+NH4)+] 162.1494, found 162.1494. 
 
(S)-4-Cyclohexyl-4-hydroxy-2-butanone ((S)-96e): Aldol product (S)-96e was prepared 
according to the general procedure. The reaction mixture was stirred for 48 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (78 mg, 458 μmol, 46%; 96:4 
er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column 
(10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 14.65 min, minor enantiomer: 
τR = 13.19 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.78-3.73 (m, 1H, CH(OH)), 2.77 (br s, 1H, OH), 2.61 (dd, J 
= 17.3, 2.7 Hz, 1H, CHHC(=O)), 2.49 (dd, J = 17.4, 9.9 Hz, 1H, CHHC(=O)), 2.15 (s, 3H, 
CH3), 1.84-1.79 (m, 1H, CH2), 1.77-1.71 (m, 2H, CH2), 1.68-1.61 (m, 2H, CH2), 1.35-1.27 
(m, 1H, CHcycl.), 1.26-1.10 (m, 3H, CH2), 1.07-0.94 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.6 (C(=O)), 72.0 (CH(OH)), 47.5 (C(=O)CH2), 43.4 
(CHcycl.), 30.9 (CH3), 29.2 (CH2), 28.5 (CH2), 26.9 (CH2), 26.6 (CH2), 26.5 (CH2). 
MS (EI-DE) m/z (%) 170 [M+] (trace), 152 (3), 137 (2), 112 (5), 109 (3), 95 (12), 87 (80), 83 
(6), 67 (14), 58 (9), 55 (26), 43 (100), 39 (9), 29 (10). 
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(R)-4-Hydroxy-6-methyl-2-heptanone ((R)-96d): Aldol product (R)-96d was prepared 
according to the general procedure. The reaction mixture was stirred for 36 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (81 mg, 562 μmol, 56%; 
96.5:3.5 er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA 
column (10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 11.39 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.10-4.04 (m, 1H, CH(OH)), 2.84 (br s, 1H, OH), 2.58 (dd, J 
= 17.7, 2.9 Hz, 1H, CHHC(=O)), 2.47 (dd, J = 17.7, 9.2 Hz, 1H, CHHC(=O)), 2.14 (s, 3H, 
C(=O)CH3), 1.80-1.72 (m, 1H, CHMe2), 1.41 (ddd, J = 13.6, 9.1, 5.6 Hz, 1H, i-PrCHH), 1.12 
(ddd, J = 13.4, 8.6, 4.5 Hz, 1H, i-PrCHH), 0.90 (d, J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 210.3 (C(=O)), 66.0 (CH(OH)), 50.8 (C(=O)CH2), 46.0 (i-
PrCH2), 30.9 (C(=O)CH3), 24.7 (CHMe2), 23.4 (CH(CH3)2), 22.1 (CH(CH3)2). 
MS (EI-DE) m/z (%) 144 [M+] (trace), 126 (9), 111 (10), 108 (25), 93 (5), 87 (100), 83 (7), 69 
(17), 58 (20), 43 (90), 29 (5). 
HRMS (CI-FE, NH3) calcd for C8H20NO2 [(M+NH4)+] 162.1494, found 162.1494. 
 
(S)-4-Cyclohexyl-4-hydroxy-2-butanone ((S)-96e): Aldol product (S)-96e was prepared 
according to the general procedure. The reaction mixture was stirred for 48 
h at 32 °C followed by in situ reduction with triethylphosphite. Purification 
of the crude product by flash column chromatography (silica gel, 10-40% 
Et2O in pentane) provided the title compound as a colorless oil (78 mg, 458 μmol, 46%; 96:4 
er). The enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column 
(10% i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 14.65 min, minor enantiomer: 
τR = 13.19 min. 
1H NMR (500 MHz, CD2Cl2) δ 3.78-3.73 (m, 1H, CH(OH)), 2.77 (br s, 1H, OH), 2.61 (dd, J 
= 17.3, 2.7 Hz, 1H, CHHC(=O)), 2.49 (dd, J = 17.4, 9.9 Hz, 1H, CHHC(=O)), 2.15 (s, 3H, 
CH3), 1.84-1.79 (m, 1H, CH2), 1.77-1.71 (m, 2H, CH2), 1.68-1.61 (m, 2H, CH2), 1.35-1.27 
(m, 1H, CHcycl.), 1.26-1.10 (m, 3H, CH2), 1.07-0.94 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.6 (C(=O)), 72.0 (CH(OH)), 47.5 (C(=O)CH2), 43.4 
(CHcycl.), 30.9 (CH3), 29.2 (CH2), 28.5 (CH2), 26.9 (CH2), 26.6 (CH2), 26.5 (CH2). 
MS (EI-DE) m/z (%) 170 [M+] (trace), 152 (3), 137 (2), 112 (5), 109 (3), 95 (12), 87 (80), 83 
(6), 67 (14), 58 (9), 55 (26), 43 (100), 39 (9), 29 (10). 
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HRMS (CI-FE, NH3) calcd for C10H22NO2 [(M+NH4)+] 188.1650, found 188.1651. 
 
4-Hydroxyoct-7-en-2-one (96f): Aldol product 96f was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C followed by 
in situ reduction with triethylphosphite. Purification of the crude product 
by flash column chromatography (silica gel, 10-40% Et2O in pentane) 
provided the title compound as a colorless oil (78 mg, 549 μmol, 55%; 96:4 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (10% i-
PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 13.35 min, minor enantiomer: τR = 
12.51 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (dddd, J = 17.0, 9.3, 7.7, 5.9 Hz, 1H, CH2=CH), 5.04 
(app. dq, 1H, J = 17.2, 1.8 Hz, CHtransH=CH), 4.96 (app. dq, 1H, J = 9.4, 1.5 Hz, 1H, 
CHHcis=CH), 4.03-3.98 (m, 1H, CH(OH)), 2.86 (d, J = 3.8 Hz, 1H, OH), 2.61 (dd, J = 17.3, 
3.0 Hz, 1H, CHHC(=O)), 2.50 (dd, J = 17.7, 9.3 Hz, 1H, CHHC(=O)), 2.24-2.07 (m, 2H, 
CH2), 2.14 (s, 3H, CH3), 1.57-1.42 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.1 (C(=O)), 138.8 (CH2=CH), 114.8 (CH2=CH), 67.3 
(CH(OH)), 50.3 (C(=O)CH2), 35.9 (=CHCH2CH2), 30.9 (CH3), 30.1 (=CHCH2). 
MS (EI-DE) m/z (%) 142 [M+] (trace), 127 (1), 124 (2), 109 (4), 100 (7), 94 (3), 87 (11), 81 
(6), 67 (8), 58 (10), 43 (100), 41 (16), 29 (10). 
HRMS (CI-FE, NH3) calcd for C8H18NO2 [(M+NH4)+] 160.1337, found 160.1338. 
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HRMS (CI-FE, NH3) calcd for C10H22NO2 [(M+NH4)+] 188.1650, found 188.1651. 
 
4-Hydroxyoct-7-en-2-one (96f): Aldol product 96f was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C followed by 
in situ reduction with triethylphosphite. Purification of the crude product 
by flash column chromatography (silica gel, 10-40% Et2O in pentane) 
provided the title compound as a colorless oil (78 mg, 549 μmol, 55%; 96:4 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (10% i-
PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 13.35 min, minor enantiomer: τR = 
12.51 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (dddd, J = 17.0, 9.3, 7.7, 5.9 Hz, 1H, CH2=CH), 5.04 
(app. dq, 1H, J = 17.2, 1.8 Hz, CHtransH=CH), 4.96 (app. dq, 1H, J = 9.4, 1.5 Hz, 1H, 
CHHcis=CH), 4.03-3.98 (m, 1H, CH(OH)), 2.86 (d, J = 3.8 Hz, 1H, OH), 2.61 (dd, J = 17.3, 
3.0 Hz, 1H, CHHC(=O)), 2.50 (dd, J = 17.7, 9.3 Hz, 1H, CHHC(=O)), 2.24-2.07 (m, 2H, 
CH2), 2.14 (s, 3H, CH3), 1.57-1.42 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.1 (C(=O)), 138.8 (CH2=CH), 114.8 (CH2=CH), 67.3 
(CH(OH)), 50.3 (C(=O)CH2), 35.9 (=CHCH2CH2), 30.9 (CH3), 30.1 (=CHCH2). 
MS (EI-DE) m/z (%) 142 [M+] (trace), 127 (1), 124 (2), 109 (4), 100 (7), 94 (3), 87 (11), 81 
(6), 67 (8), 58 (10), 43 (100), 41 (16), 29 (10). 
HRMS (CI-FE, NH3) calcd for C8H18NO2 [(M+NH4)+] 160.1337, found 160.1338. 
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HRMS (CI-FE, NH3) calcd for C10H22NO2 [(M+NH4)+] 188.1650, found 188.1651. 
 
4-Hydroxyoct-7-en-2-one (96f): Aldol product 96f was prepared according to the general 
procedure. The reaction mixture was stirred for 36 h at 32 °C followed by 
in situ reduction with triethylphosphite. Purification of the crude product 
by flash column chromatography (silica gel, 10-40% Et2O in pentane) 
provided the title compound as a colorless oil (78 mg, 549 μmol, 55%; 96:4 er). The 
enantiomeric ratio was determined by HPLC using a chiral Chiralpak IA column (10% i-
PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 13.35 min, minor enantiomer: τR = 
12.51 min. 
1H NMR (500 MHz, CD2Cl2) δ 5.84 (dddd, J = 17.0, 9.3, 7.7, 5.9 Hz, 1H, CH2=CH), 5.04 
(app. dq, 1H, J = 17.2, 1.8 Hz, CHtransH=CH), 4.96 (app. dq, 1H, J = 9.4, 1.5 Hz, 1H, 
CHHcis=CH), 4.03-3.98 (m, 1H, CH(OH)), 2.86 (d, J = 3.8 Hz, 1H, OH), 2.61 (dd, J = 17.3, 
3.0 Hz, 1H, CHHC(=O)), 2.50 (dd, J = 17.7, 9.3 Hz, 1H, CHHC(=O)), 2.24-2.07 (m, 2H, 
CH2), 2.14 (s, 3H, CH3), 1.57-1.42 (m, 2H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 210.1 (C(=O)), 138.8 (CH2=CH), 114.8 (CH2=CH), 67.3 
(CH(OH)), 50.3 (C(=O)CH2), 35.9 (=CHCH2CH2), 30.9 (CH3), 30.1 (=CHCH2). 
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HRMS (CI-FE, NH3) calcd for C10H22NO2 [(M+NH4)+] 188.1650, found 188.1651. 
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7.4.2 Organoselenium-Mediated Reductive Epoxide Opening 
7.4.2.1 General Procedure[151a] 
 
 
 
Under argon, acetic acid (15 μL, 0.25 mmol, 0.5 equiv) was added to an ethanolic solution of 
sodium phenylselenide, prepared by the reduction of diphenylselenide (234 mg, 0.75 mmol, 
1.5 equiv) with sodium borohydride (57 mg, 1.5 mmol, 3.0 equiv) in ethanol (3 mL), and the 
mixture was stirred for five minutes at room temperature. The resulting solution was added at 
once to a solution of α,β-epoxy ketone 48 (0.5 mmol, 1.0 equiv) in ethanol (2 mL) at 0 °C. 
After five minutes at room temperature, the reaction mixture was diluted with Et2O or EtOAc 
(15 mL) and washed with brine (5 mL). The aqueous layer was repeatedly extracted with 
Et2O or EtOAc (2×10 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. Purification of the crude product 
by flash column chromatography (silica gel, eluent: Et2O-CH2Cl2) provided the corresponding 
β-hydroxy ketone 124. 
 
7.4.2.2 Scope of Optically Active Cyclic Aldol Products 
 
(S)-3-Hydroxycyclohexanone ((S)-124a): The title compound was prepared according to the 
general procedure and obtained as a colorless oil (54 mg, 470 μmol, 94%; 96:4 
er) after purification by flash column chromatography (silica gel, 25-50% Et2O in 
CH2Cl2). The enantiomeric ratio was determined by GC using a chiral Hydrodex-
β-TBDAc column 25 m (35 min at 150 °C, 5 °C/min until 220°C, 10 min at 220 
°C, 0.5 bar H2); major enantiomer: τR = 17.65 min, minor enantiomer: τR = 21.68 min. 
1H NMR (500 MHz, CD2Cl2) δ 4.18-4.13 (m, 1H, CH), 2.59 (dd, J = 14.2, 4.1 Hz, 1H, 
CHCHHC(=O)), 2.35 (dd, J = 14.0, 7.4 Hz, 1H, CHCHHC(=O)), 2.27 (t, J = 6.6 Hz, 2H, 
CH2C(=O)), 2.12 (br s, 1H, OH), 2.07-1.95 (m, 2H, CH2CHHCH and CH2CHHCH2), 1.77-
1.65 (m, 2H, CH2CHHCH and CH2CHHCH2). 
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13C NMR (125 MHz, CD2Cl2): δ 209.5 (C=O), 69.8 (CH), 50.3 (CHCH2C(=O)), 40.9 
(CH2C(=O)), 32.8 (CH2CH2CH), 20.7 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 114 [M+] (64), 96 (14), 86 (7), 81 (5), 73 (18), 68 (47), 60 (60), 58 (34), 
55 (81), 44 (100), 42 (85), 31 (9), 27 (28). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
 
(S)-3-Hydroxy-3-methylcyclohexanone ((S)-124b): The title compound was prepared 
according to the general procedure and obtained as a white solid (46 mg, 357 
μmol, 89%; 95.5:4.5 er) after purification by flash column chromatography 
(silica gel, 10-20% Et2O in CH2Cl2). The enantiomeric ratio was determined by 
GC using a chiral Hydrodex-β-TBDAc column 25 m (60 min at 145 °C, 6 
°C/min until 220°C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 14.81 min. 
1H NMR (500 MHz, CD2Cl2) δ 2.40 (d, J = 14.0 Hz, 1H, CqOHCHHC(=O)), 2.36 (td, J = 
13.9, 1.8 Hz, 1H, CqOHCHHC(=O)), 2.33-2.22 (m, 2H, CH2C(=O)), 2.08-1.99 (m, 1H, 
CH2CHHCH2), 1.89-1.76 (m, 3H, CH2CHHCH2 and CH2CH2CqOH), 1.55 (br s, 1H, OH), 
1.33 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2): δ 209.8 (C=O), 74.0 (CqOH), 54.9 (CqOHCH2C(=O)), 40.5 
(CH2C(=O)), 37.7 (CH2CH2CqOH), 30.1 (CH3), 21.4 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 128 [M+] (29), 110 (16), 99 (7), 86 (34), 71 (57), 68 (74), 60 (17), 57 
(86), 55 (100), 43 (97), 41 (71), 31 (13), 29 (43). 
HRMS (EI-FE) calcd for C7H12O2 [M+] 128.0836, found 128.0837. 
 
(S)-3-Hydroxycycloheptanone ((S)-124c): The title compound was prepared according to the 
general procedure and obtained as a colorless oil (31 mg, 242 μmol, 84%; 99:1 
er) after purification by flash column chromatography (silica gel, 40-60% Et2O 
in CH2Cl2). The enantiomeric ratio was determined by GC using a chiral 
Ivadex 7/PS086 column 25 m (40 min at 105 °C, 10 °C/min until 220°C, 10 
min at 320 °C, 0.5 bar H2); major enantiomer: τR = 27.66 min, minor enantiomer: τR = 29.55 
min. 
1H NMR (500 MHz, CD2Cl2) δ 4.06-4.02 (m, 1H, CH), 2.77-2.69 (m, 2H, CHCH2C(=O)), 
2.47-2.36 (m, 2H, CH2C(=O)), 2.03 (br s, 1H, OH), 1.90-1.78 (m, 3H, CH2CHHCH and 
CH2CH2CH2), 1.77-1.72 (m, 2H, CH2CH2C(=O)), 1.61-1.55 (m, 1H, CH2CHHCH). 
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13C NMR (125 MHz, CD2Cl2): δ 209.5 (C=O), 69.8 (CH), 50.3 (CHCH2C(=O)), 40.9 
(CH2C(=O)), 32.8 (CH2CH2CH), 20.7 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 114 [M+] (64), 96 (14), 86 (7), 81 (5), 73 (18), 68 (47), 60 (60), 58 (34), 
55 (81), 44 (100), 42 (85), 31 (9), 27 (28). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
 
(S)-3-Hydroxy-3-methylcyclohexanone ((S)-124b): The title compound was prepared 
according to the general procedure and obtained as a white solid (46 mg, 357 
μmol, 89%; 95.5:4.5 er) after purification by flash column chromatography 
(silica gel, 10-20% Et2O in CH2Cl2). The enantiomeric ratio was determined by 
GC using a chiral Hydrodex-β-TBDAc column 25 m (60 min at 145 °C, 6 
°C/min until 220°C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 14.81 min. 
1H NMR (500 MHz, CD2Cl2) δ 2.40 (d, J = 14.0 Hz, 1H, CqOHCHHC(=O)), 2.36 (td, J = 
13.9, 1.8 Hz, 1H, CqOHCHHC(=O)), 2.33-2.22 (m, 2H, CH2C(=O)), 2.08-1.99 (m, 1H, 
CH2CHHCH2), 1.89-1.76 (m, 3H, CH2CHHCH2 and CH2CH2CqOH), 1.55 (br s, 1H, OH), 
1.33 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2): δ 209.8 (C=O), 74.0 (CqOH), 54.9 (CqOHCH2C(=O)), 40.5 
(CH2C(=O)), 37.7 (CH2CH2CqOH), 30.1 (CH3), 21.4 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 128 [M+] (29), 110 (16), 99 (7), 86 (34), 71 (57), 68 (74), 60 (17), 57 
(86), 55 (100), 43 (97), 41 (71), 31 (13), 29 (43). 
HRMS (EI-FE) calcd for C7H12O2 [M+] 128.0836, found 128.0837. 
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55 (81), 44 (100), 42 (85), 31 (9), 27 (28). 
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13C NMR (125 MHz, CD2Cl2): δ 209.5 (C=O), 69.8 (CH), 50.3 (CHCH2C(=O)), 40.9 
(CH2C(=O)), 32.8 (CH2CH2CH), 20.7 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 114 [M+] (64), 96 (14), 86 (7), 81 (5), 73 (18), 68 (47), 60 (60), 58 (34), 
55 (81), 44 (100), 42 (85), 31 (9), 27 (28). 
HRMS (EI-FE) calcd for C6H10O2 [M+] 114.0680, found 114.0681. 
 
(S)-3-Hydroxy-3-methylcyclohexanone ((S)-124b): The title compound was prepared 
according to the general procedure and obtained as a white solid (46 mg, 357 
μmol, 89%; 95.5:4.5 er) after purification by flash column chromatography 
(silica gel, 10-20% Et2O in CH2Cl2). The enantiomeric ratio was determined by 
GC using a chiral Hydrodex-β-TBDAc column 25 m (60 min at 145 °C, 6 
°C/min until 220°C, 10 min at 220 °C, 0.6 bar H2); major enantiomer: τR = 11.84 min, minor 
enantiomer: τR = 14.81 min. 
1H NMR (500 MHz, CD2Cl2) δ 2.40 (d, J = 14.0 Hz, 1H, CqOHCHHC(=O)), 2.36 (td, J = 
13.9, 1.8 Hz, 1H, CqOHCHHC(=O)), 2.33-2.22 (m, 2H, CH2C(=O)), 2.08-1.99 (m, 1H, 
CH2CHHCH2), 1.89-1.76 (m, 3H, CH2CHHCH2 and CH2CH2CqOH), 1.55 (br s, 1H, OH), 
1.33 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2): δ 209.8 (C=O), 74.0 (CqOH), 54.9 (CqOHCH2C(=O)), 40.5 
(CH2C(=O)), 37.7 (CH2CH2CqOH), 30.1 (CH3), 21.4 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 128 [M+] (29), 110 (16), 99 (7), 86 (34), 71 (57), 68 (74), 60 (17), 57 
(86), 55 (100), 43 (97), 41 (71), 31 (13), 29 (43). 
HRMS (EI-FE) calcd for C7H12O2 [M+] 128.0836, found 128.0837. 
 
(S)-3-Hydroxycycloheptanone ((S)-124c): The title compound was prepared according to the 
general procedure and obtained as a colorless oil (31 mg, 242 μmol, 84%; 99:1 
er) after purification by flash column chromatography (silica gel, 40-60% Et2O 
in CH2Cl2). The enantiomeric ratio was determined by GC using a chiral 
Ivadex 7/PS086 column 25 m (40 min at 105 °C, 10 °C/min until 220°C, 10 
min at 320 °C, 0.5 bar H2); major enantiomer: τR = 27.66 min, minor enantiomer: τR = 29.55 
min. 
1H NMR (500 MHz, CD2Cl2) δ 4.06-4.02 (m, 1H, CH), 2.77-2.69 (m, 2H, CHCH2C(=O)), 
2.47-2.36 (m, 2H, CH2C(=O)), 2.03 (br s, 1H, OH), 1.90-1.78 (m, 3H, CH2CHHCH and 
CH2CH2CH2), 1.77-1.72 (m, 2H, CH2CH2C(=O)), 1.61-1.55 (m, 1H, CH2CHHCH). 
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7.4.3 Synthesis of (3R,5S)-3-Hexyl-5-methyl-1,2-dioxolane (127) 
The ketalization of peroxyhemiketal 94a was conducted according to the protocol of Dussault 
et al.[114] 
n-C6H13
O O
OH
TiCl4 (1.12 equiv)
Et3SiH (3.0 equiv)
n-C6H13
O O
O
OMe
pTsOH H2O (cat.)
HO
OMe
n-C6H13
O O
cis-12794a (dr ~1:1)
98.5:1.5 er
r.t., 10 h 128
CH2Cl2, 78 °C
30 min
 
 
(5R)-5-Hexyl-3-(2-methoxyethoxy)-3-methyl-1,2-dioxolane (128):[114] p-Toluenesulfonic 
acid monohydrate (26 mg, 0.14 mmol) was added to a 
solution of peroxyhemiketal 94a (302 mg, 1.60 mmol; 
98.5:1.5 er) in 2-methoxyethanol (15 mL). After stirring for 
12 h at room temperature, the solvent was removed in vacuo and the residue subjected to flash 
column chromatography (silica gel, 5-15% Et2O in pentane) to afford peroxyketal 128 (236 
mg, 0.96 mmol, 60%) as a colorless oil. Characterized as a mixture of diastereoisomers (1:1 
dr). 
1H NMR (500 MHz, CD2Cl2) isomer 1: δ 4.27 (quint, J = 7.1 Hz, 1H, CH), 3.69-3.64 (m, 1H, 
OCH2), 3.61-3.57 (m, 1H, OCH2), 3.52-3.46 (m, 2H, OCH2), 3.34 (s, 3H, OCH3), 2.57 (dd, J 
= 12.6, 7.6 Hz, 1H, CHHCq), 2.34 (dd, J = 12.6, 8.2 Hz, 1H, CHHCq), 1.69-1.63 (m, 1H, 
CH2CHHCH), 1.60-1.54 (m, 1H, CH2CHHCH), 1.45 (s, 3H, CqCH3), 1.34-1.24 (m, 8H, 
(CH2)4CH3), 0.88 (t, J = 7.1 Hz, 3H, (CH2)5CH3); isomer 2: δ 4.37 (quint, J = 6.5 Hz, 1H, 
CH), 3.69-3.64 (m, 1H, OCH2), 3.61-3.55 (m, 1H, OCH2), 3.52-3.45 (m, 2H, OCH2), 3.33 (s, 
3H, OCH3), 2.81 (dd, J = 12.5, 7.1 Hz, 1H, CHHCq), 2.15 (dd, J = 12.8, 6.2 Hz, 1H, 
CHHCq), 1.70-1.62 (m, 1H, CH2CHHCH), 1.47 (s, 3H, CqCH3), 1.39-1.24 (m, 9H, 
CH2CHHCH and (CH2)4CH3), 0.88 (t, J = 7.1 Hz, 3H, (CH2)5CH3). 
13C NMR (125 MHz, THF-d8) δ 108.6 (Cq), 107.6 (Cq), 82.7 (CH), 81.6 (CH), 73.1 (OCH2), 
73.1 (OCH2), 62.2 (OCH2), 62.1 (OCH2), 59.2 (OCH3), 59.1 (OCH3), 53.6 (CH2Cq), 53.3 
(CH2Cq), 36.0 (CH2), 33.1 (CH2), 33.0 (CH2), 32.9 (CH2), 30.5 (CH2), 30.4 (CH2), 27.5 (CH2), 
27.3 (CH2), 23.8 (CH2), 23.8 (CH2), 20.5 (CqCH3), 19.4 (CqCH3), 14.7 (2C, (CH2)5CH3). 
MS (EI-DE) m/z (%) 246 [M+] (trace), 213 (37), 171 (2), 155 (4), 129 (4), 113 (7), 95 (9), 87 
(9), 71 (8), 59 (88), 43 (100), 29 (20). 
HRMS (ESI+) calcd for C13H26NaO4 [(M+Na)+] 269.1720, found 269.1723. 
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cis-(3R,5S)-3-Hexyl-5-methyl-1,2-dioxolane (cis-127): Peroxyketal 128 (20.0 mg, 81.2 
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7.5 Preparation of Starting Materials 
7.5.1 Preparation of Cyclic α,β-Unsaturated Ketones 
7.5.1.1 General Procedure A: Protocol of Woods[163] 
 
 
 
3-Ethoxy-2-cyclohexenone or –heptenone (135 or 136; 21.4 mmol, 1.0 equiv) in THF (15 
mL) was added dropwise to a solution of a Grignard reagent (1 M in Et2O or THF, 1.5-2.0 
equiv) at 0 °C under argon. Once the addition was complete, the resulting solution was 
allowed to warm to room temperature and stirred until TLC indicated complete disappearance 
of the starting material (2-18 h). The reaction was slowly quenched with diluted aqueous acid 
(1 N HCl or 5% H2SO4) at 0 °C. The layers were separated, and the aqueous layer extracted 
with Et2O (3×50 mL). The combined organic layers were washed successively with saturated 
aqueous NaHCO3-solution, water, and brine, dried (Na2SO4), filtered, and evaporated under 
reduced pressure. The crude product was purified by flash column chromatography (silica gel, 
eluent: Et2O-pentane) to yield 3-substituted 2-cyclohexenone and –heptenone derivatives 46. 
 
Scope of Cyclic Enones Prepared According to General Procedure A 
 
3-Isopropyl-2-cyclohexenone (46i): The title compound was prepared according to the 
general procedure A from 3-ethoxy-2-cyclohexenone (135) and isopropyl 
magnesium chloride (2 M in Et2O). Purification by flash column 
chromatography (silica gel, 20% Et2O in pentane) gave enone 46i (2.10 g, 15.2 
mmol, 71%) as a pale yellow liquid. 
1H NMR (300 MHz, CD2Cl2) δ 5.81 (q, J = 1.4 Hz, 1H, =CH), 2.41 (hept, J = 6.9 Hz, 1H, 
CHMe2), 2.33-2.28 (m, 4H, CH2C(=O) and CH2Cqol), 1.96 (quint, J = 6.2 Hz, 2H, 
CH2CH2CH2), 1.09 (d, J = 7.2 Hz, 6H, CH(CH3)2). 
13C NMR (75 MHz, CDCl3) δ 200.3 (C=O), 171.8 (Cq=CH), 123.6 (Cq=CH), 37.6 
(CH2C(=O)), 35.7 (CHMe2), 27.7 (CH2Cqol), 22.9 (CH2CH2CH2), 20.6 (2C, CH(CH3)2). 
GC-MS (GC-EI) m/z 138 [M+]. 
HRMS (EI-FE) calcd for C9H14O [M+] 138.1043, found 138.1045. 
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3-Allyl-2-cyclohexenone (46k): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cyclohexenone (135) and allyl magnesium 
chloride (2 M in THF). Purification by flash column chromatography (silica 
gel, 20% Et2O in pentane) gave enone 46k (893 mg, 6.55 mmol, 47%) as a 
colorless liquid.[195] 
1H NMR (500 MHz, CDCl3) δ 5.87 (s, 1H, Cq=CH), 5.76 (ddt, J = 16.7, 10.3, 6.8 Hz, 1H, 
CH=CH2), 5.14-5.09 (m, 2H, CH=CH2), 2.92 (d, J = 7.1 Hz, 2H, CH2CH=CH2), 2.34 (t, J = 
6.8 Hz, 2H, CH2C(=O)), 2.27 (br t, J = 6.1 Hz, 2H, CH2CH2Cqol), 1.97 (quint, J = 6.4 Hz, 2H, 
CH2CH2CH2). 
13C NMR (125 MHz, CDCl3) δ 199.8 (C=O), 164.1 (Cq=CH), 133.2 (CH=CH2), 126.3 
(Cq=CH), 118.3 (CH=CH2), 42.2 (CH2CH=CH2), 37.3 (C=OCH2), 29.5 (CH2CH2Cqol), 22.6 
(CH2CH2CH2). 
MS (EI-DE) m/z (%) 136 [M+] (74), 121 (8), 108 (42), 93 (8), 79 (100), 77 (18), 74 (1), 67 
(19), 53 (9), 41 (19), 39 (43), 29 (2), 27 (13). 
HRMS (EI-FE) calcd for C9H12O [M+] 136.0888, found 136.0888. 
 
3-Benzyl-2-cyclohexenone (46m): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cyclohexenone (135) and benzyl magnesium 
chloride (1 M in Et2O). Purification by flash column chromatography (silica 
gel, 20% Et2O in pentane) gave enone 46m (3.02 g, 16.2 mmol, 76%) as a 
colorless liquid. 
1H NMR (500 MHz, CD2Cl2) δ 7.33-7.30 (m, 2H, CHPh, m), 7.28-7.24 (m, 1H, CHPh, p), 7.21-
7.18 (m, 2H, CHPh, o), 5.80 (s, 1H, =CH), 3.52 (s, 2H, PhCH2), 2.31 (t, J = 6.8 Hz, 2H, 
CH2C(=O)), 2.25 (br t, J = 6.0 Hz, 2H, CH2Cqol), 1.94 (quint, J = 6.4 Hz, 2H, CH2CH2CH2). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 164.9 (Cqol), 137.8 (CqPh), 129.5 (2C, CHPh, o), 
129.0 (2C, CHPh, m), 127.1 (CHPh, p), 127.0 (=CH), 44.7 (PhCH2), 37.7 (CH2C(=O)), 29.6 
(CH2Cqol), 23.1 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 186 [M+] (100), 168 (8), 158 (91), 142 (9), 129 (58), 115 (34), 102 (3), 
91 (30), 77 (9), 67 (26), 51 (15), 39 (46), 27 (11). 
HRMS (EI-DE) calcd for C13H14O [M+] 186.1043, found 186.1045. 
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HRMS (EI-FE) calcd for C9H12O [M+] 136.0888, found 136.0888. 
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HRMS (EI-DE) calcd for C13H14O [M+] 186.1043, found 186.1045. 
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3-Phenyl-2-cyclohexenone (46n): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cyclohexenone (135) and phenyl magnesium 
chloride (2 M in THF). Purification by flash column chromatography (silica gel, 
30% Et2O in pentane) gave enone 46n (3.60 g, 20.9 mmol, 98%) as a white 
solid.[196] 
1H NMR (500 MHz, CD2Cl2) δ 7.57-7.55 (m, 2H, CHPh), 7.43-7.40 (m, 3H, CHPh), 6.37 (t, J 
= 1.5 Hz, 1H, =CH), 2.77 (td, J = 6.0, 1.4 Hz, 2H, CH2Cqol), 2.44 (app. t, J = 6.8 Hz, 2H, 
CH2C(=O)), 2.14 (quint, J = 6.3 Hz, 2H, CH2CH2CH2). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 159.9 (Cq=CH), 139.3 (CqPh), 130.1 (CHPh, p), 
129.0 (2C, CHPh), 126.4 (2C, CHPh), 125.6 (Cq=CH), 37.6 (CH2C(=O)), 28.4 (CH2Cqol), 23.2 
(CH2CH2CH2). 
 
3-Vinyl-2-cyclohexenone (46o): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cyclohexenone (135) and vinyl magnesium 
bromide (1 M in THF). Purification by flash column chromatography (silica 
gel, 15-25% Et2O in pentane) gave enone 46o (1.97 g, 16.1 mmol, 75%) as a 
colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.50 (dd, J = 17.6, 10.7 Hz, 1H, CH=CH2), 5.89 (s, 1H, 
Cq=CH), 5.70 (d, J = 17.7 Hz, 1H, CH=CHtransH), 5.45 (d, J = 10.7 Hz, 1H, CH=CHHcis), 
2.47 (br t, J = 6.1 Hz, 2H, CH2Cqol), 2.37 (t, J = 6.8 Hz, 2H, CH2C(=O)), 2.02 (quint, J = 6.4 
Hz, 2H, CH2CH2CH2). 
13C NMR (126 MHz, CD2Cl2) δ 200.1 (C=O), 157.1 (Cq=CH), 138.3 (CH=CH2), 128.4 
(Cq=CH), 120.7 (CH=CH2), 37.8 (CH2C(=O)), 24.6 (CH2), 22.6 (CH2). 
GC-MS (GC-EI) m/z 122 [M+]. 
HRMS (EI-FE) calcd for C8H10O [M+] 122.0730, found 122.0732. 
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3-Phenyl-2-cyclohexenone (46n): The title compound was prepared according to the general 
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3-Phenyl-2-cyclohexenone (46n): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cyclohexenone (135) and phenyl magnesium 
chloride (2 M in THF). Purification by flash column chromatography (silica gel, 
30% Et2O in pentane) gave enone 46n (3.60 g, 20.9 mmol, 98%) as a white 
solid.[196] 
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CH2C(=O)), 2.14 (quint, J = 6.3 Hz, 2H, CH2CH2CH2). 
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procedure A from 3-ethoxy-2-cyclohexenone (135) and vinyl magnesium 
bromide (1 M in THF). Purification by flash column chromatography (silica 
gel, 15-25% Et2O in pentane) gave enone 46o (1.97 g, 16.1 mmol, 75%) as a 
colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.50 (dd, J = 17.6, 10.7 Hz, 1H, CH=CH2), 5.89 (s, 1H, 
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3-Ethynyl-2-cyclohexenone (46p): The title compound was prepared according to the 
general procedure A from 3-ethoxy-2-cyclohexenone (135) and ethynyl 
magnesium bromide (0.5 M in THF). Purification by flash column chromato-
graphy (silica gel, 10-25% Et2O in pentane) gave enone 46p (1.33 g, 11.1 mmol, 
77%) as a colorless liquid. 
1H NMR (500 MHz, CD2Cl2) δ 6.21 (t, J = 1.6 Hz, 1H, =CH), 3.59 (s, 1H, ≡CH), 2.45 (td, J 
= 6.1, 1.7 Hz, 2H, CH2Cqol), 2.34 (t, J = 6.7 Hz, 2H, CH2C(=O)), 2.02 (quint, J = 6.3 Hz, 2H, 
CH2CH2CH2). 
13C NMR (125 MHz, CD2Cl2) δ 198.4 (C=O), 142.3 (Cq=CH), 134.2 (Cq=CH), 87.0 
(Cq≡CH), 82.8 (Cq≡CH), 37.6 (CH2C(=O)), 30.5 (CH2Cqol), 22.9 (CH2CH2CH2). 
GC-MS (GC-EI) m/z (%) 120 [M+] (44), 92 (100), 89 (2), 77 (4), 64 (54), 50 (12), 42 (5), 39 
(15), 27 (3). 
HRMS (EI-FE) calcd for C8H8O [M+] 120.0576, found 120.0575. 
 
3-Ethyl-2-cycloheptenone (46t): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cycloheptenone (136) and ethyl magnesium 
bromide (3 M in THF). Purification by flash column chromatography (silica gel, 
20% Et2O in pentane) gave enone 46t (570 mg, 4.12 mmol, 61%) as a pale 
yellow liquid. 3-Ethoxy-2-cycloheptenone (136) was obtained by heating a 
mixture of 1,3-cycloheptanedione (0.85 g, 6.74 mmol), dry ethanol (1.7 mL), and a catalytic 
amount of p-toluene sulfonic acid monohydrate (17 mg) in benzene (40 mL) under reflux with 
a Dean-Stark trap. After 12 h, the mixture was allowed to cool to room temperature and the 
solvent was evaporated under reduced pressure. The resulting crude 3-ethoxy-2-
cycloheptenone (136; ~90% purity) was used without further purification for the synthesis of 
3-ethyl-2-cycloheptenone (46t). 
1H NMR (400 MHz, CD2Cl2) δ 5.83 (s, 1H, =CH), 2.52 (t, J = 6.1 Hz, 2H, CH2C(=O)), 2.41 
(t, J = 5.8 Hz, 2H, CH2Cqol), 2.22 (qd, J = 7.4, 1.2 Hz, 2H, CH2CH3), 1.81-1.72 (m, 4H, 
CH2(CH2)2CH2), 1.08 (t, J = 7.4 Hz, 3H, CH2CH3). 
13C NMR (75 MHz, CD2Cl2) δ 203.9 (C=O), 163.8 (Cq=CH), 128.2 (Cq=CH), 42.5 
(CH2C(=O)), 34.1 (CqolCH2, cycl.), 32.9 (CH2CH3), 25.5 (CH2, cycl.), 21.7 (CH2, cycl.), 12.3 (CH3). 
MS (EI-DE) m/z (%) 138 [M+] (29), 109 (100), 96 (18), 81 (32), 79 (10), 67 (17), 53 (17), 39 
(20), 27 (17). 
HRMS (EI-FE) calcd for C9H14O [M+] 138.1045, found 138.1045. 
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3-Ethynyl-2-cyclohexenone (46p): The title compound was prepared according to the 
general procedure A from 3-ethoxy-2-cyclohexenone (135) and ethynyl 
magnesium bromide (0.5 M in THF). Purification by flash column chromato-
graphy (silica gel, 10-25% Et2O in pentane) gave enone 46p (1.33 g, 11.1 mmol, 
77%) as a colorless liquid. 
1H NMR (500 MHz, CD2Cl2) δ 6.21 (t, J = 1.6 Hz, 1H, =CH), 3.59 (s, 1H, ≡CH), 2.45 (td, J 
= 6.1, 1.7 Hz, 2H, CH2Cqol), 2.34 (t, J = 6.7 Hz, 2H, CH2C(=O)), 2.02 (quint, J = 6.3 Hz, 2H, 
CH2CH2CH2). 
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GC-MS (GC-EI) m/z (%) 120 [M+] (44), 92 (100), 89 (2), 77 (4), 64 (54), 50 (12), 42 (5), 39 
(15), 27 (3). 
HRMS (EI-FE) calcd for C8H8O [M+] 120.0576, found 120.0575. 
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procedure A from 3-ethoxy-2-cycloheptenone (136) and ethyl magnesium 
bromide (3 M in THF). Purification by flash column chromatography (silica gel, 
20% Et2O in pentane) gave enone 46t (570 mg, 4.12 mmol, 61%) as a pale 
yellow liquid. 3-Ethoxy-2-cycloheptenone (136) was obtained by heating a 
mixture of 1,3-cycloheptanedione (0.85 g, 6.74 mmol), dry ethanol (1.7 mL), and a catalytic 
amount of p-toluene sulfonic acid monohydrate (17 mg) in benzene (40 mL) under reflux with 
a Dean-Stark trap. After 12 h, the mixture was allowed to cool to room temperature and the 
solvent was evaporated under reduced pressure. The resulting crude 3-ethoxy-2-
cycloheptenone (136; ~90% purity) was used without further purification for the synthesis of 
3-ethyl-2-cycloheptenone (46t). 
1H NMR (400 MHz, CD2Cl2) δ 5.83 (s, 1H, =CH), 2.52 (t, J = 6.1 Hz, 2H, CH2C(=O)), 2.41 
(t, J = 5.8 Hz, 2H, CH2Cqol), 2.22 (qd, J = 7.4, 1.2 Hz, 2H, CH2CH3), 1.81-1.72 (m, 4H, 
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MS (EI-DE) m/z (%) 138 [M+] (29), 109 (100), 96 (18), 81 (32), 79 (10), 67 (17), 53 (17), 39 
(20), 27 (17). 
HRMS (EI-FE) calcd for C9H14O [M+] 138.1045, found 138.1045. 
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3-Benzyl-2-cycloheptenone (46u): The title compound was prepared according to the general 
procedure A from 3-ethoxy-2-cycloheptenone (136 vide supra) and benzyl 
magnesium chloride (1 M in Et2O). Purification by flash column 
chromatography (silica gel, 20% Et2O in pentane) gave enone 46u (551 mg, 
2.75 mmol, 41%) as a pale yellow liquid. 
1H NMR (400 MHz, CD2Cl2) δ 7.34-7.19 (m, 5H, C6H5), 5.89 (s, 1H, =CH), 3.49 (s, 2H, 
CH2Ph), 2.53 (t, J = 6.4 Hz, 2H, CH2C(=O)), 2.37 (t, J = 5.9 Hz, 2H, CH2Cqol), 1.78-1.64 (m, 
4H, CH2(CH2)2CH2). 
13C NMR (75 MHz, CD2Cl2) δ 203.8 (C=O), 160.2 (Cqol), 138.4 (CqPh), 130.9 (=CH), 129.5 
(2C, CHPh), 128.9 (2C, CHPh), 127.0 (CHPh, p), 47.3 (CH2Ph), 42.6 (CH2C(=O)), 32.7 
(CH2Cqol), 25.6 (CH2CH2Cqol), 21.7 (CH2CH2C(=O)). 
MS (EI-DE) m/z (%) 200 [M+] (14), 182 (1), 171 (4), 158 (4), 143 (3), 129 (13), 115 (12), 109 
(100), 91 (15), 81 (24), 65 (12), 53 (11), 39 (14), 27 (6). 
HRMS (EI-DE) calcd for C14H16O [M+] 200.1199, found 200.1201. 
 
7.5.1.2 General Procedure B: Saegusa Oxidation[167] 
 
 
 
To a solution of LDA, freshly prepared from n-BuLi (13.2 ml, 33.0 mmol, 1.1 equiv, 2.5M in 
hexanes) and diisopropylamine (5.06 mL, 36.0 mmol, 1.2 equiv) in THF (46 mL) at 0 °C, was 
added a cyclic ketone (30.0 mmol, 1.0 equiv) dissolved in THF (18 ml) at −78 °C. After 
stirring for 30 min, the solution was warmed to room temperature and stirred for additional 30 
min at room temperature. After re-cooling to −78 °C, TMSCl (6.47 ml, 51.0 mmol, 1.7 equiv) 
was added, and stirring was continued for 1 h. The reaction was quenched with saturated 
aqueous NH4Cl solution and extracted with Et2O (3 × 150 mL). The combined organic layers 
were dried (Na2SO4), filtered, and concentrated in vacuo. The crude silyl enol ether was 
dissolved in DMSO (600 mL), and Pd(OAc)2 (673 mg, 3.00 mmol, 10 mol%) was added. The 
flask was carefully evacuated, purged with O2, and equipped with an O2 ballon. After stirring 
for 12 h at room temperature, the reaction mixture was poured into ice water (300 mL), and 
repeatedly extracted with Et2O (2 × 300 mL). The combined organic phases were washed 
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with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, eluent: Et2O-pentane) to 
afford the corresponding pure cyclic α,β-unsaturated ketones 46. 
 
Scope of Cyclic Enones Prepared According to General Procedure B 
 
2-Cyclooctenone (46v): The title compound was prepared according to the general procedure 
B from cyclooctanone (3.79 g, 30.0 mmol). Purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) gave 2-cyclooctenone 
(46v; 2.38 g, 19.2 mmol, 64%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.33 (dt, J = 12.5, 7.1 Hz, 1H, CH2CH=), 5.94 (d, J = 12.5 Hz, 
1H, CH2CH=CH), 2.60 (t, J = 6.9 Hz, 2H, CH2C(=O)), 2.52-2.47 (m, 2H, CH2CH=), 1.82-
1.77 (m, 2H, CH2CH2C(=O)), 1.63-1.53 (m, 4H, CH2CH2CHol and CH2(CH2)2C(=O)). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 141.5 (CH2CH=), 132.2 (CH2CH=CH), 42.7 
(CH2C(=O)), 28.6 (CH2CH=), 25.3 (CH2(CH2)2C(=O)), 23.2 (CH2CH2CH=), 22.7 
(CH2CH2C(=O)). 
GC-MS (GC-EI) m/z 124 [M+] (8), 109 (1), 95 (11), 91 (2), 81 (100), 68 (40), 65 (4), 53 (39), 
51 (5), 41 (23), 39 (34), 27 (17). 
HRMS (EI-FE) calcd for C8H12O [M+] 124.0887, found 124.0888. 
 
4-Methyl-2-cyclohexenone (80a): The title compound was prepared according to the general 
procedure B from 4-methylcyclohexanone (1.84 mL, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) gave cyclohexenone 80a (1.36 g, 12.3 mmol, 82%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.80 (ddd, J = 10.2, 2.6, 1.3 Hz, 1H, =CHCH), 5.88 (dd, J = 
10.1, 2.5 Hz, 1H, CH=CHCH), 2.58-2.50 (m, 1H, CHMe), 2.42 (dt, J = 16.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.33 (ddd, J = 16.8, 12.2, 4.7 Hz, 1H, CHHC(=O)), 2.09 (dqd, J = 13.6, 5.0, 1.3 
Hz, 1H, CHHCH), 1.68-1.61 (m, 1H, CHHCH), 1.14 (d, J = 7.3 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 156.5 (=CHCH), 128.8 (CH=CHCH), 37.2 
(CH2C(=O)), 31.5 (CHMe), 31.3 (CH2CH), 20.3 (CH3). 
GC-MS (GC-EI) m/z 110 [M+] (51), 95 (4), 82 (100), 79 (4), 68 (67), 65 (6), 54 (56), 41 (18), 
39 (40), 27 (20). 
HRMS (EI-FE) calcd for C7H10O [M+] 110.0731, found 110.0732. 
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with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, eluent: Et2O-pentane) to 
afford the corresponding pure cyclic α,β-unsaturated ketones 46. 
 
Scope of Cyclic Enones Prepared According to General Procedure B 
 
2-Cyclooctenone (46v): The title compound was prepared according to the general procedure 
B from cyclooctanone (3.79 g, 30.0 mmol). Purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) gave 2-cyclooctenone 
(46v; 2.38 g, 19.2 mmol, 64%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.33 (dt, J = 12.5, 7.1 Hz, 1H, CH2CH=), 5.94 (d, J = 12.5 Hz, 
1H, CH2CH=CH), 2.60 (t, J = 6.9 Hz, 2H, CH2C(=O)), 2.52-2.47 (m, 2H, CH2CH=), 1.82-
1.77 (m, 2H, CH2CH2C(=O)), 1.63-1.53 (m, 4H, CH2CH2CHol and CH2(CH2)2C(=O)). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 141.5 (CH2CH=), 132.2 (CH2CH=CH), 42.7 
(CH2C(=O)), 28.6 (CH2CH=), 25.3 (CH2(CH2)2C(=O)), 23.2 (CH2CH2CH=), 22.7 
(CH2CH2C(=O)). 
GC-MS (GC-EI) m/z 124 [M+] (8), 109 (1), 95 (11), 91 (2), 81 (100), 68 (40), 65 (4), 53 (39), 
51 (5), 41 (23), 39 (34), 27 (17). 
HRMS (EI-FE) calcd for C8H12O [M+] 124.0887, found 124.0888. 
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Hz, 1H, CHHCH), 1.68-1.61 (m, 1H, CHHCH), 1.14 (d, J = 7.3 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 156.5 (=CHCH), 128.8 (CH=CHCH), 37.2 
(CH2C(=O)), 31.5 (CHMe), 31.3 (CH2CH), 20.3 (CH3). 
GC-MS (GC-EI) m/z 110 [M+] (51), 95 (4), 82 (100), 79 (4), 68 (67), 65 (6), 54 (56), 41 (18), 
39 (40), 27 (20). 
HRMS (EI-FE) calcd for C7H10O [M+] 110.0731, found 110.0732. 
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with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, eluent: Et2O-pentane) to 
afford the corresponding pure cyclic α,β-unsaturated ketones 46. 
 
Scope of Cyclic Enones Prepared According to General Procedure B 
 
2-Cyclooctenone (46v): The title compound was prepared according to the general procedure 
B from cyclooctanone (3.79 g, 30.0 mmol). Purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) gave 2-cyclooctenone 
(46v; 2.38 g, 19.2 mmol, 64%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.33 (dt, J = 12.5, 7.1 Hz, 1H, CH2CH=), 5.94 (d, J = 12.5 Hz, 
1H, CH2CH=CH), 2.60 (t, J = 6.9 Hz, 2H, CH2C(=O)), 2.52-2.47 (m, 2H, CH2CH=), 1.82-
1.77 (m, 2H, CH2CH2C(=O)), 1.63-1.53 (m, 4H, CH2CH2CHol and CH2(CH2)2C(=O)). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 141.5 (CH2CH=), 132.2 (CH2CH=CH), 42.7 
(CH2C(=O)), 28.6 (CH2CH=), 25.3 (CH2(CH2)2C(=O)), 23.2 (CH2CH2CH=), 22.7 
(CH2CH2C(=O)). 
GC-MS (GC-EI) m/z 124 [M+] (8), 109 (1), 95 (11), 91 (2), 81 (100), 68 (40), 65 (4), 53 (39), 
51 (5), 41 (23), 39 (34), 27 (17). 
HRMS (EI-FE) calcd for C8H12O [M+] 124.0887, found 124.0888. 
 
4-Methyl-2-cyclohexenone (80a): The title compound was prepared according to the general 
procedure B from 4-methylcyclohexanone (1.84 mL, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) gave cyclohexenone 80a (1.36 g, 12.3 mmol, 82%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.80 (ddd, J = 10.2, 2.6, 1.3 Hz, 1H, =CHCH), 5.88 (dd, J = 
10.1, 2.5 Hz, 1H, CH=CHCH), 2.58-2.50 (m, 1H, CHMe), 2.42 (dt, J = 16.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.33 (ddd, J = 16.8, 12.2, 4.7 Hz, 1H, CHHC(=O)), 2.09 (dqd, J = 13.6, 5.0, 1.3 
Hz, 1H, CHHCH), 1.68-1.61 (m, 1H, CHHCH), 1.14 (d, J = 7.3 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 156.5 (=CHCH), 128.8 (CH=CHCH), 37.2 
(CH2C(=O)), 31.5 (CHMe), 31.3 (CH2CH), 20.3 (CH3). 
GC-MS (GC-EI) m/z 110 [M+] (51), 95 (4), 82 (100), 79 (4), 68 (67), 65 (6), 54 (56), 41 (18), 
39 (40), 27 (20). 
HRMS (EI-FE) calcd for C7H10O [M+] 110.0731, found 110.0732. 
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with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, eluent: Et2O-pentane) to 
afford the corresponding pure cyclic α,β-unsaturated ketones 46. 
 
Scope of Cyclic Enones Prepared According to General Procedure B 
 
2-Cyclooctenone (46v): The title compound was prepared according to the general procedure 
B from cyclooctanone (3.79 g, 30.0 mmol). Purification by flash column 
chromatography (silica gel, 5-10% Et2O in pentane) gave 2-cyclooctenone 
(46v; 2.38 g, 19.2 mmol, 64%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.33 (dt, J = 12.5, 7.1 Hz, 1H, CH2CH=), 5.94 (d, J = 12.5 Hz, 
1H, CH2CH=CH), 2.60 (t, J = 6.9 Hz, 2H, CH2C(=O)), 2.52-2.47 (m, 2H, CH2CH=), 1.82-
1.77 (m, 2H, CH2CH2C(=O)), 1.63-1.53 (m, 4H, CH2CH2CHol and CH2(CH2)2C(=O)). 
13C NMR (125 MHz, CD2Cl2) δ 205.4 (C=O), 141.5 (CH2CH=), 132.2 (CH2CH=CH), 42.7 
(CH2C(=O)), 28.6 (CH2CH=), 25.3 (CH2(CH2)2C(=O)), 23.2 (CH2CH2CH=), 22.7 
(CH2CH2C(=O)). 
GC-MS (GC-EI) m/z 124 [M+] (8), 109 (1), 95 (11), 91 (2), 81 (100), 68 (40), 65 (4), 53 (39), 
51 (5), 41 (23), 39 (34), 27 (17). 
HRMS (EI-FE) calcd for C8H12O [M+] 124.0887, found 124.0888. 
 
4-Methyl-2-cyclohexenone (80a): The title compound was prepared according to the general 
procedure B from 4-methylcyclohexanone (1.84 mL, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 10-20% Et2O in 
pentane) gave cyclohexenone 80a (1.36 g, 12.3 mmol, 82%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.80 (ddd, J = 10.2, 2.6, 1.3 Hz, 1H, =CHCH), 5.88 (dd, J = 
10.1, 2.5 Hz, 1H, CH=CHCH), 2.58-2.50 (m, 1H, CHMe), 2.42 (dt, J = 16.7, 4.7 Hz, 1H, 
CHHC(=O)), 2.33 (ddd, J = 16.8, 12.2, 4.7 Hz, 1H, CHHC(=O)), 2.09 (dqd, J = 13.6, 5.0, 1.3 
Hz, 1H, CHHCH), 1.68-1.61 (m, 1H, CHHCH), 1.14 (d, J = 7.3 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 199.6 (C=O), 156.5 (=CHCH), 128.8 (CH=CHCH), 37.2 
(CH2C(=O)), 31.5 (CHMe), 31.3 (CH2CH), 20.3 (CH3). 
GC-MS (GC-EI) m/z 110 [M+] (51), 95 (4), 82 (100), 79 (4), 68 (67), 65 (6), 54 (56), 41 (18), 
39 (40), 27 (20). 
HRMS (EI-FE) calcd for C7H10O [M+] 110.0731, found 110.0732. 
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4-tert-Butyl-2-cyclohexenone (80b): The title compound was prepared according to the 
general procedure B from 4-tert-butylcyclohexanone (2.31 g, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 5% EtOAc in 
hexanes) gave cyclohexenone 80b (1.52 g, 9.97 mmol, 66%) as a clear oil. 
1H NMR (500 MHz, CDCl3) δ 6.99 (dt, J = 10.6, 2.1 Hz, 1H, =CHCH), 6.01 (dd, J = 10.4, 
2.8 Hz, 1H, CH=CHCH), 2.50 (dt, J = 16.9, 3.9 Hz, 1H, CHHC(=O)), 2.32 (ddd, J = 16.4, 
14.4, 4.9 Hz, 1H, CHHC(=O)), 2.20-2.16 (m, 1H, CHHCH), 2.11-2.05 (m, 1H, CHHCH), 
1.76-1.67 (m, 1H, CHt-Bu), 0.96 (s, 9H, CH3). 
13C NMR (125 MHz, CDCl3) δ 200.90 (C=O), 152.9 (=CHCH), 130.0 (CH=CHCH), 46.8 
(CHt-Bu), 37.8 (CH2C(=O)), 32.9 (CqMe3), 27.3 (3C, CH3), 24.4 (CH2CH). 
MS (EI-DE) m/z 152 [M+] (5), 137 (5), 119 (1), 109 (6), 96 (100), 91 (2), 81 (5), 67 (11), 57 
(83), 53 (6), 41 (53), 39 (23), 29 (36), 27 (19). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
 
(E)-2-Cyclododecenone (46x): The title compound was prepared according to the general 
procedure B from cyclododecanone (2.73 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the oxidation 
step. Purification by flash column chromatography (silica gel, 2% Et2O in 
pentane) gave pure (E)-enone 46x (1.40 g, 7.80 mmol, 52%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.74 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.29 
(d, J = 16.1 Hz, 1H, CH=CHCH2), 2.46-2.44 (m, 2H, CH2C(=O)), 2.28-2.24 (m, 2H, 
=CHCH2), 1.71-1.67 (m, 2H, CH2), 1.62-1.57 (m, 2H, CH2), 1.42-1.37 (m, 2H, CH2), 1.33-
1.29 (m, 4H, CH2), 1.28-1.21 (m, 4H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 203.1 (C=O), 146.7 (=CHCH2), 131.4 (CH=CHCH2), 40.2 
(CH2C(=O)), 32.8 (=CHCH2), 26.8 (CH2), 25.6 (CH2), 25.4 (CH2), 25.4 (CH2), 25.0 (CH2), 
24.8 (CH2), 24.0 (CH2). 
MS (EI) m/z (%) 180 [M+] (49), 162 (2), 151 (6), 137 (11), 123 (11), 109 (45), 98 (51), 95 
(29), 84 (39), 81 (100), 68 (65), 55 (78), 41 (76), 27 (23). 
HRMS (EI-FE) calcd for C12H20O [M+] 180.1515, found 180.1514. 
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4-tert-Butyl-2-cyclohexenone (80b): The title compound was prepared according to the 
general procedure B from 4-tert-butylcyclohexanone (2.31 g, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 5% EtOAc in 
hexanes) gave cyclohexenone 80b (1.52 g, 9.97 mmol, 66%) as a clear oil. 
1H NMR (500 MHz, CDCl3) δ 6.99 (dt, J = 10.6, 2.1 Hz, 1H, =CHCH), 6.01 (dd, J = 10.4, 
2.8 Hz, 1H, CH=CHCH), 2.50 (dt, J = 16.9, 3.9 Hz, 1H, CHHC(=O)), 2.32 (ddd, J = 16.4, 
14.4, 4.9 Hz, 1H, CHHC(=O)), 2.20-2.16 (m, 1H, CHHCH), 2.11-2.05 (m, 1H, CHHCH), 
1.76-1.67 (m, 1H, CHt-Bu), 0.96 (s, 9H, CH3). 
13C NMR (125 MHz, CDCl3) δ 200.90 (C=O), 152.9 (=CHCH), 130.0 (CH=CHCH), 46.8 
(CHt-Bu), 37.8 (CH2C(=O)), 32.9 (CqMe3), 27.3 (3C, CH3), 24.4 (CH2CH). 
MS (EI-DE) m/z 152 [M+] (5), 137 (5), 119 (1), 109 (6), 96 (100), 91 (2), 81 (5), 67 (11), 57 
(83), 53 (6), 41 (53), 39 (23), 29 (36), 27 (19). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
 
(E)-2-Cyclododecenone (46x): The title compound was prepared according to the general 
procedure B from cyclododecanone (2.73 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the oxidation 
step. Purification by flash column chromatography (silica gel, 2% Et2O in 
pentane) gave pure (E)-enone 46x (1.40 g, 7.80 mmol, 52%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.74 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.29 
(d, J = 16.1 Hz, 1H, CH=CHCH2), 2.46-2.44 (m, 2H, CH2C(=O)), 2.28-2.24 (m, 2H, 
=CHCH2), 1.71-1.67 (m, 2H, CH2), 1.62-1.57 (m, 2H, CH2), 1.42-1.37 (m, 2H, CH2), 1.33-
1.29 (m, 4H, CH2), 1.28-1.21 (m, 4H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 203.1 (C=O), 146.7 (=CHCH2), 131.4 (CH=CHCH2), 40.2 
(CH2C(=O)), 32.8 (=CHCH2), 26.8 (CH2), 25.6 (CH2), 25.4 (CH2), 25.4 (CH2), 25.0 (CH2), 
24.8 (CH2), 24.0 (CH2). 
MS (EI) m/z (%) 180 [M+] (49), 162 (2), 151 (6), 137 (11), 123 (11), 109 (45), 98 (51), 95 
(29), 84 (39), 81 (100), 68 (65), 55 (78), 41 (76), 27 (23). 
HRMS (EI-FE) calcd for C12H20O [M+] 180.1515, found 180.1514. 
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4-tert-Butyl-2-cyclohexenone (80b): The title compound was prepared according to the 
general procedure B from 4-tert-butylcyclohexanone (2.31 g, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 5% EtOAc in 
hexanes) gave cyclohexenone 80b (1.52 g, 9.97 mmol, 66%) as a clear oil. 
1H NMR (500 MHz, CDCl3) δ 6.99 (dt, J = 10.6, 2.1 Hz, 1H, =CHCH), 6.01 (dd, J = 10.4, 
2.8 Hz, 1H, CH=CHCH), 2.50 (dt, J = 16.9, 3.9 Hz, 1H, CHHC(=O)), 2.32 (ddd, J = 16.4, 
14.4, 4.9 Hz, 1H, CHHC(=O)), 2.20-2.16 (m, 1H, CHHCH), 2.11-2.05 (m, 1H, CHHCH), 
1.76-1.67 (m, 1H, CHt-Bu), 0.96 (s, 9H, CH3). 
13C NMR (125 MHz, CDCl3) δ 200.90 (C=O), 152.9 (=CHCH), 130.0 (CH=CHCH), 46.8 
(CHt-Bu), 37.8 (CH2C(=O)), 32.9 (CqMe3), 27.3 (3C, CH3), 24.4 (CH2CH). 
MS (EI-DE) m/z 152 [M+] (5), 137 (5), 119 (1), 109 (6), 96 (100), 91 (2), 81 (5), 67 (11), 57 
(83), 53 (6), 41 (53), 39 (23), 29 (36), 27 (19). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
 
(E)-2-Cyclododecenone (46x): The title compound was prepared according to the general 
procedure B from cyclododecanone (2.73 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the oxidation 
step. Purification by flash column chromatography (silica gel, 2% Et2O in 
pentane) gave pure (E)-enone 46x (1.40 g, 7.80 mmol, 52%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.74 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.29 
(d, J = 16.1 Hz, 1H, CH=CHCH2), 2.46-2.44 (m, 2H, CH2C(=O)), 2.28-2.24 (m, 2H, 
=CHCH2), 1.71-1.67 (m, 2H, CH2), 1.62-1.57 (m, 2H, CH2), 1.42-1.37 (m, 2H, CH2), 1.33-
1.29 (m, 4H, CH2), 1.28-1.21 (m, 4H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 203.1 (C=O), 146.7 (=CHCH2), 131.4 (CH=CHCH2), 40.2 
(CH2C(=O)), 32.8 (=CHCH2), 26.8 (CH2), 25.6 (CH2), 25.4 (CH2), 25.4 (CH2), 25.0 (CH2), 
24.8 (CH2), 24.0 (CH2). 
MS (EI) m/z (%) 180 [M+] (49), 162 (2), 151 (6), 137 (11), 123 (11), 109 (45), 98 (51), 95 
(29), 84 (39), 81 (100), 68 (65), 55 (78), 41 (76), 27 (23). 
HRMS (EI-FE) calcd for C12H20O [M+] 180.1515, found 180.1514. 
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4-tert-Butyl-2-cyclohexenone (80b): The title compound was prepared according to the 
general procedure B from 4-tert-butylcyclohexanone (2.31 g, 15.0 mmol). 
Purification by flash column chromatography (silica gel, 5% EtOAc in 
hexanes) gave cyclohexenone 80b (1.52 g, 9.97 mmol, 66%) as a clear oil. 
1H NMR (500 MHz, CDCl3) δ 6.99 (dt, J = 10.6, 2.1 Hz, 1H, =CHCH), 6.01 (dd, J = 10.4, 
2.8 Hz, 1H, CH=CHCH), 2.50 (dt, J = 16.9, 3.9 Hz, 1H, CHHC(=O)), 2.32 (ddd, J = 16.4, 
14.4, 4.9 Hz, 1H, CHHC(=O)), 2.20-2.16 (m, 1H, CHHCH), 2.11-2.05 (m, 1H, CHHCH), 
1.76-1.67 (m, 1H, CHt-Bu), 0.96 (s, 9H, CH3). 
13C NMR (125 MHz, CDCl3) δ 200.90 (C=O), 152.9 (=CHCH), 130.0 (CH=CHCH), 46.8 
(CHt-Bu), 37.8 (CH2C(=O)), 32.9 (CqMe3), 27.3 (3C, CH3), 24.4 (CH2CH). 
MS (EI-DE) m/z 152 [M+] (5), 137 (5), 119 (1), 109 (6), 96 (100), 91 (2), 81 (5), 67 (11), 57 
(83), 53 (6), 41 (53), 39 (23), 29 (36), 27 (19). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
 
(E)-2-Cyclododecenone (46x): The title compound was prepared according to the general 
procedure B from cyclododecanone (2.73 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the oxidation 
step. Purification by flash column chromatography (silica gel, 2% Et2O in 
pentane) gave pure (E)-enone 46x (1.40 g, 7.80 mmol, 52%) as a clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.74 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.29 
(d, J = 16.1 Hz, 1H, CH=CHCH2), 2.46-2.44 (m, 2H, CH2C(=O)), 2.28-2.24 (m, 2H, 
=CHCH2), 1.71-1.67 (m, 2H, CH2), 1.62-1.57 (m, 2H, CH2), 1.42-1.37 (m, 2H, CH2), 1.33-
1.29 (m, 4H, CH2), 1.28-1.21 (m, 4H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 203.1 (C=O), 146.7 (=CHCH2), 131.4 (CH=CHCH2), 40.2 
(CH2C(=O)), 32.8 (=CHCH2), 26.8 (CH2), 25.6 (CH2), 25.4 (CH2), 25.4 (CH2), 25.0 (CH2), 
24.8 (CH2), 24.0 (CH2). 
MS (EI) m/z (%) 180 [M+] (49), 162 (2), 151 (6), 137 (11), 123 (11), 109 (45), 98 (51), 95 
(29), 84 (39), 81 (100), 68 (65), 55 (78), 41 (76), 27 (23). 
HRMS (EI-FE) calcd for C12H20O [M+] 180.1515, found 180.1514. 
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(E)-2-Cyclopentadecenone (46w): The title compound was prepared according to the general 
procedure B from cyclopentadecanone (3.37 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the 
oxidation step. Purification by flash column chromatography (silica gel, 2% 
Et2O in pentane) gave pure (E)-enone 46w (2.16 g, 9.71 mmol, 65%) as a 
clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.78 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.16 (d, J = 16.1 Hz, 
1H, CH=CHCH2), 2.47-2.45 (m, 2H, CH2C(=O)), 2.29-2.25 (m, 2H, =CHCH2), 1.68-1.62 (m, 
2H, CH2), 1.56-1.51 (m, 2H, CH2), 1.35-1.22 (m, 16H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 201.5 (C=O), 148.0 (=CHCH2), 130.8 (CH=CHCH2), 40.1 
(CH2C(=O)), 31.7 (=CHCH2), 27.1 (CH2), 27.0 (CH2), 26.8 (3C, -(CH2)n-), 26.6 (CH2), 26.3 
(CH2), 26.1 (CH2), 25.5 (CH2), 25.3 (CH2). 
MS (EI) m/z (%) 222 [M+] (92), 207 (2), 193 (2), 179 (4), 164 (20), 151 (7), 135 (12), 121 
(14), 109 (53), 96 (63), 81 (52), 68 (57), 55 (100), 41 (78), 29 (24). 
HRMS (EI-DE) calcd for C15H26O [M+] 222.1982, found 222.1984. 
 
7.5.1.3 Synthesis of 3-tert-butylcyclohex-2-enone (46j)[166] 
A flask was charged with 10% Pd/C (96 mg, 0.09 mmol, 2.5 mol%), CH2Cl2 
(70 mL), TBHP (3.29 mL, 18.1 mmol, 5.5 M in decane, 5 equiv), K2CO3 (124 
mg, 0.91 mmol, 25 mol%), and 1-tert-butylcyclohexene (500 mg, 3.62 mmol, 
54 uL, 0.32 mmol, 1 equiv) under argon. The mixture was stirred at 0 °C for 
12 h. After removal of the solvent at 0 °C under reduced, the crude product was purified by 
flash column chromatography (silica gel, 30-60% Et2O in pentane) to provide the title 
compound (320 mg, 2.10 mmol, 58%) as a clear liquid. 
1H NMR (500 MHz, CD2Cl2) δ 5.88 (t, J = 1.3 Hz, 1H, =CH), 2.34 (td, J = 6.0, 1.3 Hz, 2H, 
CH2Cqol), 2.30 (app. t, J = 6.6 Hz, 2H, CH2C(=O)), 1.94 (quint, J = 6.3 Hz, 2H, 
CH2CH2CH2), 1.12 (s, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 200.4 (C=O), 173.9 (Cq=CH), 123.1 (Cq=CH), 37.8 
(CH2C(=O)), 36.9 (CqMe3), 28.4 (3C, C(CH3)3), 26.3 (CH2), 23.7 (CH2). 
GC-MS (GC-EI) m/z (%) 152 [M+] (31), 137 (11), 124 (35), 109 (100), 96 (67), 81 (39), 79 
(13), 67 (32), 65 (7), 57 (20), 41 (32), 29 (7). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
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(E)-2-Cyclopentadecenone (46w): The title compound was prepared according to the general 
procedure B from cyclopentadecanone (3.37 g, 15.0 mmol). Stoichiometric 
Pd(OAc)2 (3.37 g, 15.0 mmol) in acetonitrile (20 mL) was used in the 
oxidation step. Purification by flash column chromatography (silica gel, 2% 
Et2O in pentane) gave pure (E)-enone 46w (2.16 g, 9.71 mmol, 65%) as a 
clear oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.78 (td, J = 15.3, 7.7 Hz, 1H, =CHCH2), 6.16 (d, J = 16.1 Hz, 
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2H, CH2), 1.56-1.51 (m, 2H, CH2), 1.35-1.22 (m, 16H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 201.5 (C=O), 148.0 (=CHCH2), 130.8 (CH=CHCH2), 40.1 
(CH2C(=O)), 31.7 (=CHCH2), 27.1 (CH2), 27.0 (CH2), 26.8 (3C, -(CH2)n-), 26.6 (CH2), 26.3 
(CH2), 26.1 (CH2), 25.5 (CH2), 25.3 (CH2). 
MS (EI) m/z (%) 222 [M+] (92), 207 (2), 193 (2), 179 (4), 164 (20), 151 (7), 135 (12), 121 
(14), 109 (53), 96 (63), 81 (52), 68 (57), 55 (100), 41 (78), 29 (24). 
HRMS (EI-DE) calcd for C15H26O [M+] 222.1982, found 222.1984. 
 
7.5.1.3 Synthesis of 3-tert-butylcyclohex-2-enone (46j)[166] 
A flask was charged with 10% Pd/C (96 mg, 0.09 mmol, 2.5 mol%), CH2Cl2 
(70 mL), TBHP (3.29 mL, 18.1 mmol, 5.5 M in decane, 5 equiv), K2CO3 (124 
mg, 0.91 mmol, 25 mol%), and 1-tert-butylcyclohexene (500 mg, 3.62 mmol, 
54 uL, 0.32 mmol, 1 equiv) under argon. The mixture was stirred at 0 °C for 
12 h. After removal of the solvent at 0 °C under reduced, the crude product was purified by 
flash column chromatography (silica gel, 30-60% Et2O in pentane) to provide the title 
compound (320 mg, 2.10 mmol, 58%) as a clear liquid. 
1H NMR (500 MHz, CD2Cl2) δ 5.88 (t, J = 1.3 Hz, 1H, =CH), 2.34 (td, J = 6.0, 1.3 Hz, 2H, 
CH2Cqol), 2.30 (app. t, J = 6.6 Hz, 2H, CH2C(=O)), 1.94 (quint, J = 6.3 Hz, 2H, 
CH2CH2CH2), 1.12 (s, 9H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 200.4 (C=O), 173.9 (Cq=CH), 123.1 (Cq=CH), 37.8 
(CH2C(=O)), 36.9 (CqMe3), 28.4 (3C, C(CH3)3), 26.3 (CH2), 23.7 (CH2). 
GC-MS (GC-EI) m/z (%) 152 [M+] (31), 137 (11), 124 (35), 109 (100), 96 (67), 81 (39), 79 
(13), 67 (32), 65 (7), 57 (20), 41 (32), 29 (7). 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1202, found 152.1201. 
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7.5.1.4 Synthesis of 2-Methyl-2-cyclohexenone (79) 
The iron-catalyzed cross coupling reaction of 2-iodo-2-cyclohexenone (137) was conducted 
according to the protocol of Cahiez et al.[168] 
 
 
 
2-Iodo-2-cyclohexenone (137): 2-Cyclohexenone (0.97 mL, 10.0 mmol) was dissolved in 
CH2Cl2 (20 mL) under an atmosphere of argon, and cooled to 0 °C. Pyridine 
was added (20 mL) followed by iodine (6.35 g, 25.0 mmol, 2.5 equiv). The 
reaction mixture was allowed to warm to room temperature, and stirred for 14 
h. EtOAc (100 mL) was added, and the organic layer was washed successively with saturated 
aqueous Na2S2O3 solution (2×30 mL), water (30 mL), aqueous 10% CuSO4 solution (6×30 
mL), water (30 mL), and brine (30 mL). The organic layer was dried over Na2SO4, filtered, 
and concentrated. Purification by flash column chromatography (silica gel, 15-20% Et2O in 
pentane) provided the title compound (2.01 g, 9.06 mmol; 91%) as a yellow solid. 
1H NMR (500 MHz, CD2Cl2) δ 7.77 (t, J = 4.5 Hz, 1H, CHol), 2.62 (t, J = 6.7 Hz, 2H, 
CH2C(=O)), 2.42 (t, J = 5.5 Hz, 2H, CH2CHol), 2.08-2.03 (m, 2H, CH2CH2CH2). 
13C NMR (125 MHz, CD2Cl2) 192.1 (C=O), 159.9 (CHol), 103.6 (Cqol), 37.3 (CH2C(=O)), 
30.0 (CH2Cqol), 22.9 (CH2CH2CH2). 
MS (EI-DE) m/z (%) 222 [M+] (100), 194 (52), 181 (5), 166 (10), 153 (1), 127 (2), 95 (8), 67 
(9), 55 (9), 39 (29). 
HRMS (EI-DE) calcd for C6H7OI [M+] 221.9540, found 221.9542. 
 
2-Methyl-2-cyclohexenone (79): To a solution of 2-iodo-2-cyclohexenone (137) (0.5 g, 2.25 
mmol) and Fe(acac)3 (8.0 mg, 0.0225 mmol, 1 mol%) in a solvent mixture of 
THF (4.5 mL) and NMP (2.25 mL, 9 equiv) was added dropwise (within 15 
min) at 0 °C, methylmagnesium bromide (0.85 mL, 2.55 mmol, 3.0 M in THF, 
1.1 equiv), and stirring was continued for 2 h. Then the reaction mixture was hydrolyzed with 
aqueous 1M HCl (7 mL), and the aqueous layer repeatedly extracted with Et2O (3×20 mL). 
The combined organic phases were washed successively with saturated aqueous NaHCO3 
solution, water, and brine. The organic layer was dried over Na2SO4, filtered, and 
concentrated. After purification of the crude product by flash column chromatography (silica 
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gel, 5-10% Et2O in pentane) the title compound (84 mg, 760 μmol; 34% (reduced yield due to 
the high volatility of 79)) was obtained as a colorless oil. 
1H NMR (400 MHz, CD2Cl2) δ 6.75-6.73 (m, 1H, CHol), 2.39-2.36 (m, 2H, CH2C(=O)), 
2.33-2.28 (m, 2H, CH2CHol), 1.99-1.93 (m, 2H, CH2CH2CH2), 1.73-1.72 (m, 3H, CH3). 
13C NMR (100 MHz, CD2Cl2) 199.5 (C=O), 145.5 (CHol), 135.5 (Cqol), 38.4 (CH2C(=O)), 
26.1 (CH2CHol), 23.4 (CH2CH2 CH2), 15.8 (CH3). 
GC-MS (GC-EI) m/z 110 [M+]. 
HRMS (EI-FE) calcd for C7H10O [M+] 110.0731, found 110.0732. 
 
7.5.1.5 Synthesis of (S)-3-Methyl-5-phenyl-2-cyclohexenone (S)-(83)[123] 
Acetic acid (36.0 mg, 0.6 mmol, 60 mol%) was added to a solution of 9-
amino(9-deoxy)epiquinine (13; 64.7 mg, 0.2 mmol, 20 mol%) in toluene. After 
cooling to –15°C, 4-phenyl-2,6-heptandione (204 mg, 1.0 mmol) was added. 
The resulting mixture was stirred at –15°C for 48 h. The reaction mixture was 
then directly subjected to flash column chromatography (silica gel, 20% Et2O in pentane) to 
afford cyclohexenone derivative 83 (159 mg, 842 μmol, 84%; 95.5:4.5 er) as a colorless solid. 
The enantiomeric ratio was determined by HPLC using a chiral Chiralcel OJ-H column (10% 
i-PrOH in heptane, 0.5 mL/min); major enantiomer: τR = 21.71 min, minor enantiomer: τR = 
3.86 min. 
1H NMR (500 MHz, CDCl3) δ 7.36-7.33 (m, 2H, CHPh), 7.27-7.23 (m, 3H, CHPh), 5.92 (s, 
1H, =CH), (hept, J = 5.5 Hz, 1H, CHal), 2.60-2.47 (m, 4H, CH2), 2.00 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.8 (C=O), 162.0 (Cq=), 144.1 (CqPh), 129.0 (2C, CHPh), 
127.2 (2C, CHPh), 127.1 (CH), 126.6 (CH), 44.3 (CH2C(=O)), 41.2 (CHal), 39.2 (CH2Cqol), 
24.4 (CH3). 
MS (EI-DE) m/z (%) 186 [M+] (41), 171 (2), 158 (1), 142 (6), 128 (4), 115 (4), 104 (14), 91 
(4), 82 (100), 77 (7), 65 (3), 54 (10), 39 (10), 27 (2). 
HRMS (EI-DE) calcd for C13H14O [M+] 186.1043, found 186.1044. 
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7.5.2 Preparation of Acyclic α,β-Unsaturated Ketones 
7.5.2.1 General Procedure A: Cross Metathesis (CM) 
 
 
 
Methyl vinyl ketone (MVK; 12.5 mmol, 2.5 equiv) and Grubbs’ second generation catalyst 
(138; 106 mg, 0.125 mmol, 2.5 mol%) were successively added to the solution of a terminal 
alkene (5 mmol, 1 equiv) in CH2Cl2 (50 mL). The reaction mixture was heated to reflux 
overnight (12-16 h) and then allowed to cool to room temperature. The volatiles were 
removed under reduced pressure and the crude product was purified by flash column 
chromatography (silica gel, eluent: Et2O-pentane or Et2O-CH2Cl2) to obtain the corresponding 
pure (E)-enone 92. 
 
Scope of α,β-Unsaturated Ketones Prepared According to General Procedure A 
 
(E)-7-Bromo-3-hepten-2-one (92g): The title compound was prepared according to the 
general procedure A from MVK and 5-bromo-1-pentene. The crude 
product was purified by flash column chromatography (silica gel, 5-
15% Et2O in pentane) to give enone 92g (748 mg, 3.94 mmol, 78%) as 
a pale yellow oil. Contains 4% of (E)-7-chloro-3-hepten-2-one as determined by GC. 
1H NMR (500 MHz, CD2Cl2) δ 6.74 (dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.09 (dt, J = 16.1, 
1.4 Hz, 1H, CH=CHCH2), 3.44 (t, J = 6.6 Hz, 2H, BrCH2), 2.41-2.36 (m, 2H, =CHCH2), 2.21 
(s, 3H, CH3), 2.06-2.00 (m, 2H, CH2CH2CH2). 
13C NMR (125 MHz, CD2Cl2): δ 198.0 (C=O), 145.7 (=CHCH2), 132.1 (CH=CHCH2), 32.9 
(BrCH2), 31.0 (CH2CH2CH2), 30.8 (=CHCH2), 26.8 (CH3). 
GC-MS (GC-EI) m/z 190 [M+]. 
HRMS (EI-FE) calcd for C7H11BrO [M+] 189.9992, found 189.9993. 
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(E)-Ethyl 6-oxohept-4-enoate (92j): The title compound was prepared according to the 
general procedure A from MVK and ethyl 4-pentenoate. The crude 
product was purified by flash column chromatography (silica gel, 40-
55% Et2O in pentane) to give enone 92j (679 mg, 3.99 mmol, 80%) as 
a pale yellow oil. 
1H NMR (300 MHz, CD2Cl2) δ 6.77 (dt, J = 15.9, 6.3 Hz, 1H, =CHCH2), 6.08 (dt, J = 15.9, 
1.5 Hz, 1H, CH=CHCH2), 4.11 (q, J = 7.2 Hz, 2H, CH2CH3), 2.57-2.43 (m, 4H, CH2), 2.20 (s, 
3H, CH3C(=O)), 1.23 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (100 MHz, CD2Cl2) δ 198.0 (C=O), 172.2 (CO2Et), 145.7 (=CHCH2), 131.7 
(CH=CHCH2), 60.5 (CH2CH3), 32.5 (CH2CO2Et), 27.5 (=CHCH2), 26.7 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI-DE) m/z 170 [M+] (26), 155 (3), 141 (5), 124 (76), 109 (18), 97 (41), 83 (40), 68 (3), 
55 (20), 43 (100), 29 (27). 
HRMS (EI-FE) calcd for C9H14O3 [M+] 170.0941, found 170.0943. 
 
(E)-3-Octene-2,7-dione (92k): The title compound was prepared according to the general 
procedure A from MVK and 5-hexen-2-one. The crude product was 
purified by flash column chromatography (silica gel, 30-55% Et2O in 
pentane) to give enone 92k (698 mg, 4.98 mmol, 99%) as a pale yellow 
oil. 
1H NMR (300 MHz, CD2Cl2) δ 6.76 (dt, J = 15.9, 6.7 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.1, 
1.6 Hz, 1H, CH=CHCH2), 2.63-2.58 (m, 2H, CH2), 2.49-2.41 (m, 2H, CH2), 2.19 (s, 3H, 
CHolC(=O)CH3), 2.13 (s, 3H, CH3C(=O)CH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.6 (CH2C(=O)), 198.1 (CHolC(=O)), 146.3 (=CHCH2), 
131.6 (CH=CHCH2), 41.5 (CH2C(=O)), 29.7 (CH3C(=O)CH2), 26.7 (CHolC(=O)CH3), 26.2 
(=CHCH2). 
MS (EI-DE) m/z (%) 140 [M+] (15), 122 (2), 97 (82), 83 (7), 79 (6), 69 (3), 55 (5), 43 (100), 
41 (6), 27 (4). 
HRMS (EI-FE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
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(CH=CHCH2), 60.5 (CH2CH3), 32.5 (CH2CO2Et), 27.5 (=CHCH2), 26.7 (CH3C(=O)), 14.0 
(CH2CH3). 
MS (EI-DE) m/z 170 [M+] (26), 155 (3), 141 (5), 124 (76), 109 (18), 97 (41), 83 (40), 68 (3), 
55 (20), 43 (100), 29 (27). 
HRMS (EI-FE) calcd for C9H14O3 [M+] 170.0941, found 170.0943. 
 
(E)-3-Octene-2,7-dione (92k): The title compound was prepared according to the general 
procedure A from MVK and 5-hexen-2-one. The crude product was 
purified by flash column chromatography (silica gel, 30-55% Et2O in 
pentane) to give enone 92k (698 mg, 4.98 mmol, 99%) as a pale yellow 
oil. 
1H NMR (300 MHz, CD2Cl2) δ 6.76 (dt, J = 15.9, 6.7 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.1, 
1.6 Hz, 1H, CH=CHCH2), 2.63-2.58 (m, 2H, CH2), 2.49-2.41 (m, 2H, CH2), 2.19 (s, 3H, 
CHolC(=O)CH3), 2.13 (s, 3H, CH3C(=O)CH2). 
13C NMR (100 MHz, CD2Cl2) δ 206.6 (CH2C(=O)), 198.1 (CHolC(=O)), 146.3 (=CHCH2), 
131.6 (CH=CHCH2), 41.5 (CH2C(=O)), 29.7 (CH3C(=O)CH2), 26.7 (CHolC(=O)CH3), 26.2 
(=CHCH2). 
MS (EI-DE) m/z (%) 140 [M+] (15), 122 (2), 97 (82), 83 (7), 79 (6), 69 (3), 55 (5), 43 (100), 
41 (6), 27 (4). 
HRMS (EI-FE) calcd for C8H12O2 [M+] 140.0836, found 140.0837. 
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(E)-9-hydroxy-3-nonen-2-one (92l): The title compound was prepared according to the 
general procedure A from MVK and 7-hydroxy-1-heptene. Flash 
column chromatography (silica gel, 10-30% Et2O in CH2Cl2) 
afforded enone 92l (503 mg, 3.22 mmol, 64%) as a greenish oil 
(contains ruthenium trace impurities). 
1H NMR (400 MHz, CD2Cl2) δ 6.79 (dt, J = 15.9, 7.0 Hz, 1H, CH2CH=), 6.03 (dt, J = 16.2, 
1.4 Hz, 1H, CH2CH=CH), 3.59 (t, J = 6.6 Hz, 2H, CH2OH), 2.21 (app. qd overlapped, J = 
7.1, 1.4 Hz, 2H, CH2), 2.20 (s, 3H, CH3), 1.75 (br s, 1H, OH), 1.56-1.46 (m, 4H, CH2), 1.41-
1.34 (m, 2H, CH2). 
13C NMR (100 MHz, CD2Cl2) δ 198.8 (C=O), 148.6 (CH2CH=), 131.6 (CH2CH=CH), 62.9 
(CH2OH), 32.9(CH2), 32.7 (CH2), 28.3 (CH2), 26.9 (CH3), 25.7 (CH2). 
MS (EI-DE) m/z (%) 156 [M+] (1), 138 (11), 123 (9), 113 (7), 95 (55), 84 (8), 81 (32), 71 (42), 
67 (32), 58 (9), 55 (49), 53 (15), 43 (100), 41 (27), 31 (19). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1230, found 157.1229. 
 
7.5.2.2 General Procedure B: Wittig Reaction 
 
 
 
An aldehyde (20 mmol, 1 equiv) was dissolved in CH2Cl2 (30 mL) and 1-(triphenylphosphor-
anylidene)-2-propanone (6.37 g, 20 mmol, 1 equiv) was added at 0 °C. The reaction mixture 
was allowed to warm to room temperature and stirred until TLC or GC/MS analysis indicated 
complete consumption of the starting aldehyde (12-24 h). Then silica gel was added and the 
solvent was removed under reduced pressure. The residue was purified by flash column chro-
matography (silica gel, eluent: Et2O-pentane) to afford the corresponding (E)-α,β-enone 92. 
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was allowed to warm to room temperature and stirred until TLC or GC/MS analysis indicated 
complete consumption of the starting aldehyde (12-24 h). Then silica gel was added and the 
solvent was removed under reduced pressure. The residue was purified by flash column chro-
matography (silica gel, eluent: Et2O-pentane) to afford the corresponding (E)-α,β-enone 92. 
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(E)-9-hydroxy-3-nonen-2-one (92l): The title compound was prepared according to the 
general procedure A from MVK and 7-hydroxy-1-heptene. Flash 
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HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1230, found 157.1229. 
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was allowed to warm to room temperature and stirred until TLC or GC/MS analysis indicated 
complete consumption of the starting aldehyde (12-24 h). Then silica gel was added and the 
solvent was removed under reduced pressure. The residue was purified by flash column chro-
matography (silica gel, eluent: Et2O-pentane) to afford the corresponding (E)-α,β-enone 92. 
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(E)-9-hydroxy-3-nonen-2-one (92l): The title compound was prepared according to the 
general procedure A from MVK and 7-hydroxy-1-heptene. Flash 
column chromatography (silica gel, 10-30% Et2O in CH2Cl2) 
afforded enone 92l (503 mg, 3.22 mmol, 64%) as a greenish oil 
(contains ruthenium trace impurities). 
1H NMR (400 MHz, CD2Cl2) δ 6.79 (dt, J = 15.9, 7.0 Hz, 1H, CH2CH=), 6.03 (dt, J = 16.2, 
1.4 Hz, 1H, CH2CH=CH), 3.59 (t, J = 6.6 Hz, 2H, CH2OH), 2.21 (app. qd overlapped, J = 
7.1, 1.4 Hz, 2H, CH2), 2.20 (s, 3H, CH3), 1.75 (br s, 1H, OH), 1.56-1.46 (m, 4H, CH2), 1.41-
1.34 (m, 2H, CH2). 
13C NMR (100 MHz, CD2Cl2) δ 198.8 (C=O), 148.6 (CH2CH=), 131.6 (CH2CH=CH), 62.9 
(CH2OH), 32.9(CH2), 32.7 (CH2), 28.3 (CH2), 26.9 (CH3), 25.7 (CH2). 
MS (EI-DE) m/z (%) 156 [M+] (1), 138 (11), 123 (9), 113 (7), 95 (55), 84 (8), 81 (32), 71 (42), 
67 (32), 58 (9), 55 (49), 53 (15), 43 (100), 41 (27), 31 (19). 
HRMS (CI-FE, i-butane) calcd for C9H17O2 [(M+H)+] 157.1230, found 157.1229. 
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An aldehyde (20 mmol, 1 equiv) was dissolved in CH2Cl2 (30 mL) and 1-(triphenylphosphor-
anylidene)-2-propanone (6.37 g, 20 mmol, 1 equiv) was added at 0 °C. The reaction mixture 
was allowed to warm to room temperature and stirred until TLC or GC/MS analysis indicated 
complete consumption of the starting aldehyde (12-24 h). Then silica gel was added and the 
solvent was removed under reduced pressure. The residue was purified by flash column chro-
matography (silica gel, eluent: Et2O-pentane) to afford the corresponding (E)-α,β-enone 92. 
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Scope of α,β-Unsaturated Ketones Prepared According to General Procedure B 
 
(E)-6-Phenyl-3-hexen-2-one (92b): The title compound was prepared according to the 
general procedure B from hydrocinnamaldehyde and 1-(triphenylphos-
phoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give 
enone 92b (2.62 g, 15.0 mmol, 75%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.30-7.27 (m, 2H, CHPh, m), 7.21-7.16 (m, 3H, CHPh, o, p), 6.80 
(dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 1.4 Hz, 1H, CH=CHCH2), 2.78 (t, J = 
7.7 Hz, 2H, PhCH2), 2.54 (app. qd, J = 7.3, 1.4 Hz, 2H, =CHCH2), 2.21 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.1 (=CHCH2), 140.7 (CqPh), 131.7 
(CH=CHCH2), 128.5 (2C, CHPh), 128.3 (2C, CHPh), 126.2 (CHPh, p), 34.4 (CH2), 34.1 (CH2), 
26.9 (CH3). 
MS (EI-DE) m/z (%) 174 [M+] (5), 159 (4), 131 (5), 116 (16), 104 (2), 91 (100), 77 (2), 65 
(10), 51 (3), 43 (9), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
 
(E)-6-Methylhept-3-en-2-one (92d): The title compound was prepared according to the 
general procedure B from isovaleraldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92d (1.51 g, 
12.0 mmol, 60% (reduced yield due to the high volatility of 92d)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.74 (dt, J = 16.0, 7.4 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.0, 
1.4 Hz, 1H, CH=CHCH2), 2.21 (s, 3H, CH3C(=O)), 2.08 (app. td, J = 7.1, 1.3 Hz, 2H, CH2), 
1.74 (hept, J = 6.7 Hz, 1H, CHMe2), 0.90 (d, J = 6.7 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.3 (=CHCH2), 132.3 (CH=CHCH2), 41.7 
(CH2), 27.8 (CHMe2), 26.8 (CH3C(=O)), 22.3 (2C, CH(CH3)2). 
GC-MS (GC-EI) m/z 126 [M+]. 
HRMS (EI-FE) calcd for C8H14O [M+] 126.1043, found 126.1045. 
 
(E)-4-Cyclohexylbut-3-en-2-one (92e): The title compound was prepared according to the 
general procedure B from cyclohexanecarbaldehyde with 1-(triphenyl-
phosphoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give enone 92e 
(2.80 g, 18.4 mmol, 92%) as a pale yellow oil. 
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(E)-6-Phenyl-3-hexen-2-one (92b): The title compound was prepared according to the 
general procedure B from hydrocinnamaldehyde and 1-(triphenylphos-
phoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give 
enone 92b (2.62 g, 15.0 mmol, 75%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.30-7.27 (m, 2H, CHPh, m), 7.21-7.16 (m, 3H, CHPh, o, p), 6.80 
(dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 1.4 Hz, 1H, CH=CHCH2), 2.78 (t, J = 
7.7 Hz, 2H, PhCH2), 2.54 (app. qd, J = 7.3, 1.4 Hz, 2H, =CHCH2), 2.21 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.1 (=CHCH2), 140.7 (CqPh), 131.7 
(CH=CHCH2), 128.5 (2C, CHPh), 128.3 (2C, CHPh), 126.2 (CHPh, p), 34.4 (CH2), 34.1 (CH2), 
26.9 (CH3). 
MS (EI-DE) m/z (%) 174 [M+] (5), 159 (4), 131 (5), 116 (16), 104 (2), 91 (100), 77 (2), 65 
(10), 51 (3), 43 (9), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
 
(E)-6-Methylhept-3-en-2-one (92d): The title compound was prepared according to the 
general procedure B from isovaleraldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92d (1.51 g, 
12.0 mmol, 60% (reduced yield due to the high volatility of 92d)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.74 (dt, J = 16.0, 7.4 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.0, 
1.4 Hz, 1H, CH=CHCH2), 2.21 (s, 3H, CH3C(=O)), 2.08 (app. td, J = 7.1, 1.3 Hz, 2H, CH2), 
1.74 (hept, J = 6.7 Hz, 1H, CHMe2), 0.90 (d, J = 6.7 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.3 (=CHCH2), 132.3 (CH=CHCH2), 41.7 
(CH2), 27.8 (CHMe2), 26.8 (CH3C(=O)), 22.3 (2C, CH(CH3)2). 
GC-MS (GC-EI) m/z 126 [M+]. 
HRMS (EI-FE) calcd for C8H14O [M+] 126.1043, found 126.1045. 
 
(E)-4-Cyclohexylbut-3-en-2-one (92e): The title compound was prepared according to the 
general procedure B from cyclohexanecarbaldehyde with 1-(triphenyl-
phosphoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give enone 92e 
(2.80 g, 18.4 mmol, 92%) as a pale yellow oil. 
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(E)-6-Phenyl-3-hexen-2-one (92b): The title compound was prepared according to the 
general procedure B from hydrocinnamaldehyde and 1-(triphenylphos-
phoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give 
enone 92b (2.62 g, 15.0 mmol, 75%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.30-7.27 (m, 2H, CHPh, m), 7.21-7.16 (m, 3H, CHPh, o, p), 6.80 
(dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 1.4 Hz, 1H, CH=CHCH2), 2.78 (t, J = 
7.7 Hz, 2H, PhCH2), 2.54 (app. qd, J = 7.3, 1.4 Hz, 2H, =CHCH2), 2.21 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.1 (=CHCH2), 140.7 (CqPh), 131.7 
(CH=CHCH2), 128.5 (2C, CHPh), 128.3 (2C, CHPh), 126.2 (CHPh, p), 34.4 (CH2), 34.1 (CH2), 
26.9 (CH3). 
MS (EI-DE) m/z (%) 174 [M+] (5), 159 (4), 131 (5), 116 (16), 104 (2), 91 (100), 77 (2), 65 
(10), 51 (3), 43 (9), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
 
(E)-6-Methylhept-3-en-2-one (92d): The title compound was prepared according to the 
general procedure B from isovaleraldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92d (1.51 g, 
12.0 mmol, 60% (reduced yield due to the high volatility of 92d)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.74 (dt, J = 16.0, 7.4 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.0, 
1.4 Hz, 1H, CH=CHCH2), 2.21 (s, 3H, CH3C(=O)), 2.08 (app. td, J = 7.1, 1.3 Hz, 2H, CH2), 
1.74 (hept, J = 6.7 Hz, 1H, CHMe2), 0.90 (d, J = 6.7 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.3 (=CHCH2), 132.3 (CH=CHCH2), 41.7 
(CH2), 27.8 (CHMe2), 26.8 (CH3C(=O)), 22.3 (2C, CH(CH3)2). 
GC-MS (GC-EI) m/z 126 [M+]. 
HRMS (EI-FE) calcd for C8H14O [M+] 126.1043, found 126.1045. 
 
(E)-4-Cyclohexylbut-3-en-2-one (92e): The title compound was prepared according to the 
general procedure B from cyclohexanecarbaldehyde with 1-(triphenyl-
phosphoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give enone 92e 
(2.80 g, 18.4 mmol, 92%) as a pale yellow oil. 
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(E)-6-Phenyl-3-hexen-2-one (92b): The title compound was prepared according to the 
general procedure B from hydrocinnamaldehyde and 1-(triphenylphos-
phoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give 
enone 92b (2.62 g, 15.0 mmol, 75%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.30-7.27 (m, 2H, CHPh, m), 7.21-7.16 (m, 3H, CHPh, o, p), 6.80 
(dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 1.4 Hz, 1H, CH=CHCH2), 2.78 (t, J = 
7.7 Hz, 2H, PhCH2), 2.54 (app. qd, J = 7.3, 1.4 Hz, 2H, =CHCH2), 2.21 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.1 (=CHCH2), 140.7 (CqPh), 131.7 
(CH=CHCH2), 128.5 (2C, CHPh), 128.3 (2C, CHPh), 126.2 (CHPh, p), 34.4 (CH2), 34.1 (CH2), 
26.9 (CH3). 
MS (EI-DE) m/z (%) 174 [M+] (5), 159 (4), 131 (5), 116 (16), 104 (2), 91 (100), 77 (2), 65 
(10), 51 (3), 43 (9), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
 
(E)-6-Methylhept-3-en-2-one (92d): The title compound was prepared according to the 
general procedure B from isovaleraldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92d (1.51 g, 
12.0 mmol, 60% (reduced yield due to the high volatility of 92d)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.74 (dt, J = 16.0, 7.4 Hz, 1H, =CHCH2), 6.03 (dt, J = 16.0, 
1.4 Hz, 1H, CH=CHCH2), 2.21 (s, 3H, CH3C(=O)), 2.08 (app. td, J = 7.1, 1.3 Hz, 2H, CH2), 
1.74 (hept, J = 6.7 Hz, 1H, CHMe2), 0.90 (d, J = 6.7 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 198.6 (C=O), 147.3 (=CHCH2), 132.3 (CH=CHCH2), 41.7 
(CH2), 27.8 (CHMe2), 26.8 (CH3C(=O)), 22.3 (2C, CH(CH3)2). 
GC-MS (GC-EI) m/z 126 [M+]. 
HRMS (EI-FE) calcd for C8H14O [M+] 126.1043, found 126.1045. 
 
(E)-4-Cyclohexylbut-3-en-2-one (92e): The title compound was prepared according to the 
general procedure B from cyclohexanecarbaldehyde with 1-(triphenyl-
phosphoranylidene)-2-propanone. The crude product was purified by flash 
column chromatography (silica gel, 10% Et2O in pentane) to give enone 92e 
(2.80 g, 18.4 mmol, 92%) as a pale yellow oil. 
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1H NMR (500 MHz, CD2Cl2) δ 6.71 (dd, J = 16.1, 6.8 Hz, 1H, =CHCH), 5.98 (dd, J = 16.3, 
1.2 Hz, 1H, CH=CHCH), 2.20 (s, 3H, CH3), 2.18-2.11 (m, 1H, =CHCH), 1.79-1.74 (m, 4H, 
CH2), 1.70-1.66 (m, 1H, CH2), 1.35-1.27 (m, 2H, CH2), 1.24-1.11 (m, 3H, CH2). 
13C NMR (125 MHz, CD2Cl2) δ 199.0 (C=O), 153.5 (=CHCH), 129.1 (CH=CHCH), 41.0 
(=CHCH), 32.2 (2C, CHCH2), 26.9 (CH3), 26.3 (CH2), 26.1 (2C, CH2). 
GC-MS (GC-EI) m/z 152 [M+]. 
HRMS (EI-FE) calcd for C10H16O [M+] 152.1200, found 152.1201. 
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6-(Tetrahydro-2H-pyran-2-yloxy)-1-hexanol (140h): A solution of 1,6-hexanediol (2.36 g, 
20.0 mmol, 1.7 equiv) and dihydropyrane (1.10 mL, 12.0 mmol) in 
THF (100 mL) in the presence of p-toluenesulfonic acid monohydrate 
(190 mg, 1.0 mmol) was stirred at 0 °C for 12 h. Then the solution was 
poured on saturated aqueous NaHCO3 solution and extracted with Et2O. The combined orga-
nic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 40% EtOAc in hexanes) to 
provide THP-mono-protected alcohol 140h (1.44 g, 7.13 mmol, 59%) as a colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ 4.55 (t, J = 3.4 Hz, 1H, OCHO), 3.88-3.81 (m, 1H, 
OCHHTHP), 3.72 (dt, J = 9.8, 6.8 Hz, 1H, THPOCHH), 3.62 (t, J = 6.6 Hz, 2H, CH2OH), 
3.51-3.44 (m, 1H, OCHHTHP), 3.37 (dt, J = 9.6, 6.5 Hz, 1H, THPOCHH), 1.86-1.35 (m, 15H, 
CH2 and OH). 
13C NMR (125 MHz, CD2Cl2) δ 98.9 (OCHO), 67.5 (THPOCH2), 62.9 (OCH2), 62.4 (OCH2), 
32.7 (CH2), 30.8 (CH2), 29.7 (CH2), 26.0 (CH2), 25.6 (CH2), 25.5 (CH2), 19.7 (CH2). 
MS (EI-DE) m/z (%) 202 [M+] (trace), 129 (2), 117 (4), 101 (27), 85 (100), 67 (10), 55 (43), 
41 (22), 29 (9). 
HRMS (CI-FE, i-butane) calcd for C11H23O3 [(M+H)+] 203.1644, found 203.1647. 
 
6-(Tetrahydro-2H-pyran-2-yloxy)hexanal (139h): THP-mono-protected alcohol 140h (1.20 
g, 5.93 mmol) was dissolved in CH2Cl2 (15 mL) and anhydrous 
DMSO (2.36 mL, 33.2 mmol, 5.6 equiv) and Et3N (4.36 mL, 31.4 
mmol, 5.3 equiv) were added sequentially at room temperature. The 
resulting solution was cooled to 0 °C and SO3 • py complex (1.42 g, 8.90 mmol, 1.5 equiv) 
was added in several portions. The reaction mixture was kept at 0 °C for 1 h, and was then 
stirred at room temperature overnight (12 h). The reaction was quenched by the addition of 
water (10 mL) and extracted with Et2O (2×25 mL). The combined organic layers were 
washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel, 20-30% Et2O in pentane) to 
afford aldehyde 139h (754 mg, 3.77 mmol, 64%) as a colorless liquid. 
1H NMR (500 MHz, CD2Cl2) δ 9.73 (t, J = 1.7 Hz, 1H, CHO), 4.53 (t, J = 3.8 Hz, 1H, 
CHTHP), 3.83-3.79 (m, 1H, OCHHTHP), 3.69 (dt, J = 9.6, 6.7 Hz, 1H, THPOCHH), 3.47-3.43 
(m, 1H, OCHHTHP), 3.35 (dt, J = 9.6, 6.4 Hz, 1H, THPOCHH), 2.42 (td, J = 7.3, 1.7 Hz, 2H, 
CH2CHO), 1.83-1.74 (m, 1H, CH2), 1.69-1.47 (m, 9H, CH2), 1.42-1.36 (m, 2H, CH2). 
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13C NMR (125 MHz, CD2Cl2) δ 202.9 (C=O), 99.2 (O-CH-O), 67.5 (THPOCH2), 62.5 
(OCH2, THP), 44.2 (CH2CHO), 31.2 (CH2), 29.9 (CH2), 26.3 (CH2), 26.0 (CH2), 22.3 (CH2), 
20.1 (CH2). 
 
(E)-9-(Tetrahydro-2H-pyran-2-yloxy)-3-nonen-2-one (92h): The title compound was 
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temperature, the reaction mixture was successively extracted with 10% aqueous NaHCO3 (50 
mL), water (50 mL), and brine (50 mL). The organic layer was dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography (silica gel, 10-30% EtOAc in hexane) to afford the title compound (9.00 g, 
47.3 mmol, 95%) as a colorless liquid. 
1H NMR (500 MHz, CDCl3) δ 3.81 (t, J = 5.5 Hz, 2H, TBSOCH2), 3.78 (app. br q, J = 5.1 
Hz, 2H, CH2OH), 2.59 (br s, 1H, OH), 1.75 (quint, J = 5.6 Hz, 2H, CH2CH2CH2), 0.88 (s, 9H, 
Cq(CH3)3), 0.05 (s, 6H, Si(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 63.0 (OCH2), 62.5 (OCH2), 34.2 (CH2CH2CH2), 25.9 (3C, 
Cq(CH3)3), 18.1 (CqMe3), -5.5 (2C, Si(CH3)2). 
GC-MS (GC-EI) m/z (%) 133 (14), 115 (3), 105 (41), 91 (3), 75 (100), 59 (5), 45 (6), 29 (2). 
HRMS (ESI+) calcd for C9H22NaO2Si [(M+Na)+] 213.1282, found 213.1281. 
 
3-(tert-Butyldimethylsilyloxy)propanal (139i): PCC (13.1 g, 60.6 mmol, 1.5 equiv) was 
added in one portion to a solution of 3-(tert-butyldimethylsilyloxy)-1-
propanol (140i; 7.69 g, 40.4 mmol, 1.0 equiv) in CH2Cl2 (130 mL). The 
mixture was stirred for 3 h at room temperature. Then the solution was 
separated from the black insoluble material, which was repeatedly extracted with Et2O (3 × 70 
mL). The combined organic layers were filtered through a plug of silica gel and evaporated to 
afford aldehyde 139i (5.20 g, 27.6 mmol) as a colorless liquid. The aldehyde was used in the 
next step without further purification. 
1H NMR (500 MHz, CDCl3) δ 9.78 (t, J = 2.0 Hz, 1H, CHO), 3.97 (t, J = 6.0 Hz, 2H, 
CH2OTBS), 2.58 (td, J = 6.0, 2.3 Hz, 2H, CH2CHO), 0.86 (s, 9H, Cq(CH3)3), 0.04 (s, 6H, 
Si(CH3)2). 
GC-MS (GC-EI) m/z (%) 131 (72), 117 (7), 101 (100), 89 (3), 75 (33), 73 (9), 59 (27), 45 (9), 
29 (4). 
 
(E)-6-(tert-Butyldimethylsilyloxy)-3-hexen-2-one (92i): The title compound was prepared 
according to the general procedure B from 3-(tert-butyldimethyl-
silyloxy)propanal (139i) with 1-(triphenylphosphoranylidene)-2-
propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to afford enone 92i (819 mg, 3.59 mmol, 
72%) as a pale yellow oil. 
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1H NMR (500 MHz, CD2Cl2) δ 6.78 (dt, J = 16.1, 7.1 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 
1.6 Hz, 1H, CH=CHCH2), 3.74 (t, J = 6.3 Hz, 2H, TBSOCH2), 2.42 (app. qd, J = 6.6, 1.3 Hz, 
2H, =CHCH2), 2.21 (s, 3H, CH3C(=O)), 0.89 (s, 9H, Cq(CH3)3), 0.05 (s, 6H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 198.4 (C=O), 145.4 (=CHCH2), 133.1 (CH=CHCH2), 61.9 
(TBSOCH2), 36.3 (=CHCH2), 26.8 (CH3C(=O)), 26.0 (3C, Cq(CH3)3), 18.5 (CqMe3), −5.3 
(2C, Si(CH3)2). 
MS (EI-DE) m/z (%) 228 [M+] (trace), 213 (3), 198 (5), 183 (2), 171 (93), 141 (100), 127 (33), 
115 (4), 103 (6), 89 (11), 75 (27), 59 (4), 43 (6), 29 (2). 
HRMS (ESI+) calcd for C12H24NaO2Si [(M+Na)+] 251.1437, found 251.1438. 
 
(E)-5-Phenyl-3-penten-2-one (92q): The title compound was prepared according to the 
general procedure B from phenylacetaldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The reaction was constantly maintained at 0 °C. 
The crude product was purified by flash column chromatography (silica gel, 
5-10% Et2O in pentane) to afford enone 92q (414 mg, 2.58 mmol, 26%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.32-7.28 (m, 2H, CHPh), 7.24-7.21 (m, 1H, CHPh, p), 7.16-
7.15 (m, 2H, CHPh), 6.89 (dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.05 (dt, J = 16.1, 1.6 Hz, 1H, 
CH=CHCH2), 3.52 (dd, J = 6.6, 1.3 Hz, 2H, PhCH2), 2.02 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.5 (C=O), 146.3 (=CHCH2), 137.6 (CqPh), 132.0 
(CH=CHCH2), 128.8 (2C, CHPh), 128.7 (2C, CHPh), 126.8 (CHPh, p), 38.8 (CH2), 26.9 (CH3). 
MS (EI-DE) m/z (%) 160 [M+] (59), 145 (27), 127 (31), 117 (100), 102 (3), 91 (38), 89 (8), 77 
(5), 65 (17), 58 (9), 51 (11), 43 (57), 39 (15), 27 (3). 
HRMS (EI-FE) calcd for C11H12O [M+] 160.0886, found 160.0888. 
 
(E)-6,6-Dimethylhept-3-en-2-one (92r): The title compound was prepared according to the 
general procedure B from 3,3-dimethylbutanal with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92r (1.58 g, 
11.3 mmol, 56% (reduced yield due to the high volatility of 92r)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.79 (dt, J = 15.6, 7.9 Hz, 1H, =CHCH2), 6.04 (dt, J = 15.9, 
1.4 Hz, 1H, CH=CHCH2), 2.22 (s, 3H, CH3C(=O)), 2.08 (dd, J = 7.8, 1.2 Hz, 2H, CH2), 0.92 
(s, 9H, Cq(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 198.4 (C=O), 145.8 (=CHCH2), 133.2 (CH=CHCH2), 46.9 
(CH2), 31.4 (Cq), 29.4 (3C, Cq(CH3)3), 26.9 (CH3C(=O)). 
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1H NMR (500 MHz, CD2Cl2) δ 6.78 (dt, J = 16.1, 7.1 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 
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1.4 Hz, 1H, CH=CHCH2), 2.22 (s, 3H, CH3C(=O)), 2.08 (dd, J = 7.8, 1.2 Hz, 2H, CH2), 0.92 
(s, 9H, Cq(CH3)3). 
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(CH2), 31.4 (Cq), 29.4 (3C, Cq(CH3)3), 26.9 (CH3C(=O)). 
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1H NMR (500 MHz, CD2Cl2) δ 6.78 (dt, J = 16.1, 7.1 Hz, 1H, =CHCH2), 6.08 (dt, J = 16.1, 
1.6 Hz, 1H, CH=CHCH2), 3.74 (t, J = 6.3 Hz, 2H, TBSOCH2), 2.42 (app. qd, J = 6.6, 1.3 Hz, 
2H, =CHCH2), 2.21 (s, 3H, CH3C(=O)), 0.89 (s, 9H, Cq(CH3)3), 0.05 (s, 6H, Si(CH3)2). 
13C NMR (125 MHz, CD2Cl2) δ 198.4 (C=O), 145.4 (=CHCH2), 133.1 (CH=CHCH2), 61.9 
(TBSOCH2), 36.3 (=CHCH2), 26.8 (CH3C(=O)), 26.0 (3C, Cq(CH3)3), 18.5 (CqMe3), −5.3 
(2C, Si(CH3)2). 
MS (EI-DE) m/z (%) 228 [M+] (trace), 213 (3), 198 (5), 183 (2), 171 (93), 141 (100), 127 (33), 
115 (4), 103 (6), 89 (11), 75 (27), 59 (4), 43 (6), 29 (2). 
HRMS (ESI+) calcd for C12H24NaO2Si [(M+Na)+] 251.1437, found 251.1438. 
 
(E)-5-Phenyl-3-penten-2-one (92q): The title compound was prepared according to the 
general procedure B from phenylacetaldehyde with 1-(triphenylphosphor-
anylidene)-2-propanone. The reaction was constantly maintained at 0 °C. 
The crude product was purified by flash column chromatography (silica gel, 
5-10% Et2O in pentane) to afford enone 92q (414 mg, 2.58 mmol, 26%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.32-7.28 (m, 2H, CHPh), 7.24-7.21 (m, 1H, CHPh, p), 7.16-
7.15 (m, 2H, CHPh), 6.89 (dt, J = 15.9, 6.9 Hz, 1H, =CHCH2), 6.05 (dt, J = 16.1, 1.6 Hz, 1H, 
CH=CHCH2), 3.52 (dd, J = 6.6, 1.3 Hz, 2H, PhCH2), 2.02 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.5 (C=O), 146.3 (=CHCH2), 137.6 (CqPh), 132.0 
(CH=CHCH2), 128.8 (2C, CHPh), 128.7 (2C, CHPh), 126.8 (CHPh, p), 38.8 (CH2), 26.9 (CH3). 
MS (EI-DE) m/z (%) 160 [M+] (59), 145 (27), 127 (31), 117 (100), 102 (3), 91 (38), 89 (8), 77 
(5), 65 (17), 58 (9), 51 (11), 43 (57), 39 (15), 27 (3). 
HRMS (EI-FE) calcd for C11H12O [M+] 160.0886, found 160.0888. 
 
(E)-6,6-Dimethylhept-3-en-2-one (92r): The title compound was prepared according to the 
general procedure B from 3,3-dimethylbutanal with 1-(triphenylphosphor-
anylidene)-2-propanone. The crude product was purified by flash column 
chromatography (silica gel, 5% Et2O in pentane) to give enone 92r (1.58 g, 
11.3 mmol, 56% (reduced yield due to the high volatility of 92r)) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.79 (dt, J = 15.6, 7.9 Hz, 1H, =CHCH2), 6.04 (dt, J = 15.9, 
1.4 Hz, 1H, CH=CHCH2), 2.22 (s, 3H, CH3C(=O)), 2.08 (dd, J = 7.8, 1.2 Hz, 2H, CH2), 0.92 
(s, 9H, Cq(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 198.4 (C=O), 145.8 (=CHCH2), 133.2 (CH=CHCH2), 46.9 
(CH2), 31.4 (Cq), 29.4 (3C, Cq(CH3)3), 26.9 (CH3C(=O)). 
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GC-MS (GC-EI) m/z 140 [M+]. 
HRMS (CI-FE, i-butane) calcd for C9H17O [(M+H)+] 141.1280, found 141.1279. 
 
(E)-5-Benzyloxy-3-penten-2-one (105): The title compound was prepared according to the 
general procedure B from benzyloxyacetaldehyde with 1-(triphenyl-
phosphoranylidene)-2-propanone. The crude product was purified by 
flash column chromatography (silica gel, 5-15% Et2O in pentane) to 
afford enone 105 (950 mg, 4.99 mmol, 88%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.39-7.35 (m, 4H, CHPh), 7.33-7.29 (m, 1H, CHPh), 6.80 (dt, J 
= 16.1, 4.5 Hz, 1H, =CHCH2), 6.31 (d, J = 16.1, 1H, CH=CHCH2), 4.46 (s, 2H, PhCH2), 4.21 
(dd, J = 4.5, 1.7 Hz, 2H, CH2CH=), 2.24 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.4 (C=O), 143.6 (=CHCH2), 138.6 (CqPh), 130.7 
(CH=CHCH2), 128.9 (2C, CHPh), 128.3 (CHPh, p), 128.2 (2C, CHPh), 73.4 (CH2), 69.4 (CH2), 
27.6 (CH3). 
MS (EI-DE) m/z (%) 190 [M+] (trace), 160 (6), 145 (5), 132 (9), 117 (1), 107 (2), 99 (2), 91 
(100), 84 (10), 65 (9), 51 (3), 43 (13), 29 (2). 
HRMS (ESI+) calcd for C12H14O2Na [(M+Na)+] 213.0885, found 213.0886. 
 
7.5.2.3 Synthesis of (E)-2-methyl-4-hexen-3-one (92o) 
(E)-2-Methyl-4-hexen-3-one (92o) was prepared according to a procedure of Heathcock et 
al.[171] 
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= 16.1, 4.5 Hz, 1H, =CHCH2), 6.31 (d, J = 16.1, 1H, CH=CHCH2), 4.46 (s, 2H, PhCH2), 4.21 
(dd, J = 4.5, 1.7 Hz, 2H, CH2CH=), 2.24 (s, 3H, CH3). 
13C NMR (125 MHz, CDCl3) δ 198.4 (C=O), 143.6 (=CHCH2), 138.6 (CqPh), 130.7 
(CH=CHCH2), 128.9 (2C, CHPh), 128.3 (CHPh, p), 128.2 (2C, CHPh), 73.4 (CH2), 69.4 (CH2), 
27.6 (CH3). 
MS (EI-DE) m/z (%) 190 [M+] (trace), 160 (6), 145 (5), 132 (9), 117 (1), 107 (2), 99 (2), 91 
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5-Hydroxy-2-methylhexan-3-one (141): To a solution of LDA, freshly prepared by addition 
of n-BuLi (26.8 ml, 67.0 mmol, 1.05 equiv, 2.5M in hexanes) to diisopropyl-
amine (9.40 mL, 67.0 mmol, 1.05 equiv) in THF (100 mL) at 0 °C, was added 
isopropylmethylketone (6.87 mL, 63.8 mmol) at −78 °C. After 30 min, 
acetaldehyde (9.01 mL, 159.5 mmol, 2.5 equiv) was added, and after stirring for 1h, the 
reaction was quenched by addition of saturated aqueous NaHCO3-solution (40 mL) −78 °C. 
Then, the reaction mixture was allowed to warm to room temperature, and the layers were 
separated. The aqueous layer was extracted with Et2O (2×75 mL) and the combined organic 
phases were successively washed with cold 1% aqueous HCl (80 mL), saturated aqueous 
NaHCO3-solution (80 mL), and brine (80 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give aldol product 141 (7.91 g, 60.8 mmol, 95%) as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ 4.21-4.14 (m, 1H, CH(OH)), 3.23 (d, J = 3.3 Hz, 1H, OH), 
2.62 (dd, J = 18.1, 3.3 Hz, 1H, CHH), 2.58-2.49 (m, 2H, CHH and CH(CH3)2), 1.16 (d, J = 
6.1 Hz, 3H, CH(OH)CH3), 1.08 (d, J = 7.0 Hz, 3H, CH(CH3)2), 1.07 (d, J = 6.9 Hz, 3H, 
CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 216.1 (C=O), 63.9 (CH(OH)), 47.9 (CH2), 41.4 (CH(CH3)2), 
22.3 (CH(OH)CH3), 18.0 (CH(CH3)2), 17.9 (CH(CH3)2). 
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(E)-2-Methylhex-4-en-3-one (92o): The crude mesylate 142 (7.85 g, 37.7 mmol) was 
dissolved in Et2O (40 mL), and triethylamine (7.84 mL, 56.6 mmol, 1.5 equiv) 
was added. After stirring for 18 h at room temperature, water (80 mL) was 
added, and the mixture was extracted with Et2O (3 × 80 mL). The combined 
organic layers were successively washed with cold aqueous 1% HCl (80 mL), saturated 
aqueous NaHCO3 solution (80 mL), water (80 mL), and brine (80 mL). The organic phase 
was dried (Na2SO4), filtered, and evaporated. The crude product was purified by flash column 
chromatography (silica gel, 3-5% Et2O in pentane) to afford enone 92o (2.64 g, 23.6 mmol, 
62% (reduced yield due to the high volatility of 92o)) as a pale yellow oil. 
1H NMR (500 MHz, CD2Cl2) δ 6.85 (dq, J = 15.4, 6.8 Hz, 1H, =CHCH3), 6.17 (dq, J = 15.4, 
1.6 Hz, 1H, CH=CHCH3), 2.80 (hept, J = 6.8 Hz, 1H, CHal), 1.88 (dd, J = 7.0, 1.9 Hz, 3H, 
=CHCH3), 1.06 (d, J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 203.7 (C=O), 142.4 (=CHCH3), 130.3 (CH=CHCH3), 38.6 
(CHMe2), 18.6 (2C, CH(CH3)2), 18.3 (=CHCH3). 
GC-MS (GC-EI) m/z 112 [M+]. 
HRMS (EI-FE) calcd for C7H12O [M+] 112.0888, found 112.0888. 
 
7.5.2.4 Synthesis of (Z)-6-phenyl-3-hexen-2-one ((Z)-92b) 
(Z)-6-Phenyl-3-hexen-2-one ((Z)-92b) was prepared according to a reaction sequence 
described by Heathcock et al.[171] 
 
 
 
6-Phenylhex-3-yn-2-ol (143): n-BuLi (8.0 mL, 20.0 mmol, 2.5M in hexanes, 1.0 equiv) was 
added to a stirred solution of 4-phenylbut-1-yne (2.81 mL, 20.0 mmol, 
1.0 equiv) in THF (11 mL) at −78 °C. After 15 min, acetaldehyde (1.70 
mL, 30.0 mmol, 1.5 equiv) was added over 1 min. Then the reaction 
mixture was allowed to warm to room temperature and after 1 h, the 
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reaction was quenched by the addition of aqueous saturated NH4Cl-solution (20 mL) and 
repeatedly extracted with Et2O (3×50 mL). The combined organic phases were successively 
washed with water and brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (silica gel, 20% 
Et2O in pentane) and 6-phenylhex-3-yn-2-ol (143; 3.13 g, 18.0 mmol, 90%) was obtained as a 
colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ 7.32-7.29 (m, 2H, CHPh, m), 7.24-7.20 (m, 3H, CHPh, o, p), 
4.48-4.43 (m, 1H, CHOH), 2.81 (t, J = 7.5 Hz, 2H, PhCH2), 2.49 (td, J = 7.5, 1.9 Hz, 2H, 
PhCH2CH2), 1.92-1.88 (m, 1H, OH), 1.37 (d, J = 6.6 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 141.4 (CqPh), 129.1 (2C, CHPh), 128.8 (2C, CHPh), 126.8 
(CHPh, p), 84.0 (C≡C), 83.8 (C≡C), 58.9 (COH), 35.5 (PhCH2), 25.1 (CH3), 21.4 (PhCH2CH2). 
GC-MS (GC-EI) m/z (%) 173 (1), 156 (6), 141 (4), 129 (21), 115 (9), 102 (2), 91 (100), 77 
(4), 65 (16), 51 (7), 43 (9), 29 (7). 
HRMS (EI-FE) calcd for C12H15O [(M+H)+] 175.1124, found 175.1123. 
 
6-Phenylhex-3-yn-2-one (144): A solution of propargylic alcohol 143 (2.75 g, 15.8 mmol) 
and PCC (7.50 g, 34.7 mmol, 2.2 equiv) in CH2Cl2 (80 mL) was stirred 
at room temperature for 12 h. Florisil (5 g) was added to the reaction 
mixture, and stirring was continued for another 15 min. After filtration 
through a plug of silica gel (eluent: Et2O), the solvents were removed 
in vacuo giving 6-phenylhex-3-yn-2-one (144; 2.42 g, 14.1 mmol, 89%) as a clear oil, which 
was used in the next step without further purification. 
1H NMR (500 MHz, CD2Cl2) δ 7.34-7.31 (m, 2H, CHPh, m), 7.26-7.23 (m, 3H, CHPh, o, p), 2.89 
(t, J = 7.4 Hz, 2H, PhCH2), 2.67 (t, J = 7.4 Hz, 2H, PhCH2CH2), 2.26 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 184.8 (C=O), 140.2 (Cqar), 128.8 (2C, CHar), 128.7 (2C, 
CHar), 126.9 (CHPh, p), 92.9 (CH2C≡C), 82.0 (CH2C≡), 34.2 (PhCH2), 32.9 (CH3), 21.3 
(PhCH2CH2). 
MS (EI-DE) m/z (%) 172 [M+] (2), 157 (13), 144 (1), 129 (31), 115 (1), 102 (1), 91 (100), 77 
(2), 65 (13), 51 (4), 43 (14), 27 (1). 
HRMS (CI-FE, i-butane) calcd for C12H13O [(M+H)+] 173.0965, found 173.0966. 
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repeatedly extracted with Et2O (3×50 mL). The combined organic phases were successively 
washed with water and brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (silica gel, 20% 
Et2O in pentane) and 6-phenylhex-3-yn-2-ol (143; 3.13 g, 18.0 mmol, 90%) was obtained as a 
colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ 7.32-7.29 (m, 2H, CHPh, m), 7.24-7.20 (m, 3H, CHPh, o, p), 
4.48-4.43 (m, 1H, CHOH), 2.81 (t, J = 7.5 Hz, 2H, PhCH2), 2.49 (td, J = 7.5, 1.9 Hz, 2H, 
PhCH2CH2), 1.92-1.88 (m, 1H, OH), 1.37 (d, J = 6.6 Hz, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 141.4 (CqPh), 129.1 (2C, CHPh), 128.8 (2C, CHPh), 126.8 
(CHPh, p), 84.0 (C≡C), 83.8 (C≡C), 58.9 (COH), 35.5 (PhCH2), 25.1 (CH3), 21.4 (PhCH2CH2). 
GC-MS (GC-EI) m/z (%) 173 (1), 156 (6), 141 (4), 129 (21), 115 (9), 102 (2), 91 (100), 77 
(4), 65 (16), 51 (7), 43 (9), 29 (7). 
HRMS (EI-FE) calcd for C12H15O [(M+H)+] 175.1124, found 175.1123. 
 
6-Phenylhex-3-yn-2-one (144): A solution of propargylic alcohol 143 (2.75 g, 15.8 mmol) 
and PCC (7.50 g, 34.7 mmol, 2.2 equiv) in CH2Cl2 (80 mL) was stirred 
at room temperature for 12 h. Florisil (5 g) was added to the reaction 
mixture, and stirring was continued for another 15 min. After filtration 
through a plug of silica gel (eluent: Et2O), the solvents were removed 
in vacuo giving 6-phenylhex-3-yn-2-one (144; 2.42 g, 14.1 mmol, 89%) as a clear oil, which 
was used in the next step without further purification. 
1H NMR (500 MHz, CD2Cl2) δ 7.34-7.31 (m, 2H, CHPh, m), 7.26-7.23 (m, 3H, CHPh, o, p), 2.89 
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MS (EI-DE) m/z (%) 172 [M+] (2), 157 (13), 144 (1), 129 (31), 115 (1), 102 (1), 91 (100), 77 
(2), 65 (13), 51 (4), 43 (14), 27 (1). 
HRMS (CI-FE, i-butane) calcd for C12H13O [(M+H)+] 173.0965, found 173.0966. 
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(Z)-6-phenyl-3-hexen-2-one ((Z)-92b): A mixture of ketone 144 (2.0 g, 11.6 mmol), 
quinoline (20 mg, 1 wt%), 5% Pd/BaSO4 (200 mg, 10 wt%), and Et2O 
(12 mL) as the solvent were placed under a hydrogen atmosphere (1 
atm) and stirred at room temperature for 22 h. The catalyst was removed 
by filtration and the volatiles under reduced pressure. 1H NMR of the 
crude product showed the desired (Z)-enone 92b contaminated with 25% of the (E)-isomer, 
which was separated by flash column chromatography (silica gel, 10-15% Et2O in pentane). 
Pure (Z)-enone ((Z)-92b; 1.40 g, 8.04 mmol, 69%) was obtained as a pale yellow oil. 
1H NMR (500 MHz, CD2Cl2) δ 7.30-7.27 (m, 2H, CHPh, m), 7.22-7.17 (m, 3H, CHPh, o and p), 
6.15 (dt, J = 11.3, 1.3 Hz, 1H, CH=CHCH2), 6.08 (dt, J = 11.4, 7.1 Hz, 1H, =CHCH2), 2.90 
(app. qd, J = 7.6, 1.2 Hz, 2H, =CHCH2), 2.74 (t, J = 7.7 Hz, 2H, PhCH2), 2.15 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.9 (C=O), 146.5 (=CHCH2), 141.5 (CqPh), 128.5 (2C, 
CHPh, o), 128.4 (2C, CHPh, m), 127.6 (CH=CHCH2), 126.0 (CHPh, p), 35.1 (PhCH2), 31.4 (CH3), 
30.9 (=CHCH2). 
MS (EI-DE) m/z (%) 174 [M+] (19), 159 (3), 141 (2), 131 (33), 117 (7), 104 (19), 91 (100), 83 
(2), 77 (3), 65 (12), 51 (3), 43 (21), 39 (4), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
 
7.5.2.5 Synthesis of 4,8-dimethylnona-3,7-dien-2-one (100) 
4,8-Dimethylnona-3,7-dien-2-one (100) was prepared according to a procedure of Shibasaki 
et al.[172] 
 
 
 
4,8-Dimethylnona-3,7-dien-2-ol (145): MeLi (24.4 mL, 39.0 mmol, 1.3 equiv; 1.6M in Et2O) 
was added at −78 °C to a solution of citral (5.14 mL, 30.0 mmol, 1.0 
equiv; geranial/neral 64:36) in Et2O (150 mL). After stirring at the 
same temperature for 1.5 h, 1 N aqueous HCl was added slowly. The 
phases were separated and the aqueous phase was extracted twice with Et2O. The combined 
organic layers were washed with water and brine, dried (Na2SO4), and concentrated under 
reduced pressure. The residue was purified by flash column chromatography (silica gel; 20-
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(2), 77 (3), 65 (12), 51 (3), 43 (21), 39 (4), 27 (2). 
HRMS (EI-FE) calcd for C12H14O [M+] 174.1045, found 174.1045. 
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4,8-Dimethylnona-3,7-dien-2-one (100) was prepared according to a procedure of Shibasaki 
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4,8-Dimethylnona-3,7-dien-2-ol (145): MeLi (24.4 mL, 39.0 mmol, 1.3 equiv; 1.6M in Et2O) 
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30% Et2O in pentane) to give alcohol 145 (4.55 g, 27.1 mmol, 90%; E/Z 64:36) as a colorless 
liquid. Characterized as a mixture of 3E/3Z-isomers. 
1H NMR (500 MHz, CD2Cl2) δ 5.21-5.17 (m, 2H, CHol), 5.14-5.08 (m, 2H, CHol), 4.56-4.47 
(m, 2H, CHOH), 2.11-1.97 (m, 8H, CH2), 1.71-1.66 (m, 12H, CqolCH3), 1.61 (s, 6H, 
CqolCH3), 1.42-1.40 (m, 2H, OH), 1.19-1.16 (m, 6H, CHCH3). 
13C NMR (125 MHz, CD2Cl2) 3E-4,8-dimethylnona-3,7-dien-2-ol: δ 137.4 (CH2Cqol), 131.9 
(Me2Cqol), 129.8 (CHolCH), 124.3 (CHolCH2), 64.9 (CHOH), 39.8 (CH2Cqol), 26.8 
(CHolCH2), 25.7 (CH3), 23.8 (CH3), 17.7 (CH3), 16.4 (CH3); 3Z-4,8-dimethylnona-3,7-dien-2-
ol: δ 137.7 (CH2Cqol), 132.6 (Me2Cqol), 130.7 (CHolCH), 124.3 (CHolCH2), 64.4 (CHOH), 
32.5 (CH2Cqol), 26.9 (CHolCH2), 25.7 (CH3), 23.8 (CH3), 23.3 (CH3), 17.7 (CH3). 
GC-MS (GC-EI) 3E-4,8-dimethylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (4), 135 
(9), 123 (4), 107 (53), 91 (13), 79 (20), 69 (100), 53 (11), 43 (34), 41 (72), 29 (8); 3Z-4,8-di-
methylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (6), 121 (5), 107 (72), 93 (18), 82 
(28), 69 (100), 65 (6), 59 (2), 53 (13), 41 (85), 39 (19), 29 (9). 
HRMS (EI-DE) calcd for C11H20O [M+] 168.1513, found 168.1514. 
 
4,8-Dimethylnona-3,7-dien-2-one (100): To a suspension of alcohol 145 (2.20 g, 13.1 mmol) 
and powered 4Å MS (6.54 g) in CH2Cl2 (40 mL) were added 
successively at 0 °C NMO (2.67 g, 19.7 mmol, 1.5 equiv) and TPAP 
(233 mg, 0.66 mmol, 0.05 mol%). After stirring for 45 min at 
ambient temperature, the mixture was filtered through a short pad of silica gel (eluent: 
EtOAc). The filtrate was concentrated under reduced pressure and flash column 
chromatography (silica gel, 8% Et2O in pentane) afforded pure fractions of 3E- and 3Z-
isomers as colorless oils [3E-4,8-dimethylnona-3,7-dien-2-one ((E)-100; 450 mg, 2.71 mmol, 
21%); 3Z-4,8-dimethylnona-3,7-dien-2-one ((Z)-100; 303 mg, 1.82 mmol, 14%); 3Z/E-4,8-
dimethylnona-3,7-dien-2-one (1.17 g, 7.04 mmol, 54%; E/Z 73:27)]. 
(3E)-4,8-Dimethylnona-3,7-dien-2-one (E-100):  
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.11-5.07 
(m, 1H, =CHCH2), 2.17-2.11 (m overlapped, 4H, CH2), 2.13 (s 
overlapped, 3H, CH3C(=O)), 2.09 (d, J = 1.2 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.61 (s, 3H, 
CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.8 (C=O), 158.1 (CH2Cqol), 132.8 (Me2Cqol), 124.0 
(CHol), 123.5 (CHol), 41.4 (CH2Cqol), 31.9 (CH3C(=O)), 26.5 (CHolCH2), 25.7 (CH3), 19.2 
(CH3), 17.7 (CH3). 
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ol: δ 137.7 (CH2Cqol), 132.6 (Me2Cqol), 130.7 (CHolCH), 124.3 (CHolCH2), 64.4 (CHOH), 
32.5 (CH2Cqol), 26.9 (CHolCH2), 25.7 (CH3), 23.8 (CH3), 23.3 (CH3), 17.7 (CH3). 
GC-MS (GC-EI) 3E-4,8-dimethylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (4), 135 
(9), 123 (4), 107 (53), 91 (13), 79 (20), 69 (100), 53 (11), 43 (34), 41 (72), 29 (8); 3Z-4,8-di-
methylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (6), 121 (5), 107 (72), 93 (18), 82 
(28), 69 (100), 65 (6), 59 (2), 53 (13), 41 (85), 39 (19), 29 (9). 
HRMS (EI-DE) calcd for C11H20O [M+] 168.1513, found 168.1514. 
 
4,8-Dimethylnona-3,7-dien-2-one (100): To a suspension of alcohol 145 (2.20 g, 13.1 mmol) 
and powered 4Å MS (6.54 g) in CH2Cl2 (40 mL) were added 
successively at 0 °C NMO (2.67 g, 19.7 mmol, 1.5 equiv) and TPAP 
(233 mg, 0.66 mmol, 0.05 mol%). After stirring for 45 min at 
ambient temperature, the mixture was filtered through a short pad of silica gel (eluent: 
EtOAc). The filtrate was concentrated under reduced pressure and flash column 
chromatography (silica gel, 8% Et2O in pentane) afforded pure fractions of 3E- and 3Z-
isomers as colorless oils [3E-4,8-dimethylnona-3,7-dien-2-one ((E)-100; 450 mg, 2.71 mmol, 
21%); 3Z-4,8-dimethylnona-3,7-dien-2-one ((Z)-100; 303 mg, 1.82 mmol, 14%); 3Z/E-4,8-
dimethylnona-3,7-dien-2-one (1.17 g, 7.04 mmol, 54%; E/Z 73:27)]. 
(3E)-4,8-Dimethylnona-3,7-dien-2-one (E-100):  
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.11-5.07 
(m, 1H, =CHCH2), 2.17-2.11 (m overlapped, 4H, CH2), 2.13 (s 
overlapped, 3H, CH3C(=O)), 2.09 (d, J = 1.2 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.61 (s, 3H, 
CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.8 (C=O), 158.1 (CH2Cqol), 132.8 (Me2Cqol), 124.0 
(CHol), 123.5 (CHol), 41.4 (CH2Cqol), 31.9 (CH3C(=O)), 26.5 (CHolCH2), 25.7 (CH3), 19.2 
(CH3), 17.7 (CH3). 
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30% Et2O in pentane) to give alcohol 145 (4.55 g, 27.1 mmol, 90%; E/Z 64:36) as a colorless 
liquid. Characterized as a mixture of 3E/3Z-isomers. 
1H NMR (500 MHz, CD2Cl2) δ 5.21-5.17 (m, 2H, CHol), 5.14-5.08 (m, 2H, CHol), 4.56-4.47 
(m, 2H, CHOH), 2.11-1.97 (m, 8H, CH2), 1.71-1.66 (m, 12H, CqolCH3), 1.61 (s, 6H, 
CqolCH3), 1.42-1.40 (m, 2H, OH), 1.19-1.16 (m, 6H, CHCH3). 
13C NMR (125 MHz, CD2Cl2) 3E-4,8-dimethylnona-3,7-dien-2-ol: δ 137.4 (CH2Cqol), 131.9 
(Me2Cqol), 129.8 (CHolCH), 124.3 (CHolCH2), 64.9 (CHOH), 39.8 (CH2Cqol), 26.8 
(CHolCH2), 25.7 (CH3), 23.8 (CH3), 17.7 (CH3), 16.4 (CH3); 3Z-4,8-dimethylnona-3,7-dien-2-
ol: δ 137.7 (CH2Cqol), 132.6 (Me2Cqol), 130.7 (CHolCH), 124.3 (CHolCH2), 64.4 (CHOH), 
32.5 (CH2Cqol), 26.9 (CHolCH2), 25.7 (CH3), 23.8 (CH3), 23.3 (CH3), 17.7 (CH3). 
GC-MS (GC-EI) 3E-4,8-dimethylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (4), 135 
(9), 123 (4), 107 (53), 91 (13), 79 (20), 69 (100), 53 (11), 43 (34), 41 (72), 29 (8); 3Z-4,8-di-
methylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (6), 121 (5), 107 (72), 93 (18), 82 
(28), 69 (100), 65 (6), 59 (2), 53 (13), 41 (85), 39 (19), 29 (9). 
HRMS (EI-DE) calcd for C11H20O [M+] 168.1513, found 168.1514. 
 
4,8-Dimethylnona-3,7-dien-2-one (100): To a suspension of alcohol 145 (2.20 g, 13.1 mmol) 
and powered 4Å MS (6.54 g) in CH2Cl2 (40 mL) were added 
successively at 0 °C NMO (2.67 g, 19.7 mmol, 1.5 equiv) and TPAP 
(233 mg, 0.66 mmol, 0.05 mol%). After stirring for 45 min at 
ambient temperature, the mixture was filtered through a short pad of silica gel (eluent: 
EtOAc). The filtrate was concentrated under reduced pressure and flash column 
chromatography (silica gel, 8% Et2O in pentane) afforded pure fractions of 3E- and 3Z-
isomers as colorless oils [3E-4,8-dimethylnona-3,7-dien-2-one ((E)-100; 450 mg, 2.71 mmol, 
21%); 3Z-4,8-dimethylnona-3,7-dien-2-one ((Z)-100; 303 mg, 1.82 mmol, 14%); 3Z/E-4,8-
dimethylnona-3,7-dien-2-one (1.17 g, 7.04 mmol, 54%; E/Z 73:27)]. 
(3E)-4,8-Dimethylnona-3,7-dien-2-one (E-100):  
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.11-5.07 
(m, 1H, =CHCH2), 2.17-2.11 (m overlapped, 4H, CH2), 2.13 (s 
overlapped, 3H, CH3C(=O)), 2.09 (d, J = 1.2 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.61 (s, 3H, 
CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.8 (C=O), 158.1 (CH2Cqol), 132.8 (Me2Cqol), 124.0 
(CHol), 123.5 (CHol), 41.4 (CH2Cqol), 31.9 (CH3C(=O)), 26.5 (CHolCH2), 25.7 (CH3), 19.2 
(CH3), 17.7 (CH3). 
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30% Et2O in pentane) to give alcohol 145 (4.55 g, 27.1 mmol, 90%; E/Z 64:36) as a colorless 
liquid. Characterized as a mixture of 3E/3Z-isomers. 
1H NMR (500 MHz, CD2Cl2) δ 5.21-5.17 (m, 2H, CHol), 5.14-5.08 (m, 2H, CHol), 4.56-4.47 
(m, 2H, CHOH), 2.11-1.97 (m, 8H, CH2), 1.71-1.66 (m, 12H, CqolCH3), 1.61 (s, 6H, 
CqolCH3), 1.42-1.40 (m, 2H, OH), 1.19-1.16 (m, 6H, CHCH3). 
13C NMR (125 MHz, CD2Cl2) 3E-4,8-dimethylnona-3,7-dien-2-ol: δ 137.4 (CH2Cqol), 131.9 
(Me2Cqol), 129.8 (CHolCH), 124.3 (CHolCH2), 64.9 (CHOH), 39.8 (CH2Cqol), 26.8 
(CHolCH2), 25.7 (CH3), 23.8 (CH3), 17.7 (CH3), 16.4 (CH3); 3Z-4,8-dimethylnona-3,7-dien-2-
ol: δ 137.7 (CH2Cqol), 132.6 (Me2Cqol), 130.7 (CHolCH), 124.3 (CHolCH2), 64.4 (CHOH), 
32.5 (CH2Cqol), 26.9 (CHolCH2), 25.7 (CH3), 23.8 (CH3), 23.3 (CH3), 17.7 (CH3). 
GC-MS (GC-EI) 3E-4,8-dimethylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (4), 135 
(9), 123 (4), 107 (53), 91 (13), 79 (20), 69 (100), 53 (11), 43 (34), 41 (72), 29 (8); 3Z-4,8-di-
methylnona-3,7-dien-2-ol: m/z (%) 168 [M+] (trace), 150 (6), 121 (5), 107 (72), 93 (18), 82 
(28), 69 (100), 65 (6), 59 (2), 53 (13), 41 (85), 39 (19), 29 (9). 
HRMS (EI-DE) calcd for C11H20O [M+] 168.1513, found 168.1514. 
 
4,8-Dimethylnona-3,7-dien-2-one (100): To a suspension of alcohol 145 (2.20 g, 13.1 mmol) 
and powered 4Å MS (6.54 g) in CH2Cl2 (40 mL) were added 
successively at 0 °C NMO (2.67 g, 19.7 mmol, 1.5 equiv) and TPAP 
(233 mg, 0.66 mmol, 0.05 mol%). After stirring for 45 min at 
ambient temperature, the mixture was filtered through a short pad of silica gel (eluent: 
EtOAc). The filtrate was concentrated under reduced pressure and flash column 
chromatography (silica gel, 8% Et2O in pentane) afforded pure fractions of 3E- and 3Z-
isomers as colorless oils [3E-4,8-dimethylnona-3,7-dien-2-one ((E)-100; 450 mg, 2.71 mmol, 
21%); 3Z-4,8-dimethylnona-3,7-dien-2-one ((Z)-100; 303 mg, 1.82 mmol, 14%); 3Z/E-4,8-
dimethylnona-3,7-dien-2-one (1.17 g, 7.04 mmol, 54%; E/Z 73:27)]. 
(3E)-4,8-Dimethylnona-3,7-dien-2-one (E-100):  
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.11-5.07 
(m, 1H, =CHCH2), 2.17-2.11 (m overlapped, 4H, CH2), 2.13 (s 
overlapped, 3H, CH3C(=O)), 2.09 (d, J = 1.2 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.61 (s, 3H, 
CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.8 (C=O), 158.1 (CH2Cqol), 132.8 (Me2Cqol), 124.0 
(CHol), 123.5 (CHol), 41.4 (CH2Cqol), 31.9 (CH3C(=O)), 26.5 (CHolCH2), 25.7 (CH3), 19.2 
(CH3), 17.7 (CH3). 
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GC-MS (GC-EI) m/z (%) 166 [M+] (5), 151 (8), 133 (2), 123 (24), 108 (21), 98 (19), 93 (7), 
83 (56), 69 (100), 53 (10), 41 (80), 39 (16), 27 (6). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1355, found 166.1358. 
(3Z)-4,8-Dimethylnona-3,7-dien-2-one (Z-100) 
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.15-5.12 (m, 
1H, =CHCH2), 2.55 (dd, J = 7.9 Hz, 2H, CH2Cqol), 2.14-2.09 (m 
overlapped, 2H, =CHCH2), 2.11 (s overlapped, 3H, CH3C(=O)), 1.86 (d, 
J = 1.3 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.62 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.2 (C=O), 158.7 (CH2Cqol), 132.4 (Me2Cqol), 124.5 
(CHol), 124.1 (CHol), 33.9 (CH2Cqol), 31.8 (CH3C(=O)), 27.1 (CHolCH2), 25.7 (CH3), 25.5 
(CH3), 17.7 (CH3). 
GC-MS (GC-EI) m/z (%) 166 [M+] (6), 151 (10), 133 (4), 123 (34), 108 (34), 98 (23), 83 
(75), 69 (100), 65 (5), 59 (5), 55 (16), 41 (90), 39 (21), 27 (8). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1356, found 166.1358. 
 
7.6 Catalyst Synthesis 
7.6.1 Synthesis of 9-Amino(9-deoxy) Cinchona Alkaloid Derivatives 
Cinchona alkaloid-derived primary amines described in the following paragraphs were 
prepared according to literature procedures reported by Brunner et al.[49a] and Soós et al.[175] 
 
9-Amino(9-deoxy)epiquinine (9-NH2-epiQ; 13)[175] 
 
 
 
Quinine (Q; 6.48 g, 20.0 mmol) and triphenylphosphine (6.30 g, 24.0 mmol, 1.2 equiv) were 
dissolved in THF (100 mL) and the solution was cooled to 0 °C. Then diisopropyl 
azodicarboxylate (4.64 mL, 24.0 mmol, 1.2 equiv) was added all at once followed by the 
dropwise addition of a solution of diphenyl phosphoryl azide (5.16 mL, 24.0 mmol, 1.2 equiv) 
in THF (40 mL). Then the reaction mixture was allowed to warm to room temperature, stirred 
overnight (12 h), and the resulting solution was further heated to 50 °C for additional 2 h. 
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GC-MS (GC-EI) m/z (%) 166 [M+] (5), 151 (8), 133 (2), 123 (24), 108 (21), 98 (19), 93 (7), 
83 (56), 69 (100), 53 (10), 41 (80), 39 (16), 27 (6). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1355, found 166.1358. 
(3Z)-4,8-Dimethylnona-3,7-dien-2-one (Z-100) 
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.15-5.12 (m, 
1H, =CHCH2), 2.55 (dd, J = 7.9 Hz, 2H, CH2Cqol), 2.14-2.09 (m 
overlapped, 2H, =CHCH2), 2.11 (s overlapped, 3H, CH3C(=O)), 1.86 (d, 
J = 1.3 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.62 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.2 (C=O), 158.7 (CH2Cqol), 132.4 (Me2Cqol), 124.5 
(CHol), 124.1 (CHol), 33.9 (CH2Cqol), 31.8 (CH3C(=O)), 27.1 (CHolCH2), 25.7 (CH3), 25.5 
(CH3), 17.7 (CH3). 
GC-MS (GC-EI) m/z (%) 166 [M+] (6), 151 (10), 133 (4), 123 (34), 108 (34), 98 (23), 83 
(75), 69 (100), 65 (5), 59 (5), 55 (16), 41 (90), 39 (21), 27 (8). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1356, found 166.1358. 
 
7.6 Catalyst Synthesis 
7.6.1 Synthesis of 9-Amino(9-deoxy) Cinchona Alkaloid Derivatives 
Cinchona alkaloid-derived primary amines described in the following paragraphs were 
prepared according to literature procedures reported by Brunner et al.[49a] and Soós et al.[175] 
 
9-Amino(9-deoxy)epiquinine (9-NH2-epiQ; 13)[175] 
 
 
 
Quinine (Q; 6.48 g, 20.0 mmol) and triphenylphosphine (6.30 g, 24.0 mmol, 1.2 equiv) were 
dissolved in THF (100 mL) and the solution was cooled to 0 °C. Then diisopropyl 
azodicarboxylate (4.64 mL, 24.0 mmol, 1.2 equiv) was added all at once followed by the 
dropwise addition of a solution of diphenyl phosphoryl azide (5.16 mL, 24.0 mmol, 1.2 equiv) 
in THF (40 mL). Then the reaction mixture was allowed to warm to room temperature, stirred 
overnight (12 h), and the resulting solution was further heated to 50 °C for additional 2 h. 
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GC-MS (GC-EI) m/z (%) 166 [M+] (5), 151 (8), 133 (2), 123 (24), 108 (21), 98 (19), 93 (7), 
83 (56), 69 (100), 53 (10), 41 (80), 39 (16), 27 (6). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1355, found 166.1358. 
(3Z)-4,8-Dimethylnona-3,7-dien-2-one (Z-100) 
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.15-5.12 (m, 
1H, =CHCH2), 2.55 (dd, J = 7.9 Hz, 2H, CH2Cqol), 2.14-2.09 (m 
overlapped, 2H, =CHCH2), 2.11 (s overlapped, 3H, CH3C(=O)), 1.86 (d, 
J = 1.3 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.62 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.2 (C=O), 158.7 (CH2Cqol), 132.4 (Me2Cqol), 124.5 
(CHol), 124.1 (CHol), 33.9 (CH2Cqol), 31.8 (CH3C(=O)), 27.1 (CHolCH2), 25.7 (CH3), 25.5 
(CH3), 17.7 (CH3). 
GC-MS (GC-EI) m/z (%) 166 [M+] (6), 151 (10), 133 (4), 123 (34), 108 (34), 98 (23), 83 
(75), 69 (100), 65 (5), 59 (5), 55 (16), 41 (90), 39 (21), 27 (8). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1356, found 166.1358. 
 
7.6 Catalyst Synthesis 
7.6.1 Synthesis of 9-Amino(9-deoxy) Cinchona Alkaloid Derivatives 
Cinchona alkaloid-derived primary amines described in the following paragraphs were 
prepared according to literature procedures reported by Brunner et al.[49a] and Soós et al.[175] 
 
9-Amino(9-deoxy)epiquinine (9-NH2-epiQ; 13)[175] 
 
 
 
Quinine (Q; 6.48 g, 20.0 mmol) and triphenylphosphine (6.30 g, 24.0 mmol, 1.2 equiv) were 
dissolved in THF (100 mL) and the solution was cooled to 0 °C. Then diisopropyl 
azodicarboxylate (4.64 mL, 24.0 mmol, 1.2 equiv) was added all at once followed by the 
dropwise addition of a solution of diphenyl phosphoryl azide (5.16 mL, 24.0 mmol, 1.2 equiv) 
in THF (40 mL). Then the reaction mixture was allowed to warm to room temperature, stirred 
overnight (12 h), and the resulting solution was further heated to 50 °C for additional 2 h. 
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GC-MS (GC-EI) m/z (%) 166 [M+] (5), 151 (8), 133 (2), 123 (24), 108 (21), 98 (19), 93 (7), 
83 (56), 69 (100), 53 (10), 41 (80), 39 (16), 27 (6). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1355, found 166.1358. 
(3Z)-4,8-Dimethylnona-3,7-dien-2-one (Z-100) 
1H NMR (500 MHz, CD2Cl2) δ 6.06 (s, 1H, =CHC(=O)), 5.15-5.12 (m, 
1H, =CHCH2), 2.55 (dd, J = 7.9 Hz, 2H, CH2Cqol), 2.14-2.09 (m 
overlapped, 2H, =CHCH2), 2.11 (s overlapped, 3H, CH3C(=O)), 1.86 (d, 
J = 1.3 Hz, 3H, CH3), 1.68 (s, 3H, CH3), 1.62 (s, 3H, CH3). 
13C NMR (125 MHz, CD2Cl2) δ 198.2 (C=O), 158.7 (CH2Cqol), 132.4 (Me2Cqol), 124.5 
(CHol), 124.1 (CHol), 33.9 (CH2Cqol), 31.8 (CH3C(=O)), 27.1 (CHolCH2), 25.7 (CH3), 25.5 
(CH3), 17.7 (CH3). 
GC-MS (GC-EI) m/z (%) 166 [M+] (6), 151 (10), 133 (4), 123 (34), 108 (34), 98 (23), 83 
(75), 69 (100), 65 (5), 59 (5), 55 (16), 41 (90), 39 (21), 27 (8). 
HRMS (EI-FE) calcd for C11H18O [M+] 166.1356, found 166.1358. 
 
7.6 Catalyst Synthesis 
7.6.1 Synthesis of 9-Amino(9-deoxy) Cinchona Alkaloid Derivatives 
Cinchona alkaloid-derived primary amines described in the following paragraphs were 
prepared according to literature procedures reported by Brunner et al.[49a] and Soós et al.[175] 
 
9-Amino(9-deoxy)epiquinine (9-NH2-epiQ; 13)[175] 
 
 
 
Quinine (Q; 6.48 g, 20.0 mmol) and triphenylphosphine (6.30 g, 24.0 mmol, 1.2 equiv) were 
dissolved in THF (100 mL) and the solution was cooled to 0 °C. Then diisopropyl 
azodicarboxylate (4.64 mL, 24.0 mmol, 1.2 equiv) was added all at once followed by the 
dropwise addition of a solution of diphenyl phosphoryl azide (5.16 mL, 24.0 mmol, 1.2 equiv) 
in THF (40 mL). Then the reaction mixture was allowed to warm to room temperature, stirred 
overnight (12 h), and the resulting solution was further heated to 50 °C for additional 2 h. 
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Next, triphenylphosphine (6.82 g, 26.0 mmol, 1.3 equiv) was added and the heating (50 °C) 
was maintained until the gas evolution has ceased (3 h). Then, the solution was cooled to 
room temperature, and water (2 mL) was added. After stirring for 12 h, the solvents were 
removed under reduced pressure, and the residue was extracted with CH2Cl2 and 10% 
aqueous HCl (1:1, 200 mL). The phases were separated, and the aqueous phase was 
repeatedly washed with CH2Cl2 (4 × 100 mL). Then the aqueous phase was made alkaline 
with excess aqueous ammonia at 0 °C and subsequently extracted with CH2Cl2 (4 × 100 mL). 
The combined organic phases were dried (Na2SO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (silica gel, methanol/EtOAc 50:50 with 
1% aq. NH4OH) affording the title compound as a white semi-solid (4.93 g, 15.3 mmol, 76%). 
The analytical data were identical in all respects to those previously reported.[49a] 
1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 4.5 Hz, 1H, CH2'), 8.01 (d, J = 9.2 Hz, 1H, CH8'), 
7.64 (br s, 1H, CH5'), 7.43 (br d, J = 4.2 Hz, 1H, CH3'), 7.36 (dd, J = 9.1, 2.8 Hz, 1H, CH7'), 
5.78 (ddd, J = 17.3, 10.1, 7.3 Hz, 1H, CH=CH2), 5.00-4.93 (m, 2H, CH=CH2), 4.57 (br d, J = 
9.7 Hz, 1H, CH9NH2), 3.94 (s, 3H, OCH3), 3.26 (dd, J = 13.8, 10.0 Hz, 1H, CHH2), 3.21-3.15 
(m, 1H, CHH6), 3.11-3.02 (m, 1H, CH8), 2.82-2.75 (m, 2H, CHH6 and CHH2), 2.30-2.23 (m, 
1H, CH3), 1.94 (br s, 2H, NH2), 1.62-1.58 (m, 1H, CH4), 1.57-1.50 (m, 2H, CH25), 1.45-1.36 
(m, 1H, CHH7), 0.75 (ddt, J = 13.6, 7.5, 1.9 Hz, 1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 157.6 (Cq6'OMe), 147.8 (C2'H), 147.0 (Cq), 144.7 (Cq), 141.7 
(CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 121.2 (C7'H), 119.9 (C3'H), 114.3 (CH=CH2), 102.0 
(C5'H), 61.9 (C8H), 56.3 (C2H2), 55.5 (OCH3), 52.5 (C9HNH2), 40.9 (C6H2), 39.8 (C3H), 28.2 
(C5H2), 27.5 (C4H), 26.0 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (2), 199 (1), 187 (15), 160 (2), 136 (100), 108 (6), 95 (3), 82 
(8), 70 (5), 56 (4), 42 (4). 
HRMS (ESI+) calcd for C20H25N3NaO [(M+Na)+] 346.1889, found 346.1890. 
 
9-Amino(9-deoxy)epiquinidine (9-NH2-epiQD; 67):[49a] Amine 67 was prepared starting 
from quinidine (QD; 1.95 g, 6.0 mmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). After 
hydrolyzing the reaction overnight (12 h), the solvents were removed 
under reduced pressure, and the residue was extracted with CH2Cl2 and 
10% aqueous HCl (1:1, 200 mL). The phases were separated, the aqueous 
phase was concentrated in vacuo, and the residue was crystallized from 
methanol. The white precipitate was collected and dissolved in water. Then the aqueous phase 
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Next, triphenylphosphine (6.82 g, 26.0 mmol, 1.3 equiv) was added and the heating (50 °C) 
was maintained until the gas evolution has ceased (3 h). Then, the solution was cooled to 
room temperature, and water (2 mL) was added. After stirring for 12 h, the solvents were 
removed under reduced pressure, and the residue was extracted with CH2Cl2 and 10% 
aqueous HCl (1:1, 200 mL). The phases were separated, and the aqueous phase was 
repeatedly washed with CH2Cl2 (4 × 100 mL). Then the aqueous phase was made alkaline 
with excess aqueous ammonia at 0 °C and subsequently extracted with CH2Cl2 (4 × 100 mL). 
The combined organic phases were dried (Na2SO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (silica gel, methanol/EtOAc 50:50 with 
1% aq. NH4OH) affording the title compound as a white semi-solid (4.93 g, 15.3 mmol, 76%). 
The analytical data were identical in all respects to those previously reported.[49a] 
1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 4.5 Hz, 1H, CH2'), 8.01 (d, J = 9.2 Hz, 1H, CH8'), 
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MS (EI-DE) m/z (%) 323 [M+] (2), 199 (1), 187 (15), 160 (2), 136 (100), 108 (6), 95 (3), 82 
(8), 70 (5), 56 (4), 42 (4). 
HRMS (ESI+) calcd for C20H25N3NaO [(M+Na)+] 346.1889, found 346.1890. 
 
9-Amino(9-deoxy)epiquinidine (9-NH2-epiQD; 67):[49a] Amine 67 was prepared starting 
from quinidine (QD; 1.95 g, 6.0 mmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). After 
hydrolyzing the reaction overnight (12 h), the solvents were removed 
under reduced pressure, and the residue was extracted with CH2Cl2 and 
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was made alkaline by the addition of K2CO3, and repeatedly extracted with CH2Cl2 (3 × 50 
mL). The combined organic phases were dried (Na2SO4) and evaporated under reduced 
pressure affording the pure title compound (820 mg, 2.54 mmol, 42%) as a pale yellow 
viscous oil. 
1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 4.6 Hz, 1H, CH2'), 8.00 (d, J = 9.1 Hz, 1H, CH8'), 
7.60 (br s, 1H, CH5'), 7.50 (br s, 1H, CH3'), 7.34 (dd, J = 9.2, 2.7 Hz, 1H, CH7'), 5.86 (ddd, J 
= 17.0, 10.6, 6.4 Hz, 1H, CH=CH2), 5.07-5.01 (m, 2H, CH=CH2), 4.64 (br d, J = 9.1 Hz, 1H, 
CH9NH2), 3.94 (s, 3H, OCH3), 3.04-2.88 (m, 5H, CH8, CH26and CH22), 2.24 (app. br q, J = 
8.0 Hz, 1H, CH3), 2.02 (br s, 2H, NH2), 1.60-1.56 (m, 1H, CH4), 1.54-1.48 (m, 2H, CH25), 
1.11 (dd, J = 13.4, 8.8 Hz, 1H, CHH7), 0.96-0.88 (m, 1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 157.6 (Cq6'OMe), 147.8 (C2'H), 147.5 (Cq), 144.7 (Cq), 140.7 
(CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 121.6 (C7'H), 119.9 (C3'H), 114.4 (CH=CH2), 101.4 
(C5'H), 62.4 (C8H), 55.4 (OCH3), 51.6 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.4 (C3H), 27.6 
(C4H), 26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (63), 306 (10), 282 (3), 265 (2), 240 (2), 200 (8), 187 (100),  
160 (11), 137 (67), 122 (11), 108 (33), 95 (10), 82 (43), 70 (15), 56 (11), 42 (7). 
HRMS (ESI+) calcd for C20H26N3O [(M+H)+] 324.2067, found 324.2070. 
 
9-Amino(9-deoxy)epidihydroquinine (9-NH2-epiDHQ; 72):[175] Amine 72 was prepared 
starting from dihydroquinine (DHQ; 1.95 g, 3.86 mmol) following 
the same procedure described for the synthesis of 9-amino(9-
deoxy)epiquinine (13). Purification by flash column chromate-
graphy (silica gel, methanol/EtOAc 50:50 with 1% aq. NH4OH) 
gave the title compound (842 mg, 2.59 mmol, 67%) as pale yellow 
viscous oil. 
1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 4.5 Hz, 1H, CH2'), 7.99 (d, J = 9.1 Hz, 1H, CH8'), 
7.62 (br s, 1H, CH5'), 7.43 (br d, J = 4.0 Hz, 1H, CH3'), 7.34 (dd, J = 9.1, 2.8 Hz, 1H, CH7'), 
4.55 (br d, J = 9.6, 1H, CH9NH2), 3.92 (s, 3H, OCH3), 3.21 (dd, J = 13.6, 9.8 Hz, 1H, CHH2), 
3.17-3.10 (m, 1H, CHH6), 3.05-2.98 (m, 1H, CH8), 2.77-2.69 (m, 1H, CHH6), 2.47 (ddd, J = 
13.6, 4.6, 2.3 Hz, 1H, CHH2), 2.09 (br s, 2H, NH2), 1.54-1.19 (m, 7H, CH4, CH25, CHH7, 
CH3, and CH2CH3), 0.78 (t, J = 7.3 Hz, 3H, CH2CH3), 0.70 (dd, J = 13.6, 7.6 Hz, 1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 157.5 (Cq6'OMe), 147.8 (C2'H), 147.2 (Cq), 144.7 (Cq'), 131.7 
(C8'H), 128.8 (Cq4a'), 121.1 (C7'H), 119.9 (C3'H), 102.0 (C5'H), 61.7 (C8H), 57.9 (C2H2), 55.5 
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7.60 (br s, 1H, CH5'), 7.50 (br s, 1H, CH3'), 7.34 (dd, J = 9.2, 2.7 Hz, 1H, CH7'), 5.86 (ddd, J 
= 17.0, 10.6, 6.4 Hz, 1H, CH=CH2), 5.07-5.01 (m, 2H, CH=CH2), 4.64 (br d, J = 9.1 Hz, 1H, 
CH9NH2), 3.94 (s, 3H, OCH3), 3.04-2.88 (m, 5H, CH8, CH26and CH22), 2.24 (app. br q, J = 
8.0 Hz, 1H, CH3), 2.02 (br s, 2H, NH2), 1.60-1.56 (m, 1H, CH4), 1.54-1.48 (m, 2H, CH25), 
1.11 (dd, J = 13.4, 8.8 Hz, 1H, CHH7), 0.96-0.88 (m, 1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 157.6 (Cq6'OMe), 147.8 (C2'H), 147.5 (Cq), 144.7 (Cq), 140.7 
(CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 121.6 (C7'H), 119.9 (C3'H), 114.4 (CH=CH2), 101.4 
(C5'H), 62.4 (C8H), 55.4 (OCH3), 51.6 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.4 (C3H), 27.6 
(C4H), 26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (63), 306 (10), 282 (3), 265 (2), 240 (2), 200 (8), 187 (100),  
160 (11), 137 (67), 122 (11), 108 (33), 95 (10), 82 (43), 70 (15), 56 (11), 42 (7). 
HRMS (ESI+) calcd for C20H26N3O [(M+H)+] 324.2067, found 324.2070. 
 
9-Amino(9-deoxy)epidihydroquinine (9-NH2-epiDHQ; 72):[175] Amine 72 was prepared 
starting from dihydroquinine (DHQ; 1.95 g, 3.86 mmol) following 
the same procedure described for the synthesis of 9-amino(9-
deoxy)epiquinine (13). Purification by flash column chromate-
graphy (silica gel, methanol/EtOAc 50:50 with 1% aq. NH4OH) 
gave the title compound (842 mg, 2.59 mmol, 67%) as pale yellow 
viscous oil. 
1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 4.5 Hz, 1H, CH2'), 7.99 (d, J = 9.1 Hz, 1H, CH8'), 
7.62 (br s, 1H, CH5'), 7.43 (br d, J = 4.0 Hz, 1H, CH3'), 7.34 (dd, J = 9.1, 2.8 Hz, 1H, CH7'), 
4.55 (br d, J = 9.6, 1H, CH9NH2), 3.92 (s, 3H, OCH3), 3.21 (dd, J = 13.6, 9.8 Hz, 1H, CHH2), 
3.17-3.10 (m, 1H, CHH6), 3.05-2.98 (m, 1H, CH8), 2.77-2.69 (m, 1H, CHH6), 2.47 (ddd, J = 
13.6, 4.6, 2.3 Hz, 1H, CHH2), 2.09 (br s, 2H, NH2), 1.54-1.19 (m, 7H, CH4, CH25, CHH7, 
CH3, and CH2CH3), 0.78 (t, J = 7.3 Hz, 3H, CH2CH3), 0.70 (dd, J = 13.6, 7.6 Hz, 1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 157.5 (Cq6'OMe), 147.8 (C2'H), 147.2 (Cq), 144.7 (Cq'), 131.7 
(C8'H), 128.8 (Cq4a'), 121.1 (C7'H), 119.9 (C3'H), 102.0 (C5'H), 61.7 (C8H), 57.9 (C2H2), 55.5 
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(OCH3), 54.5 (C9HNH2), 41.0 (C6H2), 37.5 (C3H), 28.9 (C5H2), 27.6 (CH2CH3), 25.8 (C7H2), 
25.2 (C4H), 12.0 (CH2CH3). 
MS (EI-DE) m/z (%) 325 [M+] (47), 308 (9), 279 (1), 251 (1), 201 (4), 187 (69), 160 (9),  139 
(69), 110 (97), 96 (3), 82 (100), 70 (5), 55 (15), 41 (7). 
HRMS (ESI+) calcd for C20H27N3NaO [(M+Na)+] 348.2046, found 348.2046. 
 
9-Amino(9-deoxy)epicinchonidine (9-NH2-epiCD; 69):[175] Amine 69 was prepared starting 
from cinchonidine (CD; 1.77 g, 6.0 mmol) following the same 
procedure described for the synthesis of 9-amino(9-deoxy)epiquinine 
(13). Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title compound 
as colorless viscous oil (1.23 g, 4.19 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 4.6 Hz, 1H, CH2'), 8.33 (br s, 1H, CH5'), 8.11 (dd, 
J = 8.6, 0.8 Hz, 1H, CH8'), 7.68 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, CH7'), 7.56 (ddd, J = 8.5, 6.9, 
1.3 Hz, 1H, CH6'), 7.49 (br d, J = 4.1 Hz, 1H, CH3'), 5.77 (ddd, J = 17.2, 10.1, 7.3 Hz, 1H, 
CH=CH2), 4.99-4.91 (m, 2H, CH=CH2), 4.67 (br d, J = 9.1, 1H, CH9NH2), 3.24 (dd, J = 13.9, 
10.1 Hz, 1H, CHH2), 3.20-3.13 (m, 1H, CHH6), 3.04 (app. br q, J = 8.7 Hz, 1H, CH8), 2.81-
2.73 (m, 2H, CHH2 and CHH6), 2.27-2.21 (m, 1H, CH3), 2.01 (br s, 2H, NH2), 1.59-1.50 (m, 
3H, CH4 and CH25), 1.38 (app. br t, J = 11.6 Hz, 1H, CHH7), 0.71 (ddt, J = 13.6, 7.5, 1.9 Hz, 
1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 150.3 (C2'H), 148.7 (Cq4'), 148.6 (Cq8a'), 141.8 (CH=CH2), 
130.4 (C8'H), 128.9 (C7'H), 127.8 (Cq4a'), 126.4 (C6'H), 123.3 (C5'H), 119.6 (C3'H), 114.2 
(CH=CH2), 61.9 (C8H), 56.3 (C2H2), 51.8 (C9HNH2), 40.9 (C6H2), 39.8 (C3H), 28.1 (C5H2), 
27.5 (C4H), 26.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (1), 196 (1), 181 (1), 169 (3), 157 (12), 136 (100), 108 (6), 95 
(4), 81 (9), 70 (4), 56 (4), 42 (6), 30 (2). 
HRMS (ESI+) calcd for C19H24N3 [(M+H)+] 294.1964, found 294.1965. 
 
9-Amino(9-deoxy)epicinchonine (9-NH2-epiC; 70):[49a] Amine 70 was prepared starting 
from cinchonine (C; 1.77 g, 6.0 mmol; contains ~10% of dihydrocin-
chonine) following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). After hydrolyzing the reaction overnight 
(12 h), the solvents were removed under reduced pressure, and the 
residue was extracted with CH2Cl2 and 10% aqueous HCl (1:1, 200 mL). 
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(OCH3), 54.5 (C9HNH2), 41.0 (C6H2), 37.5 (C3H), 28.9 (C5H2), 27.6 (CH2CH3), 25.8 (C7H2), 
25.2 (C4H), 12.0 (CH2CH3). 
MS (EI-DE) m/z (%) 325 [M+] (47), 308 (9), 279 (1), 251 (1), 201 (4), 187 (69), 160 (9),  139 
(69), 110 (97), 96 (3), 82 (100), 70 (5), 55 (15), 41 (7). 
HRMS (ESI+) calcd for C20H27N3NaO [(M+Na)+] 348.2046, found 348.2046. 
 
9-Amino(9-deoxy)epicinchonidine (9-NH2-epiCD; 69):[175] Amine 69 was prepared starting 
from cinchonidine (CD; 1.77 g, 6.0 mmol) following the same 
procedure described for the synthesis of 9-amino(9-deoxy)epiquinine 
(13). Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title compound 
as colorless viscous oil (1.23 g, 4.19 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 4.6 Hz, 1H, CH2'), 8.33 (br s, 1H, CH5'), 8.11 (dd, 
J = 8.6, 0.8 Hz, 1H, CH8'), 7.68 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, CH7'), 7.56 (ddd, J = 8.5, 6.9, 
1.3 Hz, 1H, CH6'), 7.49 (br d, J = 4.1 Hz, 1H, CH3'), 5.77 (ddd, J = 17.2, 10.1, 7.3 Hz, 1H, 
CH=CH2), 4.99-4.91 (m, 2H, CH=CH2), 4.67 (br d, J = 9.1, 1H, CH9NH2), 3.24 (dd, J = 13.9, 
10.1 Hz, 1H, CHH2), 3.20-3.13 (m, 1H, CHH6), 3.04 (app. br q, J = 8.7 Hz, 1H, CH8), 2.81-
2.73 (m, 2H, CHH2 and CHH6), 2.27-2.21 (m, 1H, CH3), 2.01 (br s, 2H, NH2), 1.59-1.50 (m, 
3H, CH4 and CH25), 1.38 (app. br t, J = 11.6 Hz, 1H, CHH7), 0.71 (ddt, J = 13.6, 7.5, 1.9 Hz, 
1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 150.3 (C2'H), 148.7 (Cq4'), 148.6 (Cq8a'), 141.8 (CH=CH2), 
130.4 (C8'H), 128.9 (C7'H), 127.8 (Cq4a'), 126.4 (C6'H), 123.3 (C5'H), 119.6 (C3'H), 114.2 
(CH=CH2), 61.9 (C8H), 56.3 (C2H2), 51.8 (C9HNH2), 40.9 (C6H2), 39.8 (C3H), 28.1 (C5H2), 
27.5 (C4H), 26.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (1), 196 (1), 181 (1), 169 (3), 157 (12), 136 (100), 108 (6), 95 
(4), 81 (9), 70 (4), 56 (4), 42 (6), 30 (2). 
HRMS (ESI+) calcd for C19H24N3 [(M+H)+] 294.1964, found 294.1965. 
 
9-Amino(9-deoxy)epicinchonine (9-NH2-epiC; 70):[49a] Amine 70 was prepared starting 
from cinchonine (C; 1.77 g, 6.0 mmol; contains ~10% of dihydrocin-
chonine) following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). After hydrolyzing the reaction overnight 
(12 h), the solvents were removed under reduced pressure, and the 
residue was extracted with CH2Cl2 and 10% aqueous HCl (1:1, 200 mL). 
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(OCH3), 54.5 (C9HNH2), 41.0 (C6H2), 37.5 (C3H), 28.9 (C5H2), 27.6 (CH2CH3), 25.8 (C7H2), 
25.2 (C4H), 12.0 (CH2CH3). 
MS (EI-DE) m/z (%) 325 [M+] (47), 308 (9), 279 (1), 251 (1), 201 (4), 187 (69), 160 (9),  139 
(69), 110 (97), 96 (3), 82 (100), 70 (5), 55 (15), 41 (7). 
HRMS (ESI+) calcd for C20H27N3NaO [(M+Na)+] 348.2046, found 348.2046. 
 
9-Amino(9-deoxy)epicinchonidine (9-NH2-epiCD; 69):[175] Amine 69 was prepared starting 
from cinchonidine (CD; 1.77 g, 6.0 mmol) following the same 
procedure described for the synthesis of 9-amino(9-deoxy)epiquinine 
(13). Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title compound 
as colorless viscous oil (1.23 g, 4.19 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 4.6 Hz, 1H, CH2'), 8.33 (br s, 1H, CH5'), 8.11 (dd, 
J = 8.6, 0.8 Hz, 1H, CH8'), 7.68 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, CH7'), 7.56 (ddd, J = 8.5, 6.9, 
1.3 Hz, 1H, CH6'), 7.49 (br d, J = 4.1 Hz, 1H, CH3'), 5.77 (ddd, J = 17.2, 10.1, 7.3 Hz, 1H, 
CH=CH2), 4.99-4.91 (m, 2H, CH=CH2), 4.67 (br d, J = 9.1, 1H, CH9NH2), 3.24 (dd, J = 13.9, 
10.1 Hz, 1H, CHH2), 3.20-3.13 (m, 1H, CHH6), 3.04 (app. br q, J = 8.7 Hz, 1H, CH8), 2.81-
2.73 (m, 2H, CHH2 and CHH6), 2.27-2.21 (m, 1H, CH3), 2.01 (br s, 2H, NH2), 1.59-1.50 (m, 
3H, CH4 and CH25), 1.38 (app. br t, J = 11.6 Hz, 1H, CHH7), 0.71 (ddt, J = 13.6, 7.5, 1.9 Hz, 
1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 150.3 (C2'H), 148.7 (Cq4'), 148.6 (Cq8a'), 141.8 (CH=CH2), 
130.4 (C8'H), 128.9 (C7'H), 127.8 (Cq4a'), 126.4 (C6'H), 123.3 (C5'H), 119.6 (C3'H), 114.2 
(CH=CH2), 61.9 (C8H), 56.3 (C2H2), 51.8 (C9HNH2), 40.9 (C6H2), 39.8 (C3H), 28.1 (C5H2), 
27.5 (C4H), 26.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (1), 196 (1), 181 (1), 169 (3), 157 (12), 136 (100), 108 (6), 95 
(4), 81 (9), 70 (4), 56 (4), 42 (6), 30 (2). 
HRMS (ESI+) calcd for C19H24N3 [(M+H)+] 294.1964, found 294.1965. 
 
9-Amino(9-deoxy)epicinchonine (9-NH2-epiC; 70):[49a] Amine 70 was prepared starting 
from cinchonine (C; 1.77 g, 6.0 mmol; contains ~10% of dihydrocin-
chonine) following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). After hydrolyzing the reaction overnight 
(12 h), the solvents were removed under reduced pressure, and the 
residue was extracted with CH2Cl2 and 10% aqueous HCl (1:1, 200 mL). 
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(OCH3), 54.5 (C9HNH2), 41.0 (C6H2), 37.5 (C3H), 28.9 (C5H2), 27.6 (CH2CH3), 25.8 (C7H2), 
25.2 (C4H), 12.0 (CH2CH3). 
MS (EI-DE) m/z (%) 325 [M+] (47), 308 (9), 279 (1), 251 (1), 201 (4), 187 (69), 160 (9),  139 
(69), 110 (97), 96 (3), 82 (100), 70 (5), 55 (15), 41 (7). 
HRMS (ESI+) calcd for C20H27N3NaO [(M+Na)+] 348.2046, found 348.2046. 
 
9-Amino(9-deoxy)epicinchonidine (9-NH2-epiCD; 69):[175] Amine 69 was prepared starting 
from cinchonidine (CD; 1.77 g, 6.0 mmol) following the same 
procedure described for the synthesis of 9-amino(9-deoxy)epiquinine 
(13). Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title compound 
as colorless viscous oil (1.23 g, 4.19 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 4.6 Hz, 1H, CH2'), 8.33 (br s, 1H, CH5'), 8.11 (dd, 
J = 8.6, 0.8 Hz, 1H, CH8'), 7.68 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, CH7'), 7.56 (ddd, J = 8.5, 6.9, 
1.3 Hz, 1H, CH6'), 7.49 (br d, J = 4.1 Hz, 1H, CH3'), 5.77 (ddd, J = 17.2, 10.1, 7.3 Hz, 1H, 
CH=CH2), 4.99-4.91 (m, 2H, CH=CH2), 4.67 (br d, J = 9.1, 1H, CH9NH2), 3.24 (dd, J = 13.9, 
10.1 Hz, 1H, CHH2), 3.20-3.13 (m, 1H, CHH6), 3.04 (app. br q, J = 8.7 Hz, 1H, CH8), 2.81-
2.73 (m, 2H, CHH2 and CHH6), 2.27-2.21 (m, 1H, CH3), 2.01 (br s, 2H, NH2), 1.59-1.50 (m, 
3H, CH4 and CH25), 1.38 (app. br t, J = 11.6 Hz, 1H, CHH7), 0.71 (ddt, J = 13.6, 7.5, 1.9 Hz, 
1H, CHH7). 
13C NMR (100 MHz, CDCl3) δ 150.3 (C2'H), 148.7 (Cq4'), 148.6 (Cq8a'), 141.8 (CH=CH2), 
130.4 (C8'H), 128.9 (C7'H), 127.8 (Cq4a'), 126.4 (C6'H), 123.3 (C5'H), 119.6 (C3'H), 114.2 
(CH=CH2), 61.9 (C8H), 56.3 (C2H2), 51.8 (C9HNH2), 40.9 (C6H2), 39.8 (C3H), 28.1 (C5H2), 
27.5 (C4H), 26.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (1), 196 (1), 181 (1), 169 (3), 157 (12), 136 (100), 108 (6), 95 
(4), 81 (9), 70 (4), 56 (4), 42 (6), 30 (2). 
HRMS (ESI+) calcd for C19H24N3 [(M+H)+] 294.1964, found 294.1965. 
 
9-Amino(9-deoxy)epicinchonine (9-NH2-epiC; 70):[49a] Amine 70 was prepared starting 
from cinchonine (C; 1.77 g, 6.0 mmol; contains ~10% of dihydrocin-
chonine) following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). After hydrolyzing the reaction overnight 
(12 h), the solvents were removed under reduced pressure, and the 
residue was extracted with CH2Cl2 and 10% aqueous HCl (1:1, 200 mL). 
N
N
NH2
2
3
4
5
6
7
8
2´
3´
4´
5´
6´
7´
8´
8a´
4a´
9
C19H23N3
293,41
C19H23N3
293,41
N
N
NH2
7´
2
3
4
5
6
7
8
2´
3´
4´
5´
6´8´
8a´
4a´
9
7  Experimental Part 
248 
The phases were separated, the aqueous phase was concentrated in vacuo, and the residue was 
crystallized from methanol. The white precipitate was collected and dissolved in water. Then 
the aqueous phase was made alkaline by the addition of K2CO3, and repeatedly extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were dried (Na2SO4) and evaporated 
under reduced pressure affording the pure title compound (808 mg, 2.75 mmol, 46%; 
contaminated by 9-amino(9-deoxy)epidihydrocinchonine (~10%)) as colorless viscous oil. 
1H NMR (300 MHz, CDCl3) δ 8.87 (d, J = 4.5 Hz, 1H, CH2'), 8.33 (br d, J = 8.0 Hz, 1H, 
CH5'), 8.11 (dd, J = 8.5, 0.9 Hz, 1H, CH8'), 7.69 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H, CH7'), 7.59-
7.53 (m, 2H, CH3' and CH6'), 5.84 (ddd, J = 16.6, 11.1, 6.6 Hz, 1H, CH=CH2), 5.07-5.01 (m, 
2H, CH=CH2), 4.73 (br d, J = 9.8, 1H, CH9NH2), 3.07-2.87 (m, 5H, CH8, CH26and CH22), 
2.25 (app. br q, J = 8.4 Hz, 1H, CH3), 1.99 (br s, 2H, NH2), 1.57-1.48 (m, 3H, CH4 and CH25), 
1.09 (dd, J = 13.3, 8.8 Hz, 1H, CHH7), 0.97-0.88 (m, 1H, CHH7). 
13C NMR (75 MHz, CDCl3) δ 150.3 (C2'H), 149.0 (Cq4'), 148.6 (Cq8a'), 140.6 (CH=CH2), 
130.4 (C8'H), 129.0 (C7'H), 127.9 (Cq4a'), 126.3 (C6'H), 123.3 (C5'H), 119.7 (C3'H), 114.5 
(CH=CH2), 62.2 (C8H), 51.4 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.7 (C3H), 27.7 (C4H), 
26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (87), 276 (13), 252 (6), 235 (3), 211 (3), 183 (9), 169 (14), 157 
(90), 136 (100), 122 (14), 115 (4), 108 (46), 95 (18), 82 (70), 70 (23), 56 (20), 42 (21). 
HRMS (ESI+) calcd for C19H23N3Na [(M+Na)+] 316.1785, found 316.1784. 
 
9-Amino(9-deoxy)-epi-6'-isopropoxycinchonidine (71):[175] Amine 71 was prepared starting 
from 6'-isopropoxycinchonidine (146; 650 mg, 1.84 mmol) 
following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). Purification by flash column chro-
matography (silica gel, methanol/EtOAc 50:50 with 1% 
aq. NH4OH) gave the title compound (498 mg, 1.41 mmol, 77%) as 
pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ 8.71 (d, J = 4.4 Hz, 1H, CH2'), 8.01 (d, J = 9.1 Hz, 1H, CH8'), 
7.66 (br s, 1H, CH5'), 7.42 (br s, 1H, CH3'), 7.34 (dd, J = 9.3, 2.7 Hz, 1H, CH7'), 5.78 (ddd, J 
= 17.3, 9.9, 7.6 Hz, 1H, CH=CH2), 5.00-4.93 (m, 2H, CH=CH2), 4.72 (hept, J = 6.1 Hz, 1H, 
CHMe2), 4.55 (br s, 1H, CH9NH2), 3.26 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.22-3.15 (m, 1H, 
CHH6), 3.10-3.01 (m, 1H, CH8), 2.81-2.75 (m, 2H, CHH6 and CHH2), 2.28-2.24 (m, 1H, 
CH3), 1.89 (br s, 2H, NH2), 1.62-1.60 (m, 1H, CH4), 1.56-1.51 (m, 2H, CH25), 1.43-1.40 (m, 
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The phases were separated, the aqueous phase was concentrated in vacuo, and the residue was 
crystallized from methanol. The white precipitate was collected and dissolved in water. Then 
the aqueous phase was made alkaline by the addition of K2CO3, and repeatedly extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were dried (Na2SO4) and evaporated 
under reduced pressure affording the pure title compound (808 mg, 2.75 mmol, 46%; 
contaminated by 9-amino(9-deoxy)epidihydrocinchonine (~10%)) as colorless viscous oil. 
1H NMR (300 MHz, CDCl3) δ 8.87 (d, J = 4.5 Hz, 1H, CH2'), 8.33 (br d, J = 8.0 Hz, 1H, 
CH5'), 8.11 (dd, J = 8.5, 0.9 Hz, 1H, CH8'), 7.69 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H, CH7'), 7.59-
7.53 (m, 2H, CH3' and CH6'), 5.84 (ddd, J = 16.6, 11.1, 6.6 Hz, 1H, CH=CH2), 5.07-5.01 (m, 
2H, CH=CH2), 4.73 (br d, J = 9.8, 1H, CH9NH2), 3.07-2.87 (m, 5H, CH8, CH26and CH22), 
2.25 (app. br q, J = 8.4 Hz, 1H, CH3), 1.99 (br s, 2H, NH2), 1.57-1.48 (m, 3H, CH4 and CH25), 
1.09 (dd, J = 13.3, 8.8 Hz, 1H, CHH7), 0.97-0.88 (m, 1H, CHH7). 
13C NMR (75 MHz, CDCl3) δ 150.3 (C2'H), 149.0 (Cq4'), 148.6 (Cq8a'), 140.6 (CH=CH2), 
130.4 (C8'H), 129.0 (C7'H), 127.9 (Cq4a'), 126.3 (C6'H), 123.3 (C5'H), 119.7 (C3'H), 114.5 
(CH=CH2), 62.2 (C8H), 51.4 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.7 (C3H), 27.7 (C4H), 
26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (87), 276 (13), 252 (6), 235 (3), 211 (3), 183 (9), 169 (14), 157 
(90), 136 (100), 122 (14), 115 (4), 108 (46), 95 (18), 82 (70), 70 (23), 56 (20), 42 (21). 
HRMS (ESI+) calcd for C19H23N3Na [(M+Na)+] 316.1785, found 316.1784. 
 
9-Amino(9-deoxy)-epi-6'-isopropoxycinchonidine (71):[175] Amine 71 was prepared starting 
from 6'-isopropoxycinchonidine (146; 650 mg, 1.84 mmol) 
following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). Purification by flash column chro-
matography (silica gel, methanol/EtOAc 50:50 with 1% 
aq. NH4OH) gave the title compound (498 mg, 1.41 mmol, 77%) as 
pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ 8.71 (d, J = 4.4 Hz, 1H, CH2'), 8.01 (d, J = 9.1 Hz, 1H, CH8'), 
7.66 (br s, 1H, CH5'), 7.42 (br s, 1H, CH3'), 7.34 (dd, J = 9.3, 2.7 Hz, 1H, CH7'), 5.78 (ddd, J 
= 17.3, 9.9, 7.6 Hz, 1H, CH=CH2), 5.00-4.93 (m, 2H, CH=CH2), 4.72 (hept, J = 6.1 Hz, 1H, 
CHMe2), 4.55 (br s, 1H, CH9NH2), 3.26 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.22-3.15 (m, 1H, 
CHH6), 3.10-3.01 (m, 1H, CH8), 2.81-2.75 (m, 2H, CHH6 and CHH2), 2.28-2.24 (m, 1H, 
CH3), 1.89 (br s, 2H, NH2), 1.62-1.60 (m, 1H, CH4), 1.56-1.51 (m, 2H, CH25), 1.43-1.40 (m, 
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The phases were separated, the aqueous phase was concentrated in vacuo, and the residue was 
crystallized from methanol. The white precipitate was collected and dissolved in water. Then 
the aqueous phase was made alkaline by the addition of K2CO3, and repeatedly extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were dried (Na2SO4) and evaporated 
under reduced pressure affording the pure title compound (808 mg, 2.75 mmol, 46%; 
contaminated by 9-amino(9-deoxy)epidihydrocinchonine (~10%)) as colorless viscous oil. 
1H NMR (300 MHz, CDCl3) δ 8.87 (d, J = 4.5 Hz, 1H, CH2'), 8.33 (br d, J = 8.0 Hz, 1H, 
CH5'), 8.11 (dd, J = 8.5, 0.9 Hz, 1H, CH8'), 7.69 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H, CH7'), 7.59-
7.53 (m, 2H, CH3' and CH6'), 5.84 (ddd, J = 16.6, 11.1, 6.6 Hz, 1H, CH=CH2), 5.07-5.01 (m, 
2H, CH=CH2), 4.73 (br d, J = 9.8, 1H, CH9NH2), 3.07-2.87 (m, 5H, CH8, CH26and CH22), 
2.25 (app. br q, J = 8.4 Hz, 1H, CH3), 1.99 (br s, 2H, NH2), 1.57-1.48 (m, 3H, CH4 and CH25), 
1.09 (dd, J = 13.3, 8.8 Hz, 1H, CHH7), 0.97-0.88 (m, 1H, CHH7). 
13C NMR (75 MHz, CDCl3) δ 150.3 (C2'H), 149.0 (Cq4'), 148.6 (Cq8a'), 140.6 (CH=CH2), 
130.4 (C8'H), 129.0 (C7'H), 127.9 (Cq4a'), 126.3 (C6'H), 123.3 (C5'H), 119.7 (C3'H), 114.5 
(CH=CH2), 62.2 (C8H), 51.4 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.7 (C3H), 27.7 (C4H), 
26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (87), 276 (13), 252 (6), 235 (3), 211 (3), 183 (9), 169 (14), 157 
(90), 136 (100), 122 (14), 115 (4), 108 (46), 95 (18), 82 (70), 70 (23), 56 (20), 42 (21). 
HRMS (ESI+) calcd for C19H23N3Na [(M+Na)+] 316.1785, found 316.1784. 
 
9-Amino(9-deoxy)-epi-6'-isopropoxycinchonidine (71):[175] Amine 71 was prepared starting 
from 6'-isopropoxycinchonidine (146; 650 mg, 1.84 mmol) 
following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). Purification by flash column chro-
matography (silica gel, methanol/EtOAc 50:50 with 1% 
aq. NH4OH) gave the title compound (498 mg, 1.41 mmol, 77%) as 
pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ 8.71 (d, J = 4.4 Hz, 1H, CH2'), 8.01 (d, J = 9.1 Hz, 1H, CH8'), 
7.66 (br s, 1H, CH5'), 7.42 (br s, 1H, CH3'), 7.34 (dd, J = 9.3, 2.7 Hz, 1H, CH7'), 5.78 (ddd, J 
= 17.3, 9.9, 7.6 Hz, 1H, CH=CH2), 5.00-4.93 (m, 2H, CH=CH2), 4.72 (hept, J = 6.1 Hz, 1H, 
CHMe2), 4.55 (br s, 1H, CH9NH2), 3.26 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.22-3.15 (m, 1H, 
CHH6), 3.10-3.01 (m, 1H, CH8), 2.81-2.75 (m, 2H, CHH6 and CHH2), 2.28-2.24 (m, 1H, 
CH3), 1.89 (br s, 2H, NH2), 1.62-1.60 (m, 1H, CH4), 1.56-1.51 (m, 2H, CH25), 1.43-1.40 (m, 
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The phases were separated, the aqueous phase was concentrated in vacuo, and the residue was 
crystallized from methanol. The white precipitate was collected and dissolved in water. Then 
the aqueous phase was made alkaline by the addition of K2CO3, and repeatedly extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were dried (Na2SO4) and evaporated 
under reduced pressure affording the pure title compound (808 mg, 2.75 mmol, 46%; 
contaminated by 9-amino(9-deoxy)epidihydrocinchonine (~10%)) as colorless viscous oil. 
1H NMR (300 MHz, CDCl3) δ 8.87 (d, J = 4.5 Hz, 1H, CH2'), 8.33 (br d, J = 8.0 Hz, 1H, 
CH5'), 8.11 (dd, J = 8.5, 0.9 Hz, 1H, CH8'), 7.69 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H, CH7'), 7.59-
7.53 (m, 2H, CH3' and CH6'), 5.84 (ddd, J = 16.6, 11.1, 6.6 Hz, 1H, CH=CH2), 5.07-5.01 (m, 
2H, CH=CH2), 4.73 (br d, J = 9.8, 1H, CH9NH2), 3.07-2.87 (m, 5H, CH8, CH26and CH22), 
2.25 (app. br q, J = 8.4 Hz, 1H, CH3), 1.99 (br s, 2H, NH2), 1.57-1.48 (m, 3H, CH4 and CH25), 
1.09 (dd, J = 13.3, 8.8 Hz, 1H, CHH7), 0.97-0.88 (m, 1H, CHH7). 
13C NMR (75 MHz, CDCl3) δ 150.3 (C2'H), 149.0 (Cq4'), 148.6 (Cq8a'), 140.6 (CH=CH2), 
130.4 (C8'H), 129.0 (C7'H), 127.9 (Cq4a'), 126.3 (C6'H), 123.3 (C5'H), 119.7 (C3'H), 114.5 
(CH=CH2), 62.2 (C8H), 51.4 (C9HNH2), 49.5 (C6H2), 47.4 (C2H2), 39.7 (C3H), 27.7 (C4H), 
26.7 (C5H2), 25.0 (C7H2). 
MS (EI-DE) m/z (%) 293 [M+] (87), 276 (13), 252 (6), 235 (3), 211 (3), 183 (9), 169 (14), 157 
(90), 136 (100), 122 (14), 115 (4), 108 (46), 95 (18), 82 (70), 70 (23), 56 (20), 42 (21). 
HRMS (ESI+) calcd for C19H23N3Na [(M+Na)+] 316.1785, found 316.1784. 
 
9-Amino(9-deoxy)-epi-6'-isopropoxycinchonidine (71):[175] Amine 71 was prepared starting 
from 6'-isopropoxycinchonidine (146; 650 mg, 1.84 mmol) 
following the same procedure described for the synthesis of 9-
amino(9-deoxy)epiquinine (13). Purification by flash column chro-
matography (silica gel, methanol/EtOAc 50:50 with 1% 
aq. NH4OH) gave the title compound (498 mg, 1.41 mmol, 77%) as 
pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ 8.71 (d, J = 4.4 Hz, 1H, CH2'), 8.01 (d, J = 9.1 Hz, 1H, CH8'), 
7.66 (br s, 1H, CH5'), 7.42 (br s, 1H, CH3'), 7.34 (dd, J = 9.3, 2.7 Hz, 1H, CH7'), 5.78 (ddd, J 
= 17.3, 9.9, 7.6 Hz, 1H, CH=CH2), 5.00-4.93 (m, 2H, CH=CH2), 4.72 (hept, J = 6.1 Hz, 1H, 
CHMe2), 4.55 (br s, 1H, CH9NH2), 3.26 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.22-3.15 (m, 1H, 
CHH6), 3.10-3.01 (m, 1H, CH8), 2.81-2.75 (m, 2H, CHH6 and CHH2), 2.28-2.24 (m, 1H, 
CH3), 1.89 (br s, 2H, NH2), 1.62-1.60 (m, 1H, CH4), 1.56-1.51 (m, 2H, CH25), 1.43-1.40 (m, 
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overlapped, 1H, CHH7), 1.42 (d overlapped, J = 6.3 Hz, 3H, CH(CH3)2), 1.41 (d overlapped, 
J = 6.3 Hz, 3H, CH(CH3)2), 0.78-0.73 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 155.8 (Cq6'Oi-Pr), 147.8 (C2'H), 146.8 (Cq4'), 144.5 (Cq8a'), 
141.6 (CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 122.1 (C7'H), 119.8 (C3'H), 114.4 (CH=CH2), 
104.7 (C5'H), 70.2 (OCHMe2), 61.9 (C8H), 56.2 (C2H2), 51.5 (C9HNH2), 40.9 (C6H2), 39.7 
(C3H), 28.0 (C5H2), 27.5 (C4H), 26.0 (C7H2), 22.1 (CH(CH3)2), 21.8 (CH(CH3)2). 
MS (EI-DE) m/z (%) 351 [M+] (3), 336 (1), 308 (2), 291 (1), 215 (12), 173 (12), 146 (7), 136 
(100), 108 (7), 95 (4), 81 (10), 56 (4), 43 (14). 
HRMS (EI-DE) calcd for C22H29N3O [M+] 351.2312, found 351.2311. 
 
9-Amino(9-deoxy)quinine (9-NH2-Q; 73):[175] Amine 73 was prepared starting from 9-
epiquinine (147; 1.24 g, 3.82 mmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). 
Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title 
compound as yellowish viscous oil (861 mg, 2.66 mmol, 70%). The 
analytical data were identical in all respects to those previously reported.[49b] 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.7 Hz, 1H, CH2'), 7.98 (d, J = 9.1 Hz, 1H, CH8'), 
7.40 (d, J = 2.5 Hz, 1H, CH5'), 7.34 (d overlapped, J = 4.7 Hz, 1H, CH3'), 7.32 (dd overlapped, 
J = 9.1, 2.5 Hz, 1H, CH7'), 5.90 (ddd, J = 17.3, 10.2, 7.3 Hz, 1H, CH=CH2), 5.05-5.00 (m, 2H, 
CH=CH2), 4.60 (d, J = 9.5, 1H, CH9NH2), 3.93 (s, 3H, OCH3), 3.18 (app. q, J = 8.6 Hz, 1H, 
CH8), 3.01 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 2.99-2.91 (m, 1H, CHH6), 2.62 (ddd, J = 13.8, 
4.2, 2.4 Hz, 1H, CHH2), 2.53 (ddd, J = 14.2, 10.6, 4.1 Hz, 1H, CHH6), 2.28-2.23 (m, 1H, 
CH3), 2.15-2.08 (m, 1H, CHH7), 2.00-1.77 (br s, 2H, NH2), 1.89-1.85 (m, 1H, CH4), 1.69-
1.60 (m, 1H, CHH5), 1.54-1.46 (m, 2H, CHH5 and CHH7). 
13C NMR (125 MHz, CDCl3) δ 157.6 (Cq6'OMe), 149.2 (Cq4'), 147.9 (C2'H), 144.8 (Cq8a'), 
141.9 (CH=CH2), 131.9 (C8'H), 127.6 (Cq4a'), 121.1 (C7'H), 118.3 (C3'H), 114.4 (CH=CH2), 
101.2 (C5'H), 60.6 (C8H), 56.2 (C2H2), 55.6 (OCH3), 53.8 (C9HNH2), 41.9 (C6H2), 39.7 (C3H), 
27.8 (C5H2), 27.7 (C4H), 26.5 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (2), 213 (1), 199 (1), 187 (15), 160 (3), 136 (100), 108 (7), 95 
(4), 81 (12), 70 (6), 56 (6), 42 (8). 
HRMS (ESI+) calcd for C20H25N3NaO [(M+Na)+] 346.1886, found 346.1890. 
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overlapped, 1H, CHH7), 1.42 (d overlapped, J = 6.3 Hz, 3H, CH(CH3)2), 1.41 (d overlapped, 
J = 6.3 Hz, 3H, CH(CH3)2), 0.78-0.73 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 155.8 (Cq6'Oi-Pr), 147.8 (C2'H), 146.8 (Cq4'), 144.5 (Cq8a'), 
141.6 (CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 122.1 (C7'H), 119.8 (C3'H), 114.4 (CH=CH2), 
104.7 (C5'H), 70.2 (OCHMe2), 61.9 (C8H), 56.2 (C2H2), 51.5 (C9HNH2), 40.9 (C6H2), 39.7 
(C3H), 28.0 (C5H2), 27.5 (C4H), 26.0 (C7H2), 22.1 (CH(CH3)2), 21.8 (CH(CH3)2). 
MS (EI-DE) m/z (%) 351 [M+] (3), 336 (1), 308 (2), 291 (1), 215 (12), 173 (12), 146 (7), 136 
(100), 108 (7), 95 (4), 81 (10), 56 (4), 43 (14). 
HRMS (EI-DE) calcd for C22H29N3O [M+] 351.2312, found 351.2311. 
 
9-Amino(9-deoxy)quinine (9-NH2-Q; 73):[175] Amine 73 was prepared starting from 9-
epiquinine (147; 1.24 g, 3.82 mmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). 
Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title 
compound as yellowish viscous oil (861 mg, 2.66 mmol, 70%). The 
analytical data were identical in all respects to those previously reported.[49b] 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.7 Hz, 1H, CH2'), 7.98 (d, J = 9.1 Hz, 1H, CH8'), 
7.40 (d, J = 2.5 Hz, 1H, CH5'), 7.34 (d overlapped, J = 4.7 Hz, 1H, CH3'), 7.32 (dd overlapped, 
J = 9.1, 2.5 Hz, 1H, CH7'), 5.90 (ddd, J = 17.3, 10.2, 7.3 Hz, 1H, CH=CH2), 5.05-5.00 (m, 2H, 
CH=CH2), 4.60 (d, J = 9.5, 1H, CH9NH2), 3.93 (s, 3H, OCH3), 3.18 (app. q, J = 8.6 Hz, 1H, 
CH8), 3.01 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 2.99-2.91 (m, 1H, CHH6), 2.62 (ddd, J = 13.8, 
4.2, 2.4 Hz, 1H, CHH2), 2.53 (ddd, J = 14.2, 10.6, 4.1 Hz, 1H, CHH6), 2.28-2.23 (m, 1H, 
CH3), 2.15-2.08 (m, 1H, CHH7), 2.00-1.77 (br s, 2H, NH2), 1.89-1.85 (m, 1H, CH4), 1.69-
1.60 (m, 1H, CHH5), 1.54-1.46 (m, 2H, CHH5 and CHH7). 
13C NMR (125 MHz, CDCl3) δ 157.6 (Cq6'OMe), 149.2 (Cq4'), 147.9 (C2'H), 144.8 (Cq8a'), 
141.9 (CH=CH2), 131.9 (C8'H), 127.6 (Cq4a'), 121.1 (C7'H), 118.3 (C3'H), 114.4 (CH=CH2), 
101.2 (C5'H), 60.6 (C8H), 56.2 (C2H2), 55.6 (OCH3), 53.8 (C9HNH2), 41.9 (C6H2), 39.7 (C3H), 
27.8 (C5H2), 27.7 (C4H), 26.5 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (2), 213 (1), 199 (1), 187 (15), 160 (3), 136 (100), 108 (7), 95 
(4), 81 (12), 70 (6), 56 (6), 42 (8). 
HRMS (ESI+) calcd for C20H25N3NaO [(M+Na)+] 346.1886, found 346.1890. 
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overlapped, 1H, CHH7), 1.42 (d overlapped, J = 6.3 Hz, 3H, CH(CH3)2), 1.41 (d overlapped, 
J = 6.3 Hz, 3H, CH(CH3)2), 0.78-0.73 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 155.8 (Cq6'Oi-Pr), 147.8 (C2'H), 146.8 (Cq4'), 144.5 (Cq8a'), 
141.6 (CH=CH2), 131.8 (C8'H), 128.7 (Cq4a'), 122.1 (C7'H), 119.8 (C3'H), 114.4 (CH=CH2), 
104.7 (C5'H), 70.2 (OCHMe2), 61.9 (C8H), 56.2 (C2H2), 51.5 (C9HNH2), 40.9 (C6H2), 39.7 
(C3H), 28.0 (C5H2), 27.5 (C4H), 26.0 (C7H2), 22.1 (CH(CH3)2), 21.8 (CH(CH3)2). 
MS (EI-DE) m/z (%) 351 [M+] (3), 336 (1), 308 (2), 291 (1), 215 (12), 173 (12), 146 (7), 136 
(100), 108 (7), 95 (4), 81 (10), 56 (4), 43 (14). 
HRMS (EI-DE) calcd for C22H29N3O [M+] 351.2312, found 351.2311. 
 
9-Amino(9-deoxy)quinine (9-NH2-Q; 73):[175] Amine 73 was prepared starting from 9-
epiquinine (147; 1.24 g, 3.82 mmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). 
Purification by flash column chromatography (silica gel, 
methanol/EtOAc 50:50 with 1% aq. NH4OH) gave the title 
compound as yellowish viscous oil (861 mg, 2.66 mmol, 70%). The 
analytical data were identical in all respects to those previously reported.[49b] 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.7 Hz, 1H, CH2'), 7.98 (d, J = 9.1 Hz, 1H, CH8'), 
7.40 (d, J = 2.5 Hz, 1H, CH5'), 7.34 (d overlapped, J = 4.7 Hz, 1H, CH3'), 7.32 (dd overlapped, 
J = 9.1, 2.5 Hz, 1H, CH7'), 5.90 (ddd, J = 17.3, 10.2, 7.3 Hz, 1H, CH=CH2), 5.05-5.00 (m, 2H, 
CH=CH2), 4.60 (d, J = 9.5, 1H, CH9NH2), 3.93 (s, 3H, OCH3), 3.18 (app. q, J = 8.6 Hz, 1H, 
CH8), 3.01 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 2.99-2.91 (m, 1H, CHH6), 2.62 (ddd, J = 13.8, 
4.2, 2.4 Hz, 1H, CHH2), 2.53 (ddd, J = 14.2, 10.6, 4.1 Hz, 1H, CHH6), 2.28-2.23 (m, 1H, 
CH3), 2.15-2.08 (m, 1H, CHH7), 2.00-1.77 (br s, 2H, NH2), 1.89-1.85 (m, 1H, CH4), 1.69-
1.60 (m, 1H, CHH5), 1.54-1.46 (m, 2H, CHH5 and CHH7). 
13C NMR (125 MHz, CDCl3) δ 157.6 (Cq6'OMe), 149.2 (Cq4'), 147.9 (C2'H), 144.8 (Cq8a'), 
141.9 (CH=CH2), 131.9 (C8'H), 127.6 (Cq4a'), 121.1 (C7'H), 118.3 (C3'H), 114.4 (CH=CH2), 
101.2 (C5'H), 60.6 (C8H), 56.2 (C2H2), 55.6 (OCH3), 53.8 (C9HNH2), 41.9 (C6H2), 39.7 (C3H), 
27.8 (C5H2), 27.7 (C4H), 26.5 (C7H2). 
MS (EI-DE) m/z (%) 323 [M+] (2), 213 (1), 199 (1), 187 (15), 160 (3), 136 (100), 108 (7), 95 
(4), 81 (12), 70 (6), 56 (6), 42 (8). 
HRMS (ESI+) calcd for C20H25N3NaO [(M+Na)+] 346.1886, found 346.1890. 
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7.6.2 Synthesis of 9-epiquinine (147) 
9-Epiquinine (147) was prepared according to the protocol of Hoffmann et al.[176] 
 
 
 
O-Tosyl quinine (149): Sodium hydride (207 mg, 8.62 mmol, 1.4 equiv; 60 wt% suspension 
in mineral oil) was added all at once to a solution of quinine (2.0 g, 
6.16 mmol) in THF (35 mL), and the resulting suspension was heated 
to 70 °C for 2 h. Then, the reaction mixture was cooled to 0 °C, and a 
solution of tosyl chloride (1.64 g, 8.62 mmol, 1.4 equiv) in THF (10 
mL) was added dropwise. Once the addition was complete, heating 
(70 °C) was continued for 10 h. The solvents were removed under 
reduced pressure, and the residue was extracted with Et2O and 1N aqueous HCl (1:1, 60 mL). 
The phases were separated, and the aqueous phase was repeatedly washed with Et2O (3×20 
mL). Then the aqueous phase was made alkaline (pH ~11) by the addition of 2N aqueous 
NaOH, and subsequently extracted with Et2O (3×60 mL). The combined organic phases were 
washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The crude product 
was filtered through a short plug of silica gel (eluent: 10% MeOH in Et2O) affording O-
tosylated quinine 149 as a white solid (1.73 g, 3.62 mmol, 59%). 
1H NMR (300 MHz, CDCl3) δ 8.49 (d, J = 4.5 Hz, 1H, CH2'), 7.85 (d, J = 9.0 Hz, 1H, CH8'), 
7.30-7.08 (m, 5H, CH3', CH5', CH7', and 2×CHtolyl), 6.75 (d, J = 7.5 Hz, 2H, CHtolyl), 6.07 (br 
s, 1H, CH9OTs), 5.80 (ddd, J = 17.5, 10.0, 7.3 Hz, 1H, CH=CH2), 5.01-4.94 (m, 2H, 
CH=CH2), 3.92 (s, 3H, OCH3), 3.38-3.20 (m, 1H), 3.15-3.01 (m, 1H), 2.97-2.88 (m, 1H), 
2.64-2.43 (m, 2H), 2.28-2.19 (m, 1H), 2.14 (s, 3H, C6H4CH3), 2.10-1.97 (m, 1H), 1.91-1.85 
(m, 1H), 1.78-1.60 (m, 2H), 1.57-1.45 (m, 1H). 
MS (EI-DE) m/z 478 [M+] (1), 323 (1), 306 (15), 251 (4), 225 (4), 172 (6), 136 (100), 81 (4), 
55 (2). 
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9-Epiquinine (147) : O-Tosyl quinine (149; 1.70 g, 3.55 mmol) and L-tartaric acid (533 mg, 
3.55 mmol) were dissolved in water (34 mL). The reaction mixture 
was heated to 100 °C for 12 h; then cooled to room temperature and 
neutralized with 1N aqueous NaOH. The aqueous phase was separated 
and repeatedly extracted with CH2Cl2. The combined organic phases 
were dried (Na2SO4), filtered, and concentrated. Purification of the 
crude product by flash column chromatography (silica gel, 
methanol/EtOAc 20:80 with 0.5% aq. NH4OH) gave 9-epiquinine (147; 1.15 g, 3.55 mmol, 
quant.) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.70 (d, J = 4.5 Hz, 1H, CH2'), 8.02 (d, J = 9.4 Hz, 1H, CH8'), 
7.64 (d, J = 2.6 Hz, 1H, CH5'), 7.39 (d, J = 4.9 Hz, 1H, CH3'), 7.36 (dd, J = 9.0, 2.9 Hz, 1H, 
CH7'), 5.73 (ddd, J = 17.1, 9.9, 7.1 Hz, 1H, CH=CH2), 5.02-4.92 (m, 3H, CH=CH2 and 
CH9OH), 3.93 (s, 3H, OCH3), 3.26 (dd, J = 13.8, 10.0 Hz, 1H, CHH2), 3.22-3.04 (m, 2H, 
CHH6 and CH8), 2.83-2.74 (m, 2H, CHH6 and CHH2), 2.36-2.27 (m, 1H, CH3), 1.74-1.69 (m, 
1H, CH4), 1.63-1.57 (m, 2H, CH25), 1.51-1.41 (m, 1H, CHH7), 0.96 (ddt, J = 13.6, 7.9, 1.8 Hz, 
1H, CHH7). 
MS (EI-DE) m/z (%) 324 [M+] (1), 189 (4), 160 (2), 136 (100), 117 (3), 95 (2), 81 (6), 67 (1), 
55 (3), 42 (4). 
HRMS (ESI+) calcd for C20H25N2O2 [(M+H)+] 325.1913, found 325.1911. 
 
7.6.3 Synthesis of 6'-isopropoxycinchonidine (146) 
6'-Isopropoxycinchonidine (146) was prepared through a synthetic route reported by 
Berkessel et al.[92d] 
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6'-Hydroxycinchonidine (148): Under vigorous stirring, BBr3 (2.93 mL, 30.8 mmol, 4.0 
equiv) in CH2Cl2 (30 mL) was slowly added to a solution of quinine 
(2.5 g, 7.71 mmol) in CH2Cl2 (250 mL) at –78 °C. The reaction 
mixture was allowed to warm to room temperature, and then 
refluxed for 2h. The reaction was quenched by the addition of 10% 
aqueous NaOH (130 mL) at 0 °C, and stirring was maintained for 1 h. 
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4.89 (dt, J = 10.4, 1.3 Hz, 1H, CH=CHHcis), 4.67 (sept, J = 6.1 Hz, 1H, OCHMe2), 3.94 (br s, 
1H, OH), 3.57-3.48 (m, 1H, CHH6), 3.16-3.06 (m, 2H, CHH2 and CH8), 2.71-2.64 (m, 2H, 
CHH2 and CHH6), 2.32-2.25 (m, 1H, CH3), 1.83-1.80 (m, 1H, CH4), 1.78-1.71 (m, 2H, CHH5 
and CHH7), 1.53-1.45 (m, 2H, CHH5 and CHH7), 1.33 (dd, J = 6.0 Hz, 6H, OCH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 155.9 (Cq6'Oi-Pr), 147.4 (C2'H), 147.0 (Cq4'), 143.9 (Cq8a'), 
141.4 (CH=CH2), 131.5 (C8'H), 126.5 (Cq4a'), 122.7 (C7'H), 118.4 (C3'H), 114.6 (CH=CH2), 
103.5 (C5'H), 71.6 (C9HOH), 70.1 (OCHMe2), 60.0 (C8H), 56.9 (C2H2), 43.3 (C6H2), 39.6 
(C3H), 27.7 (C4H), 27.3 (C5H2), 22.0 (OCH(CH3)2), 21.5 (OCH(CH3)2), 21.4 (C7H2). 
MS (EI-DE) m/z (%) 352 [M+] (2), 309 (4), 217 (2), 200 (1), 186 (1), 174 (4), 158 (2), 136 
(100), 117 (2), 95 (3), 81 (7), 67 (2), 55 (4), 43 (10). 
HRMS (EI-DE) calcd for C22H28N2O2 [M+] 352.2154, found 352.2151. 
 
7.6.4 Synthesis of 9-amino(9-deoxy)epi-6'-hydroxycinchonidine (68) 
A literature-known procedure by the Chen group was followed.[161] 
 
BBr3 (23 mL, 23.0 mmol, 1.0M in CH2Cl2, 4.6 equiv) was added to a solution of amine 13 
(1.62 g, 5.01 mmol) in CH2Cl2 (15 mL) at –78 °C. The mixture was slowly warmed to room 
temperature and stirred for 12 h. The reaction was quenched by the addition of water (50 mL) 
at 0 °C, and further stirred for 4 h to ensure complete hydrolysis. The phases were separated, 
and the aqueous phase was washed with CH2Cl2 (3×50 mL). Subsequently the aqueous phase 
was neutralized with excess aqueous ammonia at 0 °C, and repeatedly extracted with EtOAc 
(3×50 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated. 
The residue was purified by flash column chromatography (silica gel, methanol/EtOAc 50:50 
with 1% aq. NH4OH) affording the title compound as a yellow solid (936 mg, 3.03 mmol, 
60%). The analytical data were identical in all respects to those previously reported.[161] 
1H NMR (500 MHz, CDCl3) δ 8.65 (d, J = 4.4 Hz, 1H, CH2'), 7.93 (d, J = 9.2 Hz, 1H, CH8'), 
7.60 (br s, 1H, CH5'), 7.34 (br s, 1H, CH3'), 7.27 (dd, J = 8.9, 2.2 Hz, 1H, CH7'), 5.75 (ddd, J 
= 17.3, 9.6, 7.4 Hz, 1H, CH=CH2), 4.98-4.93 (m, 2H, CH=CH2), 4.90-4.63 (br s, 2H, NH2), 
4.48 (br s, 1H, CH9NH2), 3.20 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.14-3.06 (m, 1H, CH8), 
3.05-2.97 (m, 1H, CHH6), 2.78-2.65 (m, 2H, CHH6 and CHH2), 2.26-2.20 (m, 1H, CH3), 
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103.5 (C5'H), 71.6 (C9HOH), 70.1 (OCHMe2), 60.0 (C8H), 56.9 (C2H2), 43.3 (C6H2), 39.6 
(C3H), 27.7 (C4H), 27.3 (C5H2), 22.0 (OCH(CH3)2), 21.5 (OCH(CH3)2), 21.4 (C7H2). 
MS (EI-DE) m/z (%) 352 [M+] (2), 309 (4), 217 (2), 200 (1), 186 (1), 174 (4), 158 (2), 136 
(100), 117 (2), 95 (3), 81 (7), 67 (2), 55 (4), 43 (10). 
HRMS (EI-DE) calcd for C22H28N2O2 [M+] 352.2154, found 352.2151. 
 
7.6.4 Synthesis of 9-amino(9-deoxy)epi-6'-hydroxycinchonidine (68) 
A literature-known procedure by the Chen group was followed.[161] 
 
BBr3 (23 mL, 23.0 mmol, 1.0M in CH2Cl2, 4.6 equiv) was added to a solution of amine 13 
(1.62 g, 5.01 mmol) in CH2Cl2 (15 mL) at –78 °C. The mixture was slowly warmed to room 
temperature and stirred for 12 h. The reaction was quenched by the addition of water (50 mL) 
at 0 °C, and further stirred for 4 h to ensure complete hydrolysis. The phases were separated, 
and the aqueous phase was washed with CH2Cl2 (3×50 mL). Subsequently the aqueous phase 
was neutralized with excess aqueous ammonia at 0 °C, and repeatedly extracted with EtOAc 
(3×50 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated. 
The residue was purified by flash column chromatography (silica gel, methanol/EtOAc 50:50 
with 1% aq. NH4OH) affording the title compound as a yellow solid (936 mg, 3.03 mmol, 
60%). The analytical data were identical in all respects to those previously reported.[161] 
1H NMR (500 MHz, CDCl3) δ 8.65 (d, J = 4.4 Hz, 1H, CH2'), 7.93 (d, J = 9.2 Hz, 1H, CH8'), 
7.60 (br s, 1H, CH5'), 7.34 (br s, 1H, CH3'), 7.27 (dd, J = 8.9, 2.2 Hz, 1H, CH7'), 5.75 (ddd, J 
= 17.3, 9.6, 7.4 Hz, 1H, CH=CH2), 4.98-4.93 (m, 2H, CH=CH2), 4.90-4.63 (br s, 2H, NH2), 
4.48 (br s, 1H, CH9NH2), 3.20 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.14-3.06 (m, 1H, CH8), 
3.05-2.97 (m, 1H, CHH6), 2.78-2.65 (m, 2H, CHH6 and CHH2), 2.26-2.20 (m, 1H, CH3), 
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4.89 (dt, J = 10.4, 1.3 Hz, 1H, CH=CHHcis), 4.67 (sept, J = 6.1 Hz, 1H, OCHMe2), 3.94 (br s, 
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CHH2 and CHH6), 2.32-2.25 (m, 1H, CH3), 1.83-1.80 (m, 1H, CH4), 1.78-1.71 (m, 2H, CHH5 
and CHH7), 1.53-1.45 (m, 2H, CHH5 and CHH7), 1.33 (dd, J = 6.0 Hz, 6H, OCH(CH3)2). 
13C NMR (125 MHz, CDCl3) δ 155.9 (Cq6'Oi-Pr), 147.4 (C2'H), 147.0 (Cq4'), 143.9 (Cq8a'), 
141.4 (CH=CH2), 131.5 (C8'H), 126.5 (Cq4a'), 122.7 (C7'H), 118.4 (C3'H), 114.6 (CH=CH2), 
103.5 (C5'H), 71.6 (C9HOH), 70.1 (OCHMe2), 60.0 (C8H), 56.9 (C2H2), 43.3 (C6H2), 39.6 
(C3H), 27.7 (C4H), 27.3 (C5H2), 22.0 (OCH(CH3)2), 21.5 (OCH(CH3)2), 21.4 (C7H2). 
MS (EI-DE) m/z (%) 352 [M+] (2), 309 (4), 217 (2), 200 (1), 186 (1), 174 (4), 158 (2), 136 
(100), 117 (2), 95 (3), 81 (7), 67 (2), 55 (4), 43 (10). 
HRMS (EI-DE) calcd for C22H28N2O2 [M+] 352.2154, found 352.2151. 
 
7.6.4 Synthesis of 9-amino(9-deoxy)epi-6'-hydroxycinchonidine (68) 
A literature-known procedure by the Chen group was followed.[161] 
 
BBr3 (23 mL, 23.0 mmol, 1.0M in CH2Cl2, 4.6 equiv) was added to a solution of amine 13 
(1.62 g, 5.01 mmol) in CH2Cl2 (15 mL) at –78 °C. The mixture was slowly warmed to room 
temperature and stirred for 12 h. The reaction was quenched by the addition of water (50 mL) 
at 0 °C, and further stirred for 4 h to ensure complete hydrolysis. The phases were separated, 
and the aqueous phase was washed with CH2Cl2 (3×50 mL). Subsequently the aqueous phase 
was neutralized with excess aqueous ammonia at 0 °C, and repeatedly extracted with EtOAc 
(3×50 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated. 
The residue was purified by flash column chromatography (silica gel, methanol/EtOAc 50:50 
with 1% aq. NH4OH) affording the title compound as a yellow solid (936 mg, 3.03 mmol, 
60%). The analytical data were identical in all respects to those previously reported.[161] 
1H NMR (500 MHz, CDCl3) δ 8.65 (d, J = 4.4 Hz, 1H, CH2'), 7.93 (d, J = 9.2 Hz, 1H, CH8'), 
7.60 (br s, 1H, CH5'), 7.34 (br s, 1H, CH3'), 7.27 (dd, J = 8.9, 2.2 Hz, 1H, CH7'), 5.75 (ddd, J 
= 17.3, 9.6, 7.4 Hz, 1H, CH=CH2), 4.98-4.93 (m, 2H, CH=CH2), 4.90-4.63 (br s, 2H, NH2), 
4.48 (br s, 1H, CH9NH2), 3.20 (dd, J = 13.9, 10.1 Hz, 1H, CHH2), 3.14-3.06 (m, 1H, CH8), 
3.05-2.97 (m, 1H, CHH6), 2.78-2.65 (m, 2H, CHH6 and CHH2), 2.26-2.20 (m, 1H, CH3), 
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1.57-1.53 (m, 1H, CH4), 1.49-1.40 (m, 2H, CHH5 and CHH7), 1.37-1.29 (m, 1H, CHH5), 
0.72-0.63 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 156.6 (Cq6'OH), 146.5 (C2'H), 146.4 (Cq4'), 143.4 (Cq8a'), 
141.4 (CH=CH2), 131.1 (C8'H), 129.2 (Cq4a'), 122.7 (C7'H), 118.9 (C3'H), 114.7 (CH=CH2), 
105.1 (C5'H), 61.7 (C8H), 56.0 (C2H2), 50.7 (C9HNH2), 40.8 (C6H2), 39.6 (C3H), 27.7 (C5H2), 
27.4 (C4H), 26.1 (C7H2). 
MS (ESI+) m/z (%) 309 [M+] (trace), 294 (2), 225 (1), 212 (1), 199 (1), 185 (1), 173 (14), 159 
(1), 136 (100), 122 (3), 108 (9), 95 (5), 82 (11), 56 (6), 44 (10). 
HRMS (ESI+) calcd for C19H24N3O [(M+H)+] 310.1914, found 310.1914. 
 
7.6.5 Synthesis of 2-(α-aminobenzyl)quinuclidine (86a) 
2-(α-Hydroxybenzyl)quinuclidine (150) was prepared according to a procedure of Kessar et 
al.[177a] 
 
 
 
2-(α-Hydroxybenzyl)quinuclidine (150):[177a] Quinuclidine (1.11 g, 10.0 mmol, 1.0 equiv) 
was dissolved in THF (60 mL) and treated with BF3 • Et2O (1.38 mL, 11.0 
mmol, 1.1 equiv) at 0 °C for 40 min. In the meantime, s-BuLi (15.7 mL, 
22.0 mmol, 2.2 equiv; 1.4 M in cyclohexane) was added to a solution of 
potassium tert-butoxide (2.47 g, 22.0 mmol, 2.2 equiv) in THF (60 mL) at 
−78 °C, and the resulting solution was stirred for 30 min. Then, the solution of the 
quinuclidine−BF3 complex was added slowly to the flask containing the Schlosser base 
solution. After stirring for 4 h at −78 °C, freshly distilled benzaldehyde (2.22 mL, 22.0 mmol) 
dissolved in THF (20 mL) was added dropwise. The temperature was maintained at −78 °C 
for 30 min and then allowed to rise to −30 °C over a period of 1 h. The reaction was quenched 
with 10% aqueous HCl (50 mL) and repeatedly extracted with 10% aqueous HCl (2 × 40 mL). 
The phases were separated. The aqueous phase was made alkaline with excess aqueous 
NH4OH solution, and was then repeatedly extracted with Et2O (3 × 100 mL) and EtOAc (3 × 
100 mL). The combined Et2O/EtOAc layers were washed with brine (60 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude product contained mainly the 
N
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C14H19NO
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1.57-1.53 (m, 1H, CH4), 1.49-1.40 (m, 2H, CHH5 and CHH7), 1.37-1.29 (m, 1H, CHH5), 
0.72-0.63 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 156.6 (Cq6'OH), 146.5 (C2'H), 146.4 (Cq4'), 143.4 (Cq8a'), 
141.4 (CH=CH2), 131.1 (C8'H), 129.2 (Cq4a'), 122.7 (C7'H), 118.9 (C3'H), 114.7 (CH=CH2), 
105.1 (C5'H), 61.7 (C8H), 56.0 (C2H2), 50.7 (C9HNH2), 40.8 (C6H2), 39.6 (C3H), 27.7 (C5H2), 
27.4 (C4H), 26.1 (C7H2). 
MS (ESI+) m/z (%) 309 [M+] (trace), 294 (2), 225 (1), 212 (1), 199 (1), 185 (1), 173 (14), 159 
(1), 136 (100), 122 (3), 108 (9), 95 (5), 82 (11), 56 (6), 44 (10). 
HRMS (ESI+) calcd for C19H24N3O [(M+H)+] 310.1914, found 310.1914. 
 
7.6.5 Synthesis of 2-(α-aminobenzyl)quinuclidine (86a) 
2-(α-Hydroxybenzyl)quinuclidine (150) was prepared according to a procedure of Kessar et 
al.[177a] 
 
 
 
2-(α-Hydroxybenzyl)quinuclidine (150):[177a] Quinuclidine (1.11 g, 10.0 mmol, 1.0 equiv) 
was dissolved in THF (60 mL) and treated with BF3 • Et2O (1.38 mL, 11.0 
mmol, 1.1 equiv) at 0 °C for 40 min. In the meantime, s-BuLi (15.7 mL, 
22.0 mmol, 2.2 equiv; 1.4 M in cyclohexane) was added to a solution of 
potassium tert-butoxide (2.47 g, 22.0 mmol, 2.2 equiv) in THF (60 mL) at 
−78 °C, and the resulting solution was stirred for 30 min. Then, the solution of the 
quinuclidine−BF3 complex was added slowly to the flask containing the Schlosser base 
solution. After stirring for 4 h at −78 °C, freshly distilled benzaldehyde (2.22 mL, 22.0 mmol) 
dissolved in THF (20 mL) was added dropwise. The temperature was maintained at −78 °C 
for 30 min and then allowed to rise to −30 °C over a period of 1 h. The reaction was quenched 
with 10% aqueous HCl (50 mL) and repeatedly extracted with 10% aqueous HCl (2 × 40 mL). 
The phases were separated. The aqueous phase was made alkaline with excess aqueous 
NH4OH solution, and was then repeatedly extracted with Et2O (3 × 100 mL) and EtOAc (3 × 
100 mL). The combined Et2O/EtOAc layers were washed with brine (60 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude product contained mainly the 
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1.57-1.53 (m, 1H, CH4), 1.49-1.40 (m, 2H, CHH5 and CHH7), 1.37-1.29 (m, 1H, CHH5), 
0.72-0.63 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 156.6 (Cq6'OH), 146.5 (C2'H), 146.4 (Cq4'), 143.4 (Cq8a'), 
141.4 (CH=CH2), 131.1 (C8'H), 129.2 (Cq4a'), 122.7 (C7'H), 118.9 (C3'H), 114.7 (CH=CH2), 
105.1 (C5'H), 61.7 (C8H), 56.0 (C2H2), 50.7 (C9HNH2), 40.8 (C6H2), 39.6 (C3H), 27.7 (C5H2), 
27.4 (C4H), 26.1 (C7H2). 
MS (ESI+) m/z (%) 309 [M+] (trace), 294 (2), 225 (1), 212 (1), 199 (1), 185 (1), 173 (14), 159 
(1), 136 (100), 122 (3), 108 (9), 95 (5), 82 (11), 56 (6), 44 (10). 
HRMS (ESI+) calcd for C19H24N3O [(M+H)+] 310.1914, found 310.1914. 
 
7.6.5 Synthesis of 2-(α-aminobenzyl)quinuclidine (86a) 
2-(α-Hydroxybenzyl)quinuclidine (150) was prepared according to a procedure of Kessar et 
al.[177a] 
 
 
 
2-(α-Hydroxybenzyl)quinuclidine (150):[177a] Quinuclidine (1.11 g, 10.0 mmol, 1.0 equiv) 
was dissolved in THF (60 mL) and treated with BF3 • Et2O (1.38 mL, 11.0 
mmol, 1.1 equiv) at 0 °C for 40 min. In the meantime, s-BuLi (15.7 mL, 
22.0 mmol, 2.2 equiv; 1.4 M in cyclohexane) was added to a solution of 
potassium tert-butoxide (2.47 g, 22.0 mmol, 2.2 equiv) in THF (60 mL) at 
−78 °C, and the resulting solution was stirred for 30 min. Then, the solution of the 
quinuclidine−BF3 complex was added slowly to the flask containing the Schlosser base 
solution. After stirring for 4 h at −78 °C, freshly distilled benzaldehyde (2.22 mL, 22.0 mmol) 
dissolved in THF (20 mL) was added dropwise. The temperature was maintained at −78 °C 
for 30 min and then allowed to rise to −30 °C over a period of 1 h. The reaction was quenched 
with 10% aqueous HCl (50 mL) and repeatedly extracted with 10% aqueous HCl (2 × 40 mL). 
The phases were separated. The aqueous phase was made alkaline with excess aqueous 
NH4OH solution, and was then repeatedly extracted with Et2O (3 × 100 mL) and EtOAc (3 × 
100 mL). The combined Et2O/EtOAc layers were washed with brine (60 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude product contained mainly the 
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1.57-1.53 (m, 1H, CH4), 1.49-1.40 (m, 2H, CHH5 and CHH7), 1.37-1.29 (m, 1H, CHH5), 
0.72-0.63 (m, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 156.6 (Cq6'OH), 146.5 (C2'H), 146.4 (Cq4'), 143.4 (Cq8a'), 
141.4 (CH=CH2), 131.1 (C8'H), 129.2 (Cq4a'), 122.7 (C7'H), 118.9 (C3'H), 114.7 (CH=CH2), 
105.1 (C5'H), 61.7 (C8H), 56.0 (C2H2), 50.7 (C9HNH2), 40.8 (C6H2), 39.6 (C3H), 27.7 (C5H2), 
27.4 (C4H), 26.1 (C7H2). 
MS (ESI+) m/z (%) 309 [M+] (trace), 294 (2), 225 (1), 212 (1), 199 (1), 185 (1), 173 (14), 159 
(1), 136 (100), 122 (3), 108 (9), 95 (5), 82 (11), 56 (6), 44 (10). 
HRMS (ESI+) calcd for C19H24N3O [(M+H)+] 310.1914, found 310.1914. 
 
7.6.5 Synthesis of 2-(α-aminobenzyl)quinuclidine (86a) 
2-(α-Hydroxybenzyl)quinuclidine (150) was prepared according to a procedure of Kessar et 
al.[177a] 
 
 
 
2-(α-Hydroxybenzyl)quinuclidine (150):[177a] Quinuclidine (1.11 g, 10.0 mmol, 1.0 equiv) 
was dissolved in THF (60 mL) and treated with BF3 • Et2O (1.38 mL, 11.0 
mmol, 1.1 equiv) at 0 °C for 40 min. In the meantime, s-BuLi (15.7 mL, 
22.0 mmol, 2.2 equiv; 1.4 M in cyclohexane) was added to a solution of 
potassium tert-butoxide (2.47 g, 22.0 mmol, 2.2 equiv) in THF (60 mL) at 
−78 °C, and the resulting solution was stirred for 30 min. Then, the solution of the 
quinuclidine−BF3 complex was added slowly to the flask containing the Schlosser base 
solution. After stirring for 4 h at −78 °C, freshly distilled benzaldehyde (2.22 mL, 22.0 mmol) 
dissolved in THF (20 mL) was added dropwise. The temperature was maintained at −78 °C 
for 30 min and then allowed to rise to −30 °C over a period of 1 h. The reaction was quenched 
with 10% aqueous HCl (50 mL) and repeatedly extracted with 10% aqueous HCl (2 × 40 mL). 
The phases were separated. The aqueous phase was made alkaline with excess aqueous 
NH4OH solution, and was then repeatedly extracted with Et2O (3 × 100 mL) and EtOAc (3 × 
100 mL). The combined Et2O/EtOAc layers were washed with brine (60 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude product contained mainly the 
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threo isomer of 150 (669 mg, 3.08 mmol, 31%) which was purified by flash column 
chromatography (silica gel, 15-25% methanol in EtOAc with 1% aq. NH4OH). Afterwards, 
the original reaction mixture was extracted again with 10% aqueous HCl (2 × 50 mL). The 
phases were separated and the aqueous phase was made alkaline with excess aqueous NH4OH 
solution. Backextraction of the aqueous phase II with EtOAc (3 × 100 mL) gave - after 
washing of the combined EtOAc layers with brine (60 mL), drying (Na2SO4), filtering, and 
evaporating - a crude product which contained predominantly the erythro isomer of 150. 
Purification by flash column chromatography (silica gel, 15-25% methanol in EtOAc with 1% 
aq. NH4OH) and subsequent recrystallization from Et2O gave pure erythro-150 (555 mg, 2.55 
mmol, 26%) as a white solid. The physical data were identical in all respects to those 
previously reported.[197] 
threo-150: 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.3 Hz, 2H, CHPh, o), 
7.32 (t, J = 7.3 Hz, 2H, CHPh, m), 7.28-7.25 (m, 1H, CHPh, p), 4.36 (d, J = 
9.8 Hz, 1H, CH9OH), 3.10-3.04 (m, 1H, CHH), 2.95 (app. t, J = 7.7 Hz, 
2H, CH2), 2.80-2.73 (m, 2H, CHH and CH8), 1.97 (br s, 1H, OH), 1.78-
1.74 (m, 1H, CH4), 1.53-1.42 (m, 4H, CH23 and CH25), 1.34-1.28 (m, 1H, CHH7), 1.11 (ddt, J 
= 13.1, 8,4, 1.9 Hz, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 141.1 (CqPh), 128.3 (2C, CHPh, m), 127.8 (CHPh, p), 127.3 (2C, 
CHPh, o), 74.4 (C9HOH), 62.8 (C8H), 49.5 (CH2), 41.4 (CH2), 29.2 (C7H2), 26.6 (CH2), 25.6 
(CH2), 21.5 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (51), 200 (25), 188 (13), 176 (15), 158 (7), 140 (5), 120 (4), 
110 (69), 105 (11), 98 (23), 91 (17), 82 (100), 77 (27), 68 (9), 55 (89), 42 (34), 29 (23). 
HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
erythro-150: 1H NMR (500 MHz, CDCl3) δ 7.35-7.30 (m, 4H, CHPh), 
7.27-7.22 (m, 1H, CHPh, p), 4.85 (d, J = 6.3 Hz, 1H, CH9OH), 3.45 (br s, 
1H, OH), 3.29-3.22 (m, 1H, CHH2), 3.02 (dd, J = 16.4, 8.8 Hz, 1H, CH8), 
2.90-2.76 (m, 2H, CH26), 2.69-2.63 (m, 1H, CHH2), 1.87-1.84 (m, 1H, 
CH4), 1.71-1.66 (m, 1H, CHH7), 1.65-1.59 (m, 1H, CHH7), 1.55-1.43 (m, 4H, CH23 and 
CH25). 
13C NMR (125 MHz, CD2Cl2) δ 143.8 (CqPh), 128.2 (2C, CHPh), 127.4 (CHPh, p), 126.4 (2C, 
CHPh), 76.0 (C9HOH), 61.4 (C8H), 50.3 (C6H2), 43.3 (C2H2), 28.0 (C7H2), 26.4 (CH2), 25.5 
(CH2), 21.9 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (44), 200 (30), 188 (13), 176 (18), 158 (18), 140 (5), 120 (5), 
110 (95), 98 (25), 91 (19), 82 (93), 77 (30), 68 (9), 55 (100), 42 (36), 29 (26). 
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threo isomer of 150 (669 mg, 3.08 mmol, 31%) which was purified by flash column 
chromatography (silica gel, 15-25% methanol in EtOAc with 1% aq. NH4OH). Afterwards, 
the original reaction mixture was extracted again with 10% aqueous HCl (2 × 50 mL). The 
phases were separated and the aqueous phase was made alkaline with excess aqueous NH4OH 
solution. Backextraction of the aqueous phase II with EtOAc (3 × 100 mL) gave - after 
washing of the combined EtOAc layers with brine (60 mL), drying (Na2SO4), filtering, and 
evaporating - a crude product which contained predominantly the erythro isomer of 150. 
Purification by flash column chromatography (silica gel, 15-25% methanol in EtOAc with 1% 
aq. NH4OH) and subsequent recrystallization from Et2O gave pure erythro-150 (555 mg, 2.55 
mmol, 26%) as a white solid. The physical data were identical in all respects to those 
previously reported.[197] 
threo-150: 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.3 Hz, 2H, CHPh, o), 
7.32 (t, J = 7.3 Hz, 2H, CHPh, m), 7.28-7.25 (m, 1H, CHPh, p), 4.36 (d, J = 
9.8 Hz, 1H, CH9OH), 3.10-3.04 (m, 1H, CHH), 2.95 (app. t, J = 7.7 Hz, 
2H, CH2), 2.80-2.73 (m, 2H, CHH and CH8), 1.97 (br s, 1H, OH), 1.78-
1.74 (m, 1H, CH4), 1.53-1.42 (m, 4H, CH23 and CH25), 1.34-1.28 (m, 1H, CHH7), 1.11 (ddt, J 
= 13.1, 8,4, 1.9 Hz, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 141.1 (CqPh), 128.3 (2C, CHPh, m), 127.8 (CHPh, p), 127.3 (2C, 
CHPh, o), 74.4 (C9HOH), 62.8 (C8H), 49.5 (CH2), 41.4 (CH2), 29.2 (C7H2), 26.6 (CH2), 25.6 
(CH2), 21.5 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (51), 200 (25), 188 (13), 176 (15), 158 (7), 140 (5), 120 (4), 
110 (69), 105 (11), 98 (23), 91 (17), 82 (100), 77 (27), 68 (9), 55 (89), 42 (34), 29 (23). 
HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
erythro-150: 1H NMR (500 MHz, CDCl3) δ 7.35-7.30 (m, 4H, CHPh), 
7.27-7.22 (m, 1H, CHPh, p), 4.85 (d, J = 6.3 Hz, 1H, CH9OH), 3.45 (br s, 
1H, OH), 3.29-3.22 (m, 1H, CHH2), 3.02 (dd, J = 16.4, 8.8 Hz, 1H, CH8), 
2.90-2.76 (m, 2H, CH26), 2.69-2.63 (m, 1H, CHH2), 1.87-1.84 (m, 1H, 
CH4), 1.71-1.66 (m, 1H, CHH7), 1.65-1.59 (m, 1H, CHH7), 1.55-1.43 (m, 4H, CH23 and 
CH25). 
13C NMR (125 MHz, CD2Cl2) δ 143.8 (CqPh), 128.2 (2C, CHPh), 127.4 (CHPh, p), 126.4 (2C, 
CHPh), 76.0 (C9HOH), 61.4 (C8H), 50.3 (C6H2), 43.3 (C2H2), 28.0 (C7H2), 26.4 (CH2), 25.5 
(CH2), 21.9 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (44), 200 (30), 188 (13), 176 (18), 158 (18), 140 (5), 120 (5), 
110 (95), 98 (25), 91 (19), 82 (93), 77 (30), 68 (9), 55 (100), 42 (36), 29 (26). 
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threo isomer of 150 (669 mg, 3.08 mmol, 31%) which was purified by flash column 
chromatography (silica gel, 15-25% methanol in EtOAc with 1% aq. NH4OH). Afterwards, 
the original reaction mixture was extracted again with 10% aqueous HCl (2 × 50 mL). The 
phases were separated and the aqueous phase was made alkaline with excess aqueous NH4OH 
solution. Backextraction of the aqueous phase II with EtOAc (3 × 100 mL) gave - after 
washing of the combined EtOAc layers with brine (60 mL), drying (Na2SO4), filtering, and 
evaporating - a crude product which contained predominantly the erythro isomer of 150. 
Purification by flash column chromatography (silica gel, 15-25% methanol in EtOAc with 1% 
aq. NH4OH) and subsequent recrystallization from Et2O gave pure erythro-150 (555 mg, 2.55 
mmol, 26%) as a white solid. The physical data were identical in all respects to those 
previously reported.[197] 
threo-150: 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.3 Hz, 2H, CHPh, o), 
7.32 (t, J = 7.3 Hz, 2H, CHPh, m), 7.28-7.25 (m, 1H, CHPh, p), 4.36 (d, J = 
9.8 Hz, 1H, CH9OH), 3.10-3.04 (m, 1H, CHH), 2.95 (app. t, J = 7.7 Hz, 
2H, CH2), 2.80-2.73 (m, 2H, CHH and CH8), 1.97 (br s, 1H, OH), 1.78-
1.74 (m, 1H, CH4), 1.53-1.42 (m, 4H, CH23 and CH25), 1.34-1.28 (m, 1H, CHH7), 1.11 (ddt, J 
= 13.1, 8,4, 1.9 Hz, 1H, CHH7). 
13C NMR (125 MHz, CDCl3) δ 141.1 (CqPh), 128.3 (2C, CHPh, m), 127.8 (CHPh, p), 127.3 (2C, 
CHPh, o), 74.4 (C9HOH), 62.8 (C8H), 49.5 (CH2), 41.4 (CH2), 29.2 (C7H2), 26.6 (CH2), 25.6 
(CH2), 21.5 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (51), 200 (25), 188 (13), 176 (15), 158 (7), 140 (5), 120 (4), 
110 (69), 105 (11), 98 (23), 91 (17), 82 (100), 77 (27), 68 (9), 55 (89), 42 (34), 29 (23). 
HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
erythro-150: 1H NMR (500 MHz, CDCl3) δ 7.35-7.30 (m, 4H, CHPh), 
7.27-7.22 (m, 1H, CHPh, p), 4.85 (d, J = 6.3 Hz, 1H, CH9OH), 3.45 (br s, 
1H, OH), 3.29-3.22 (m, 1H, CHH2), 3.02 (dd, J = 16.4, 8.8 Hz, 1H, CH8), 
2.90-2.76 (m, 2H, CH26), 2.69-2.63 (m, 1H, CHH2), 1.87-1.84 (m, 1H, 
CH4), 1.71-1.66 (m, 1H, CHH7), 1.65-1.59 (m, 1H, CHH7), 1.55-1.43 (m, 4H, CH23 and 
CH25). 
13C NMR (125 MHz, CD2Cl2) δ 143.8 (CqPh), 128.2 (2C, CHPh), 127.4 (CHPh, p), 126.4 (2C, 
CHPh), 76.0 (C9HOH), 61.4 (C8H), 50.3 (C6H2), 43.3 (C2H2), 28.0 (C7H2), 26.4 (CH2), 25.5 
(CH2), 21.9 (C4H). 
MS (EI-DE) m/z (%) 217 [M+] (44), 200 (30), 188 (13), 176 (18), 158 (18), 140 (5), 120 (5), 
110 (95), 98 (25), 91 (19), 82 (93), 77 (30), 68 (9), 55 (100), 42 (36), 29 (26). 
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threo isomer of 150 (669 mg, 3.08 mmol, 31%) which was purified by flash column 
chromatography (silica gel, 15-25% methanol in EtOAc with 1% aq. NH4OH). Afterwards, 
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washing of the combined EtOAc layers with brine (60 mL), drying (Na2SO4), filtering, and 
evaporating - a crude product which contained predominantly the erythro isomer of 150. 
Purification by flash column chromatography (silica gel, 15-25% methanol in EtOAc with 1% 
aq. NH4OH) and subsequent recrystallization from Et2O gave pure erythro-150 (555 mg, 2.55 
mmol, 26%) as a white solid. The physical data were identical in all respects to those 
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110 (69), 105 (11), 98 (23), 91 (17), 82 (100), 77 (27), 68 (9), 55 (89), 42 (34), 29 (23). 
HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
erythro-150: 1H NMR (500 MHz, CDCl3) δ 7.35-7.30 (m, 4H, CHPh), 
7.27-7.22 (m, 1H, CHPh, p), 4.85 (d, J = 6.3 Hz, 1H, CH9OH), 3.45 (br s, 
1H, OH), 3.29-3.22 (m, 1H, CHH2), 3.02 (dd, J = 16.4, 8.8 Hz, 1H, CH8), 
2.90-2.76 (m, 2H, CH26), 2.69-2.63 (m, 1H, CHH2), 1.87-1.84 (m, 1H, 
CH4), 1.71-1.66 (m, 1H, CHH7), 1.65-1.59 (m, 1H, CHH7), 1.55-1.43 (m, 4H, CH23 and 
CH25). 
13C NMR (125 MHz, CD2Cl2) δ 143.8 (CqPh), 128.2 (2C, CHPh), 127.4 (CHPh, p), 126.4 (2C, 
CHPh), 76.0 (C9HOH), 61.4 (C8H), 50.3 (C6H2), 43.3 (C2H2), 28.0 (C7H2), 26.4 (CH2), 25.5 
(CH2), 21.9 (C4H). 
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HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
 
erythro-2-(α-Aminobenzyl)quinuclidine (erythro-86): erythro-86 was prepared starting 
from threo-150 (200 mg, 920 μmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). The 
reaction was always kept between 0 °C and room temperature. Purification 
by flash column chromatography (silica gel, methanol/EtOAc 40:60 with 
1% aq. NH4OH) gave erythro-86 as a white semi-solid (90.3 mg, 418 μmol, 45%). The 
enantiomers were separated by chiral HPLC (Chiralcel OD, 20 μm, 250 × 20 mm BIAX 
column; 10% i-PrOH in i-hexane with 0.1% diethylamine, 10 mL/min, 1.3 MPa, 308 K). 
Optical rotation [α]25D = +61.0 (c = 0.7, CHCl3); [α]25D = −63.0 (c = 0.6, CHCl3). 
1H NMR (500 MHz, CD2Cl2) δ 7.31-7.26 (m, 4H, CHPh), 7.23-7.19 (m, 1H, CHPh, p), 3.87 (d, 
J = 9.5 Hz, 1H, CH9NH2), 3.05-2.97 (m, 1H, CHH2), 2.87 (dd, J = 17.4, 8.9 Hz, 1H, CH8), 
2.76-2.73 (m, 2H, CH26), 2.61-2.55 (m, 1H, CHH2), 1.95-1.89 (m, 1H, CHH7), 1.87-1.83 (m, 
1H, CH4), 1.79 (br s, 2H, NH2), 1.54-1.43 (m, 5H, CH25, CH23 and CHH7). 
13C NMR (125 MHz, CD2Cl2) δ 147.1 (CqPh), 128.5 (2C, CHPh), 127.2 (2C, CHPh), 127.0 
(CHPh, p), 62.7 (C8H), 60.1 (C9HNH2), 50.3 (C6H2), 42.5 (C2H2), 32.6 (C7H2), 27.2 (CH2), 26.0 
(CH2), 22.6 (C4H). 
MS (EI-DE) m/z (%) 216 [M+] (6), 199 (1), 158 (1), 145 (2), 132 (3), 106 (48), 91 (4), 82 
(100), 79 (10), 69 (4), 55 (11), 42 (8), 28 (12). 
HRMS (EI-DE) calcd for C14H20N2 [M+] 216.1625, found 216.1626. 
 
threo-2-(α-Aminobenzyl)quinuclidine (threo-86): threo-86 was prepared starting from 
erythro-150 (200 mg, 920 μmol) following the same procedure described 
for the synthesis of 9-amino(9-deoxy)epiquinine (13). The reaction was 
always kept between 0 °C and room temperature. Purification by flash 
column chromatography (silica gel, methanol/EtOAc 40:60 with 1% 
aq. NH4OH) gave threo-86 as a white semi-solid (121 mg, 561 μmol, 61%). 
1H NMR (500 MHz, CD2Cl2) δ 7.38 (d, J = 7.6 Hz, 2H, CHPh, o), 7.31 (t, J = 7.6 Hz, 2H, 
CHPh, m), 7.24 (t, J = 7.1 Hz, 1H, CHPh, p), 3.79 (d, J = 10.1 Hz, 1H, CH9NH2), 3.07-3.00 (m, 
1H, CHH2), 2.93 (app. t, J = 7.7 Hz, 2H, C6H2), 2.75 (dd overlapped, J = 18.6, 9.5 Hz, 1H, 
CH8), 2.74-2.68 (m overlapped, 1H, CHH2), 1.92 (br s, 2H, NH2), 1.66-1.64 (m, 1H, CH4), 
1.47-1.41 (m, 4H, CH23 and CH25), 1.16-1.10 (m, 1H, CHH7), 0.98-0.94 (m, 1H, CHH7). 
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(100), 79 (10), 69 (4), 55 (11), 42 (8), 28 (12). 
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erythro-150 (200 mg, 920 μmol) following the same procedure described 
for the synthesis of 9-amino(9-deoxy)epiquinine (13). The reaction was 
always kept between 0 °C and room temperature. Purification by flash 
column chromatography (silica gel, methanol/EtOAc 40:60 with 1% 
aq. NH4OH) gave threo-86 as a white semi-solid (121 mg, 561 μmol, 61%). 
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HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
 
erythro-2-(α-Aminobenzyl)quinuclidine (erythro-86): erythro-86 was prepared starting 
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(CHPh, p), 62.7 (C8H), 60.1 (C9HNH2), 50.3 (C6H2), 42.5 (C2H2), 32.6 (C7H2), 27.2 (CH2), 26.0 
(CH2), 22.6 (C4H). 
MS (EI-DE) m/z (%) 216 [M+] (6), 199 (1), 158 (1), 145 (2), 132 (3), 106 (48), 91 (4), 82 
(100), 79 (10), 69 (4), 55 (11), 42 (8), 28 (12). 
HRMS (EI-DE) calcd for C14H20N2 [M+] 216.1625, found 216.1626. 
 
threo-2-(α-Aminobenzyl)quinuclidine (threo-86): threo-86 was prepared starting from 
erythro-150 (200 mg, 920 μmol) following the same procedure described 
for the synthesis of 9-amino(9-deoxy)epiquinine (13). The reaction was 
always kept between 0 °C and room temperature. Purification by flash 
column chromatography (silica gel, methanol/EtOAc 40:60 with 1% 
aq. NH4OH) gave threo-86 as a white semi-solid (121 mg, 561 μmol, 61%). 
1H NMR (500 MHz, CD2Cl2) δ 7.38 (d, J = 7.6 Hz, 2H, CHPh, o), 7.31 (t, J = 7.6 Hz, 2H, 
CHPh, m), 7.24 (t, J = 7.1 Hz, 1H, CHPh, p), 3.79 (d, J = 10.1 Hz, 1H, CH9NH2), 3.07-3.00 (m, 
1H, CHH2), 2.93 (app. t, J = 7.7 Hz, 2H, C6H2), 2.75 (dd overlapped, J = 18.6, 9.5 Hz, 1H, 
CH8), 2.74-2.68 (m overlapped, 1H, CHH2), 1.92 (br s, 2H, NH2), 1.66-1.64 (m, 1H, CH4), 
1.47-1.41 (m, 4H, CH23 and CH25), 1.16-1.10 (m, 1H, CHH7), 0.98-0.94 (m, 1H, CHH7). 
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HRMS (EI-DE) calcd for C14H19NO [M+] 217.1465, found 217.1467. 
 
erythro-2-(α-Aminobenzyl)quinuclidine (erythro-86): erythro-86 was prepared starting 
from threo-150 (200 mg, 920 μmol) following the same procedure 
described for the synthesis of 9-amino(9-deoxy)epiquinine (13). The 
reaction was always kept between 0 °C and room temperature. Purification 
by flash column chromatography (silica gel, methanol/EtOAc 40:60 with 
1% aq. NH4OH) gave erythro-86 as a white semi-solid (90.3 mg, 418 μmol, 45%). The 
enantiomers were separated by chiral HPLC (Chiralcel OD, 20 μm, 250 × 20 mm BIAX 
column; 10% i-PrOH in i-hexane with 0.1% diethylamine, 10 mL/min, 1.3 MPa, 308 K). 
Optical rotation [α]25D = +61.0 (c = 0.7, CHCl3); [α]25D = −63.0 (c = 0.6, CHCl3). 
1H NMR (500 MHz, CD2Cl2) δ 7.31-7.26 (m, 4H, CHPh), 7.23-7.19 (m, 1H, CHPh, p), 3.87 (d, 
J = 9.5 Hz, 1H, CH9NH2), 3.05-2.97 (m, 1H, CHH2), 2.87 (dd, J = 17.4, 8.9 Hz, 1H, CH8), 
2.76-2.73 (m, 2H, CH26), 2.61-2.55 (m, 1H, CHH2), 1.95-1.89 (m, 1H, CHH7), 1.87-1.83 (m, 
1H, CH4), 1.79 (br s, 2H, NH2), 1.54-1.43 (m, 5H, CH25, CH23 and CHH7). 
13C NMR (125 MHz, CD2Cl2) δ 147.1 (CqPh), 128.5 (2C, CHPh), 127.2 (2C, CHPh), 127.0 
(CHPh, p), 62.7 (C8H), 60.1 (C9HNH2), 50.3 (C6H2), 42.5 (C2H2), 32.6 (C7H2), 27.2 (CH2), 26.0 
(CH2), 22.6 (C4H). 
MS (EI-DE) m/z (%) 216 [M+] (6), 199 (1), 158 (1), 145 (2), 132 (3), 106 (48), 91 (4), 82 
(100), 79 (10), 69 (4), 55 (11), 42 (8), 28 (12). 
HRMS (EI-DE) calcd for C14H20N2 [M+] 216.1625, found 216.1626. 
 
threo-2-(α-Aminobenzyl)quinuclidine (threo-86): threo-86 was prepared starting from 
erythro-150 (200 mg, 920 μmol) following the same procedure described 
for the synthesis of 9-amino(9-deoxy)epiquinine (13). The reaction was 
always kept between 0 °C and room temperature. Purification by flash 
column chromatography (silica gel, methanol/EtOAc 40:60 with 1% 
aq. NH4OH) gave threo-86 as a white semi-solid (121 mg, 561 μmol, 61%). 
1H NMR (500 MHz, CD2Cl2) δ 7.38 (d, J = 7.6 Hz, 2H, CHPh, o), 7.31 (t, J = 7.6 Hz, 2H, 
CHPh, m), 7.24 (t, J = 7.1 Hz, 1H, CHPh, p), 3.79 (d, J = 10.1 Hz, 1H, CH9NH2), 3.07-3.00 (m, 
1H, CHH2), 2.93 (app. t, J = 7.7 Hz, 2H, C6H2), 2.75 (dd overlapped, J = 18.6, 9.5 Hz, 1H, 
CH8), 2.74-2.68 (m overlapped, 1H, CHH2), 1.92 (br s, 2H, NH2), 1.66-1.64 (m, 1H, CH4), 
1.47-1.41 (m, 4H, CH23 and CH25), 1.16-1.10 (m, 1H, CHH7), 0.98-0.94 (m, 1H, CHH7). 
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13C NMR (125 MHz, CD2Cl2) δ 144.1 (CqPh), 128.6 (2C, CHPh, o), 128.5 (2C, CHPh, m), 127.5 
(CHPh, p), 62.5 (C8H), 58.9 (C9HNH2), 50.3 (C6H2), 41.8 (C2H2), 31.0 (C7H2), 27.3 (CH2), 26.1 
(CH2), 22.3 (C4H). 
MS (EI-DE) m/z (%) 216 [M+] (3), 158 (1), 146 (5), 130 (2), 118 (2), 106 (42), 91 (4), 82 
(100), 79 (11), 68 (5), 55 (14), 42 (12), 28 (23). 
HRMS (EI-DE) calcd for C14H20N2 [M+] 216.1628, found 216.1626. 
 
7.6.6 Synthesis of Amino Acid-Derived Diamines 
Amino acid-derived diamines were prepared according to standard peptide coupling protocols 
followed by amide reduction.[198] 
 
Synthesis of (S)-phenylglycine-N,N-dimethylamide (154a) 
 
 
 
To a solution of N-Boc-(S)-phenylglycine (1.51 g, 6.00 mmol, 1.0 equiv) in CH2Cl2 (48 mL) 
was added O-(benzotriazol-1-yl)-tetramethyluronium hexafluorophosphate (HBTU, 2.28 g, 
6.00 mmol, 1.0 equiv), and the white suspension was stirred for 5 min, followed by the 
sequential addition of diisopropylethylamine (3.06 mL, 18.0 mmol, 3.0 equiv) and dimethyl-
amine (0.33 mL, 6.60 mmol, 1.1 equiv). After 18 h at room temperature, the reaction mixture 
was combined with CH2Cl2 (50 mL) and water (50 mL). The organic layer was separated, 
repeatedly washed with aqueous 1N HCl (3×30 mL), dried (Na2SO4), filtered, and concen-
trated under reduced pressure. The crude N-Boc-protected N,N-dimethylamide was treated 
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Synthesis of (S)-tert-leucine-N,N-dimethylamide (154b): N,N-dimethylamide 154b was 
obtained from (S)-N-Boc-tert-leucine by the method described for N,N-
dimethylamide 154a. Flash column chromatography (silica gel, 10-25% 
methanol in EtOAc) gave N,N-dimethylamide 154b as a white solid (949 
mg, 6.00 mmol, 95% yield). 
1H NMR (500 MHz, CDCl3) δ 3.56 (s, 1H, CH), 3.06 (s, 3H, N(CH3)2), 2.95 (s, 3H, 
N(CH3)2), 2.11 (br s, 2H, NH2), 0.96 (s, 9H, C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 174.2 (C=O), 57.6 (CHNH2), 38.1 (CqMe3), 35.6 (CH3), 35.3 
(CH3), 26.3 (3C, Cq(CH3)3). 
 
Synthesis of (S)-tryptophane-N,N-dimethylamide (154c): N,N-dimethylamide 154c was 
obtained from (S)-N-Boc-tryptophane by the method described for 
N,N-dimethylamide 154a. Flash column chromatography (silica gel, 
10-30% methanol in EtOAc) gave N,N-dimethylamide 154c as a pale 
yellow solid (505 mg, 2.16 mmol, 36%). 
1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H, NH), 7.52 (d, J = 7.8 Hz, 1H, CHindol), 7.34 (d, 
J = 8.0 Hz, 1H, CHindol), 7.16 (app. t, J = 7.6 Hz, 1H, CHindol), 7.10-7.07 (m, 2H, CHindol), 
4.08-4.05 (m, 1H, CHNH2), 3.11 (dd, J = 14.6, 6.4 Hz, 1H, CHH), 2.94 (dd, J = 14.6, 7.7 Hz, 
1H, CHH), 2.84 (s, 3H, CH3), 2.76 (s, 3H, CH3), 2.40 (br s, 2H, NH2). 
 
Synthesis of (S)-phenylalanine amide (152) 
 
NH2
NH2
O
NH2
OMe
O
NH3 (7M in MeOH)
r.t., 12 h
152
Ph Ph
C9H12N2O
164,20
 
 
(S)-Phenylalanine methyl ester (3.30 g, 18.4 mmol) was dissolved in a methanolic solution of 
ammonia (13.1 mL, 92.0 mmol, 5.0 equiv; 7M in methanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine amide (152; white solid; 3.02 g, >99% yield) was used in the next step without 
further purification. 
1H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 7.4 Hz, 2H, CHPh, m), 7.25-7.23 (m overlapped, 1H, 
CHPh, p), 7.22 (d overlapped, J = 7.6 Hz, 2H, CHPh, o), 7.11 (br s, 1H, C(=O)NHH), 6.00 (br s, 
NH2
NMe2
t-Bu
O
C8H18N2O
158,24
NH2
NMe2
HN
O
C13H17N3O
231,29
7  Experimental Part 
258 
 
Synthesis of (S)-tert-leucine-N,N-dimethylamide (154b): N,N-dimethylamide 154b was 
obtained from (S)-N-Boc-tert-leucine by the method described for N,N-
dimethylamide 154a. Flash column chromatography (silica gel, 10-25% 
methanol in EtOAc) gave N,N-dimethylamide 154b as a white solid (949 
mg, 6.00 mmol, 95% yield). 
1H NMR (500 MHz, CDCl3) δ 3.56 (s, 1H, CH), 3.06 (s, 3H, N(CH3)2), 2.95 (s, 3H, 
N(CH3)2), 2.11 (br s, 2H, NH2), 0.96 (s, 9H, C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 174.2 (C=O), 57.6 (CHNH2), 38.1 (CqMe3), 35.6 (CH3), 35.3 
(CH3), 26.3 (3C, Cq(CH3)3). 
 
Synthesis of (S)-tryptophane-N,N-dimethylamide (154c): N,N-dimethylamide 154c was 
obtained from (S)-N-Boc-tryptophane by the method described for 
N,N-dimethylamide 154a. Flash column chromatography (silica gel, 
10-30% methanol in EtOAc) gave N,N-dimethylamide 154c as a pale 
yellow solid (505 mg, 2.16 mmol, 36%). 
1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H, NH), 7.52 (d, J = 7.8 Hz, 1H, CHindol), 7.34 (d, 
J = 8.0 Hz, 1H, CHindol), 7.16 (app. t, J = 7.6 Hz, 1H, CHindol), 7.10-7.07 (m, 2H, CHindol), 
4.08-4.05 (m, 1H, CHNH2), 3.11 (dd, J = 14.6, 6.4 Hz, 1H, CHH), 2.94 (dd, J = 14.6, 7.7 Hz, 
1H, CHH), 2.84 (s, 3H, CH3), 2.76 (s, 3H, CH3), 2.40 (br s, 2H, NH2). 
 
Synthesis of (S)-phenylalanine amide (152) 
 
NH2
NH2
O
NH2
OMe
O
NH3 (7M in MeOH)
r.t., 12 h
152
Ph Ph
C9H12N2O
164,20
 
 
(S)-Phenylalanine methyl ester (3.30 g, 18.4 mmol) was dissolved in a methanolic solution of 
ammonia (13.1 mL, 92.0 mmol, 5.0 equiv; 7M in methanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine amide (152; white solid; 3.02 g, >99% yield) was used in the next step without 
further purification. 
1H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 7.4 Hz, 2H, CHPh, m), 7.25-7.23 (m overlapped, 1H, 
CHPh, p), 7.22 (d overlapped, J = 7.6 Hz, 2H, CHPh, o), 7.11 (br s, 1H, C(=O)NHH), 6.00 (br s, 
NH2
NMe2
t-Bu
O
C8H18N2O
158,24
NH2
NMe2
HN
O
C13H17N3O
231,29
7  Experimental Part 
258 
 
Synthesis of (S)-tert-leucine-N,N-dimethylamide (154b): N,N-dimethylamide 154b was 
obtained from (S)-N-Boc-tert-leucine by the method described for N,N-
dimethylamide 154a. Flash column chromatography (silica gel, 10-25% 
methanol in EtOAc) gave N,N-dimethylamide 154b as a white solid (949 
mg, 6.00 mmol, 95% yield). 
1H NMR (500 MHz, CDCl3) δ 3.56 (s, 1H, CH), 3.06 (s, 3H, N(CH3)2), 2.95 (s, 3H, 
N(CH3)2), 2.11 (br s, 2H, NH2), 0.96 (s, 9H, C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 174.2 (C=O), 57.6 (CHNH2), 38.1 (CqMe3), 35.6 (CH3), 35.3 
(CH3), 26.3 (3C, Cq(CH3)3). 
 
Synthesis of (S)-tryptophane-N,N-dimethylamide (154c): N,N-dimethylamide 154c was 
obtained from (S)-N-Boc-tryptophane by the method described for 
N,N-dimethylamide 154a. Flash column chromatography (silica gel, 
10-30% methanol in EtOAc) gave N,N-dimethylamide 154c as a pale 
yellow solid (505 mg, 2.16 mmol, 36%). 
1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H, NH), 7.52 (d, J = 7.8 Hz, 1H, CHindol), 7.34 (d, 
J = 8.0 Hz, 1H, CHindol), 7.16 (app. t, J = 7.6 Hz, 1H, CHindol), 7.10-7.07 (m, 2H, CHindol), 
4.08-4.05 (m, 1H, CHNH2), 3.11 (dd, J = 14.6, 6.4 Hz, 1H, CHH), 2.94 (dd, J = 14.6, 7.7 Hz, 
1H, CHH), 2.84 (s, 3H, CH3), 2.76 (s, 3H, CH3), 2.40 (br s, 2H, NH2). 
 
Synthesis of (S)-phenylalanine amide (152) 
 
NH2
NH2
O
NH2
OMe
O
NH3 (7M in MeOH)
r.t., 12 h
152
Ph Ph
C9H12N2O
164,20
 
 
(S)-Phenylalanine methyl ester (3.30 g, 18.4 mmol) was dissolved in a methanolic solution of 
ammonia (13.1 mL, 92.0 mmol, 5.0 equiv; 7M in methanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine amide (152; white solid; 3.02 g, >99% yield) was used in the next step without 
further purification. 
1H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 7.4 Hz, 2H, CHPh, m), 7.25-7.23 (m overlapped, 1H, 
CHPh, p), 7.22 (d overlapped, J = 7.6 Hz, 2H, CHPh, o), 7.11 (br s, 1H, C(=O)NHH), 6.00 (br s, 
NH2
NMe2
t-Bu
O
C8H18N2O
158,24
NH2
NMe2
HN
O
C13H17N3O
231,29
7  Experimental Part 
258 
 
Synthesis of (S)-tert-leucine-N,N-dimethylamide (154b): N,N-dimethylamide 154b was 
obtained from (S)-N-Boc-tert-leucine by the method described for N,N-
dimethylamide 154a. Flash column chromatography (silica gel, 10-25% 
methanol in EtOAc) gave N,N-dimethylamide 154b as a white solid (949 
mg, 6.00 mmol, 95% yield). 
1H NMR (500 MHz, CDCl3) δ 3.56 (s, 1H, CH), 3.06 (s, 3H, N(CH3)2), 2.95 (s, 3H, 
N(CH3)2), 2.11 (br s, 2H, NH2), 0.96 (s, 9H, C(CH3)3). 
13C NMR (125 MHz, CDCl3) δ 174.2 (C=O), 57.6 (CHNH2), 38.1 (CqMe3), 35.6 (CH3), 35.3 
(CH3), 26.3 (3C, Cq(CH3)3). 
 
Synthesis of (S)-tryptophane-N,N-dimethylamide (154c): N,N-dimethylamide 154c was 
obtained from (S)-N-Boc-tryptophane by the method described for 
N,N-dimethylamide 154a. Flash column chromatography (silica gel, 
10-30% methanol in EtOAc) gave N,N-dimethylamide 154c as a pale 
yellow solid (505 mg, 2.16 mmol, 36%). 
1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H, NH), 7.52 (d, J = 7.8 Hz, 1H, CHindol), 7.34 (d, 
J = 8.0 Hz, 1H, CHindol), 7.16 (app. t, J = 7.6 Hz, 1H, CHindol), 7.10-7.07 (m, 2H, CHindol), 
4.08-4.05 (m, 1H, CHNH2), 3.11 (dd, J = 14.6, 6.4 Hz, 1H, CHH), 2.94 (dd, J = 14.6, 7.7 Hz, 
1H, CHH), 2.84 (s, 3H, CH3), 2.76 (s, 3H, CH3), 2.40 (br s, 2H, NH2). 
 
Synthesis of (S)-phenylalanine amide (152) 
 
NH2
NH2
O
NH2
OMe
O
NH3 (7M in MeOH)
r.t., 12 h
152
Ph Ph
C9H12N2O
164,20
 
 
(S)-Phenylalanine methyl ester (3.30 g, 18.4 mmol) was dissolved in a methanolic solution of 
ammonia (13.1 mL, 92.0 mmol, 5.0 equiv; 7M in methanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine amide (152; white solid; 3.02 g, >99% yield) was used in the next step without 
further purification. 
1H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 7.4 Hz, 2H, CHPh, m), 7.25-7.23 (m overlapped, 1H, 
CHPh, p), 7.22 (d overlapped, J = 7.6 Hz, 2H, CHPh, o), 7.11 (br s, 1H, C(=O)NHH), 6.00 (br s, 
NH2
NMe2
t-Bu
O
C8H18N2O
158,24
NH2
NMe2
HN
O
C13H17N3O
231,29
7 Experimental Part 
 259
1H, C(=O)NHH), 3.60 (dd, J = 9.5, 4.1 Hz, 1H, CHNH2), 3.26 (dd, J = 13.7, 4.2 Hz, 1H, 
CHH), 2.70 (dd, J = 13.7, 9.6 Hz, 1H, CHH), 1.38 (br s, 2H, CHNH2). 
13C NMR (125 MHz, CDCl3) δ 177.5 (C=O), 137.8 (CqPh), 129.2 (2C, CHPh), 128.7 (2C, 
CHPh), 126.8 (CHPh, p), 56.5 (CHNH2), 40.9 (CH2). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 147 (2), 131 (1), 120 (100), 103 (14), 91 (18), 77 (9), 
73 (31), 65 (7), 51 (4), 42 (4), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H13N2O [(M+H)+] 165.1027, found 165.1028. 
 
Synthesis of (S)-phenylalanine-N-methylamide (153) 
 
NH2
NHMe
O
NH2
OMe
O
MeNH2 (8M in EtOH)
r.t., 12 h
Ph Ph
C10H14N2O
178,23
153  
 
(S)-Phenylalanine methyl ester (3.59 g, 20.0 mmol) was dissolved in an ethanolic solution of 
methylamine (12.5 mL, 100 mmol, 5.0 equiv; 8M in ethanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine-N-methylamide (153; white solid; 3.56 g, >99% yield) was used in the next 
step without further purification. 
1H NMR (500 MHz, CDCl3) δ 7.29-7.17 (m, 6H, C6H5 and NHMe), 3.57 (dd, J = 9.5, 3.8 Hz, 
1H, CHNH2), 3.25 (dd, J = 13.8, 4.0 Hz, 1H, CHH), 2.78 (d, J = 5.0 Hz, 3H, CH3), 2.64 (dd, 
J = 14.0, 9.9 Hz, 1H, CHH), 1.41 (br s, 2H, NH2). 
13C NMR (125 MHz, CDCl3) δ 174.7 (C=O), 137.9 (CqPh), 129.2 (2C, CHPh), 128.6 (2C, 
CHPh), 126.7 (CHPh, p), 56.4 (CHNH2), 40.9 (CH2), 25.8 (CH3). 
MS (EI-DE) m/z (%) 178 [M+] (1), 161 (2), 131 (2), 120 (100), 103 (11), 91 (13), 87 (29), 77 
(7), 69 (5), 58 (4), 51 (2), 42 (7), 30 (3). 
HRMS (CI-FE, i-butane) calcd for C10H15N2O [(M+H)+] 179.1183, found 179.1184. 
 
Synthesis of (S)-3-Phenylpropane-1,2-diamine (87) 
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phenylalanine-N-methylamide (153; white solid; 3.56 g, >99% yield) was used in the next 
step without further purification. 
1H NMR (500 MHz, CDCl3) δ 7.29-7.17 (m, 6H, C6H5 and NHMe), 3.57 (dd, J = 9.5, 3.8 Hz, 
1H, CHNH2), 3.25 (dd, J = 13.8, 4.0 Hz, 1H, CHH), 2.78 (d, J = 5.0 Hz, 3H, CH3), 2.64 (dd, 
J = 14.0, 9.9 Hz, 1H, CHH), 1.41 (br s, 2H, NH2). 
13C NMR (125 MHz, CDCl3) δ 174.7 (C=O), 137.9 (CqPh), 129.2 (2C, CHPh), 128.6 (2C, 
CHPh), 126.7 (CHPh, p), 56.4 (CHNH2), 40.9 (CH2), 25.8 (CH3). 
MS (EI-DE) m/z (%) 178 [M+] (1), 161 (2), 131 (2), 120 (100), 103 (11), 91 (13), 87 (29), 77 
(7), 69 (5), 58 (4), 51 (2), 42 (7), 30 (3). 
HRMS (CI-FE, i-butane) calcd for C10H15N2O [(M+H)+] 179.1183, found 179.1184. 
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1H, C(=O)NHH), 3.60 (dd, J = 9.5, 4.1 Hz, 1H, CHNH2), 3.26 (dd, J = 13.7, 4.2 Hz, 1H, 
CHH), 2.70 (dd, J = 13.7, 9.6 Hz, 1H, CHH), 1.38 (br s, 2H, CHNH2). 
13C NMR (125 MHz, CDCl3) δ 177.5 (C=O), 137.8 (CqPh), 129.2 (2C, CHPh), 128.7 (2C, 
CHPh), 126.8 (CHPh, p), 56.5 (CHNH2), 40.9 (CH2). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 147 (2), 131 (1), 120 (100), 103 (14), 91 (18), 77 (9), 
73 (31), 65 (7), 51 (4), 42 (4), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H13N2O [(M+H)+] 165.1027, found 165.1028. 
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1H, C(=O)NHH), 3.60 (dd, J = 9.5, 4.1 Hz, 1H, CHNH2), 3.26 (dd, J = 13.7, 4.2 Hz, 1H, 
CHH), 2.70 (dd, J = 13.7, 9.6 Hz, 1H, CHH), 1.38 (br s, 2H, CHNH2). 
13C NMR (125 MHz, CDCl3) δ 177.5 (C=O), 137.8 (CqPh), 129.2 (2C, CHPh), 128.7 (2C, 
CHPh), 126.8 (CHPh, p), 56.5 (CHNH2), 40.9 (CH2). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 147 (2), 131 (1), 120 (100), 103 (14), 91 (18), 77 (9), 
73 (31), 65 (7), 51 (4), 42 (4), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H13N2O [(M+H)+] 165.1027, found 165.1028. 
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(S)-Phenylalanine methyl ester (3.59 g, 20.0 mmol) was dissolved in an ethanolic solution of 
methylamine (12.5 mL, 100 mmol, 5.0 equiv; 8M in ethanol), and the resulting solution was 
stirred at room temperature overnight (12 h). The volatiles were removed in vacuo and (S)-
phenylalanine-N-methylamide (153; white solid; 3.56 g, >99% yield) was used in the next 
step without further purification. 
1H NMR (500 MHz, CDCl3) δ 7.29-7.17 (m, 6H, C6H5 and NHMe), 3.57 (dd, J = 9.5, 3.8 Hz, 
1H, CHNH2), 3.25 (dd, J = 13.8, 4.0 Hz, 1H, CHH), 2.78 (d, J = 5.0 Hz, 3H, CH3), 2.64 (dd, 
J = 14.0, 9.9 Hz, 1H, CHH), 1.41 (br s, 2H, NH2). 
13C NMR (125 MHz, CDCl3) δ 174.7 (C=O), 137.9 (CqPh), 129.2 (2C, CHPh), 128.6 (2C, 
CHPh), 126.7 (CHPh, p), 56.4 (CHNH2), 40.9 (CH2), 25.8 (CH3). 
MS (EI-DE) m/z (%) 178 [M+] (1), 161 (2), 131 (2), 120 (100), 103 (11), 91 (13), 87 (29), 77 
(7), 69 (5), 58 (4), 51 (2), 42 (7), 30 (3). 
HRMS (CI-FE, i-butane) calcd for C10H15N2O [(M+H)+] 179.1183, found 179.1184. 
 
Synthesis of (S)-3-Phenylpropane-1,2-diamine (87) 
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LiAlH4 (228 mg, 6.00 mmol, 2.0 equiv) was added in portions to a solution of amide 152 (493 
mg, 3.00 mmol) in THF (21 mL) at 0 °C. The reaction was heated to reflux until TLC analysis 
indicated complete disappearance of the starting material (18 h), and was then carefully 
quenched by the sequential addition of water, 15% aqueous NaOH, and water. The reaction 
mixture was repeatedly extracted with Et2O, and the combined organic layers were dried 
(Na2SO4), filtered, and evaporated. Purification of the residue by short path distillation (bp 
50-55 °C at 3.1-2 mbar) gave pure diamine 87 as a colorless liquid (255 mg, 1.55 mmol, 52%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.6 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.3 Hz, 2H, CHPh, o), 2.99-2.94 (m, 1H, CHNH2), 2.80 (dd, J = 12.6, 4.1 
Hz, 1H, CHHNH2), 2.77 (dd, J = 13.3, 4.8 Hz, 1H, PhCHH), 2.54 (dd, J = 12.6, 7.9 Hz, 1H, 
CHHNH2), 2.49 (dd, J = 13.6, 8.5 Hz, 1H, PhCHH), 1.56-1.46 (br m, 4H, NH2). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 55.0 (CHNH2), 48.0 (CH2NH2), 42.3 (PhCH2). 
MS (EI-DE) m/z (%) 150 [M+] (trace), 132 (1), 120 (100), 103 (17), 91 (19), 77 (11), 65 (8), 
59 (54), 51 (5), 42 (11), 30 (51), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H15N2 [(M+H)+] 151.1236, found 151.1235. 
 
Synthesis of (S)-N1-methyl-3-phenylpropane-1,2-diamine (88): Diamine 88 was obtained 
from the corresponding N-methylamide 153 according to the procedure 
described for the synthesis diamine 87 (LiAlH4 (2.0 equiv); 4 h at reflux). 
Short path distillation (bp 38-39 °C at 4.2-4.4-2 mbar) gave pure diamine 
88 as a colorless liquid (218 mg, 1.33 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.4 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.6 Hz, 2H, CHPh, o), 3.10 (ddd, J = 12.8, 8.6, 4.3 Hz, 1H, CHNH2), 2.77 
(dd, J = 13.4, 4.9 Hz, 1H, PhCHH), 2.65 (dd, J = 11.8, 3.9 Hz, 1H, CHHNHMe), 2.49 (dd, J 
= 13.4, 8.7 Hz, 1H, PhCHH), 2.44 (dd overlapped, J = 11.7, 8.5 Hz, 1H, CHHNHMe), 2.43 (s 
overlapped, 3H, CH3), 1.47 (br s, 3H, NH2 and NHMe). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 58.3 (CH2NHMe), 52.3 (CHNH2), 42.9 (PhCH2), 36.5 (CH3). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 132 (1), 120 (100), 103 (12), 91 (12), 77 (7), 73 (28), 
65 (5), 56 (3), 44 (68), 30 (11). 
HRMS (CI-FE, i-butane) calcd for C10H17N2 [(M+H)+] 165.1392, found 165.1392. 
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LiAlH4 (228 mg, 6.00 mmol, 2.0 equiv) was added in portions to a solution of amide 152 (493 
mg, 3.00 mmol) in THF (21 mL) at 0 °C. The reaction was heated to reflux until TLC analysis 
indicated complete disappearance of the starting material (18 h), and was then carefully 
quenched by the sequential addition of water, 15% aqueous NaOH, and water. The reaction 
mixture was repeatedly extracted with Et2O, and the combined organic layers were dried 
(Na2SO4), filtered, and evaporated. Purification of the residue by short path distillation (bp 
50-55 °C at 3.1-2 mbar) gave pure diamine 87 as a colorless liquid (255 mg, 1.55 mmol, 52%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.6 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.3 Hz, 2H, CHPh, o), 2.99-2.94 (m, 1H, CHNH2), 2.80 (dd, J = 12.6, 4.1 
Hz, 1H, CHHNH2), 2.77 (dd, J = 13.3, 4.8 Hz, 1H, PhCHH), 2.54 (dd, J = 12.6, 7.9 Hz, 1H, 
CHHNH2), 2.49 (dd, J = 13.6, 8.5 Hz, 1H, PhCHH), 1.56-1.46 (br m, 4H, NH2). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 55.0 (CHNH2), 48.0 (CH2NH2), 42.3 (PhCH2). 
MS (EI-DE) m/z (%) 150 [M+] (trace), 132 (1), 120 (100), 103 (17), 91 (19), 77 (11), 65 (8), 
59 (54), 51 (5), 42 (11), 30 (51), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H15N2 [(M+H)+] 151.1236, found 151.1235. 
 
Synthesis of (S)-N1-methyl-3-phenylpropane-1,2-diamine (88): Diamine 88 was obtained 
from the corresponding N-methylamide 153 according to the procedure 
described for the synthesis diamine 87 (LiAlH4 (2.0 equiv); 4 h at reflux). 
Short path distillation (bp 38-39 °C at 4.2-4.4-2 mbar) gave pure diamine 
88 as a colorless liquid (218 mg, 1.33 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.4 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.6 Hz, 2H, CHPh, o), 3.10 (ddd, J = 12.8, 8.6, 4.3 Hz, 1H, CHNH2), 2.77 
(dd, J = 13.4, 4.9 Hz, 1H, PhCHH), 2.65 (dd, J = 11.8, 3.9 Hz, 1H, CHHNHMe), 2.49 (dd, J 
= 13.4, 8.7 Hz, 1H, PhCHH), 2.44 (dd overlapped, J = 11.7, 8.5 Hz, 1H, CHHNHMe), 2.43 (s 
overlapped, 3H, CH3), 1.47 (br s, 3H, NH2 and NHMe). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 58.3 (CH2NHMe), 52.3 (CHNH2), 42.9 (PhCH2), 36.5 (CH3). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 132 (1), 120 (100), 103 (12), 91 (12), 77 (7), 73 (28), 
65 (5), 56 (3), 44 (68), 30 (11). 
HRMS (CI-FE, i-butane) calcd for C10H17N2 [(M+H)+] 165.1392, found 165.1392. 
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LiAlH4 (228 mg, 6.00 mmol, 2.0 equiv) was added in portions to a solution of amide 152 (493 
mg, 3.00 mmol) in THF (21 mL) at 0 °C. The reaction was heated to reflux until TLC analysis 
indicated complete disappearance of the starting material (18 h), and was then carefully 
quenched by the sequential addition of water, 15% aqueous NaOH, and water. The reaction 
mixture was repeatedly extracted with Et2O, and the combined organic layers were dried 
(Na2SO4), filtered, and evaporated. Purification of the residue by short path distillation (bp 
50-55 °C at 3.1-2 mbar) gave pure diamine 87 as a colorless liquid (255 mg, 1.55 mmol, 52%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.6 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.3 Hz, 2H, CHPh, o), 2.99-2.94 (m, 1H, CHNH2), 2.80 (dd, J = 12.6, 4.1 
Hz, 1H, CHHNH2), 2.77 (dd, J = 13.3, 4.8 Hz, 1H, PhCHH), 2.54 (dd, J = 12.6, 7.9 Hz, 1H, 
CHHNH2), 2.49 (dd, J = 13.6, 8.5 Hz, 1H, PhCHH), 1.56-1.46 (br m, 4H, NH2). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 55.0 (CHNH2), 48.0 (CH2NH2), 42.3 (PhCH2). 
MS (EI-DE) m/z (%) 150 [M+] (trace), 132 (1), 120 (100), 103 (17), 91 (19), 77 (11), 65 (8), 
59 (54), 51 (5), 42 (11), 30 (51), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H15N2 [(M+H)+] 151.1236, found 151.1235. 
 
Synthesis of (S)-N1-methyl-3-phenylpropane-1,2-diamine (88): Diamine 88 was obtained 
from the corresponding N-methylamide 153 according to the procedure 
described for the synthesis diamine 87 (LiAlH4 (2.0 equiv); 4 h at reflux). 
Short path distillation (bp 38-39 °C at 4.2-4.4-2 mbar) gave pure diamine 
88 as a colorless liquid (218 mg, 1.33 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.4 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.6 Hz, 2H, CHPh, o), 3.10 (ddd, J = 12.8, 8.6, 4.3 Hz, 1H, CHNH2), 2.77 
(dd, J = 13.4, 4.9 Hz, 1H, PhCHH), 2.65 (dd, J = 11.8, 3.9 Hz, 1H, CHHNHMe), 2.49 (dd, J 
= 13.4, 8.7 Hz, 1H, PhCHH), 2.44 (dd overlapped, J = 11.7, 8.5 Hz, 1H, CHHNHMe), 2.43 (s 
overlapped, 3H, CH3), 1.47 (br s, 3H, NH2 and NHMe). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 58.3 (CH2NHMe), 52.3 (CHNH2), 42.9 (PhCH2), 36.5 (CH3). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 132 (1), 120 (100), 103 (12), 91 (12), 77 (7), 73 (28), 
65 (5), 56 (3), 44 (68), 30 (11). 
HRMS (CI-FE, i-butane) calcd for C10H17N2 [(M+H)+] 165.1392, found 165.1392. 
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LiAlH4 (228 mg, 6.00 mmol, 2.0 equiv) was added in portions to a solution of amide 152 (493 
mg, 3.00 mmol) in THF (21 mL) at 0 °C. The reaction was heated to reflux until TLC analysis 
indicated complete disappearance of the starting material (18 h), and was then carefully 
quenched by the sequential addition of water, 15% aqueous NaOH, and water. The reaction 
mixture was repeatedly extracted with Et2O, and the combined organic layers were dried 
(Na2SO4), filtered, and evaporated. Purification of the residue by short path distillation (bp 
50-55 °C at 3.1-2 mbar) gave pure diamine 87 as a colorless liquid (255 mg, 1.55 mmol, 52%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.6 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.3 Hz, 2H, CHPh, o), 2.99-2.94 (m, 1H, CHNH2), 2.80 (dd, J = 12.6, 4.1 
Hz, 1H, CHHNH2), 2.77 (dd, J = 13.3, 4.8 Hz, 1H, PhCHH), 2.54 (dd, J = 12.6, 7.9 Hz, 1H, 
CHHNH2), 2.49 (dd, J = 13.6, 8.5 Hz, 1H, PhCHH), 1.56-1.46 (br m, 4H, NH2). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 55.0 (CHNH2), 48.0 (CH2NH2), 42.3 (PhCH2). 
MS (EI-DE) m/z (%) 150 [M+] (trace), 132 (1), 120 (100), 103 (17), 91 (19), 77 (11), 65 (8), 
59 (54), 51 (5), 42 (11), 30 (51), 28 (6). 
HRMS (CI-FE, i-butane) calcd for C9H15N2 [(M+H)+] 151.1236, found 151.1235. 
 
Synthesis of (S)-N1-methyl-3-phenylpropane-1,2-diamine (88): Diamine 88 was obtained 
from the corresponding N-methylamide 153 according to the procedure 
described for the synthesis diamine 87 (LiAlH4 (2.0 equiv); 4 h at reflux). 
Short path distillation (bp 38-39 °C at 4.2-4.4-2 mbar) gave pure diamine 
88 as a colorless liquid (218 mg, 1.33 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.4 Hz, 2H, CHPh, m), 7.21 (d, J = 7.6 Hz, 1H, 
CHPh, p), 7.18 (d, J = 7.6 Hz, 2H, CHPh, o), 3.10 (ddd, J = 12.8, 8.6, 4.3 Hz, 1H, CHNH2), 2.77 
(dd, J = 13.4, 4.9 Hz, 1H, PhCHH), 2.65 (dd, J = 11.8, 3.9 Hz, 1H, CHHNHMe), 2.49 (dd, J 
= 13.4, 8.7 Hz, 1H, PhCHH), 2.44 (dd overlapped, J = 11.7, 8.5 Hz, 1H, CHHNHMe), 2.43 (s 
overlapped, 3H, CH3), 1.47 (br s, 3H, NH2 and NHMe). 
13C NMR (125 MHz, CDCl3) δ 139.1 (CqPh), 129.2 (2C, CHPh), 128.5 (2C, CHPh), 126.3 
(CHPh, p), 58.3 (CH2NHMe), 52.3 (CHNH2), 42.9 (PhCH2), 36.5 (CH3). 
MS (EI-DE) m/z (%) 164 [M+] (trace), 132 (1), 120 (100), 103 (12), 91 (12), 77 (7), 73 (28), 
65 (5), 56 (3), 44 (68), 30 (11). 
HRMS (CI-FE, i-butane) calcd for C10H17N2 [(M+H)+] 165.1392, found 165.1392. 
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Synthesis of (S)-N1,N1-dimethyl-3-phenylpropane-1,2-diamine (89d): Diamine 89d was 
obtained from the corresponding N,N-dimethylamide hydrochloride salt 
according to the procedure described for diamine 87 (LiAlH4 (3.0 equiv); 
12 h at room temperature). Short path distillation (bp 52 °C at 2.2-1 mbar) 
gave pure diamine 89d as a colorless liquid (315 mg, 1.77 mmol, 44%). 
1H NMR (500 MHz, CD2Cl2) δ 7.29 (t, J = 7.6 Hz, 2H, CHPh, m), 7.22-7.18 (m, 3H, 
CHPh, o and p), 3.10 (app. sept, J = 4.5 Hz, 1H, CHNH2), 2.72 (dd, J = 13.2, 4.4 Hz, 1H, 
PhCHH), 2.42 (dd, J = 13.3, 8.5 Hz, 1H, PhCHH), 2.20 (s, 6H, CH3), 2.19 (dd, J = 11.7, 9.3 
Hz, 1H, CHHNMe2), 2.17 (dd, J = 12.1, 4.5 Hz, 1H, CHHNMe2), 1.27 (br s, 2H, NH2). 
13C NMR (125 MHz, CD2Cl2) δ 140.3 (CqPh), 129.7 (2C, CHPh), 128.6 (2C, CHPh), 126.3 
(CHPh, p), 67.0 (CH2NMe2), 50.5 (CHNH2), 46.0 (2C, CH3), 42.7 (PhCH2). 
MS (EI-DE) m/z (%) 178 [M+] (4), 161 (1), 132 (1), 120 (65), 103 (7), 91 (12), 77 (4), 70 (3), 
65 (4), 58 (100), 51 (1), 42 (9), 30 (5). 
HRMS (EI-FE) calcd for C11H18N2 [M+] 178.1469, found 178.1470. 
 
Synthesis of (S)-N1,N1-dimethyl-2-phenylethane-1,2-diamine (89a): Diamine 89a was 
obtained from the corresponding N,N-dimethylamide 154a according to the 
procedure described for diamine 87 (LiAlH4 (3.0 equiv); 4 h at room 
temperature). Short path distillation (bp 95-96 °C at 1.2-1.4-1 mbar) gave 
pure diamine 89a as a colorless liquid (396 mg, 2.41 mmol, 71%). 
1H NMR (500 MHz, CD2Cl2) δ 7.38 (d, J = 7.3 Hz, 2H, CHPh, o), 7.31 (t, J = 7.6 Hz, 2H, 
CHPh, m), 7.24-7.21 (m, 1H, CHPh, p), 4.05 (dd, J = 10.2, 3.9 Hz, 1H, CHNH2), 2.39 (dd, J = 
12.0, 10.4 Hz, 1H, CHH), 2.26 (s, 6H, CH3), 2.19 (dd, J = 12.0, 4.1 Hz, 1H, CHH), 1.67 (br s, 
2H, NH2). 
13C NMR (125 MHz, CD2Cl2) δ 145.5 (CqPh), 128.5 (2C, CHPh), 127.2 (CHPh, p), 127.1 (2C, 
CHPh), 68.8 (CH2), 53.6 (CHNH2), 45.8 (2C, CH3). 
GC-MS (GC-EI) m/z (%) 118 (1), 106 (10), 91 (1), 79 (5), 58 (100), 51 (2), 42 (5), 30 (4). 
HRMS (CI-FE, i-butane) calcd for C10H17N2 [(M+H)+] 165.1391, found 165.1392. 
 
Synthesis of (S)-N1,N1-dimethyl-2-tert-butylethane-1,2-diamine (89b): Diamine 89b (clear 
liquid; 228 mg, 1.39 mmol, 46%) was obtained from the corresponding 
N,N-dimethylamide 154b according to the procedure described for diamine 
87 (LiAlH4 (3.0 equiv) in Et2O; 4 h at room temperature). 
1H NMR (500 MHz, CD2Cl2) δ 2.55 (dd, J = 9.6, 4.0 Hz, 1H, CH), 2.18 (s, 
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6H, N(CH3)2), 2.13-2.07 (m, 2H, CH2), 1.30 (br s, 2H, NH2), 0.86 (s, 9H, Cq(CH3)3). 
13C NMR (125 MHz, CD2Cl2) δ 62.1 (CH2), 57.2 (CH), 45.9 (2C, N(CH3)2), 33.3 (Cq), 26.3 
(3C, Cq(CH3)3). 
 
Synthesis of (S)-N1,N1-dimethyl-3-(1H-indol-3-yl)-propane-1,2-diamine (89c): Diamine 
89c was obtained from the corresponding N,N-dimethylamide 154c 
according to the procedure described for diamine 87 (LiAlH4 (3.0 
equiv); 3 h at room temperature). Flash column chromatography 
(silica gel, methanol/EtOAc 50:50 with 1% aq. NH4OH) gave pure 
diamine 89c as a pale yellow solid (260 mg, 1.22 mmol, 69%). 
1H NMR (500 MHz, CDCl3) δ 8.22 (br s, 1H, NH), 7.61 (d, J = 7.3 Hz, 1H, CHar, 7.34 (d, J = 
8.2 Hz, 1H, CHar), 7.18 (app. t, J = 8.0 Hz, 1H, CHar), 7.10 (app. t, J = 7.7 Hz, 1H, CHar), 
7.06 (s, 1H, CHarNH), 3.25 (app. sept, J = 4.6 Hz, 1H, CHNH2), 2.91 (dd, J = 14.2, 4.1 Hz, 
1H, CqarCHH), 2.64 (dd, J = 14.2, 8.5 Hz, 1H, CqarCHH), 2.31 (dd, J = 12.0, 9.5 Hz, 1H, 
CHHNMe2), 2.25-2.23 (m overlapped, 1H, CHHNMe2), 2.23 (s ovelapped, 6H, CH3), 2.03 
(br s, 2H, NH2). 
13C NMR (125 MHz, CDCl3) δ 136.4 (Cqar), 127.7 (Cqar), 122.7 (CHar), 122.0 (CHar), 119.3 
(CHar), 118.9 (CHar), 113.0 (Cqar), 111.2 (CHar), 66.5 (CH2NMe2), 48.8 (CHNH2), 45.9 (2C, 
CH3), 31.5 (CqarCH2). 
 
7.6.7 Synthesis of (1R,2R)-N-iso-propyl-1,2-diphenylethylene-1,2-diamine (61)[199] 
 
 
 
(1R,2R)-DPEN (200 mg, 0.94 mmol) and 4Å molecular sieves (500 mg) were placed in a 
flask, and THF (2 mL) and acetone (0.3 mL) were successively added. After stirring 
overnight (12 h), GC/MS analysis indicated full conversion to the corresponding acetonide. 
The mixture was filtered through Celite (eluent: Et2O) and the filtrate was concentrated to 
give the crude acetonide 155, which was used without further purification in the next step. 
1H NMR (300 MHz, CDCl3) δ 7.29-7.19 (m, 10H, C6H5), 4.24 (s, 2H, CHCH), 2.04 (br s, 2H, 
NH), 1.53 (s, 6H, Cq(CH3)2). 
The crude acetonide 155 was dissolved in ethanol (7 mL) and treated with NaBH4 (54 mg, 
1.41 mmol, 1.5 equiv). After stirring overnight, water and 1N aqueous NaOH (2:1, 7 mL), and 
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the reaction mixture was repeatedly extracted with Et2O (3×20 mL). The combined organic 
layers were washed with brine, dried (Na2SO4), filtered, and concentrated to give analytically 
pure (1R,2R)-N-isopropyl-1,2-diphenylethylene-1,2-diamine (61; 407 mg, 1.60 mmol, 63%) 
as a colorless oil. The analytical data were identical in all respects to those previously 
reported.[182]  
1H NMR (400 MHz, CD2Cl2) δ 7.21-7-09 (m, 10H, C6H5), 3.93 (d, J = 7.6 Hz, 1H, CHCH), 
3.78 (d, J = 7.6 Hz, 1H, CHCH), 2.51 (sept, J = 6.1 Hz, 1H, CHMe2), 1.72 (br s, 3H, NH2 and 
NH), 0.95 (dd, J = 6.3 Hz, 6H, CH(CH3)2). 
13C NMR (100 MHz, CD2Cl2) δ 144.5 (CqPh), 143.0 (CqPh), 128.2 (2C, CHPh), 128.2 (2C, 
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(S)-(3,3'-Dibromo-1,1'-binaphthyl-2,2'-diyl)bis(oxy)bis(triphenylsilane) ((S)-157c): (S)-
3,3'-Dibromo-1,1'-binaphthyl-2,2'-diol (158b) (3.50 g, 7.88 mmol) was 
dissolved in DMF (47 mL) and then imidazole (1.64 g, 24.0 mmol) 
followed by triphenylsilyl chloride (5.90 g, 20.0 mmol) was added. The 
mixture was stirred at room temperature for 5 h, then poured into 
saturated aqueous NaHCO3 solution, and extracted with CH2Cl2. The 
organic layers were washed again with saturated aqueous NaHCO3 solution, dried (Na2SO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, 1:2 CH2Cl2/hexane) to furnish bis(triphenyl)silyl ether 158c (7.15 g, 7.44 mmol, 
94%) as a colorless solid. 
1H NMR (300 MHz, CDCl3) δ 7.57 (s, 2H), 7.38-7.30 (m, 4H), 7.21-6.95 (m, 32H), 
6.74 (d, J = 8.3 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 147.2 (Cq), 134.4, 134.2 (Cq), 133.6, 133.3, 132.8, 132.2, 
131.8, 128.9 (Cq), 128.7 (Cq), 128.4 (Cq), 128.2, 126.9 (Cq), 126.7, 126.2, 126.0, 125.0, 
124.9, 123.2 (Cq), 122.5 (Cq), 116.1 (Cq). 
MS (EI-DE) m/z 960 [M+] (27), 880 (1), 259 (100), 181 (6), 105 (1). 
HRMS (ESI+) calcd for C56H44N1O2Si2Br2 [(M+NH4)+] 976.1267, found 976.1272. 
 
(S)-3,3'-Bis(triphenylsilyl)-1,1'-binaphthyl-2,2´-diol ((S)-159): To a solution of 158c (6.60 
g, 6.87 mmol) in dry THF (100 mL) was added dropwise t-BuLi (11.7 mL, 
19.9 mmol; 1.7 M in pentane) over a period of 10 min at 0 °C. The mixture 
was stirred at room temperature for 1 h, poured into saturated aqueous 
NH4Cl solution, and extracted with CH2Cl2. The combined extracts were 
dried (Na2SO4), filtered, and concentrated. Pure diol (S)-159 (4.66 g, 5.81 
mmol, 85%) was obtained after flash column chromatography (silica gel, 1:2 CH2Cl2/hexane). 
1H NMR (300 MHz, CDCl3) δ 7.84 (s, 2H), 7.62-7.56 (m, 8H), 7.35-7.18 (m, 30H), 5.22 (s, 
2H). 
13C NMR (75 MHz, CDCl3) δ 155.5 (Cq), 141.0, 135.3, 133.7 (Cq), 133.3 (Cq), 128.5, 128.2, 
128.0, 127.2, 126.8 (Cq), 122.9, 122.8 (Cq), 122.6 (Cq), 109.6 (Cq). 
MS (EI-DE) m/z 802 [M+] (7), 724 (8), 646 (100), 567 (5), 491 (4), 429 (5), 369 (2), 323 (6), 
284 (27), 245 (9), 78 (1). 
HRMS (ESI+) calcd for C56H46N1O2Si2 [(M+NH4)+] 820.3069, found 820.3062. 
 
SiPh3
SiPh3
OH
OH
C56H42O2Si2
803,10
Br
Br
OSiPh3
OSiPh3
C56H40Br2O2Si2
960,89
7  Experimental Part 
264 
(S)-(3,3'-Dibromo-1,1'-binaphthyl-2,2'-diyl)bis(oxy)bis(triphenylsilane) ((S)-157c): (S)-
3,3'-Dibromo-1,1'-binaphthyl-2,2'-diol (158b) (3.50 g, 7.88 mmol) was 
dissolved in DMF (47 mL) and then imidazole (1.64 g, 24.0 mmol) 
followed by triphenylsilyl chloride (5.90 g, 20.0 mmol) was added. The 
mixture was stirred at room temperature for 5 h, then poured into 
saturated aqueous NaHCO3 solution, and extracted with CH2Cl2. The 
organic layers were washed again with saturated aqueous NaHCO3 solution, dried (Na2SO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, 1:2 CH2Cl2/hexane) to furnish bis(triphenyl)silyl ether 158c (7.15 g, 7.44 mmol, 
94%) as a colorless solid. 
1H NMR (300 MHz, CDCl3) δ 7.57 (s, 2H), 7.38-7.30 (m, 4H), 7.21-6.95 (m, 32H), 
6.74 (d, J = 8.3 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 147.2 (Cq), 134.4, 134.2 (Cq), 133.6, 133.3, 132.8, 132.2, 
131.8, 128.9 (Cq), 128.7 (Cq), 128.4 (Cq), 128.2, 126.9 (Cq), 126.7, 126.2, 126.0, 125.0, 
124.9, 123.2 (Cq), 122.5 (Cq), 116.1 (Cq). 
MS (EI-DE) m/z 960 [M+] (27), 880 (1), 259 (100), 181 (6), 105 (1). 
HRMS (ESI+) calcd for C56H44N1O2Si2Br2 [(M+NH4)+] 976.1267, found 976.1272. 
 
(S)-3,3'-Bis(triphenylsilyl)-1,1'-binaphthyl-2,2´-diol ((S)-159): To a solution of 158c (6.60 
g, 6.87 mmol) in dry THF (100 mL) was added dropwise t-BuLi (11.7 mL, 
19.9 mmol; 1.7 M in pentane) over a period of 10 min at 0 °C. The mixture 
was stirred at room temperature for 1 h, poured into saturated aqueous 
NH4Cl solution, and extracted with CH2Cl2. The combined extracts were 
dried (Na2SO4), filtered, and concentrated. Pure diol (S)-159 (4.66 g, 5.81 
mmol, 85%) was obtained after flash column chromatography (silica gel, 1:2 CH2Cl2/hexane). 
1H NMR (300 MHz, CDCl3) δ 7.84 (s, 2H), 7.62-7.56 (m, 8H), 7.35-7.18 (m, 30H), 5.22 (s, 
2H). 
13C NMR (75 MHz, CDCl3) δ 155.5 (Cq), 141.0, 135.3, 133.7 (Cq), 133.3 (Cq), 128.5, 128.2, 
128.0, 127.2, 126.8 (Cq), 122.9, 122.8 (Cq), 122.6 (Cq), 109.6 (Cq). 
MS (EI-DE) m/z 802 [M+] (7), 724 (8), 646 (100), 567 (5), 491 (4), 429 (5), 369 (2), 323 (6), 
284 (27), 245 (9), 78 (1). 
HRMS (ESI+) calcd for C56H46N1O2Si2 [(M+NH4)+] 820.3069, found 820.3062. 
 
SiPh3
SiPh3
OH
OH
C56H42O2Si2
803,10
Br
Br
OSiPh3
OSiPh3
C56H40Br2O2Si2
960,89
7  Experimental Part 
264 
(S)-(3,3'-Dibromo-1,1'-binaphthyl-2,2'-diyl)bis(oxy)bis(triphenylsilane) ((S)-157c): (S)-
3,3'-Dibromo-1,1'-binaphthyl-2,2'-diol (158b) (3.50 g, 7.88 mmol) was 
dissolved in DMF (47 mL) and then imidazole (1.64 g, 24.0 mmol) 
followed by triphenylsilyl chloride (5.90 g, 20.0 mmol) was added. The 
mixture was stirred at room temperature for 5 h, then poured into 
saturated aqueous NaHCO3 solution, and extracted with CH2Cl2. The 
organic layers were washed again with saturated aqueous NaHCO3 solution, dried (Na2SO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, 1:2 CH2Cl2/hexane) to furnish bis(triphenyl)silyl ether 158c (7.15 g, 7.44 mmol, 
94%) as a colorless solid. 
1H NMR (300 MHz, CDCl3) δ 7.57 (s, 2H), 7.38-7.30 (m, 4H), 7.21-6.95 (m, 32H), 
6.74 (d, J = 8.3 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 147.2 (Cq), 134.4, 134.2 (Cq), 133.6, 133.3, 132.8, 132.2, 
131.8, 128.9 (Cq), 128.7 (Cq), 128.4 (Cq), 128.2, 126.9 (Cq), 126.7, 126.2, 126.0, 125.0, 
124.9, 123.2 (Cq), 122.5 (Cq), 116.1 (Cq). 
MS (EI-DE) m/z 960 [M+] (27), 880 (1), 259 (100), 181 (6), 105 (1). 
HRMS (ESI+) calcd for C56H44N1O2Si2Br2 [(M+NH4)+] 976.1267, found 976.1272. 
 
(S)-3,3'-Bis(triphenylsilyl)-1,1'-binaphthyl-2,2´-diol ((S)-159): To a solution of 158c (6.60 
g, 6.87 mmol) in dry THF (100 mL) was added dropwise t-BuLi (11.7 mL, 
19.9 mmol; 1.7 M in pentane) over a period of 10 min at 0 °C. The mixture 
was stirred at room temperature for 1 h, poured into saturated aqueous 
NH4Cl solution, and extracted with CH2Cl2. The combined extracts were 
dried (Na2SO4), filtered, and concentrated. Pure diol (S)-159 (4.66 g, 5.81 
mmol, 85%) was obtained after flash column chromatography (silica gel, 1:2 CH2Cl2/hexane). 
1H NMR (300 MHz, CDCl3) δ 7.84 (s, 2H), 7.62-7.56 (m, 8H), 7.35-7.18 (m, 30H), 5.22 (s, 
2H). 
13C NMR (75 MHz, CDCl3) δ 155.5 (Cq), 141.0, 135.3, 133.7 (Cq), 133.3 (Cq), 128.5, 128.2, 
128.0, 127.2, 126.8 (Cq), 122.9, 122.8 (Cq), 122.6 (Cq), 109.6 (Cq). 
MS (EI-DE) m/z 802 [M+] (7), 724 (8), 646 (100), 567 (5), 491 (4), 429 (5), 369 (2), 323 (6), 
284 (27), 245 (9), 78 (1). 
HRMS (ESI+) calcd for C56H46N1O2Si2 [(M+NH4)+] 820.3069, found 820.3062. 
 
SiPh3
SiPh3
OH
OH
C56H42O2Si2
803,10
Br
Br
OSiPh3
OSiPh3
C56H40Br2O2Si2
960,89
7  Experimental Part 
264 
(S)-(3,3'-Dibromo-1,1'-binaphthyl-2,2'-diyl)bis(oxy)bis(triphenylsilane) ((S)-157c): (S)-
3,3'-Dibromo-1,1'-binaphthyl-2,2'-diol (158b) (3.50 g, 7.88 mmol) was 
dissolved in DMF (47 mL) and then imidazole (1.64 g, 24.0 mmol) 
followed by triphenylsilyl chloride (5.90 g, 20.0 mmol) was added. The 
mixture was stirred at room temperature for 5 h, then poured into 
saturated aqueous NaHCO3 solution, and extracted with CH2Cl2. The 
organic layers were washed again with saturated aqueous NaHCO3 solution, dried (Na2SO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, 1:2 CH2Cl2/hexane) to furnish bis(triphenyl)silyl ether 158c (7.15 g, 7.44 mmol, 
94%) as a colorless solid. 
1H NMR (300 MHz, CDCl3) δ 7.57 (s, 2H), 7.38-7.30 (m, 4H), 7.21-6.95 (m, 32H), 
6.74 (d, J = 8.3 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 147.2 (Cq), 134.4, 134.2 (Cq), 133.6, 133.3, 132.8, 132.2, 
131.8, 128.9 (Cq), 128.7 (Cq), 128.4 (Cq), 128.2, 126.9 (Cq), 126.7, 126.2, 126.0, 125.0, 
124.9, 123.2 (Cq), 122.5 (Cq), 116.1 (Cq). 
MS (EI-DE) m/z 960 [M+] (27), 880 (1), 259 (100), 181 (6), 105 (1). 
HRMS (ESI+) calcd for C56H44N1O2Si2Br2 [(M+NH4)+] 976.1267, found 976.1272. 
 
(S)-3,3'-Bis(triphenylsilyl)-1,1'-binaphthyl-2,2´-diol ((S)-159): To a solution of 158c (6.60 
g, 6.87 mmol) in dry THF (100 mL) was added dropwise t-BuLi (11.7 mL, 
19.9 mmol; 1.7 M in pentane) over a period of 10 min at 0 °C. The mixture 
was stirred at room temperature for 1 h, poured into saturated aqueous 
NH4Cl solution, and extracted with CH2Cl2. The combined extracts were 
dried (Na2SO4), filtered, and concentrated. Pure diol (S)-159 (4.66 g, 5.81 
mmol, 85%) was obtained after flash column chromatography (silica gel, 1:2 CH2Cl2/hexane). 
1H NMR (300 MHz, CDCl3) δ 7.84 (s, 2H), 7.62-7.56 (m, 8H), 7.35-7.18 (m, 30H), 5.22 (s, 
2H). 
13C NMR (75 MHz, CDCl3) δ 155.5 (Cq), 141.0, 135.3, 133.7 (Cq), 133.3 (Cq), 128.5, 128.2, 
128.0, 127.2, 126.8 (Cq), 122.9, 122.8 (Cq), 122.6 (Cq), 109.6 (Cq). 
MS (EI-DE) m/z 802 [M+] (7), 724 (8), 646 (100), 567 (5), 491 (4), 429 (5), 369 (2), 323 (6), 
284 (27), 245 (9), 78 (1). 
HRMS (ESI+) calcd for C56H46N1O2Si2 [(M+NH4)+] 820.3069, found 820.3062. 
 
SiPh3
SiPh3
OH
OH
C56H42O2Si2
803,10
Br
Br
OSiPh3
OSiPh3
C56H40Br2O2Si2
960,89
7 Experimental Part 
 265
(S)-3,3'-Bis(triphenylsilyl)-1,1'-binaphthyl-2,2'-diol phosphate ((S)-7b): Diol 159 (2.20 g, 
2.74 mmol) was suspended in pyridine (10 mL) and phosphorus 
oxychloride (0.5 mL, 5.48 mmol) was added dropwise at room tempera-
ture with rapid stirring. The resulting suspension was heated to 95 °C for 
24 h. Then, the reaction mixture was cooled to room temperature and 
water (2 mL) was added. The resulting biphasic suspension was heated to 
95 °C for an additional 6 h. The reaction mixture was diluted with CH2Cl2 and repeatedly 
extracted with 1N aqueous HCl. The combined organic phases were dried (Na2SO4), filtered, 
and concentrated under reduced pressure. Purification by flash column chromatography (silica 
gel, 2% methanol in CH2Cl2) provided phosphoric acid derivative (S)-7b (2.18 g, 2.52 mmol, 
92%) as a white solid. The analytical data were identical in all respects to those previously 
reported.[182] 
1H NMR (400 MHz, (CD3)2SO) δ 7.94 (s, 2H), 7.80 (d, J = 7.5 Hz, 2H), 7.60-7.57 (m, 12H), 
7.37-7.28 (m, 22H), 7.06 (d, J = 8.0 Hz, 2H). 
13C NMR (75 MHz, (CD3)2SO) δ 152.1 (Cq), 152.1 (Cq), 141.1 (Cq), 136.3, 134.0 (Cq), 
133.5 (Cq), 129.8, 129.5, 128.8, 127.7 (Cq), 126.2 (Cq), 125.8, 125.4 (Cq), 121.2 (Cq). 
31P NMR (161 MHz, (CD3)2SO) δ 2.49 (s). 
MS (ESI-) m/z 863 [(M-H)-]. 
HRMS (ESI-) calcd for C56H40O4Si2P1 [(M-H)] 863.2222, found 863.2208. 
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HRMS (ESI-) calcd for C56H40O4Si2P1 [(M-H)] 863.2222, found 863.2208. 
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13C NMR (75 MHz, (CD3)2SO) δ 152.1 (Cq), 152.1 (Cq), 141.1 (Cq), 136.3, 134.0 (Cq), 
133.5 (Cq), 129.8, 129.5, 128.8, 127.7 (Cq), 126.2 (Cq), 125.8, 125.4 (Cq), 121.2 (Cq). 
31P NMR (161 MHz, (CD3)2SO) δ 2.49 (s). 
MS (ESI-) m/z 863 [(M-H)-]. 
HRMS (ESI-) calcd for C56H40O4Si2P1 [(M-H)] 863.2222, found 863.2208. 
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